

Nicholas J. Santoro (Nev. Bar No. 532)
Jason D. Smith (Nev. Bar No. 9691)
SANTORO WHITMIRE, LTD.
10100 W. Charleston Blvd., Suite 250
Las Vegas, NV 89135
Tel: (702) 948-8771 / Fax: (702) 948-8773
E-mail: nsantoro@santoronevada.com,
jsmith@santoronevada.com

Christopher N. Sipes (admitted *pro hac vice*)
Einar Stole (admitted *pro hac vice*)
Michael N. Kennedy (admitted *pro hac vice*)
Megan P. Keane (admitted *pro hac vice*)
Eric R. Sonnenschein (admitted *pro hac vice*)
Alaina M. Whitt (admitted *pro hac vice*)
Han Park (admitted *pro hac vice*)
Jordan L. Moran (admitted *pro hac vice*)
COVINGTON & BURLING LLP
One CityCenter, 850 Tenth Street, NW
Washington, DC 20001
Tel: (202) 662-6000 / Fax: (202) 662-6291
E-mail: csipes@cov.com, estole@cov.com,
mkennedy@cov.com, mkeane@cov.com,
esonnenschein@cov.com, awhitt@cov.com,
hpark@cov.com, jmoran@cov.com

*Attorneys for Plaintiffs Amarin Pharma, Inc. and
Amarin Pharmaceuticals Ireland Limited*

**UNITED STATES DISTRICT COURT
DISTRICT OF NEVADA**

AMARIN PHARMA, INC. and AMARIN
PHARMACEUTICALS IRELAND LIMITED,

Plaintiffs,

v.

HIKMA PHARMACEUTICALS USA INC.,
et al.,

Defendants.

CASE NO.: 2:16-cv-02525-MMD-NJK

(Consolidated with
2:16-cv-02562-MMD-NJK)

PRETRIAL ORDER

1 After pretrial proceedings in this case,

2 IT IS ORDERED:

3 **I. NATURE OF THE ACTION**

4 1. This is a civil action for patent infringement arising under the patent laws of the
5 United States, 35 U.S.C. § 100, *et seq.*, including 35 U.S.C. § 271(e)(2), and the Declaratory
6 Judgment Act, 28 U.S.C. §§ 2201 and 2202, arising from Defendants' filing of Abbreviated New
7 Drug Applications ("ANDAs") under Section 505(j) of the Federal Food, Drug, and Cosmetic
8 Act ("FDCA"), 21 U.S.C. § 355(j), seeking approval from the United States Food and Drug
9 Administration ("FDA") to market generic versions of Plaintiffs' VASCEPA[®] product.

10 2. Plaintiffs Amarin Pharma, Inc. and Amarin Pharmaceuticals Ireland Limited
11 (collectively, "Plaintiffs" or "Amarin") originally alleged infringement of U.S. Patent No.
12 8,293,728 ("the '728 Patent"), U.S. Patent No. 8,318,715 ("the '715 Patent"), U.S. Patent No.
13 8,357,677 ("the '677 Patent"), U.S. Patent No. 8,367,652 ("the '652 Patent"), U.S. Patent No.
14 8,377,920 ("the '920 Patent"), U.S. Patent No. 8,399,446 ("the '446 Patent"), U.S. Patent No.
15 8,415,335 ("the '335 Patent"), U.S. Patent No. 8,426,399 ("the '399 Patent"), U.S. Patent No.
16 8,431,560 ("the '560 Patent"), U.S. Patent No. 8,440,650 ("the '650 Patent"), U.S. Patent No.
17 8,518,929 ("the '929 Patent"), U.S. Patent No. 8,524,698 ("the '698 Patent"), U.S. Patent No.
18 8,546,372 ("the '372 Patent"), and U.S. Patent No. 8,617,594 ("the '594 Patent") (collectively,
19 the "Patents-in-Suit") by Defendants Hikma Pharmaceuticals USA Inc. and Hikma
20 Pharmaceuticals International Limited (collectively, "Hikma") and Defendants Dr. Reddy's
21 Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd. (collectively, "DRL") (Hikma and DRL
22 collectively, "Defendants").

23 3. Pursuant to the Court's previous orders, *see* Case No. 2:16-cv-02525, ECF Nos.
24 203, 229, Amarin will assert at trial only the following fifteen (15) claims from the '728, '715,
25 '677, '652, '560, and '929 Patents (collectively, the "Asserted Patents"): Claims 1, 13, and 16 of
26 the '728 Patent, Claim 14 of the '715 Patent, Claims 1, 7, and 8 of the '677 Patent, Claims 1, 7,
27 and 8 of the '652 Patent, Claims 4, 7, and 17 of the '560 Patent, and Claims 1 and 5 of the '929
28

1 Patent (collectively, the “Asserted Claims”).

2 4. Defendants originally brought counterclaims for a declaratory judgment that the
3 Patents-in-Suit are not infringed and/or are invalid.

4 5. Amarin Pharmaceuticals Ireland Limited is the owner of the Patents-in-Suit.

5 6. On July 26, 2012, FDA approved a New Drug Application (“NDA”), No. 202057,
6 for 1 g icosapent ethyl capsules. FDA approved a supplement to NDA No. 202057 for 500 mg
7 icosapent ethyl capsules on February 16, 2017.

8 7. Amarin Pharmaceuticals Ireland Limited is the holder of NDA No. 202057.
9 Amarin Pharma, Inc. is Amarin Pharmaceuticals Ireland Limited’s agent in the United States for
10 purposes of communicating with FDA regarding NDA No. 202057.

11 8. Amarin markets both strengths of the approved drug product under the tradename
12 VASCEPA®.

13 9. The Patents-in-Suit are listed in the FDA publication *Approved Drug Products*
14 *with Therapeutic Equivalence Evaluations* (the “Orange Book”) in connection with NDA No.
15 202057.

16 10. In a letter dated September 21, 2016, Hikma’s predecessor, Roxane Laboratories,
17 Inc., notified Amarin that it had filed ANDA No. 209457 with paragraph IV certifications under
18 Section 505(j)(2)(A)(vii)(IV) of the FDCA, 21 U.S.C. § 355(j)(2)(A)(vii)(IV), seeking FDA
19 approval to market a generic version of VASCEPA® (icosapent ethyl) 1 g capsules.

20 11. In a letter dated September 22, 2016, DRL notified Amarin that it had filed
21 ANDA No. 209499 with paragraph IV certifications under Section 505(j)(2)(A)(vii)(IV) of the
22 FDCA, 21 U.S.C. § 355(j)(2)(A)(vii)(IV), seeking FDA approval to market a generic version of
23 VASCEPA® (icosapent ethyl) 1 g capsules.

24 12. On October 31, 2016, Amarin filed a complaint for patent infringement against
25 Hikma¹ in this Court, alleging that Hikma’s submission of ANDA No. 209457 to obtain FDA’s

26
27 ¹ The original complaint was against Hikma’s predecessors, which have since been replaced by
28

1 approval for a generic version of the 1 gram strength of VASCEPA[®] before the expiration of the
2 Patents-in-Suit constitutes infringement of the Patents-in-Suit under 35 U.S.C. § 271(e)(2), and
3 that, if Hikma were to commercially use, offer for sale, or sell its generic version of VASCEPA[®],
4 or induce or contribute to such conduct, it would further infringe the Patents-in-Suit under 35
5 U.S.C. § 271(a), (b), and/or (c). The Court designated the action as Case No. 2:16-cv-02525.

6 13. On November 4, 2016, Amarin filed a complaint for patent infringement against
7 DRL in this Court, alleging that DRL's submission of ANDA No. 209499 to obtain FDA's
8 approval for a generic version of the 1 gram strength of VASCEPA[®] before the expiration of the
9 Patents-in-Suit constitutes infringement of the Patents-in-Suit under 35 U.S.C. § 271(e)(2), and
10 that, if DRL were to commercially use, offer for sale, or sell its generic version of VASCEPA[®],
11 or induce or contribute to such conduct, it would further infringe the Patents-in-Suit under 35
12 U.S.C. § 271(a), (b), and/or (c). The Court designated that action as Case No. 2:16-cv-02562.

13 14. On January 10, 2017, the Court consolidated Case No. 2:16-cv-02562 with Case
14 No. 2:16-cv-02525, with Case No. 2:16-cv-02525 serving as the base case.

15 15. In a letter dated July 11, 2018, DRL notified Amarin that it had filed a supplement
16 to ANDA No. 209499 with paragraph IV certifications under Section 505(j)(2)(A)(vii)(IV) of the
17 FDCA, 21 U.S.C. § 355(j)(2)(A)(vii)(IV), seeking FDA approval to market a generic version of
18 VASCEPA[®] (icosapent ethyl) 500 mg capsules.

19 16. On August 24, 2018, Amarin filed a complaint for patent infringement against
20 DRL in this Court, alleging that DRL's submission of its supplement to ANDA No. 209499 to
21 obtain FDA's approval for a generic version of 500 mg strength VASCEPA[®] before the
22 expiration of the '728, '715, '677, '652, '920, '335, '399, '650, '929, '698, '372, and '594
23 Patents constitutes infringement of these patents under 35 U.S.C. § 271(e)(2), and that, if DRL
24 were to commercially use, offer for sale, or sell its generic version of VASCEPA[®], or induce or
25 contribute to such conduct, it would further infringe these patents under 35 U.S.C. § 271(a), (b),

26 _____ (continued)
27 the current Hikma Defendants. (ECF Nos. 52, 132, 185.)
28

1 and/or (c). The Court designated that action as Case No. 2:18-cv-01596.

2 17. Amarin and DRL have stipulated that the final judgment in Case No. 2:16-cv-
3 02525 will be binding on Amarin and DRL as though that judgment were also made in Case No.
4 2:18-cv-01596. (Case No. 2:18-cv-01596, ECF No. 27.)

5 18. In the present case, Case No. 2:15-cv-02525, Plaintiffs seek the following relief:

- 6 a. A judgment that Defendants have infringed the Asserted Claims under 35
7 U.S.C. § 271(e)(2)(A);
- 8 b. An order pursuant to 35 U.S.C. § 271(e)(4)(A) providing that the effective
9 date of any FDA approval of Defendants' ANDAs is not earlier than the
10 expiration date of the Asserted Patents or any later expiration of
11 exclusivity for the Asserted Patents to which Plaintiffs are or become
12 entitled;
- 13 c. A permanent injunction restraining and enjoining Defendants and their
14 officers, agents, servants, employees, parents, subsidiaries, divisions,
15 affiliates, and those persons in active concert or participation with any of
16 them, from making, using, selling, offering to sell, or importing any
17 product that infringes the Asserted Claims, including the products
18 described in Defendants' ANDAs;
- 19 d. A judgment declaring that making, using, selling, offering to sell, or
20 importing the products described in Defendants' ANDAs, or inducing or
21 contributing to such conduct, would constitute infringement of the
22 Asserted Claims by Defendants pursuant to 35 U.S.C. § 271(a), (b), and/or
23 (c);
- 24 e. A finding that this is an exceptional case, and an award of attorney's fees
25 in this action pursuant to 35 U.S.C. § 285;
- 26 f. Costs and expenses in this action; and
- 27 g. Such further and other relief as this Court determines to be just and proper.

19. Defendants seek the following relief:

- a. A judgment declaring that Defendants would not and will not directly, indirectly, contributorily, and/or by inducement, infringe any claim of the Asserted Patents, either literally or under the doctrine of equivalents;
- b. A judgment declaring that the claims in the Asserted Patents are invalid for failure to comply with one or more provisions of the Patent Act, 35 U.S.C. §§ 100 *et seq.*;
- c. A judgment awarding Defendants their reasonable costs and attorneys' fees incurred in connection with this action pursuant to 35 U.S.C. § 285; and
- d. Such further and other relief as this Court may deem just and proper.

20. On October 28, 2019, the Court granted summary judgment for Defendants on Plaintiffs' theory of contributory infringement. As a result, Amarin will not assert at trial that Defendants are liable for contributing to infringement under 35 U.S.C. § 271(c). However, Amarin preserves its right to appeal the Court's ruling on contributory infringement.

21. On October 28, 2019, the Court granted Amarin's motion for partial summary judgment "to the extent it seeks to prevent Defendants from asserting a written description defense at trial." ECF No. 278 at 1–2. As a result, Defendants will not assert at trial that the Asserted Claims are invalid for lack of written description under 35 U.S.C. § 112. However, Defendants preserve their right to appeal the Court's ruling on written description.

22. Defendants have withdrawn, and will not assert at trial, the defense that the Asserted Claims are invalid as anticipated under 35 U.S.C. § 102.

23. Defendants have withdrawn, and will not assert at trial, the defense that the Asserted Claims are invalid as indefinite or not enabled under 35 U.S.C. § 112.²

² It is also Plaintiffs' position that Defendants have not preserved their ability to assert the defense that the Asserted Claims are drawn to ineligible subject matter under 35 U.S.C. § 101.

1 **II. STATEMENT OF JURISDICTION**

2 24. This Court has jurisdiction over this action pursuant to 28 U.S.C. §§ 1331 and
3 1338(a) because it arises under the Patent Laws of the United States, 35 U.S.C. § 100, *et seq.*

4 25. For purposes of this action only, venue is proper pursuant to 28 U.S.C. §§ 1391
5 and 1400(b).

6 26. For purposes of this action only, no party contests personal jurisdiction or venue
7 in this Court.

8 **III. ADMITTED FACTS**

9 The following facts are admitted by the parties and require no proof:

10 **A. THE PARTIES**

11 27. Plaintiff Amarin Pharma, Inc. is a company organized and existing under the laws
12 of Delaware with its principal place of business at 440 Route 22, Bridgewater, NJ 08807.

13 28. Plaintiff Amarin Pharmaceuticals Ireland Limited is a company incorporated
14 under the laws of Ireland with registered offices at 88 Harcourt Street, Dublin 2, Dublin, Ireland.

15 29. Defendant Hikma Pharmaceuticals USA Inc. is a company organized and existing
16 under the laws of Delaware with its principal place of business at 246 Industrial Way West,
17 Eatontown, NJ 07724.

18 30. Defendant Hikma Pharmaceuticals International Limited is a company
19 incorporated under the laws of the United Kingdom with registered offices at 1 New Burlington
20 Place, London, England W1S 2HR.

21 31. Defendant Dr. Reddy's Laboratories, Inc. is a company organized and existing
22 under the laws of New Jersey with its principal place of business at 107 College Road East,
23 Princeton, NJ 08540.

24 32. Defendant Dr. Reddy's Laboratories, Ltd. is an Indian public limited liability
25 company organized and existing under the laws of India and having a principal place of business
26 at 8-2-337, Road No. 3, Banjara Hills, Hyderabad, Andhra Pradesh 500 034, India.

B. THE ASSERTED PATENTS

33. Amarin Pharmaceuticals Ireland Limited is the owner of the Asserted Patents.

34. Each of the Asserted Patents is entitled “METHODS OF TREATING HYPERTRIGLYCERIDEMIA.”

35. The U.S. Applications that ultimately issued as the Asserted Patents are continuations of U.S. Application No. 12/702,889, filed on February 9, 2010, which ultimately issued as U.S. Patent No. 8,293,727 (“the ’727 Patent”).

36. The Asserted Patents further claim priority to U.S. Provisional Application No. 61/151,291, filed on February 10, 2009, and U.S. Provisional Application No. 61/173,755, filed on April 29, 2009.

37. Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, and Paresh Soni are named as inventors of the Asserted Patents.

38. Pursuant to 21 U.S.C. § 355(b)(1), the Asserted Patents are listed in the Orange Book—published by FDA and formally known as *Approved Drug Products with Therapeutic Equivalence Evaluations*—in connection with NDA No. 202057.

1. The ’728 Patent

39. The United States Patent and Trademark Office (“PTO”) issued the ’728 Patent on October 23, 2012.

40. Amarin Pharmaceuticals Ireland Limited filed U.S. Application No. 13/349,153, which ultimately issued as the ’728 Patent, on January 12, 2012.

41. U.S. Application No. 13/349,153 is a continuation of U.S. Application No. 12/702,889, filed on February 9, 2010, now the ’727 Patent.

2. The ’715 Patent

42. The PTO issued the ’715 Patent on November 27, 2012.

43. The PTO issued a Certificate of Correction to the ’715 Patent on August 11, 2015.

44. The PTO issued a Certificate of Correction to the ’715 Patent on May 21, 2019.

45. Amarin Pharmaceuticals Ireland Limited filed U.S. Application No. 13/282,145,

1 which ultimately issued as the '715 Patent, on October 26, 2011.

2 46. U.S. Application No. 13/282,145 is a continuation of U.S. Application No.
3 12/702,889, filed on February 9, 2010, now the '727 Patent.

4 **3. The '677 Patent**

5 47. The PTO issued the '677 Patent on January 22, 2013.

6 48. Amarin Pharmaceuticals Ireland Limited filed U.S. Application No. 13/608,775,
7 which ultimately issued as the '677 Patent, on September 10, 2012.

8 49. U.S. Application No. 13/608,775 is a continuation of U.S. Application No.
9 13/349,153, filed on January 12, 2012, now the '728 Patent, which is a continuation of U.S.
10 Application No. 12/702,889, filed on February 9, 2010, now the '727 Patent.

11 **4. The '652 Patent**

12 50. The PTO issued the '652 Patent on February 5, 2013.

13 51. Amarin Pharmaceuticals Ireland Limited filed U.S. Application No. 13/610,247,
14 which ultimately issued as the '652 Patent, on September 11, 2012.

15 52. U.S. Application No. 13/610,247 is a continuation of U.S. Application No.
16 13/349,153, filed on January 12, 2012, now the '728 Patent, which is a continuation of U.S.
17 Application No. 12/702,889, filed on February 9, 2010, now the '727 Patent.

18 **5. The '560 Patent**

19 53. The PTO issued the '560 Patent on April 30, 2013.

20 54. Amarin Pharmaceuticals Ireland Limited filed U.S. Application No. 13/711,329,
21 which ultimately issued as the '560 Patent, on December 11, 2012.

22 55. U.S. Application No. 13/711,329 is a continuation of U.S. Application No.
23 13/623,450, filed on September 20, 2012, now the '920 Patent, which is a continuation of U.S.
24 Application No. 13/349,153, filed on January 12, 2012, now the '728 Patent, which is a
25 continuation of U.S. Application No. 12/702,889, filed on February 9, 2010, now the '727
26 Patent.

6. The '929 Patent

56. The PTO issued the '929 Patent on August 27, 2013.

57. Amarin Pharmaceuticals Ireland Limited filed U.S. Application No. 13/776,242, which ultimately issued as the '929 Patent, on February 25, 2013.

58. U.S. Application No. 13/776,242 is a continuation of U.S. Application No. 13/711,329, filed on December 11, 2012, now the '560 Patent, which is a continuation of U.S. Application No. 13/623,450, filed on September 20, 2012, now the '920 Patent, which is a continuation of U.S. Application No. 13/349,153, filed on January 12, 2012, now the '728 Patent, which is a continuation of U.S. Application No. 12/702,889, filed on February 9, 2010, now the '727 Patent.

7. Prior-Art References

59. Epadel Capsules 300, Japan Pharmaceutical Reference 369 (2nd ed. 1991) ("Epadel JPR") was published in 1991 and is prior art to the Asserted Patents.

60. Matsuzawa et al., *Effect of Long-Term Administration of Ethyl Icosapentate (MND-21) in Hyperlipidaemic Patients*, 7 J. Clin. Therapeutic & Medicines 1801–1816 (1991) ("Matsuzawa") was published in 1991 and is prior art to the Asserted Patents.

61. Takaku et al., *Study on the Efficacy and Safety of Ethyl Icosapentate (MND-21) in Treatment of Hyperlipidemia Based on a Long-Term Administration Test*, 7 J. Clin. Therapeutics & Medicine 191–213 (1991) ("Takaku") was published in 1991 and is prior art to the Asserted Patents.

62. Wojenski et al., *Eicosapentaenoic Acid Ethyl Ester as an Antithrombotic Agent: Comparison to an Extract of Fish Oil*, Biochim. Biophys. Acta., 1081(1):33–38 (1991) ("Wojenski") was published in 1991 and is prior art to the Asserted Patents.

63. Nozaki et al., *Effects of Purified Eicosapentaenoic Acid Ethyl Ester on Plasma Lipoproteins in Primary Hypercholesterolemia*, 62 Int'l J. Vitamin & Nutrition Res. 256–60 (1992) ("Nozaki") was published in 1992 and is prior art to the Asserted Patents.

64. Hayashi et al., *Decreases in Plasma Lipid Content and Thrombotic Activity by*

1 *Ethyl Icosapentate Purified from Fish Oils*, 56(1) Curr. Therap. Res. 24–31 (1995) (“Hayashi”)
2 was published in 1995 and is prior art to the Asserted Patents.

3 65. Shinozaki et al., *The Long-Term Effect of Eicosapentaenoic Acid on Serum Levels*
4 *of Lipoprotein (a) and Lipids in Patients with Vascular Disease*, 2(2) J. Atheroscl. Thromb. 107–
5 09 (1996) (“Shinozaki”) was published in 1995 and is prior art to the Asserted Patents.

6 66. Grimsgaard et al., *Highly Purified Eicosapentaenoic Acid and Docosahexaenoic*
7 *Acid in Humans Have Similar Triacylglycerol- Lowering Effects but Divergent Effects on Serum*
8 *Fatty Acids*, 66 Am. J. Clin. Nutr. 649–59 (1997) (“Grimsgaard”) was published in 1997 and is
9 prior art to the Asserted Patents.

10 67. Harris et al., *Safety and Efficacy of Omacor in Severe Hypertriglyceridemia*, J.
11 *Cardiov. Risk*, 4:385–391 (1997) (“Harris”) was published in 1997 and is prior art to the
12 Asserted Patents.

13 68. Saito et al., *Results of Clinical Usage of Improved Formulation (MND- 21S)*
14 *Epadel Capsule 300 with Respect to Hyperlipidemia*, 26(12) Jpn. Pharmacol. Ther. 2047–62
15 (1998) (“Saito”) was published in 1998 and is prior art to the Asserted Patents.

16 69. Nakamura et al., *Joint Effects of HMG-CoA Reductase Inhibitors and*
17 *Eicosapentaenoic Acids on Serum Lipid Profile and Plasma Fatty Acid Concentrations in*
18 *Patients with Hyperlipidemia*, 29(1) Int. J. Clin. Lab. Res. 22–25 (1999) (“Nakamura”) was
19 published in 1999 and is prior art to the Asserted Patents.

20 70. Kurabayashi et al., *Eicosapentaenoic Acid Effect on Hyperlipidemia in*
21 *Menopausal Japanese Women*, *Obstet. Gynecol.* 96:521–8 (2000) (“Kurabayashi”) was
22 published in 2000 and is prior art to the Asserted Patents.

23 71. Mori et al., *Purified Eicosapentaenoic and Docosahexaenoic Acids Have*
24 *Differential Effects on Serum Lipids and Lipoproteins, LDL Particle Size, Glucose, and Insulin*
25 *in Mildly Hyperlipidemic Men*, 71 Am. J. Clinical Nutrition 1085–94 (2000) (“Mori 2000”) was
26 published in 2000 and is prior art to the Asserted Patents.

27 72. National Institutes of Health, National Heart, Lung, and Blood Institute,
28

1 “Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment
2 Panel III, Executive Summary,” May 2001) (“ATP III Guidelines”) was published in 2001 and is
3 prior art to the Asserted Patents.

4 73. Katayama et al., *Efficacy and Safety of Ethyl Icosapentate (Epadel®) Given for a*
5 *Long Term Against Hyperlipidemia*, 21 Prog. Med. 457–467 (2001) (“Katayama”) was published
6 in 2001 and is prior art to the Asserted Patents.

7 74. Nestel et al., *The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid*
8 *increase systemic arterial compliance in humans*, 76 Am. J. Clin. Nutr. 76:326–30 (2002)
9 (“Nestel”) was published in 2002 and is prior art to the Asserted Patents.

10 75. Okumura et al., *Eicosapentaenoic Acid Improves Endothelial Function in*
11 *Hypertriglyceridemic Subjects Despite Increased Lipid Oxidizability*, 324 Am. J. Med. Sci. 247–
12 53 (2002) (“Okumura”) was published in 2002 and is prior art to the Asserted Patents.

13 76. Park & Harris, *Omega-3 Fatty Acid Supplementation Accelerates Chylomicron*
14 *Triglyceride Clearance*, 44 J. LIPID RES. 44:455-463 (2003) (“Park”) was published in 2003
15 and is prior art to the Asserted Patents.

16 77. Yokoyama et al., *Effects of eicosapentaenoic acid on cardiovascular events in*
17 *Japanese patients with hypercholesterolemia: Rationale, design, and baseline characteristics of*
18 *the Japan EPA Lipid Intervention Study (JELIS)*, 146 Am. Heart J. 613–20 (2003) (“Yokoyama
19 2003”) was published in 2003 and is prior art to the Asserted Patents.

20 78. Omacor® Label (2004) (“Omacor 2004”) was published in 2004 and is prior art
21 to the Asserted Patents.

22 79. Maki et al., *Lipid responses to a dietary docosahexaenoic acid supplement in men*
23 *and women with below average levels of high density lipoprotein cholesterol*, 24 J. Am. Col.
24 Nutr. 189–99 (2005) (“Maki”) was published in 2005 and is prior art to the Asserted Patents.

25 80. Geppert et al., *Microalgal Docosahexaenoic Acid Decreases Plasma*
26 *Triacylglycerol in Normolipidaemic Vegetarians: A Randomized Trial*, 95 Brit. J. Nutrition 779–
27 86 (2006) (“Geppert”) was published in 2006 and is prior art to the Asserted Patents.

81. Omacor®, Physicians' Desk Reference 2735 (60d ed. 2006) ("Omacor PDR") was published in 2006 and is prior art to the Asserted Patents.

82. Lovaza®, Physicians' Desk Reference 2699 (62d ed. 2007) ("Lovaza PDR") was published in 2007 and is prior art to the Asserted Patents.

83. Lovaza® Label 2007 ("Lovaza 2007") was published in 2007 and is prior art to the Asserted Patents.

84. Satoh et al., *Purified Eicosapentaenoic Acid Reduces Small Dense LDL, Remnant Lipoprotein Particles, and C-Reactive Protein in Metabolic Syndrome*, 30 Diabetes Care 144–146 (2007) ("Satoh") was published in 2007 and is prior art to the Asserted Patents.

85. Epadel Capsules 300 Package Insert, January 2007 Update (Version 5) (ICOSAPENT_DFNDTS00008961–969) ("Epadel PI 2007") was published in 2007 and is prior art to the Asserted Patents.

86. Yokoyama et al., *Effects of Eicosapentaenoic Acid on Major Coronary Events in Hypercholesterolaemic Patients (JELIS): a Randomized Open-Label, Blinded Endpoint Analysis*, 369 Lancet 1090–98 (2007) ("Yokoyama 2007") was published in 2007 and is prior art to the Asserted Patents.

87. WO 2007/142118 ("WO '118") was published on December 13, 2007 and is prior art to the Asserted Patents.

88. WO 2008/004900 ("WO '900") was published on January 10, 2008 and is prior art to the Asserted Patents.

89. American Heart Association, *Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report*, 106 Circulation 3143 (2002) was published in 2002 and is prior art to the Asserted Patents.

90. Agren et al., *Fish Diet, Fish Oil and Docosahexaenoic Acid Rich Oil Lower Fasting and Postprandial Plasma Lipid Levels*, 50 European J. Clinical Nutrition 765 (1996) was published in 1996 and is prior art to the Asserted Patents.

91. Oh et al., *Management of Hypertriglyceridemia*, 75 American Family Physician 1365 (2007) was published in 2007 and is prior art to the Asserted Patents.

92. Isley et al., *Pilot Study of Combined Therapy With ω -3 Fatty Acids and Niacin in Atherogenic Dyslipidemia*, 1 J. Clinical Lipidology 211 (2007) was published in 2007 and is prior art to the Asserted Patents.

93. McLennan et al., *The cardiovascular protective role of docosahexaenoic acid*, 300 European J. Pharmacology 83 (1996) was published in 1996 and is prior art to the Asserted Patents.

94. Bays et al., *Prescription Omega-3 Fatty Acids and Their Lipid Effects: Physiologic Mechanisms of Action and Clinical Implications*, 6 Expert Reviews Cardiovascular Therapy 391 (2008) was published in 2008 and is prior art to the Asserted Patents.

95. Bays, *Rationale for Prescription Omega-3-Acid Ethyl Ester Therapy for Hypertriglyceridemia: A Primer for Clinicians*, 44 Drugs of Today 205 (2008) was published in 2008 and is prior art to the Asserted Patents.

96. Mori et al., *Effect of Eicosapentaenoic Acid and Docosahexaenoic Acid on Oxidative Stress and Inflammatory Markers in Treated-Hypertensive Type 2 Diabetic Subjects*, 35 Free Radic. Biol. Med. 772 (2003) was published in 2003 and is prior art to the Asserted Patents.

97. Rambjor et al., *Eicosapentaenoic Acid Is Primarily Responsible for Hypotriglyceridemic Effect of Fish Oil in Humans*, 31 Lipids S-45 (1996) was published in 1996 and is prior art to the Asserted Patents.

98. Balk et al., *Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: A systematic review*, 189 Atherosclerosis 19 (2006) was published in 2006 and is prior art to the Asserted Patents.

99. Woodman, et al., *Docosahexaenoic acid but not eicosapentaenoic acid increases LDL particle size in treated hypertensive type 2 diabetic patients*, 26 Diabetes Care 253 (2003) was published in 2003 and is prior art to the Asserted Patents.

1 100. Woodman, et al., *Effects of purified eicosapentaenoic acid and docosahexaenoic*
2 *acid on platelet, fibrinolytic and vascular function in Type 2 diabetic patients*, 166
3 *Atherosclerosis* 85 (2003) was published in 2003 and is prior art to the Asserted Patents.

4 101. Mori et al., *Docosahexaenoic Acid but Not Eicosapentaenoic Acid Lowers*
5 *Ambulatory Blood Pressure and Heart Rate in Humans*, 34 *Hypertension* 253 (1999) was
6 published in 1999 and is prior art to the Asserted Patents.

7 102. Nilsen et al., *Effects of a High-Dose Concentrate of n-3 Fatty Acids or Corn Oil*
8 *Introduced Early After an Acute Myocardial Infarction on Serum Triacylglycerol and HDL*
9 *Cholesterol*, 74 *Am. J. Clinical Nutrition* 50 (2001) was published in 2001 and is prior art to the
10 Asserted Patents.

11 103. Mori et al., *Differential Effects of Eicosapentaenoic Acid and Docosahexaenoic*
12 *Acid on Vascular Reactivity of the Forearm Microcirculation in Hyperlipidemic, Overweight*
13 *Men*, 102 *Circulation* 1264 (2000) was published in 2000 and is prior art to the Asserted Patents.

14 104. Austin et al., *Hypertriglyceridemia as a Cardiovascular Risk Factor*, 81 *Am. J.*
15 *Cardiology* 7B (1998) was published in 1998 and is prior art to the Asserted Patents.

16 105. Hooper et al., *Risks and Benefits of Omega 3 Fats for Mortality, Cardiovascular*
17 *Disease, and Cancer: Systematic Review*, 332 *BMJ* 752 (2006) was published in 2006 and is
18 prior art to the Asserted Patents.

19 106. Rader, *Lipid Disorders*, in *Textbook of Cardiovascular Medicine* 55 (Eric J.
20 Topol ed., 3d ed. 2007) was published in 2007 and is prior art to the Asserted Patents.

21 107. von Schacky, *A review of omega-3 ethyl esters for cardiovascular prevention and*
22 *treatment of increased blood triglyceride levels*, 2 *Vascular Health and Risk Management* 251
23 (2006) was published in 2006 and is prior art to the Asserted Patents.

24 108. Hamazaki et al., *Docosahexaenoic Acid-Rich Fish Oil Does Not Affect Serum*
25 *Lipid Concentrations of Normolipidemic Young Adults*, 126 *The Journal of Nutrition* 2784
26 (1996) was published in 1996 and is prior art to the Asserted Patents.

27 109. Conquer et al., *Supplementation with an Algae Source of Docosahexaenoic Acid*
28

1 *Increases (n-3) Fatty Acid Status and Alters Selected Risk Factors for Heart Disease in*
2 *Vegetarian Subjects*, 126 *The Journal of Nutrition* 3032 (1996) was published in 1996 and is
3 prior art to the Asserted Patents.

4 110. McKenney, *Prescription omega-3 fatty acids for the treatment of*
5 *hypertriglyceridemia*, 64 *Am. J. Health-System Pharmacy* 595 (2007) was published in 2007 and
6 is prior art to the Asserted Patents.

7 111. McKenney et al., *Role of Prescription Omega-3 Fatty Acids in the Treatment of*
8 *Hypertriglyceridemia*, 27 *Pharmacotherapy* 715 (2007) was published in 2007 and is prior art to
9 the Asserted Patents.

10 112. Center for Drug Evaluation and Research, FDA, Application Number 21-654,
11 Statistical Review(s) (2004) ("Lovaza Statistical Review") was published in 2004 and is prior art
12 to the Asserted Patents.

13 113. Center for Drug Evaluation and Research, FDA, Approval Package for
14 Application Number 21-654, Medical Review (2004) ("Lovaza Medical Review") was published
15 in 2004 and is prior art to the Asserted Patents.

16 114. Buckley et al., *Circulating triacylglycerol and apoE levels in response to EPA*
17 *and docosahexaenoic acid supplementation in adult human subjects*, 92 *British J. Nutrition*
18 477(2004) was published in 2004 and is prior art to the Asserted Patents.

19 115. Nelson et al., *The Effect of Dietary Docosahexaenoic Acid on Plasma*
20 *Lipoproteins and Tissue Fatty Acid Composition in Humans*, 32 *Lipids* 1137 (1997) was
21 published in 1997 and is prior art to the Asserted Patents.

22 116. Woodman et al., *Effects of Purified Eicosapentaenoic and Docosahexaenoic*
23 *Acids on Glycemic Control, Blood Pressure, and Serum Lipids in Type 2 Diabetic Patients with*
24 *Treated Hypertension*, 76 *Am. J. Clinical Nutrition* 1007 (2002) was published in 2002 and is
25 prior art to the Asserted Patents.

26 117. Grundy et al., *Diagnosis and Management of the Metabolic Syndrome: An*
27 *American Heart Association/Nat'l Heart, Lung, and Blood Institute Scientific Statement*, 21
28

1 Current Opinion Cardiology 1 (2006) was published in 2006 and is prior art to the Asserted
2 Patents.

3 118. Itoi, H. et al., *Comparison of the long-term effects of oral estriol with the effects*
4 *of conjugated estrogen on serum lipid profile in early menopausal women*, 36 *Maturitas* 217
5 (2000) was published in 2000 and is prior art to the Asserted Patents.

6 119. Weber et al., *Docosahexaenoic Acid Selectively Attenuates Induction of Vascular*
7 *Cell Adhesion Molecule-1 and Subsequent Monocytic Cell Adhesion to Human Endothelial Cells*
8 *Stimulated by Tumor Necrosis Factor- α* , 15 *Arteriosclerosis Thrombosis Vascular Biology* 622
9 (1995) was published in 1995 and is prior art to the Asserted Patents.

10 120. Carlson et al., *On the rise in low density and high density lipoproteins in response*
11 *to the treatment of hypertriglyceridaemia in type IV and type V hyperlipoproteinaemias*, 26
12 *Atherosclerosis* 603 (1977) was published in 1977 and is prior art to the Asserted Patents.

13 121. Mahley et al., *Drug Therapy for Hypercholesterolemia and Dyslipidemia*, in *The*
14 *Pharmacological Basis of Therapeutics* 933 (Goodman Gilman et al. eds., 11th ed. 2005) was
15 published in 2005 and is prior art to the Asserted Patents.

16 122. Grimsgaard et al., *Effects of highly purified eicosapentaenoic acid and*
17 *docosahexaenoic acid on hemodynamics in humans*, 68 *Am. J. Clin. Nutr.* 52 (1998) was
18 published in 1998 and is prior art to the Asserted Patents.

19 123. Harris, W., *Fish Oils and Plasma Lipid and Lipoprotein Metabolism in Humans:*
20 *A Critical Review*, 30 *J. Lipid Research* 785 (1989) was published in 1989 and is prior art to the
21 Asserted Patents.

22 124. Maitra et al., *Comparison of two assays for measuring LDL cholesterol*, 43
23 *Clinical Chemistry* 1040 (1997) was published in 1997 and is prior art to the Asserted Patents.

24 125. Nauck et al., *Methods for Measurement of LDL-Cholesterol: A Critical*
25 *Assessment of Direct Measurement by Homogeneous Assays versus Calculation*, 48 *Clinical*
26 *Chemistry* 236 (2002) was published in 2002 and is prior art to the Asserted Patents.

27 126. Rifai et al., *Measurement of Low-Density-Lipoprotein Cholesterol in Serum: a*
28

1 *Status Report*, 38 Clin. Chem. 150 (1992) was published in 1992 and is prior art to the Asserted
2 Patents.

3 127. Westerveld et al., Effects of Low-Dose EPA-E on Glycemic Control, Lipid
4 Profile, Lipoprotein(a), Platelet Aggregation, Viscosity, and Platelet and Vessel Wall Interaction
5 in NIDDM, 16 Diabetes Care 683 (1993) was published in 1993 and is prior art to the Asserted
6 Patents.

7 128. LOPID®, Physicians' Desk Reference 1626 (44th ed. 1990) was published in
8 1990 and is prior art to the Asserted Patents.

9 129. LOPID® Physicians' Desk Reference 2554 (58th ed. 2004) was published in
10 2004 and is prior art to the Asserted Patents.

11 130. TRICOR® Label (2004) was published in 2004 and is prior art to the Asserted
12 Patents.

13 131. TRICOR® Physicians' Desk Reference 527 (61st ed. 2007) was published in
14 2007 and is prior art to the Asserted Patents.

15 132. EP 0 273 708 A2 was issued on July 6, 1988 and is prior art to the Asserted
16 Patents.

17 133. EP 0 277 747 was issued on August 10, 1988 and is prior art to the Asserted
18 Patents.

19 134. EP 0 347 509 was issued on December 27, 1988 and is prior art to the Asserted
20 Patents.

21 135. U.S. Patent No. 5,215,630 was issued on June 1, 1993 and is prior art to the
22 Asserted Patents.

23 136. U.S. Patent No. 5,840,944 was issued on November 24, 1998 and is prior art to
24 the Asserted Patents.

25 137. U.S. Patent No. 6,303,330 was issued on November 6, 2001 and is prior art to the
26 Asserted Patents.

27 138. U.S. Patent No. 6,384,077 was issued on May 7, 2002 and is prior art to the
28

1 Asserted Patents.

2 139. U.S. Patent No. 6,846,942 was issued on January 25, 2005 and is prior art to the
3 Asserted Patents.

4 140. U.S. Patent Application Publication No. 2003/0104048 was published on June 5,
5 2003 and is prior art to the Asserted Patents.

6 141. U.S. Patent Application Publication No. 2006/0134178 was published on June 22,
7 2006 and is prior art to the Asserted Patents.

8 142. Ando, *Eicosapent Acid Reduces Plasma Levels of Remnant Lipoproteins and*
9 *Prevents in Vivo Peroxidation of LDL in Dialysis Patients*, 10 J. AM NEPHROL 2177 (1999) was
10 published in 1999 and is prior art to the Asserted Patents.

11 143. Chan et al., *Factorial study of the effects of atorvastatin and fish oil on*
12 *dyslipidaemia in visceral obesity*, 32 EUROPEAN J. OF CLINICAL INVESTIGATION 429-436 (2002)
13 was published in 2002 and is prior art to the Asserted Patents.

14 144. Contacos et al., *Effect of Pravastatin and w-3 Fatty Acids on Plasma Lipids and*
15 *Lipoproteins in Patients With Combined Hyperlipidemia*, 13 ARTERIOR THROMB VASC BIOL.
16 1755-1762 (1993) was published in 1993 and is prior art to the Asserted Patents.

17 145. Kelley et al., *Docosahexaenoic Acid Supplementation Improves Fasting and*
18 *Postprandial Lipid Profiles in Hpertriglyceridemic Men*, 86:2 CLINICAL NUTRITION 324-333
19 (2007) was published in 2007 and is prior art to the Asserted Patents.

20 146. Leigh-Firbank et al, *Eicosapentaenoic Acid and Docosahexaenic Acid from Fish*
21 *Oils: Differential Associations with Lipid Responses*, 87 BRITISH J. OF NUTRITION 435-445
22 (2002) was published in 2002 and is prior art to the Asserted Patents.

23 147. Lovegrove, et al., *Moderate Fish-oil Supplementation Reverses Low-Platelet,*
24 *Long-chain n-3 Polyunsaturated Fatty Acid Status and Reduces Plasma Triacylglycerol*
25 *Concentrations in British Indo-Asians*, 79 CLINICAL NUTRITION 974-982 (2004) was published in
26 2004 and is prior art to the Asserted Patents.

27 148. Matak, et al., *Effect of Eicosapentaenoic Acid in Combination with HMG-CoA*
28

1 *Reductase Inhibitor on Lipid Metabolism*, 5:1 INTERNATIONAL MEDICAL J. 35-36 (1998) was
2 published in 1998 and is prior art to the Asserted Patents.

3 149. Pownall, et al., *Correlation of Serum Triglyceride and Its Reduction by ω -3 Fatty*
4 *Acids with Lipid Transfer Activity and the Neutral Lipid Compositions of High-density and Low-*
5 *density Lipoproteins*, ATHEROSCLEROSIS (1998) was published in 1998 and is prior art to the
6 Asserted Patents.

7 150. Theobald, et al., *LDL Cholesterol-raising Effect of Low-dose Docosahexaenoic*
8 *Acid in Middle-aged Men and Women*, 79:4 CLINICAL NUTRITION 558-563 (2004) was published
9 in 2004 and is prior art to the Asserted Patents.

10 151. Virani and Nambi, *The Role of Lipoprotein-associated Phospholipase A2 As a*
11 *Marker for Atherosclerosis*, 9 CURRENT ATHEROSCLEROSIS REPORTS 97-103 (2007) was
12 published in 2007 and is prior art to the Asserted Patents.

13 152. Sanders, *Triglyceride-Lowering Effect of Marine Polyunsaturates in Patients with*
14 *Hypertriglyceridemia*, 5 ARTERIOSCLEROSIS 459-465 (1985) was published in 1985 and is prior
15 art to the Asserted Patents.

16 **C. NDA No. 202057**

17 153. On July 26, 2012, FDA approved NDA No. 202057 for 1 g icosapent ethyl
18 capsules.

19 154. On February 16, 2017, FDA approved a supplement to NDA No. 202057 for 500
20 mg icosapent ethyl capsules.

21 155. On March 28, 2019, Amarin submitted to FDA a supplement to NDA No.
22 202057, seeking an additional indication for VASCEPA[®] based on the results of the REDUCE-
23 IT cardiovascular outcomes study.

24 156. Amarin Pharmaceuticals Ireland Limited is the holder of NDA No. 202057.

25 157. Amarin Pharma, Inc. is Amarin Pharmaceuticals Ireland Limited's agent for
26 purposes of communication with FDA regarding NDA No. 202057.

27 158. Amarin Pharmaceuticals Ireland Limited and Amarin Pharma, Inc. market the 1 g
28

1 and 500 mg strengths of the approved drug product under the tradename VASCEPA[®].

2 **D. HIKMA'S ANDA No. 209457**

3 159. On or about September 21, 2016, Hikma Pharmaceuticals PLC and Roxane
4 Laboratories, Inc., through Roxane Laboratories, Inc., submitted to FDA an ANDA (ANDA No.
5 209457) with paragraph IV certifications under Section 505(j)(2)(A)(vii)(IV) of the FDCA, 21
6 U.S.C. § 355(j)(2)(A)(vii)(IV), seeking approval to market a generic version of Vascepa[®]
7 (icosapent ethyl) 1 g capsules as Icosapent Ethyl Capsules, 1 gram ("Hikma's ANDA Product").

8 160. Pursuant to 21 U.S.C. § 355(j)(2)(B), in a letter dated September 21, 2016, Hikma
9 Pharmaceuticals PLC and Roxane Laboratories, Inc. notified Amarin that they had submitted to
10 FDA ANDA No. 209457, with paragraph IV certifications for the Patents-in-Suit.

11 161. On or about December 8, 2016, Roxane Laboratories, Inc. transferred ANDA No.
12 209457 to West-Ward Pharmaceuticals International Limited.

13 162. On or about December 8, 2016, West-Ward Pharmaceuticals International
14 Limited appointed West-Ward Pharmaceuticals Corp. as its agent for purposes of communication
15 with FDA regarding ANDA No. 209457.

16 163. West-Ward Pharmaceuticals International Limited has changed its name to Hikma
17 Pharmaceuticals International Limited. Hikma Pharmaceuticals International Limited is now the
18 owner of ANDA No. 209457.

19 164. West-Ward Pharmaceuticals Corp. has changed its name to Hikma
20 Pharmaceuticals USA Inc. Hikma Pharmaceuticals USA Inc. remains Hikma Pharmaceuticals
21 International Limited's agent for purposes of communications with FDA regarding ANDA No.
22 209457.

23 **E. DRL'S ANDA No. 209499**

24 165. On or about September 22, 2016, DRL, through Dr. Reddy's Laboratories, Inc.,
25 submitted to FDA an ANDA (ANDA No. 209499) with paragraph IV certifications under
26 Section 505(j)(2)(A)(vii)(IV) of the FDCA, 21 U.S.C. § 355(j)(2)(A)(vii)(IV), seeking approval
27 to market a generic version of Vascepa[®] (icosapent ethyl) 1 g capsules as Icosapent Ethyl
28

1 Capsules, 1 gram (“DRL’s ANDA Product”).

2 166. Pursuant to 21 U.S.C. § 355(j)(2)(B), in a letter dated September 22, 2016, DRL
3 notified Amarin that it had submitted to FDA ANDA No. 209499, with paragraph IV
4 certifications for the Patents-in-Suit.

5 167. On or about July 11, 2018, DRL, through Dr. Reddy’s Laboratories, Inc.,
6 submitted to FDA a supplement to ANDA No. 209499 with paragraph IV certifications under
7 Section 505(j)(2)(A)(vii)(IV) of the FDCA, 21 U.S.C. § 355(j)(2)(A)(vii)(IV), for 500 mg
8 icosapent ethyl capsules purportedly bioequivalent to VASCEPA®.

9 168. Pursuant to 21 U.S.C. § 355(j)(2)(B), in a letter dated July 11, 2018, DRL notified
10 Amarin that it had submitted to FDA a supplement to ANDA No. 20499, with paragraph IV
11 certifications for the ’728, ’715, ’677, ’652, ’920, ’335, ’399, ’650, ’929, ’698, ’372, and ’594
12 patents.

13 **IV. STIPULATED FACTS**

14 For purposes of this case only, the parties stipulate to the following facts, which require
15 no proof at trial:

16 **A. VASCEPA®**

17 169. VASCEPA® contains a “pharmaceutical composition,” as required by Claims 1,
18 13, and 16 of the ’728 Patent, Claim 14 of the ’715 Patent, Claims 1, 7, and 8 of the ’677 Patent,
19 Claims 1, 7, and 8 of the ’652 Patent, and Claims 1 and 5 of the ’929 Patent.

20 170. The “pharmaceutical composition” in VASCEPA® comprises “at least about 96%,
21 by weight of all fatty acids present, ethyl eicosapentaenoate[,] and substantially no
22 docosahexaenoic acid or its esters,” as required by Claims 1, 13, and 16 of the ’728 Patent,
23 Claims 1, 7, and 8 of the ’677 Patent, and Claims 1, 7, and 8 of the ’652 Patent.

24 171. VASCEPA® contains a “pharmaceutical composition” “wherein no fatty acid of
25 the pharmaceutical composition, except for ethyl-EPA, comprises more than about 0.6% by
26 weight of all fatty acids combined,” as required by Claim 16 of the ’728 Patent.

27 172. The “pharmaceutical composition” in VASCEPA® comprises “at least about 96%
28

1 by weight, ethyl eicosapentaenoate (ethyl-EPA) and substantially no docosahexaenoic acid
2 (DHA) or its esters,” as required by Claim 14 of the ’715 Patent.

3 173. VASCEPA[®] comprises a “capsule comprising about 900 mg to about 1 g of ethyl
4 eicosapentaenoate and not more than about 3% docosahexaenoic acid or its esters, by weight of
5 total fatty acids present,” as required by Claims 4, 7, and 17 of the ’560 Patent.

6 174. The “pharmaceutical composition” in a daily dose of VASCEPA[®] comprises
7 “about 4 g of ethyl eicosapentaenoate and not more than about 4% docosahexaenoic acid or its
8 esters, by weight of all fatty acids,” as required by Claims 1 and 5 of the ’929 Patent.

9 **B. Hikma’s ANDA Product**

10 175. Hikma’s ANDA Product, if approved, will contain a “pharmaceutical
11 composition,” as required by Claims 1, 13, and 16 of the ’728 Patent, Claim 14 of the ’715
12 Patent, Claims 1, 7, and 8 of the ’677 Patent, Claims 1, 7, and 8 of the ’652 Patent, and Claims 1
13 and 5 of the ’929 Patent.

14 176. The “pharmaceutical composition” in Hikma’s ANDA Product, if approved, will
15 comprise “at least about 96%, by weight of all fatty acids present, ethyl eicosapentaenoate[,] and
16 substantially no docosahexaenoic acid or its esters,” as required by Claims 1, 13, and 16 of the
17 ’728 Patent, Claims 1, 7, and 8 of the ’677 Patent, and Claims 1, 7, and 8 of the ’652 Patent.

18 177. Hikma’s ANDA Product, if approved, will contain a “pharmaceutical
19 composition” “wherein no fatty acid of the pharmaceutical composition, except for ethyl-EPA,
20 comprises more than about 0.6% by weight of all fatty acids combined,” as required by Claim 16
21 of the ’728 Patent.

22 178. The “pharmaceutical composition” in Hikma’s ANDA Product, if approved, will
23 comprise “at least about 96% by weight, ethyl eicosapentaenoate (ethyl-EPA) and substantially
24 no docosahexaenoic acid (DHA) or its esters,” as required by Claim 14 of the ’715 Patent.

25 179. Hikma’s ANDA Product, if approved, will comprise a “capsule comprising about
26 900 mg to about 1 g of ethyl eicosapentaenoate and not more than about 3% docosahexaenoic
27 acid or its esters, by weight of total fatty acids present,” as required by Claims 4, 7, and 17 of the
28

1 '560 Patent.

2 180. The “pharmaceutical composition” in a daily dose of Hikma’s ANDA Product, if
3 approved, will comprise “about 4 g of ethyl eicosapentaenoate and not more than about 4%
4 docosahexaenoic acid or its esters, by weight of all fatty acids,” as required by Claims 1 and 5 of
5 the '929 Patent.

6 **C. DRL’s ANDA Product**

7 181. DRL’s ANDA Product, if approved, will contain a “pharmaceutical composition,”
8 as required by Claims 1, 13, and 16 of the '728 Patent, Claim 14 of the '715 Patent, Claims 1, 7,
9 and 8 of the '677 Patent, Claims 1, 7, and 8 of the '652 Patent, and Claims 1 and 5 of the '929
10 Patent.

11 182. The “pharmaceutical composition” in DRL’s ANDA Product, if approved, will
12 comprise “at least about 96%, by weight of all fatty acids present, ethyl eicosapentaenoate[,] and
13 substantially no docosahexaenoic acid or its esters,” as required by Claims 1, 13, and 16 of the
14 '728 Patent, Claims 1, 7, and 8 of the '677 Patent, and Claims 1, 7, and 8 of the '652 Patent.

15 183. DRL’s ANDA Product, if approved, will contain a “pharmaceutical composition”
16 “wherein no fatty acid of the pharmaceutical composition, except for ethyl-EPA, comprises more
17 than about 0.6% by weight of all fatty acids combined,” as required by Claim 16 of the '728
18 Patent.

19 184. The “pharmaceutical composition” in DRL’s ANDA Product, if approved, will
20 comprise “at least about 96% by weight, ethyl eicosapentaenoate (ethyl-EPA) and substantially
21 no docosahexaenoic acid (DHA) or its esters,” as required by Claim 14 of the '715 Patent.

22 185. DRL’s ANDA Product, if approved, will comprise a capsule comprising 950 mg
23 to 1050 mg of ethyl eicosapentaenoate. DRL will not assert the claim limitation from Claims 4,
24 7, and 17 of the '560 Patent that recites a “capsule comprising about 900 mg to about 1 g of ethyl
25 eicosapentaenoate” as a basis for noninfringement of Claims 4, 7, and 17 of the '560 Patent.

26 186. DRL’s ANDA Product, if approved, will comprise “a capsule comprising . . . not
27 more than about 3% docosahexaenoic acid or its esters, by weight of total fatty acids present,” as
28

1 required by Claims 4, 7, and 17 of the '560 Patent.

2 187. The "pharmaceutical composition" in a daily dose of DRL's ANDA Product, if
3 approved, will comprise "about 4 g of ethyl eicosapentaenoate and not more than about 4%
4 docosahexaenoic acid or its esters, by weight of all fatty acids," as required by Claims 1 and 5 of
5 the '929 Patent.

6 **V. UNCONTESTED FACTS**

7 The following facts, though not admitted, will not be contested at trial by evidence to the
8 contrary:

9 **A. VASCEPA[®]**

10 188. VASCEPA[®] is "indicated as an adjunct to diet to reduce triglyceride (TG) levels
11 in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia."

12 189. The dosage form for VASCEPA[®] 1-gram capsules is a "1-gram amber-colored,
13 oblong, soft-gelatin capsule."

14 190. The daily dose of VASCEPA[®] 1-gram capsules is "4 grams per day taken as . . .
15 two 1-gram capsules twice daily with food."

16 191. The active pharmaceutical ingredient in VASCEPA[®] is icosapent ethyl, which is
17 the ethyl ester of the omega-3 fatty acid, eicosapentaenoic acid ("EPA"). The terms icosapent
18 ethyl, ethyl-EPA, eicosapentaenoic acid ethyl ester, ethyl eicosapentaenoate, and ethyl
19 eicosapent are used interchangeably in this case.

20 **B. Hikma's ANDA Product**

21 192. VASCEPA[®] is the Reference Listed Drug ("RLD") for ANDA No. 209457.

22 193. The indication set forth in the proposed labeling for Hikma's ANDA Product,
23 submitted in connection with ANDA No. 209457, is "as an adjunct to diet to reduce triglyceride
24 (TG) levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia."

25 194. The dosage form of Hikma's ANDA Product, if approved, will be a 1-gram soft-
26 gelatin capsule.

27 195. The daily dose of Hikma's ANDA Product, if approved, will be 4 grams per day
28

1 taken as two 1-gram capsules twice daily with food.

2 196. Hikma's ANDA Product, if approved, will be bioequivalent to VASCEPA®.

3 197. Hikma's ANDA Product, if approved, will contain icosapent ethyl.

4 **C. DRL's ANDA Product**

5 198. VASCEPA® is the RLD for ANDA No. 209499.

6 199. The indication set forth in the proposed labeling for DRL's ANDA Product,
7 submitted in connection with ANDA No. 209499, is "as an adjunct to diet to reduce triglyceride
8 (TG) levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia."

9 200. The dosage form of DRL's ANDA Product, if approved, will be a 1-gram soft-
10 gelatin capsule.

11 201. The daily dose of DRL's ANDA Product, if approved, will be 4 grams per day
12 taken as two 1-gram capsules twice daily with food.

13 202. DRL's ANDA Product, if approved, will be bioequivalent to VASCEPA®.

14 203. DRL's ANDA Product, if approved, will contain icosapent ethyl.

15 **VI. ISSUES OF FACT FOR TRIAL**

16 204. The issues of fact listed in this section will be tried and determined upon trial. The
17 parties reserve the right to modify the below list as necessary or appropriate as the case proceeds.
18 Should the Court determine that any issue identified below as an issue of fact is more properly
19 considered an issue of law, the parties respectfully request that it be so considered.

20 **A. Plaintiffs' Proposed Issues of Fact**

21 **1. Infringement**

22 205. Whether Defendants will induce doctors and/or patients to use Hikma's ANDA
23 Products in an infringing manner.

24 206. Whether Defendants will induce doctors and/or patients to use DRL's ANDA
25 Products in an infringing manner.

26 **2. Validity**

27 207. Whether Defendants have demonstrated by clear and convincing evidence that the
28

1 Asserted Claims would have been obvious under 35 U.S.C. § 103 to a person of ordinary skill in
2 the art at the time the invention was made in view of the prior art Defendants present, including
3 whether Defendants have proved by clear and convincing evidence that the Asserted Claims are
4 obvious after consideration of objective indicia of non-obviousness.

5 208. Whether a person of ordinary skill in the art at the time of the invention would
6 have been motivated to arrive at the claimed inventions. *E.g.*:

- 7 • Whether a person of ordinary skill in the art at the time of the invention would
8 have been motivated to use 4 g/day highly purified EPA (at least 96% by
9 weight with substantially no DHA) to lower triglycerides in persons with
10 severe hypertriglyceridemia.
- 11 • Whether a person of ordinary skill in the art at the time of the invention would
12 have been motivated to use 4 g/day highly purified EPA (at least 96% by
13 weight with substantially no DHA) to lower triglycerides in persons with
14 severe hypertriglyceridemia wherein no fatty acid except for ethyl-EPA
15 comprises more than about 0.6% by weight of all fatty acids combined.

16 209. Whether a person of ordinary skill in the art at the time of the invention would
17 have had a reasonable expectation of success in arriving at the claimed inventions. *E.g.*:

- 18 • Whether a person of ordinary skill in the art at the time of the invention would
19 have reasonably expected success in using highly purified EPA (at least 96%
20 by weight with substantially no DHA) to lower triglycerides in persons with
21 severe hypertriglyceridemia without substantially increasing LDL-C.
- 22 • Whether a person of ordinary skill in the art at the time of the invention would
23 have reasonably expected success in using highly purified EPA (at least 96%
24 by weight with substantially no DHA) to lower triglycerides and to reduce
25 apolipoprotein B in persons with severe hypertriglyceridemia.
- 26 • Whether a person of ordinary skill in the art at the time of the invention would
27 have reasonably expected success in using highly purified EPA (at least 96%
28

1 by weight with substantially no DHA) to lower triglycerides and to reduce
 2 apolipoprotein B without substantially increasing LDL-C in persons with
 3 severe hypertriglyceridemia.

- 4 • Whether a person of ordinary skill in the art at the time of the invention would
 5 have reasonably expected success in using highly purified EPA (at least 96%
 6 by weight with substantially no DHA) to lower triglycerides in persons with
 7 severe hypertriglyceridemia without substantially increasing LDL-C and to
 8 reduce triglycerides by at least 25%.
- 9 • Whether a person of ordinary skill in the art at the time of the invention would
 10 have reasonably expected success in using highly purified EPA (at least 96%
 11 by weight with substantially no DHA) in persons with severe
 12 hypertriglyceridemia to effect a statistically significant reduction in
 13 triglycerides and apolipoprotein B without effecting a statistically significant
 14 increase in LDL-C.
- 15 • Whether a person of ordinary skill in the art at the time of the invention would
 16 have reasonably expected success in using highly purified EPA (with not
 17 more than 3% DHA) to reduce triglycerides by at least about 10% without
 18 increasing LDL-C by more than 5% in persons with severe
 19 hypertriglyceridemia.
- 20 • Whether a person of ordinary skill in the art at the time of the invention would
 21 have reasonably expected success in using highly purified EPA (with not
 22 more than 3% DHA) to reduce triglycerides by at least about 20% without
 23 increasing LDL-C in persons with severe hypertriglyceridemia.

24 210. Whether there was a small, finite number of identified and predictable solutions to
 25 treat patients with very-high TGs, and whether a person of ordinary skill in the art would have
 26 been motivated to choose highly purified EPA (at least 96% by weight with substantially no
 27 DHA) with a reasonable expectation of success in arriving at the claimed inventions.

211. Whether the Asserted Claims would have been obvious over Defendants' proposed prior art combinations (including whether the proposed combinations disclosed all elements of the Asserted Claims and whether the proposed prior art combinations would have provided motivation and a reasonable expectation of success in arriving at the claimed inventions). *E.g.*:

- Whether claim 1 of the '728 patent, claims 1 and 8 of the '677 patent, claims 1 and 8 of the '652 patent, claims 4, 7, and 17 of the '560 patent, and claims 1 and 5 of the '929 patent are invalid for obviousness over the combination of Lovaza® PDR,³ Mori 2000,⁴ and optionally Hayashi⁵ and Kurabayashi.⁶
- Whether claim 13 of the '728 patent, claim 7 of the '677 patent, and claim 7 of the '652 patent are invalid for obviousness over the combination of Lovaza® PDR, Mori 2000, Hayashi, and optionally Kurabayashi.
- Whether claim 16 of the '728 patent is invalid for obviousness over the combination of Lovaza® PDR, Mori 2000, WO '900,⁷ and optionally Hayashi and Kurabayashi.
- Whether claim 14 of the '715 patent is invalid for obviousness over the combination of the Lovaza® PDR, Mori 2000, Kurabayashi, and optionally Hayashi.
- Whether claim 4 of the '560 patent and claim 1 of the '929 patent are invalid

³ Lovaza®, Physicians' Desk Reference 2699 (62d ed. 2007).

⁴ Mori et al., *Purified Eicosapentaenoic and Docosahexaenoic Acids Have Differential Effects on Serum Lipids and Lipoproteins, LDL Particle Size, Glucose, and Insulin in Mildly Hyperlipidemic Men*, 71 Am. J. Clinical Nutrition 1085 (2000).

⁵ Hayashi et al., *Decreases in Plasma Lipid Content and Thrombotic Activity by Ethyl Icosapentate Purified from Fish Oils*, 56 Curr. Therap. Res. 24 (1995).

⁶ Kurabayashi et al., *Eicosapentaenoic Acid Effect on Hyperlipidemia in Menopausal Japanese Women*, 96 Obstet. Gynecol. 521 (2000).

⁷ WO 2008/004900, *Production of Ultrapure EPA and Polar Lipids from Largely Heterotrophic Culture* (Jan. 10, 2008).

1 for obviousness over the combination of Epadel PI 2007,⁸ Lovaza® PDR,
2 Hayashi, and optionally Mori 2000 and WO '900.

- 3 • Whether claims 7 and 17 of the '560 patent and claim 5 of the '929 patent are
4 invalid for obviousness over the combination of Epadel PI 2007, Lovaza®
5 PDR, Hayashi, and optionally Mori 2000, Kurabayashi, and WO '900.

6 212. Whether Defendants have proved that the Asserted Claims are obvious to a clear
7 and convincing standard after consideration of the following objective indicia of non-
8 obviousness:

- 9 • Whether the claimed inventions satisfied a long-felt need for a safe, well-
10 tolerated medication that lowers triglycerides in persons with severe
11 hypertriglyceridemia without substantially raising LDL-C.
- 12 • Whether the claimed inventions satisfied a long-felt need for a triglyceride-
13 lowering agent that significantly lowers cardiovascular risk over and above
14 the risk reduction provided by appropriate statin therapy.
- 15 • Whether the claimed inventions satisfied a long-felt need for a treatment for
16 diabetic patients with severe hypertriglyceridemia that does not raise LDL-C
17 and decreases apolipoprotein B.
- 18 • Whether the claimed inventions unexpectedly satisfied a long-felt need for a
19 triglyceride-lowering medication that also lowers cardiovascular disease risk
20 in diabetic patients.
- 21 • Whether others failed to develop a well-tolerated triglyceride-lowering
22 medication that avoided substantial increases in LDL-C in persons with severe
23 hypertriglyceridemia.
- 24 • Whether other attempts to make an improved omega-3 fatty acid treatment
25 following Lovaza® failed to address all of the shortcomings in existing

26
27 ⁸ Epadel Capsules 300, January 2007 Update (Version 5).

1 products.

- 2 • Whether others failed to arrive at a triglyceride-lowering medication that
- 3 significantly lowered cardiovascular risk over and above the risk reduction
- 4 provided by appropriate statin therapy.
- 5 • Whether the dramatic reduction in cardiovascular risk over and above the risk
- 6 reduction provided by appropriate statin therapy from administration of the
- 7 claimed inventions was unexpected.
- 8 • Whether the effect of lowering triglycerides in persons with severe
- 9 hypertriglyceridemia without substantially increasing LDL-C from
- 10 administration of the claimed inventions was unexpected.
- 11 • Whether the effect of lowering apolipoprotein B levels in patients with severe
- 12 hypertriglyceridemia from administration of the claimed inventions was
- 13 unexpected.
- 14 • Whether the avoidance of eructation in patients taking 4 g/day of a highly
- 15 purified omega-3 fatty acid from administration of the claimed inventions was
- 16 unexpected.
- 17 • Whether the claimed invention is unexpectedly associated with the following
- 18 beneficial physiological effects: (i) stabilization of membrane, (ii)
- 19 improvement of endothelial function, (iii) stabilization and/or regression of
- 20 plaque, and (iv) anti-inflammatory effects, including reduction of high
- 21 sensitivity C-reactive protein, which, combined, dramatically and
- 22 unexpectedly reduce cardiovascular risk over and above the risk reduction
- 23 provided by appropriate statin therapy.
- 24 • Whether there was skepticism about whether the claimed inventions could
- 25 avoid a substantial increase in LDL-C in patients with severe
- 26 hypertriglyceridemia.
- 27 • Whether there was skepticism about whether the claimed inventions could
- 28

lower apolipoprotein B levels in patients with severe hypertriglyceridemia.

- Whether there was skepticism about whether the claimed inventions could prevent coronary heart disease or otherwise reduce cardiovascular risk over and above the risk reduction provided by appropriate statin therapy.
- Whether the claimed invention has received industry praise recognizing that it lowers triglycerides in individuals with severe hypertriglyceridemia without substantially increasing LDL-C.
- Whether the claimed invention has received industry praise for its cardiovascular benefits.
- Whether the claimed invention is a commercial success.

213. Whether there is a nexus between the objective indicia of non-obviousness and the Asserted Claims.

3. Remedies

214. Whether this case is “exceptional” within the meaning of 35 U.S.C. § 285.

215. The amount of Plaintiffs’ reasonable attorney fees and costs.

216. Whether Plaintiffs are entitled to a declaration that the effective date of any FDA approval of Defendants’ ANDAs shall not be earlier than the expiration date of the Asserted Patents or any later expiration of exclusivity for the Asserted Patents to which Plaintiffs are or become entitled.

217. Whether Plaintiffs are entitled to any requested injunctive relief.

B. Defendants’ Proposed Issues of Fact

1. Noninfringement

218. Whether Plaintiffs have met their burden of proving each and every element of their claims for induced infringement.

219. Whether the proposed labeling for Defendants’ accused products not only describes an infringing use, but specifically encourages, recommends, or promotes infringement as to each and every limitation of the Asserted Claims, including, but not limited to:

- Whether the proposed labeling specifically encourages, recommends, or promotes the administration of Defendants' accused products for at least about 12 weeks, including whether "severe (≥ 500 mg/dL) hypertriglyceridemia" is necessarily "a chronic condition requiring indefinite treatment" with a drug (ECF No. 278 at 9);
- Whether the proposed labeling specifically encourages, recommends, or promotes the administration of Defendants' accused products to effect a statistically significant reduction in triglycerides and a reduction in fasting triglycerides of at least about 25%, 20%, and 10%;
- Whether the proposed labeling specifically encourages, recommends, or promotes the administration of Defendants' accused products to effect a reduction in apolipoprotein B, to effect a statistically significant reduction in apolipoprotein B, and without effecting a statistically significant increase in apolipoprotein B;
- Whether the proposed labeling specifically encourages, recommends, or promotes the administration of Defendants' accused products without increasing LDL-C, without increasing LDL-C by more than 5%, without substantially increasing LDL-C, and without effecting a statistically significant increase in LDL-C;
- Whether the proposed labeling specifically encourages, recommends, or promotes the administration of Defendants' accused products to a subject who does not receive concurrent lipid altering therapy.

220. Whether physicians will use Defendants' accused products for the use claimed in each and every Asserted Claim, including, but not limited to:

- The use of Defendants' accused products to effect a statistically significant reduction in triglycerides and a reduction in fasting triglycerides of at least about 25%, 20%, and 10%;

- The use of Defendants' accused products to effect a reduction in apolipoprotein B, to effect a statistically significant reduction in apolipoprotein B, and without effecting a statistically significant increase in apolipoprotein B;
- The use of Defendants' accused products to reduce triglycerides without increasing LDL-C, without increasing LDL-C by more than 5%, without substantially increasing LDL-C, and without effecting a statistically significant increase in LDL-C.

221. To the extent the Court construes the scope of FDA approval as a question of fact, whether Defendants are seeking FDA approval for their accused products for the use claimed in each and every Asserted Claim, including, but not limited to:

- The use of Defendants' accused products to effect a statistically significant reduction in triglycerides and a reduction in fasting triglycerides of at least about 25%, 20%, and 10%;
- The use of Defendants' accused products to effect a reduction in apolipoprotein B, to effect a statistically significant reduction in apolipoprotein B, and without effecting a statistically significant increase in apolipoprotein B;
- The use of Defendants' accused products to reduce triglycerides without increasing LDL-C, without increasing LDL-C by more than 5%, without substantially increasing LDL-C, and without effecting a statistically significant increase in LDL-C.

2. Invalidity

222. Whether the Asserted Claims are invalid as obvious, including obvious to try, is a question of law based on subsidiary factual questions, including, but not limited to:

- (1) The scope and content of the prior art (as of the alleged priority date and/or at the time the alleged invention was made); (2) the level of ordinary

skill in the pertinent art; (3) the differences between the prior art and the Asserted Claims; and (4) any alleged secondary considerations;

- Whether a person of ordinary skill in the art (as of the alleged priority date and/or at the time the alleged invention was made) would have been motivated to combine the teachings of the prior art to derive the claimed subject matter with a reasonable expectation of success;
- Whether there was a finite number of known choices in the prior art, and a reasonable expectation of success for the choice that is tried;
- Whether any secondary considerations probative of nonobviousness exist that are commensurate in scope with, and have a nexus to, the merits of the claimed invention, including whether any offered secondary consideration actually results from what is both claimed and allegedly novel in the Asserted Claims.

3. **Remedies**

223. Whether this case is “exceptional” within the meaning of 35 U.S.C. § 285.

224. The amount of Defendants’ reasonable attorney fees and costs.

225. Whether Defendants are entitled to a declaration that they will not directly, indirectly, contributorily, and/or by inducement, infringe any claim of the Patents-in-Suit.

226. Whether Defendants are entitled to a declaration that the Asserted Claims are invalid for failure to comply with one or more provisions of the Patent Act, 35 U.S.C. § 100 *et seq.*

VII. ISSUES OF LAW TO BE TRIED

227. To the extent that the parties’ Statements of Issues of Fact contain issues of law, those issues are incorporated herein by reference. Should the Court determine that any issue identified in this list as an issue of law is more properly considered an issue of fact, the parties incorporate such issues by reference into their Statement of Issues of Fact.

228. The parties agree that the cases cited in the Statements of Issues of Law are

1 exemplary only and do not preclude them from relying on additional cases in pre- and post-trial
2 briefing.

3 229. The following are issues of law to be tried and determined at trial:

4 **A. Plaintiffs' Statement of Issues of Law**

5 **1. Infringement**

6 230. Whether Amarin has proven by a preponderance of the evidence that Defendants
7 will induce doctors and/or patients to use Defendants' ANDA Products in an infringing manner.
8 *See, e.g.:*

- 9 • 35 U.S.C. § 271(b) and (e)(2);
- 10 • *Bayer AG v. Elan Pharm. Research Corp.*, 212 F.3d 1241, 1247 (Fed. Cir.
11 2000) ("Determination of a claim of infringement involves a two step inquiry.
12 First, the claims are construed, a question of law in which the scope of the
13 asserted claims is defined. Second, the claims, as construed, are compared to
14 the accused device. This is a question of fact. To prevail, the plaintiff must
15 establish by a preponderance of the evidence that the accused device infringes
16 one or more claims of the patent either literally or under the doctrine of
17 equivalents.");
- 18 • *Sunovion Pharm., Inc. v. Teva Pharm. USA, Inc.*, 731 F.3d 1271, 1278 (Fed.
19 Cir. 2013) ("Although no traditional patent infringement has occurred until a
20 patented product is made, used, or sold, under the Hatch-Waxman framework,
21 the filing of an ANDA itself constitutes a technical act of infringement for
22 jurisdictional purposes. But the ultimate infringement question is determined
23 by traditional patent law principles, and if a product that an ANDA applicant
24 is asking the FDA to approve for sale falls within the scope of an issued
25 patent, a judgment of infringement must necessarily ensue.");
- 26 • *Vanda Pharm. Inc. v. W.-Ward Pharm. Int'l Ltd.*, 887 F.3d 1117, 1126 (Fed.
27 Cir. 2018) ("Section 202 of the [Hatch-Waxman] Act, codified at 35 U.S.C.

§ 271(e)(2)(A), created an ‘artificial’ act of infringement. That provision provides in relevant part: ‘It shall be *an act of infringement* to submit . . . *an application* under section 505(j) of the Federal Food, Drug, and Cosmetic Act[, codified at 21 U.S.C. § 355(j),] . . . *for a drug* claimed in a patent or *the use of which is claimed in a patent*, . . . if the purpose of such submission is to obtain approval under such Act to engage in the commercial manufacture, use, or sale of a drug . . . claimed in a patent or the use of which is claimed in a patent before the expiration of such patent.’ It ‘facilitates the early resolution of patent disputes between generic and pioneering drug companies by providing that the mere act of filing a Paragraph IV ANDA constitutes an act of patent infringement.’ Litigation does not have to be delayed until actual sale of an accused product.” (citations omitted));

- *Abbott Labs. v. TorPharm, Inc.*, 300 F.3d 1367, 1373 (Fed. Cir. 2002) (“An infringement inquiry provoked by an ANDA filing under 35 U.S.C. § 271(e)(2)(A) is focused on the product that is likely to be sold following FDA approval. This determination is based on consideration of all relevant evidence, including the ANDA filing, other materials submitted by the accused infringer to the FDA, and other evidence provided by the parties.”);
- *Eli Lilly & Co. v. Teva Parenteral Medicines, Inc.*, 845 F.3d 1357, 1364 (Fed. Cir. 2017) (“A patentee seeking relief under § 271(e)(2) bears the burden of proving infringement by a preponderance of the evidence.”);
- *O2 Micro Int’l Ltd. v. Beyond Innovation Tech. Co., Ltd.*, 449 F. App’x 923, 928 (Fed. Cir. 2011) (“A patentee may prove infringement by direct or circumstantial evidence, *Lucent Technologies, Inc. v. Gateway, Inc.*, 580 F.3d 1301, 1318 (Fed. Cir. 2009); a patentee is not required to present direct evidence of infringement, *Symantec Corp. v. Computer Associates International, Inc.*, 522 F.3d 1279, 1293 (Fed. Cir. 2008). . . . Nor is a

1 patentee required to prove direct infringement to a complete certainty. A
2 patentee is only required to prove direct infringement by a preponderance of
3 the evidence—that is more likely than not that the direct infringement
4 occurred. *Lucent*, 580 F.3d at 1317–18.”);

- 5 • *Barry v. Medtronic, Inc.*, 914 F.3d 1310, 1334 (Fed. Cir. 2019) (“‘The
6 patentee must also show that the alleged infringer possessed the requisite
7 intent to induce infringement, which we have held requires that the alleged
8 infringer knew or should have known his actions would induce actual
9 infringements.’ ‘Circumstantial evidence can support a finding of specific
10 intent to induce infringement.’ ‘[I]nducement can be found where there is
11 [e]vidence of active steps taken to encourage direct infringement, which can
12 in turn be found in advertising an infringing use or instructing how to engage
13 in an infringing use.’” (citations omitted));
- 14 • *Global-Tech Appliances, Inc. v. SEB S.A.*, 563 U.S. 754, 766 (2011) (“Induced
15 infringement under § 271(b) requires knowledge that the induced acts
16 constitute patent infringement.”);
- 17 • *Warsaw Orthopedic, Inc. v. NuVasive, Inc.*, 824 F.3d 1344, 1347 (Fed. Cir.
18 2016) (“*Commil*, in reaffirming *Global-Tech*, also necessarily reaffirmed that
19 willful blindness can satisfy the knowledge requirement for active inducement
20 under § 271(b) . . . even in the absence of actual knowledge. *Global-Tech*
21 also held that knowledge of infringement can be inferred from circumstantial
22 evidence. In this respect, *Global-Tech* affirmed the Supreme Court’s and our
23 court’s earlier precedents, which held that the ‘requisite intent to induce
24 infringement may be inferred from all of the circumstances.’” (citations
25 omitted));
- 26 • *Vanda Pharm. Inc.*, 887 F.3d at 1129 (“Circumstantial evidence can support a
27 finding of specific intent to induce infringement. We have held that
28

1 ‘[i]nducement can be found where there is ‘[e]vidence of active steps taken to
2 encourage direct infringement,’ which can in turn be found in ‘advertising an
3 infringing use or instructing how to engage in an infringing use.’ Where ‘the
4 proposed label instructs users to perform the patented method . . . the
5 proposed label may provide evidence of [the ANDA applicant’s] affirmative
6 intent to induce infringement.’ When proof of specific intent depends on the
7 label accompanying the marketing of a drug inducing infringement by
8 physicians, ‘[t]he label must encourage, recommend, or promote
9 infringement.’ The contents of the label itself may permit the inference of
10 specific intent to encourage, recommend, or promote infringement.” (citations
11 omitted));

- 12 • *Sanofi v. Watson Labs. Inc.*, 875 F.3d 636, 644 (Fed. Cir. 2017) (“This court
13 has accordingly explained that, for a court to find induced infringement, ‘[i]t
14 must be established that the defendant possessed specific intent to encourage
15 another’s infringement.’ The court has articulated certain necessary
16 conditions: the plaintiff must show ‘that the alleged infringer’s actions
17 induced infringing acts and that he knew or should have known his actions
18 would induce actual infringements.’ And the court has repeatedly explained
19 that, for the finder of fact to find the required intent to encourage, ‘[w]hile
20 proof of intent is necessary, direct evidence is not required; rather,
21 circumstantial evidence may suffice.’ When proof of intent to encourage
22 depends on the label accompanying the marketing of a drug, ‘[t]he label must
23 encourage, recommend, or promote infringement.’” (citations omitted));
- 24 • *Eli Lilly & Co. v. Actavis Elizabeth LLC*, 435 F. App’x 917, 926 (Fed. Cir.
25 2011) (the Federal Circuit has “long held that the sale of a product specifically
26 labeled for use in a patented method constitutes inducement to infringe that
27 patent, and usually it is also contributory infringement.”);

- 1 • *Eli Lilly & Co.*, 845 F.3d, at 1363–64 (“When the alleged inducement relies
2 on a drug label’s instructions, ‘[t]he question is not just whether [those]
3 instructions describ[e] the infringing mode, . . . but whether the instructions
4 teach an infringing use *such that* we are willing to infer from those
5 instructions an affirmative intent to infringe the patent.’ ‘The label must
6 encourage, recommend, or promote infringement.’”(citations omitted));
- 7 • *Vanda Pharm. Inc.*, 887 F.3d at 1131 (what the label encourages,
8 recommends, or promotes is interpreted from the perspective of the health
9 care practitioner; and relying on the “Dosage and Administration” and
10 “Pharmacokinetics” sections of a label to affirm a finding of induced
11 infringement);
- 12 • *Sanofi v. Lupin Atl. Holdings S.A.*, 282 F. Supp. 3d 818, 827–28 (D. Del.
13 2017) (the label is interpreted from the perspective of a practicing clinician);
- 14 • *Bayer Schering Pharma AG v. Lupin, Ltd.*, 676 F.3d 1316, 1324 (Fed. Cir.
15 2012) (when alleged inducement relies on a drug label, the question is
16 whether “the label, taken in its entirety,” encourages, recommends, or
17 promotes an infringing use);
- 18 • *Sanofi.*, 875 F.3d at 645–46 (relying on the “Clinical Studies” section of a
19 label to affirm a finding of induced infringement);
- 20 • *Pernix Ireland Pain DAC v. Alvogen Malta Operations Ltd.*, 323 F. Supp. 3d
21 566, 585 (D. Del. 2018) (relying on the “Pharmacokinetics” section and
22 “dosing instructions and clinical data” in a label to find induced
23 infringement);
- 24 • *Eli Lilly & Co.*, 845 F.3d at 1369 (“[E]vidence that the product labeling that
25 Defendants seek would inevitably lead some physicians to infringe establishes
26 the requisite intent for inducement.”);
- 27 • *Bayer Schering Pharma AG*, 676 F.3d at 1323–24 (finding no induced
28

1 infringement of method requiring physician to administer a contraceptive drug
2 to simultaneously cause three effects in a patient in need of all three effects,
3 because the drug was indicated only for one effect (*i.e.*, the contraceptive
4 effect); but contrasting that patent with a hypothetical patent that “claim[s] a
5 method of achieving a contraceptive effect in a patient in need of
6 contraception in which the drug used to achieve the contraceptive effect has
7 two generally beneficial additional effects”); *see also* Summary Judgment
8 Order at 14–15, *Amarin Pharma, Inc. v. W.-Ward Pharma. Int’l Ltd.*, Case
9 No. 2:16-cv-02525-MMD-NJK, ECF No. 278, 2019 WL 5576940, at *8 (D.
10 Nev. Oct. 28, 2019) (“The Court agrees with Plaintiffs. Again, the Court
11 cannot ignore at this stage the expert testimony Plaintiffs point to indicating
12 that a doctor who administers Vascepa with the primary purpose of reducing
13 triglycerides, but also because there are additional benefits, would still be
14 using Vascepa in an ‘on label’ way. And *Bayer* does not require otherwise.
15 The patent in *Bayer* was ‘narrowly focused on simultaneously achieving three
16 effects in premenopausal or menopausal patients in need of all three effects; as
17 the parties stipulated, the claim limitation referring to a ‘patient in need
18 thereof’ means a patient with a ‘perceived need for’ all three effects.’ *Bayer*,
19 676 F.3d at 1323. The patents at issue here are all focused on a method for
20 reducing triglyceride levels in a particular patient population by giving that
21 patient a particular drug composition for at least 12 weeks. *See, e.g.*, Claim 1
22 of the ’728 Patent. The benefits described and claimed in the Other Health
23 Benefit Claims are merely additional benefits—nothing in the patent requires
24 that a doctor only prescribe a drug because a patient has a perceived need for
25 both the primary and additional benefits. Thus, the Court agrees with
26 Plaintiffs that the patents at issue here are more similar to the hypothetical
27 situation described for contrast in *Bayer*, than the patent claims at issue in
28

Bayer.” (ECF citations omitted)).

2. Validity

231. Whether Defendants have proven invalidity of the Asserted Claims by a showing of clear and convincing evidence. An issued patent enjoys a presumption of validity under 35 U.S.C. § 282. In order to overcome the presumption of validity, Defendants bear the burden of proving invalidity by clear and convincing evidence. *Microsoft Corp. v. i4i Ltd. Partnership*, 564 U.S. 91, 95 (2011). That burden is constant and does not shift at any time to the patent owner. *Id.* at 97.

232. The only validity issue remaining in the case is whether the Asserted Claims are invalid for obviousness under 35 U.S.C. § 103. *See supra* ¶¶ 21–23.

233. Whether Defendants, as the patent challengers, have proven by clear and convincing evidence that the Asserted Claims would have been obvious to a person of ordinary skill in the art at the time of the invention. *See, e.g.*:

- *Graham v. John Deere Co. of Kansas City*, 383 U.S. 1, 17 (1966) (holding that whether a patent claim is obvious is ultimately a question of law based on four underlying facts: (1) “the scope and content of the prior art”; (2) “the level of ordinary skill in the pertinent art”; (3) “the differences between the prior art and the claims at issue”; and (4) “[s]uch secondary considerations as commercial success, long-felt but unsolved need, and the failure of others”);
- *Procter & Gamble Co. v. Teva Pharm. USA, Inc.*, 566 F.3d 989, 994 (Fed. Cir. 2009) (“A party seeking to invalidate a patent based on obviousness must demonstrate ‘by clear and convincing evidence that a skilled artisan would have been motivated to combine the teachings of the prior art references to achieve the claimed invention, and that the skilled artisan would have had a reasonable expectation of success in doing so.’”) (quoting *Pfizer, Inc. v. Apotex, Inc.*, 480 F.3d 1348, 1361 (Fed. Cir. 2007));
- *KSR Int’l Co. v. Teleflex Inc.*, 550 U.S. 398, 421 (2007) (a fact-finder must

guard against hindsight bias and “be cautious of arguments reliant upon *ex post* reasoning”) (citing *Graham*, 383 U.S. at 36);

- *In re Suong-Hyu Hyon*, 679 F.3d 1363, 1371 (Fed. Cir. 2012) (Judge Newman, dissenting) (“It is impermissible to use the claimed invention as an instruction manual or ‘template’ to piece together the teaching of the prior art so that the claimed invention is obvious.”) (citing *In re Fritch*, 972 F.2d 1260, 1266 (Fed. Cir. 1992));
- *In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litig.*, 676 F.3d 1063, 1072 (Fed. Cir. 2012) (“Evidence of obviousness, especially when that evidence is proffered in support of an ‘obvious-to-try’ theory, is insufficient unless it indicates that the possible options skilled artisans would have encountered were ‘finite,’ ‘small,’ or ‘easily traversed,’ and that skilled artisans would have had a reason to select the route that produced the claimed invention.”) (quoting *Ortho-McNeil Pharm., Inc. v. Mylan Labs., Inc.*, 520 F.3d 1358, 1364 (Fed. Cir. 2008));
- *Leo Pharm. Prods., Ltd. v. Rea*, 726 F.3d 1346, 1357 (Fed. Cir. 2013) (holding that a pharmaceutical formulation was not obvious to try where even if it was obvious to experiment with different options, “there is nothing to indicate that a skilled artisan would have had a reasonable expectation that such an experiment would succeed in being therapeutically effective.”) (quoting *Cyclobenzaprine*, 676 F.3d at 1070).

234. Part of the obviousness inquiry will consider whether objective indicia of non-obviousness support the Asserted Claims. Here, the Asserted Claims are supported by evidence of satisfaction of long-felt but unmet needs, failure of others to prepare the claimed invention, unexpected benefits created by the claimed invention, skepticism by skilled artisans, industry praise of the invention, and commercial success. *See, e.g.:*

- *Graham*, 383 U.S. at 17–18 (“Such secondary considerations as commercial

1 success, long felt but unsolved needs, failure of others, etc., might be utilized
2 to give light to the circumstances surrounding the origin of the subject matter
3 sought to be patented. As indicia of obviousness or nonobviousness, these
4 inquiries may have relevancy.”);

- 5 • *In re Rouffet*, 149 F.3d 1350, 1355 (Fed. Cir. 1998) (explaining that objective
6 evidence of nonobviousness may include copying, long felt but unsolved
7 need, failure of others, commercial success, unexpected results created by the
8 claimed invention, unexpected properties of the claimed invention, licenses
9 showing industry respect for the invention, and skepticism of skilled artisans
10 before the invention);
- 11 • *Cyclobenzaprine*, 676 F.3d at 1075 (“The district court erred, however, by
12 making its finding that the patents in suit were obvious before it considered
13 the objective considerations and by shifting the burden of persuasion to [the
14 patent-holder]. In doing so, the district court contravened this court's
15 precedent requiring that a fact finder consider all evidence relating to
16 obviousness before finding a patent invalid on those grounds, and the court
17 imposed a burden-shifting framework in a context in which none exists.”);
- 18 • *Id.* at 1079 (“The objective considerations, when considered with the balance
19 of the obviousness evidence in the record, guard as a check against hindsight
20 bias.”) (citing *Graham*, 383 U.S. at 36);
- 21 • *Pro-Mold & Tool Co., Inc. v. Great Lakes Plastics, Inc.*, 75 F.3d 1568, 1573
22 (Fed. Cir. 1996) (“It is the secondary considerations that are often the most
23 probative and determinative of the ultimate conclusion of obviousness or
24 nonobviousness.”);
- 25 • *Stratoflex, Inc. v. Aeroquip Corp.*, 713 F.2d 1530, 1538 (Fed. Cir. 1983) (“It is
26 jurisprudentially inappropriate to disregard any relevant evidence on any issue
27 in any case, patent cases included. Thus evidence rising out of the so-called
28

‘secondary considerations’ must always when present be considered en route to a determination of obviousness.”);

- *Ruiz v. A.B. Chance Co.*, 234 F.3d 654, 663 (Fed. Cir. 2000) (“Our precedent clearly establishes that the district court must make *Graham* findings before invalidating a patent for obviousness.”);
- *Leo Pharm.*, 726 F.3d at 1358 (holding that objective indicia weighed against a finding of obviousness and stating that “[o]bjective indicia of nonobviousness play a critical role in the obviousness analysis. They are ‘not just a cumulative or confirmatory part of the obviousness calculus but constitute[] independent evidence of nonobviousness.’”) (quoting *Ortho–McNeil Pharm., Inc. v. Mylan Labs., Inc.*, 520 F.3d 1358, 1365 (Fed. Cir. 2008)).

3. Remedies

235. Whether Plaintiffs are entitled to a declaratory judgment that Defendants’ making, using, selling, offering to sell, or importing the products described in Defendants’ ANDAs, or inducing such conduct, would constitute infringement of the Asserted Claims. *See, e.g.*:

- 28 U.S.C. § 2201;
- 35 U.S.C. § 271(e)(2);
- *Allergan, Inc. v. Alcon Labs.*, 324 F.3d 1322, 1330 (Fed. Cir. 2003) (§ 271(e)(2) creates an “act of infringement” based upon the filing of an ANDA, which permits the district court to exercise its jurisdiction under 28 U.S.C. § 1338(a))
- *Teva Pharm. USA, Inc. v. Novartis Pharm. Corp.*, 482 F.3d 1330, 1342 (Fed. Cir. 2007) (under 35 U.S.C. § 271, filing of an ANDA creates a “controversy” sufficient to confer jurisdiction on the district court over a declaratory judgment action).

236. Whether Plaintiffs are entitled to a permanent injunction enjoining Defendants

1 and their officers, agents, servants, employees, parents, subsidiaries, divisions, affiliates, and
 2 those persons in active concert or participation with any of them, from making, using, selling,
 3 offering to sell, or importing their ANDA Products, or inducing any such conduct, until after the
 4 expiration of the Asserted Patents, including any extensions and additional periods of
 5 exclusivity. *See, e.g.:*

- 6 • 35 U.S.C. § 271(e)(4);
- 7 • 35 U.S.C. § 283.

8 237. Whether Plaintiffs are entitled to reasonable attorney fees and costs pursuant to 35
 9 U.S.C. § 285. *See, e.g.:*

- 10 • 35 U.S.C. § 285;
- 11 • 35 U.S.C. § 271(e)(4);
- 12 • *Octane Fitness, LLC v. ICON Health & Fitness, Inc.*, 134 S. Ct. 1749, 1756
 13 (2014) (“[A]n ‘exceptional’ case is simply one that stands out from others
 14 with respect to the substantive strength of a party’s litigating position
 15 (considering both the governing law and the facts of the case) District
 16 courts may determine whether a case is ‘exceptional’ in the case-by-case
 17 exercise of their discretion, considering the totality of the circumstances.”).

18 **B. Defendants’ Statement of Issues of Law**

19 **1. Noninfringement**

20 238. Whether Plaintiffs have met their burden of proving both specific intent and
 21 action to induce infringement of each Asserted Claim—including by proving direct infringement
 22 as to each and every limitation of the Asserted Claims as construed by the Court, and by proving
 23 that the proposed labeling for Defendants’ accused products not only describes an infringing use,
 24 but specifically encourages, recommends, or promotes direct infringement as to each and every
 25 limitation of the Asserted Claims as construed by the Court.⁹ *See, e.g.,*

26
 27 ⁹ The parties have stipulated that Defendants’ accused products meet certain limitations of the

- 1 • 35 U.S.C. § 271(b) (“Whoever actively induces infringement of a patent shall
2 be liable as an infringer”);
- 3 • *Mirror Worlds, LLC v. Apple Inc.*, 692 F.3d 1351, 1358 (Fed. Cir. 2012) (“To
4 infringe a method claim, all steps of the claimed method must be
5 performed.”);
- 6 • *Creative Compounds, LLC v. Starmark Labs.*, 651 F.3d 1303, 1314 (Fed. Cir.
7 2011) (“The patentee bears the burden of proving infringement by a
8 preponderance of the evidence. If the patentee fails to meet that burden, the
9 patentee loses regardless of whether the accused comes forward with any
10 evidence to the contrary.” (quotation omitted));
- 11 • *Meyer Intellectual Properties Ltd. v. Bodum, Inc.*, 690 F.3d 1354, 1366 (Fed.
12 Cir. 2012) (“To prevail on an inducement claim, a patentee must establish
13 that: (1) there has been direct infringement; (2) the defendant, with knowledge
14 of the patent, actively and knowingly aided and abetted such direct
15 infringement. It is well-established that a finding of direct infringement is a
16 prerequisite to a finding of inducement.” (citation omitted));
- 17 • *Grunenthal GMBH v. Alkem Labs. Ltd.*, 919 F.3d 1333, 1339 (Fed. Cir. 2019)
18 (“In this case, the question of induced infringement turns on whether
19 [defendants] have the specific intent, based on the contents of their proposed
20 labels, to encourage physicians to use their proposed ANDA products to treat
21 polyneuropathic pain. In other words, we ask whether the label encourages,
22 recommends, or promotes infringement.... The pertinent question is whether
23 the proposed label instructs users to perform the patented method.”)
24 (affirming judgment of no induced infringement because “the proposed

25 _____ (continued)

26 Asserted Claims in Section IV. Those limitations are the only exceptions to Plaintiffs’ burden of
27 proving infringement as to each and every limitation of the Asserted Claims at trial.

1 ANDA labels do not specifically encourage use” of the drug for
2 infringement);

- 3 • *Takeda Pharm. U.S.A., Inc. v. W.-Ward Pharm. Corp.*, 785 F.3d 625, 631
4 (Fed. Cir. 2015) (“The question is not just whether instructions describe the
5 infringing mode, but whether the instructions teach an infringing use of the
6 device *such that* we are willing to infer from those instructions an affirmative
7 intent to infringe the patent. Merely describing an infringing mode is not the
8 same as recommending, encouraging, or promoting an infringing use, or
9 suggesting that an infringing use ‘should’ be performed. The label must
10 encourage, recommend, or promote infringement. The mere existence of
11 direct infringement by physicians, while necessary to find liability for induced
12 infringement, is not sufficient for inducement. As we stated in *Warner–*
13 *Lambert* in the ANDA context, it is well-established that mere knowledge of
14 possible infringement by others does not amount to inducement; specific
15 intent and action to induce infringement must be proven.”) (quotations and
16 alterations omitted);
- 17 • *HZNP Medicines LLC v. Actavis Labs. UT, Inc.*, 940 F. 3d 680, 702 (Fed. Cir.
18 2019) (“Merely describing the infringing use, or knowing of the possibility of
19 infringement, will not suffice; specific intent and action to induce
20 infringement must be shown.”) (internal quotations omitted) (finding no
21 induced infringement where labeled instructions described all of the claimed
22 method steps, but “only require[d] the first step of th[e] method);
- 23 • *Horizon Pharma Ireland Ltd. v. Actavis Labs., UT, Inc.*, No. 14-7992
24 (NLH/AMD), Order on Summary Judgment (D.N.J. Mar. 16, 2017)
25 (“permission does not amount to encouragement”); *aff’d sub nom. HZNP*, 940
26 F. 3d 680 (Fed. Cir. 2019);
- 27 • *Warner-Lambert Co. v. Apotex Corp.*, 316 F.3d 1348, 1365 (Fed. Cir. 2003)

1 (“Especially where a product has substantial noninfringing uses, intent to
2 induce infringement cannot be inferred even when the defendant has actual
3 knowledge that some users of its product may be infringing the patent.”);

- 4 • *In re Depomed Patent Litig.*, No. 13-4057(CCC-MF), 2016 WL 7163647, at
5 *58, *69 (D.N.J. Sept. 30, 2016) (“It is not enough that a user following the
6 instructions may end up practicing the patented method”—finding no
7 induced infringement where “less than 5%” of uses were noninfringing and
8 95% of uses infringed), *aff’d sub nom. Grunenthal*, 919 F.3d 1333 (Fed. Cir.
9 2019);
- 10 • *Shire LLC v. Amneal Pharms., LLC*, No. 11-3781(SRC), 2014 WL 2861430,
11 at *5 (D.N.J. June 23, 2014) (finding no inducement where the defendants’
12 proposed label was “indifferent” to the claimed use and, “[a]t most, [the
13 defendant’s label] may be understood to permit an infringing use, but
14 permission is different from encouragement”).¹⁰

15 239. Whether Plaintiffs have met their burden of proving that Defendants are seeking
16 FDA approval for the use claimed in each and every Asserted Claim. *See, e.g.,*

- 17 • *Allergan, Inc. v. Alcon Labs., Inc.*, 324 F.3d 1322, 1332 (Fed. Cir. 2003) (“a
18 method of use patent holder may not sue an ANDA applicant for induced
19 infringement of its patent, if the ANDA applicant is not seeking FDA
20 approval for the use claimed in the patent and if the use claimed in the patent
21 is not FDA-approved”);
- 22 • *Bayer Schering Pharma AG.*, 676 F.3d at 1326 (“[T]he FDA has not
23

24 ¹⁰ *See also, e.g., Bayer Schering Pharma AG v. Lupin, Ltd.*, 676 F.3d 1316, 1319 (Fed. Cir.
25 2012); *United Therapeutics Corp. v. Sandoz, Inc.*, Nos. 12-cv-01617, 13-cv-316, 2014 WL
26 4259153, at *21 (D.N.J. Aug. 29, 2014); *Allergan, Inc. v. Alcon Labs., Inc.*, 324 F.3d 1322, 1334
27 (Fed. Cir. 2003); *AstraZeneca Pharms. LP v. Apotex Corp.*, 669 F.3d 1370, 1380 (Fed. Cir.
28 2012); *Allergan, Inc. v. Sandoz Inc.*, 2011 WL 3794364, at *6 (E.D. Tex. Aug. 25, 2011); *ICN
Pharm., Inc. v. Geneva Pharm. Tech. Corp.*, 272 F. Supp. 2d 1028, 1049 (C.D. Cal. 2003).

approved [the patented] use and th[us] the defendants cannot be held liable for infringement of the patent.”);

- *AstraZeneca Pharms. LP v. Apotex Corp.*, 669 F.3d 1370, 1379 (Fed. Cir. 2012) (“[A] patented method of using a drug can only be infringed under § 271(e)(2) by filing an ANDA that seeks approval to market the drug for that use.”);
- *Warner-Lambert*, 316 F.3d at 1354-55 (“[I]t is not an act of infringement to submit an ANDA for approval to market a drug for a use when neither the drug nor that use is covered by an existing patent, and the patent at issue is for a use not approved under the NDA.”).

2. Invalidity

240. Whether there is clear and convincing evidence that the Asserted Claims are invalid as obvious under 35 U.S.C. § 103, including whether the Asserted Claims would have been obvious to try, based on “the level of ordinary skill in the art, the scope and content of the prior art, the differences between the claims and the prior art, motivation to modify or combine with a reasonable expectation of success, and objective indicia of nonobviousness.” *Acorda Therapeutics, Inc. v. Roxane Labs., Inc.*, 903 F.3d 1310, 1328 (Fed. Cir. 2018); *see also, e.g.*,

- 35 U.S.C. § 103(a) (“A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains.”);¹¹
- *Graham v. John Deere Co. of Kansas City*, 383 U.S. 1, 17–18 (1966) (holding

¹¹ Because the Asserted Patents claim priority to applications that predate March 16, 2013, the applicable version of the Patent Act (35 U.S.C. § 100 *et seq.*) predates the amendments enacted by the Leahy-Smith America Invents Act, Pub. L. No. 112-29, 125 Stat. 284 (2011).

1 that whether a patent claim is obvious is ultimately a question of law based on
2 four underlying facts: (1) the scope and content of the prior art; (2) the level of
3 ordinary skill in the pertinent art; (3) the differences between the prior art and
4 the claims at issue; and (4) secondary considerations);

- 5 • *KSR Int'l Co. v. Teleflex Inc.*, 550 U.S. 398, 406-07 (2007) (“When there is a
6 design need or market pressure to solve a problem and there are a finite
7 number of identified, predictable solutions, a person of ordinary skill has good
8 reason to pursue the known options within his or her technical grasp. If this
9 leads to the anticipated success, it is likely the product not of innovation but of
10 ordinary skill and common sense. In that instance the fact that a combination
11 was obvious to try might show that it was obvious.”);
- 12 • *Hoffman-La Roche Inc. v. Apotex, Inc.*, 748 F.3d 1326, 1340 (Fed. Cir. 2014)
13 (“For an invention to be obvious to try, there must be a finite number of
14 known choices in the prior art, and a reasonable expectation of success for the
15 choice that is tried.”);
- 16 • *Bayer Healthcare Pharm., Inc. v. Watson Pharm., Inc.*, 713 F.3d 1369, 1375
17 (Fed. Cir. 2013) (“With every limitation of the asserted claims thus disclosed
18 in the cited references, the question, as the district court recognized, becomes
19 whether a person of ordinary skill in the art would have been motivated to
20 combine those teachings to derive the claimed subject matter with a
21 reasonable expectation of success.”);
- 22 • *Aventis Pharma Deutschland GmbH v. Lupin Ltd.*, 499 F.3d 1292, 1301 (Fed.
23 Cir. 2007) (“[I]f it is known that some desirable property of a mixture derives
24 in whole or in part from a particular one of its components, or if the prior art
25 would provide a person of ordinary skill in the art with reason to believe that
26 this is so, the purified compound is prima facie obvious over the mixture even
27 without an explicit teaching that the ingredient should be concentrated or
28

1 purified.”);

- 2 • *Pfizer, Inc. v. Apotex, Inc.*, 480 F.3d 1348, 1364 (Fed. Cir. 2007) (“case law is
3 clear that obviousness cannot be avoided simply by a showing of some degree
4 of unpredictability in the art so long as there was a reasonable probability of
5 success”—“the expectation of success need only be reasonable, not
6 absolute”);
- 7 • *In re Huai-Hung Kao*, 639 F.3d 1057, 1068 (Fed. Cir. 2011) (“For objective
8 evidence of secondary considerations to be accorded substantial weight, its
9 proponent must establish a nexus between the evidence and the merits of the
10 *claimed invention*. Where the offered secondary consideration actually results
11 from something other than what is both claimed and *novel* in the claim, there
12 is no nexus to the merits of the claimed invention.”);
- 13 • *Asyst Techs., Inc. v. Emtrak, Inc.*, 544 F.3d 1310, 1316 (Fed. Cir. 2008)
14 (“[O]bjective evidence of non-obviousness must be commensurate in scope
15 with the claims which the evidence is offered to support.”);
- 16 • *ZUP, LLC v. Nash Mfg., Inc.*, 896 F.3d 1365, 1374 (Fed. Cir. 2018)
17 (“Obviousness is ultimately a legal determination, and a strong showing of
18 obviousness may stand even in the face of considerable evidence of secondary
19 considerations.”);
- 20 • *In re Fulton*, 391 F.3d 1195, 1200 (Fed. Cir. 2004) (“our case law does not
21 require that a particular combination must be the preferred, or the most
22 desirable, combination described in the prior art in order to provide motivation
23 for the current invention”—“a known or obvious composition does not
24 become patentable simply because it has been described as somewhat inferior
25 to some other product for the same use”) (quotation omitted).
- 26 • *Allergan, Inc. v. Apotex Inc.*, 754 F.3d 952, 967 (Fed. Cir. 2014) (“The
27 invention date is the date of conception.... While defendants bear the burden
28

of persuasion to show that the [cited] references are prior art to the [asserted] patent by clear and convincing evidence, the patentee nevertheless must meet its burden of production to demonstrate an earlier conception date.”).

3. Remedies

241. Whether Defendants are entitled to a judgment declaring that the manufacture, use, offering for sale, sale, or importation of Defendants’ ANDA Products will not induce infringement of the Asserted Claims. *See, e.g.,*

- 35 U.S. C. §§ 271(b) and (e)(2);
- *Grunenthal*, 919 F.3d at 1339; *Takeda*, 785 F.3d at 631; *HZNP*, 940 F.3d 702; *In re Depomed*, 2016 WL 7163647, at *58, *aff’d sub nom. Grunenthal*, 919 F.3d 1333; *Shire*, 2014 WL 2861430, at *5.

242. Whether Defendants are entitled to a judgment declaring that the Asserted Claims are invalid. *See, e.g.,*

- 35 U.S.C. § 103;
- *Graham*, 383 U.S. at 17–18; *Aventis*, 499 F. 3d at 1301; *Pfizer*, 480 F.3d at 1372; *Hoffman-La Roche*, 748 F.3d at 1340; *Bayer*, 713 F.3d at 1375.

243. Whether Defendants are entitled to a judgment declaring this case exceptional within the meaning of 35 U.S.C. § 285 and awarding Defendants costs and expenses. *See, e.g.,*

- 35 U.S.C. § 285;
- *Octane Fitness*, 572 U.S. at 553-54 (“The court in exceptional cases may award reasonable attorney fees to the prevailing party.”); *id.* (“[A]n ‘exceptional’ case is simply one that stands out from others with respect to the substantive strength of a party’s litigating position District courts may determine whether a case is ‘exceptional’ in the case-by-case exercise of their discretion, considering the totality of the circumstances.”).

VIII. EXHIBITS AND DEPOSITIONS

A. Exhibits

244. Plaintiffs' list of pre-marked exhibits that they intend to offer at trial, except solely for purposes of impeachment, is attached as Exhibit A. Inclusion of an exhibit on this list shall not be construed as an agreement or admission that the document can be properly introduced into evidence by any party. Defendants' objections to Plaintiffs' exhibits are also found in this exhibit (Exhibit A).

245. Defendants' list of pre-marked exhibits that they intend to offer at trial, except solely for purposes of impeachment, is attached as Exhibit B. Inclusion of an exhibit on this list shall not be construed as an agreement or admission that the document can be properly introduced into evidence by any party. Plaintiffs' objections to Defendants' exhibits are also found in this exhibit (Exhibit B).

246. The parties reserve the right to rely on any document identified on any other party's Preliminary Trial Exhibit List. The parties agree that documents used solely for the purposes of impeachment need not be included on the exhibit list. *See* D. Nev. Local Rule 16-3(c).

247. The parties further reserve the right to revise or supplement their Preliminary Trial Exhibit Lists in light of, for example, developments concerning Amarin's sNDA, including without limitation relating to the resolution of Defendants' motion to compel (ECF No. 268) and the FDA's action on Amarin's sNDA.

248. The parties will be presenting exhibits electronically and will need a time to test the Court's audio-video equipment at the Court's convenience.

B. Presentation of Deposition Testimony

249. Subject to the Court's preferences, the parties agree that designated deposition testimony will be played live during trial via video or read into the record. Any designated deposition testimony that is played or read into the record during the trial will count against the allotted 27 hours of trial time for the party designating the testimony.

1 250. Plaintiffs may offer excerpts from the following depositions. Designations by
2 page and lines for each deposition are found in Exhibit C. Defendants' counter-designations and
3 objections to Plaintiffs' deposition designations, along with Plaintiffs' rebuttal designations and
4 objections to Defendants' counter-designations, are also found in Exhibit C. Plaintiffs reserve
5 the right to add designations from Defendants' experts if they are not called at trial.

- 6 • Jerald M. Andry
- 7 • Jaya Lakshmi Ayyagari
- 8 • Andrea Cady
- 9 • Mehar S. Manku, Ph.D.
- 10 • Ian Osterloh
- 11 • Anuj Srivastava
- 12 • Howard S. Weintraub, M.D.
- 13 • Ronald Howard Wharton, M.D.

14 251. Defendants may offer excerpts from the following depositions. Designations by
15 page and lines for each deposition are found in Exhibit D. Plaintiffs' counter-designations and
16 objections to Defendants' deposition designations, along with Defendants' rebuttal designations
17 and objections to Plaintiffs' counter-designations are also found in Exhibit D. Defendants
18 reserve the right to add designations from Plaintiffs' experts if they are not called at trial.

- 19 • Harold E. Bays, M.D.
- 20 • Aaron Berg
- 21 • Rebecca Juliano, Ph.D.
- 22 • Steven Ketchum, Ph.D.
- 23 • Philip Lavin, Ph.D.
- 24 • Mehar S. Manku, Ph.D.
- 25 • Michael Miller, M.D.
- 26 • Ian Osterloh
- 27 • Howard S. Weintraub, M.D.

- Ronald Howard Wharton, M.D.

IX. WITNESS LISTS

252. Plaintiffs may call the following witnesses live at trial¹²:

- Aaron Berg, Amarin Pharma, 440 Route 22, Bridgewater, NJ 08807.
- Rebecca A. Betensky, Ph.D., NYU College of Global Public Health, 715 Broadway, 10th Floor, New York, NY 10003.
- Matthew Budoff, M.D., Harbor-UCLA Medical Center, 1124 West Carson Street, RB-2, Torrance, CA 90502.
- Firhaad Ismail, M.D., 2470 East Flamingo Road, Suite C, Las Vegas, NV 89121.
- Rebecca Juliano, Ph.D., Amarin Pharma, 440 Route 22, Bridgewater, NJ 08807.
- Steve Ketchum, Ph.D., Amarin Pharma, 440 Route 22, Bridgewater, NJ 08807.
- Stephen G. Kunin, Maier & Maier PLLC, 345 S. Patrick Street, Alexandria, VA 22314.
- Mehar S. Manku, Ph.D., 21 Hollywood Drive, Birmingham B47 5PS, Great Britain.
- R. Preston Mason, Ph.D., Elucida Research, 100 Cummings Center, Suite 135L, Beverly, MA 01915.
- Ian Osterloh, Beechen House, Beech Hill, Bridge, Kent CT4 5AU, Great Britain.
- Carl C. Peck, M.D., 5955 Balm Ridge Way, San Luis Obispo, CA 93401.
- Peter Paul Toth, M.D., CGH Medical Center, 101 East Miller Road, Sterling,

¹² Plaintiffs have agreed to not present any testimony from Jonathan Curtis, Ph.D. at trial, whether live or by deposition, based on Defendants' agreement to the stipulated facts set forth in Section IV, above.

IL 61081.

- Custodian of records, Amarin, 440 Route 22, Bridgewater, NJ 08807.
- Custodian of records, DRL, 107 College Road East, Princeton, NJ 08540.
- Custodian of records, Hikma, 1809 Wilson Road, Columbus, OH 43228.
- Plaintiffs reserve the right not to call witnesses identified in this list, as the witness list is not a commitment that Plaintiffs will call or designate any particular witness at trial. *See* ECF No. 281, at 3 n.1.

253. Defendants may call the following witnesses live at trial¹³:

- Edward Fisher, M.D., NYU School of Medicine, 550 First Ave., New York, NY 10016.
- Nicholas Godici, 7071 Heron Cir., Carlsbad, CA 92011.
- Jay Heinecke, M.D., 2351 A Yale Ave. E., Seattle, WA 98102.
- Ivan Hofmann, Gleason IP, One Gateway Center, Suite 525, 420 Fort Duquesne Boulevard, Pittsburg, PA 15222.
- Peter Mathers, Kleinfeld, Kaplan and Becker, LLP, 1850 M Street, NW #800, Washington, D.C. 20036.
- Jonathan Sheinberg, M.D., Baylor Scott & White Healthcare, 5656 Bee Caves Rd., Bldg. M, #300, Austin, TX 78796.
- Custodian of records, Amarin, 440 Route 22, Bridgewater, NJ 08807.
- Custodian of records, DRL, 107 College Road East, Princeton, NJ 08540.
- Custodian of records, Hikma, 1809 Wilson Road, Columbus, OH 43228.
- In addition to the witnesses listed above, Defendants reserve the right to call any witness designated by Amarin to testify at trial. For any witness that is first called to testify by Amarin and then called to testify by Defendants,

¹³ Defendants will not present any testimony from John Kornak, Ph.D., at trial, whether live or by deposition.

Defendants reserve the right to examine that witness beyond the scope of Amarin's direct examination.

- Defendants also reserve the right not to call witnesses identified by Defendants, as the witness list is not a commitment that Defendants will call or designate any particular witness at trial.

X. PENDING MOTIONS *IN LIMINE*

254. Plaintiffs filed the following motions *in limine*:

- Plaintiffs' motion to exclude any testimony or evidence asserting irregularities during prosecution of the Asserted Patents, including any attack on two declarations by Philip Lavin, Ph.D., (the "Lavin Declarations").
- Plaintiffs' motion to exclude at trial any testimony, evidence, or argument that March 2008 is not the priority date of the Asserted Patents.

255. Defendants filed the following motions *in limine*:¹⁴

- Defendants' motion to exclude any testimony, evidence, or argument that relies on preclinical rat and mice studies discussed in Defendants' proposed labeling to support Amarin's claims for induced infringement.
- Defendants' motion to exclude any testimony from Amarin's FDA expert, Dr. Carl Peck, that is offered in rebuttal to testimony by Defendants' clinical non-infringement expert, Dr. Jonathan Sheinberg.

¹⁴ As noted in Paragraph 247, Defendants also have a pending motion to compel Amarin to produce its correspondence with the FDA relating to its supplemental New Drug Application, which seeks to expand the labeled indication for Amarin's branded drug product, Vascepa®, and is based on Amarin's "REDUCE-IT" clinical trial. ECF. Nos. 268, 276. Defendants' motion alternatively requests that if Amarin is not compelled to produce the requested FDA correspondence, any argument or evidence concerning REDUCE-IT should be excluded at trial. ECF No. 268 at 13 n.3. Plaintiffs have opposed Defendants' motion, *see* ECF No. 272, and disagree that the footnote in Defendants' motion was sufficient to request alternative relief. *See, e.g.*, ECF No. 272 at 10 n.6.

XI. ADDITIONAL STIPULATIONS AND PROCEDURES

256. The parties agree on the following order of proof at trial

- Plaintiffs' case-in-chief on infringement
- Defendants' rebuttal case on infringement and case-in-chief on invalidity (including objective indicia)
- Plaintiffs' rebuttal case on invalidity (including objective indicia) and infringement
- Defendants' rebuttal case on invalidity (including objective indicia).

257. Subject to the Court's discretion, trial time will be divided equally between Plaintiffs and Defendants. Each side (Plaintiffs and Defendants) will be allotted 27 hours that can be used for opening statements, presentation of evidence and cross-examination, objections, and motions at counsel's discretion.

A. Stipulations Relating to Exhibits

258. Legible photostatic or other copies of documents (or portions thereof) may be marked for identification, and offered and received in evidence at the trial, with the same force and effect as the originals, subject to correction should error appear and subject to any and all objections as could be made to the original thereof. The originals of such copies shall be available for inspection at the trial upon reasonable notice.

259. Any exhibit listed by a party may be offered as an exhibit by that party or by an adverse party, subject to appropriate evidentiary objections. Any exhibit, once admitted at trial, may be used equally by any party, subject to the Federal Rules of Evidence.

260. The parties agree that the listing of an exhibit by a party does not waive any objections that such party may have by the use of the same exhibit by another party.

261. The parties agree that any description of a document or other material on an exhibit list is provided for convenience only and shall not be used as an admission or otherwise as evidence regarding the document or material.

262. The parties agree that they will not dispute the authenticity of any document that

1 was produced during discovery, which on its face appears to have been authored by an employee
 2 or officer of a party, or by a third-party engaged by a party in the ordinary course of business,
 3 and that such documents shall be deemed *prima facie* authentic, subject to the right of the party
 4 against whom such a document is offered to adduce evidence to the contrary and subject to any
 5 contrary determination or ruling by the Court.

6 263. The parties agree that if either party removes or otherwise withdraws an exhibit
 7 from its exhibit list, the other party may amend its exhibit list to include that same exhibit. The
 8 parties also agree that the parties may make objections to such exhibit, other than an objection
 9 based on untimely listing.

10 **B. Stipulations Relating to the Discovery Confidentiality Order**

11 264. The parties agree that the trial of this action shall be conducted in open Court,
 12 absent a Court Order permitting the sealing of such proceedings. It is agreed that any party or
 13 non-party whose information is subject to the Discovery Confidentiality Order entered in this
 14 action (ECF No. 69) may request that testimony or an exhibit, subject to the Discovery
 15 Confidentiality Order, be placed under seal and handled in accordance with the Discovery
 16 Confidentiality Order.

17 265. The parties have agreed that the individuals designated as In-House Counsel in
 18 accordance with Paragraph 7(c) of the Discovery Confidentiality Order, or other In-House
 19 Counsel agreed to by the parties, may attend any closed portion of the trial. The parties also have
 20 agreed that the following individuals may attend any closed portion of the trial, but will not be
 21 subject to Paragraphs 10–11 of the Discovery Confidentiality Order due to their presence at trial.

- 22 • Joseph Kennedy, General Counsel, Amarin
- 23 • Barbara Kurys, Vice President, Intellectual Property, Amarin
- 24 • Anjum Swaroop, Vice President and Head, Intellectual Property, DRL
- 25 • Andrew Allen, Senior Director, Legal Counsel, Intellectual Property, DRL
- 26 • Deepti Jain, Director, Associate Counsel, Intellectual Property, DRL
- 27 • Samuel Park, U.S. General Counsel and Global Head of IP, Hikma

- Neema Kumar, Senior IP and Litigation Counsel, Hikma

C. Stipulations and Procedures Relating to Exchange of Witnesses, Exhibits, and Demonstratives

266. The parties will exchange by electronic mail lists of any exhibits and copies of demonstratives, slides, or deposition excerpts they intend to use in opening statements by 1:00 p.m. PT one calendar day before the intended use. If it is not feasible to exchange certain demonstratives by electronic mail due to size, the parties shall use secure FTP or other electronic media. The receiving party will identify any objections to such demonstrative exhibits, slides, or deposition excerpts to be used in opening statements no later than 7:00 p.m. PT one calendar day before the intended use. The parties will meet and confer regarding any objections by 8:00 p.m. PT the day before the intended use.

267. The parties will give one another advance notice of the witnesses they intend to call whether live or by deposition testimony, along with the exhibits and demonstratives to be used with each witness, and the order of presentation of those witnesses.

268. Unless otherwise agreed between the parties, the parties will identify via e-mail the witnesses they intend to call (whether live or by deposition) and the order in which they will be called by 7:00 p.m. PT two calendar days before the witness will testify.

269. Although the parties agree that advance exchange of exhibits and copies of demonstratives is proper, the parties disagree on the timing of the exchange. The parties' respective positions are set forth below:

1. Plaintiffs' Proposal

270. In Plaintiffs' view, advance exchange of these materials must take place by 7:00 p.m. PT two calendar days before the materials are to be used at trial. This timing ensures that the parties have sufficient time to review and fully consider the exchanged materials, raise any objections to those materials, and participate in meaningful meet and confer(s). Plaintiffs' proposed timeline thus more effectively promotes resolution of issues and is more likely to minimize the number of disputes that require the Court's intervention.

1 271. Plaintiffs therefore propose that the party presenting the witness will produce to
2 the opposing party by electronic mail (or secure FTP or electronic media as specified above) the
3 following materials by 7:00 p.m. PT two calendar days before such materials are intended to be
4 used at trial:

- 5 • A list of the exhibits that the party will use during the direct examination of
- 6 each witness identified by exhibit number; and
- 7 • A color copy of each demonstrative exhibit that the party will use during the
- 8 direct examination of each witness (except for demonstrative exhibits that will
- 9 be created live in the courtroom).

10 272. The receiving party will identify any objections to the exhibits and demonstratives
11 by 7:00 p.m. PT one calendar day before the materials are intended to be used at trial. The parties
12 will meet and confer regarding any objections by 10:00 p.m. PT before trial resumes on the
13 following day.

14 273. For example, under Plaintiffs' proposal, the parties will confirm which witnesses
15 they intend to call on Monday by Saturday at 7:00 p.m. PT, as well as identify any relevant
16 exhibits and produce copies of the demonstrative exhibits for the witnesses. The receiving party
17 will then provide any objections to the exhibits and demonstratives by Sunday at 7:00 p.m. PT,
18 and the parties will meet and confer on these objections by 10:00 p.m. PT on Sunday.

19 **2. Defendants' Proposal**

20 274. In Defendants' view, advance exchange of these materials must take place by
21 7:00 p.m. PT one calendar day before the materials are to be used at trial. This timing ensures
22 that the parties have sufficient time to finalize these materials, particularly since witnesses may
23 be rebutting testimony from the previous day. This timing further minimizes the potential for
24 disputes requiring the Court's intervention relating to changes or supplements to the
25 materials. Defendants' proposal provides sufficient time for the parties to fully consider the
26 exchanged materials, raise any objections to those materials, and participate in a meaningful
27 meet and confer.

1 begins.

2 **D. Stipulations Relating to the Presentation of Deposition Testimony at Trial**

3 280. Unless otherwise ordered by the Court, any deposition designations that a party
4 wishes to admit will be played in court or read into the record. For those depositions that have
5 been videotaped, to the extent admissible, a party may introduce the deposition excerpt by
6 videotape or by reading into the record, as requested by the Court. If a party opts to introduce
7 deposition testimony by videotape, any counter-designations of that same witness's deposition
8 testimony must also be submitted by videotape. When deposition designation excerpts are
9 introduced, all admissible deposition counter-designation excerpts, whether offered by videotape
10 or by transcript, will be introduced simultaneously in the sequence in which the testimony was
11 originally given.

12 281. If the Court intends to hear designated deposition testimony during the trial day
13 (whether read live or played by videotape), the parties will provide the Court with an objection
14 "ruling sheet" for each designated witness by 9:00 a.m. PT the day the testimony is to be
15 introduced. The ruling sheet will detail, by page and line number, any outstanding objections to
16 the proposed testimony. As the testimony is introduced, the parties will stop at the point of each
17 objection for the Court to consider and rule on the objection(s). If an objection is sustained, the
18 objected-to-testimony will not be read or played into the record.

19 282. Any designated deposition testimony that is played during the trial will count
20 against the allotted 27 hours of trial time for the party designating the testimony.

21 283. The parties will give one another advance notice of the deposition designations to
22 be introduced at trial, according to the following schedule:

- 23 • 7:00 p.m. PT two calendar days before a deposition is to be introduced, the
24 party planning to use the deposition ("party 1") provides affirmative
25 designations.
- 26 • 12:00 p.m. (noon) PT one day before the deposition is to be introduced, the
27 opposing party ("party 2") provides any objections that it maintains and any
28

counter-designations it wishes to be introduced.

- 7:00 p.m. PT one day before the deposition is to be introduced, party 1 provides any objections that it maintains with respect to any counter-designations and any rebuttal designations it wishes to be introduced. To the extent the deposition is to be played on DVD or video, party 1 also provides a DVD or video containing all of the designations. This video may be provided on DVD delivered to the other party or on an FTP site. The designations on the video will be arranged in chronological order, with any objections made on the record excised.
- 9:00 p.m. PT one day before the deposition is to be introduced, party 2 provides any objections that it maintains with respect to any rebuttal designations.
- Thereafter, the parties will meet and confer regarding any objections.

284. When exchanging deposition designations, the parties shall identify any deposition testimony that is being relied upon solely for the purpose of supporting the admissibility of a trial exhibit using the heading “For Exhibit Admissibility Only.”

285. The parties agree that any deposition testimony to be used at trial may be used whether or not transcripts of such depositions have been signed and filed pursuant to Fed. R. Civ. P. 30(e).

286. The listing of a deposition designation does not constitute an admission as to the admissibility of the testimony. Nor is it a waiver of any applicable objection.

287. If applicable, a party’s designation, counter-designation, or rebuttal designation of a page and line from a particular transcript shall be automatically deemed to include any errata indicated for that page and line in the associated errata sheets.

E. Stipulations Regarding Demonstrative Exhibits and Rule 1006

288. The parties have agreed that demonstrative exhibits, Rule 1006 exhibits not already produced in discovery, physical exhibits, specimens, and demonstrative exhibit models

that the parties intend to use at trial do not need to be included on their respective lists of trial exhibits. The notice provisions of this paragraph shall not apply to demonstrative and Rule 1006 exhibits created in the courtroom during testimony at trial or the enlargement, simple highlighting, ballooning, or excerption of trial exhibits or testimony. Plaintiffs' demonstratives will be identified with PDX numbers. Defendants' demonstratives will be identified with DDX numbers.

289. The parties have further agreed to meet and confer in good faith regarding any demonstrative exhibits, Rule 1006 exhibits, physical exhibits, specimens, and demonstrative exhibit models, in an effort to resolve any disputes or objections prior to the use of such exhibits in Court. Any disputes or objections that cannot be resolved shall be raised with the Court prior to using any such exhibits in opening statements or during examination of a witness at 8:30 a.m. PT (or at a time otherwise convenient for the Court) before trial begins on the day a party intends to use such material(s).

XII. TRIAL DATES

290. Trial is scheduled to commence before the Honorable Miranda M. Du, United States District Judge, at Las Vegas, Nevada, on January 13, 2020, at 9:00 a.m. PT. (Case No. 2:16-cv-02525, ECF No. 213.)

XIII. ESTIMATED NUMBER OF TRIAL DAYS

291. It is estimated that the trial will take a total of 9 days.

APPROVED AS TO FORM AND CONTENT:

DATED: December 6, 2019

Respectfully submitted,

/s/ Jason D. Smith

Nicholas J. Santoro (Nev. Bar No. 532)
Jason D. Smith (Nev. Bar No. 9691)
SANTORO WHITMIRE, LTD.
10100 W. Charleston Blvd., Suite 250
Las Vegas, NV 89135
Tel: (702) 948-8771 / Fax: (702) 948-8773
Email: nsantoro@santoronevada.com,
jsmith@santoronevada.com

/s/ Caroline Sun

Michael D. Rounds (Nev. Bar No. 4734)
Ryan J. Cudnik (Nev. Bar No. 12948)
**BROWNSTEIN HYATT FARBER
SCHRECK, LLP**
5371 Kietzke Lane
Reno, NV 89511
Tel.: (775) 324-4100 / Fax: (775) 333-8171
Email: mrounds@bhfs.com,
rcudnik@bhfs.com

Christopher N. Sipes (admitted *pro hac vice*)
Einar Stole (admitted *pro hac vice*)
Michael N. Kennedy (admitted *pro hac vice*)
Megan P. Keane (admitted *pro hac vice*)
Eric R. Sonnenschein (admitted *pro hac vice*)
Alaina M. Whitt (admitted *pro hac vice*)
Han Park (admitted *pro hac vice*)
Jordan L. Moran (admitted *pro hac vice*)
COVINGTON & BURLING LLP
One CityCenter, 850 Tenth Street, NW
Washington, DC 20001
Tel: (202) 662-6000 / Fax: (202) 662-6291
Email: csipes@cov.com, estole@cov.com,
mkennedy@cov.com, mkeane@cov.com,
esonnenschein@cov.com, awhitt@cov.com,
hpark@cov.com, jmoran@cov.com

*Attorneys for Plaintiffs Amarin Pharma, Inc.
and Amarin Pharmaceuticals Ireland
Limited*

/s/ Claire A. Fundakowski

W. West Allen (Nev. Bar No. 5566)

HOWARD & HOWARD

3800 Howard Hughes Parkway, Suite 1000
Las Vegas, NV 89169
Tel.: (775) 677-4843
Email: wwa@h2law.com

George C. Lombardi (admitted *pro hac vice*)
WINSTON & STRAWN LLP
35 W. Wacker Drive
Chicago, IL 60601
Tel: (312) 558-5969
Email: glombard@winston.com

Charles B. Klein (admitted *pro hac vice*)
Claire A. Fundakowski (admitted *pro hac vice*)
WINSTON & STRAWN LLP
1700 K Street N.W.
Washington, DC 20006
Tel.: (202) 282-5000
Email: cklein@winston.com,
cfundakowski@winston.com

Eimeric Reig-Plessis (admitted *pro hac vice*)
WINSTON & STRAWN LLP

Constance S. Huttner (admitted *pro hac vice*)
Frank D. Rodriguez (admitted *pro hac vice*)
Caroline Sun (admitted *pro hac vice*)
Beth Finkelstein (admitted *pro hac vice*)
**WINDELS MARX LANE &
MITTENDORF, LLP**
1 Giralda Farms, Suite 100
Madison, NJ 07940
Tel.: (973) 966-3200 / Fax: (973) 966-3250
Email: chuttner@windelsmarx.com,
frodriguez@windelsmarx.com,
csun@windelsmarx.com,
bfinkelstein@windelsmarx.com

*Attorneys for Defendants Dr. Reddy's
Laboratories, Inc. and Dr. Reddy's
Laboratories, Ltd.*

1 101 California Street
2 San Francisco, CA 94111
3 Tel.: (415) 591-6808
4 Email: ereigplessis@winston.com


5 *Attorneys for Defendants Hikma*
6 *Pharmaceuticals USA Inc. and Hikma*
7 *Pharmaceuticals International Limited*

8 **XIV. ACTION BY THE COURT**

9 This case is set for court trial on the fixed calendar on January 13, 2020, at 9:00 a.m. A
10 pretrial status conference will be held on December 17, 2019.

11 This pretrial order has been approved by the parties to this action as evidenced by the
12 signatures of their attorneys hereon, and the order is hereby entered and will govern the trial of
13 this case. This order may not be amended except by court order and based upon the parties'
14 agreement or to prevent manifest injustice.

15 DATED: December 9, 2019

16 

17 UNITED STATES DISTRICT JUDGE
18
19
20
21
22
23
24
25
26
27
28

CERTIFICATE OF SERVICE

I hereby certify that on December 6, 2019, I caused true and correct copy of **[PROPOSED] PRETRIAL ORDER** to be filed with the Clerk of the Court using the Court's CM/ECF system, and service was thereby effected electronically on the following counsel of record in this matter:

Howard & Howard Attorneys, PLLC

W. West Allen, Esq.

Email: wwa@h2law.com

Winston & Strawn LLP

George C. Lombardi

Email: glombard@winston.com

Charles Klein

Email: cklein@winston.com

Clarie A. Fundakowski

Email: cfundakowski@winston.com

Eimeric Reig-Plessis

Email: ereigplessis@winston.com

Locke Lord LLP

Alan B. Clement

Email: aclement@lockelord.com

Myoka Kim Goodin

Email: mkgoodin@lockelord.com

Nina Vachhani

Email: nvachhani@lockelord.com

Jennifer Coronel

Email: jennifer.coronel@lockelord.com

Attorneys for Defendants Hikma Pharmaceuticals USA, Inc. and Hikma Pharmaceuticals International Limited

Brownstein Hyatt Farber Schreck, LLP

Michael D. Rounds

Email: mrounds@bhfs.com

Ryan James Cudnik

Email: rcudnik@bhfs.com

Windels Marx Lane & Mittendorf, LLP

Constance S. Huttner

Email: chuttner@windelsmarx.com

Frank D. Rodriguez

Email: frrodriguez@windelsmarx.com

Caroline Sun

Email: csun@windelsmarx.com

Beth Finkelstein

Email: bfinkelstein@windelsmarx.com

James Barabas

Email: jbarabas@windelsmarx.com

Attorneys for Defendants Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.

/s/ Rachel Jenkins

An employee of Santoro Whitmire

INDEX OF EXHIBITS

- Exhibit A: Plaintiffs' Preliminary Exhibit List
- Exhibit B: Defendants' Preliminary Exhibit List
- Exhibit C: Plaintiffs' Deposition Designations
- Exhibit D: Defendants' Deposition Designations

EXHIBIT A

Plaintiffs' Preliminary Exhibit List

Exhibit A – Plaintiffs’ Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
1	335 Patent Assignment	AMRN00289793	AMRN00289803	A, C
2	372 Patent Assignment	AMRN00289862	AMRN00289868	A, C
3	372 Patent Assignment	AMRN00289869	AMRN00289870	A
4	399 Patent Assignment	AMRN00289804	AMRN00289814	A, C
5	446 Patent Assignment	AMRN00289782	AMRN00289792	A, C
6	521 Patent Assignment	AMRN00289871	AMRN00289877	A, C
7	560 Patent Assignment	AMRN00289815	AMRN00289825	A, C
8	594 Patent Assignment	AMRN00289878	AMRN00289884	A, C
9	650 Patent Assignment	AMRN00289826	AMRN00289836	A, C
10	652 Patent Assignment	AMRN00289760	AMRN00289770	A, C
11	677 Patent Assignment	AMRN00289749	AMRN00289759	A, C
12	698 Patent Assignment	AMRN00289853	AMRN00289859	A, C
13	698 Patent Assignment	AMRN00289860	AMRN00289861	A
14	715 Patent Assignment	AMRN00289738	AMRN00289748	A, C
15	728 Patent Assignment	AMRN00289727	AMRN00289737	A, C
16	920 Patent Assignment	AMRN00289771	AMRN00289781	A, C
17	929 Patent Assignment	AMRN00289844	AMRN00289850	A, C
18	929 Patent Assignment	AMRN00289851	AMRN00289852	A
19	225 Patent Assignment	AMRN00289837	AMRN00289843	A, C
20	U.S. Patent No. 8,293,727	AMRN03061427	AMRN03061447	
21	U.S. Patent No. 8,293,728	AMRN-PEXP-0000001	AMRN-PEXP-0000022	
22	U.S. Patent No. 8,318,715 & Certificate of Correction	AMRN-PEXP-0000023	AMRN-PEXP-0000045	
23	U.S. Patent No. 8,318,715 Approval of Certificate of Correction (filed Mar. 26, 2019)	AMRN-PEXP-0008411	AMRN-PEXP-0008411	
24	U.S. Patent No. 8,318,715 Request for Certificate of Correction (filed Mar. 26, 2019)	AMRN-PEXP-0008412	AMRN-PEXP-0008414	
25	U.S. Patent No. 8,357,677	AMRN-PEXP-0000046	AMRN-PEXP-0000067	

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
26	U.S. Patent No. 8,367,652	AMRN-PEXP-0000068	AMRN-PEXP-0000090	
27	U.S. Patent No. 8,377,920	AMRN-PEXP-0000091	AMRN-PEXP-0000113	
28	U.S. Patent No. 8,399,446	AMRN-PEXP-0000114	AMRN-PEXP-0000136	
29	U.S. Patent No. 8,415,335	AMRN-PEXP-0000137	AMRN-PEXP-0000160	
30	U.S. Patent No. 8,431,560	AMRN-PEXP-0000161	AMRN-PEXP-0000183	
31	U.S. Patent No. 8,518,929	AMRN-PEXP-0000184	AMRN-PEXP-0000206	
32	U.S. Patent No. 8,524,698 & Certificate of Correction	AMRN-PEXP-0000207	AMRN-PEXP-0000230	
33	U.S. Patent No. 8,426,399	N/A	N/A	NPI
34	U.S. Patent No. 8,426,399 Certificate of Correction	N/A	N/A	
35	U.S. Patent No. 8,440,650	N/A	N/A	
36	U.S. Patent No. 8,546,372	N/A	N/A	
37	U.S. Patent No. 8,617,594	N/A	N/A	
38	File History of U.S. Patent No. 8,293,727 (U.S. Patent Application No. 12/702,889)	AMRN03058106	AMRN03059969	
39	File History of U.S. Patent No. 8,293,728	AMRN00206053	AMRN00212773	
40	File History of U.S. Patent No. 8,318,715 & Certificate of Correction	AMRN00212774	AMRN00219280	
41	File History of U.S. Patent No. 8,357,677	AMRN00219281	AMRN00225724	
42	File History of U.S. Patent No. 8,367,652	AMRN00225725	AMRN00232139	
43	File History of U.S. Patent No. 8,377,920	AMRN00232140	AMRN00239831	
44	File History of U.S. Patent No. 8,399,446	AMRN00239832	AMRN00247573	
45	File History of U.S. Patent No. 8,415,335	AMRN00247574	AMRN00255303	
46	File History of U.S. Patent No. 8,426,372 ("the '372 Patent")	AMRN00288609	AMRN00288853	
47	File History of U.S. Patent No. 8,426,399 ("the '399 Patent")	AMRN00255304	AMRN00263073	
48	File History of U.S. Patent No. 8,426,594 ("the '594 Patent")	AMRN00289112	AMRN00289726	

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
49	File History of U.S. Patent No. 8,426,650 ("the '650 Patent")	AMRN00271242	AMRN00279417	
50	File History of U.S. Patent No. 8,431,560	AMRN00263074	AMRN00271241	
51	File History of U.S. Patent No. 8,518,929	AMRN00287378	AMRN00287988	
52	File History of U.S. Patent No. 8,524,698 & Certificate of Correction	AMRN00287989	AMRN00288608	
53	Harold E. Bays Decl., in file history of U.S. Patent No. 8,293,727 (U.S. Patent Application No. 12/702,889) (Jan. 8, 2012) ("Bays Decl. II")	AMRN03059316	AMRN03059331	
54	Harold E. Bays Decl., in file history of U.S. Patent No. 8,293,727 (U.S. Patent Application No. 13/349,153) (June 6, 2012) ("Bays Decl. IV")	AMRN00212350	AMRN00212359	NPI
55	Harold E. Bays Decl., in file history of U.S. Patent No. 8,293,727 (U.S. Patent Application No. 12/702,889) (May 18, 2011)	AMRN03058234	AMRN03058253	
56	Harold E. Bays Decl., in file history of U.S. Patent No. 8,293,727 (U.S. Patent Application No. 12/702,889) (May 18, 2011)	AMRN03058234	AMRN03059940	C, NPI, DUPE
57	Harold E. Bays Decl., in file history of U.S. Patent No. 8,293,727 (U.S. Patent Application No. 12/702,889) (May 8, 2012) ("Bays Decl. III")	AMRN03059815	AMRN03059823	
58	Howard Weintraub Decl., in file history of U.S. Patent No. 8,293,727 (U.S. Patent Application No. 12/702,889) (May 26, 2011) ("Weintraub Decl. I")	AMRN03058275	AMRN03058277	

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
59	Howard Weintraub Decl., in file history of U.S. Patent No. 8,293,727 (U.S. Patent Application No. 12/702,889) (Sept. 19, 2011)	AMRN03059081	AMRN03059228	
60	715 Patent Certificate of Correction (May 21, 2019)	AMRN-PEXP-0009764	AMRN-PEXP-0009764	
61	FDA Correspondence dated July 23, 2018	DRLEEPS 0097312	DRLEEPS 0097344	C, L, NPI
62	Letter from R. Krishna to Office of Generic Drugs (Aug. 29, 2018)	DRLEEPS 0137849	DRLEEPS 0137888	L
63	Manual of Patent Examining Procedure (MPEP), Eighth Edition Revisions 8 and 9, including sections cited in Report, available at http://www.uspto.gov/web/offices/pac/mp/ep/ .	N/A	N/A	H, I, R, U
64	International Patent Application No. WO 02/02105 A1	ICOSAPENT_DFNDTS00 013779	ICOSAPENT_DFNDTS00 013807	F, H, R, U
65	ANDA No. 209499 - Forms and Cover Letter (Modules 1.1-1.2)	DRLEEPS 0000001	DRLEEPS 0000034	C, L
66	ANDA No. 209499 - Administrative Information	DRLEEPS 0000035	DRLEEPS 0000056	C, L
67	ANDA No. 209499 - References (Module 1.4)	DRLEEPS 0000057	DRLEEPS 0000068	L
68	ANDA No. 209499 - Other Correspondence (Module 1.12)	DRLEEPS 0000069	DRLEEPS 0000077	C, L
69	ANDA No. 209499 - Labeling (Module 1.14)	DRLEEPS 0000078	DRLEEPS 0000162	C, L
70	ANDA No. 209499 - CTD Summaries (Module 2)	DRLEEPS 0000163	DRLEEPS 0000336	C, L

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
71	ANDA No. 209499 - Bioavailability and Bioequivalence Reports (Module 5.3)	DRLEEPA 0000337	DRLEEPA 0000357	I, L
72	ANDA No. 209499 - Quality (Module 3)	DRLEEPA 0000358	DRLEEPA 0002565	C, L, NPI
73	ANDA No. 209499 - Correspondence dated Sept. 8, 2016	DRLEEPA 0002706	DRLEEPA 0002903	C, L, NPI
74	Email from R. Srinivasa to A. Patel et al. (Nov. 9, 2017)	DRLEEPA 0097345	DRLEEPA 0097345	L, R, U
75	Letter from U. Chaudhry (FDA) to S. Rao (Nov. 9, 2017)	DRLEEPA 0097346	DRLEEPA 0097348	L, R, U
76	Email from S. Rao to R. Yalla et al. (Nov. 30, 2017)	DRLEEPA 0097349	DRLEEPA 0097349	L, R, U
77	Letter from D. Toyer McKan (FDA) to S. Rao (Nov. 29, 2017)	DRLEEPA 0097350	DRLEEPA 0097352	L, R, U
78	Letter from U. Chaudhry to S. Rao (Nov. 30, 2017)	DRLEEPA 0097353	DRLEEPA 0097357	L, R, U
79	Letter from D. Toyer McKan to S. Rao (Jan. 7, 2019)	DRLEEPA 0137834	DRLEEPA 0137838	L, R, U
80	FDA Correspondence - Form 356(h)	DRLEEPA 0137842	DRLEEPA 0137848	L
81	Email from H. La to R. Yalla (Oct. 17, 2018)	DRLEEPA 0137890	DRLEEPA 0137892	L, R, U
82	Email from D. Marchuk to R. Yalla (Nov. 14, 2018)	DRLEEPA 0137893	DRLEEPA 0137894	L, R, U
83	Email from C. Cottle-Delisle to G. Prasad (Dec. 27, 2018)	DRLEEPA 0137895	DRLEEPA 0137898	L, R, U
84	Email from S. Rao to C. Cottle-Delisle (Dec. 27, 2018)	DRLEEPA 0137899	DRLEEPA 0137901	L, R, U
85	Email from G. Prasad to C. Cottle-Delisle (Dec. 27, 2018)	DRLEEPA 0137902	DRLEEPA 0137905	L, R, U
86	Letter from D. Toyer McKan to S. Rao (Jan. 7, 2019)	DRLEEPA 0137906	DRLEEPA 0137910	L, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
87	FDA Correspondence dated July 30, 2019	DRLEEPA 0137911	DRLEEPA 0137920	L, R, U
88	Letter from R. Yalla to Office of Generic Drugs (Jul. 30, 2019)	DRLEEPA 0137921	DRLEEPA 0137922	L, R, U
89	Letter from D. Toyer McKan to S. Rao (Jan. 7, 2019)	DRLEEPA 0137923	DRLEEPA 0137927	L, R, U
90	Letter from C. Krumbholz to FDA (Jan. 24, 2019)	DRLEEPA 0137928	DRLEEPA 0137929	L, R, U
91	FDA Correspondence dated Jan. 7, 2019	DRLEEPA 0137930	DRLEEPA 0137931	L, R, U
92	FDA Correspondence dated Jan. 7, 2019 (Attachment 1)	DRLEEPA 0137932	DRLEEPA 0137982	L, R, U
93	FDA Correspondence dated Jan. 7, 2019 (Attachment 2)	DRLEEPA 0137983	DRLEEPA 0138049	L, R, U
94	Summary Report for Data Comparison of Impurities and Oligomers (July 2019)	DRLEEPA 0138050	DRLEEPA 0138081	L, R, U
95	ANDA Section 3.2: Drug Substance	DRLEEPA 0138082	DRLEEPA 0138084	L
96	Certificate of Analysis dated June 25, 2019	DRLEEPA 0138085	DRLEEPA 0138106	L
97	eCTD DTD version 3.2	DRLEEPA 0138108	DRLEEPA 0138108	L
98	Letter from D. Marchuk to S. Rao (Aug. 5, 2019)	DRLEEPA 0138109	DRLEEPA 0138110	L
99	ANDA No. 209457 - Forms and Cover Letter	WWIC0-NV-000028	WWIC0-NV-000068	C, I, L, R, U
100	ANDA No. 209457 - Administrative Information (Module 1.3)	WWIC0-NV-000069	WWIC0-NV-000084	I, L, R, U
101	ANDA No. 209457 - References (Module 1.4)	WWIC0-NV-000085	WWIC0-NV-000097	I, L, R, U
102	ANDA No. 209457 - Other Correspondence (Module 1.12)	WWIC0-NV-000098	WWIC0-NV-000103	I, L, R, U
103	ANDA No. 209457 - Labeling (Module 1.14)	WWIC0-NV-000104	WWIC0-NV-000163	I, L, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
104	ANDA No. 209457 - CTD Summaries (Module 2)	WWICO-NV-000164	WWICO-NV-000414	I, L, R, U
105	ANDA No. 209457 - Quality (Module 3)	WWICO-NV-000415	WWICO-NV-002156	I, L, R, U
106	ANDA No. 209457 - Bioavailability and Bioequivalence Reports (Module 5)	WWICO-NV-002157	WWICO-NV-002410	I, L, R, U
107	FDA Correspondence dated Sept. 7, 2016	WWICO-NV-002411	WWICO-NV-002855	C, L, R, U
108	West-Ward Certificate of Analysis Lot No. 3079110A (June 8, 2017)	WWICO-NV-099995	WWICO-NV-099995	L, R, U
109	West-Ward Certificate of Analysis Lot No. 1362418 (July 19, 2016)	WWICO-NV-099994	WWICO-NV-099994	L, R, U
110	Letter from T. Adams (FDA) to S. Smith (Hikma) (April 2017)	WWICO-NV-099952	WWICO-NV-099956	L, R, U
111	Email from T. Adams (FDA) to S. Smith (Hikma) (May 2, 2017)	WWICO-NV-099957	WWICO-NV-099957	L, R, U
112	eCTD DTD version 3.2	WWICO-NV-099958	WWICO-NV-099959	L, R, U
113	ANDA 209457 FDA Application to Market a New or Abbreviated New Drug or Biologic for Human Use (June 15, 2017)	WWICO-NV-099963	WWICO-NV-099967	L, R, U
114	Letter from S. Smith (Hikma) to T. Adams (FDA) (June 15, 2017)	WWICO-NV-099968	WWICO-NV-099969	L, R, U
115	Letter from T. Adams (FDA) to S. Smith (Hikma) (April 2017)	WWICO-NV-099970	WWICO-NV-099974	L, R, U
116	FDA ANDA Correspondence - Quality	WWICO-NV-099975	WWICO-NV-099993	L, R, U
117	Raw Material Specification	WWICO-NV-099996	WWICO-NV-099999	L, R, U
118	Supplemental Validation Report	WWICO-NV-100000	WWICO-NV-100012	L, R, U
119	Certificate of Analysis Lot No. A2008	WWICO-NV-100013	WWICO-NV-100014	L, R, U
120	Certificate of Analysis Lot No. A4001	WWICO-NV-100015	WWICO-NV-100016	L, R, U
121	Certificate of Analysis Lot No. A5005	WWICO-NV-100017	WWICO-NV-100020	L, R, U
122	Raw Material Specification	WWICO-NV-100021	WWICO-NV-100022	L, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
123	West-Ward Specification - Icosapent Ethyl Capsules, 1 gram	WWICO-NV-100023	WWICO-NV-100025	L, R, U
124	Finished Products Test Method	WWICO-NV-100026	WWICO-NV-100040	L, R, U
125	West-Ward Analytical Procedure	WWICO-NV-100041	WWICO-NV-100048	L, R, U
126	Signature Page	WWICO-NV-100049	WWICO-NV-100059	L, R, U
127	Report (June 6, 2017)	WWICO-NV-100060	WWICO-NV-100068	L, R, U
128	Dissolution Data dated June 9, 2017	WWICO-NV-100069	WWICO-NV-100082	L, R, U
129	Dissolution Data dated June 6, 2017	WWICO-NV-100083	WWICO-NV-100105	L, R, U
130	Impurity Report dated May 18, 2017	WWICO-NV-100106	WWICO-NV-100124	L, R, U
131	Report dated June 1, 2017	WWICO-NV-100125	WWICO-NV-100151	L, R, U
132	West-Ward Certificate of Analysis	WWICO-NV-100152	WWICO-NV-100154	L, R, U
133	Stability Protocol	WWICO-NV-100155	WWICO-NV-100156	L, R, U
134	Solutions Stability Summary Report	WWICO-NV-100157	WWICO-NV-100160	L, R, U
135	West-Ward Stability Data (June 6, 2017)	WWICO-NV-100161	WWICO-NV-100168	L, R, U
136	40/75 Blank Table: Icosapent Ethyl Capsules, 1 gram	WWICO-NV-100169	WWICO-NV-100170	L, R, U
137	FDA Correspondence dated June 27, 2018	WWICO-NV-162295	WWICO-NV-162299	L, R, U
138	eCTD 3.2	WWICO-NV-162310	WWICO-NV-162310	L, R, U
139	ANDA No. 209457 eCTD	WWICO-NV-162311	WWICO-NV-162311	L, R, U
140	FDA Correspondence dated Sept. 28, 2018	WWICO-NV-162312	WWICO-NV-162316	L, R, U
141	Email from C. Koukoutsis to U. Chaudhry (Sept. 28, 2018)	WWICO-NV-162317	WWICO-NV-162318	L, R, U
142	Letter from T. Adams to S. Smith (April 2017)	WWICO-NV-162319	WWICO-NV-162323	L, R, U
143	Email from T. Adams to S. Smith (May 2, 2017)	WWICO-NV-162324	WWICO-NV-162324	L, R, U
144	Letter from D. Toyer McKan to S. Smith (Oct. 25, 2017)	WWICO-NV-162325	WWICO-NV-162330	L, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
145	Letter from C. Jacobs to J. Andry (Oct. 3, 2018)	WWICO-NV-162331	WWICO-NV-162333	L, R, U
146	FDA Correspondence dated Nov. 28, 2018	WWICO-NV-162448	WWICO-NV-162452	L, R, U
147	Letter from T. Adams to J. Andry (Apr. 3, 2019)	WWICO-NV-162453	WWICO-NV-162456	L, R, U
148	FDA correspondence (undated)	WWICO-NV-162457	WWICO-NV-162458	L, R, U
149	Letter from J. Connell to T. Adams (Apr. 11, 2019)	WWICO-NV-162459	WWICO-NV-162459	L, R, U
150	FDA Correspondence dated April 11, 2019	WWICO-NV-162460	WWICO-NV-162464	L, R, U
151	Letter from D. Toyer McKan to J. Andry (Jun. 10, 2019)	WWICO-NV-162465	WWICO-NV-162469	L, R, U
152	FDA Correspondence dated July 18, 2019	WWICO-NV-162470	WWICO-NV-162474	L, R, U
153	Letter from J. Connell to C. Jacobs (Jul. 18, 2019)	WWICO-NV-162475	WWICO-NV-162475	L, R, U
154	ANDA No. 209457: Bioequivalence	WWICO-NV-162476	WWICO-NV-162480	L, R, U
155	FDA Correspondence dated July 4, 2019	WWICO-NV-162481	WWICO-NV-162487	L, R, U
156	FDA Correspondence dated June 10, 2019	WWICO-NV-162488	WWICO-NV-162493	L, R, U
157	Certificate of Analysis (July 2019)	WWICO-NV-162494	WWICO-NV-162494	L, R, U
158	Certificate of Analysis (July 2019)	WWICO-NV-162495	WWICO-NV-162495	L, R, U
159	Bhatt et al., <i>Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles</i> , J Am Coll Cardiol. 2019 Aug 27;74(8):1159-1161.	N/A	N/A	F, H, N, R, U
160	Gupta et al., <i>An update on pharmacotherapies in diabetic dyslipidemia</i> , Prog Cardiovasc Dis. 2019 Aug 20. pii: S0033-0620(19)30105-7.	N/A	N/A	F, H, N, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
161	Patel et al., <i>Cardiovascular risk reduction with icosapent ethyl</i> , Curr Opin Cardiol. 2019 Aug 28.	N/A	N/A	F, H, N, R, U
162	American Diabetes Association, <i>10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes--2019</i> , Diabetes Care 2019;42(Suppl. 1): 5103-5123	AMRN-PEXP-0008656	AMRN-PEXP-0008681	H, R, U
163	Mach et al., <i>2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk</i> , 00 European Heart Journal 1-78 (2019).	N/A	N/A	F, H, N, R, U
164	National Lipid Association, <i>NLA Position on the Use of Icosapent Ethyl in High and Very-high-risk Patients</i> , National Lipid Association (Sept. 13, 2019).	N/A	N/A	F, H, N, R, U
165	Skulas-Ray et al., <i>Omega-3 Fatty Acids for the Management of Hypertriglyceridemia</i> , 140 Circulation e673 (2019).	N/A	N/A	F, H, N, R, U
166	Corrected Opening Expert Report of Dr. Firhaad Ismail, M.D., F.A.C.E. (June 21, 2019)	N/A	N/A	F, H, R, U
167	Expert Report of Sean Nicholson (March 11, 2019)	N/A	N/A	F, H, R, U
168	Expert Report of Stephen G. Kunin (Responsive) (May 10, 2019)	N/A	N/A	F, H, R, U
169	Opening Expert Report of Dr. Firhaad Ismail, M.D., F.A.C.E. (January 9, 2019)	N/A	N/A	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
170	Opening Expert Report of Dr. Jonathan Curtis, Ph. D. (DRL/VASCEPA) (March 11, 2019)	N/A	N/A	F, H, R, U
171	Opening Expert Report of Dr. Jonathan Curtis, Ph. D. (Hikma/VASCEPA) (March 11, 2019)	N/A	N/A	F, H, R, U
172	Opening Expert Report of Dr. Matthew Budoff, M.D., Regarding DRL's ANDA Product And VASCEPA (March 11, 2019)	N/A	N/A	F, H, R, U
173	Opening Expert Report of Dr. Matthew Budoff, M.D., Regarding Hikma's ANDA Product And VASCEPA (March 11, 2019)	N/A	N/A	F, H, R, U
174	Opening Expert Report of Peter Paul Toth, M.D., Ph. D. (March 7, 2019)	N/A	N/A	F, H, R, U
175	Opening Expert Report of R. Preston Mason, Ph. D. (March 08, 2019)	N/A	N/A	F, H, R, U
176	Reply Expert Report of Firhaad Ismail, M.D., F.A.C.E. (June 10, 2019)	N/A	N/A	F, H, R, U
177	Reply Expert Report of Matthew Budoff, M.D., Regarding Defendants' ANDA Products and VASCEPA (June 10, 2019)	N/A	N/A	F, H, R, U
178	Reply Expert Report of Peter Toth, M.D., Ph.D. (June 10, 2019)	N/A	N/A	F, H, R, U
179	Reply Expert Report of R. Preston Mason, Ph.D. (June 10, 2019)	N/A	N/A	F, H, R, U
180	Reply Expert Report of Sean Nicholson (June 10, 2019)	N/A	N/A	F, H, R, U
181	Responsive Expert Report of Peter Toth, M.D., Ph. D. (May 10, 2019)	N/A	N/A	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
182	Surreply Expert Report of Rebecca A. Betensky, Ph. D. (Aug. 22, 2019)	N/A	N/A	F, H, R, U
183	Reply Expert Report of Carl C. Peck, M.D. (June 10, 2019)	N/A	N/A	F, H, R, U
184	Hikma Pharmaceuticals' Rule 26(a)(1) Initial Disclosures	N/A	N/A	L, R, U
185	Notice of 30(b)(6) Deposition	N/A	N/A	L, R, U
186	Notice of Deposition of Jerald Andry	N/A	N/A	L, R, U
187	Proposed Package Label for Icosapent Ethyl (July 2016)	WWIC0-NV-000104	WWIC0-NV-000105	L, R, U
188	Proposed Package Insert For Icosapent Ethyl (July 2016)	WWIC0-NV-000109	WWIC0-NV-000117	L, R, U
189	Side-by-Side Comparison of Insert/Outsert for Icosapent Ethyl	WWIC0-NV-000139	WWIC0-NV-000149	L, R, U
190	Highlights of Prescribing Information for VASCEPA	WWIC0-NV-000151	WWIC0-NV-000162	L, R, U
191	Correspondence between Sarah A. Smith to Rhonda Rowell (Sept. 7, 2016)	WWIC0-NV-002423	WWIC0-NV-002427	L, R, U
192	Letter from S. Smith to S. Pyon (Jan. 10, 2017)	WWIC0-NV-002805	WWIC0-NV002806	L, R, U
193	Letter from S. Pyon to S. Smith (Dec. 23, 2016)	WWIC0-NV-002807	WWIC0-NV-002809	L, R, U
194	Revised Proposed Package Label For Icosapent Ethyl (December 2016)	WWIC0-NV-002844	WWIC0-NV-002844	L, R, U
195	ANDA 209457: Labeling	WWIC0-NV-002810	WWIC0NV-002812	L, R, U
196	Email from J. Andry to T. Amann et al. (May 15, 2013)	WWICO-NV-056968	WWICO-NV-056969	L, R, U
197	FDA Correspondence (Dec. 8, 2016)	WWICO-NV-000010	WWICO-NV-000027	C, L, R, U
198	ANDA Original Application 206264 (Nov. 15, 2013)	WWICO-NV-002877	WWICO-NV-002878	L, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
199	Letter from S. Smith to T. Adams (June 15, 2017)	WWICO-NV-099968	WWICO-NV-099993	C, L, R, U
200	Email from M. Annibaldi to S. Smith et al. (Sept. 7, 2016)	WWICO-NV-107615	WWICO-NV-107618	C, L, R, U
201	FDA Form 356h West-Ward Pharmaceuticals Corp. Application For Name Change to Hikma Pharmaceuticals USA (June 27, 2018)	WWICO-NV-162295	WWICO-NV-162302	L, R, U
202	Waiver Request from Dr. Reddy's (July 25, 2016)	DRLEEPS 0000076	DRLEEPS 0000077	L, R
203	Dr. Reddy's Icosapent Ethyl Description	DRLEEPS 0000125	DRLEEPS 0000148	L
204	Icosapent Ethyl Capsules, 1g Abbreviated ANDA Quality Overall Summary	DRLEEPS 0000223	DRLEEPS 0000282	L
205	Dr. Reddy's Batch Analysis	DRLEEPS 0000868	DRLEEPS 0000958	L
206	Letter to Office of Generic Drugs from Dr. Reddy's (Jan. 4, 2017)	DRLEEPS 0002801	DRLEEPS 0002807	L
207	Icosapent Ethyl Highlights of Prescribing Information	DRLEEPS 0002827	DRLEEPS 0002838	L
208	FDA correspondence dated December 23, 2016	DRLEEPS 0002895	DRLEEPS 0002897	L
209	Letter from T. Adams (FDA) to S. Rao (April 2017)	DRLEEPS 0013771	DRLEEPS 0013775	L, R
210	Letter from Dr. Reddys to FDA dated March 29, 2013	DRLEEPS 0013799	DRLEEPS 0013804	L
211	Letter from Dr. Reddys to Office of Generic Drugs (June 15, 2017)	DRLEEPS 0016400	DRLEEPS 0016401	L
212	FDA correspondence dated April 13, 2017	DRLEEPS 0016403	DRLEEPS 0016412	L, R
213	Specification Reports	DRLEEPS 0016422	DRLEEPS 0016433	L, R
214	FDA Correspondence Dated Oct. 25, 2017	DRLEEPS 0016912	DRLEEPS 0016917	L, R

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
215	Letter to Office of Generic Drugs from Dr. Reddy's (Nov. 2, 2017)	DRLEEPA 0016935	DRLEEPA 0016942	L, R
216	Email from A. Patel to A. Karunakar et al. (May 31, 2016)	DRLEEPA 0031208	DRLEEPA 0031209	F, H, L, R, U
217	ANDA No. 205616 Correspondence from FDA (undated)	DRLEEPA 0031210	DRLEEPA 0031211	F, H, L, R, U
218	Document Produced in Native Format Placeholder	DRLEEPA 0031892	DRLEEPA 0031892	F, H, L, R, U
219	Email from S. Bhamare to H. Ahmed et al. (July 27, 2016)	DRLEEPA 0034257	DRLEEPA 0034260	F, L, R
220	Email from J. Singh to H. Ahmed (June 13, 2016)	DRLEEPA 0031890	DRLEEPA 0031891	F, L, R, U
221	ANDA Document Tracker & Related Spreadsheets	DRLEEPA 0059163	DRLEEPA 0059163	F, L, R, U
222	ANDA Document Tracker & Related Spreadsheets	DRLEEPA 0076086	DRLEEPA 0076086	F, L, R, U
223	Application to Market a New or Abbreviated New Drug or Biologic for Human Use	DRLEEPA 0095538	DRLEEPA 0095575	L
224	Email from A. Allen to U. Topiwala et al. (May 31, 2016)	DRLEEPA 0124709	DRLEEPA 0124726	F, H, L, R, U
225	Amarin's Notice of Deposition Under 30(b)(6) to DRL	N/A	N/A	L, R
226	Email from D. Shelhoff to A. Whitt et al. re: Amarin Pharma Inc. et al. v. Hikma Pharmaceuticals USA Inc. et al., 16-cv-2525 (Oct. 8, 2018)	N/A	N/A	L, R
227	Notice of Deposition of Jaya Lakshmi Ayyagari	N/A	N/A	L, R

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
228	ANDA No. 209499, Submission of ANDA Application	DRLEPA 0000024	DRLEPA 0000030	L
229	Icosapent, Ethyl Capsule 1g, <i>Finished Product Release Specifications</i>	DRLEPA 0016874	DRLEPA 0016878	L
230	USPTO Office Action Summary (March 2, 2012)	AMRN03059744	AMRN03059769	
231	Kornak V3 Coding	AMRN-PEXP-0011080	AMRN-PEXP-0011097	R, U
232	Kornak V3 Calculations	AMRN-PEXP-0011098	AMRN-PEXP-0011119	R, U
233	Kornak V5 Coding	AMRN-PEXP-0011120	AMRN-PEXP-0011131	A
234	Kornak V5 Calculations	AMRN-PEXP-0011132	AMRN-PEXP-0011145	A
235	Redline of Kornak V3 & V5 Coding	AMRN-PEXP-0011146	AMRN-PEXP-0011163	A, F, H, R, U
236	Redline of Kornak V3 & V5 Calculations	AMRN-PEXP-0011164	AMRN-PEXP-0011186	A, F, H, R, U
237	Casella & Berger, Statistical Inference (2d ed. 2002)	AMRN-PEXP-0011375	AMRN-PEXP-0012053	H, U
238	Jacobian output R	AMRN-PEXP-0012054	AMRN-PEXP-0012055	A, H, R, U
239	Jacobian code	AMRN-PEXP-0012056	AMRN-PEXP-0012057	A, H, R, U
240	Jacobian code calculations	AMRN-PEXP-0012058	AMRN-PEXP-0012059	A, H, R, U
241	lavinV5 ICOSAPENT_DFNDT 00020683.R	ICOSAPENT_DFNDT 00020683	ICOSAPENT_DFNDT 00020683	
242	lavinV3 ICOSAPENT_DFNDT 00020685.R	ICOSAPENT_DFNDT 00020685	ICOSAPENT_DFNDT 00020685	R, U
243	Email from B. Finkelstein re Corrected Reply Expert Report of John Kornak 6.13.2019	N/A	N/A	R, U
244	U.S. Centers for Disease Control National Health and Nutrition Examination Survey: Intake of Calories and Selected Nutrients for the United States Population, 1999–2000	AMRN00206048	AMRN00206049	H, R

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
245	U.S. Dept. of Agriculture, Average Daily Intake of Food by Food Source and Demographic Characteristics, 2007–10	AMRN00206050	AMRN00206052	H, R, U
246	Oh et al., <i>Management of Hypertriglyceridemia</i> , 75 American Family Physician 1365 (2007)	AMRN01200251	AMRN01200257	H, R, U
247	Amarin NDA 202057 – § 3.2.P.5 Control of Drug Product [VASCEPA, Capsules]	AMRN03137774	AMRN03137781	R, U
248	Budoff, <i>Triglycerides and Triglyceride-Rich Lipoproteins in the Causal Pathway of Cardiovascular Disease</i> , 118 Am. J. Cardiology 138 (2016)	AMRN03145671	AMRN03145678	R, U
249	American College of Cardiology CardioSmart, <i>Very High Triglycerides</i> , https://www.cardiosmart.org/Heart-Conditions/High-Cholesterol/High-Cholesterol-Home/Very-High-Triglycerides , https://www.cardiosmart.org/Heart-Conditions/High-Cholesterol/High-Cholesterol-Home/Very-High-Triglycerides	AMRN-PEXP-0000366	AMRN-PEXP-0000372	H, R
250	Wright et al., <i>Dietary Intake of Ten Key Nutrients for Public Health, United States: 1999–2000</i> , Advance Data From Vital & Health Statistics, No. 334 (Apr. 17, 2003), available at: https://www.cdc.gov/nchs/data/ad/ad334.pdf	AMRN-PEXP-0000373	AMRN-PEXP-0000376	H, R

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
251	Guyatt et al., <i>Evidence-Based Medicine: A New Approach to Teaching the Practice of Medicine</i> , 268 JAMA 2420 (1992)	AMRN-PEXP-0000377	AMRN-PEXP-0000382	H, R, U
252	Sackett et al., <i>Evidence Based Medicine: What It Is and What It Isn't</i> , 312 BMJ 71 (1996)	AMRN-PEXP-0000383	AMRN-PEXP-0000384	H, R, U
253	Budoff et al., <i>Effect of Vascepa (Icosapent Ethyl) on Progression of Coronary Atherosclerosis in Patients With Elevated Triglycerides (200–499 mg/dL) on Statin Therapy: Rationale and Design of the EVAPORATE Study</i> , 41 Clinical Cardiology 13 (2018)	AMRN-PEXP-0000385	AMRN-PEXP-0000391	R, U
254	Icosapent, Ethyl Capsule 1g, <i>Certificate of Analysis</i>	DRLEEPA 0001632	DRLEEPA 0001647	L, R, U
255	ANDA No. 209499, In-vitro - In-vivo Study Reports	DRLEEPA 0002566	DRLEEPA 0002705	L, R, U
256	ANDA No. 209499 – § 5.3 Bioavailability/Bioequivalence	DRLEEPA 0016051	DRLEEPA 0016221	L, R, U
257	FDA Correspondence dated July 10, 2018	DRLEEPA 0095538	DRLEEPA 0097311	F, L, R, U
258	Defendants Dr. Reddy's Laboratories, Inc., and Dr. Reddy's Laboratories, Ltd. Responses to Plaintiffs' First Set of Requests for Admission (Nos. 1-333), Civil No. 2:16-02525 (Oct. 15, 2018)	N/A	N/A	H, L, R, U
259	Joint Stipulation Regarding Agreement that DRL's Proposed ANDA Product Meets Certain Claim Limitations Order, ECF No. 159, Civil No. 2:16-02525 (Dec. 3, 2018)	N/A	N/A	L, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
260	Amarin, <i>Amarin Announces Market Introduction of Vascepa (icosapent ethyl) Capsules for the Treatment of Very High Triglycerides</i> (Jan. 24, 2013), https://investor.amarincorp.com/news-releases/news-release-details/amarin-announces-market-introduction-vascepar-icosapent-ethyl	WWICO-NV-074728	WWICO-NV-074730	L, R, U
261	Defendants' Responses to Plaintiffs' Requests for Admission (Nos. 1–129) (Oct. 12, 2018)	N/A	N/A	H, R, U
262	E-mail from M. Goodin to M. Kennedy et al. (Apr. 23, 2018)	N/A	N/A	L, R, U
263	Side by Side Comparison of Previously Submitted Labeling and Proposed FPL Labeling	WWIC0-NV-002845	WWIC0-NV-0028454	C, L, R, U
264	Amarin Certificate of Analysis for NDA 202057 by Banner – § 3.2.P.5 Control of Drug Product [AMR101, Capsules]	AMRN00186631	AMRN00186658	R, U
265	Berglund et al., <i>Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline 97</i> Journal of Clinical Endocrinology and Metabolism 2969 (2012)	AMRN02340783	AMRN02340803	F
266	NDA No. 202057, NDA Approval (Jul. 26, 2012)	AMRN02973175	AMRN02973191	
267	LOVAZA® Prescribing Information (2010)	AMRN03059150	AMRN03059159	H, R, U
268	Baigent et al., <i>Efficacy and Safety of Cholesterol-Lowering Treatment: Prospective Meta-Analysis of Data from</i>	AMRN03130228	AMRN03130239	H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	<i>90,056 Participants in 14 Randomised Trials of Statins</i> , 366 Lancet 1267 (2005)			
269	Miller et al., <i>Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association</i> , 123 Circulation 2292 (2011)	AMRN03146607	AMRN03146649	H, R, U
270	Amarin Pharma Inc., <i>Clinical Study Report: A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR 101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease REDUCE-IT (Reduction of Cardiovascular Events with EPA — Intervention Trial)(draft)</i> (Jan. 29, 2019)	AMRN03164813	AMRN03165069	R, U
271	Amarin Pharma Inc., <i>Clinical Study Report: A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease REDUCE-IT (Reduction of Cardiovascular Events with EPA — Intervention Trial)</i> (ver. 1.0) (Feb. 27, 2019)	AMRN03168530	AMRN03168883	R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
272	Bhatt et al., <i>Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia</i> , 380 N. Engl. J. Med. 11 (2019)	AMRN-PEXP-0000689	AMRN-PEXP-0000700	R, U
273	ANDA No. 209457, Submission of ANDA Application No. 209457	WWIC0-NV-000049	WWIC0-NV-000052	L, R, U
274	ANDA No. 209457, Proposed Prescribing Information (Revised December 2016)	WWIC0-NV-002835	WWIC0-NV-002843	L, R, U
275	FDA, “ <i>Combating Antibiotic Resistance</i> ,” available at https://www.fda.gov/consumers/consumer-updates/combating-antibiotic-resistance	AMRN-PEXP-0009113	AMRN-PEXP-0009116	A, F, H, R, U
276	Jackowski et al., <i>Provision of Lifestyle Counseling and the Prescribing of Pharmacotherapy for Hyperlipidemia Among US Ambulatory Patients: A National Assessment of Office-Based Physician Visits</i> , 18 Am. J. Cardiovascular Drugs 65 (2017)	AMRN-PEXP-0009303	AMRN-PEXP-0009309	F, H, R, U
277	Jacobson et al., <i>National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report</i> , 9 J. of Clinical Lipidology 129 (2015)	AMRN-PEXP-0009310	AMRN-PEXP-0009350	F, H, R, U
278	Pejic, <i>Should We Treat Moderately Elevated Triglycerides? Yes: Treatment of Moderately Elevated Triglycerides Is Supported by the Evidence</i> [Editorial], 83 Am. Family Physician 1 (2011)	AMRN-PEXP-0009488	AMRNPEXP-0009489	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
279	Reilly, <i>The Essence of EBM: Practicing What We Teach Remains a Big Challenge</i> , 329 BMJ 991 (2004)	AMRN-PEXP-0009511	AMRN-PEXP-0009512	F, H, R, U
280	Grundy et al., <i>2018 ACC/AHA Multisociety Guideline on the Management of Blood Cholesterol</i> , American College of Cardiology (2018), https://www.acc.org/latest-in-cardiology/ten-pointstoremember/2018/11/09/14/28/2018-guideline-on-management-of-blood-cholesterol	AMRN-PEXP-0010618	AMRN-PEXP-0010737	F, H, R, U
281	Pejic et al., <i>Hypertriglyceridemia</i> , 19 J. Am. Board Fam Med 310 (2006)	AMRN-PEXP-0010738	AMRN-PEXP-0010744	F, H, R, U
282	Willson et al., <i>Ethnicity/Race, Use of Pharmacotherapy, Scope of Physician-Ordered Cholesterol Screening, and Provision of Diet/Nutrition or Exercise Counseling during US Office-Based Visits by Patients with Hyperlipidemia</i> , 10 American Journal of Cardiovascular Drugs 105 (2010)	AMRN-PEXP-0010745	AMRN-PEXP-0010753	F, H, R, U
283	LAMISIL® Prescribing Information (2019)	ICOSAPENT_DFNDT00015617	ICOSAPENT_DFNDT00015629	F, H, R, U
284	LEVAQUIN® Prescribing Information (2018)	ICOSAPENT_DFNDT00015630	ICOSAPENT_DFNDT00015687	F, H, R, U
285	LOVENOX® Prescribing Information (2018)	ICOSAPENT_DFNDT00015711	ICOSAPENT_DFNDT00015751	F, H, R, U
286	VASCEPA DTC TV Advertisement Script	AMRN03149719	AMRN03149723	F, H, R, U
287	Vascepa® Print Advertisement	AMRN03149773	AMRN03149774	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
288	Karalis et al., <i>A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids</i> , 34 Adv Ther 300, 309	AMRN-PEXP-0001515	AMRN-PEXP-0001538	F, H, R, U
289	NDA No. 202057, Medical Review(s) (Jul. 25, 2012)	ICOSAPENT_DFNDT00015424	ICOSAPENT_DFNDT00015567	F
290	LOVAZA® Prescribing Information (2014)	ICOSAPENT_DFNDT00016641	ICOSAPENT_DFNDT00016653	H, R, U
291	Notice of Deposition 30(b)(6)	N/A	N/A	L, R, U
292	Notice of Deposition of Andrea Cady	N/A	N/A	L, R, U
293	Section 3.2.P.5.3 of ANDA 209457: Validation of Analytical Procedures	WWIC0-NV-001211	WWIC0-NV-001347	C, I, L, R, U
294	Module 2: Quality Overall Summary Roxane Laboratories Inc.	WWIC0-NV-000164	WWIC0-NV-000179	C, I, L, R, U
295	Section 3.2.S.4.1 of ANDA 209457: Specification	WWIC0-NV-000427	WWIC0-NV-000430	C, I, L, R, U
296	Section 3.2.S.4.2 of ANDA 209457: Analytical Procedures	WWIC0-NV-000431	WWIC0-NV-000484	C, I, L, R, U
297	Section 3.2.S.4.3 of ANDA 209457: Validation of Analytical Procedures	WWIC0-NV-000485	WWIC0-NV-000656	C, I, L, R, U
298	Section 3.2.S.4.4 of ANDA 209457: Batch Analysis	WWIC0-NV-000657	WWIC0-NV-000686	C, I, L, R, U
299	Section 3.2.P.1 of ANDA 209457: Description and Composition of the Drug Product	WWIC0-NV-000719	WWIC0-NV-000721	I, L, R, U
300	Section 3.2.P.2 of ANDA 209457: Pharmaceutical Development	WWIC0-NV-000722	WWIC0-NV-000880	C, I, L, R, U
301	Section 3.2.P.5.1 of ANDA 209457: Specifications	WWIC0-NV-001158	WWIC0-NV-001160	I, L, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
302	Section 3.2.P.5.2 of ANDA 209457: Analytical Procedures	WWIC0-NV-001161	WWIC0-NV-001210	C, I, L, R, U
303	Section 3.2.P.5.4 of ANDA 209457: Batch Analysis	WWIC0-NV-001348	WWIC0-NV-001371	C, I, L, R, U
304	Section 3.2.P.8.1 of ANDA 209457: Stability Summary and Conclusion	WWIC0-NV-001439	WWIC0-NV-001459	C, I, L, R, U
305	Stability Data Icosapent Ethyl (West-Ward) (Sept. 6, 2016)	WWIC0-NV-002692	WWIC0-NV-002702	L, R, U
306	Information Request to T. Adams from: S. Smith and Related Communication (June 15, 2017)	WWIC0-NV-099968	WWIC0-NV-099993	C, L, R, U
307	Email from J. McGlone to T. Miller et al. (Dec. 3, 2012)	WWICO-MV-093674	WWICO-MV-093692	C, L, R, U
308	Email from J. McGlone to Dr. S. Uraizee (Nov. 26, 2012)	WWICO-NV-093693	WWICO-NV-093712	C, L, R, U
309	Specification for Icosapent Ethyl (West-Ward) (June 13, 2017)	WWICO-NV-1000023	WWICO-NV-1000025	L, R, U
310	Finished Products Test Method and Related Documents (June 13, 2017)	WWICO-NV-1000026	WWICO-NV-1000040	L, R, U
311	Amarin Pharma Inc., <i>Drug Substance</i>	AMRN00000225	AMRN00000238	R, U
312	Amarin Pharma Inc., <i>Comparison of Related Substances in Drug Substance Batches and Corresponding AMR101 Capsule, 1 g Batches</i> (5/14/2009)	AMRN00000491	AMRN00000491	R, U
313	Amarin Pharma Inc., <i>Control of Drug Substance</i> (5/14/2009)	AMRN00000585	AMRN00000595	R, U
314	Amarin Pharma Inc., <i>Comparison of Related Substances in Drug Substance Batches and Corresponding AMR101 Capsule, 1 g Batches</i> (5/13/2009)	AMRN00020568	AMRN00020568	R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
315	IND 102457-s0046, 2.3.P.5 Control of Drug Product	AMRN00100895	AMRN00100908	R, U
316	NDA No. 202057, 2.3.S.4 Control of Drug Substance [icosapent ethyl, Nisshin Pharma Inc.]	AMRN00115239	AMRN00115243	R, U
317	NDA 202057, 3.2.P.5 Control of Drug Product [AMR101, Capsules], Justification of Specifications	AMRN00116059	AMRN00116073	R, U
318	NDA 202057, 2.3.P.2 Pharmaceutical Development [AMR101, Capsules]	AMRN00186470	AMRN00186479	R, U
319	NDA 202057, 3.2.P.5 Control of Drug Product [AMR101, Capsules], Batch Analysis	AMRN00189290	AMRN00189301	R, U
320	NDA 202057, 2.3.S.4 Control of Drug Substance [icosapent ethyl, Chemport, Inc.]	AMRN00189740	AMRN00189740	R, U
321	NDA 202057, 2.3.S.4 Control of Drug Substance [icosapent ethyl, BASF]	AMRN00190387	AMRN00190387	R, U
322	NDA 202057, 2.3.S.4 Control of Drug Substance [icosapent ethyl, Finorga]	AMRN00199987	AMRN00199987	R, U
323	NDA 202057, 3.2.P.5.4 Batch Analysis	AMRN00200042	AMRN00200043	R, U
324	NDA 202057, 2.3.S.4 Control of Drug Substance [icosapent ethyl, Nisshin Pharma Inc.]	AMRN00200627	AMRN00200627	R, U
325	NDA 202057, 3.2.P.5 Control of Drug Product [VASCEPA, Capsules], Batch Analysis	AMRN03133712	AMRN03133722	R, U
326	NDA 202057, 1.13.5 Summary of Manufacturing Changes	AMRN03136091	AMRN03136094	R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
327	NDA 202057, 2.3.P.5 Control of Drug Product [VASCEPA, Capsules]	AMRN03137600	AMRN03137637	R, U
328	NDA 202057, 3.2.P.5 Control of Drug Product [VASCEPA, Capsules], Analytical Procedures	AMRN03137782	AMRN03137805	R, U
329	NDA 202057, 3.2.P.5.4 Batch Analysis	AMRN03137854	AMRN03137856	R, U
330	ANDA 209499, <i>In-Vitro Dissolution Data</i>	DRLEEPS 0000325	DRLEEPS 0000357	L
331	Dr. Reddy's, Module 3 Quality — 3.2.P.2 Pharmaceutical Development	DRLEEPS 0003860	DRLEEPS 0003965	L
332	ANDA 209499, 5.3 <i>Bioavailability/Bioequivalence</i>	DRLEEPS 0004209	DRLEEPS 0004379	L
333	<i>Certificate of Analysis: Analytical Testing of Icosapent Ethyl Capsule 1 gram</i> (Lot No. 2J00034)	DRLEEPS 0011662	DRLEEPS 0011665	L
334	<i>Certificate of Analysis: Analytical Testing of Icosapent Ethyl Capsule 1 gram</i> (Lot No. 2J00045) (Mar. 2013)	DRLEEPS 0011666	DRLEEPS 0011669	L
335	<i>Certificate of Analysis: Analytical Testing of Icosapent Ethyl Capsule 1 gram</i> (Lot No. 2K00243) (Dec. 2013)	DRLEEPS 0013530	DRLEEPS 0013534	L
336	NDA 202057, 3.2.P.5 Control of Drug Product [AMR101, Capsules], Analytical Procedures	AMRN00186607	AMRN00186630	R, U
337	NDA 202057, 3.2.P.5 Control of Drug Product [AMR101, Capsules], Justification of Specifications	AMRN00186666	AMRN00186683	R, U
338	NDA 202057, 3.2.P.5 Control of Drug Product [AMR101, Capsules], Justification of Specifications	AMRN00188964	AMRN00188981	R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
339	NDA 202057, 3.2.P.5.1-2 Specifications for VASCEPA Capsules, 1g	AMRN03137779	AMRN03137781	R, U
340	ANDA 209457, 2.3 Quality Overall Summary (QOS)	WWICO-NV-000196	WWICO-NV-000225	I, L, R, U
341	<i>Certificate of Analysis: Icosapent Ethyl Capsules, 1 gram (Lot No. 1569547)</i>	WWICO-NV-000405	WWICO-NV-000408	L, R, U
342	<i>Certificate of Analysis: Vascepa (Lot No. 2J00045)</i>	WWICO-NV-000409	WWICO-NV-000410	L, R, U
343	West-Ward, Pharmaceutical Development Report of Icosapent Ethyl Capsules, 1 gram, (July 2016)	WWICO-NV-000724	WWICO-NV-000790	L, R, U
344	<i>Certificates of Analysis: Icosapent Ethyl Capsules, 1 g (Lot Nos. 1362418, 1463425, 1569547)</i>	WWICO-NV-001349	WWICO-NV-001371	C, L, R, U
345	<i>Certificate of Analysis: Vascepa (Lot No. 2K00056)</i>	WWICO-NV-023240	WWICO-NV-023240	L, R, U
346	<i>Certificate of Analysis: Vascepa (Lot No. 2K00067)</i>	WWICO-NV-023241	WWICO-NV-023241	L, R, U
347	<i>Certificate of Analysis: Ethyl Icosapentate (Icosapent Ethyl) (Lot No. 05264002)</i>	WWICO-NV-122070	WWICO-NV-122071	L, R, U
348	ANDA 206264, 2.7.1.2 Summary of Results of Individual Studies	WWICO-NV-158523	WWICO-NV-158537	L, R, U
349	<i>Certificates of Analysis: Icosapent Ethyl Capsules, 1 g (Lot Nos. 1362418, 1463425, 1569547)</i>	WWICO-NV-162334	WWICO-NV-162360	C, L, R, U
350	<i>Certificates of Analysis: Icosapent Ethyl Capsules, 1 g (Lot Nos. 3079110, 3368301, 3368523)</i>	WWICO-NV-162361	WWICO-NV-162376	C, L, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
351	West-Ward, <i>Certificate of Analysis: Vascepa</i> (Lot No. 5B01002)	WWICO-NV-162377	WWICO-NV-162378	L, R, U
352	<i>Certificate of Analysis: Vascepa</i> (Lot. No. 6F01860)	WWICO-NV-162384	WWICO-NV-162386	L, R, U
353	<i>Certificate of Analysis: Vascepa</i> (Lot No. 6F01871)	WWICO-NV-162387	WWICO-NV-162389	L, R, U
354	<i>Certificates of Analysis: Icosapent Ethyl</i> (Lot Nos. 37662, 61268, 61269, 61271)	WWICO-NV-162390	WWICO-NV-162405	C, L, R, U
355	<i>Certificate of Analysis: Icosapent Ethyl Capsules</i> , 1 gram (Lot. No. 3368523)	WWICO-NV-162410	WWICO-NV-162413	L, R, U
356	NDA 202057, 3.2.P.5.4 Batch Analysis	AMRN03137859	AMRN03137860	R, U
357	Table of Contents, Specificity of Additional Impurities	WWICO-NV-100000	WWICO-NV-100012	L, R, U
358	Executed Errata Sheet for the February 15, 2018 Deposition of Michael Miller	N/A	N/A	F, H, R, U
359	Executed Errata Sheet for the July 1, 2019 Deposition of Carl Peck	N/A	N/A	F, H, R, U
360	Executed Errata Sheet for the July 10, 2019 Deposition of Peter P. Toth	N/A	N/A	F, H, R, U
361	Executed Errata Sheet for the July 17, 2019 Deposition of Matthew Budoff	N/A	N/A	F, H, R, U
362	Executed Errata Sheet for the July 2, 2019 Deposition of Sean Nicholson	N/A	N/A	F, H, R, U
363	Executed Errata Sheet for the June 19, 2019 Deposition of R. Preston Mason	N/A	N/A	F, H, R, U
364	Executed Errata Sheet for the June 20, 2019 Deposition of Stephen Kunin	N/A	N/A	F, H, R, U
365	Executed Errata Sheet for the June 25, 2019 Deposition of Firhaad Ismail	N/A	N/A	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
366	Executed Errata Sheet for the November 5, 2018 Deposition of Harold Bays	N/A	N/A	F, H, R, U
367	Executed Errata Sheet for the November 5, 2018 Deposition of Ian Osterloh	N/A	N/A	F, H, R, U
368	Executed Errata Sheet for the October 16, 2018 Deposition of Aaron Berg	N/A	N/A	F, H, R, U
369	Executed Errata Sheet for the October 24, 2018 Deposition of Steven Ketchum	N/A	N/A	F, H, R, U
370	Executed Errata Sheet for the October 30, 2018 Deposition of Rebecca Juliano	N/A	N/A	F, H, R, U
371	Executed Errata Sheet for the September 14, 2018 Deposition of Howard Weintraub	N/A	N/A	F, H, R, U
372	Executed Errata Sheet for the September 21, 2018 Deposition of Philip Lavin	N/A	N/A	F, H, R, U
373	Chapman et al., <i>Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management</i> , European Heart Journal (2011) 32, 1345-1361	N/A	N/A	F, H
374	Feingold et al., <i>Diabetes and Dyslipidemia</i> , Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc; 2000	N/A	N/A	H, R, U
375	Siscovick et al., <i>Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease</i> , 135 Circulation e867 (2017)	ICOSAPENT_DFNDT000 18006	ICOSAPENT_DFNDT000 18023	H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
376	Kurabayashi et al., <i>Eicosapentaenoic Acid Effect on Hyperlipidemia in Menopausal Japanese Women</i> , 96 The American College of Obstetricians and Gynecologists 521 (2000)	ICOSAPENT_DFNDTS00006237	ICOSAPENT_DFNDTS00006244	
377	USPTO Office Communication (June 20, 2011)	AMRN03058824	AMRN03058835	
378	USPTO Response to Office Action Dated June 20, 2011	AMRN03058867	AMRN03058907	
379	Interview Agenda with David Fournier and John Kappos (April 24, 2012)	AMRN03059782	AMRN03059788	
380	Notice of Allowance and Fees Due (Sept. 6, 2012)	AMRN03059927	AMRN03059940	
381	Manual of Patent Examining Procedure 1302.13 (Signing)	N/A	N/A	H, R, U
382	In Limine Order Granting Defendant Medtronic's Motion to Exclude the Testimony of Nicholas Godici	N/A	N/A	F, H, N, R, U
383	Methods of Treating and/or Preventing Cardiovascular Diseases and Disorder	N/A	N/A	F, N, R, U
384	Oram, Heinecke, et al., <i>When Good Cholesterol Turns Bad: The Evolving Saga of CETP Inhibitors and Clinical Strategies to Elevate High-density Lipoprotein</i> , Current Atherosclerosis Reports 2007, 9:425-427	N/A	N/A	F, H
385	Isley et al., <i>Pilot Study of Combined Therapy With ω-3 Fatty Acids and Niacin in Atherogenic Dyslipidemia</i> , 1 J. Clinical Lipidology 211 (2007)	AMRN00621043	AMRN00621049	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
386	McLennan et al., <i>The cardiovascular protective role of docosahexaenoic acid</i> , 300 European J. Pharmacology 83 (1996)	AMRN00621419	AMRN00621425	R, U
387	NIASPAN® Label (2003)	AMRN-PEXP-0001692	AMRN-PEXP-0001712	R
388	TRICOR® Label (2004)	AMRN-PEXP-0001915	AMRN-PEXP-0001932	F, H, R, U
389	Mitchell, <i>Regulator Rebuffs Merck's Cholesterol Drug</i> , Chemistry World (May 28, 2008), https://www.chemistryworld.com/news/regulator-rebuffs-mercks-cholesteroldrug/3003426.article	AMRN-PEXP-0009429	AMRN-PEXP-0009431	F, H, R, U
390	Historical Revenue & COGS	AMRN03171431_CONFIDENTIAL	AMRN03171431_CONFIDENTIAL	U
391	Rx View	AMRN-PEXP-0007102_CONFIDENTIAL	AMRN-PEXP-0007102_CONFIDENTIAL	U
392	Treatment Insights View	AMRN-PEXP-0007104_CONFIDENTIAL	AMRN-PEXP-0007104_CONFIDENTIAL	U
393	American Diabetes Association, <i>Standards of Medical Care in Diabetes—2008</i> , 31 Diabetes Care S12 (2008)	AMRN00098010	AMRN00098052	U
394	Assmann et al., <i>Hypertriglyceridemia and Elevated Lipoprotein(a) Are Risk Factors for Major Coronary Events in Middle-Aged Men</i> , 77 Am. J. Cardiology 1179 (1996)	AMRN00934904	AMRN00934909	F, H, R, U
395	Sacks, <i>After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study: Implications for Fenofibrate</i> , 102	AMRN01235531	AMRN01235537	H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	American Journal of Cardiology 34L (2008)			
396	Heart Protection Study Collaborative Group, <i>MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial</i> , 361 The Lancet 2005 (2003)	AMRN01382864	AMRN01382875	F
397	Klempfner et al., <i>Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Disease: Twenty-Two-Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry</i> , 9 Circ. Cardiovasc. Qual. Outcomes 100 (2016)	AMRN03146442	AMRN03146454	F, H, R, U
398	American Diabetes Association, <i>Standards of Medical Care in Diabetes—2009</i> , 32 Diabetes Care S13 (2009)	AMRN-PEXP-0000722	AMRN-PEXP-0000770	U
399	American Diabetes Association, <i>Implications of the United Kingdom Prospective Diabetes Study</i> , 25 Diabetes Care S28 (2002)	AMRN-PEXP-0000771	AMRN-PEXP-0000775	F, H, R, U
400	American Diabetes Association, <i>Standards of Medical Care in Diabetes—2018</i> , 41 Diabetes Care S1 (2018)	AMRN-PEXP-0000776	AMRN-PEXP-0000925	F, H, R, U
401	Bays et al., <i>National Lipid Association Annual Summary of Clinical Lipidology 2015</i> , 8 Journal of Clinical Lipidology S1 (2014)	AMRN-PEXP-0001153	AMRN-PEXP-0001188	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
402	Gaede et al., <i>Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes</i> , 358 N. Eng. J. Med. 580 (2008)	AMRN-PEXP-0001388	AMRN-PEXP-0001399	F, H, R, U
403	Garber et al., <i>Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2018 Executive Summary</i> , 24 Endocrine Practice 91 (2018)	AMRN-PEXP-0001400	AMRN-PEXP-0001429	F, H, R, U
404	Grundy et al., <i>2018 ACC/AHA Multisociety Guideline on the Management of Blood Cholesterol</i> , American College of Cardiology (Nov. 10, 2018), https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2018/11/09/14/28/2018-guideline-on-management-of-blood-cholesterol	AMRN-PEXP-0001461	AMRNPEXP-0001466	F, H, R, U, DUPE
405	Holman et al., <i>10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes</i> , 359 N. Eng. J. Med. 1577 (2008)	AMRN-PEXP-0001473	AMRN-PEXP-0001485	F, H, R, U
406	Hopkins et al., <i>Plasma Triglycerides and Type III Hyperlipidemia Are Independently Associated with Premature Familial Coronary Artery Disease</i> , 45 Journal of the American College of Cardiology 1003 (2005)	AMRN-PEXP-0001486	AMRN-PEXP-0001495	F, H, R, U
407	National Diabetes Education Program, <i>Diabetes and Cardiovascular Disease</i> , National Institutes of Health and the	AMRN-PEXP-0001622	AMRN-PEXP-0001666	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	Centers for Disease Control and Prevention (2013), https://www.niddk.nih.gov/search?s=all&q=ndep-diabetes-cvd			
408	Schnell et al., <i>Updates on cardiovascular outcome trials in diabetes</i> , 16 <i>Cardiovascular Diabetology</i> 1 (2017)	AMRN-PEXP-0001784	AMRN-PEXP-0001796	F, H, R, U
409	Jellinger et al., <i>American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease</i> , 23 <i>Endocrine Practice</i> 1 (2017)	AMRN-PEXP-0001944	AMRN-PEXP-0002030	F, H, R, U
410	American Diabetes Association, <i>Standards of Medical Care in Diabetes—2019</i> , 42 <i>Diabetes Care</i> S1 (2019)	AMRN-PEXP-0007748	AMRN-PEXP-0007951	H, R, U
411	Goldberg, <i>Clinical Trial Experience with Extended-Release Niacin (Niaspan): Dose-Escalation Study</i> , 82 <i>Am. J. Cardiology</i> 35U (1998)	AMRN-PEXP-0007952	AMRN-PEXP-0007958	F, H, R, U
412	Jacobson et al., <i>Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other Lipids: A review</i> , 6 <i>J. of Clinical Lipidology</i> 5 (2012)	AMRN00302233	AMRN00302246	H, R, U
413	Miller et al., <i>Triglycerides and Cardiovascular Disease: A Scientific Statement from the American Heart Association</i> , 123 <i>Circulation</i> 00-00 (2011).	AMRN02283764	AMRN02283806	H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
414	Bays et al., <i>Prescription Omega-3 Fatty Acids and Their Lipid Effects: Physiologic Mechanisms of Action and Clinical Implications</i> , 6 Expert Reviews Cardiovascular Therapy 391 (2008)	AMRN03145052	AMRN03145070	H, R, U
415	Goldberg et al., <i>A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia</i> , 28 Diabetes Care 1547 (2005)	AMRN-PEXP- 00009174	AMRN-PEXP- 00009181	F, H, R, U
416	Miller et al., <i>Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial</i> , 51 J. of Am. College of Cardiology 724 (2008)	AMRN-PEXP- 0009422	AMRN-PEXP- 0009428	F, H, R, U
417	Hickson et al., <i>Implications of Removing Rosiglitazone's Black Box Warning and Restricted Access Program on the Uptake of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors Among Patients with Type 2 Diabetes</i> , 25 J. of Managed Care & Specialty Pharmacy 72 (2019)	AMRN-PEXP-0009235	AMRN-PEXP-0009242	F, H, R, U
418	Abbott et al., <i>Diabetes and the Risk of Stroke</i> , 257 JAMA 949 (1987)	AMRN-PEXP-0008423	AMRN-PEXP-0008428	F, H, R, U
419	Dash et al., <i>Residual cardiovascular risk among people with diabetes</i> , 21 Diabetes Obes. Metab. 28 (2019)	AMRN-PEXP-0009032	AMRN-PEXP-0009042	F, H, R, U
420	Garber et al., <i>Consensus Statement by the American Association of Clinical Endocrinologists and American College</i>	AMRN-PEXP-0009132	AMRN-PEXP-0009164	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	<i>of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2019 Executive Summary</i> , 25 Endocrine Practice 69 (2019)			
421	Hu et al., <i>Elevated Risk of Cardiovascular Disease Prior to Clinical Diagnosis of Type 2 Diabetes</i> , 25 Diabetes Care 1129 (2002)	AMRN-PEXP-0009274	AMRN-PEXP-0009279	F, H, R, U
422	Jayanna et al., <i>The extent to which statins have improved cardiovascular outcomes: Lessons from randomized trials and observational studies of "real world" practice in people with diabetes</i> , 21 Diabetes Obes. Metab. 17 (2019)	AMRN-PEXP-0009351	AMRN-PEXP-0009361	F, H, R, U
423	Nissen et al., <i>An Updated Meta-analysis of Risk for Myocardial Infarction and Cardiovascular Mortality</i> , 170 Arch. Intern. Med. 1191 (2010)	AMRN-PEXP-0009432	AMRN-PEXP-0009442	F, H, R, U
424	Nissen et al., <i>Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes</i> , 356 N. Am. J. Med. 2457 (2007)	AMRN-PEXP-0009443	AMRN-PEXP-0009457	F, H, R, U
425	O'Riordan, <i>Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND</i> , tctMD (Aug. 26, 2018)	AMRN-PEXP-0009483	AMRN-PEXP-0009487	H, R, U
426	Oh et al., <i>Management of Hypertriglyceridemia</i> , 75 Am. Family Physician 1365 (2007)	ICOSAPENT_DFNDT00016657	ICOSAPENT_DFNDT00016661	H, R, U
427	Cymet, <i>Should We Treat Moderately Elevated Triglycerides? No: Reducing Moderately Elevated Triglycerides Is Not</i>	ICOSAPENT_DFNDT00017821	ICOSAPENT_DFNDT00017822	H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	<i>Proven to Improve Patient Outcomes [Editorial]</i> , 83 American Family Physician 247 (2011)			
428	Elam et al., <i>The ACCORD-Lipid Study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus</i> [Author manuscript], 6 Clin Lipidol. 9 (2015)	ICOSAPENT_DFNDT000 17840	ICOSAPENT_DFNDT000 17861	H, R, U
429	Hartz et al., <i>Hypertriglyceridemia in Diabetes Mellitus: Implications for Pediatric Care</i> , 2 Journal of the Endocrine System 297 (2018)	ICOSAPENT_DFNDT000 17908	ICOSAPENT_DFNDT000 17923	H, R, U
430	Kris-Etherton et al., <i>Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease</i> , 106 Circulation 2747 (2002)	ICOSAPENT_DFNDT000 17924	ICOSAPENT_DFNDT000 17934	H, R, U
431	LeRoith et al., <i>Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline</i> , 104 J. of Clinical Endocrinology and Metabolism 1520 (2019)	ICOSAPENT_DFNDT000 17935	ICOSAPENT_DFNDT000 17989	H, R, U
432	Shek et al., <i>Statin-fibrate combination therapy</i> [Abstract], 35 Annals of Pharmacotherapy 7 (2001)	ICOSAPENT_DFNDT000 18004	ICOSAPENT_DFNDT000 18005	H, R, U
433	Allen et al., <i>Nonadherence, Clinical Inertia, or Therapeutic Inertia?</i> , 15 J. of Managed Care Pharmacy 690 (2009)	N/A	N/A	F, H, N, R, U
434	Christian et al., <i>Prevalence of Severe (500 to 2,000 mg/dl) Hypertriglyceridemia in United States Adults</i> , 107 Am. J. Cardiol. 891 (2011)	AMRN0088729	AMRN00887735	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
435	Emdin et al., <i>Mendelian Randomization</i> , 318 Am. Med. Assoc. 1925 (2017)	N/A	N/A	F, H, N, R, U
436	Harris et al., <i>Safety and efficacy of Omacor in severe hypertriglyceridemia</i> , 4 J. of Cardiovascular Risk 385 (1997)	AMRN00290443	AMRN00290449	H, R, U
437	Hu et al., <i>Safety of statins: an update</i> , 3 Therapeutic Advances in Drug Safety 133 (2012)	N/A	N/A	F, H, N, R, U
438	Rice et al., <i>Conducting omega-3 clinical trials with cardiovascular outcomes: Proceedings of a workshop held at ISSFAL 2014</i> , 107 Prostaglandins, Leukotrienes and Essential Fatty Acids 30 (2016)	N/A	N/A	F, H, N, R, U
439	Bhatt et al., <i>Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with IcosapentEthyl–Intervention Trial</i> , 40 Clinical Cardiology 138 (2017)	AMRN03145547	AMRN03145557	F, H, R, U
440	Ganda et al., <i>Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management</i> , 72 J. of the Am. College of Cardiology 330 (2018)	AMRN-PEXP-0000467	AMRN-PEXP-0000480	F, H, R, U
441	Tajuddin et al., <i>Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus</i> , 9 Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 109 (2016)	AMRN-PEXP-0001808	AMRN-PEXP-0001817	F, H, R, U
442	American Diabetes Association, <i>American Diabetes Association® Issues Critical</i>	AMRN-PEXP-0009621	AMRN-PEXP-0009622	H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	<i>Updates to the 2019 Standards of Medical Care in Diabetes</i> , available at http://www.diabetes.org/newsroom/press-releases/2019/ada-issues-critical-updates-to-2019-standards-of-care.html			
443	Austin, <i>Plasma Triglyceride as a Risk Factor for Coronary Heart Disease</i> , 129 Am. J. of Epidemiology 249 (1989)	ICOSAPENT_DFNDT00016786	ICOSAPENT_DFNDT00016796	H, R, U
444	Vashitz et al., <i>Physician adherence to the dyslipidemia guidelines is as challenging an issue as patient adherence</i> , 28 Family Practice 524 (2011)	N/A	N/A	F, H, N, R, U
445	Carroll, et al., <i>Trends in Lipids and Lipoproteins in US Adults</i> , 1988-2010, 308 JAMA 154 (2012)	ICOSAPENT_DFNDT00020631	ICOSAPENT_DFNDT00020640	H, R, U
446	June 27, 2012, Response to Non-Final Office Action Dated April 4, 2012	AMRN00212303	AMRN00212329	
447	Final Rejection maintaining the prior rejections of the pending claims 1-9 and 12-23. (Aug. 2011)	AMRN03059004	AMRN03059028	
448	Request for Continued Examination and Response to the Office Action Dated August 18, 2011.	AMRN03059035	AMRN03059056	
449	Nonfinal Office Action (Nov. 2011)	AMRN03059251	AMRN03059272	
450	January 13, 2012, Response to Non-Final Office Action Dated November 4, 2011.	AMRN03059282	AMRN03059315	
451	May 16, 2012, Response to Non-Final Office Action Dated March 2, 2012.	AMRN03059789	AMRN03059814	
452	37 C.F.R. § 1.104	N/A	N/A	H, R, U
453	37 C.F.R. § 1.104(e)	N/A	N/A	H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
454	37 C.F.R. § 1.312	N/A	N/A	H, R, U
455	37 C.F.R. § 1.313	N/A	N/A	H, R, U
456	http://www.uspto.gov/web/offices/pac/dapp/index.html as it existed on December 31, 2004, via http://web.archive.org/web/20041205214857/www.uspto.gov/web/offices/pac/dapp/index.html , last visited on April 24, 2019.	N/A	N/A	A, H, R, U
457	MPEP § 1302.03	N/A	N/A	H, R, U
458	MPEP § 1302.14	N/A	N/A	H, R, U
459	MPEP § 1303	N/A	N/A	H, R, U
460	MPEP § 2141	N/A	N/A	H, R, U
461	MPEP § 2144	N/A	N/A	H, R, U
462	MPEP § 2145	N/A	N/A	H, R, U
463	MPEP § 714.14	N/A	N/A	H, R, U
464	MPEP § 714.16	N/A	N/A	H, R, U
465	MPEP § 716.02	N/A	N/A	H, R, U
466	MPEP § 716.04	N/A	N/A	H, R, U
467	MPEP §§ 608.01(p)(II)	N/A	N/A	H, R, U
468	MPEP Foreword	N/A	N/A	H, R, U
469	Email from L. Crutchley to S. Sedlack et al. re: CONFIDENTIAL: Amarin Expert Panel Meeting for AMR-101 (ethyl-EPA) Meeting Package (With Attachments) (Nov. 26, 2008)	AMRN00588927	AMRN00589018	F, H, R, U
470	Email from I. Osterloh to R. Braeckman et al. re: 12-Dec-2008 Expert Panel Meeting Comments on AMR101 Phase 3 Studies (with attachment) (Dec. 15, 2008)	AMRN01531053	AMRN01531058	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
471	Overview of Hypertriglyceridemia, Michael H. Criqui MD, MPH, AMR 101 Expert Panel Meeting, Boston (Dec. 12, 2008)	AMRN01574093	AMRN01574115	F, H, R, U
472	Email from D. Doogan to M. Manku et al. re: Omacor (Omega-3-Acid Ethyl Esters) - Current Clinical Trials (Mar. 24, 2008)	AMRN01672057	AMRN01672060	F, H, R, U
473	Email from D. Doogan to S. Sedlack et al. re: Final Slides for Arisaph (With Attachments) (Jul. 31, 2009)	AMRN01673821	AMRN01673924	F, H, R, U
474	Email from M. Manku to D. Cunningham et al. re: Japanese publications-translations (With Attachments) (Mar. 13, 2008)	AMRN01688238	AMRN01688360	F, H, R, U
475	Email from M. Manku to A. Cooke et al. re: EPA reduces cholesterol absorption from GIT tract and inhibits its synthesis in liver (With Attachments) (Mar. 16, 2008)	AMRN01688512	AMRN01688519	F, H, R, U
476	Email from M. Manku to D. Cunningham et al. re: [No Subject] (Mar. 25, 2008)	AMRN01688572	AMRN01688573	F, H, R, U
477	Email from M. Manku to A. Cooke et al. re: Meeting with Mochida's internal R and D team (With Attachments) (Apr. 18, 2008)	AMRN01688641	AMRN01688653	F, H, R, U
478	Email from M. Manku to A. Cooke et al. re: FW: Final Slides for Boston (With Attachments) (Dec. 11, 2008)	AMRN01688980	AMRN01689008	F, H, R, U
479	Amarin Portfolio Review Meeting - November 27th, 2007	AMRN02105815	AMRN02105823	F, H, R, U
480	Email from S. Sedlack to A. Cooke et al. re: FW: Minutes and slides from EPA	AMRN02129382	AMRN02129413	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	Triglycerides meeting - Thursday 20th December 2007 (With Attachments) (Jan. 11, 2008)			
481	Letter from David Zuchero to Mary Parks re: P-IND 102,457; AMR101 (ethyl eicosapentaenoate [Ethyl-EPA]); Treatment of Hypertriglyceridemia; Type B Meeting Information Package (Jun. 16, 2008)	AMRN02973472	AMRN02973592	F, H, R, U
482	Letter from David Zuchero to Mary Parks re: Ethyl-EPA (ethyl eicosapentaenoate); Treatment of Hyperlipidemia; Request for Type B Meeting; Pre-IND Meeting (May 9, 2008)	AMRN03105910	AMRN03105941	F, H, R, U
483	Sanders et al., <i>Influence of an Algal Triacylglycerol Containing Docosahexaenoic Acid (22: 6n-3) and Docosapentaenoic Acid (22: 5n-6) on Cardiovascular Risk Factors in Healthy Men and Women</i> , 95 Br. J. Nutr. 525 (2006)	AMRN00351379	AMRN00351385	F, H, R, U
484	Lussier-Cacan et al., <i>Influence of Probucol on Enhanced LDL Oxidation After Fish Oil Treatment of Hypertriglyceridemic Patients</i> , 13 Arterioscler Thromb Vasc Biol. 1790 (1993)	AMRN00479369	AMRN00479377	F, H, R, U
485	Glass et al., <i>Atherosclerosis: The Road Ahead</i> , 104 Cell 503 (2001)	AMRN00877900	AMRN00877913	F, H, R, U
486	Bays et al., <i>Prescription Omega-3 Fatty Acids and Their Lipid Effects: Physiologic</i>	AMRN00992095	AMRN00992113	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	<i>Mechanisms of Action and Clinical Implications</i> , 6 Expert Rev. Cardiovasc. Ther. 391 (2008)			
487	Walter et al., <i>Circulating Lipid Hydroperoxides Predict Cardiovascular Events in Patients with Stable Coronary Artery Disease The PREVENT Study</i> , 51 J. Am. Coll. Cardiol. 1196 (2008)	AMRN01055036	AMRN01055044	F, H, R, U
488	Walter et al., <i>Serum Levels of Thiobarbituric Acid Reactive Substances Predict Cardiovascular Events in Patients with Stable Coronary Artery Disease</i> , 44 J. Am. Coll. Cardiol. 1996 (2004)	AMRN01055045	AMRN01055051	F, H, R, U
489	Mesa et al., <i>Effects Of Oils Rich in Eicosapentaenoic and Docosahexaenoic Acids on the Oxidizability and Thrombogenicity of Low-Density Lipoprotein</i> , 175 Atherosclerosis 333 (2004)	AMRN01219306	AMRN01219316	F, H, R, U
490	Ridker et al., <i>Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein</i> , 359:21 N. Engl. J. Med. 2195 (2008)	AMRN01235642	AMRN01235654	F, H, R, U
491	Mori et al., <i>Effect of Eicosapentaenoic Acid and Docosahexaenoic Acid on Oxidative Stress and Inflammatory Markers in Treated-Hypertensive Type 2 Diabetic Subjects</i> , 35 Free Radic. Biol. Med. 772 (2003)	AMRN01392123	AMRN01392132	F, H, R, U
492	Kromhout et al., <i>N-3 Fatty Acids and Cardiovascular Events after Myocardial</i>	AMRN01404742	AMRN01404753	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	<i>Infarction</i> , 363 N. Engl. J. Med., 2015 (2010)			
493	Ciubotaru et al., <i>Dietary Fish Oil Decreases C-Reactive Protein, Interleukin-6, and Triacylglycerol to HDL-Cholesterol Ratio in Postmenopausal Women on HRT</i> , 14 J. Nutr. Biochem. 513 (2003)	AMRN01647159	AMRN01647167	F, H, R, U
494	Sundrarjun et al., <i>Effects of n-3 Fatty Acids on Serum Interleukin-6, Tumour Necrosis Factor-α and Soluble Tumour Necrosis Factor Receptor P55 in Active Rheumatoid Arthritis</i> , 32 J. Int. Med. Res. 443 (2004)	AMRN01651878	AMRN01651889	F, H, R, U
495	Satoh et al., <i>Purified Eicosapentaenoic Acid Reduces Small Dense LDL, Remnant Lipoprotein Particles, and C-Reactive Protein in Metabolic Syndrome</i> , 30 Diabetes Care 144 (2007)	AMRN01688644	AMRN01688646	H, R, U
496	Mickleborough et al., <i>Eicosapentaenoic Acid Is More Effective Than Docosahexaenoic Acid in Inhibiting Proinflammatory Mediator Production and Transcription from LPS-Induced Human Asthmatic Alveolar Macrophage Cells</i> , 28 Clin. Nutr. 71 (2009)	AMRN02087845	AMRN02087851	F, H, R, U
497	Kelley et al., <i>DHA Supplementation Decreases Serum C-Reactive Protein and Other Markers of Inflammation in Hypertriglyceridemic Men</i> , 139 J. Nutr. 495 (2009).	AMRN02515803	AMRN02515809	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
498	Chan et al., Effect of Atorvastatin and Fish Oil on Plasma High-Sensitivity C-Reactive Protein Concentrations in Individuals with Visceral Obesity, 48 Clin. Chem. 877 (2002)	AMRN02765207	AMRN02765213	F, H, R, U
499	Tricor® Label (2010)	AMRN03059120	AMRN03059123	F, H, R, U
500	Mason et al., <i>Eicosapentaenoic Acid Inhibits Glucose-Induced Membrane Cholesterol Crystalline Domain Formation Through a Potent Antioxidant Mechanism</i> , 1848 Biochim. Biophys. Acta. 502 (2015)	AMRN03130062	AMRN03130069	H, R, U
501	Nelson et al., <i>Potential Benefits of Eicosapentaenoic Acid on Atherosclerotic Plaques</i> , 91 Vasc. Pharmacol. 1 (2017)	AMRN03130071	AMRN03130079	F, H, R, U
502	Bays et al., <i>Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients with Metabolic Syndrome</i> , 13 Metab. Syndr. Relat. Disord. 239 (2015)	AMRN03130080	AMRN03130089	F, H, R, U
503	Crestor® Label (2009)	AMRN03130189	AMRN03130227	A, F, H, R, U
504	Bays et al., <i>Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients with Very High Triglyceride Levels (From the Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With an Open-Label Extension [MARINE] Trial)</i> , 108 Am. J. Cardiol. 682 (2011)	AMRN03144927	AMRN03144935	H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
505	Bays et al., <i>Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR Studies</i> , 13 Am. J. Cardiovasc. Drugs 37 (2013)	AMRN03144936	AMRN03144945	F, H, R, U
506	Borow et al., <i>Biologic Plausibility, Cellular Effects, and Molecular Mechanisms of Eicosapentaenoic Acid (EPA) in Atherosclerosis</i> , 242 Atherosclerosis 357 (2015)	AMRN03145576	AMRN03145585	F, H, R, U
507	Mason et al., <i>Eicosapentaenoic Acid Reduces Membrane Fluidity, Inhibits Cholesterol Domain Formation, and Normalizes Bilayer Width in Atherosclerotic-Like Model Membranes</i> , 1858 Biochim. Biophys. Acta. 3131 (2016)	AMRN03146567	AMRN03146576	H, R, U
508	Mason & Sherratt, <i>Omega-3 Fatty Acid Fish Oil Dietary Supplements Contain Saturated Fats and Oxidized Lipids That May Interfere with Their Intended Biological Benefits</i> , 483 Biochem. Biophys. Res. Commun. 425 (2017)	AMRN03146583	AMRN03146587	H, R, U
509	Abela et al., <i>Cholesterol Crystals Cause Mechanical Damage to Biological Membranes: A Proposed Mechanism of Plaque Rupture and Erosion Leading to Arterial Thrombosis</i> , 28 Clin. Cardiol. 413 (2005)	AMRN-PEXP-0000416	AMRN-PEXP-0000423	F, H, R, U
510	Albert et al., <i>Effect of Statin Therapy on C-Reactive Protein Levels: The</i>	AMRN-PEXP-0000424	AMRN-PEXP-0000434	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	<i>Pravastatin Inflammation/CRP Evaluation (PRINCE): A Randomized Trial and Cohort Study</i> , 286 JAMA 64 (2001)			
511	Ansell et al., <i>hsCRP and HDL Effects of Statins Trial (CHEST): Rapid Effect of Statin Therapy on C-Reactive Protein and High-Density Lipoprotein Levels A Clinical Investigation</i> , 5 Heart Dis. 2 (2003)	AMRN-PEXP-0000435	AMRN-PEXP-0000440	F, H, R, U
512	Ballantyne et al., <i>Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, And Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study</i> , 109 Circulation 837 (2004)	AMRN-PEXP-0000441	AMRN-PEXP-0000447	F, H, R, U
513	Behrendt et al., <i>Endothelial Function: From Vascular Biology to Clinical Applications</i> , 90 Am. J. Cardiol. 40L (2002)	AMRN-PEXP-0000448	AMRN-PEXP-0000456	F, H, R, U
514	Dunbar et al., <i>Effects of Omega-3 Carboxylic Acids on Lipoprotein Particles and Other Cardiovascular Risk Markers in High-Risk Statin-Treated Patients with Residual Hypertriglyceridemia: A Randomized, Controlled, Double-Blind Trial</i> , 14 Lipids Health Dis. 98 (2015)	AMRN-PEXP-0000457	AMRN-PEXP-0000466	F, H, R, U
515	Geelen et al., <i>Intake of n-3 Fatty Acids from Fish Does Not Lower Serum Concentrations of C-Reactive Protein in</i>	AMRN-PEXP-0000481	AMRN-PEXP-0000483	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	<i>Healthy Subjects</i> , 58 Eur. J. Clin. Nutr. 1440 (2004)			
516	Harats et al., <i>Fish Oil Ingestion in Smokers and Nonsmokers Enhances Peroxidation of Plasma Lipoproteins</i> , 90 Atherosclerosis 127 (1991)	AMRN-PEXP-0000484	AMRN-PEXP-0000496	F, H, R, U
517	Jialal et al., <i>Effect of Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitor Therapy on High Sensitive C-Reactive Protein Levels</i> , 103 Circulation 1933 (2001)	AMRN-PEXP-0000497	AMRN-PEXP-0000500	F, H, R, U
518	Karasawa et al., <i>Role of NLRP3 Inflammasomes in Atherosclerosis</i> , 24 J. Atheroscler. Thromb. 443 (2017)	AMRN-PEXP-0000501	AMRN-PEXP-0000509	F, H, R, U
519	Kellner-Weibel et al., <i>Crystallization of Free Cholesterol in Model Macrophage Foam Cells</i> , 19 Arterioscler. Thromb. Vasc. Biol. 1891 (1999)	AMRN-PEXP-0000510	AMRN-PEXP-0000518	F, H, R, U
520	Libby, et al., <i>Inflammation in Atherosclerosis: From Pathophysiology to Practice</i> , 54 J Am Coll Cardiol. 2129 (2009)	AMRN-PEXP-0000519	AMRN-PEXP-0000535	F, H, R, U
521	Madsen et al., <i>C-Reactive Protein and n-3 Fatty Acids in Patients with a Previous Myocardial Infarction</i> , 46 Eur. J. Nutr. 428 (2007)	AMRN-PEXP-0000536	AMRN-PEXP-0000538	F, H, R, U
522	Mason et al., <i>Eicosapentaenoic Acid Improves Endothelial Function and Nitric Oxide Bioavailability in a Manner That Is Enhanced in Combination with a Statin</i> , 103 Biomed. Pharmacother. 1231 (2018)	AMRN-PEXP-0000539	AMRN-PEXP-0000545	H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
523	Montecucco & Mach, New Evidences for C-reactive Protein (CRP) Deposits in the Arterial Intima as a Cardiovascular Risk Factor, 3 Clin. Interv. Aging 341 (2008)	AMRN-PEXP-0000570	AMRN-PEXP-0000578	F, H, R, U
524	Murphy et al., <i>Impact of Foods Enriched with n-3 Long-Chain Polyunsaturated Fatty Acids on Erythrocyte n-3 Levels and Cardiovascular Risk Factors</i> , 97 Br. J. Nutr. 749 (2007)	AMRN-PEXP-0000579	AMRN-PEXP-0000587	F, H, R, U
525	Musunuru et al., <i>Surprises from Genetic Analyses of Lipid Risk Factors for Atherosclerosis</i> , 118 Circ. Res. 579 (2016)	AMRN-PEXP-0000588	AMRN-PEXP-0000594	F, H, R, U
526	Pai et al., <i>Inflammatory Markers and the Risk of Coronary Heart Disease in Men and Women</i> , 351 N. Engl. J. Med. 2599 (2004)	AMRN-PEXP-0000595	AMRN-PEXP-0000606	F, H, R, U
527	Ridker et al., <i>Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events</i> , 347 N. Engl. J. Med. 1557 (2002)	AMRN-PEXP-0000607	AMRN-PEXP-0000615	F, H, R, U
528	Ridker, <i>From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream to Identify Novel Targets for Atheroprotection</i> , 118 Circ. Res. 145 (2016)	AMRN-PEXP-0000616	AMRN-PEXP-0000627	F, H, R, U
529	Sherratt & Mason, <i>Eicosapentaenoic Acid and Docosahexaenoic Acid Have Distinct Membrane Locations and Lipid Interactions as Determined by X-Ray</i>	AMRN-PEXP-0000628	AMRN-PEXP-0000634	H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	<i>Diffraction</i> , 212 Chem. Phys. Lipids 73 (2018)			
530	Sherratt & Mason, <i>Eicosapentaenoic Acid Inhibits Oxidation of High Density Lipoprotein Particles in a Manner Distinct from Docosahexaenoic Acid</i> , 496 Biochem. Biophys. Res. Commun. 335 (2018)	AMRN-PEXP-0000635	AMRN-PEXP-0000638	H, R, U
531	Suzukawa et al, Effects of Fish Oil Fatty Acids on Low Density Lipoprotein Size, Oxidizability, and Uptake by Macrophages, 36 J. Lipid Res. 473 (1995)	AMRN-PEXP-0000639	AMRN-PEXP-0000650	F, H, R, U
532	Tsimikas, Oxidized Low-density Lipoprotein Biomarkers in Atherosclerosis, 8 Curr. Atheroscler. Rep. 55 (2006)	AMRN-PEXP-0000651	AMRN-PEXP-0000657	F, H, R, U
533	Tsitouras et al., <i>High Omega-3 Fat Intake Improves Insulin Sensitivity and Reduces CRP and IL6, But Does Not Affect Other Endocrine Axes in Healthy Older Adults</i> , 40 Horm. Metab. Res. 199 (2008)	AMRN-PEXP-0000658	AMRN-PEXP-0000664	F, H, R, U
534	Watanabe et al., <i>A Randomized Controlled Trial of Eicosapentaenoic Acid in Patients with Coronary Heart Disease on Statins</i> , 70 J. Cardiol. 537 (2017)	AMRN-PEXP-0000665	AMRN-PEXP-0000672	F, H, R, U
535	Witztum et al., <i>Role of Oxidized Low Density Lipoprotein in Atherogenesis</i> , 88 J. Clin. Invest. 1785 (1991)	AMRN-PEXP-0000681	AMRN-PEXP-0000688	F, H, R, U
536	Mason, <i>New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular</i>	AMRN-PEXP-0007367	AMRN-PEXP-0007377	H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	<i>Disease</i> , 21 Curr. Atheroscler. Rep. (2019), https://doi.org/10.1007/s11883-019-0762-1			
537	Vascepa® Label (2012)	ICOSAPENT_DFNDTS00005825	ICOSAPENT_DFNDTS00005836	H, R, U
538	Oikawa et al., <i>Suppressive Effect of EPA on the Incidence of Coronary Events in Hypercholesterolemia with Impaired Glucose Metabolism: Sub- Analysis of the Japan EPA Lipid Intervention Study (JELIS)</i> , 206 Atherosclerosis 535 (2009)	AMRN00309368	AMRN00309372	F, H, R, U
539	Ishikawa et al., <i>Preventive Effects of Eicosapentaenoic Acid on Coronary Artery Disease in Patients With Peripheral Artery Disease: Subanalysis of the JELIS Trial</i> , 74 Circ. J. 1451 (2010)	AMRN00352323	AMRN00352329	F, H, R, U
540	Sasaki et al., <i>Relationship Between Coronary Artery Disease and Non-HDL-C, and Effect of Highly Purified EPA on the Risk of Coronary Artery Disease in Hypercholesterolemic Patients Treated with Statins: Sub-Analysis of the Japan EPA Lipid Intervention Study (JELIS)</i> , 19 J. Atheroscler. Thromb. 194 (2012)	AMRN00477883	AMRN00477893	F, H, R, U
541	Origasa et al., <i>Clinical Importance of Adherence to Treatment with Eicosapentaenoic Acid by Patients with Hypercholesterolemia</i> , 74 Circ. J. 510 (2010)	AMRN00916813	AMRN00916820	F, H, R, U
542	Albert et al., <i>Fish Oil Supplements in New Zealand Are Highly Oxidised and Do Not</i>	AMRN03143174	AMRN03143179	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	<i>Meet Label Content of n-3 PUFA</i> , 5:7928 Sci. Rep. (2015)			
543	Itakura et al., <i>Relationships Between Plasma Fatty Acid Composition and Coronary Artery Disease</i> , 18 J. Atheroscler. Thromb. 99 (2011)	AMRN03146288	AMRN03146296	F, H, R, U
544	Matsuzaki et al., <i>Incremental Effects of Eicosapentaenoic Acid on Cardiovascular Events in Statin-Treated Patients with Coronary Artery Disease: Secondary Prevention Analysis from JELIS</i> , 73 Circ. J. 1283 (2009)	AMRN03146599	AMRN03146606	F, H, R, U
545	Auger et al., <i>Effects of the Local Anesthetic Tetracaine on the Structural and Dynamic Properties of Lipids in Model Membranes: A High-Pressure Fourier Transform Infrared Study</i> , 27 Biochem. 6086 (1988)	AMRN-PEXP-0008701	AMRN-PEXP-0008708	F, H, R, U
546	Auger et al., <i>Interactions of the Local Anesthetic Tetracaine with Membranes Containing Phosphatidylcholine and Cholesterol: A 2H NMR Study</i> , 27 Biochem. 4660 (1988)	AMRN-PEXP-0008709	AMRN-PEXP-0008716	F, H, R, U
547	Boulanger et al., <i>Multiple Binding Sites for Local Anesthetics in Membranes: Characterization of the Sites and Their Equilibria by Deuterium NMR of Specifically Deuterated Procaine and Tetracaine</i> , 58 Can. J. Biochem. 986 (1980)	AMRN-PEXP-0008840	AMRN-PEXP-0008850	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
548	Bryan & Grisham, <i>Methods to Detect Nitric Oxide and Its Metabolites in Biological Samples</i> , 43 Free Radic. Biol. Med. 645 (2007)	AMRN-PEXP-0008886	AMRN-PEXP-0008898	F, H, R, U
549	Csonka et al., <i>Measurement of NO in Biological Samples</i> , 172 Br. J. Pharmacol. 1620 (2015)	AMRN-PEXP-0009019	AMRN-PEXP-0009031	F, H, R, U
550	Garcia-Hernandez et al., <i>Effect of Omega-3 Dietary Supplements with Different Oxidation Levels in the Lipidic Profile of Women: A Randomized Controlled Trial</i> , 64 Int. J. of Food Sci. Nutr. 993 (2013)	AMRN-PEXP-0009165	AMRN-PEXP-0009173	F, H, R, U
551	Poppitt et al., <i>Effects of Moderate-Dose Omega-3 Fish Oil on Cardiovascular Risk Factors and Mood After Ischemic Stroke: A Randomized, Controlled Trial</i> , 40 Stroke 3485 (2009)	AMRN-PEXP-0009490	AMRN-PEXP-0009497	F, H, R, U
552	Sigma-Aldrich, cis-5,8,11,14,17-Eicosapentaenoic Acid, https://www.sigmaaldrich.com/catalog/product/sigma/e2011?lang=en&region=US (last visited June 5, 2019)	AMRN-PEXP-0009532	AMRN-PEXP-0009535	A, F, H, R, U
553	Tanaka et al., <i>Reduction in the Recurrence of Stroke by Eicosapentaenoic Acid for Hypercholesterolemic Patients: Subanalysis of the JELIS Trial</i> , 39 Stroke 2052 (July 2008)	AMRN-PEXP-0009581	AMRN-PEXP-0009587	F, H, R, U
554	Zapata-Morin et al., <i>The Interaction of Local Anesthetics with Lipid Membranes</i> , 53 J. Mol. Graph. Model. 200 (2014)	AMRN-PEXP-0009615	AMRN-PEXP-0009620	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
555	Terano et al., <i>Eicosapentaenoic Acid as a Modulator of Inflammation</i> , 35 Biochem. Pharmacol. 779 (1986)	ICOSAPENT_DFNDT000 16823	ICOSAPENT_DFNDT000 16829	H, R, U
556	Brinton & Mason, <i>Prescription Omega-3 Fatty Acid Products Containing Highly Purified Eicosapentaenoic Acid (EPA)</i> , 16:23 Lipids Health Dis. (2017)	ICOSAPENT_DFNDT000 17808	ICOSAPENT_DFNDT000 17820	H, R, U
557	Omura et al., <i>Eicosapentaenoic Acid (EPA) Induces Ca²⁺-Independent Activation and Translocation of Endothelial Nitric Oxide Synthase and Endothelium-Dependent Vasorelaxation</i> , 487 FEBS Lett. 361 (2001)	ICOSAPENT_DFNDT000 17995	ICOSAPENT_DFNDT000 18000	H, R, U
558	Surette, <i>The Science Behind Dietary Omega-3 Fatty Acids</i> , 178 Can. Med. Assoc. J. 177 (Jan. 2008)	ICOSAPENT_DFNDT000 18024	ICOSAPENT_DFNDT000 18027	H, R, U
559	Suzuki et al., <i>Eicosapentaenoic Acid Protects Endothelial Cells Against Anoikis Through Restoration of cFLIP</i> , 42 Hypertension 342 (2003)	ICOSAPENT_DFNDT000 18028	ICOSAPENT_DFNDT000 18034	H, R, U
560	Thies et al., <i>Association of n-3 Polyunsaturated Fatty Acids with Stability of Atherosclerotic Plaques: a Randomised Controlled Trial</i> , 361 Lancet 477 (2003)	ICOSAPENT_DFNDTS00 012078	ICOSAPENT_DFNDTS00 012086	H, R, U
561	Rambjor et al., <i>Eicosapentaenoic Acid Is Primarily Responsible for Hypotriglyceridemic Effect of Fish Oil in Humans</i> , 31 Lipids S-45 (1996)	AMRN00290974	AMRN00290980	F, H, R, U
562	Balk et al., <i>Effects of omega-3 fatty acids on serum markers of cardiovascular</i>	AMRN00971519	AMRN00971530	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	<i>disease risk: A systematic review</i> , 189 <i>Atherosclerosis</i> 19 (2006)			
563	Woodman, et al., <i>Docosahexaenoic acid but not eicosapentaenoic acid increases LDL particle size in treated hypertensive type 2 diabetic patients</i> , 26 <i>Diabetes Care</i> 253 (2003)	AMRN01066627	AMRN01066627	F, H, R, U
564	Woodman, et al., <i>Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in Type 2 diabetic patients</i> , 166 <i>Atherosclerosis</i> 85 (2003)	AMRN01172851	AMRN01172859	F, H, R, U
565	Mori et al., <i>Docosahexaenoic Acid but Not Eicosapentaenoic Acid Lowers Ambulatory Blood Pressure and Heart Rate in Humans</i> , 34 <i>Hypertension</i> 253 (1999)	AMRN01177185	AMRN01177193	F, H, R, U
566	LOVAZA® Label (2007)	AMRN01187779	AMRN01187780	
567	Nilsen et al., <i>Effects of a High-Dose Concentrate of n-3 Fatty Acids or Corn Oil Introduced Early After an Acute Myocardial Infarction on Serum Triacylglycerol and HDL Cholesterol</i> , 74 <i>Am. J. Clinical Nutrition</i> 50 (2001)	AMRN01213518	AMRN01213524	F, H, R, U
568	De Caterina et al., <i>The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells</i> , 14 <i>Arteriosclerosis</i>	AMRN01400409	AMRN01400417	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	Thrombosis Vascular Biology 1829 (1994)			
569	Amarin Pharma, Inc., <i>Notes from Amarin's Expert Panel Meeting</i> (Dec. 12, 2008)	AMRN01511308	AMRN01511312	F, H, R, U
570	Letter from Steven Ketchum to Jean-Marc Guettier, M.D. re: NDA 202057 seq0113; VASCEPA® (icosapent ethyl) Capsules; Final Printed Carton and Container Labels for approved NDA 202057/S-019 (With Attachments) (Mar. 01, 2017)	AMRN03132167	AMRN03132181	R, U
571	FDA, <i>Guidance for Industry: Distributing Scientific and Medical Publications on Unapproved New Uses - Recommended Practices</i> (Feb. 2014) (Draft)	N/A	N/A	H, R, U
572	FDA, <i>Guidance for Industry: Dosage and Administration Section of Labeling for Human Prescription Drug and Biological Products — Content and Format</i> (Mar. 2010)	AMRN-PEXP-0010229	AMRN-PEXP-0010241	H, R, U
573	FDA, <i>Guidance for Industry: Indications and Usage Section of Labeling for Human Prescription Drug and Biological Products — Content and Format (Draft)</i> (July 2018)	AMRN-PEXP-0010242	AMRN-PEXP-0010261	H, R, U
574	DRL Proposed Prescribing Information (2018)	DRLEIPA 0095591	DRLEIPA 0095647	L
575	Niaspan Label, Barceloneta, Puerto Rico: AbbVie, Ltd. (Apr. 2015)	AMRN03147061	AMRN03147083	H, R, U
576	Amarin Presentation, "2017 Operating Plan" (2017)	AMRN03151453	AMRN03151514	H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
577	AplusA Bell Fella Report, "Vascepa® (Icosapent ethyl), US Market Surveillance Study (ATU) Wave 2, Final Report of Findings" (Apr. 2017)	AMRN03151516	AMRN03151633	H, R, U
578	Amarin Presentation, "Omega 3 Pricing History"	AMRN03151788	AMRN03151789	F, H, R, U
579	Amarin Presentation, "Vascepa DTC Launch" (Nov. 2017)	AMRN03151790	AMRN03151824	F, H, R, U
580	ZS Associates Presentation, "Vascepa Wave 2 PhysPulse Findings" (Aug. 2014)	AMRN03151826	AMRN03151937	F, H, R, U
581	AplusA Report, "Vascepa® (Icosapent ethyl), US Market Surveillance Study (ATU), Final Report of Findings" (Jan. 2016)	AMRN03151938	AMRN03152047	F, H, R, U
582	PharmaSight Research Presentation, "VASCEPA® New Campaign Message Convergence Exploration: Healthcare Practitioners and Sales Professionals/Representatives" (May 2015)	AMRN03152048	AMRN03152161	F, H, R, U
583	GfK Presentation, "VASCEPA SFE, Q23 2017, Quantitative Research, Final Report Prepared for Amarin" (Sep. 2017)	AMRN03152279	AMRN03152308	F, H, R, U
584	PharmaSight Research Presentation, "Vascepa® New Promotional Campaign Exploration: Phase 1: Message Testing" (Nov. 2014)	AMRN03152472	AMRN03152521	F, H, R, U
585	Amarin Presentation, "Marketing Update" (Dec. 2017)	AMRN03159866	AMRN03159902	F, H, R, U
586	Amarin Presentation, "Marketing Update, January POAs, 2018" (Jan. 2018)	AMRN03159988	AMRN03160021	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
587	Historical Revenue Q1 2013-Q2 2018	AMRN03163817	AMRN03163817	F, H, R, U
588	Quarterly Financial Summary Q1 2013-Q2 2018	AMRN03163818	AMRN03163818	F, H, R, U
589	Historical Revenue Q1 2013-Q4 2018	AMRN03171431	AMRN03171431	F, H, R, U
590	Quarterly Financial Summary Q1 2013-Q4 2018	AMRN03171432	AMRN03171432	F, H, R, U
591	Antara Label, Baltimore, MD: Lupin Pharma (Nov. 2018)	AMRN-PEXP-0002044	AMRN-PEXP-0002063	F, H, R, U
592	Fenoglide Label, Bridgewater, NJ: Valeant Pharmaceuticals North America LLC (May 2018)	AMRN-PEXP-0002064	AMRN-PEXP-0002079	F, H, R, U
593	Fibricor Label, Philadelphia, PA: AR Scientific, Inc. (Aug. 2009)	AMRN-PEXP-0002080	AMRN-PEXP-0002089	F, H, R, U
594	Lipofen Label, Juncos, Puerto Rico: Galephar Pharmaceutical Research Inc. (Jan. 2006)	AMRN-PEXP-0002090	AMRN-PEXP-0002109	F, H, R, U
595	Lopid Label, New York: Parke-Davis (2017)	AMRN-PEXP-0002110	AMRN-PEXP-0002124	F, H, R, U
596	Tricor Label, North Chicago, IL: Abbott Laboratories (2004)	AMRN-PEXP-0002125	AMRN-PEXP-0002138	F, H, R, U, DUPE
597	Acemoglu, Daron, and Joshua Linn, <i>Market Size and Innovation: Theory and Evidence from the Pharmaceutical Industry</i> , 119 Quarterly Journal of Economics 1049 (2004)	AMRN-PEXP-0002139	AMRN-PEXP-0002181	F, H, R, U
598	Berndt, Ernst R., <i>The U.S. Pharmaceutical Industry: Why Major Growth In Times Of Cost Containment?</i> , 20 Health Affairs 100 (2001)	AMRN-PEXP-0002182	AMRN-PEXP-0002196	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
599	Berndt, Ernst R., and Joseph P. Newhouse, <i>Pricing and Reimbursement in the U.S. Pharmaceutical Markets</i> , in Patricia M. Danzon and Sean Nicholson eds., <i>The Oxford Handbook of the Economics of the Biopharmaceutical Industry</i> , New York: Oxford University Press, pp. 201–265 (2012)	AMRN-PEXP-0002197	AMRN-PEXP-0002263	F, H, R, U
600	Berndt, Ernst R., et al., <i>Decline in Economic Returns from New Drugs Raises Questions about Sustaining Innovations</i> , 34 <i>Health Affairs</i> 245 (2015)	AMRN-PEXP-0002264	AMRN-PEXP-0002271	F, H, R, U
601	Berndt, Ernst R., et al., <i>Information, Marketing, and Pricing in the U.S. Antiulcer Drug Market</i> , 85 <i>The American Economic Review</i> 100 (1995)	AMRN-PEXP-0002272	AMRN-PEXP-0002278	F, H, R, U
602	Brealey, Richard A., and Stewart C. Myers, <i>Principles of Corporate Finance</i> , Fifth Edition, New York: The McGraw-Hill Companies (1996)	AMRN-PEXP-0002279	AMRN-PEXP-0002305	F, H, R, U
603	Budish, Eric, et al., <i>Do Firms Underinvest in Long-Term Research? Evidence from Cancer Clinical Trials?</i> , 105 <i>American Economic Review</i> 2044 (2015)	AMRN-PEXP-0002306	AMRN-PEXP-0002348	F, H, R, U
604	Carlton, Dennis W., and Jeffrey M. Perloff, <i>Modern Industrial Organization, Third Edition</i> , Reading, MA: Addison Wesley Longman Inc. (1999)	AMRN-PEXP-0002349	AMRN-PEXP-0002394	F, H, R, U
605	Cohen, Frederic J., <i>Macro Trends in Pharmaceutical Innovation</i> , 4 <i>Nature</i> 78 (2005)	AMRN-PEXP-0002395	AMRN-PEXP-0002401	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
606	Cutler, David M., and Mark McClellan, <i>Is Technological Change in Medicine Worth It?</i> , 20 Health Affairs 11 (2001)	AMRN-PEXP-0002402	AMRN-PEXP-0002420	F, H, R, U
607	DiMasi et al., <i>R&D Costs and Returns to New Drug Development: A Review of the Evidence</i> , in Patricia M. Danzon and Sean Nicholson eds., <i>The Oxford Handbook of the Economics of the Biopharmaceutical Industry</i> , New York: Oxford University Press, pp. 21–46 (2012)	AMRN-PEXP-0002421	AMRN-PEXP-0002448	F, H, R, U
608	DiMasi, Joseph A., et al., <i>Innovation in the pharmaceutical industry: New estimates of R&D Costs</i> , 47 <i>Journal of Health Economics</i> 20 (2016)	AMRN-PEXP-0002449	AMRN-PEXP-0002462	F, H, R, U
609	Duggan et al., <i>Estimating the Impact of Medical Innovation: A Case Study of HIV Antiretroviral Treatments</i> , 11 <i>Forum for Health Economics & Policy</i> 1 (2008)	AMRN-PEXP-0002463	AMRN-PEXP-0002501	F, H, R, U
610	Ewald et al., <i>Treatment options for severe hypertriglyceridemia (SHTG): the role of apheresis</i> , 7 <i>Clinical Research in Cardiology</i> suppl. 1, available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3374106 (2012)	AMRN-PEXP-0002502	AMRN-PEXP-0002506	F, H, R, U
611	Garthwaite et al., <i>Empirical Evidence on the Value of Pharmaceuticals</i> , in Patricia M. Danzon and Sean Nicholson eds., <i>The Oxford Handbook of the Economics of the Biopharmaceutical Industry</i> , New York: Oxford University Press, pp. 463–492 (2012)	AMRN-PEXP-0002507	AMRN-PEXP-0002538	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
612	Grabowski, Follow-on biologics: data exclusivity and the balance between innovation and competition, <i>Nature Reviews Drug Discovery</i> , pp. 1–10, available at https://dukespace.lib.duke.edu/dspace/bits/tream/handle/10161/6709/PublishedCopy.pdf?sequence=1&isAllowed=y (2008)	AMRN-PEXP-0002539	AMRN-PEXP-0002548	F, H, R, U
613	Grabowski, <i>Patents, Innovation and Access to New Pharmaceuticals</i> , 5 <i>Journal of International Economic Law</i> 849 (2002)	AMRN-PEXP-0002549	AMRN-PEXP-0002568	F, H, R, U
614	Grabowski et al., <i>Pharmaceutical Patent Challenges: Company Strategies and Litigation Outcomes</i> , 3 <i>American Journal of Health Economics</i> 33 (2017)	AMRN-PEXP-0002569	AMRN-PEXP-0002595	F, H, R, U
615	Grabowski et al., <i>Returns on Research and Development for 1990s New Drug Introductions</i> , 20 <i>Pharmacoeconomics</i> 11 (2002)	AMRN-PEXP-0002596	AMRN-PEXP-0002614	F, H, R, U
616	Hartmann et al., <i>Application of Real Options Analysis for the Pharmaceutical R&D Project Valuation—Empirical Results From a Survey</i> , 35 <i>Research Policy</i> 343 (2006)	AMRN-PEXP-0002615	AMRN-PEXP-0002626	F, H, R, U
617	Lakdawalla, <i>Economics of the Pharmaceutical Industry</i> , 56 <i>Journal of Economic Literature</i> 397 (2018)	AMRN-PEXP-0002627	AMRN-PEXP-0002679	F, H, R, U
618	Lichtenberg, <i>Are the Benefits of Newer Drugs Worth Their Cost? Evidence from</i>	AMRN-PEXP-0002706	AMRN-PEXP-0002716	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	<i>the 1996 MEPS</i> , 20 Health Affairs 241 (2001)			
619	Lichtenberg, <i>Availability of New Drugs and Americans' Ability to Work</i> , 47 Journal of Occupational and Environmental Medicine 373 (2005)	AMRN-PEXP-0002717	AMRN-PEXP-0002724	F, H, R, U
620	Mizik et al., <i>Are Physicians 'Easy Marks'? Quantifying the Effects of Detailing and Sampling on New Prescriptions</i> , 50 Management Science 1704 (2004)	AMRN-PEXP-0002725	AMRN-PEXP-0002737	F, H, R, U
621	Rosenthal et al., <i>Promotion of Prescription Drugs to Consumers</i> , 346 The New England Journal of Medicine 498 (2002)	AMRN-PEXP-0002738	AMRN-PEXP-0002745	F, H, R, U
622	Scherer, <i>The Link Between Gross Profitability and Pharmaceutical R&D Spending</i> , 20 Health Affairs 216 (2001)	AMRN-PEXP-0002746	AMRN-PEXP-0002750	F, H, R, U
623	Scherer, <i>Pricing, Profits, and Technological Progress in the Pharmaceutical Industry</i> , 7 Journal of Economic Perspectives 97 (1993)	AMRN-PEXP-0002751	AMRN-PEXP-0002770	F, H, R, U
624	Sokal et al., <i>The Hatch-Waxman Act: Encouraging Innovation and Generic Drug Competition</i> , Current Topics in Medicinal Chemistry, pp. 1–16, at https://www.finnegan.com/en/insights/the-hatch-waxman-act-encouraging-innovation-andgeneric-drug.html (2010)	AMRN-PEXP-0002771	AMRN-PEXP-0002786	F, H, R, U
625	Stevens et al., <i>The Role of Public-Sector Research in the Discovery of Drugs and</i>	AMRN-PEXP-0002787	AMRN-PEXP-0002794	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	<i>Vaccines</i> , 364 The New England Journal of Medicine 535 (2011)			
626	Trusheim et al., <i>Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules?</i> , 13 Forum for Health Economics & Policy 1 (2010)	AMRN-PEXP-0002795	AMRN-PEXP-0002839	F, H, R, U
627	Venkataraman et al., <i>The Debate on Influencing Doctors' Decisions: Are Drug Characteristics the Missing Link?</i> , 53 Management Science 1688 (2007)	AMRN-PEXP-0002840	AMRN-PEXP-0002854	F, H, R, U
628	Amarin, SEC Form 20-F for Fiscal Year Ended December 31, 2018 (Oct. 2009)	AMRN-PEXP-0004409	AMRN-PEXP-0004946	H, R, U
629	Amarin, SEC Form 20-F for Fiscal Year Ended December 31, 2009 (Jun. 2010)	AMRN-PEXP-0004947	AMRN-PEXP-0005115	H, R, U
630	Amarin, SEC Form 10-K for Fiscal Year Ended December 31, 2010 (Mar. 2011)	AMRN-PEXP-0005116	AMRN-PEXP-0005303	H, R, U
631	Amarin, SEC Form 10-K for Fiscal Year Ended December 31, 2011 (Feb. 2012)	AMRN-PEXP-0005304	AMRN-PEXP-0005519	H, R, U
632	Amarin, SEC Form 10-K for Fiscal Year Ended December 31, 2012 (Feb. 2013)	AMRN-PEXP-0005520	AMRN-PEXP-0005698	H, R, U
633	Amarin, SEC Form 10-K for Fiscal Year Ended December 31, 2013 (Feb. 2014)	AMRN-PEXP-0005699	AMRN-PEXP-0005833	H, R, U
634	Amarin, SEC Form 10-K for Fiscal Year Ended December 31, 2014 (Mar. 2015)	AMRN-PEXP-0005834	AMRN-PEXP-0005983	H, R, U
635	Amarin, SEC Form 10-K for Fiscal Year Ended December 31, 2015 (Feb. 2016)	AMRN-PEXP-0005984	AMRN-PEXP-0006145	H, R, U
636	Amarin, SEC Form 10-K for Fiscal Year Ended December 31, 2016 (Mar. 2017)	AMRN-PEXP-0006146	AMRN-PEXP-0006326	H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
637	Amarin, SEC Form 10-K for Fiscal Year Ended December 31, 2017 (Feb. 2018)	AMRN-PEXP-0006327	AMRN-PEXP-0006620	H, R, U
638	Dr. Reddy's Laboratories, SEC Form 6-K for the Quarter Ended December 31, 2017 (Feb. 2018)	AMRN-PEXP-0006621	AMRN-PEXP-0006712	H, L, R, U
639	Dr. Reddy's Laboratories, SEC Form 6-K for the Quarter Ended September 30, 2018 (Nov. 2018)	AMRN-PEXP-0006713	AMRN-PEXP-0006772	H, L, R, U
640	Reliant Pharmaceuticals, Inc., Pre-effective Amendment No. 3 to Form S-1 dated August 10, 2007 (Oct. 2007)	AMRN-PEXP-0006773	AMRN-PEXP-0007098	A, F, H, R, U
641	Amarin NDTI Jan 08 to Nov 12 010819.xlsx	AMRN-PEXP-0007099	AMRN-PEXP-0007099	A, F, R, U
642	IQVIA_Amarin_Lovaza Total Promo_2005-2012.xlsx	AMRN-PEXP-0007100	AMRN-PEXP-0007100	A, F, H, R, U
643	Lovaza 120418.xlsx	AMRN-PEXP-0007101	AMRN-PEXP-0007101	A, F, H, R, U
644	Monthly Module Views- Rx (NPA)_1_Dec-18-2018(1).xlsx	AMRN-PEXP-0007102	AMRN-PEXP-0007102	A, F, R, U
645	Monthly Module Views- Sales (NSP)_1_Jan-02-2019.xlsx	AMRN-PEXP-0007103	AMRN-PEXP-0007103	A, F, R, U
646	Prod TG Levels Dec 12 to Nov 18 NDTI_Jan-08-2019.xlsx	AMRN-PEXP-0007104	AMRN-PEXP-0007104	A, F, R, U
647	Total Promotional Dollars.xlsx	AMRN-PEXP-0007105	AMRN-PEXP-0007105	A, F, R, U
648	Beatty et al., Alert: Takeaways from KOL Call on AMRN's REDUCE-IT Results, Citi Research (Oct. 2018)	AMRN-PEXP-0007106	AMRN-PEXP-0007113	F, H, R, U
649	Beatty et al., <i>TP Increase to \$17 (+\$12) after REDUCE-IT Hits Primary Endpoint</i> , Citi Research (Sep. 2018)	AMRN-PEXP-0007114	AMRN-PEXP-0007124	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
650	Boris et al., <i>REDUCE-IT CV Outcomes Trial Generates Paradigm Shifting 25% CV Risk Reduction</i> , SunTrust Robinson Humphrey (Sep. 2018)	AMRN-PEXP-0007125	AMRN-PEXP-0007133	F, H, R, U
651	Boris et al., <i>REDUCE-IT Exceeds Expectations on All Five MACE Components</i> , SunTrust Robinson Humphrey (Nov. 2018)	AMRN-PEXP-0007134	AMRN-PEXP-0007152	F, H, R, U
652	Chen et al., <i>Buckle Up, Because Vascepa Rxs Could Take Off Soon</i> , Cantor Fitzgerald (Nov. 2018)	AMRN-PEXP-0007153	AMRN-PEXP-0007166	F, H, R, U
653	Song et al., <i>Stock Has Room to Move Higher, Vascepa Potential SoC –Raising PT to \$15</i> , Jefferies Research Services (Sep. 2018)	AMRN-PEXP-0007173	AMRN-PEXP-0007181	F, H, R, U
654	Triglide Label, East Brunswick, NJ: Casper Pharma LLC (2018)	AMRN-PEXP-0007182	AMRN-PEXP-0007198	F, H, R, U
655	Amarin, SEC Form 10-K for Fiscal Year Ended December 31, 2018 (Feb. 2019)	AMRN-PEXP-0007482	AMRN-PEXP-0007685	H, R, U
656	Fein et al., <i>Embracing a Decidedly Non-Orphan Disease Company; Reit Buy and Raising PT to \$51</i> , H.C. Wainwright & Co. (Nov. 2018)	AMRN-PEXP-0007686	AMRN-PEXP-0007691	F, H, a R, U
657	Beatty et al., <i>Amarin Corp (AMRN) 2019 Revenue Guidance Lower Than Expectations, TP \$20 (-\$8)</i> , Citi Research Equities (Jan. 2019)	AMRN-PEXP-0007707	AMRN-PEXP-0007717	F, H, R, U
658	Fein et al., <i>Expect the Continued Underlying Vascepa Demand to Drive Value; Reit Buy and \$51 PT</i> , H.C. Wainwright & Co. (Feb. 2019)	AMRN-PEXP-0007718	AMRN-PEXP-0007722	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
659	IQVIA TRx_NRx_Retail \$ _Jan19_Feb-22-2019.xlsx	AMRN-PEXP-0007723	AMRN-PEXP-0007723	A, F, R, U
660	IQVIA_USC_32130_32900_Sales (NSP) 1 Mar-05-2019.xlsx	AMRN-PEXP-0007724	AMRN-PEXP-0007724	F, H, R, U
661	Yee et al., <i>Easy and great tuck-in for pharma global salesforce</i> , Jefferies Research Services (Feb. 2019)	AMRN-PEXP-0007725	AMRN-PEXP-0007735	F, H, R, U
662	Prod TG Levels Feb 13 to Jan 19_Feb-21-2019.xlsx	AMRN-PEXP-0007736	AMRN-PEXP-0007736	F, H, R, U
663	Boris et al., <i>Lowering Sales on Slower Ramp & Execution Risk; Keener Focus on Shareholder Value Needed</i> , SunTrust Robinson Humphrey (Jan. 2019)	AMRN-PEXP-0007737	AMRN-PEXP-0007747	F, H, R, U
664	Harrington, <i>Cost of Capital for Pharmaceutical, Biotechnology, and Medical Device Firms</i> , in <i>The Oxford Handbook of the Economics of the Biopharmaceutical Industry</i> , New York: Oxford University Press, pp. 75–99 (2012)	AMRN-PEXP-0007959	AMRN-PEXP-0007985	F, H, R, U
665	Amarin, <i>Amarin Receives Special Protocol Assessment Agreement from the FDA for Phase 3 Cardiovascular Trial</i> , available at https://investor.amarincorp.com/static-files/2c93bb06-a6cb-4a61-bd17-8c6d78a06949	AMRN00629031	AMRN00629033	F, H, R, U
666	Amarin Corporation, <i>Amarin Announces Submission of Supplemental New Drug Application (SNDAs) for Vascepa® for the Treatment of Patients with High</i>	AMRN01103649	AMRN01103651	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	<i>Triglycerides with Mixed Dyslipidemia</i> , available at https://investor.amarincorp.com/news-releases/news-releasedetails/amarin-announces-submission-supplemental-new-drug-application-1			
667	ATP III Guidelines At-A-Glance Quick Desk Reference, Circulation 106:25	AMRN01171357	AMRN01171362	A, F, H, R, U
668	Lakdawalla et al., <i>Incentives to Innovate</i> , in Patricia M. Danzon and Sean Nicholson, eds., <i>The Oxford Handbook of the Economics of the Biopharmaceutical Industry</i> , New York: Oxford University Press, pp. 143–166	AMRN-PEXP-0002680	AMRN-PEXP-0002705	F, H, R, U
669	Gobe Newswire, <i>Amarin Provides Preliminary 2018 Results and 2019 Outlook</i> , available at https://www.nasdaq.com/press-release/amarin-provides-preliminary-2018-results-and-2019-outlook-20190104-00643	AMRN-PEXP-0002858	AMRN-PEXP-0002867	F, H, R, U
670	Budwell, <i>Why Amarin Corporation Stock is Exploding Higher Today</i> , <i>The Motley Fool</i> , available at https://www.fool.com/investing/2018/09/24/why-amarin-corporation-stock-is-exploding-higher-t.aspx	AMRN-PEXP-0002868	AMRN-PEXP-0002871	F, H, R, U
671	StreetInsider, <i>FDA on Fence About Vascepa (AMRN) Anchor Approval, Panel a Key Event</i> , available at https://www.streetinsider.com/Analyst+C	AMRN-PEXP-0002872	AMRN-PEXP-0002873	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	omments/FDA+on+Fence>About+Vascep a+%28AMRN%29+ANCHOR+Approval %2C+Panel+a+Key+Event+- +MKM+Partners/8773823.html			
672	Drug Channels, <i>Interpreting IMS' Shiny Happy New Forecast</i> , available at https://www.drugchannels.net/2009/10/interpreting-ims-shiny-happy-new.html	AMRN-PEXP-0002874	AMRN-PEXP-0002877	F, H, R, U
673	Business Wire, <i>Pharma Reps Can Now Access Formulary Data Anytime, Anywhere</i> , available at https://www.businesswire.com/news/home/20120419005069/en/Pharma-Reps-Access-Formulary-Data-Anytime	AMRN-PEXP-0002878	AMRN-PEXP-0002879	F, H, R, U
674	Amarin, <i>Clinical Program</i> , available at https://www.amarincorp.com/products.html	AMRN-PEXP-0003150	AMRN-PEXP-0003157	F, H, R, U
675	Amarin, <i>First Amendment Decision a Win for Amarin and Physician Plaintiffs</i> , available at https://investor.amarincorp.com/news-releases/news-release-details/first-amendment-decisionwin-amarin-and-physician-plaintiffs	AMRN-PEXP-0003158	AMRN-PEXP-0003161	F, H, R, U
676	Amarin Corporation, <i>Amarin Announces FDA Acceptance for Filing of AMR101 NDA</i> , available at https://investor.amarincorp.com/news-releases/news-release-details/amarinannounces-fda-acceptance-filing-amr101-nda	AMRN-PEXP-0003162	AMRN-PEXP-0003163	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
677	Amarin Corporation, <i>Amarin Announces Patent Litigation Settlement Agreement with Teva</i> , available at https://investor.amarincorp.com/news-releases/news-release-details/amarinannounces-patent-litigation-settlement-agreement-teva	AMRN-PEXP-0003164	AMRN-PEXP-0003167	F, H, R, U
678	Amarin Corporation, <i>REDUCE-IT™ Cardiovascular Outcomes Study of Vascepa® (icosapent ethyl) Capsules Met Primary Endpoint</i> , available at https://investor.amarincorp.com/newsreleases/news-release-details/reduce-ittm-cardiovascular-outcomes-study-vascepar-icosapent	AMRN-PEXP-0003168	AMRN-PEXP-0003171	F, H, R, U
679	American College of Cardiology, <i>Japan EPA Lipid Intervention Study</i> , at https://www.acc.org/latest-in-cardiology/clinical-trials/2010/02/23/19/10/jelis ,	AMRN-PEXP-0003172	AMRN-PEXP-0003174	
680	Bond et al., <i>Sales, Promotion, and Product Differentiation in Two Prescription Drug Markets</i> , Federal Trade Commission (Feb. 1977)	AMRN-PEXP-0003175	AMRN-PEXP-0003350	F, H, R, U
681	CLI Houston, <i>The role of reverse engineering in the development of generic formulations</i> , available at http://www.clihouston.com/news/the-role-of-reverse-engineering-in-the-development-of-generic-formulations.html	AMRN-PEXP-0003351	AMRN-PEXP-0003354	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
682	ClinicalTrials.gov, <i>A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients with Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event. (REDUCE-IT)</i> , available at https://clinicaltrials.gov/ct2/show/NCT01492361	AMRN-PEXP-0003355	AMRN-PEXP-0003362	F, H, R, U
683	ClinicalTrials.gov, <i>Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL) (ANCHOR)</i> , available at https://www.clinicaltrials.gov/ct2/show/study/NCT01047501?term=AMR101&rank=3	AMRN-PEXP-0003363	AMRN-PEXP-0003368	F, H, R, U
684	ClinicalTrials.gov, <i>Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL (MARINE)</i> , available at https://www.clinicaltrials.gov/ct2/show/NCT01047683?term=AMR101&rank=2 ,	AMRN-PEXP-0003369	AMRN-PEXP-0003374	F, H, R, U
685	Congressional Budget Office, <i>Research and Development in the Pharmaceutical Industry</i> , (Oct. 2006)	AMRN-PEXP-0003375	AMRN-PEXP-0003439	F, H, R, U
686	Cook et al., <i>An Industrial Implementation of the Biopharmaceuticals Classification</i>	AMRN-PEXP-0003440	AMRN-PEXP-0003443	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	<i>System</i> , Dissolution Technologies, available at http://www.dissolutiontech.com/DTresour/0502art/DTMay02_art1.htm			
687	Decision Resources Group, <i>Fingertip Formulary</i> , available at https://lookup.decisionresourcesgroup.com/ (Oct. 19, 2018)	AMRN-PEXP-0003444	AMRN-PEXP-0003459	A, F, H, R, U
688	Diabetes Patient Advocacy Coalition, <i>How the FDA Drug Approval Process Works</i> , available at http://diabetespac.org/fda-drug-approval-process/	AMRN-PEXP-0003460	AMRN-PEXP-0003465	F, H, R, U
689	Dr. Reddy's, <i>Annual Report for 2017-2018</i>	AMRN-PEXP-0003466	AMRN-PEXP-0003725	H, L, R, U
690	Dr. Reddy's, <i>Press Presentation – Q2 FY19</i> , (Oct. 2018) available at http://www.drreddys.com/media/729539/dr-reddys-press-presentation-q2-fy-19.pdf	AMRN-PEXP-0003726	AMRN-PEXP-0003738	H, L, R, U
691	Drugs@FDA, <i>Drugs@FDA: FDA Approved Drug Products</i> , available at https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm , search for "fenofibrate"	AMRN-PEXP-0003739	AMRN-PEXP-0003739	A, F, H, R, U
692	Drugs@FDA, <i>Drugs@FDA: FDA Approved Drug Products [Niaspan]</i> , available at https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020381	AMRN-PEXP-0003740	AMRN-PEXP-0003744	A, F, H, R, U
693	Drugs@FDA, <i>Letter [Barr Generic Niacin]</i> , available at	AMRN-PEXP-0003745	AMRN-PEXP-0003748	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/076378ltr.pdf			
694	Drugs@FDA, <i>Drugs@FDA: FDA Approved Drug Products [Lopid]</i> , available at https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018422	AMRN-PEXP-0003749	AMRN-PEXP-0003750	A, F, H, R, U
695	Drugs@FDA, <i>NDA 20381: NDA Approval Letter [Niaspan Coadministration with Statin Revoked]</i> , available at https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/020381Orig1s051ltr.pdf	AMRN-PEXP-0003751	AMRN-PEXP-0003753	F, H, R, U
696	FDA, <i>Abbreviated New Drug Application (ANDA): Generics</i> , available at http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics	AMRN-PEXP-0003754	AMRN-PEXP-0003756	H, R, U
697	FDA, <i>FDA Listing of Authorized Generics as of December 27, 2018</i> , available at https://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/UCM183605.pdf	AMRN-PEXP-0003757	AMRN-PEXP-0003838	H, R, U
698	FDA, <i>Guidance for Industry. 180-Day Exclusivity: Questions and Answers</i> , available at https://www.fda.gov/downloads/Drugs/Gu	AMRN-PEXP-0003839	AMRN-PEXP-0003868	H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	idanceComplianceRegulatoryInformation/Guidances/UCM536725.pdf			
699	FDA, <i>Inside Clinical Trials: Testing Medical Products in People</i> , available at http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm143531.htm	AMRN-PEXP-0003869	AMRN-PEXP-0003875	H, R, U
700	FDA, <i>Small Business Assistance: Frequently Asked Questions for New Drug Product Exclusivity</i> , available at https://www.fda.gov/drugs/developmentapprovalprocess/smallbusinessassistance/ucm069962.htm	AMRN-PEXP-0003876	AMRN-PEXP-0003879	H, R, U
701	Federal Trade Commission, <i>Emerging Health Care Issues: Follow-on Biologic Drug Competition</i> , Federal Trade Commission Report	AMRN-PEXP-0003880	AMRN-PEXP-0003999	H, R, U
702	Hikma Pharmaceuticals PLC, <i>Better Health. Within Reach. Every Day</i> , Annual Report 2017	AMRN-PEXP-0004000	AMRN-PEXP-0004813	H, L, R, U
703	Mayo Clinic, <i>Statins: Are these cholesterol-lowering drugs right for you?</i> , available at https://www.mayoclinic.org/diseases-conditions/high-blood-cholesterol/in-depth/statins/art-20045772	AMRN-PEXP-0004184	AMRN-PEXP-0004189	F, H, R, U
704	Mayo Clinic, <i>Triglycerides: Why Do They Matter?</i> , available at https://www.mayoclinic.org/diseases-conditions/high-blood-cholesterol/indepth/triglycerides/art-20048186	AMRN-PEXP-0004190	AMRN-PEXP-0004193	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
705	Pharmaceutical Research and Manufacturers of America, 2016 Biopharmaceutical Research Industry Profile, Washington, DC: PhRMA	AMRN-PEXP-0004194	AMRN-PEXP-0004279	F, H, R, U
706	Pharmaceutical Research and Manufacturers of America, "2018 Annual Membership Survey"	AMRN-PEXP-0004280	AMRN-PEXP-0004287	F, H, R, U
707	PubChem, <i>Fenofibrate</i> , available at https://pubchem.ncbi.nlm.nih.gov/compound/fenofibrate	AMRN-PEXP-0004288	AMRN-PEXP-0004359	F, H, R, U
708	Sweeney et al., <i>Hypertriglyceridemia Medication</i> , Medscape, available at https://emedicine.medscape.com/article/126568-medication	AMRN-PEXP-0004360	AMRN-PEXP-0004368	R, U
709	Vascepa, <i>Pure EPA Omega-3 VASCEPA®</i> , available at https://www.vascepa.com	AMRN-PEXP-0004369	AMRN-PEXP-0004381	F, H, R, U
710	Winegarden, <i>The Economics of Pharmaceutical Pricing</i> , Pacific Research Institute, 2014, pp. 1–27, available at https://www.pacificresearch.org/why-pharmaceutical-prices-droponce-drugs-are-off-patent/ ,	AMRN-PEXP-0004382	AMRN-PEXP-0004408	F, H, R, U
711	Cantor Fitzgerald, <i>If you had Any Concerns Going Into 2019, REDUCE-IT</i> (2019)	AMRN-PEXP-0007205	AMRN-PEXP-0007219	F, H, R, U
712	Cantor Fitzgerald, <i>Don't Die Of A Broken Heart; Physician Survey Shows How Vascepa Can Help</i> (2019)	AMRN-PEXP-0007220	AMRN-PEXP-0007254	F, H, R, U
713	Ference et al., <i>Association of Triglyceride-Lowering LPL Variants and LDL-C</i> –	AMRN-PEXP-0007255	AMRN-PEXP-0007264	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	<i>Lowering LDLR Variants With Risk of Coronary Heart Disease</i> , 321 JAMA 364 (2019)			
714	Jefferies LLC, Conference Call on Cardiovascular Drugs, Conference No. 7178953 (Dec. 20, 2018)	AMRN-PEXP-0007338	AMRN-PEXP-0007366	F, H, R, U
715	Gingerich, <i>Icosapent Ethyl Reduces Cardiovascular Death Risk 20% in REDUCE-IT Trial</i> , MD Magazine (Nov. 11, 2018)	AMRN-PEXP-0007478	AMRN-PEXP-0007480	F, H, R, U
716	Amarin Corporation, <i>Amarin Reports Record Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Operations</i> , available at https://investor.amarincorp.com/news-releases/news-release-details/amarin-reports-record-fourth-quarter-and-full-year-2018	AMRN-PEXP-0007692	AMRN-PEXP-0007706	F, H, R, U
717	Fidelity Investments, <i>AMRN Stock Snapshot</i> , available at https://eresearch.fidelity.com/eresearch/evaluate/snapshot.jhtml?symbols=AMRN	AMRN-PEXP-0007986	AMRN-PEXP-0007988	A, F, H, R, U
718	Decision Resources Group, <i>Fingertip Formulary</i> , available at https://lookup.decisionresourcesgroup.com/ (March 1, 2019)	AMRN-PEXP-0008014	AMRN-PEXP-0008073	A, F, H, R, U
719	Vascepa, <i>Pure EPA Omega-3 VASCEPA®</i> , available at https://www.vascepa.com	AMRN-PEXP-0008074	AMRN-PEXP-0008076	F, H, R, U
720	Amarin Corporation, <i>Amarin Announces FDA Review Division Response to</i>	N/A	N/A	F, H, N, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	<i>ANCHOR SPA Agreement Reinstatement Request</i> , available at https://investor.amarincorp.com/news-releases/news-release-details/amarin-announces-fda-review-divisionresponse-anchor-spa-0 , last accessed January 1, 2019.			
721	Board of Trustees, Federal Old-Age and Survivors Insurance and Federal Disability Insurance Trust Funds, <i>The 2018 Annual Report of the Board of Trustees, Federal Old-Age and Survivors Insurance and Federal Disability Insurance Trust Funds</i> (Jun. 2018)	AMRN-PEXP-0002880	AMRN-PEXP-0003149	F, H, R, U
722	Aitken et al., <i>The Regulation of Prescription Drug Competition and Market Responses: Patterns in Prices and Sales Following Loss of Exclusivity, in Measuring and Modeling Health Care Costs</i> (Ana Aizcorbe et al. eds. 2018)	AMRN-PEXP-0008429	AMRN-PEXP-0008485	F, H, R, U
723	Amarin Form 10-Q for the Quarterly Period Ended March 31, 2018 (May 2018)	AMRN-PEXP-0008486	AMRN-PEXP-0008565	H, R, U
724	Amarin Form 10-Q for the Quarterly Period Ended March 31, 2019 (May 2019)	AMRN-PEXP-0008566	AMRN-PEXP-0008651	H, R, U
725	Amarin, <i>U.S. FDA Grants Priority Review For Vascepa (Icosapent Ethyl)</i> , Amarin Corporation, available at https://investor.amarincorp.com/newsreleases/news-release-details/us-fda-grants-priority-review-vasceparicosapent-ethyl	AMRN-PEXP-0008652	AMRN-PEXP-0008655	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
726	Andrews, Matthew J., <i>Amarin Corporation (AMRN) – Q3: Vascepa TRx Grinding Higher; T minus 10 months and Counting for REDUCE-IT</i> , Jefferies (Nov. 2017)	AMRN-PEXP-0008682	AMRN-PEXP-0008689	F, H, R, U
727	Beatty, Joel, <i>Amarin Corp (AMRN) – 3Q16: Vascepa Sales Flat, but Script Growth Remains Strong</i> , Citi Research Equities (Nov. 2016)	AMRN-PEXP-0008723	AMRN-PEXP-0008732	F, H, R, U
728	Beatty et al., <i>Amarin Corp(AMRN) – Vascepa Sales Impress with Steady Growth; Outcomes Data 3Q18</i> (Nov. 2017)	AMRN-PEXP-0008733	AMRN-PEXP-0008743	F, H, R, U
729	Boris et al., <i>Amarin Corporation plc (AMRN) – 2Q17 PostView- Raising '17 Sales on Vascepa Performance, but Maintaining EPS</i> , SunTrust Robinson Humphrey (Aug. 2017)	AMRN-PEXP-0008812	AMRN-PEXP-0008828	F, H, R, U
730	Boris et al., <i>Amarin Corporation plc (AMRN) – 3Q16 Preview – Raising Sales & Lowering LPS on Higher Vascepa Sales</i> , SunTrust Robinson Humphrey (Nov. 2016)	AMRN-PEXP-0008829	AMRN-PEXP-0008839	F, H, R, U
731	Brav, Alon et al., <i>An Empirical Analysis of Analysts' Target Prices: Shortterm Informativeness and Long-term Dynamics</i> , Journal of Finance 58, 2003	AMRN-PEXP-0008851	AMRN-PEXP-0008885	F, H, R, U
732	Cantor Fitzgerald, <i>Equities</i> , available at https://www.cantor.com/ourbusiness/equities	AMRN-PEXP-0008910	AMRN-PEXP-0008920	A, F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
733	Chen et al., <i>Amarin Coporation plc (AMRN) – Rising Tide Carrying Up This Ship; Strong 3Q17 Underscores Vascepa Underappreciated</i> , Cantor Fitzgerald (Nov. 2017)	AMRN-PEXP-0008921	AMRN-PEXP-0008934	F, H, R, U
734	Citi Bank, <i>Investments: Identifying Opportunities and Risks Across Many Asset Classes and Countries Requires Access to the Highest Quality Insights and Analysis</i> , available at https://www.privatebank.citibank.com/home/investments/citi-research.html	AMRN-PEXP-0008935	AMRN-PEXP-0008941	A, F, H, R, U
735	Conti et al., <i>Specialty Drug Prices and Utilization after Loss of U.S. Patent Exclusivity, 2001-2007</i> , Ana Aizcorbe, Colin Baker, Ernst R. Berndt and David M. Cutler, eds., <i>Measuring and Modeling Health Care Costs</i> , Chicago: University of Chicago Press for the National Bureau of Economic Research, 2018.	AMRN-PEXP-0008942	AMRN-PEXP-0009018	F, H, R, U
736	FINRA, <i>Research Analyst Qualification Exam (Series 86/87): Content Outline</i> , (2015) http://www.finra.org/sites/default/files/Industry/p006473.pdf	AMRN-PEXP-0009117	AMRN-PEXP-0009131	F, H, R, U
737	Gönül et al., <i>Promotion of Prescription Drugs and Its Impact on Physicians' Choice Behavior</i> , <i>Journal of Marketing</i> 65, no. 3, 2001.	AMRN-PEXP-0009182	AMRN-PEXP-0009191	F, H, R, U
738	Grabowski et al., <i>Generic Competition and Market Exclusivity Periods in</i>	AMRN-PEXP-0009192	AMRN-PEXP-0009204	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	<i>Pharmaceuticals, Managerial and Decision Economics</i> 27 (2007)			
739	Grabowski et al., <i>Updated Trends in US brand-name and generic drug competition</i> , <i>Journal of Medical Economics</i> , 2016.	AMRN-PEXP-0009205	AMRN-PEXP-0009213	F, H, R, U
740	Hemphill et al., <i>Evergreening, Patent Challenges, and Effective Market Life in Pharmaceuticals</i> , <i>Journal of Health Economics</i> 31, 2012.	AMRN-PEXP-0009222	AMRN-PEXP-0009234	F, H, R, U
741	Hong et al., <i>Bad News Travels Slowly: Size, Analyst Coverage, and the Profitability of Momentum Strategies</i> , <i>Journal of Finance</i> 55, 2000.	AMRN-PEXP-0009243	AMRN-PEXP-0009273	F, H, R, U
742	Hurwitz et al., <i>Persuasion or Information? Promotion and the Shares of Brand Name and Generic Pharmaceuticals</i> , <i>Journal of Law & Economics</i> 31, no. 2, 1988.	AMRN-PEXP-0009280	AMRN-PEXP-0009302	F, H, R, U
743	Leffler, Keith B., <i>Persuasion or Information? The Economics of Prescription Drug Advertising</i> , <i>Journal of Law & Economics</i> 24, no. 1, 1981.	AMRN-PEXP-0009365	AMRN-PEXP-0009395	F, H, R, U
744	Ong, <i>Amarin Corporation (AMRN) – Q3: Vascepa Continues its Steady Growth</i> , Jefferies (Nov. 2016)	AMRN-PEXP-0009463	AMRN-PEXP-0009472	F, H, R, U
745	OPTUMRx, <i>Therapeutic Class Overview: Omega-3 Fatty Acids</i> , https://www.medicaid.nv.gov/Downloads/provider/Omega-	AMRN-PEXP-0009473	AMRN-PEXP-0009482	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	3_Fatty_Acids_2018-03.pdf, AMRN-PEXP-0009473 (Nov. 2017)			
746	QuintileIMS Institute, <i>Estimate of Medicare Part D Costs After Accounting for Manufacturer Rebates</i> , QuintilesIMS Institute, 2016, available at https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/estimate-of-medicare-part-d-costs-afteraccounting-for-manufacturer-rebates.pdf	AMRN-PEXP-0009498	AMRN-PEXP-0009510	F, H, R, U
747	Russo, <i>Amarin Corporation plc (AMRN) – REDUCE-IT Timeline Remains on Track, Positive Revenue Guidance to Upper Half</i> , Cantor Fitzgerald (Nov. 2016)	AMRN-PEXP-0009513	AMRN-PEXP-0009522	F, H, R, U
748	“Form 10-K,” United States Securities and Exchange Commission, available at https://www.sec.gov/about/forms/form10-k.pdf	AMRN-PEXP-0009588	AMRN-PEXP-0009599	H, R, U
749	Wehmhoefer, Richard, <i>Statistics in Litigation</i> , McGraw-Hill, 1985.	AMRNPEXP-0009600	AMRNPEXP-0009606	F, H, R, U
750	Howe et al., <i>The Predictive Content of Aggregate Analyst Recommendations</i> , <i>Journal of Accounting Research</i> 47, 2009.	AMRN-PEXP-0010583	AMRN-PEXP-0010606	F, H, R, U
751	Whitehouse, <i>Financial Analysts and Their Role in Financial Communication and Investor Relations</i> , <i>The Handbook of Financial Communication and Investor Relations</i> , 2017.	AMRN-PEXP-0010607	AMRN-PEXP-0010616	F, H, R, U
752	Fein et al., <i>Amarin Corporation (AMRN) – Continued Uptick in Vascepa Scripts to</i>	ICOSAPENT_DFNDT00016535	ICOSAPENT_DFNDT00016539	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	<i>Support a Cash Flow Positive 2017</i> , H.C. Wainwright & Co. Equity Research (Mar. 2017)			
753	Email from L. Crutchley to Dr. Bays et al. re: CONFIDENTIAL: Amarin Expert Panel Meeting for AMR-101 (ethyl-EPA) Meeting Package (With Attachments) (Nov. 26, 2008)	AMRN00597991	AMRN00598096	R, U
754	Ian Osterloh Notes from Amarin's Expert Panel Meeting 12th December 2008, Boston	AMRN01531055	AMRN01531058	F, H, R, U
755	Email from I. Osterloh to D. Doogan et al. re: EPA Hypertriglyceridemia Project Status and Investor Due Diligence (With Attachments) (March 10, 2008)	AMRN01671916	AMRN01671933	F, H, R, U
756	Email from I. Osterloh to D. Doogan et al. re: CV strategy (Mar. 20, 2008)	AMRN01671955	AMRN01671959	F, H, R, U
757	Email from I. Osterloh to P. Wicker re: Miraxion - US experts (Jan. 23, 2008)	PW-AMRN00000603	PW-AMRN00000604	F, H, R, U
758	FDA, CDER, <i>Summary Minutes of the Endocrinologic and Metabolic Drugs Advisory Committee Meeting</i> (Oct. 16, 2013)	AMRN01400429	AMRN01400433	H, R, U
759	Vascepa® Statistical Review	AMRN01624147	AMRN01624223	F, H, R, U
760	FDA Briefing Document, <i>Endocrinologic and Metabolic Drugs, Advisory Committee Meeting</i> (Oct. 16, 2013)	AMRN03106502	AMRN03106617	H, R, U
761	FDA, Complete Response Letter, <i>NDA No. 202057/S-005</i> (Apr. 27, 2015)	AMRN03132005	AMRN03132009	H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
762	FDA Office of Prescription Drug Promotion, Letter re NDA #202057, Dec. 4, 2017	AMRN03160122	AMRN03160125	F, H, R, U
763	ALIMTA® Labeling (2019)	AMRN-PEXP-0009765	AMRN-PEXP-0009802	F, H, R, U
764	Coumadin® Labeling (2017)	AMRN-PEXP-0009803	AMRN-PEXP-0009834	F, H, R, U
765	Eliquis® Labeling (2019)	AMRN-PEXP-0009835	AMRN-PEXP-0009879	H, R, U
766	FDA, <i>About FDA Product Approval</i>	AMRN-PEXP-0009880	AMRN-PEXP-0009880	F, H, R, U
767	FDA, CDER, Office of Clinical Pharmacology, <i>Good Review Practices: Clinical Pharmacology Review of New Molecular Entity (NME) New Drug Applications (NDAs) and Original Biologic License Applications (BLAs)</i> (Sept. 2016)	AMRN-PEXP-0009881	AMRN-PEXP-0009900	H, R, U
768	FDA, CDER, Office of New Drugs, <i>Good Review Practice: Clinical Review Template</i> (Dec. 2010)	AMRN-PEXP-0009901	AMRN-PEXP-0010019	H, R, U
769	FDA, CDER, Office of New Drugs, <i>Good Review Practice: Good Review Management Principles and Practices for Effective IND Development and Review</i> (Apr. 2013)	AMRN-PEXP-0010020	AMRN-PEXP-0010061	H, R, U
770	FDA, CDER, Office of Pharmaceutical Science, <i>Chemistry Review of Question-based Review (QbR) Submissions</i> (Nov. 2014)	AMRN-PEXP-0010062	AMRN-PEXP-0010073	H, R, U
771	FDA, CDER, <i>Office of the Center Director, Scientific / Regulatory Dispute Resolution for Individuals Within a Management Chain</i> (Sept. 2010)	AMRN-PEXP-0010074	AMRN-PEXP-0010078	H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
772	FDA, <i>Compliance Program Guidance Manual: Chapter 46 - New Drug Evaluation: Program 7346.832, Pre-Approval Inspections</i> (2010)	AMRN-PEXP-0010079	AMRN-PEXP-0010131	H, R, U
773	FDA, <i>Development & Approval Process (Drugs)</i>	AMRN-PEXP-0010132	AMRN-PEXP-0010135	H, R, U
774	FDA, <i>Guidance for Industry: Clinical Drug Interaction Studies — Study Design, Data Analysis, and Clinical Implications</i> (Oct. 2017)	AMRN-PEXP-0010136	AMRN-PEXP-0010167	H, R, U
775	FDA, <i>Guidance for Industry: Clinical Pharmacology Section of Labeling for Human Prescription Drug and Biological Products — Content and Format</i> (Dec. 2016)	AMRN-PEXP-0010168	AMRN-PEXP-0010186	H, R, U
776	FDA, <i>Guidance for Industry: Clinical Studies Section of Labeling for Human Prescription Drug and Biological Products — Content and Format</i> (Jan. 2006)	AMRN-PEXP-0010187	AMRN-PEXP-0010211	H, R, U
777	FDA, <i>Guidance for Industry: Determining Whether to Submit an ANDA or a 505(b)(2) Application</i> (May 2019)	AMRN-PEXP-0010212	AMRN-PEXP-0010228	H, R, U
778	FDA, <i>Guidance for Industry: Labeling for Human Prescription Drug and Biological Products – Implementing the PLR Content and Format Requirements</i> (Feb. 2013)	AMRN-PEXP-0010262	AMRN-PEXP-0010295	H, R, U
779	FDA, <i>Guidance for Industry: M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing</i>	AMRN-PEXP-0010296	AMRN-PEXP-0010325	H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	<i>Authorization for Pharmaceuticals</i> (Jan. 2010)			
780	<i>FDA, Guidance for Industry: Medical Product Communications that Are Consistent with the FDA-Required Labeling — Questions and Answers</i> (Jun. 2018)	AMRN-PEXP-0010326	AMRN-PEXP-0010347	H, R, U
781	<i>FDA, Guidance for Industry: Patient Counseling Information Section of Labeling for Human Prescription Drug and Biological Products — Content and Format</i> (Dec. 2014)	AMRN-PEXP-0010348	AMRN-PEXP-0010359	H, R, U
782	<i>FDA, Guidance for Industry: Refuse to File: NDA and BLA Submissions to CDER (Draft)</i> (Dec. 2017)	AMRN-PEXP-0010360	AMRN-PEXP-0010370	H, R, U
783	<i>FDA, Guidance for Industry: Warnings and Precautions, Contraindications, and Boxed Warning Sections of Labeling for Human Prescription Drug and Biological Products — Content and Format</i> (Oct. 2011)	AMRN-PEXP-0010371	AMRN-PEXP-0010385	H, R, U
784	<i>FDA, Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors- FDA Inspections of Clinical Investigators</i> (June 2010)	AMRN-PEXP-0010386	AMRN-PEXP-0010394	H, R, U
785	<i>FDA, Office of New Drugs</i>	AMRN-PEXP-0010395	AMRN-PEXP-0010397	F, H, R, U
786	<i>FDA, The Drug Development Process</i>	AMRN-PEXP-0010398	AMRN-PEXP-0010399	F, H, R, U
787	<i>FDA, The FDA's Drug Review Process: Ensuring Drugs Are Safe and Effective</i>	AMRN-PEXP-0010400	AMRN-PEXP-0010403	F, H, R, U
788	<i>FDA, What We Do</i>	AMRN-PEXP-0010404	AMRN-PEXP-0010405	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
789	Gerlie Gieser, Office of Clinical Pharmacology, <i>FDA, Clinical Pharmacology 1: Phase 1 Studies and Early Drug Development</i>	AMRN-PEXP-0010406	AMRN-PEXP-0010440	F, H, R, U
790	Kremzner & Osborne, FDA, <i>An Introduction to the Improved FDA Prescription Drug Labeling</i>	AMRN-PEXP-0010441	AMRN-PEXP-0010508	F, H, R, U
791	Letter from Audrey Gassman, Deputy Director for Safety, FDA Ctr. for Drug Evaluation and Research, to Elinor Chen, Director of Worldwide Regulatory Affairs, Merck Sharp & Dohme Corp., Supplement Approval & Release REMS Requirement (July 1, 2011)	AMRN-PEXP-0010509	AMRN-PEXP-0010511	F, H, R, U
792	Letter from Audrey Gassman, Deputy Director for Safety, FDA Ctr. for Drug Evaluation and Research, to Elinor Chen, Director of Worldwide Regulatory Affairs, Merck Sharp & Dohme Corp., Supplement Approval and attached labeling (Jan. 25, 2011)	AMRN-PEXP-0010512	AMRN-PEXP-0010540	F, H, R, U
793	Letter from Christine P. Nguyen, Deputy Director for Safety, FDA Ctr. for Drug Evaluation and Research, to Barbra Weiss, Sr. Scientist of Global Regulatory Affairs, Merck Sharp & Dohme Corp., Supplement Approval and attached labeling (Apr. 8, 2015)	AMRN-PEXP-0010541	AMRN-PEXP-0010570	F, H, R, U
794	Letter from Hylton V. Joffe, Director of the Division of Reproductive and Urologic Products, FDA Ctr. for Drug	AMRN-PEXP-0010571	AMRN-PEXP-0010574	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	Evaluation and Research, to Elinor Chen, Director of Worldwide Regulatory Affairs, Merck Sharp & Dohme Corp., Supplement Approval (Apr. 19, 2013)			
795	NovoNordisk, <i>Victoza</i> ® Provided an Additional Benefit of Greater Weight Loss in 2 Head-to-Head Trials	AMRN-PEXP-0010575	AMRN-PEXP-0010582	F, H, R, U
796	21 C.F.R., Ch. 1, Subch. A, Pt. 58 (2018)	N/A	N/A	H, R, U
797	21 C.F.R., Ch. 1, Subch. C, Pt. 200 (2018)	N/A	N/A	H, R, U
798	21 C.F.R., Ch. 1, Subch. C, Pt. 201 (2018)	N/A	N/A	H, R, U
799	21 C.F.R., Ch. 1, Subch. C, Pt. 202 (2018)	N/A	N/A	H, R, U
800	21 C.F.R., Ch. 1, Subch. D, Pt. 300 (2018)	N/A	N/A	H, R, U
801	21 C.F.R., Ch. 1, Subch. D, Pt. 310 (2018)	N/A	N/A	H, R, U
802	21 C.F.R., Ch. 1, Subch. D, Pt. 312 (2018)	N/A	N/A	H, R, U
803	21 C.F.R., Ch. 1, Subch. D, Pt. 314 (2018)	N/A	N/A	H, R, U
804	44 Fed. Reg. 37434 (June 26, 1979)	N/A	N/A	H, R, U
805	71 Fed. Reg. 3921 (Jan. 24, 2006)	N/A	N/A	H, R, U
806	73 Fed. Reg. 49603 (Aug. 22, 2008)	N/A	N/A	H, R, U
807	Amarin Pharma Inc., Clinical Study Report, <i>Study AMR-01-01-0016, A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With an Open-Label Extension to Evaluate the Efficacy and Safety of AMR101 in Patients With Fasting Triglyceride Levels ≥ 500 mg/dL & ≤ 2000 mg/dL: The AMR101 MARINE Study</i> (2011)	AMRN00053457	AMRN00054134	H, R, U
808	Amarin Pharma Inc., <i>Clinical Study Report: A Phase 3, Multi-Center,</i>	AMRN02406289	AMRN02406501	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	<i>Placebo-Controlled, Randomized, Double-Blind, 12-Week Study to Evaluate the Effect of Two Doses of AMR101 on Fasting Serum Triglyceride Levels in Patients with Persistent High Triglyceride Levels (≥ 200 mg/dL and < 500mg/dL) Despite Statin Therapy: The AMR101 ANCHOR Study (2011)</i>			
809	21 C.F.R. § 105	N/A	N/A	H, R, U
810	Center for Drug Evaluation and Research Application Number: 202057Orig1s000 Medical Review(s)	ICOSAPENT DFNDT00015424	ICOSAPENT DFNDT00015567	H, R, U
811	ELIQUIS® Prescribing Information (2019)	AMRN-PEXP-0009062	AMRN-PEXP-0009106	H, R, U
812	Email from C. Hunashimarad to A. Srivastava (Jan. 17, 2013)	DRLEEPA 0010223	DRLEEPA 0010224	F, H, L, R, U
813	Email from C. Kirankumare to C. Arabindakshya Mishra (Oct. 15, 2012)	DRLEEPA 0039452	DRLEEPA 0039452	F, H, L, R, U
814	Email from R. Pillai to A. Mukherjee (Mar. 30, 2013)	DRLEEPA 0040430	DRLEEPA 0040431	F, H, L, R, U
815	Development Strategy	DRLEEPA 0042505	DRLEEPA 0042551	F, H, L, R, U
816	Email from ravip@drreddys.com to kirankumarch@drreddys.com (Apr. 26, 2012)	DRLEEPA 0044514	DRLEEPA 0044516	F, H, L, R, U
817	Email from C. Praveen to sujeetksingh@drreddys.com (July 2, 2012)	DRLEEPA 0047404	DRLEEPA 0047404	F, H, L, R, U
818	AMR-101 Financial	DRLEEPA 0047405	DRLEEPA 0047438	F, H, L, R, U
819	Development Strategy	DRLEEPA0039453	DRLEEPA0039483	F, H, L, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
820	Email from K. Hunashimarad to P. Yuen (July 31, 2014)	DRLEPA0093878	DRLEPA0093885	F, H, L, R, U
821	Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) to Dr. Reddy's Laboratories, Inc. & Dr. Reddy's Laboratories, LTD.	N/A	N/A	L, R
822	Amarin, Pharma Inc., <i>Amarin's AMR101 Meets Pivotal Phase 3 Study Endpoints With Highly Statistically Significant Reductions in Triglycerides at 4 Gram and 2 Gram Doses in MARINE Trial With No Statistically Significant Increase in LDL-C and Safety Profile Similar to Placebo</i> (Nov. 29, 2010), https://investor.amarincorp.com/news-releases/news-release-details/amarins-amr101-meets-pivotal-phase-3-study-endpoints-highly	AMRN00204090	AMRN00204092	F, H, R, U
823	Contacos et al., <i>Effect of Pravastatin and co-3 Fatty Acids on Plasma Lipids and Lipoproteins in Patients With Combined Hyperlipidemia</i> , 13 <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> 1755 (1993)	AMRN00290334	AMRN00290341	F, H, R, U
824	Harris et al., <i>Safety and efficacy of Omacor in severe hypertriglyceridemia</i> , 4 <i>J. Cardiovascular Risk</i> 385 (1997)	AMRN00290443	AMRN00290449	F, H, R, U, DUPE
825	LOPID® Physicians' Desk Reference 2554 (58th ed. 2004)	AMRN00290574	AMRN00290578	F, H, R, U
826	OMACOR® Physicians' Desk Reference 2735 (60th ed. 2006)	AMRN00290904	AMRN00290906	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
827	Rader et al, <i>Disorders of Lipoprotein Metabolism</i> , in Harrison's Principles of Internal Medicine 2286 (Dennis L. Kasper et al. eds., 16th ed., 2005)	AMRN00290951	AMRN00290973	F, H, R, U
828	TRICOR® Physicians' Desk Reference 502 (62d ed. 2008)	AMRN00291159	AMRN00291163	F, H, R, U
829	Mochida Pharmaceuticals Co., Ltd., Translation of international application (WO '118) (2008)	AMRN00291241	AMRN00291284	H, R, U
830	Brickates Kennedy, <i>Amarin soars on triglyceride-drug hopes</i> , MarketWatch (Apr. 18, 2011), https://www.marketwatch.com/story/amarin-soars-on-triglyceride-drug-hopes-2011-04-18	AMRN00291393	AMRN00291394	F, H, R, U
831	Videotape: Medscape Education Town Hall (Nov. 2011)	AMRN00291692	AMRN00291697	F, H, R, U
832	VASCEPA® Prescribing Information (2013)	AMRN00308767	AMRN00308777	H, R, U
833	Friedewald et al., <i>The Editor's Roundtable: Hypertriglyceridemia</i> , 112 Am. J. Cardiology 1133 (2013)	AMRN00870632	AMRN00870640	F, H, R, U
834	Christian et al., <i>Determining Triglyceride Reductions Needed for Clinical Impact in Severe Hypertriglyceridemia</i> , 127 Am. J. Med. 36 (2014)	AMRN00872270	AMRN00872279	F, H, R, U
835	Maki et al., <i>Prescription Omega-3 Carboxylic Acids for the Treatment of Severe Hypertriglyceridemia</i> , 9 Clinical Lipidology 399 (2014)	AMRN00888851	AMRN00888858	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
836	Bradberry et al., <i>Overview of Omega-3 Fatty Acid Therapies</i> , 38 P&T 681 (2013)	AMRN00899152	AMRN00899162	F, H, R, U
837	Kastelein et al., <i>Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa for Lowering Very high triglycerides (EVOLVE) trial</i> , 8 J. Clinical Lipidology 94 (2014)	AMRN00900482	AMRN00900494	F, H, R, U
838	The Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group, <i>Prevention of Cardiovascular Events and Death With Pravastatin in Patients With Coronary Heart Disease and a Broad of Initial Cholesterol Levels</i> , 339 N. Eng. J. Med. 1349 (1998)	AMRN00971785	AMRN00971793	F, H, R, U, NPI
839	Sacks et al., <i>The Effect of Pravastatin on Coronary Events After Myocardial Infarction in Patients With Average Cholesterol Levels</i> , 335 N. Eng. J. Med. 1001 (1996)	AMRN00971921	AMRN00971929	F, H, R, U
840	Shepherd et al., <i>Prevention of Coronary Heart Disease With Pravastatin in Men with Hypercholesterolemia</i> , 333 N. Eng. J. Med. 1301 (1995)	AMRN00971962	AMRN00971968	F, H, R, U
841	Feagan et al., <i>Omega-3 Free Fatty Acids for the Maintenance of Remission in Crohn Disease</i> , 14 JAMA 1690 (2008)	AMRN01029703	AMRN01029711	F, H, R, U
842	Mori et al., <i>The Independent Effects of Eicosapentaenoic Acid and Docosahexaenoic Acid on Cardiovascular</i>	AMRN01212517	AMRN01212526	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	<i>Risk Factors in Humans</i> , 9 Current Op. Clinical Nutrition & Metabolic Care 95 (2006)			
843	Hassan et al., <i>Retrospective Case Series of Patients With Diabetes or Prediabetes Who Were Switched From Omega-3-Acid Ethyl Esters to Icosapent Ethyl</i> , 4 Cardiology Therapy 83 (2015)	AMRN01237873	AMRN01237883	F, H, R, U
844	Rubins et al., <i>Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men With Low Levels of High-Density Lipoprotein Cholesterol</i> , 341 N. Eng. J. Med. 410 (1999)	AMRN01371516	AMRN01371524	F, H, R, U
845	Scandinavian Simvastatin Survival Study Group, <i>Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)</i> , 344 Lancet 1383 (1994)	AMRN01378780	AMRN01378786	F, H, R, U
846	Austin et al., <i>Hypertriglyceridemia as a Cardiovascular Risk Factor</i> , 81 Am. J. Cardiology 7B (1998)	AMRN01400315	AMRN01400320	F, H, R, U
847	AstraZeneca, <i>AstraZeneca to Acquire Omthera Pharmaceuticals Including NDA-Ready Novel Dyslipidemia Treatment to Complement Cardiovascular Portfolio</i> (May 28, 2013), https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-omthera-pharmaceuticals-dyslipidemia-treatment-cardiovascular-	AMRN01693437	AMRN01693439	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	28052013.html#modal-historic-confirmation			
848	Hooper et al., <i>Risks and Benefits of Omega 3 Fats for Mortality, Cardiovascular Disease, and Cancer: Systematic Review</i> , 332 BMJ 752 (2006)	AMRN02976620	AMRN02976628	F, H, R, U
849	EPANOVA® Label (2014)	AMRN03129984	AMRN03129994	H, R, U
850	OMTRYG® Label (2014)	AMRN03130027	AMRN03130041	H, R, U
851	BIP Study Group, <i>Secondary Prevention by Raising HDL Cholesterol and Reducing Triglycerides in Patients With Coronary Artery Disease</i> , 102 Circulation 21 (2000)	AMRN03145539	AMRN03145546	F, H, R, U
852	Fialkow, <i>Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements Are Not Substitutes for Prescription Products</i> , 16 AM. J. Cardiovascular Drugs 229 (2016)	AMRN03146087	AMRN03146097	F, H, R, U
853	Frick et al., <i>Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men With Dyslipidemia</i> , 317 N. Eng. J. Med. 1237 (1987)	AMRN03146130	AMRN03146138	F, H, R, U
854	Handelsman et al., <i>Triglycerides, Atherosclerosis, and Cardiovascular Outcome Studies: Focus on Omega-3 Fatty Acids</i> , 23 Endocrine Practice 100 (2017)	AMRN03146193	AMRN03146205	F, H, R, U
855	Cannon et al., <i>Ezetimibe Added to Statin Therapy After Acute Coronary</i>	AMRN03157137	AMRN03157147	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	<i>Syndromes</i> , 372 N. Eng. J. Med. 2387 (2015)			
856	Terry, Nothing Fishy Here: Amarin's Fish Oil-Based Drug Dramatically Reduces Cardiovascular Risk, BioSpace (Sept. 24, 2018) https://www.biospace.com/article/nothing-fishy-here-amarin-s-fish-oil-based-drug-dramatically-reduces-cardiovascular-risk	AMRN03163940	AMRN03163943	F, H, R, U
857	Nisen, <i>Fish-Oil Heart Medicine Is Rarest of Drug Breakthroughs</i> , Bloomberg Opinion (Sept. 24, 2018), https://www.bloomberg.com/opinion/articles/2018-09-24/amarin-amrn-fish-oil-heart-medicine-win-is-rarest-drug-success	AMRN03163944	AMRN03163947	F, H, R, U
858	Hamilton et al., <i>Amarin surges as trial results exceed expectations</i> , Irish Times (Sept. 24, 2018), https://www.irishtimes.com/business/health-pharma/amarin-surges-as-trial-results-exceed-expectations-1.3639526	AMRN03163951	AMRN03163952	F, H, R, U
859	Neale, <i>REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides</i> , TCTMD (Nov. 10, 2018), https://www.tctmd.com/news/reduce-it-prescription-fish-oil-prevents-cv-events-patients-high-triglycerides	AMRN03163963	AMRN03163969	F, H, R, U
860	<i>Amarin Corporation (AMRN) PT Raised to \$51 at H.C. Wainwright; REDUCE-IT Update is a 'Home Run'</i> , Street Insider	AMRN03163970	AMRN03163970	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	(Nov. 12, 2018), https://www.streetinsider.com/Analyst+Comments/Amarin+Corporation+%28AMRN%29+PT+Raised+to+%2451+at+H.C.+Wainwright%3B+REDUCE-IT+Update+is+a+Home+run/14814097			
861	NEJM REDUCE IT Letter to the Editor 2-23-19 Version 6 DLB	AMRN03168890	AMRN03168892	F, H, R, U
862	Badimon, <i>CETP Inhibition and HDL: What Is the Trial REVEALing?</i> , 114 Cardiovascular Res. e15 (2018)	AMRN-PEXP-0001151	AMRN-PEXP-0001152	F, H, R, U
863	Brinton et al., <i>Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA)</i> , 16 Lipids in Health and Disease 23 (2017)	AMRN-PEXP-0001189	AMRN-PEXP-0001201	F, H, R, U
864	Carey, <i>FDA Rejects Merck's Cordaptive</i> , Bloomberg Law (Apr. 29, 2008), https://www.bloomberg.com/news/articles/2008-04-29/fda-rejects-mercks-cordaptivebusinessweek-business-news-stock-market-and-financial-advice	AMRN-PEXP-0001202	AMRN-PEXP-0001204	F, H, R, U
865	Carroll, <i>Amarin Scores a Big Win for its Cardio Outcomes Study on Vascepa – Stock Races Higher as Analysts Applaud</i> , Endpoints News (Sept. 24, 2018), https://endpts.com/amarin-claims-a-big-win-for-their-outcomes-study-on-vascepa-and-you-can-bet-that-makes-some-people-very-unhappy/	AMRN-PEXP-0001205	AMRN-PEXP-0001207	F, H, R, U
866	Castaldo, <i>Switching statin-treated patients from fenofibrate to the prescription</i>	AMRN-PEXP-0001208	AMRN-PEXP-0001215	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	<i>omega-3 therapy icosapent ethyl: a retrospective case series</i> , 32 <i>Drugs & Therapy Perspective</i> 162 (2016)			
867	Coronary Drug Project Research Group, <i>Clofibrate and Niacin in Coronary Heart Disease</i> , 231 <i>J. Am. Med. Assoc.</i> 360 (1975)	AMRN-PEXP-0001216	AMRN-PEXP-0001237	F, H, R, U
868	Crocker, <i>Amarin's Vascepa: Reject the Noise and Accept the Facts</i> , Seeking Alpha (Nov. 28, 2018), https://seekingalpha.com/article/4225047-amarins-vascepa-reject-noise-accept-facts	AMRN-PEXP-0001238	AMRN-PEXP-0001250	F, H, R, U
869	U.S. Dep't of Health & Human Services, Food and Drug Administration, <i>Drugs@FDA: FDA Approved Drug Products NDA 018422 (LOPID)</i> , https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018422	AMRN-PEXP-0001251	AMRN-PEXP-0001252	F, H, R, U
870	U.S. Dep't of Health & Human Services, Food and Drug Administration, <i>Drugs@FDA: FDA Approved Drug Products NDA 021203 (TRICOR)</i> , https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021203	AMRN-PEXP-0001253	AMRN-PEXP-0001254	F, H, R, U
871	U.S. Dep't of Health & Human Services, Food and Drug Administration, <i>Drugs@FDA: FDA Approved Drug Products NDA 022224 (TRILIPIX)</i> , http://www.accessdata.fda.gov/scripts/cde	AMRN-PEXP-0001255	AMRN-PEXP-0001256	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	r/daf/index.cfm?event=overview.process &varApplNo=022224			
872	<i>Epanova for the Treatment of Hypertriglyceridemia</i> , Drug Development Technology (Oct. 10, 2018), https://www.drugdevelopment-technology.com/projects/epanova-for-the-treatment-of-hypertriglyceridemia/	AMRN-PEXP-0001257	AMRN-PEXP-0001261	F, H, R, U
873	U.S. Dep't of Health & Human Services, Food and Drug Administration, Supplement Approval, NDA 20381/S-051 (Apr. 27, 2015)	AMRN-PEXP-0001262	AMRN-PEXP-0001264	F, H, R, U
874	U.S. Dep't of Health & Human Services, Food and Drug Administration, <i>FDA Briefing Document Endocrinologic and Metabolic Drugs Advisory Committee Meeting</i> (Oct. 16, 2013)	AMRN-PEXP-0001265	AMRN-PEXP-0001379	H, R, U
875	Fidler, <i>Amarin Soars as Fish Oil Pill Cuts Risk of Strokes in Long-Awaited Study</i> , XConomy (Sept. 24, 2018), https://xconomy.com/new-york/2018/09/24/amarin-soars-as-fish-oil-pill-cuts-risk-of-strokes-in-long-awaited-study/	AMRN-PEXP-0001385	AMRN-PEXP-0001387	F, H, R, U
876	Garnett, <i>Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors</i> , 52 Am. J. Health-System Pharmacy 1639 (1995)	AMRN-PEXP-0001430	AMRN-PEXP-0001438	F, H, R, U
877	Ginsberg, <i>Lipoprotein Metabolism and its Relationship to Atherosclerosis</i> , 78 Med. Clinics N. Am. 1 (1994)	AMRN-PEXP-0001439	AMRN-PEXP-0001458	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
878	Gorriz et al., <i>Rhabdomyolysis and Acute Renal Failure Associated With Gemfibrozil Therapy</i> , 74 Nephron 437 (1996)	AMRN-PEXP-0001459	AMRN-PEXP-0001460	F, H, R, U
879	Hughes, <i>REDUCE-IT: 'A New Era' in CVD Prevention With High-Dose EPA</i> , Medscape (Nov. 10, 2018), https://www.medscape.com/viewarticle/904737	AMRN-PEXP-0001496	AMRN-PEXP-0001499	F, H, R, U
880	Ito, <i>A Comparative Overview of Prescription Omega-3 Fatty Acid Products</i> , 40 P&T 826 (2015)	AMRN-PEXP-0001500	AMRN-PEXP-0001511	F, H, R, U
881	Jarcho and Keaney, <i>Proof That Lower Is Better – LDL Cholesterol and IMPROVE-IT</i> , 372 N. Eng. J. Med. 2448 (2015)	AMRN-PEXP-0001512	AMRN-PEXP-0001514	F, H, R, U
882	Kones, <i>Primary Prevention of Coronary Heart Disease: Integration of New Data, Evolving Views, Revised Goals, and Role of Rosuvastatin in Management. A comprehensive survey</i> , 5 Drug Design, Development and Therapy 325 (2011)	AMRN-PEXP-0001539	AMRN-PEXP-0001594	F, H, R, U
883	Levy, <i>Drugs Used in the Treatment of Hyperlipoproteinemias</i> , in <i>The Pharmacological Basis of Therapeutics</i> 834 (Goodman & Gilman eds., 6th ed. 1980)	AMRN-PEXP-0001595	AMRN-PEXP-0001610	F, H, R, U
884	Motorhead, <i>Amarin: 85% of Doctors Polled at AHA Conference Intend to Prescribe VASCEPA</i> , Seeking Alpha (Nov. 14, 2018), https://seekingalpha.com/article/4222150-	AMRN-PEXP-0001615	AMRN-PEXP-0001621	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	amarin-85-percent- doctors-polled-aha-conference-intend-prescribe-vascepa			
885	NIACOR® Label (2000)	AMRN-PEXP-0001667	AMRN-PEXP-0001672	H, R, U
886	NIACOR® Physicians' Desk Reference 3239 (57th ed. 2003)	AMRN-PEXP-0001673	AMRN-PEXP-0001674	F, H, R, U
887	NIASPAN® Physicians' Desk Reference 1505 (53d ed. 1999)	AMRN-PEXP-0001713	AMRN-PEXP-0001717	F, H, R, U
888	Nicholls, <i>CETP-Inhibition and HDL-Cholesterol: A Story of CV Risk or CV Benefit, or Both</i> , 104 Clinical Pharmacology & Therapeutics 297 (2018)	AMRN-PEXP-0001718	AMRN-PEXP-0001721	F, H, R, U
889	Oliver et al., <i>WHO Cooperative Trial on Primary Prevention of Ischaemic Heart Disease with Clofibrate to Lower Serum Cholesterol: Final Mortality Follow-up</i> , 15 The Lancet 600 (1984)	AMRN-PEXP-0001722	AMRN-PEXP-0001726	F, H, R, U
890	Omtryg Summary Review for: NDA No. 204977 (2014)	AMRN-PEXP-0001727	AMRN-PEXP-0001736	F, H, R, U
891	Rader, <i>Lipid Disorders</i> , in Textbook of Cardiovascular Medicine 55 (Eric J. Topol ed., 3d ed. 2007)	AMRN-PEXP-0001745	AMRN-PEXP-0001769	F, H, R, U
892	Sabatine et al., <i>Evolocumab and Clinical Outcomes in Patients With Cardiovascular Disease</i> , 376 N. Eng. J. Med. 1713 (2017)	AMRN-PEXP-0001770	AMRN-PEXP-0001779	F, H, R, U
893	Sarbolouki et al., <i>Eicosapentaenoic acid improves insulin sensitivity and blood sugar in overweight type 2 diabetic mellitus patients: a double-blind randomised clinical trial</i> , 54 Sing. Med. J. 387 (2013)	AMRN-PEXP-0001780	AMRN-PEXP-0001783	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
894	Schwartz et al., <i>Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome</i> , 379 N Eng. J. Med. 2097, 2097 (2018)	AMRN-PEXP-0001797	AMRN-PEXP-0001807	F, H, R, U
895	Taylor et al., <i>Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a Double-Blind, Placebo-Controlled Study of Extended-Release Niacin on Atherosclerosis Progression in Secondary Prevention Patients Treated with Statins</i> , 110 Circulation 3512, 3515 (2004)	AMRN-PEXP-0001818	AMRN-PEXP-0001823	F, H, R, U
896	Pearson, <i>Clinical Trial Evidence for Treatment of Dyslipidemia in the Prevention of Cardiovascular Disease</i> , in <i>The Johns Hopkins Textbook of Dyslipidemia</i> (Peter O. Kwiterovich, Jr. ed., 2009)	AMRN-PEXP-0001850	AMRN-PEXP-0001858	F, H, R, U
897	Lilly and Rader, <i>Disorders of HDL Metabolism</i> , in <i>The Johns Hopkins Textbook of Dyslipidemia</i> (Peter O. Kwiterovich, Jr. ed., 2009)	AMRN-PEXP-0001873	AMRN-PEXP-0001886	F, H, R, U
898	Sniderman et al., <i>ApoB and the Atherogenic ApoB Dyslipoproteinemias</i> , in <i>The Johns Hopkins Textbook of Dyslipidemia</i> (Peter O. Kwiterovich, Jr. ed., 2009)	AMRN-PEXP-0001887	AMRN-PEXP-0001901	F, H, R, U
899	Trygg Pharma Inc., <i>Efficacy Study to Treat Subjects with Severe Hypertriglyceridemia</i> , U.S. National Library of Medicine (NCT01229566)	AMRN-PEXP-0001939	AMRN-PEXP-0001943	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	ClinicalTrials.gov (last updated Nov. 24, 2011), (Nov. 24, 2011), https://clinicaltrials.gov/ct2/show/NCT01229566			
900	Patel et al., <i>Effects of eicosapentaenoic acid and docosahexaenoic acid on lipoproteins in hypertriglyceridemia</i> , 23 Current Opinion in Endocrinology & Diabetes and Obesity 145 (2016)	AMRN-PEXP-0007199	AMRN-PEXP-0007203	F, H, R, U
901	Brigham and Women's Hospital, <i>REDUCE-IT clinical trial results</i> Brigham and Women's Hospital, YouTube (Dec. 19, 2018), https://www.youtube.com/watch?v=IW71A72XwNk	AMRN-PEXP-0007204	AMRN-PEXP-0007204	F, H, R, U, NPI
902	Hackett, <i>'Phenomenal' REDUCE-IT establishes triglyceride theory</i> , Chest Physician (Nov. 20, 2018)	AMRN-PEXP-0007329	AMRN-PEXP-0007330	F, H, R, U
903	Conference Coverage: AHA 2018-Chicago, MDedge (2018)	AMRN-PEXP-0007331	AMRN-PEXP-0007331	F, H, R, U
904	Hamazaki et al., <i>Docosahexaenoic Acid-Rich Fish Oil Does Not Affect Serum Lipid Concentrations of Normolipidemic Young Adults</i> , 126 The Journal of Nutrition 2784 (1996)	AMRN-PEXP-0007332	AMRN-PEXP-0007337	F, H, R, U
905	von Schacky, <i>A review of omega-3 ethyl esters for cardiovascular prevention and treatment of increased blood triglyceride levels</i> , 2 Vascular Health and Risk Management 251 (2006)	AMRN-PEXP-0007466	AMRN-PEXP-0007477	H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
906	Miller, MD REDUCE-IT Trial, MDmag (2018)	AMRN-PEXP-0007481	AMRN-PEXP-0007481	F, H, R, U, NPI
907	Rambjor et al., <i>Eicosapentaenoic Acid Is Primarily Responsible for Hypotriglyceridemic Effect of Fish Oil in Humans</i> , 31 Lipids S-45 (1996)	ICOSAPENT_DFNDTS00006763	ICOSAPENT_DFNDTS00006769	H, R, U
908	<i>Composition for Preventing the Occurrence of Cardiovascular Event in Multiple Risk Patient</i> , Mochida Pharmaceutical Co., Ltd.	ICOSAPENT_DFNDTS00007058	ICOSAPENT_DFNDTS00007107	H, R, U
909	Geppert, <i>Microalgal docosahexaenoic acid decreases plasma triacylglycerol in normolipidaemic vegetarians: a randomised trial</i> , 95 The British Journal of Nutrition 779 (2006)	ICOSAPENT_DFNDTS00006126	ICOSAPENT_DFNDTS00006135	H, R, U
910	<i>EPADEL Capsules 300</i> , Japan Pharmaceutical Reference (JPR) Administration and Products in Japan, The Second Edition (1991-1992)	ICOSAPENT_DFNDTS00006169	ICOSAPENT_DFNDTS00006173	
911	Leigh-Firbank et al., <i>Eicosapentaenoic acid and docosahexaenoic acid from fish oils: differential associations with lipid responses</i> , 87 Brit. J. Nutrition 435 (2002)	ICOSAPENT_DFNDTS00006245	ICOSAPENT_DFNDTS00006255	H, R, U
912	Nestel et al., <i>The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans</i> , 76 American Journal of Clinical Nutrition 326 (2002)	ICOSAPENT_DFNDTS00006544	ICOSAPENT_DFNDTS00006548	H, R, U
913	National Institute of Health, <i>Third Report of the National Cholesterol Education</i>	ICOSAPENT_DFNDTS00006549	ICOSAPENT_DFNDTS00006587	H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Executive Summary, (2001)			
914	Nozaki et al., <i>Effects of Purified Eicosapentaenoic Acid Ethyl Ester on Plasma Lipoproteins in Primary Hypercholesterolemia</i> , 62 Int'l J. Vitamin & Nutrition Res. 256 (1992)	ICOSAPENT_DFNDTS00006588	ICOSAPENT_DFNDTS00006594	H, R, U
915	Park and Harris, <i>Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance</i> , 44 Journal of Lipid Research 455 (2003)	ICOSAPENT_DFNDTS00006701	ICOSAPENT_DFNDTS00006709	H, R, U
916	Saito et al., <i>Results of Clinical Usage of Improved Formulation (MND-21S) EPADEL CAPSULE 300 with Respect to Hyperlipidemia</i> , 26 Japanese Pharmacology & Therapeutics (1998)	ICOSAPENT_DFNDTS00006791	ICOSAPENT_DFNDTS00006823	H, R, U
917	Satoh et al., <i>Purified Eicosapentaenoic Acid Reduces Small Dense LDL, Remnant Lipoprotein Particles and C-Reactive Protein in Metabolic Syndrome</i> , 30 Diabetes Care 144 (2007)	ICOSAPENT_DFNDTS00006832	ICOSAPENT_DFNDTS00006836	H, R, U
918	Agren et al., <i>Fish diet, fish oil and docosahexaenoic acid rich oil lower fasting and postprandial plasma lipid levels</i> , 50 European Journal of Clinical Nutrition 765 (1996)	AMRN00289896	AMRN00289904	H, R, U
919	Bays, <i>Rationale for Prescription Omega-3-Acid Ethyl Ester Therapy for</i>	AMRN00290221	AMRN00290264	H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	<i>Hypertriglyceridemia: A Primer for Clinicians</i> , 44 <i>Drugs of Today</i> 205 (2008)			
920	Conquer et al., <i>Supplementation with an Algae Source of Docosahexaenoic Acid Increases (n-3) Fatty Acid Status and Alters Selected Risk Factors for Heart Disease in Vegetarian Subjects</i> , 126 <i>The Journal of Nutrition</i> 3032 (1996)	AMRN00290326	AMRN00290333	H, R, U
921	Mahley et al., <i>Drug Therapy for Hypercholesterolemia and Dyslipidemia</i> , in <i>The Pharmacological Basis of Therapeutics</i> 971 (Goodman & Gilman eds., 10th ed. 2001)	AMRN00290358	AMRN00290392	H, R, U
922	LOVAZA®, <i>Physicians' Desk Reference</i> 2699 (62d ed. 2008)	AMRN00290591	AMRN00290594	
923	McKenney, <i>Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia</i> , 64 <i>Am. J. Health-System Pharmacy</i> 595 (2007)	AMRN00290739	AMRN00290751	F, H, R, U
924	McKenney, <i>Dyslipidemias, Atherosclerosis, and Coronary Heart Disease</i> , in <i>Applied Therapeutics: The Clinical Use of Drugs</i> 13-1 (Mary Anne Koda-Kimble et al. eds., 8th ed. 2005)	AMRN00290752	AMRN00290796	F, H, R, U
925	McKenney et al., <i>Role of Prescription Omega-3 Fatty Acids in the Treatment of Hypertriglyceridemia</i> , 27 <i>Pharmacotherapy</i> 715 (2007)	AMRN00290797	AMRN00290810	F, H, R, U
926	Bays, <i>Fish Oils in the Treatment of Dyslipidemia and Cardiovascular Diseases</i> , in <i>The Johns Hopkins Textbook</i>	AMRN00291100	AMRN00291152	C, F, H, R, U, NPI

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	of Dyslipidemia (Peter O. Kwiterovich, Jr. ed., 2009)			
927	Kwiterovich, Jr., <i>Lipid, Apolipoprotein, and Lipoprotein Metabolism: Implications for the Diagnosis and Treatment of Dyslipidemia</i> , in The Johns Hopkins Textbook of Dyslipidemia (Peter O. Kwiterovich, Jr. ed., 2009)	AMRN00291100	AMRN00291125	F, H, R, U
928	Miller, <i>Disorders of Hypertriglyceridemia</i> , in The Johns Hopkins Textbook of Dyslipidemia (Peter O. Kwiterovich, Jr. ed., 2009)	AMRN00291100	AMRN00291139	H, R, U, NPI
929	O'Riordan, <i>MARINE: Ethyl-EPA Reduces Triglyceride Levels Without Raising LDL Cholesterol</i> , Medscape (Nov. 30, 2010), https://www.medscape.com/viewarticle/733304	AMRN00291600	AMRN00291602	H, R, U
930	Bonds et al., <i>Effect of Long-Chain ω-3 Fatty Acids and Lutein+Zeaxanthin Supplements on Cardiovascular Outcomes</i> , 174 JAMA Internal Med. 763 (2014)	AMRN00862631	AMRN00862639	H, R, U
931	Albert et al., <i>Oxidation of Marine Omega-3 Supplements and Human Health</i> , 2013 BioMed Research Int'l 1 (2013)	AMRN00864826	AMRN00864833	F, H, R, U
932	GISSI-Prevenzione Investigators, <i>Dietary Supplementation with n-3 Polyunsaturated Fatty Acids and Vitamin E After Myocardial Infarction: Results of the GISSI-Prevenzione Trial</i> , 354 Lancet 447 (1999)	AMRN00944984	AMRN00944992	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
933	Kromhout et al., <i>n-3 Fatty Acids and Cardiovascular Events after Myocardial Infarction</i> , 363 N. Eng. J. Med. 21 (2010)	AMRN01219025	AMRN01219036	F, H, R, U
934	GISSI-HF Investigators, <i>Effect of n-3 Polyunsaturated Fatty Acids in Patients with Chronic Heart Failure (the GISSI-HF trial): A Randomised, Double-Blind, Placebo-Controlled Trial</i> , 372 Lancet 1223 (2008)	AMRN01349929	AMRN01349936	F, H, R, U
935	OMACOR® Label (2004)	AMRN01406463	AMRN01406473	F, H, R, U
936	Rauch et al., <i>OMEGA, a Randomized, Placebo-Controlled Trial to Test the Effect of Highly Purified Omega-3 Fatty Acids on Top of Modern Guideline-Adjusted Therapy After Myocardial Infarction</i> , 122 Circulation 2152 (2010)	AMRN01521522	AMRN01521530	F, H, R, U
937	TRILIPIX® Label (2008)	AMRN01598389	AMRN01598425	F, H, R, U
938	Einvik et al., <i>A Randomized Clinical Trial on n-3 Polyunsaturated Fatty Acids Supplementation and All-Cause Mortality in Elderly Men at High Cardiovascular Risk</i> , 17 Eur. J. Cardiovascular Prevention & Rehabilitation 588 (2010)	AMRN02642567	AMRN02642572	H, R, U
939	Center for Drug Evaluation and Research, FDA, Application Number 21-654, Statistical Review(s) (2004) (Lovaza Statistical Review)	AMRN03059165	AMRN03059229	H, R, U
940	VASCEPA® Prescribing Information (2017)	AMRN03132168	AMRN03132177	
941	Boden et al., <i>Niacin in Patients with Low HDL Cholesterol Levels Receiving</i>	AMRN03143149	AMRN03143161	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	<i>Intensive Statin Therapy</i> , 365 N. Engl. J. Med. 24 (2011)			
942	Ballantyne et al, <i>Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester Therapy in Statin-Treated Patients with Persistent High Triglycerides (from the ANCHOR Study)</i> , 110 Am. J. Cardiology 984 (2012)	AMRN03144838	AMRN03144846	H, R, U
943	Ginsberg et al., <i>Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus</i> , 362 N. Eng. J. Med. (2010)	AMRN03146139	AMRN03146150	H, R, U
944	Landray et al., <i>Effects of Extended-Release Niacin With Laropiprant in High-Risk Patients</i> , 371 N. Eng. J. Med. 203 (2014)	AMRN03146265	AMRN03146274	F, H, R, U
945	Keech et al., <i>Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD Study): randomised controlled trial</i> , 366 Lancet 1849 (2005)	AMRN03146421	AMRN03146433	F, H, R, U
946	Kleiner et al., <i>A Comparison of Actual Versus Stated Label Amounts of EPA and DHA in Commercial Omega-3 Dietary Supplements in the United States</i> , 95 J. Sci. Food Agric. 1260 (2015)	AMRN03146434	AMRN03146441	F, H, R, U
947	<i>Withdrawal of Approval of Indications Related to the Coadministration with Statins in Applications for Niacin Extended-Release Tablets and Fenofibric Acid Delayed-Release Capsules</i> , 81 Fed. Reg. 22,612 (Apr. 18, 2016)	AMRN03146455	AMRN03146456	H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
948	Bosch et al., <i>n-3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia</i> , 367 N. Eng. J. Med. (2012)	AMRN03147161	AMRN03147170	H, R, U
949	Roncaglioni et al., <i>n-3 Fatty Acids in Patients With Multiple Cardiovascular Risk Factors</i> , 368 N. Eng. J. Med. 1800 (2013)	AMRN03147275	AMRN03147283	H, R, U
950	Ritter et al., <i>Quality Analysis of Commercial Fish Oil Preparations</i> , 93 J. Science FoodAgriculture 1935 (2013)	AMRN03147308	AMRN03147312	F, H, R, U
951	Feuerstein, <i>Amarin Fish Oil Capsule Shows Dramatic Benefit for Cardiovascular Patients, Potentially Upending Market</i> , STAT News (Sept. 24, 2018), https://www.statnews.com/2018/09/24/amarin-fish-oil-capsule-shows-dramatic-benefit-for-cardiovascular-patients/	AMRN03163953	AMRN03163956	F, H, R, U
952	O'Connor, <i>Fish Oil Drug May Prevent Heart Attack and Strokes in High-Risk Patients</i> , The New York Times (Sept. 25, 2018), https://www.nytimes.com/2018/09/25/well/fish-oil-heartattack-stroke-triglycerides-omega-3s.html	AMRN03163960	AMRN03163962	F, H, R, U
953	Abdelhamid et al., <i>Omega-3 Fatty Acids for the Primary and Secondary Prevention of Cardiovascular Disease (Review)</i> , 7 Cochrane Database of Systematic Review (2018)	AMRN03163971	AMRN03164713	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
954	Aung et al., <i>Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks</i> , 3 JAMA Cardiology 225 (2018)	AMRN03164724	AMRN03164732	H, R, U
955	Bhatt et al., <i>Supplementary Appendix to Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia</i> , N. Eng. J. Med. (Nov. 10, 2018), https://www.nejm.org/doi/suppl/10.1056/NEJMoal812792/suppl_file/nejmoa1812792_appendix.pdf	AMRN03164735	AMRN03164784	F, H, R, U
956	Blacher et al., <i>Cardiovascular effects of B-vitamins and/or N-3 fatty acids: the Su.Fol.Om3 trial</i> , 167 Int'l J. Cardiology 508 (2013)	AMRN03164797	AMRN03164802	H, R, U
957	Amarin Pharma Inc., <i>REDUCE-IT Post-Text Tables, Figures, and Graphs</i> (draft)	AMRN03165070	AMRN03167962	F, H, R, U
958	Amarin Pharma Inc., <i>REDUCE-IT Protocols, Statistical Analysis, and Disclosure of Potential Conflicts of Interest</i>	AMRN03167963	AMRN03168515	F, H, R, U
959	Kastelein et al., <i>FISHing for the Miracle of Eicosapentaenoic Acid</i> , New Eng. J. Med. (Nov. 16, 2018)	AMRN03168528	AMRN03168529	F, H, R, U
960	Amarin Pharma Inc., <i>REDUCE-IT Post-Text Tables, Figures, and Graphs</i> (ver. 1.0)	AMRN03168893	AMRN03171430	F, H, R, U
961	Bowman et al., <i>Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus</i> , 379 N. Eng. J. Med. 1540 (2018)	AMRN-PEXP-0000701	AMRN-PEXP-0000711	H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
962	Manson et al., <i>Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer</i> , 380 N. Eng. J. Med. 23 (Nov. 10, 2018)	AMRN-PEXP-0000712	AMRN-PEXP-0000721	H, R, U
963	Haffner et al., <i>Mortality From Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infraction</i> , 339 N. Engl. J. Med. 229 (1998)	AMRN-PEXP-0001467	AMRN-PEXP-0001472	F, H, R, U
964	LOPID®, Physicians' Desk Reference 1626 (44th ed. 1990)	AMRN-PEXP-0001611	AMRN-PEXP-0001614	F, H, R, U
965	ORIGIN Trial Investigators, <i>Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE)</i> , 39 Diabetes Care 709 (2016)	AMRN-PEXP-0001737	AMRN-PEXP-0001744	H, R, U
966	TRICOR® Physicians' Desk Reference 527 (61st ed. 2007)	AMRN-PEXP-0001933	AMRN-PEXP-0001938	F, H, R, U
967	Grimsgaard et al., <i>Highly purified eicosapentaenoic acid and docasahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids¹⁻³</i> , 66 Am. J. Clinical Nutrition 649 (1997)	ICOSAPENT_DFNDTS00006136	ICOSAPENT_DFNDTS00006146	H, R, U
968	U.S. Food & Drug Admin., Memorandum of Meeting Minutes (Dec. 16, 2013)	AMRN03019190	AMRN03019222	F, H, R, U
969	Braeckman et al., <i>Pharmacokinetic and Triglyceride-Lowering Pharmacodynamic Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) Across Clinical Studies</i>	AMRN03133220	AMRN03133221	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	(Abstract), 128 Circulation A19343 (2013)			
970	Archila et al., <i>Boston Doc Day 'Lipid Panel' Recap: Room for New Players in the LDL-C Category; Docs Seek Multifocal Approach to Management</i> , Stifel (Jan. 16, 2019)	AMRN-PEXP-0008690	AMRN-PEXP-0008694	F, H, R, U
971	Ascherio et al., <i>Dietary Intake of Marine n-3 Fatty Acids, Fish Intake, and the Risk of Coronary Disease Among Men</i> , 332 N. Eng. J. Med. 977 (1995)	AMRN-PEXP-0008695	AMRN-PEXP-0008700	F, H, R, U
972	Backes et al., <i>Effectiveness and Tolerability of Every-Other-Day Rosuvastatin Dosing in Patients with Prior Statin Intolerance</i> , 42 Annals of Pharmacotherapy 341 (2008)	AMRN-PEXP-0008717	AMRN-PEXP-0008722	F, H, R, U
973	Bhatt et al., <i>Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT</i> , J. Am. Coll. Cardiology (Feb. 28, 2019) (Accepted Manuscript)	AMRN-PEXP-0008744	AMRN-PEXP-0008811	F, H, R, U
974	Caduceus Research, <i>Why the REDUCE-IT Trial Will Fail, Seeking Alpha</i> (Sept. 12, 2018), https://seekingalpha.com/article/4205748-reduce-trial-will-fail	AMRN-PEXP-0008899	AMRN-PEXP-0008909	F, H, R, U
975	Eur. Meds. Agency, <i>PRAC Considers that Benefit-Risk Balance of Tredaptive, Pelzont and Trevaclyn (Nicotinic Acid/Laropiprant) Is</i>	AMRN-PEXP-0009107	AMRN-PEXP-0009109	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	<i>Negative</i> (Jan. 10, 2013), https://www.ema.europa.eu/en/documents/referral/tredaptive-pelzont-trevaclyn-article-20-procedure-prac-considers-benefit-risk-balance-tredaptive/nicotinic-acid-negative-questionsanswers_en.pdf			
976	Guallar et al., <i>A Prospective Study of Plasma Fish Oil Levels and Incidence of Myocardial Infarction in U.S. Male Physicians</i> , 25 J. Am. Coll. Cardiology 387 (1995)	AMRN-PEXP-0009214	AMRN-PEXP-0009221	F, H, R, U
977	Lan et al. <i>Icosapent Ethyl for Dyslipidemia in Patients with Diabetes and Coronary Artery Disease: Act Now to Reduce It</i> , Diabetes Obesity Metabolism 1 (2019)	AMRN-PEXP-0009362	AMRN-PEXP-0009364	F, H, R, U
978	Lim, <i>Hypertriglyceridaemia – REDUCE-IT with Icosapent Ethyl</i> , 16 Nature Reviews Cardiology 1 (2019)	AMRN-PEXP-0009413	AMRN-PEXP-0009413	F, H, R, U
979	Maccubbin et al., <i>Flushing Profile of Extended-Release Niacin/Laropiprant Versus Gradually Titrated Niacin Extended-Release in Patients With Dyslipidemia With and Without Ischemic Cardiovascular Disease</i> , 104 Am. J. Cardiology 74 (2009)	AMRN-PEXP-0009414	AMRN-PEXP-0009421	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
980	Oh et al., <i>Genetic Determinants of Statin Intolerance</i> , 6 Lipids in Health and Disease 7 (2007)	AMRN-PEXP-0009458	AMRN-PEXP-0009462	F, H, R, U
981	Wood et al., <i>Empirical Evidence of Bias in Treatment Effect Estimates in Controlled Trials with Different Interventions and Outcomes: Meta-Epidemiological Study</i> , 336 BMJ 601 (2008)	AMRN-PEXP-0009607	AMRN-PEXP-0009614	F, H, R, U
982	Bansal et al., <i>Fasting Compared with Nonfasting Triglycerides and Risk of Cardiovascular Events in Women</i> , 298 JAMA 309 (2007)	ICOSAPENT_DFNDT000 16285	ICOSAPENT_DFNDT000 16292	H, R, U
983	Friedewald et al., <i>The Editor's Round Table: Current Perspectives on Triglycerides and Atherosclerosis</i> , 117 Am. J. Cardiology 1697 (2016)	ICOSAPENT_DFNDT000 16336	ICOSAPENT_DFNDT000 16341	F, H, R, U
984	Cucuzzella, <i>Why Should We Treat Isolated High Triglycerides?</i> , 53 J. Family Practice 138 (2004)	ICOSAPENT_DFNDT000 17638	ICOSAPENT_DFNDT000 17649	H, R, U
985	Amarin Pharma Inc., Formal Dispute Resolution Request re Rescission of the Special Protocol Assessment Agreement for the ANCHOR Study (Feb. 27, 2014)	AMRN00111661	AMRN00111747	H, R, U
986	Center for Drug Evaluation & Research, FDA, Endocrinologic and Metabolic Drugs Advisory Committee Meeting Transcript (Oct. 16, 2013)	AMRN00112253	AMRN00112568	H, R, U
987	U.S. Dep't of Health & Human Services, Food and Drug Administration,	AMRN00204264	AMRN00204280	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	<i>Memorandum of Meeting Minutes</i> (July 14, 2008)			
988	Bays et al., <i>Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-Center, placebo-controlled, Randomized, double-blind, 12-week study with an open-label Extension [MARINE] Trial)</i> , 108 Am. J. Cardiology 682 (2011)	AMRN00281133	AMRN00281141	F, H, R, U
989	American Heart Association, <i>Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report</i> , 106 Circulation 3143 (2002)	AMRN00289915	AMRN00290194	H, R, U
990	Letter from Curtis J. Rosebraugh, Director, U.S. Food & Drug Admin. Ctr. for Drug Evaluation and Research, to Steven Ketchum, President of Research and Development, Amarin Pharma Inc. (Apr. 22, 2014)	AMRN03019328	AMRN03019361	F, H, R, U
991	Mason et al., <i>Eicosapentaenoic Acid Inhibits Oxidation of ApoB Containing Lipoprotein Particles of Different Size in Vitro when Administered Alone or in Combination with Atorvastatin Active Metabolite Compared with Other Triglyceride-lowering Agents</i> ,	AMRN03130052	AMRN03130059	H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	68 J. Cardiovascular Pharmacology 33 (2016)			
992	Hilleman et al., <i>Prescription Omega-3 Fatty Acid Products and Dietary Supplements Are Not Interchangeable</i> , 25 Managed Care 46 (2016)	AMRN03146251	AMRN03146259	F, H, R, U
993	Nosaka et al., <i>Early Initiation of Eicosapentaenoic Acid and Statin Treatment is Associated with Better Clinical Outcomes than Statin Alone in Patients with Acute Coronary Syndromes: 1-Year Outcomes of a Randomized Controlled Study</i> , 228 Int'l J. Cardiology 173 (2017)	AMRN03147120	AMRN03147126	F, H, R, U
994	Declaration of Curtis Rosebraugh, <i>Amarin Pharma, Inc. v. U.S. Food & Drug Admin.</i> , Civil No. 1:15-CV-03588 (S.D.N.Y. June 23, 2015), ECF No. 54.	AMRN-PEXP-0009043	AMRN-PEXP-0009061	F, H, R, U
995	Eur. Meds. Agency, <i>Tredaptive, Pelzont and Trevaclyn Suspended Across the EU</i> (Mar. 22, 2013), https://www.ema.europa.eu/en/documents/referral/tredaptive-pelzont-trevaclynsuspended-across-eu_en.pdf	AMRN-PEXP-0009110	AMRN-PEXP-0009112	F, H, R, U
996	Stone et al., <i>2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to</i>	AMRN-PEXP-0009536	AMRN-PEXP-0009580	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	<i>Reduce Atherosclerotic Cardiovascular Risk in Adults</i> , 63 JACC 2889 (2014)			
997	Buckley et al., Circulating triacylglycerol and apoE levels in response to EPA and docosahexaenoic acid supplementation in adult human subjects, 92 British J. Nutrition 477(2004)	AMRN00290275	AMRN00290281	H, R, U
998	Nelson et al., <i>The Effect of Dietary Docosahexaenoic Acid on Plasma Lipoproteins and Tissue Fatty Acid Composition in Humans</i> , 32 Lipids 1137 (1997)	AMRN00290858	AMRN00290867	F, H, R, U
999	Woodman et al., Effects of Purified Eicosapentaenoic and Docosahexaenoic Acids on Glycemic Control, Blood Pressure, and Serum Lipids in Type 2 Diabetic Patients with Treated Hypertension, 76 Am. J. Clinical Nutrition 1007 (2002)	AMRN00291334	AMRN00291342	F, H, R, U
1000	Davidson et al., Efficacy and Tolerability of Adding Prescription Omega-3 Fatty Acids 4 g/d to Simvastatin 50 mg/d in Hypertriglyceridemic Patients: An 8-week, Randomized, Double-Blind, Placebo-Controlled Study, 29 Clinical Therapeutics 1354 (2007)	AMRN00309308	AMRN00309321	F, H, R, U
1001	Harris, W., <i>n-3 Fatty Acids and Serum Lipoproteins: Human Studies</i> , 65 Am. J. Clinical Nutrition 1645S (1997)	AMRN00328752	AMRN00328761	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
1002	Friedberg et al., <i>Fish Oil and Glycemic Control in Diabetes</i> , 21 Diabetes Care 494 (1998)	AMRN00479764	AMRN00479770	F, H, R, U
1003	Christian et al., <i>Prevalence of Severe (500 to 2,000 mg/dl) Hypertriglyceridemia in United States Adults</i> , 107 Am. J. Cardiology 891 (2011)	AMRN00887729	AMRN00887735	F, H, R, U, DUPE
1004	Reiner et al., <i>ECS/EAS Guidelines for the Management of Dyslipidaemias</i> , 32 European Heart J. 1769 (2011)	AMRN01272398	AMRN01272447	F, H, R, U
1005	Sniderman et al., <i>Non-HDL Cholesterol and ApoB in Dyslipidaemia</i> , 114 Clinical Science 149 (2008)	AMRN01382004	AMRN01382010	F, H, R, U
1006	Ryan et al., <i>Clinical Overview of Algal-Docosahexaenoic Acid: Effects on Triglyceride Levels and Other Cardiovascular Risk Factors</i> , 16 Am. J. Therapeutics 183 (2009)	AMRN01502584	AMRN01502593	F, H, R, U
1007	Jellinger et al., Am. Ass'n of Clinical Endocrinologists and Am. Coll. of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease, 23 (Suppl 2) Endocrine Practice Supp. 1 (2017)	AMRN03157212	AMRN03157298	F, H, R, U
1008	C. Bortz & C. Duran letters in response to FOIA 2004-19393	AMRN-PEXP-0008089	AMRN-PEXP-0008093	F, H, R, U
1009	American Pharmacist Association, <i>Triglycerides, HDL Cholesterol, and Other Secondary Targets of Lipid-Lowering Therapy</i> (2006)	AMRN-PEXP-0008094	AMRN-PEXP-0008101	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
1010	Bays et al., <i>Icosabutate for the Treatment of Very High Triglycerides: A Placebo-Controlled, Randomized, Double-Blind, 12-Week Clinical Trial</i> , 10 J. Clinical Lipidology 181 (2016)	AMRN-PEXP-0008102	AMRN-PEXP-0008114	F, H, R, U
1011	Bays, <i>Rationale for Prescription Omega-3-Acid Ethyl Ester Therapy for Hypertriglyceridemia: A Primer for Clinicians</i> , 44 Drugs of Today 205 (2008)	AMRN-PEXP-0008136	AMRN-PEXP-0008179	F, H, R, U
1012	Cheng, et al., <i>Prospective Double-Blind Study of Cee3 in Peri and Postmenopausal Women: Effects on Bone Loss and Lipoprotein Lipids</i> , 105 Chinese Medical Journal 929 (1992)	AMRN-PEXP-0008187	AMRN-PEXP-0008191	F, H, R, U
1013	Department of Veterans Affairs and Department of Defense, VA/DoD Clinical Practice Guideline for the Management of Dyslipidemia for Cardiovascular Risk Reduction, Version 3.0 (2014)	AMRN-PEXP-0008192	AMRN-PEXP-0008303	F, H, R, U
1014	Djoussé et al., <i>Dietary Linolenic Acid Is Inversely Associated with Calcified Atherosclerotic Plaque in the Coronary Arteries: The National Heart, Lung, and Blood Institute Family Heart Study</i> , 111 Circulation 2921 (2005)	AMRN-PEXP-0008304	AMRN-PEXP-0008309	F, H, R, U
1015	Drood et al., <i>Nicotinic Acid for the Treatment of Hyperlipoproteinemia</i> , 31 J. Clin. Pharmacol. 641 (1991)	AMRN-PEXP-0008310	AMRN-PEXP-0008319	F, H, R, U
1016	Endocrine Society, <i>Endocrine Society Releases Guidelines on Diagnosis and</i>	AMRN-PEXP-0008320	AMRN-PEXP-0008321	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	<i>Management of Hypertriglyceridemia</i> , 88 Am. Fam. Physician (2013)			
1017	Grundy et al., Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/Nat'l Heart, Lung, and Blood Institute Scientific Statement, 21 Current Opinion Cardiology 1 (2006)	AMRN-PEXP-0008322	AMRN-PEXP-0008327	F, H, R, U
1018	Itoi, H. et al., <i>Comparison of the long-term effects of oral estriol with the effects of conjugated estrogen on serum lipid profile in early menopausal women</i> , 36 Maturitas 217 (2000)	AMRN-PEXP-0008328	AMRN-PEXP-0008333	F, H, R, U
1019	Maitra et al., <i>Comparison of two assays for measuring LDL cholesterol</i> , 43 Clinical Chemistry 1040 (1997)	AMRN-PEXP-0008373	AMRN-PEXP-0008380	F, H, R, U
1020	Nauck et al., <i>Methods for Measurement of LDL-Cholesterol: A Critical Assessment of Direct Measurement by Homogeneous Assays versus Calculation</i> , 48 Clinical Chemistry 236 (2002)	AMRN-PEXP-0008381	AMRN-PEXP-0008399	F, H, R, U
1021	Rifai et al., <i>Measurement of Low-Density-Lipoprotein Cholesterol in Serum: a Status Report</i> , 38 Clin. Chem. 150 (1992)	AMRN-PEXP-0008400	AMRN-PEXP-0008410	F, H, R, U
1022	Westerveld et al., Effects of Low-Dose EPA-E on Glycemic Control, Lipid Profile, Lipoprotein(a), Platelet Aggregation, Viscosity, and Platelet and Vessel Wall Interaction in NIDDM, 16 Diabetes Care 683 (1993)	AMRN-PEXP-0008415	AMRN-PEXP-0008422	H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
1023	E-mail from I. Osterloh to D. Boal et al., re Omacor – FDA Medical Review (Jan. 8, 2008)	PW-AMRN00003913	PW-AMRN00003913	F, H, R, U
1024	Weber et al., Docosahexaenoic Acid Selectively Attenuates Induction of Vascular Cell Adhesion Molecule-1 and Subsequent Monocytic Cell Adhesion to Human Endothelial Cells Stimulated by Tumor Necrosis Factor- α , 15 Arteriosclerosis Thrombosis Vascular Biology 622 (1995)	AMRN-PEXP-0000673	AMRN-PEXP-0000680	F, H, R, U
1025	Bays et al., Prescription Omega-3 Fatty Acids and Their Lipid Effects: Physiologic Mechanisms of Action and Clinical Implications, 6 Expert Reviews Cardiovascular Therapy 391 (2008)	AMRN-PEXP-0008115	AMRN-PEXP-0008135	F, H, R, U
1026	Carlson et al., <i>On the rise in low density and high density lipoproteins in response to the treatment of hypertriglyceridaemia in type IV and type V hyperlipoproteinaemias</i> , 26 Atherosclerosis 603 (1977)	AMRN-PEXP-0008180	AMRN-PEXP-0008186	F, H, R, U
1027	Mahley et al., <i>Drug Therapy for Hypercholesterolemia and Dyslipidemia, in The Pharmacological Basis of Therapeutics</i> 933 (Goodman Gilman et al. eds., 11th ed. 2005)	AMRN-PEXP-0008334	AMRN-PEXP-0008372	F, H, R, U
1028	Grimsgaard et al., <i>Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on hemodynamics</i>	ICOSAPENT_DFNDTS00009272	ICOSAPENT_DFNDTS00009279	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	<i>in humans</i> , 68 Am. J. Clin. Nutr. 52 (1998)			
1029	Harris, W., <i>Fish Oils and Plasma Lipid and Lipoprotein Metabolism in Humans: A Critical Review</i> , 30 J. Lipid Research 785 (1989)	ICOSAPENT_DFNDTS00009994	ICOSAPENT_DFNDTS00010016	F, H, R, U
1030	U.S. Food & Drug Admin., Ctr. for Drug Evaluation and Research, Approval Package for Application No. 21-654 (2004) ("LOVAZA® Medical Review")	PW-AMRN00003914	PW-AMRN00003968	F, H, R, U
1031	Calabresi et al., <i>Omacor in Familial Combined Hyperlipidemia: Effects on Lipids and Low Density Lipoprotein Subclasses</i> , 148 Atherosclerosis 387-96 (2000) ("Calabresi").	ICOSAPENT_DFNDTS00005916	ICOSAPENT_DFNDTS00005925	F, H, R, U
1032	Mori et al., <i>The Independent Effects of Eicosapentaenoic Acid and Docosahexaenoic Acid on Cardiovascular Risk Factors in Humans</i> , 9 Current Op. Clinical Nutrition & Metabolic Care 95 (2006)	ICOSAPENT_DFNDTS00011016	ICOSAPENT_DFNDTS00011025	H, R, U
1033	Bays et al., <i>Prescription Omega-3 Fatty Acids and Their Lipid Effects: Physiologic Mechanisms of Action and Clinical Implications</i> , 6 Expert Reviews Cardiovascular Therapy 391 (2008)	AMRN00206290	AMRN00206308	H, R, U
1034	LOVAZA®, Physicians' Desk Reference 2699 (62d ed. 2008)	ICOSAPENT_DFNDTS00006710	ICOSAPENT_DFNDTS00006713	

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
1035	Exhibit A to the Surreply Expert Report of Rebecca A. Betensky, Ph.D.: Curriculum Vitae of Rebecca A. Betensky	AMRN-PEXP-0011338	AMRN-PEXP-0011374	H, R, U
1036	Exhibit B to the Surreply Expert Report of Rebecca A. Betensky, Ph.D.: Prior Testimony	N/A	N/A	H, R, U
1037	Exhibit C to the Surreply Expert Report of Rebecca A. Betensky, Ph.D.: Materials Considered List	N/A	N/A	H, R, U
1038	Exhibit D to the Surreply Expert Report of Rebecca A. Betensky, Ph.D.: Jacobin Output R	AMRN-PEXP-0012054	AMRN-PEXP-0012055	E, H, R, U
1039	Exhibit B to the Opening Report [DRL] of Matthew Budoff: List of Prior Litigation Matters	N/A	N/A	H, R, U
1040	Exhibit C to the Opening Report [DRL] of Matthew Budoff: Materials Considered List	N/A	N/A	H, R, U
1041	Exhibit A to the Opening Report [Hikma] of Matthew Budoff: Curriculum Vitae of Matthew Budoff	AMRN-PEXP-0000231	AMRN-PEXP-0000365	H, R, U
1042	Exhibit B to the Opening Report [Hikma] of Matthew Budoff: List of Prior Litigation Matters	N/A	N/A	H, R, U
1043	Exhibit C to the Opening Report [Hikma] of Matthew Budoff: Materials Considered List	N/A	N/A	H, R, U
1044	Exhibit A to the Reply Report of Matthew Budoff: Materials Considered List	N/A	N/A	H, R, U
1045	Exhibit B to the Reply Report of Matthew Budoff: Curriculum Vitae	AMRN-PEXP-0010795	AMRN-PEXP-0010936	H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
1046	Exhibit B to the Opening Report [DRL] of Jonathan Curtis: Materials Considered List	N/A	N/A	H, R, U
1047	Exhibit A to the Opening Report [Hikma] of Jonathan Curtis: Curriculum Vitae of Jonathan Curtis	AMRN-PEXP-0007989	AMRN-PEXP-0008013	H, R, U
1048	Exhibit B to the Opening Report [Hikma] of Jonathan Curtis: Materials Considered List	N/A	N/A	H, R, U
1049	Exhibit A to the Opening Report of Firhaad Ismail: Curriculum Vitae of Firhaad Ismail	AMRN-PEXP-0008077	AMRN-PEXP-0008088	H, R, U
1050	Exhibit B to the Opening Report of Firhaad Ismail: Materials Considered List	N/A	N/A	H, R, U
1051	Exhibit A to the Reply Report of Firhaad Ismail: Materials Considered List	N/A	N/A	H, R, U
1052	Exhibit A to the Responsive Report of Stephen G. Kunin: Biography of Stephen G. Kunin	N/A	N/A	H, R, U
1053	Exhibit B to the Responsive Report of Stephen G. Kunin: Prior Expert Testimony of Stephen G. Kunin in the Last Four Years	N/A	N/A	H, R, U
1054	Exhibit C to the Responsive Report of Stephen G. Kunin: List of Materials Considered	N/A	N/A	H, R, U
1055	Exhibit D to the Responsive Report of Stephen G. Kunin: Relationship of '727 Patent and Asserted Patents	N/A	N/A	E, H, R, U
1056	Appendix to the Opening Report of R. Preston Mason	N/A	N/A	H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
1057	Exhibit A to the Opening Report of R. Preston Mason: Curriculum Vitae of R. Preston Mason	AMRN-PEXP-0000546	AMRN-PEXP-0000569	H, R, U
1058	Exhibit B to the Opening Report of R. Preston Mason: Materials Considered List	N/A	N/A	H, R, U
1059	Exhibit A to the Reply Report of R. Preston Mason: Materials Considered List	N/A	N/A	H, R, U
1060	Appendix A to the Opening Report of Sean Nicholson: Appendix and Exhibit List	N/A	N/A	H, R, U
1061	Appendix B to the Opening Report of Sean Nicholson: Curriculum Vitae of Sean Nicholson	AMRN-PEXP-0002031	AMRN-PEXP-0002043	H, R, U
1062	Appendix C to the Opening Report of Sean Nicholson: Prior Testimony of Sean Nicholson in the Last Four Years	N/A	N/A	H, R, U
1063	Appendix D to the Opening Report of Sean Nicholson: Materials Considered List	N/A	N/A	H, R, U
1064	Appendix E to the Opening Report of Sean Nicholson: Document Produced in Native Format	N/A	N/A	E, H, R, U
1065	Exhibit 1 to the Opening Report of Sean Nicholson: Amarin Annual R&D Expenditures	N/A	N/A	E, H, R, U
1066	Exhibit 2 to the Opening Report of Sean Nicholson: Drugs Indicated for Reducing Triglycerides	N/A	N/A	E, H, R, U
1067	Exhibit 3 to the Opening Report of Sean Nicholson: Dollar Sales of Vascepa® based on IQVIA Data	N/A	N/A	E, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
1068	Exhibit 4 to the Opening Report of Sean Nicholson: Dollar Sales of Vascepa® based on Amarin Internal Documents	N/A	N/A	E, H, R, U
1069	Exhibit 5 to the Opening Report of Sean Nicholson: Dollar Sales of Vascepa® and Prescription Omega-3 Competitors based on IQVIA Data	N/A	N/A	E, H, R, U
1070	Exhibit 6 to the Opening Report of Sean Nicholson: Dollar Sales of Molecules Indicated for Reducing TG Levels based on IQVIA Data	N/A	N/A	E, H, R, U
1071	Exhibit 7 to the Opening Report of Sean Nicholson: Total Prescriptions of Vascepa® based on IQVIA Data	N/A	N/A	E, H, R, U
1072	Exhibit 8 to the Opening Report of Sean Nicholson: New Prescriptions of Vascepa® based on IQVIA Data	N/A	N/A	E, H, R, U
1073	Exhibit 9 to the Opening Report of Sean Nicholson: Total Prescriptions of Vascepa® and Prescription Omega-3 Competitors based on IQVIA Data	N/A	N/A	E, H, R, U
1074	Exhibit 10 to the Opening Report of Sean Nicholson: New Prescriptions of Vascepa® and Prescription Omega-3 Competitors based on IQVIA Data	N/A	N/A	E, H, R, U
1075	Exhibit 11 to the Opening Report of Sean Nicholson: Total Prescriptions of Molecules Indicated for Reducing TG Levels based on IQVIA Data	N/A	N/A	E, H, R, U
1076	Exhibit 12 to the Opening Report of Sean Nicholson: New Prescriptions of	N/A	N/A	E, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	Molecules Indicated for Reducing TG Levels based on IQVIA Data			
1077	Exhibit 13 to the Opening Report of Sean Nicholson: Shares of Vascepa® and Prescription Omega-3 Competitors based on IQVIA Data	N/A	N/A	E, H, R, U
1078	Exhibit 14 to the Opening Report of Sean Nicholson: Analyst Projections of Amarin Net Sales	N/A	N/A	E, H, R, U
1079	Exhibit 15 to the Opening Report of Sean Nicholson: Commercial Formulary Placement	N/A	N/A	E, H, R, U
1080	Exhibit 16 to the Opening Report of Sean Nicholson: Medicare Formulary Placement	N/A	N/A	E, H, R, U
1081	Exhibit 17 to the Opening Report of Sean Nicholson: Medicaid Formulary Placement	N/A	N/A	E, H, R, U
1082	Exhibit 18 to the Opening Report of Sean Nicholson: Health Care Exchange Formulary Placement	N/A	N/A	E, H, R, U
1083	Exhibit 19 to the Opening Report of Sean Nicholson: Commercial Formulary Placement	N/A	N/A	E, H, R, U
1084	Exhibit 20 to the Opening Report of Sean Nicholson: Medicare Formulary Placement	N/A	N/A	E, H, R, U
1085	Exhibit 21 to the Opening Report of Sean Nicholson: Medicaid Formulary Placement	N/A	N/A	E, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
1086	Exhibit 22 to the Opening Report of Sean Nicholson: Health Care Exchange Formulary Placement	N/A	N/A	E, H, R, U
1087	Exhibit 23 to the Opening Report of Sean Nicholson: Amarin Annual Operating Income	N/A	N/A	E, H, R, U
1088	Exhibit 24 to the Opening Report of Sean Nicholson: Analyst Projections of Amarin Operating Income	N/A	N/A	E, H, R, U
1089	Exhibit 25 to the Opening Report of Sean Nicholson: Projected Amarin Net Sales Based on Analyst Reports	N/A	N/A	E, H, R, U
1090	Exhibit 26 to the Opening Report of Sean Nicholson: Projected Amarin Profit Margin Based on Analyst Reports	N/A	N/A	E, H, R, U
1091	Exhibit 27 to the Opening Report of Sean Nicholson: Average Projected Amarin Cumulative Operating Income Based on Net Present Value Calculations	N/A	N/A	E, H, R, U
1092	Exhibit 28 to the Opening Report of Sean Nicholson: Marketing-to-Sales Ratio of Vascepa® and Lovaza® Years After Launch based on IQVIA Data	N/A	N/A	E, H, R, U
1093	Exhibit 29 to the Opening Report of Sean Nicholson: Promotional Dollars of Vascepa® and Lovaza® Years After Launch based on IQVIA Data	N/A	N/A	E, H, R, U
1094	Exhibit 30 to the Opening Report of Sean Nicholson: Price per Prescription of Vascepa® and Prescription Omega-3 Competitors based on IQVIA Data	N/A	N/A	E, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
1095	Exhibit 31a to the Opening Report of Sean Nicholson: Vascepa® Drug Appearances by TG Level	N/A	N/A	E, H, R, U
1096	Exhibit 31b to the Opening Report of Sean Nicholson: Lovaza® Drug Appearances by TG Level	N/A	N/A	E, H, R, U
1097	Appendix and Exhibit List to the Reply Report of Sean Nicholson	N/A	N/A	H, R, U
1098	Appendix A to the Reply Report of Sean Nicholson: Curriculum Vitae of Sean Nicholson	AMRN-PEXP-0010782	AMRN-PEXP-0010794	H, R, U
1099	Appendix B to the Reply Report of Sean Nicholson: Prior Testimony of Sean Nicholson in the Last Five Years	N/A	N/A	H, R, U
1100	Appendix C to the Reply Report of Sean Nicholson: Materials Considered List	N/A	N/A	H, R, U
1101	Appendix D to the Reply Report of Sean Nicholson: Document Produced in Native Format	N/A	N/A	E, H, R, U
1102	Exhibit 1 to the Reply Report of Sean Nicholson: Average Projected Amarin Cumulative Operating Income Based on Net Present Value Calculations, Excluding H.C. Wainwright	N/A	N/A	E, H, R, U
1103	Exhibit 2 to the Reply Report of Sean Nicholson: Net Present Value by Analyst	N/A	N/A	E, H, R, U
1104	Exhibit 3a to the Reply Report of Sean Nicholson: Analyst Projections vs. Realized Values	N/A	N/A	E, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
1105	Exhibit 3b to the Reply Report of Sean Nicholson: Analyst Projections vs. Realized Values	N/A	N/A	E, H, R, U
1106	Exhibit 4 to the Reply Report of Sean Nicholson: Percent of Total Prescriptions of Molecules Indicated for Reducing TG Levels based on IQVIA Data	N/A	N/A	E, H, R, U
1107	Exhibit 5 to the Reply Report of Sean Nicholson: Percent of New Prescriptions of Molecules Indicated for Reducing TG Levels based on IQVIA Data	N/A	N/A	E, H, R, U
1108	Exhibit 6 to the Reply Report of Sean Nicholson: Percent of Sales of Molecules Indicated for Reducing TG Levels based on IQVIA Data	N/A	N/A	E, H, R, U
1109	Exhibit A to the Reply Report of Carl Peck: Curriculum Vitae of Carl Peck	AMRN-PEXP-0010754	AMRN-PEXP-0010781	H, R, U
1110	Exhibit B to the Reply Report of Carl Peck: Prior Testimony	N/A	N/A	H, R, U
1111	Exhibit C to the Reply Report of Carl Peck: Materials Considered List	N/A	N/A	H, R, U
1112	Exhibit D to the Reply Report of Carl Peck: Asserted Claims	N/A	N/A	E, H, R, U
1113	Appendix to the Opening Report of Peter Toth	N/A	N/A	H, R, U
1114	Exhibit A to the Opening Report of Peter Toth: Curriculum Vitae of Peter Toth	AMRN-PEXP-0007378	AMRN-PEXP-0007465	H, R, U
1115	Exhibit B to the Opening Report of Peter Toth: Materials Considered List	N/A	N/A	H, R, U
1116	Exhibit C to the Opening Report of Peter Toth: Asserted Claims	N/A	N/A	E, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
1117	Exhibit A to the Responsive Report of Peter Toth: Materials Considered List	N/A	N/A	H, R, U
1118	Exhibit B to the Responsive Report of Peter Toth: Dr. Heinecke's Obviousness Combinations	N/A	N/A	E, H, R, U
1119	Exhibit A to the Reply Report of Peter Toth: Materials Considered List	N/A	N/A	H, R, U
1120	MPEP [8th Ed. R8] 608.01(p)(II) - Improper Incorporation	N/A	N/A	H, R, U
1121	MPEP [8th Ed. R8] 2144 - Supporting a Rejection Under 35 U.S.C. 103 [R-6]	N/A	N/A	H, R, U
1122	Opening Report of Matthew Budoff, M.D., Regarding Hikma's ANDA Product and Vascepa (Deposition Exhibit 1)	N/A	N/A	E, U
1123	Corrected Joint Stipulation Regarding Agreement that DRL's Proposed ANDA Product Meets Certain Claim Limitations	N/A	N/A	L
1124	Oxycontin® Prescribing Information	ICOSAPENT_DFNDT000 15571	ICOSAPENT_DFNDT000 15616	H, R, U
1125	Victoza® Prescribing Information	ICOSAPENT_DFNDT000 15815	ICOSAPENT_DFNDT000 15827	H, R, U
1126	Saxenda® Prescribing Information	ICOSAPENT_DFNDT000 15828	ICOSAPENT_DFNDT000 15839	H, R, U
1127	George & Johnson, Atherosclerosis: Molecular and Cellular Mechanisms (2010)	AMRN-PEXP-0007265	AMRN-PEXP-0007328	H, R, U
1128	Executed Errata Sheet for the October 4, 2019 Deposition of Rebecca Betensky	N/A	N/A	F, H, R, U, NPI
1129	FOSAMAX® Prescribing Information (2018)	ICOSAPENT_DFNDT000 15688	ICOSAPENT_DFNDT000 15710	H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
1130	Apr. Provisional Application for US 61 173,755	ICOSAPENT DFNDTS00003330	ICOSAPENT DFNDTS00003383	F, H, R, U
1131	Feb. Provisional Application for US 61 151, 291	ICOSAPENT DFNDTS00003279	ICOSAPENT DFNDTS00003329	F, H, R, U
1132	Email from M. Manku to D. Cunningham et al. (March 24, 2008)	AMRN01688564	AMRN01688568	F, H, R, U
1133	Email from D. Doogan to M. Manku et al. (March 24, 2008)	AMRN01672033	AMRN01672034	F, H, R, U
1134	Email from Ian Osterloh to M. Manku (Apr. 02, 2008)	AMRN02175545	AMRN02175547	F, H, R, U
1135	Email from M. Manku to I. Osterloh (Apr. 21, 2008)	AMRN01688658	AMRN01688660	F, H, R, U
1136	FDA Meeting Minutes (July 14, 2008)	AMRN02973136	AMRN02973139	F, H, R, U
1137	Amarin Comments to FDA (Sept. 26, 2008)	AMRN00819347	AMRN00819348	F, H, R, U
1138	Amarin Expert Panel Meeting Background Information (Nov. 19, 2008)	AMRN00204283	AMRN00204318	F, H, R, U
1139	End-of-Phase-II Information Package	AMRN00204139	AMRN00204259	F, H, R, U
1140	Roxane/Hikma PIV Letter (Sept. 2016) (Pages 1-6)	N/A	N/A	L, R, U
1141	Dr. Reddy's PIV Letter - 500mg (July 2018)	N/A	N/A	L
1142	Dr Reddy's PIV Letter (Sept. 2016)	N/A	N/A	L
1143	Special Protocol - Agreement (AMR-01-01-0016) (May 1, 2009)	AMRN00471606	AMRN00471609	F, H, R, U
1144	Special Protocol - Agreement (AMR-01-01-0017) (July 6, 2009)	AMRN00586725	AMRN00586728	F, H, R, U
1145	FDA Meeting Minutes from March 16, 2011 Pre-NDA Meeting (Mar. 23, 2011)	AMRN01001238	AMRN01001262	F, H, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
1146	Special Protocol - Agreement (AMR-01-01-0019) (Aug. 5, 2011)	AMRN02973101	AMRN02973103	F, H, R, U
1147	FDA Letter re NDA Acknowledgment (Sept. 27, 2011)	AMRN00365523	AMRN00365526	F, H, R, U
1148	FDA Letter re Acceptance of NDA 202057 (Dec. 8, 2011)	AMRN02973169	AMRN02973174	F, H, R, U
1149	FDA Summary Review NDA No. 202057 (July 26, 2012)	AMRN01408794	AMRN014087802	F, H, R, U
1150	FDA Chemistry Review NDA No. 202057 (July 26, 2012)	AMRN01405003	AMRN01405048	F, H, R, U
1151	FDA Clinical Pharmacology Review NDA No. 202057 (July 26, 2012)	AMRN01623925	AMRN01624010	F, H, R, U
1152	FDA Pharmacology Review NDA No. 202057 (July 26, 2012)	AMRN01624011	AMRN01624146	F, H, R, U
1153	Declaration of Ronald H. Wharton, M.D., In Support of Defendants' Claim Construction	N/A	N/A	E, H, L, R, U
1154	Mori et al., Differential Effects of Eicosapentaenoic Acid and Docosahexaenoic Acid on Vascular Reactivity of the Forearm Microcirculation in Hyperlipidemic, Overweight Men, 102 Circulation 1264 (2000)	AMRN01200183	AMRN01200188	
1155	Schulz et al., Empirical Evidence of Bias, Dimensions of Methodological Quality Associated with Estimates of Treatment Effects in Controlled Trials, 273 The J. Am. Med. Ass'n 357 (1995)	AMRN-PEXP-0009525	AMRN-PEXP-0009531	H, R, U
1156	ANDA 209457 - Patent Information	WWIC0-NV-000079	WWIC0-NV-000084	L
1157	ANDA 209499 - Patent Information	DRLEPA 0000049	DRLEPA 0000056	L

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
1158	Amarin Pharma Inc., <i>Endocrinologic and Metabolic Drug Advisory Committee Briefing Document</i> , Nov. 14, 2019.	N/A	N/A	A, E, F, H, I, N, R, U
1159	Amarin Pharma Inc., <i>Endocrinologic and Metabolic Drug Advisory Committee Presentation</i> , No date.	N/A	N/A	A, E, F, H, I, N, R, U
1160	FDA Center for Drug Evaluation and Research, <i>Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Roster</i> , Nov. 6, 2019.	N/A	N/A	E, F, H, I, N, R, U
1161	Curriculum Vitae of Matthew Budoff	N/A	N/A	H, R, U, DUPE
1162	Transcript of the Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee (Nov. 14, 2019)	N/A	N/A	A, E, F, H, I, N, R, U
1163	Amarin Pharma Inc., <i>Errata to Amarin Pharmaceuticals Ireland Limited Advisory Committee Meeting Document</i> , Nov. 14, 2019.	N/A	N/A	A, E, F, H, I, N, R, U
1164	Erratum to the FDA Briefing Document (Nov. 14, 2019)	N/A	N/A	A, E, F, H, I, N, R, U
1165	FDA Center for Drug Evaluation and Research, <i>Endocrinologic and Metabolic Drugs Advisory Committee Meeting Briefing Document</i> , Nov. 14, 2019.	N/A	N/A	A, E, F, H, I, N, R, U
1166	Sharretts, <i>FDA Introductory Remarks to the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting</i> , Nov. 14, 2019.	N/A	N/A	A, E, F, H, I, N, R, U
1167	FDA Center for Drug Evaluation and Research, <i>Final Agenda: Endocrinologic</i>	N/A	N/A	E, F, H, I, N, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	<i>and Metabolic Drugs Advisory Committee Meeting, Nov. 14, 2019.</i>			
1168	FDA Center for Drug Evaluation and Research, <i>Final Roster: Endocrinologic and Metabolic Drugs Advisory Committee Meeting, Nov. 14, 2019.</i>	N/A	N/A	E, F, H, I, N, R, U
1169	FDA Center for Drug Evaluation and Research, <i>Final Questions: Endocrinologic and Metabolic Drugs Advisory Committee Meeting, Nov. 14, 2019.</i>	N/A	N/A	E, F, H, I, N, R, U
1170	Institute for Clinical and Economic Review (ICER), <i>Additive Therapies for Cardiovascular Disease: Effectiveness and Value: Final Evidence Report, Oct. 17, 2019.</i>	N/A	N/A	A, E, F, H, I, N, R, U
1171	Institute for Clinical and Economic Review (ICER), <i>Additive Therapies for Cardiovascular Disease: Final Policy Recommendations, Oct. 17, 2019.</i>	N/A	N/A	A, E, F, H, I, N, R, U
1172	Curriculum Vitae of Peter Toth (Nov. 15, 2019)	N/A	N/A	H, R, U, DUPE
1173	FDA Center for Drug Evaluation and Research, <i>Endocrinologic and Metabolic Drugs Advisory Committee Meeting Webcast Information, Nov. 14, 2019.</i>	N/A	N/A	E, F, H, I, N, R, U
1174	November 14, 2019, Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) - Webcast Recording, Start of Meeting to Morning Break.	N/A	N/A	A, E, F, H, I, N, R, U, NPI

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
	https://collaboration.fda.gov/poku8qu000zj/			
1175	November 14, 2019, Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) - Webcast Recording, Morning Break to Afternoon Break. https://collaboration.fda.gov/pgu58b2olhg v/	N/A	N/A	A, E, F, H, I, N, R, U, NPI
1176	November 14, 2019, Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) - Webcast Recording, Afternoon Break to End of Meeting. https://collaboration.fda.gov/pegir9sba12n/	N/A	N/A	A, E, F, H, I, N, R, U, NPI
1177	Bhatt et al., <i>REDUCE-IT USA</i> , Circulation 10.1161/CIRCULATIONAHA.119.044440 (2019).	N/A	N/A	E, F, H, N, R, U
1178	Bhatt et al., <i>REDUCE-IT USA: Slides from the 2019 American Heart Association Meeting (AHA)</i> , American Heart Association (2019).	N/A	N/A	A, E, F, H, N, R, U
1179	Supplement to Bhatt et al., <i>REDUCE-IT USA</i> , Circulation 10.1161/CIRCULATIONAHA.119.044440 (2019)	N/A	N/A	A, E, F, H, N, R, U
1180	FDA Correspondence: Advice/Information Request (May 12, 2010)	AMRN02972982	AMRN02972984	E, F, R, U

Plaintiffs' Preliminary Exhibit List*Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.*

Civil Action No. 2:16-cv-02525-MMD-NJK

PX No.	Document Description	Beg Bates	End Bates	Objections
1181	FDA Correspondence: Acknowledgement -- Prior Approval Supplement (Feb. 22, 2013)	AMRN02974004	AMRN02974006	E, F, R, U
1182	FDA Correspondence: Filing Communication (May 1, 2013)	AMRN02973106	AMRN02973108	E, F, R, U
1183	FDA Correspondence: Special Protocol Assessment -- Rescind Agreement (Oct. 29, 2013)	AMRN02973024	AMRN02973026	E, F, R, U
1184	FDA Correspondence: Appeal Denied (Sept. 11, 2014)	AMRN00552398	AMRN00552409	E, F, R, U

Defendants' Objection Legends – 11/22/2019
Subject to Supplementation and Revision

Objection Key for Defendants' Objections to Amarin's Trial Exhibit List

Objection Code	Description	Basis
A	Requires authentication or identification	Fed. R. Evid. 901
C	Improper compilation of separate documents	Fed. R. Evid. 403, 901, 1006
E	Improper expert testimony	Fed. R. Evid. 104, 701, 702, 703; Fed. R. Civ. P. 26
F	Lack of foundation or personal knowledge	Fed. R. Evid. 602, 901
H	Hearsay	Fed. R. Evid. 801, 802, 805
I	Incomplete document or testimony	Fed. R. Evid. 106, 403
L	Limited admissibility	Fed. R. Evid. 105
N	Not produced in discovery	Fed. R. Civ. P. 37; Fed. R. Evid. 403
O	Predicate fact required for admissibility	Fed. R. Evid. 104
R	Lack of relevance	Fed. R. Evid. 402
S	Improper summary	Fed. R. Evid. 1006
U	Unduly prejudicial, confusing, wasteful, cumulative	Fed. R. Evid. 403
NPI	Documents are not properly identified and/or were not provided to objecting party. The objecting party reserves the right to further object after inspection or examination of the properly identified documents.	
ILL	Illegible	
DUPE	Duplicative of another exhibit also included on the exhibit list.	

EXHIBIT B

Defendants' Preliminary Exhibit List

Trial Ex. No.	Bates Range	Doc Date	Dep. Ex. No. (if applicable)	Description	Party:	Plaintiffs' Objections
1500	AMRN-PEXP-0000001-22	10/23/2012		U.S. Patent No. 8,293,728	Defendants	JTX
1501	AMRN00206053-12773			U.S. Patent No. 8,293,728 File History	Defendants	JTX
1502	AMRN-PEXP-0000023-45	11/27/2012		U.S. Patent No. 8,318,715	Defendants	JTX
1503	AMRN00212774-19280			U.S. Patent No. 8,318,715 File History	Defendants	JTX
1504	AMRN-PEXP-0000046-67	1/22/2013		U.S. Patent No. 8,357,677	Defendants	JTX
1505	AMRN00219281-25724			U.S. Patent No. 8,357,677 File History	Defendants	JTX
1506	AMRN-PEXP-0000068-90	2/5/2013		U.S. Patent No. 8,367,652	Defendants	JTX
1507	AMRN00225725-32139			U.S. Patent No. 8,367,652 File History	Defendants	JTX
1508	AMRN-PEXP-0000091-113	2/19/2013		U.S. Patent No. 8,377,920	Defendants	JTX
1509	AMRN00232140-9831			U.S. Patent No. 8,377,920 File History	Defendants	JTX
1510	AMRN-PEXP-0000114-36	3/19/2013		U.S. Patent No. 8,399,446	Defendants	JTX
1511	AMRN00239832-47573			U.S. Patent No. 8,399,446 File History	Defendants	JTX
1512	AMRN-PEXP-0000137-60	4/9/2013		U.S. Patent No. 8,415,335	Defendants	JTX
1513	AMRN00247574-55303			U.S. Patent No. 8,415,335 File History	Defendants	JTX
1514	AMRN-PEXP-0000161-83	4/30/2013		U.S. Patent No. 8,431,560	Defendants	JTX
1515	AMRN00263074-71241			U.S. Patent No. 8,431,560 File History	Defendants	JTX
1516	AMRN-PEXP-0000184-206	8/27/2013		U.S. Patent No. 8,518,929	Defendants	JTX
1517	AMRN00287378-988			U.S. Patent No. 8,518,929 File History	Defendants	JTX
1518	AMRN-PEXP-0000207-30	9/3/2013		U.S. Patent No. 8,524,698	Defendants	JTX
1519	AMRN00287989-8608			U.S. Patent No. 8,524,698 File History	Defendants	JTX
1520	AMRN03061427-47	10/23/2012		U.S. Patent No. 8,293,727	Defendants	JTX
1521	AMRN03058106-9969			U.S. Patent No. 8,293,727 File History	Defendants	JTX
1522	AMRN00204453-503	2/10/2009		U.S. Provisional Application Nos. 61/151,291	Defendants	JTX
1523	AMRN00204504-557	4/29/2009		U.S. Provisional Application Nos. 61/173,755	Defendants	JTX
1524	ICOSAPENT_DFNDTS00007058-107	12/13/2007		WO 2007/142118 and English translation	Defendants	702; 801; A
1525	ICOSAPENT_DFNDTS00007108-50	1/10/2008		WO 2008/004900	Defendants	702; 801
1526	ICOSAPENT_DFNDTS00006549-87	5/1/2001		National Institutes of Health, National Heart, Lung, and Blood Institute, "Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III, Executive Summary," May 2001)	Defendants	801
1527	ICOSAPENT_DFNDTS00006169-73	1/1/1991		Epadel Capsules 300, Japan Pharmaceutical Reference 369 (2nd ed. 1991)	Defendants	702; 801; A
1528	ICOSAPENT_DFNDTS00008961-969	1/1/2007		Epadel Capsules 300, January 2007 Update (Version 5)	Defendants	702; 801; A
1529	ICOSAPENT_DFNDTS00006126-35	4/1/2006		Geppert et al., Microalgal Docosahexaenoic Acid Decreases Plasma Triacylglycerol in Normolipidaemic Vegetarians: A Randomized Trial, 95 BRIT. J. NUTRITION 779 (2006)	Defendants	702; 801
1530	ICOSAPENT_DFNDTS00006136-46	4/18/1997		Grimsgaard et al., Highly Purified Eicosapentaenoic Acid and Docosahexaenoic Acid in Humans Have Similar Triacylglycerol-Lowering Effects but Divergent Effects on Serum Fatty Acids, 66 AM. J. CLIN. NUTR. 649-59 (1997)	Defendants	702; 801
1531	ICOSAPENT_DFNDTS00006152-58	9/29/1997		Harris et al., Safety and Efficacy of Omacor in Severe Hypertriglyceridemia, J. CARDIOV. RISK, 4:385-391 (1997)	Defendants	801

Trial Ex. No.	Bates Range	Doc Date	Dep. Ex. No. (if applicable)	Description	Party:	Plaintiffs' Objections
1532	ICOSAPENT_DFNDTS00006159-68	1/1/1995		Hayashi et al., Decreases in Plasma Lipid Content and Thrombotic Activity by Ethyl Icosapentate Purified from Fish Oils, 56(1) CURR. THERAP. RES. 24-31 (1995)	Defendants	403; 702; 801
1533	ICOSAPENT_DFNDTS00006174-6200	1/1/2001		Katayama et al., Efficacy and Safety of Ethyl Icosapentate (Epadel®) Given for a Long Term Against Hyperlipidemia, 21 PROG. MED. 457 (2001) and English translation	Defendants	402; 403; 702; 801; A
1534	ICOSAPENT_DFNDTS00006237-44	10/1/2000		Kurabayashi et al., Eicosapentaenoic Acid Effect on Hyperlipidemia in Menopausal Japanese Women. OBSTET. GYNECOL. 96:521-8 (2000)	Defendants	702; 801
1535	ICOSAPENT_DFNDTS00006710-13	1/1/2007		Lovaza®, Physicians' Desk Reference 2699 (62d ed. 2007)	Defendants	801
1536	ICOSAPENT_DFNDTS00006426-36	1/1/2005		Maki et al., Lipid responses to a dietary docosahexaenoic acid supplement in men and women with below average levels of high density lipoprotein cholesterol, 24 J. AM. COL. NUTR. 189-99 (2005)	Defendants	402; 403; 702; 801
1537	ICOSAPENT_DFNDTS00006440-96	1/1/1991		Matsuzawa et al., Effect of Long-Term Administration of Ethyl Icosapentate (MND-21) in Hyperlipidaemic Patients, 7 J. CLIN. THERAPEUTIC & MEDICINES 1801 (1991) and English translation	Defendants	402; 403; 702; 801; A
1538	ICOSAPENT_DFNDTS00011026-35	1/1/2000		Mori et al., Purified Eicosapentaenoic and Docosahexaenoic Acids Have Differential Effects on Serum Lipids and Lipoproteins, LDL Particle Size, Glucose, and Insulin in Mildly Hyperlipidemic Men, 71 AM. J. CLINICAL NUTRITION 1085 (2000)	Defendants	702; 801
1539	ICOSAPENT_DFNDTS00006540-43	1/12/1999		Nakamura et al., Joint Effects of HMG-CoA Reductase Inhibitors and Eicosapentaenoic Acids on Serum Lipid Profile and Plasma Fatty Acid Concentrations in Patients with Hyperlipidemia, 29(1) INT. J. CLIN. LAB. RES. 22-25 (1999)	Defendants	402; 403; 702; 801
1540	ICOSAPENT_DFNDTS00006544-48	1/1/2002		Nestel et al., The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans. 76 AM. J. CLIN. NUTR. 326 (2002)	Defendants	702; 801
1541	ICOSAPENT_DFNDTS00006588-94	1/1/1992		Nozaki et al., Effects of Purified Eicosapentaenoic Acid Ethyl Ester on Plasma Lipoproteins in Primary Hypercholesterolemia, 62 INT'L J. VITAMIN & NUTRITION RES. 256-60 (1992)	Defendants	702; 801
1542	ICOSAPENT_DFNDTS00006595-6601	1/1/2002	Kornak 8	Okumura et al., Eicosapentaenoic Acid Improves Endothelial Function in Hypertriglyceridemic Subjects Despite Increased Lipid Oxidizability, 324 AM. J. MED. SCI. 247-53 (2002)	Defendants	402; 403; 702; 801
1543	ICOSAPENT_DFNDTS00006618-26	1/1/2004		Omacor® Label (2004)	Defendants	801; A; B
1544	ICOSAPENT_DFNDTS00006714-17	1/1/2006		Omacor®, Physicians' Desk Reference 2735 (60d ed. 2006)	Defendants	801; A

Trial Ex. No.	Bates Range	Doc Date	Dep. Ex. No. (if applicable)	Description	Party:	Plaintiffs' Objections
1545	ICOSAPENT_DFNDTS00006701-6709	12/1/2002		Park & Harris, Omega-3 Fatty Acid Supplementation Accelerates Chylomicron Triglyceride Clearance, 44 J. LIPID RES. 44:455-463 (2003)	Defendants	702; 801;
1546	ICOSAPENT_DFNDTS00006791-6823	1/1/1998		Saito et al., Results of Clinical Usage of Improved Formulation (MND-21S) Epadel Capsule 300 with Respect to Hyperlipidemia, 26(12) JPN. PHARMACOL. THER. 2047-62 (1998) and English translation	Defendants	702; 801; A
1547	ICOSAPENT_DFNDTS00006785-90	6/19/2008		Saito et al., Effects of EPA on Coronary Artery Disease in Hypercholesterolemic Patients with Multiple Risk Factors: Sub-Analysis of Primary Prevention Cases from the Japan EPA Lipid Intervention Study (JELIS), 200 ATHEROSCLEROSIS 135-40 (2008)	Defendants	402; 403; 702; 801
1548	ICOSAPENT_DFNDTS00006832-36	1/1/2007		Satoh et al., Purified Eicosapentaenoic Acid Reduces Small Dense LDL, Remnant Lipoprotein Particles, and C-Reactive Protein in Metabolic Syndrome, 30 DIABETES CARE 144 (2007)	Defendants	702; 801
1549	ICOSAPENT_DFNDTS00011751-3	1/1/1996		Shinozaki et al., The Long-Term Effect of Eicosapentaenoic Acid on Serum Levels of Lipoprotein (a) and Lipids in Patients with Vascular Disease, 2(2) J. ATHEROSCL. THROMB. 107-09 (1996)	Defendants	402; 403; 702; 801
1550	ICOSAPENT_DFNDTS00006864-6904	11/1/1991		Takaku et al., Study on the Efficacy and Safety of Ethyl Icosapentate (MND-21) in Treatment of Hyperlipidemia Based on a Long-Term Administration Test, 7 J. CLIN. THERAPEUTICS & MEDICINE 191 (1991) and English translation	Defendants	402; 403; 702; 801; A
1551	ICOSAPENT_DFNDTS00014511-6	1/1/1991		Wojenski et al., Eicosapentaenoic Acid Ethyl Ester as an Antithrombotic Agent: Comparison to an Extract of Fish Oil, BIOCHIM. BIOPHYS. ACTA., 1081(1):33-38 (1991)	Defendants	402; 403; 702; 801
1552	ICOSAPENT_DFNDTS00007166-73	10/1/2003		Yokoyama et al., Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: Rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS), 146 AM. HEART J. 613-20 (2003)	Defendants	402; 403; 702; 801
1553	ICOSAPENT_DFNDTS00007157-65	3/31/2007		Yokoyama et al., Effects of Eicosapentaenoic Acid on Major Coronary Events in Hypercholesterolaemic Patients (JELIS): a Randomized Open-Label, Blinded Endpoint Analysis, 369 LANCET 1090-98 (2007)	Defendants	402; 403; 702; 801
1554		3/10/2019		Opening Expert Report of Matthew Budoff, M.D., Regarding Hikma's ANDA product and Vascepa® with Exhibits A-C	Defendants	
1555		3/11/2019		Opening Expert Report of Matthew Budoff, M.D., Regarding DRL's ANDA product and Vascepa®	Defendants	
1556		6/10/2019		Reply Expert Report of Matthew Budoff, M.D., Regarding Defendants' ANDA Products and Vascepa® and Exhibits A-B	Defendants	

Trial Ex. No.	Bates Range	Doc Date	Dep. Ex. No. (if applicable)	Description	Party:	Plaintiffs' Objections
1557	AMRN02712524-26	1/11/2014		Email between Ketchum and Budoff re Vascepa (icosapent ethyl) [formerly AMR101]: Congressional Heart and Stroke Coalition	Defendants	106; 402; 403; 701; 801; A
1558	AMRN03132005-09	4/27/2015		FDA Complete Response, NDA 202057/S-005	Defendants	801; A
1559		8/24/2016		Dollars for Docs: 2015 Edition	Defendants	402; 403; 702; 801; A
1560		12/31/2016		OpenPaymentsData.CMS.gov 2016 data for Matthew J. Budoff Summary	Defendants	402; 403; 702; 801; A
1561		12/31/2016		OpenPaymentsData.CMS.gov 2016 data for Matthew J. Budoff General Payments	Defendants	402; 403; 702; 801; A
1562		12/31/2017		OpenPaymentsData.CMS.gov 2017 data for Matthew J. Budoff General Payments	Defendants	402; 403; 702; 801; A
1563		12/31/2018		OpenPaymentsData.CMS.gov 2018 data for Matthew J. Budoff General Payments	Defendants	402; 403; 702; 801; A
1564	AMRN03171996-2021	4/18/2012		Investigator Services Agreement	Defendants	402; 403; 801; A
1565	AMRN03172022-29	3/26/2013		Amendment #1 to Investigator Services Agreement	Defendants	402; 403; 801; A
1566	AMRN03172030-34	6/21/2013		Amendment #2 to Investigator Services Agreement	Defendants	402; 403; 801; A
1567	AMRN03172035-42	6/21/2013		Amendment #3 to Investigator Services Agreement	Defendants	402; 403; 801; A
1568	AMRN03172043	12/5/2014		Amendment to Speaker Services Agreement of 2014	Defendants	402; 403; 801; A
1569	AMRN03172044-48	12/15/2016		Services Agreement	Defendants	402; 403; 801; A
1570	AMRN03172049-51	10/3/2017		Services Agreement	Defendants	402; 403; 801; A
1571	AMRN03172052-60	7/13/2018		Consultancy Agreement	Defendants	402; 403; 801; A
1572	AMRN03172061-64	8/21/2018		Amarin Mutual Confidentiality Agreement	Defendants	402; 403; 801; A
1573	AMRN03172065-73	2/25/2019		Consultancy Agreement	Defendants	402; 403; 801; A
1574		5/10/2019	Fisher 1	Responsive Expert Report of Edward A. Fisher, M.D., M.P.H., Ph.D.	Defendants	702; 801; A
1575		5/10/2019	Fisher 2	List of Materials Considered by Dr. Edward A. Fisher	Defendants	801; A
1576		5/1/2018	Fisher 3	Curriculum Vitae of Edward A. Fisher, M.D., M.P.H., Ph.D.	Defendants	801; A
1577		1/3/2019	Fisher 4	Feingold and Grunfeld, Diabetes and Dyslipidemia. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK305900/?report=printable (last accessed 06/25/2019)	Defendants	801
1578	AMRN01187779-80	8/1/2007	Fisher 5	Lovaza® Label	Defendants	801
1579		4/29/2011	Fisher 6	Chapman, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. European Heart Journal 32:1345-1361 (2011).	Defendants	801
1580	AMRN-PEXP-0008656-81	1/1/2019	Fisher 7	American Diabetes Association, 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes – 2019. Diabetes Care 42(1): S103-S123 (January 2019).	Defendants	801
1581	AMRN00291600-602	11/30/2010	Fisher 13	O'Riordan, MARINE: Ethyl-EPA Reduces Triglyceride Levels Without Raising LDL Cholesterol. www.medscape.com (November 30, 2010).	Defendants	801
1582	ICOSAPENT_DFNDTS00018006-23	4/11/2017	Fisher 14	Siscovick, et al. Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease: A Science Advisory From the American Heart Association. Circulation 135:e867-e8884 (2017).	Defendants	801
1583		6/10/2019	Godici 1	Reply Expert Report of Nicholas P. Godici with Exhibits A-C.	Defendants	702; 801; A
1584		5/10/2019	Godici 2	Expert Report of Stephen G. Kunin	Defendants	
1585	AMRN03058824-35	6/20/2011	Godici 3	Non-Final Rejection, U.S. Patent Application No. 12/702,889.	Defendants	106; 801
1586	AMRN03058867-907	6/23/2011	Godici 4	Response to the Office Action Dated June 20, 2011, U.S. Patent Application No. 12/702,889.	Defendants	106; 801
1587	AMRN03059004-28	8/18/2011	Godici 5	Final Rejection, U.S. Patent Application No. 12/702,889.	Defendants	106; 801

Trial Ex. No.	Bates Range	Doc Date	Dep. Ex. No. (if applicable)	Description	Party:	Plaintiffs' Objections
1588	AMRN03059744-69	3/2/2012	Godici 6	Non-Final Rejection, U.S. Patent Application No. 12/702,889.	Defendants	106; 801
1589	AMRN03059830-34	5/10/2012	Godici 8	Declaration of Philip Lavin under 37 C.F.R. § 1.132, U.S. Patent Application No. 12/702,889.	Defendants	106; 402; 403; 801
1590	AMRN03059782-88	4/24/2012	Godici 9	Interview Agenda and Summary, U.S. Patent Application No. 12/702,889.	Defendants	106; 801
1591	AMRN03059927-40	9/6/2012	Godici 10	Notice of Allowance, U.S. Patent Application No. 12/702,889.	Defendants	106; 801
1592			Godici 11	37 CFR 1.104 Nature of examination Rev. 5, Aug. 2006	Defendants	801; A
1593	AMRN03059815-23	5/8/2012	Godici 12	Declaration III of Harold E. Bays Under 37 C.F.R. § 1.132, U.S. Patent Application No. 12/702,889.	Defendants	106; 801
1594		9/20/2016	Godici 13	<i>In Limine</i> Order Granting Defendant Medtronic's Motion to Exclude the Testimony of Nicholas Godici, Barry v. Medtronic. E.D. Tex. No. 1:14-cv-104	Defendants	801; A
1595		3/11/2019	Heinecke 1	Opening Expert Report of Jay W. Heinecke, M.D. on Invalidity of the Asserted Claims of the Patents-In-Suit with Exhibits 1-2.	Defendants	702; 801; A
1596		5/10/2019	Heinecke 2	Rebuttal Expert Report of Jay W. Heinecke, M.D. on Invalidity of the Asserted Claims of the Patents-In-Suit with Materials Considered	Defendants	702; 801; A
1597		6/7/2019	Heinecke 3	Reply Expert Report of Jay W. Heinecke, M.D. on invalidity of the Asserted Claims of the Patents-In-Suit with Materials Considered	Defendants	702; 801; A
1598	AMRN-PEXP-0001915-32	11/5/2004	Heinecke 4	TRICOR® Approved Labeling	Defendants	801
1599	AMRN-PEXP-0001692-1712	1/1/2003	Heinecke 6	Niaspan® Label	Defendants	801
1600	AMRN-PEXP-0008180-86.	1/1/1977	Heinecke 7	Carlson, et al. ON the Rise in Low Density and High Density Lipoproteins in Response to the Treatment of Hypertriglyceridaemia in Type IV and Type V Hyperlipoproteinaemias. <i>Atherosclerosis</i> 26:603-609 (1977).	Defendants	801
1601	AMRN-PEXP-00621043-49	5/13/2007	Heinecke 8	Isley, et al. Pilot study of combined therapy with w-3 fatty acids and niacin in atherogenic dyslipidemia, <i>Journal of Clinical Lipidology</i> 1:211-217 (2007).	Defendants	801
1602	AMRN-PEXP-0009429-31	5/28/2008	Heinecke 9	Mitchell, Peter. Regulator rebuffs Merck's cholesterol drug. chemistryworld.com/news/regulator-rebuffs-rnercks-cholesterol-diug/3003426.article	Defendants	801
1603	AMRN-PEXP-0009110-12	3/22/2013	Heinecke 10	European Medicines Agency press release, Tredaptive, Pelzont and Trevaclyn suspended across the EU.	Defendants	801
1604		1/1/2007	Heinecke 11	Oram and Heinecke, When Good Cholesterol Turns Bad: The Evolving Saga of CETP Inhibitors and Clinical Strategies to Elevate High-density Lipoprotein. <i>Current Atherosclerosis Reports</i> 9:425-427 (2007).	Defendants	801
1605	AMRN-PEXP-0007466-77	1/1/2006	Heinecke 13	Schacky, A review of omega-3 ethyl esters for cardiovascular prevention and treatment of increased blood triglyceride levels. <i>Vascular Health and Risk Management</i> 2(3):251-262 (2006).	Defendants	801
1606		5/10/2019	Hofmann 1	Rebuttal Expert Report of Ivan T. Hofmann with Appendices 1-3	Defendants	702; 801; A
1607	AMRN-PEXP-0007104	11/30/2018	Hofmann 4	Spreadsheet: Treatment Insights View	Defendants	801
1608	AMRN03171431	12/31/2018	Hofmann 5	Spreadsheet: Historical Revenue Historical Revenue Q1 2013-Q4 2018	Defendants	801
1609	AMRN-PEXP-0007102	11/30/2018	Hofmann 6	Spreadsheet: Rx View	Defendants	801
1610		1/9/2019	Ismail 1	Opening Expert Report of Firhaad Ismail, M.D., F.A.C.E. with Exhibits A-B	Defendants	
1611		3/7/2019	Ismail 2	Corrected Opening Expert Report of Firhaad Ismail, M.D., F.A.C.E.	Defendants	
1612		6/10/2019	Ismail 5	Reply Expert Report of Firhaad Ismail, M.D., F.A.C.E. with Exhibit A	Defendants	
1613	AMRN03171905-13	6/10/2013	Ismail 6	Speaker Services Agreement	Defendants	402; 403; 801; A
1614	AMRN03171896-1904	2/11/2014	Ismail 7	2014 Speaker Contract	Defendants	402; 403; 801; A
1615	AMRN03171914-20	1/5/2015	Ismail 8	Speaker Services Agreement	Defendants	402; 403; 801; A
1616	AMRN03171921-26	1/12/2016	Ismail 9	2016 Speaker Services Agreement	Defendants	402; 403; 801; A

Trial Ex. No.	Bates Range	Doc Date	Dep. Ex. No. (if applicable)	Description	Party:	Plaintiffs' Objections
1617		10/18/2010	Ismail 10	Ornstein, et al. Dollars for Doctors. Docs on Pharma Payroll Have Blemished Records, Limited Credentials. https://www.propublica.org/article/dollars-to-doctors-physician-disciplinary-records# (last accessed 6/11/19)	Defendants	402; 403; 702; 801; A
1618		7/15/2011	Ismail 11	Dollars for Docs, Top Earners. https://web.archive.org/web/20110715123145/http://projects.propublica.org/docdollars/top_earners	Defendants	402; 403; 702; 801; A
1619		6/25/2009	Ismail 12	State of Nevada Pharmacy & Therapeutics Committee Meeting Minutes	Defendants	402; 403; 801; A
1620	AMRN00974580	7/11/2012	Ismail 13	Email between Riedell and Meehan re Summary & Next Steps: Vascepa Speaker Programs	Defendants	106; 402; 403; 801; A; F
1621	AMRN00974582	5/17/2011	Ismail 14	Spreadsheet: Controlled List Speakers 05172011	Defendants	402; 403; 801; A; B; F
1622	AMRN02390922	3/25/2013	Ismail 15	Email between Padmanabhan and Budsock	Defendants	106; 402; 403; 801; A; DESC
1623	AMRN02390926		Ismail 16	Spreadsheet of consultant payments	Defendants	402; 403; 801; A
1624	AMRN-PEXP-0001808-17.	4/19/2016	Ismail 18	Tajuddin, et al. Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2016;9 109-118.	Defendants	801
1625		6/10/2019	Kornak 1	Reply Expert Report of John Kornak, Ph.D. with Exhibits A-B	Defendants	702; 801; A
1626		6/13/2019	Kornak 2	Corrected Reply Expert Report of John Kornak, Ph.D. with Exhibits A-B	Defendants	702; 801; A
1627		6/13/2019	Kornak 3	Redlined Corrected Reply Expert Report of John Kornak, Ph.D. with Exhibits A-B	Defendants	702; 801; A
1628			Kornak 4	document titled lavinV3 ICOSAPENT_DFNDT 00020685.R	Defendants	106; 702; 801; A; DESC
1629			Kornak 5	document titled reportPlots ICOSAPENT_DFNDT 00020684.R	Defendants	106; 702; 801; A; DESC
1630			Kornak 6	document titled lavinV5 ICOSAPENT_DFNDT 00020683.R	Defendants	106; 702; 801; A; DESC
1631			Kornak 7	document titled lavinV5 ICOSAPENT_DFNDT 00020683.R Calculations	Defendants	106; 702; 801; A; DESC
1632	ICOSAPENT_DFNDT00020641-82	1/1/2011	Kornak 9	Miller, et al. Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation 123:2292-2333 (2011).	Defendants	801
1633	ICOSAPENT_DFNDT00020631-40	10/17/2012	Kornak 10	Carroll, et al. Trends in Lipids and Lipoproteins in U.S. Adults, 1988-2010. JAMA 308(15):1545-54 (2012).	Defendants	801
1634		5/10/2019	Kunin 1	Expert Report of Stephen G. Kunin with Exhibits A-D	Defendants	
1635	AMRN03059780-814	04/20 – 05/16/2012	Kunin 5	Interview Agenda, Applicant Initiated Interview Summary, Response to Non-Final Office Action Dated March 2, 2012 U.S. Patent Application No. 12/702,889.	Defendants	106; 801
1636	AMRN00212303-389	6/27/2012	Kunin 6	Response to Non-Final Action Dated April 4, 2012, U.S. Patent Application No. 13/349,153.	Defendants	106; 801
1637	AMRN03059338-58	12/16/2011	Kunin 7	Declaration of Philip Lavin Under 37 C.F.R. §1.132, U.S. Patent Application No. 12/702,889.	Defendants	106; 402; 403; 801; A
1638	AMRN-PEXP-0000546-569		Mason 1	Curriculum Vitae, Dr. R. Preston Mason	Defendants	
1639		3/8/2019	Mason 2	Opening Expert Report of R. Preston Mason, Ph.D. with Appendix A and Exhibits A-B	Defendants	

Trial Ex. No.	Bates Range	Doc Date	Dep. Ex. No. (if applicable)	Description	Party:	Plaintiffs' Objections
1640		6/10/2019	Mason 3	Reply Expert Report of R. Preston Mason, Ph.D. with Exhibit A	Defendants	
1641	AMRN-PEXP-0000689-700	1/3/2019	Mason 5	Bhatt, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 380(1):11-22 (January 3, 2019)	Defendants	801
1642		10/22/2014	Mason 6	Mason and Jacob, Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism. Biochemica et Biophysical Acta 1848:502-509 (2015).	Defendants	801
1643	AMRN01366206-34		Mason 7	Mason and Jacob, Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism, version with track changes.	Defendants	801; A; F
1644	AMRN01366205	5/19/2014	Mason 8	Email between Stirtan and Mason re RP Mason Draft manuscript: EPA vs. DHA and TG-lowering agents (antioxidation, Cholesterol Domains) – AMRN comments	Defendants	106; 402; 403; 701; 801; A
1645	AMRN03146567-76	10/5/2016	Mason 9	Mason, et al. Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes. Biochemica et Biophysical Acta 1858:3131-3140 (2016).	Defendants	801; B
1646	AMRN-PEXP-0000539-45	4/16/2018	Mason 10	Mason, et al. Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin. Biomedicine & Pharmacotherapy 103:1231-1237 (2018).	Defendants	801
1647	AMRN02187308-9	4/30/2009	Mason 11	Email between Mason and Rowe re CDA	Defendants	106; 402; 403; 701; 801; A
1648	AMRN03171738-40	4/23/2009	Mason 12	Amarin Confidentiality Agreement	Defendants	402; 403; 801; A
1649	AMRN02187310-15	4/10/2009	Mason 13	Self-Medlin, et al. Glucose promotes membrane cholesterol crystalline domain formation by lipid peroxidation. Biochimica et Biophysica Acta xxx:xxx-xxx (2009)	Defendants	402; 403; 702; 801; A
1650	AMRN02187316	5/5/2009	Mason 14	Email between Mason and Rowe re agreement	Defendants	106; 402; 403; 801; A
1651	AMRN01636840-41	5/22/2009	Mason 15	Email between Soni, Rowe, Stirtan, Grandolfi, Manku, and Doogan re Amarin 2009 Project Protocol	Defendants	106; 402; 403; 701; 801; A
1652	AMRN02188384-88		Mason 16	Effects of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) on Lipid Peroxidation and Membrane Structural Organization	Defendants	402; 403; 702; 801; A; DESC
1653	AMRN00769425	6/8/2009	Mason 17	Email between Rowe and Mason re JELIS studies	Defendants	106; 402; 403; 701; 801; A
1654	AMRN00799606	5/9/2014	Mason 18	Email between Bress and Stirtan re Preston Mason Work-Order: For sign-off	Defendants	106; 402; 403; 801; A; F
1655	AMRN00799607	5/7/2014	Mason 19	Mason and Jacob Research proposal: Comparative Effects of Eicosapentaenoic Acid (EPA), Docosahexanoic Acid (DHA), Fenofibrate, Niacin, Gemfibrozil – Alone or in Combination with Atorvastatin Metabolite – on Human Endothelial Function Following Exposure to oxLDL	Defendants	402; 403; 801; A; DESC
1656	AMRN01434884-88	8/21/2014	Mason 20	Email between Ketchum and Thero re Preston Mason: Important publication development that involves add'l funding	Defendants	106; 402; 403; 701; 801; A
1657	AMRN02915248-54	3/30/2012	Mason 21	Email between Mason and Stirtan re ACC-Meeting with Preston Mason (2 pm Sat, Hyatt at Convention Center)	Defendants	106; 402; 403; 801; A
1658	AMRN00389762-64	3/25/2012	Mason 22	Email between Mason and Stirtan re ACC-Meeting with Preston Mason (2 pm Sat, Hyatt at Convention Center)	Defendants	106; 402; 403; 801; A
1659	AMRN00389765-86		Mason 23	Mason, EPA Enhanced Nitric Oxide Bioavailability: Potential Synergistic Actions with Statins.	Defendants	402; 403; 801
1660	AMRN003171846-48	1/1/2016	Mason 24	Services Agreement	Defendants	402; 403; 801; A

Trial Ex. No.	Bates Range	Doc Date	Dep. Ex. No. (if applicable)	Description	Party:	Plaintiffs' Objections
1661	AMRN003171757-59	10/1/2015	Mason 25	Services Agreement	Defendants	402; 403; 801; A
1662	AMRN003171752-56	4/14/2016	Mason 26	Services Agreement	Defendants	402; 403; 801; A
1663	AMRN003171732-34	10/12/2015	Mason 27	Services Agreement	Defendants	402; 403; 801; A
1664	AMRN003171791-95	12/9/2016	Mason 28	Services Agreement	Defendants	402; 403; 801; A
1665	AMRN003171743-51	7/12/2018	Mason 29	Consultancy Agreement	Defendants	402; 403; 801; A
1666	AMRN003171796-804	3/7/2011	Mason 30	Facsimile from Mason to Mandura attaching W-9 and Consultancy Agreement	Defendants	402; 403; 801; A
1667		2/4/2016	Mason 31	Getler, No Compliments for 'Supplements'. https://www.pbs.org/publiceditor/blogslobudsman/2016/02/04/no-compliments-for-supplements/ last accessed June 13, 2019	Defendants	402; 403; 801; A
1668		12/21/2016	Mason 32	Mason, et al. Omega-3 fatty acid fish oil dietary supplements contain saturated fats and oxidized lipids that may interfere with their intended biological benefits. Biochemical and Biophysical Research Communications 483:425-429 (2017).	Defendants	402; 403; 801
1669	AMRN002752198-2210	2/16/2012	Mason 33	Email between Soni, Stirtan, and Braeckman re Follow up from AHA on human endothelial function and nitric oxide studies – [From Preston Mason – Confidential]	Defendants	106; 402; 403; 701; 801; A; F
1670		9/4/2014	Mason 34	U.S. Patent Application Publication 2014/0249225 A1	Defendants	402; 403; 801
1671		1/8/2019	Mason 35	U.S. Patent 10,172,818 B2	Defendants	402; 403; 801
1672	AMRN002305585-86	1/28/2014	Mason 36	Email between Mason and Stirtan re Summary of New Findings with EPA with attachment	Defendants	106; 402; 403; 801; A
1673		5/10/2019	Mathers 1	Rebuttal Expert Report of Peter R. Mathers on Non-Infringement of the Asserted Claims of the Patents-in-Suit	Defendants	702; 801; A
1674		5/10/2019	Mathers 2	Materials Considered in Rebuttal Expert Report of Peter R. Mathers on Non-Infringement of the Asserted Claims of the Patents-In-Suit	Defendants	801; A
1675			Mathers 3	Peter R. Mathers Bio	Defendants	801; A
1676	AMRN03132168-77	3/1/2017	Mathers 4	Final Printed Carton and Container Labels for approved NDA 202057/S-019	Defendants	801; DUP
1677	ICOSAPENT_DFNDT00018232-51	2/1/2014	Mathers 7	FDA, Distributing Scientific and Medical Publications on Unapproved and New Uses— Recommend Practices: Guidance for Industry (2014) (“FDA Unapproved Use Guidance”)	Defendants	402; 403; 801; DESC
1678	AMRN-PEXP-0010229-241	3/1/2010	Mathers 9	Guidance for Industry, Clinical Studies Section of Labeling for Human Prescription Drug and Biological Products – Content and Format	Defendants	801
1679	ICOSAPENT_DFNDT00015711-51	12/1/2018	Mathers 10	Lovenox label	Defendants	801; DUP
1680	AMRN-PEXP-0009835-79	6/1/2019	Mathers 11	Eliquis® Label	Defendants	801
1681	AMRN-PEXP-0010242-261	7/1/2018	Mathers 12	FDA, Indications and Usage Section of Labeling for Human Prescription Drug and Biological Products —Content and Format: Guidance for Industry, at 10 (2018) (“FDA Labeling Guidance”)	Defendants	801
1682	AMRN-PEXP-0010187	1/1/2006	Mathers 13	Guidance for Industry, Clinical Studies Section of Labeling for Human Prescription Drug and Biological Products – Content and Format	Defendants	801; DESC
1683		3/11/2019	Nicholson 1	Expert Report of Sean Nicholson with Appendices A-E and Exhibits 1-31B	Defendants	
1684		6/10/2019	Nicholson 2	Reply Expert Report of Sean Nicholson with Appendixes A-D and Exhibits 1-6	Defendants	
1685	AMRN-PEXP-0007707-17	1/7/2019	Nicholson 4	Beatty, Joel, and Shawn M Egan, “Amarin Corp (AMRN) 2019 Revenue Guidance Lower Than Expectations, TP \$20 (-\$8),” Citi Research	Defendants	801
1686	AMRN-PEXP-0002182-96	3/1/2001	Nicholson 5	Berndt, The U.S. Pharmaceutical Industry: Why Major Growth In Times of Cost Containment? Health Affairs 20(2):100-114 (Mar/Apr 2001)	Defendants	801

Trial Ex. No.	Bates Range	Doc Date	Dep. Ex. No. (if applicable)	Description	Party:	Plaintiffs' Objections
1687	AMRN-PEXP-0002272-78	5/1/1995	Nicholson 6	Berndt, et al. Information, Marketing, and Pricing in the U.S. Antiulcer Drug Market. The American Economic Review 85(2): 100-105 (May 1995)	Defendants	801
1688	AMRN-PEXP-0002402-20	9/1/2001	Nicholson 7	Cutler and McClellan, Is Technological Change in Medicine Worth? Health Affairs 20(5): 11-29 (Sept/Oct 2001)	Defendants	801
1689		6/10/2019	Peck 1	Reply Expert Report of Carl C. Peck, M.D.	Defendants	
1690			Peck 2	Carl C. Peck, M.D. Prior Testimony	Defendants	
1691		6/10/2019	Peck 3	Materials Considered by C. Peck, M.D., June 10, 2019 Reply Expert Report	Defendants	
1692		4/30/2019	Peck 4	Curriculum Vitae, Carl C. Peck, M.D., Dr. h.c. (Uppsala)	Defendants	
1693	ICOSAPENT_DFNDT00018074-94	6/30/2015	Peck 6	21 C.F.R. §201.57	Defendants	801; A
1694	AMRN00053457-54134	6/15/2011	Peck 7	Clinical Study Report: A Phase 3, Multi-center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With an Open-Label Extension to Evaluate the Efficacy and Safety of AMR101 in Patients With Fasting Triglyceride Levels?500 mg/dL and ?2000 mg/dL: The AMR101 MARINE Study. Results of the Double-Blind Treatment Period. Final Version.	Defendants	801
1695	ICOSAPENT_DFNDT00018207-31	1/1/2006	Peck 8	Guidance for Industry, Clinical Studies Section of Labeling for Human Prescription Drug and Biological Products – Content and Format	Defendants	801; A
1696	AMRN03149773-4		Peck 9	Vascepa advertisement, “Vascepa looks different because it is different.”	Defendants	402; 403; 801; A
1697		5/10/2019	Sheinberg 1	Rebuttal Expert Report of Jonathan I. Sheinberg, M.D., F.A.C.C., on Noninfringement of the Asserted Claims of the Patents-in-Suit with Exhibits A-B	Defendants	702; 801; A
1698	AMRN03132168-77	2/1/2017	Sheinberg 2	Vascepa label	Defendants	801; DUP
1699	DRLEPA 0095591-647		Sheinberg 3	Dr. Reddy's Icosapent Ethyl Capsules, .5 gram ANDA 1.14.1.2 Annotated Draft Labeling Text	Defendants	JTX
1700	WWICO-NV-002835-43	12/1/2016	Sheinberg 4	West-Ward Icosapent Ethyl Capsules label	Defendants	JTX
1701	ICOSAPENT_DFNDT00015424-567	7/25/2012	Sheinberg 5	CDER Application Number 202057Orig1s000 Medical Review(s)	Defendants	801
1702	ICOSAPENT_DFNDT00015711-51	12/1/2018	Sheinberg 7	Lovenox label	Defendants	801; DUP
1703	AMRN-PEXP-0009062-9106	6/1/2019	Sheinberg 8	Eliquis® label	Defendants	801
1704		3/7/2019	Toth 1	Opening Expert Report of Peter Paul Toth, M.D., Ph.D. with Exhibits A-C	Defendants	
1705		5/10/2019	Toth 2	Responsive Expert Report of Peter Toth, M.D., Ph.D. with Exhibits A-B	Defendants	
1706		6/10/2019	Toth 3	Reply Expert Report of Peter Toth, M.D., Ph.D. with Exhibit A	Defendants	
1707	AMRN00290358-92	1/1/2001	Toth 5	Mahley and Bersot, Drug Therapy for Hypercholesterolemia and Dyslipidemia. Chapter 36 in Goodman & Gilman's The Pharmaceutical Basis of Therapeutics, 10th Ed. (2001).	Defendants	801
1708		10/17/2014	Toth 10	Toth, et al. Clinical and economic outcomes in a real-world population of patients with elevated triglyceride levels. Atherosclerosis 237:790-797 (2014).	Defendants	402; 403; 801
1709			Toth 16	Transcript of Hypertriglyceridemia: Managing Triglycerides to Reduce Cardiovascular Risk. https://www.medscape.org/viewarticle/839217_transcript , last accessed 06/30/2019.	Defendants	402; 403; 801
1710		1/1/2009	Toth 17	Toth, et al. Drug Therapy for Hypertriglyceridemia: Fibrates and Omega-3 Fatty Acids. Curr Atheroscler Rep. 11(1):71-79 (Jan. 2009).	Defendants	402; 403; 801
1711	AMRN03171927-37	8/24/2018	Toth 19	Consultancy Agreement	Defendants	402; 403; 801; A
1712	AMRN03171938-46	11/5/2014	Toth 20	Consultancy Agreement	Defendants	402; 403; 801; A
1713	AMRN03171947-54	5/23/2016	Toth 21	Consultancy Agreement	Defendants	402; 403; 801; A
1714	AMRN03171955-62	5/23/2016	Toth 22	Consultancy Agreement	Defendants	402; 403; 801; A
1715	AMRN03171963-73	3/28/2018	Toth 23	Consultancy Agreement	Defendants	402; 403; 801; A
1716	AMRN03171974-84	6/18/2018	Toth 24	Consultancy Agreement	Defendants	402; 403; 801; A

Trial Ex. No.	Bates Range	Doc Date	Dep. Ex. No. (if applicable)	Description	Party:	Plaintiffs' Objections
1717	AMRN03171985-89	12/15/2016	Toth 25	Services Agreement	Defendants	402; 403; 801; A
1718	AMRN03171990-92	10/17/2017	Toth 26	Services Agreement	Defendants	402; 403; 801; A
1719	AMRN03171993-95	8/23/2017	Toth 27	Services Agreement	Defendants	402; 403; 801; A
1720	AMRN02386752-54	6/27/2013	Toth 28	Speaker Program Metrics & Utilization as of June 27, 2013	Defendants	402; 403; 801; A; F
1721			Toth 29	ProPublica Dollars for Docs, Peter Toth, 2013 Payment Breakdown, https://projects.propublica.org/docdollars/doctors/pid/266019 , last accessed 06/24/2019	Defendants	402; 403; 801; A
1722			Toth 30	ProPublica Dollars for Docs, Peter Toth, 2014 Payment Breakdown, https://projects.propublica.org/docdollars/doctors/pid/266019 , last accessed 06/24/2019	Defendants	402; 403; 801; A
1723			Toth 31	ProPublica Dollars for Docs, Peter Toth, 2015 Payment Breakdown, https://projects.propublica.org/docdollars/doctors/pid/266019 , last accessed 06/24/2019	Defendants	402; 403; 801; A
1724			Toth 32	ProPublica Dollars for Docs, Peter Toth, 2016 Payment Breakdown, https://projects.propublica.org/docdollars/doctors/pid/266019 , last accessed 06/24/2019	Defendants	402; 403; 801; A
1725	AMRN00305102-105	8/25/2014	Toth 33	Email between Toth and Everett re Ad-Board Follow Up	Defendants	106; 402; 403; 801; A
1726		10/18/2010	Toth 34	Graham, 25 top-earning doctors in Illinois. https://www.chicagotribune.com/lifestyles/health/chi-na-docdollars-profiles-sidebar-htmlstory.html , last accessed 06/24/2019.	Defendants	402; 403; 801; A
1727		5/11/2014	Toth 35	Giuliani, Local doctor is in ... the money. www.saukvalley.com/2014/04/08/local-doctor-is-in-the-money/ac259h/?xsl=/pri.nl.xsl , last accessed 06/25/2019	Defendants	402; 403; 801; A
1728		8/14/2018	Bays 1	Subpoena to Testify at a Deposition in a Civil Action directed to Harold E. Bays	Defendants	801; A
1729	HB-AMRN000000001-7	1/1/2018	Bays 2	Harold E. Bays 2018 Curriculum Vitae	Defendants	801
1730	AMRN00009725-32	5/20/2009	Bays 3	Statement of Investigator with Harold Bays 2009 Curriculum Vitae	Defendants	801
1731	AMRN03022105		Bays 4	Native Spreadsheet: Amarin Corp. Consultant Spend 2009-2011	Defendants	402; 403; 801; A; F
1732	AMRN01493345-6	9/9/2013	Bays 5	Email between Elson and Ketchum re Ad Comm estimated espenses with attached spreadsheet	Defendants	106; 402; 403; 801; A; F
1733	AMRN01502780-2	10/7/2008	Bays 6	Email between Bays and Soni re Invitation to Attend Amarin Expert Panel Meeting in Boston, USA	Defendants	106; 402; 403; 801; A
1734	AMRN01635508	11/4/2008	Bays 7	Email between Crutchley and Bays re Dr. Bays – Honorarium for Amarin Expert Panel Meeting in Boston	Defendants	106; 402; 403; 801; A
1735	AMRN01519654-5	11/24/2008	Bays 8	Email between Crutchley, Soni, Wicker, Osterloh, and Manku re Status Update Amarin Expert Panel Meeting – December 11-12	Defendants	106; 402; 403; 801; A; F

Trial Ex. No.	Bates Range	Doc Date	Dep. Ex. No. (if applicable)	Description	Party:	Plaintiffs' Objections
1736	ICOSAPENT_DFNDTS00007488-7529 AMRN00598067 AMRN00598068-76 AMRN00598077-82 AMRN00598083-96		Bays 10	Group Exhibit: 1) Bays, Rationale for Prescription Omega-3-Acid Ethyl Ester Therapy for Hypertriglyceridemia: A Primer for Clinicians. Drugs of Today 44(3): 205-246 (2008); 2) Lovaza Label; 3) Yokoyama, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded endpoint analysis. The Lancet 369:1090-98 (March 31, 2007); 4) Harris, The omega-3 index as a risk factor for coronary heart disease. Am J Clin Nutr 87(suppl):1997S-2002S (2008); 5) Davidson, et al. Efficacy and Tolerability of Adding Prescription Omega-3 Fatty Acids 4 g/d to Simvastatin 40 mg/d in Hypertriglyceridemic Patients: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Study. Clinical Therapeutics 29(7): 1354-1367 (July 2007).	Defendants	402; 403; 702; 801; MD; DUP; DESC
1737		1/1/2009	Bays 11	Tricor, in Physicians' Desk Reference 63 Ed. pp. 520-24 (2009)	Defendants	801
1738	AMRN02273377	1/14/2011	Bays 12	Email between Braeckman and Bays re MARINE manuscript	Defendants	106; 402; 403; 801; A
1739	AMRN01062083-114		Bays 13	Bays, et al: Eicosapentaenoic Acid Ethyl Ester (AMR101) Theraoy in Patients with Very High Triglyceride Levels: The MARINE Trial.	Defendants	402; 403; 801; A; B
1740	AMRN02903388-9	1/14/2011	Bays 14	Email between Bays and Braeckman re MARINE manuscript	Defendants	106; 402; 403; 701; 801; A
1741	AMRN00524816-24	1/1/2011	Bays 15	Bays, et al. Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients with Very High Triglyceride Levels (from the Multi-center, Placebo-controlled, Randomized, double-blind, 12-week study with an open-label Extension [MARINE] Trial). Am J Cardiol 108:682-690 (2011).	Defendants	801
1742	AMRN03058234-36	5/18/2011	Bays 16	Declaration of Harold E. Bays Under 37 C.F.R. § 1.132, Application No. 12/702,889	Defendants	106; 801
1743	AMRN02056723-25		Bays 17	Draft of Declaration of Harold E. Bays Under 37 C.F.R. § 1.132, Application No. 12/702,889	Defendants	106; 402; 403; 801; A; B
1744	AMRN03059316-37	1/8/2012	Bays 18	Declaration of Harold E. Bays Under 37 C.F.R. § 1.132, Patent Application No. 12/702,889	Defendants	106; 801
1745	AMRN03059251-72	11/4/2011	Bays 19	Non-Final Rejection, Patent Application No. 12/702,889	Defendants	106; 801
1746	AMRN03059282-315	1/13/2012	Bays 21	Response to Non-Final Office Action Dated November 4, 2011, Patent Application No. 12/702,889	Defendants	106; 801
1747	ICOSAPENT_DFNDTS00007482-87.		Bays 22	Bays, Clinical Overview of Omacor: A Concentrated Formulation of Omega-3 Polyunsaturated Fatty Acids. AM J Cardiol 98(Suppl):71i-76i (2006).	Defendants	801
1748	AMRN03059815-29	5/8/2012	Bays 23	Declaration III of Harold E. Bays Under 37 C.F.R. § 1.132, U.S. Patent Application No. 12/702,889.	Defendants	106; 801
1749	AMRN03059789-814	5/16/2012	Bays 25	Response to Non-Final Office Action Dated March 2, 2012, Patent Application No. 12/702,889	Defendants	106; 801
1750	AMRN03030162-71	6/26/2012	Bays 26	Declaration of Harold E. Bays Under 37 C.F.R. § 1.132, Patent Application No. 13/458,496	Defendants	106; 801
1751			Berg 1	Aaron Berg LinkedIn profile, https://www.linkedin.com/in/aaron-berg-7b13033/ last accessed 8/25/2018	Defendants	801; A
1752	AMRN02165596-618	6/1/2009	Berg 2	Amarin AMR101 in Hypertriglyceridemia, Non-confidential presentation	Defendants	402; 403; 801; A
1753	AMRN00826821	4/23/2013	Berg 3	Email between Shalaby, Thero, and Berg re Notes	Defendants	106; 402; 403; 701; 801; A

Trial Ex. No.	Bates Range	Doc Date	Dep. Ex. No. (if applicable)	Description	Party:	Plaintiffs' Objections
1754	AMRN02336076-78	2/22/2013	Berg 4	Email between Berg, Padmanabhan, Boothe, and Boatman re Need more EPA feedback for JZs update for tomorrow, Send tonight?	Defendants	106; 402; 403; 801; A
1755	AMRN00893179	2/7/2013	Berg 5	Email between Berg and Gilhooly re Central Files – Please look at	Defendants	106; 402; 403; 801; A
1756	AMRN01493374-80		Berg 6	Presentation: Why Approve Now WN	Defendants	402; 403; 801; A
1757	AMRN00820445	3/28/2013	Berg 7	Email between Sedlack and Berg re off label	Defendants	106; 402; 403; 801; A
1758	AMRN00828482	5/29/2013	Berg 8	Email between Thero and Berg, re E Brinton attempts to set the record straight – we need to discuss proactively having docs (at least steering committee members) appropriately media trained.	Defendants	106; 402; 403; 801; A
1759	AMRN02344161-2	12/19/2012	Berg 9	Email between Berg, Bashe, Kuhl, and Jones re basf president interview re 03	Defendants	106; 402; 403; 801; A
1760	AMRN-02344006-7	11/30/2012	Berg 10	Email between Berg, Bashe, and Kuhl re Market Research/supplement use	Defendants	106; 402; 403; 801; A
1761		4/9/2014	Berg 11	Email between Gilhooly, Berg, Mayes, Delacluyse, Sharp-Stenken, and Beck re Teva WAC and attaching Vascepa Net Price gen Lovaza slide	Defendants	106; 402; 403; 801; A
1762		9/14/2013	Berg 12	Email forward from Berg to Thero re generic Lovaza – perception versus reality	Defendants	106; 402; 403; 801; A
1763	AMRN02160507		Berg 13	GSK Reduction in Lovaza Direct Selling Effort Leads to Lower Rx Volume	Defendants	402; 403; 801; A
1764	AMRN00829792-96	12/21/2012	Berg 14	Email between Bashe and Berg re Why Merck's Niacin Failure Will Scare Drug Researchers	Defendants	106; 402; 403; 801; A
1765	AMRN00842379-81	11/20/2012	Berg 15	Email between Berg and Rigo re Market	Defendants	106; 402; 403; 801; A
1766		4/9/2014	Berg 16	Email between Gilhooly and Ameres re Generic WAC Price Communication	Defendants	106; 402; 403; 801; A
1767		10/25/2014	Berg 17	Email between Gilhooly, Berg, Galdo, Ameres, and Beck re some help	Defendants	106; 402; 403; 801; A
1768	AMRN02344070-1	12/12/2012	Berg 18	Email between Berg and Bashe re Tomorrow	Defendants	106; 402; 403; 801; A
1769		9/30/2012	Berg 19	plot diagrams titled Sales Volume – Japan and Icosapent Unit Volume – Japan	Defendants	402; 403; 801; A
1770	AMRN02344042-44	12/10/2012	Berg 20	Email between Berg and Kuhl re guidelines and OM-3 use	Defendants	106; 402; 403; 801; A
1771	AMRN00303084	1/1/2014	Berg 21	Vascepa Celebrity Campaign	Defendants	402; 403; 801; A
1772	AMRN02352366	6/30/2015	Berg 22	Vascepa Celebrity Brand Campaign	Defendants	402; 403; 801; A
1773	AMRN00859728-74	2/1/2014	Berg 23	Amarin Commercial Update	Defendants	402; 403; 801; A
1774	AMRN02376107-9	3/31/2014	Berg 24	Email between Berg and Thero re Amarin Potential News Later Today	Defendants	106; 402; 403; 801; A
1775	AMRN02376664-5	4/3/2014	Berg 25	Email between Berg and Bashe re Kowa deal	Defendants	106; 402; 403; 801; A
1776		10/1/2014	Berg 26	Amarin Sales and Marketing Update	Defendants	402; 403; 801; A
1777			Berg 27	Spreadsheet: Amarin Corporation 2013-14 Budget, Marketing	Defendants	402; 403; 801; A
1778		4/4/2006	Berg 28	U.S. Patent 7,022,713	Defendants	402; 403; 801
1779			Berg 29	Elephant Analytics, Amarin: How The Co-Promotion Agreement With Kowa Affects Required Sales Targets. https://seekingalpha.com/article/2119273-amarin-how-the-co-promotion-agreement-with-kowa-affects-required-sales-targets , last accessed 07/24/2018	Defendants	402; 403; 801

Trial Ex. No.	Bates Range	Doc Date	Dep. Ex. No. (if applicable)	Description	Party:	Plaintiffs' Objections
1780	AMRN00870842	4/2/2014	Berg 30	Email between Steier, Berg, Gilhooly, and Bruno re FYI – Amrin Media Coverage – Wednesday PM	Defendants	106; 402; 403; 801; A
1781	AMRN03163817		Berg 31	Native Spreadsheet re sales and price data Q1 2013 – Q2 2018	Defendants	402; 403; 801; A; DESC
1782	AMRN03163818		Berg 32	Native Spreadsheet re Quarterly Information Operating Loss Detail, SG&A Detail, and Net Sales Detail Q1-13 to Q2-18	Defendants	402; 403; 801; A; DESC
1783	AMRN03151451		Berg 33	Native Spreadsheet re Quarterly Information Operating Loss Detail, SG&A Detail, and Net Sales Detail Q1-13 to Q3-17	Defendants	402; 403; 801; A; DESC
1784	AMRN03151452		Berg 34	Native Spreadsheet re Quarterly Information Operating Loss Detail, SG&A Detail, and Net Sales Detail Q1-13 to Q2-17	Defendants	402; 403; 801; A; DESC
1785		8/22/2018	Berg 35	Defendants' Joint Notice of Rule 30(b)(6) Deposition of Plaintiffs	Defendants	801; A
1786		10/8/2018	Berg 36	Email between Park, Clement, and Others re Amarin Pharma Inc. et al. v. Hikma Pharmaceuticals USA Inc. et al., 16-cv-2525	Defendants	106; 402; 403; 801; A
1787	AMRN00842922		Berg 37	Summary of 2013 and 2014 Commercial Spends and Vendors (excluding staffing)	Defendants	402; 403; 801; A
1788			Berg 38	Vascepa marketing material	Defendants	402; 403; 801; A
1789	AMRN01493356-60		Berg 39	KOL Expertise, Question and Answer	Defendants	402; 403; 801; A
1790		8/22/2018	Juliano 1	Defendants' Joint Notice of Rule 30(b)(6) Deposition of Plaintiffs	Defendants	801; A
1791	AMRN02099244-48	11/28/2007	Juliano 3	Memorandum from Boal to Stewart re Idis Proposal for “Names Patient Sales” of Miraxion.	Defendants	402; 403; 801; A
1792	AMRN01650526-34	1/1/2001	Juliano 4	Peet, et al. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophrenia Research 49:243-251 (2001).	Defendants	402; 403; 702; 801
1793	AMRN02129382-413	1/11/2008	Juliano 5	Email between Sedlack, Cooke, Cunningham, and Holmes re Minutes and Slides from EPA Triglycerides meeting – Thursday 20th December 2007 with attachments	Defendants	106; 402; 403; 801; A; DESC
1794	AMRN01671916-33	3/10/2008	Juliano 6	Email between Osterloh, Doogan, Wood, Cooke, Cunningham, Boal, and Shilling re EPA Hypertriglyceridemia Project Status and Investor Due Diligence with attachment	Defendants	106; 402; 403; 801; A
1795	AMRN02263071-74	12/17/2007	Juliano 8	EPA for Hypertriglyceridemia: Project Summary December 17, 2017	Defendants	402; 403; 801; A; DESC
1796	AMRN01672057-58	3/24/2008	Juliano 9	Email between Doogan, Manku, Osterloh, Cooke, and Lynch re Omacor (Omega 3-Acid Ethyl Esters) – Current Clinical Trials	Defendants	106; 402; 403; 801; A
1797	AMRN01688512-9	3/16/2008	Juliano 10	Email between Manku, Cooke, Cunningham, and Lynch re EPA reduces cholesterol absorption from GIT tract and inhibits its synthesis in liver, attaching Mizuguchi 1992 article	Defendants	106; 402; 403; 801; A
1798	AMRN02113623-4	1/1/2010	Juliano 12	Cosgrove, AMR101 Takes on Lovaza: Amarin enters final phase of testing for its promising fish oil medication for high cholesterol. Rodman publishing 2010.	Defendants	402; 403; 801; A
1799	AMRN00624045-51	11/15/2009	Juliano 13	Email between Soni and Aralihalli attaching Saito 2008 article.	Defendants	106; 402; 403; 702; 801; A
1800	AMRN01171835-59	3/1/2010	Juliano 14	Amarin Next Generation Lipid Modification in Cardiovascular Disease: Investor Presentation	Defendants	402; 403; 801; A
1801	AMRN00731202-13	1/1/2002	Juliano 15	Peet and Horrobin, A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. Journal of Psychiatric Research 36:7-18 (2002).	Defendants	402; 403; 702; 801
1802	AMRN01688238	3/13/2008	Juliano 16	Email between Manku, Cunningham, Holmes, and Cooke re Japanese publications – translations	Defendants	106; 402; 403; 801; A

Trial Ex. No.	Bates Range	Doc Date	Dep. Ex. No. (if applicable)	Description	Party:	Plaintiffs' Objections
1803	AMRN01566346-7	2/25/2010	Juliano 17	Email between Doogan, Rogan, and others re Investor Feedback attaching spreadsheet	Defendants	106; 402; 403; 801; A
1804	AMRN00597991-8096	11/26/2008	Juliano 18	Email between Crutchley, Bays, mcricui@ucsd.edu, and Hawkins re CONFIDENTIAL: Amarin Expert Panel Meeting for AMR-101 (ethyl-EPA) Meeting Package with attachments	Defendants	106; 402; 403; 801; A; DESC
1805	AMRN01451526-639	9/24/2012	Juliano 19	Email between Philip and Ketchum re Exec Summary RCM Series with attachment	Defendants	106; 402; 403; 801; A; DESC
1806			Juliano 20	Kris-Etherton, et al. Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease. Circulation 106:2747-2757 (2002).	Defendants	801; B; DESC
1807		3/15/2017	Juliano 21	Plaintiffs' Initial Disclosures	Defendants	801; A
1808			Ketchum 1	Steve Ketchum LinkedIn profile	Defendants	801; A
1809		8/22/2018	Ketchum 3	Defendants' Joint Notice of Rule 30(b)(6) Deposition of Plaintiffs	Defendants	801; A; DUP
1810	AMRN03163819-937	7/18/2016	Ketchum 4	Amarin AMR101 (icosapent ethyl) Capsules Investigator's Brochure Ed. 6.0	Defendants	801
1811	AMRN03163938-9	7/18/2016	Ketchum 5	Explanation of Changes Document AMR101, AMR101 Investigator's Brochure Version 6	Defendants	801
1812		5/19/2008	Ketchum 6	Amarin Corporation PLC SEC Form 20-F	Defendants	402; 403; 801; A
1813	AMRN01224085-105	12/20/2007	Ketchum 10	Presentation titled Amarin Ethyl EPA Hypertriglyceridemia Project Meeting	Defendants	402; 403; 801; A
1814	AMRN00731672-682	3/10/2008	Ketchum 11	Ethyl-EPA for Hypertriglyceridemia: Rationale and Outline of Proposed Development Program	Defendants	801; A
1815	AMRN0786849-860	4/22/2011	Ketchum 12	Email between Trefny and Stirtan attaching Lovaza label Dec2010 Tracked Changes	Defendants	106; 402; 403; 701; 801; A
1816	AMRN02973472-592	6/15/2008	Ketchum 13	P-IND 102,457, AMR101 Type B Meeting Information Package	Defendants	801
1817	ICOSAPENT_DFNDTS00003384-3403	12/31/2010	Ketchum 14	Amarin Corp PLC\UK Form 10-K Annual Report	Defendants	402; 403; 801; A
1818	AMRN03019033-115	1/16/2009	Ketchum 15	P-IND 102,457 AMR101 Request for Special Protocol Assessment: Phase 3 Study and final protocol AMR-01-01-0016	Defendants	106; 801; A; B
1819	AMRN02714826-57	10/14/2013	Ketchum 16	Email between Philip and Juliano attaching FDA EMDAC Amarin indication Brinton slides 10-16-31.1	Defendants	106; 402; 403; 701; 801; A
1820	AMRN01451526-28	9/24/2012	Ketchum 17	Email between Philip and Ketchum re Exec Summary RCM Series	Defendants	106; 402; 403; 801; A; DESC
1821	AMRN01451529	9/24/2012	Ketchum 18	Email between Philip and Ketchum re Regional Consultant Meetings Summaries	Defendants	106; 402; 403; 801; A
1822	AMRN01683571-72	1/13/2012	Ketchum 19	Email between Sedlack, Kalinowski, Grandolfi, and Manku re Mochida selling API	Defendants	106; 402; 403; 701; 801; A
1823	AMRN01535416-20	6/22/2010	Ketchum 20	Email between Grandlofi and Soni attaching AMR101 vs. Epadel Chromatograms (Primera data).ppt	Defendants	106; 402; 403; 701; 801; A
1824	AMRN03107357-72	7/14/2008	Ketchum 21	Memorandum of Pre-IND Meeting Minutes	Defendants	801; A
1825	AMRN02716805-21	1/10/2014	Ketchum 22	Email between Bashe and Ketchum attaching Scientific Statement Against FDA Rescission of SPA for Vascepa (IPE)	Defendants	106; 402; 403; 701; 801; A; DESC
1826	AMRN02343575-80	12/7/2013	Ketchum 23	Email between Philip, Berg, and Thero re phone call dates/times attaching Brinton letter to FDA Commissioner	Defendants	106; 402; 403; 701; 801; A
1827	AMRN01573009-38	6/15/2011	Ketchum 24	Email between Schultz and Soni re 3pm showing in New London, attaching Amarin Investor Presentation	Defendants	106; 402; 403; 701; 801; A
1828		8/1/2011	Ketchum 25	Amarin Next Generation Lipid Modification in Cardiovascular Disease: Investor Presentation	Defendants	402; 403; 801; A
1829	AMRN00731643		Ketchum 27	Amarin Cardioprotective Effects of Omega-3 Fatty Acids, AMR101 for Triglyceride Lowering	Defendants	402; 403; 801; A; DESC

Trial Ex. No.	Bates Range	Doc Date	Dep. Ex. No. (if applicable)	Description	Party:	Plaintiffs' Objections
1830	AMRN01397826-57	1/1/2011	Ketchum 28	Amarin Next Generation Lipid Modification in Cardiovascular Disease: Investor Presentation	Defendants	402; 403; 801; A; DESC
1831	AMRN00204446-52		Ketchum 29	Rationale for Development of Ethyl-EPA for the Treatment of Hypertroglyceridemia	Defendants	402; 403; 801; A
1832	AMRN03164813-5069	1/29/2019	Ketchum 30	Clinical Study Report: A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease	Defendants	801; B
1833	AMRN03167963-8515	8/2/2011	Ketchum 31	Clinical Study Report: A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events with EPA – Intervention Trial. Final v 1.0	Defendants	801; B; DESC
1834	AMRN03169860-3170135	2/24/2019	Ketchum 32	Amarin Efficacy Data, AMR-01-01-0019	Defendants	801; A
1835	AMRN03168893-9177	2/24/2019	Ketchum 33	Amarin Demographic Data, AMR-01-01-0019	Defendants	801; A
1836	AMRN00111661-747	2/27/2014	Ketchum 34	Letter to Dr. Rosenbraugh and Formal Dispute Resolution Project Manager re Formal Dispute Resolution Request, IND 103457 for Vascepa®	Defendants	402; 403; 801; A
1837	AMRN01478848	2/27/2014	Ketchum 35	Letter to Guettier re Formal Dispute Resolution Request, IND 103457 (S0077)	Defendants	106; 402; 403; 801; A
1838	AMRN03156518-30	3/1/2019	Ketchum 36	Juliano and Ketchum, REDUCE-ITTM Presentation.	Defendants	402; 403; 801; A; DESC
1839	AMRN01472289-90	9/2/2014	Ketchum 37	Email between Ketchum, Juliano, Doyle, and Stirtan re mineral oil issue	Defendants	106; 402; 403; 701; 801; A
1840	AMRN01455752	5/3/2013	Ketchum 38	Email between Ketchum and Berry re Preps for Monday 2pm team call	Defendants	106; 402; 403; 701; 801; A
1841	AMRN02702785-90	6/10/2013	Ketchum 39	Email between Ketchum and Berry re DMC Lipid Monitoring Guideline with attachments	Defendants	106; 402; 403; 701; 801; A
1842		7/20/2011	Ketchum 40	Email between Soni and Ballantyne re Placebo controls with AMR101 & Lovaza	Defendants	106; 402; 403; 701; 801; A; DESC
1843	N/A	9/24/2018	Lavin 1	Subpoena To Testify at a Deposition in a Civil Action directed to Philip Lavin	Defendants	801; A
1844	AMRN03140245-46	11/9/2011	Lavin 2	Letter From K&L Gates To P. Lavin re Consulting Agreement With Respect To U.S. Patent Application Serial Number	Defendants	402; 403; 801; A
1845	PL-AMRN000000001	4/25/2018	Lavin 3	CV Philip T. Lavin	Defendants	801; A; DESC
1846	N/A	7/26/2016	Lavin 4	U.S. Patent 9,389,893 B2 (Stavros et al.)	Defendants	402; 403; 801
1847	N/A	N/A	Lavin 5	Daly, et al., "Enteral Nutrition With Supplemental Arginine, RNA, And Omega-3 Fatty Acids In Patients After Operation: Immunologic, Metabolic, And Clinical Outcome," (1992).	Defendants	402; 403; 702; 801
1848	N/A	N/A	Lavin 6	American Statistical Association 1986 Proceedings Of Biopharmaceutical Section	Defendants	402; 403; 801; A
1849	N/A	N/A	Lavin 7	Lavin, "Practical Considerations In The Coordination Of Clinical Trials," Clinical Trials Issues And Approaches (1983).	Defendants	402; 403; 801
1850	N/A	N/A	Lavin 8	Menon, et al., "Sample Size Calculation For Poisson Endpoint Using The Exact Distribution Of Difference Between Two Poisson Random Variables," (2011).	Defendants	402; 403; 702; 801

Trial Ex. No.	Bates Range	Doc Date	Dep. Ex. No. (if applicable)	Description	Party:	Plaintiffs' Objections
1851	AMRN03024311	N/A	Lavin 10	Title Methods Of Treating Hypertriglyceridemia - 3717958/67	Defendants	106; 801; A; DESC
1852	AMRN03025234-255	2/9/2010	Lavin 11	Request For Continued Examination And Reponse To Office Action Dated August 18, 2011	Defendants	106; 801
1853	AMRN03105910-41	5/9/2008	Manku 4	Request for Type-B Meeting: Pre-IND Meeting	Defendants	801
1854	AMRN01688238-360	3/13/2008	Manku 6	Email between Manku, Cunningham, Holmes, and Cooke re Japanese publications – translations with attachments	Defendants	106; 402; 403; 801; A
1855	AMRN01672057-60	3/24/2008	Manku 8	Email between Doogan, Manku, Osterloh, Cooke, and Lynch re Omacor (Omega 3-Acid Ethyl Esters) – Current Clinical Trials	Defendants	106; 402; 403; 801; A
1856	AMRN01688641-53	4/18/2008	Manku 9	Email between Manku, Cooke, Doogan, Lynch, and Osterloh re Meeting with Mochida's internal R and D team, attaching Satoh 2007 and Mizuguchi 1993 references	Defendants	106; 402; 403; 801; A
1857	AMRN01688572-3	3/25/2008	Manku 10	Email between Manku, Cunningham, Holmes, and Cooke RE:	Defendants	106; 402; 403; 801; A
1858	AMRN0588927-9018	11/26/2008	Manku 11	Email between Crutchley, Sedlack, and others re Amarin Expert Panel Meeting for AMR-101 (ethyl-EPA) Meeting Package and attaching Amarin Expert Panel Meeting Materials	Defendants	106; 402; 403; 801; A
1859	AMRN01574093-115	12/12/2008	Manku 15	Presentation: Overview of Hypertriglyceridemia. AMR 101 Expert Panel Meeting, Boston	Defendants	801
1860	AMRN01531053-58	12/15/2008	Manku 16	Email between Osterloh, Braeckman, Soni, Doogan, Crutchley, and Manku re 12 Dec-2008 Expert Panel Meeting Comments on AMR101 Phase 3 Studies and attaching Ian's Notes from Amarin's Expert Panel Meeting 12th December 2008	Defendants	106; 402; 403; 801; A
1861	AMRN01688980-9008	12/11/2008	Manku 18	Email from Manku to Cooke and Lynch re Final Slides for Boston attaching Boston Dec 12 08.ppt [Pleiotropic effects of EPA in Cardiovascular Diseases]	Defendants	106; 402; 403; 801; A
1862	AMRN01673821-924	7/31/2009	Manku 19	Email between Doogan, Sedlack, and others re Final Slides for Arisaph attaching Partnering Presentation V6 July 31st.ppt	Defendants	106; 402; 403; 801; A
1863		1/29/2018	Miller 1	Defendants' Notice of Deposition of Dr. Michael Miller	Defendants	801; A
1864		11/1/2017	Miller 2	Declaration of Michael Miller, MD, FACC, FAHA, FNLA, FASPC on Claim Construction [Dkt. 89-1]	Defendants	106; 402; 403; 801
1865		11/1/2017	Miller 3	Materials Considered [Dkt. 89-4]	Defendants	801; A
1866		2/2/2018	Miller 4	Reply Declaration of Michael Miller, MD, FACC, FAHA, FNLA, FASPC on Claim Construction [Dkt. 113-1]	Defendants	106; 402; 403; 801
1867		11/1/2017	Miller 5	Curriculum Vitae of Michael Miller [Dkt. 89-3]	Defendants	801; A
1868	AMRN03022275-6	3/4/2010	Miller 6	Email between Soni and Miller re Amarin	Defendants	106; 402; 403; 801; A
1869	AMRN01017280-1	3/24/2010	Miller 7	DRAFT NOTES, Meeting with Michael Miller – University of Maryland School of Medicine	Defendants	402; 403; 801; A
1870	AMRN02739796	12/1/2010	Miller 8	Dr. Michael Miller's Consulting time for Amarin (Sept thru Dec, 2010)	Defendants	402; 403; 801; A
1871	AMRN02769565	6/1/2011	Miller 9	Dr. Michael Miller's Consulting time for Amarin (Jan thru June, 2011)	Defendants	402; 403; 801; A
1872	AMRN03121925-31		Miller 10	2014 Clinical Development Department Goals – Status 2014	Defendants	402; 403; 801; A; F
1873	AMRN01077327	12/1/2011	Miller 11	Dr. Michael Miller's Consulting time for Amarin (July thru December, 2011)	Defendants	402; 403; 801; A
1874	AMRN01638777-8	11/19/2010	Miller 12	Email between Soni and Schwarzkopf attaching spreadsheet: KOL Contacts – 19Nov2010	Defendants	106; 402; 403; 801; A
1875	AMRN02702696	5/28/2013	Miller 13	Email between Ketchum and Miller re Available to touch base this afternoon?	Defendants	106; 402; 403; 801; A

Trial Ex. No.	Bates Range	Doc Date	Dep. Ex. No. (if applicable)	Description	Party:	Plaintiffs' Objections
1876	AMRN00289915-290194	9/1/2002	Miller 15	Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 106:3143-3421 (2002)	Defendants	801
1877			Miller 16	Exhibit 18 to Plaintiffs' Opening Markman Brief [Dkt. 89-20 to 86-26], Excerpts from the File History of U.S. Patent No. 8,293,727	Defendants	106; 402; 403; 801; A; DESC
1878	ICOSAPENT_DFNDTS00010211-25	5/1/2007	Miller 18	Jacobson, et al. Hypertriglyceridemia and Cardiovascular Risk Reduction, Clinical Therapeutics 29(5):763-777 (2007).	Defendants	702; 801
1879	AMRN03130228-239	9/27/2005	Miller 20	Exhibit 28 to Plaintiffs' Opening Markman Brief [Dkt. 89-37], C. Baigent et al., Efficacy and Safety of Cholesterol-Lowering Treatment: Prospective Meta-Analysis of Data from 90,056 Participants in 14 Randomised Trials of Statins, 366 LANCET 1267-78 (2005).	Defendants	106; 402; 403; 801
1880	AMRN01693774-6	8/10/2007	Osterloh 1	Email between Doogan, Osterloh, and Cunningham re Test Message	Defendants	106; 402; 403; 801; A
1881	AMRN02105815-23	11/27/2007	Osterloh 2	Amarin Portfolio Review Meeting	Defendants	402; 403; 801
1882	AMRN01671955-59	3/20/2008	Osterloh 6	Email between Osterloh, Doogan, Cunningham, and Cooke re CV strategy	Defendants	106; 402; 403; 801; A
1883	AMRN02263119-22	3/7/2008	Osterloh 7	EPA for Hypertriglyceridemia, Minutes of project team meeting	Defendants	402; 403; 801
1884	AMRN02175481-2	3/19/2008	Osterloh 8	Email between Mallard, Cooke, Osterloh, Wood, Doogan, and Shilling re Investor Calls and evidence to support EPA tg programme	Defendants	106; 402; 403; 801; A
1885	AMRN0167916-33	3/10/2008	Osterloh 10	Email between Osterloh, Doogan, Wood, Cooke, Cunningham, Boal, and Shilling re EOA Hypertriglyceridemia Project Status and Investor Due Diligence attaching EPA Briefing Document	Defendants	106; 402; 403; 801; A
1886	PW-AMRN00000603-4	1/23/2008	Osterloh 11	Email between Osterloh and Wicker re Miraxion – US experts	Defendants	106; 402; 403; 801; A
1887	PW-AMRN00000192-3	11/19/2007	Osterloh 12	Email between Osterloh and Wicker re Amarin – Confidential	Defendants	106; 402; 403; 801; A
1888	PW-AMRN00001186-89	3/30/2008	Osterloh 13	Email between Osterloh, Morgan, and others re Agenda & EPA claim scenarios	Defendants	106; 402; 403; 801; A
1889	AMRN01531055-58	12/12/2008	Osterloh 14	Ian's Notes from Amarin's Expert Panel Meeting	Defendants	801
1890	AMRN02088919-925	12/12/2008	Osterloh 15	Hypertriglyceridemia Expert Panel Meeting	Defendants	402; 403; 701; 801; A; F
1891	HW-AMRN00000001-11		Weintraub 1	Curriculum Vitae of Howard S. Weintraub	Defendants	801
1892		9/9/2018	Weintraub 2	Webpage: Howard Weintraub / NYU Langone Health, https://nyulangone.org/doctors/1457347767/howard-weintraub , last accessed	Defendants	801; A; DESC
1893	AMRN03115613-21	7/13/2013	Weintraub 3	Consultancy Agreement	Defendants	402; 403; 801; A
1894	AMRN01540795	4/10/2011	Weintraub 4	Email between Soni and Weintraub RE:	Defendants	106; 402; 403; 801; A
1895		9/9/2018	Weintraub 5	Dollars for Docs, Howard Weintraub. https://projects.propublica.org/docdollars/doctors/print/202475 , last accessed	Defendants	402; 403; 702; 801; A
1896	AMRN02900115-17	5/18/2011	Weintraub 6	Email between Rowe and Weintraub re question	Defendants	106; 402; 403; 801; A
1897	AMRN03058275-83	5/23/2011	Weintraub 7	Declaration of Howard Weintraub Under 37 C.F.R. § 1.132, Application No. 12/702,889	Defendants	106; 801
1898	AMRN03140226-7	8/22/2011	Weintraub 8	K&L Gates unexecuted Consulting Agreement with Respect to U.S. Patent Application Serial Number 12/702,889	Defendants	402; 403; 801; A
1899	AMRN02844821-4849	12/1/2010	Weintraub 9	Canaccord Genuity Expert Call: Amrn 101, Marine Trial Data. Edited Transcript	Defendants	402; 403; 801; A

Trial Ex. No.	Bates Range	Doc Date	Dep. Ex. No. (if applicable)	Description	Party:	Plaintiffs' Objections
1900	AMRN00768524-25	11/19/2010	Weintraub 10	Email between Rowe and Weintraub re Canaccord Genuity consultation request – Hypertriglyceridemia and AMR101	Defendants	106; 402; 403; 801; A
1901	AMRN02894016-20	12/1/2010	Weintraub 11	Email between Weintraub and Rowe re everything still ok for tomorrow at 5pm et?	Defendants	106; 402; 403; 801; A
1902	AMRN02325273-81	7/19/2013	Weintraub 12	Weintraub, Update on marine omega-3 fatty acids: Management of dyslipidemia and current omega-3 treatment options. Atherosclerosis 230:381-389 (2013).	Defendants	402; 403; 801
1903		10/6/2011	Weintraub 13	Wei and Jacobson, Effects of Eicosapentaenoic Acid Versus Docosahexaenoic Acid on Serum Lipids: A Systematic Review and Meta-Analysis. Curr Atheroscler Rep 13:474-483 (2011).	Defendants	402; 403; 702; 801
1904	AMRN00924808-21	1/1/2012	Weintraub 14	Jacobson, et al. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: A review. Journal of Clinical Lipidology 6:5-18 (2012).	Defendants	402; 403; 702; 801
1905	AMRN03058229-31	5/11/2011	Weintraub 15	Applicant Initiated Interview Request Form, Application No. 12/702,889	Defendants	106; 801; A
1906	AMRN03059081-229	9/7/2011	Weintraub 16	Declaration of Howard Weintraub Under 37 C.F.R. §1.132 and Exhibits	Defendants	106; 801
1907	AMRN03059035-56	9/21/2011	Weintraub 17	Request for Continued Examination and Response to Office Action Dated August 18, 2011	Defendants	106; 801
1908	AMRN00482295-303	1/1/2011	Weintraub 18	Bays, et al. Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, placebo-controlled, Randomized, double-blind, 12-week study with an open-label Extension [MARINE] Trial), Am J Cardiol 108:682-690 (2011)	Defendants	801; DUP
1909	AMRN02203920-46	1/1/2001	Weintraub 19	Tomoyuki, et al. Research Report: Efficacy and Safety of Ethyl Icosapentate (Epadel®) Given for a Long Term against Hyperlipidemia. Prog. Med. 21: 457-467 (2001).	Defendants	402; 403; 702; 801
1910	AMRN02709601-2	8/1/2013	Weintraub 20	Weintraub Invoice for Consultative Services July-August 2013.	Defendants	402; 403; 801; A
1911	AMRN02576725-6	7/26/2013	Weintraub 21	Email between Doyle and Weintraub re Confidential: Vascepa Advisory Committee	Defendants	106; 402; 403; 801; A
1912	AMRN02585990-4	7/15/2013	Weintraub 22	Email between Bress and Weintraub re Confidential: Vascepa Advisory Committee	Defendants	106; 402; 403; 801; A
1913		12/12/2017	Wharton 1	Declaration of Ronald H. Wharton, M.D., in Support of Defendants' Claim Construction [Dkt. 102-1]	Defendants	801
1914		3/26/2017	Wharton 2	Curriculum Vitae, Ronald H. Wharton M.D. [Dkt. 102-4]	Defendants	801; A
1915		12/12/2017	Wharton 6	Materials Considered in Declaration of Ronald Wharton in Support of Defendants' Responsive Claim Construction Brief [Dkt. 102-3]	Defendants	801; A
1916		1/1/2000	Wharton 7	Exhibit 4 to Defendants' Responsive Claim Construction Brief [Dkt. 102-6], Calabresi et al., Omacor in Familial Combined Hyperlipidemia: Effects on Lipids and Low Density Lipoprotein Subclasses, Atherosclerosis 148:387-96 (2000)	Defendants	801; DESC
1917	ICOSAPENT_DFNDTS00011016-25	1/1/2006	Wharton 8	Exhibit 5 to Defendants' Responsive Claim Construction Brief [Dkt. 102-7], Mori et. al., The Independent Effects of Eicosapentaenoic Acid and Docosahexaenoic Acid on Cardiovascular Risk Factors in Humans, Current Opinion Clinical Nutrition & Metabolic Care 9:95-104 (2006).	Defendants	801
1918			Wharton 10	Exhibit 19 to Plaintiffs' Opening Markman Brief [Dkt. 89-27], Excerpts from the File History of U.S. Patent No. 8,293,728	Defendants	106; 801; A; DESC
1919		11/28/2018		Errata Sheet for the October 16, 23018 Transcript of Aaron Berg	Defendants	801; A
1920		7/17/2019		Errata for the Deposition of Nicholas P. Godici, June 25, 2019	Defendants	801; A
1921		7/26/2019		Errata Sheet for the June 19, 2019 Deposition Transcript of Ivan T. Hofmann	Defendants	801; A
1922		12/10/2018		Errata Sheet for the Transcript of Rebecca Juliano, Ph.D.	Defendants	801; A

Trial Ex. No.	Bates Range	Doc Date	Dep. Ex. No. (if applicable)	Description	Party:	Plaintiffs' Objections
1923		10/24/2018		Errata Sheet for the October 24, 2018 Transcript of Steven Ketchum, Ph.D.	Defendants	801; A
1924		8/16/2019		Errata Sheet for the July 9, 2019 Transcript of John Kornak	Defendants	801; A
1925		7/30/2019		Errata Sheet for the June 20, 2019 Transcript of Stephen Kunin	Defendants	801; A
1926		11/1/2018		Errata Sheet for the September 21, 2018 Deposition of Philip T. Lavin	Defendants	801; A
1927				Errata Sheet for the June 27, 2019 Deposition of Peter Mathers	Defendants	801; A
1928		3/20/2018		Errata Sheet for the February 15, 2018 Deposition of Michael Miller	Defendants	801; A
1929		8/14/2019		Errata Sheet for the July 2, 2019 Deposition of Sean Nicholson	Defendants	801; A
1930				Errata Sheet for the July 2, 2019 Deposition of Jonathan I. Sheinberg	Defendants	801; A
1931		11/29/2018		Errata Sheet for the September 14, 2018 Deposition of Howard S. Weintraub	Defendants	801; A
1932	AMRN01400429-33	10/16/2013		Summary Minutes of the Endocrinologic and Metabolic Drugs Advisory Committee Meeting (Oct. 16, 2013) ("Advisory Committee Minutes")	Defendants	801
1933	AMRN00289896-904	7/9/1996		Agren et al., Fish Diet, Fish Oil and Docosahexaenoic Acid Rich Oil Lower Fasting and Postprandial Plasma Lipid Levels, 50 European J. Clinical Nutrition 765, 770 (1996) ("Agren").	Defendants	801
1934	AMRN03164724-32	1/31/2018		Aung et al., Associations of Omega-3 Fatty Acid Supplement Use with Cardiovascular Disease Risks: Meta-Analysis of 10 Trials Involving 77,917 Individuals, 3 JAMA Cardiology 225 (2018).	Defendants	801
1935	ICOSAPENT_DFNDT00016786-96	2/1/1989		Austin, Plasma triglyceride as a risk factor for coronary heart disease. The epidemiologic evidence and beyond., Am J Epidemiol. 1989 Feb;129(2):249-59	Defendants	801
1936	ICOSAPENT_DFNDT00018101-02			21 C.F.R. § 312.22	Defendants	801; A
1937	ICOSAPENT_DFNDT00018103-08			21 C.F.R. § 314.3	Defendants	801; A
1938	ICOSAPENT_DFNDT00018148-206			21 U.S.C. § 355	Defendants	801; A
1939				35 U.S.C. §111	Defendants	801; A
1940				37 CFR §1.63	Defendants	801; A
1941				37 CFR §1.75	Defendants	801; A
1942				37 CFR 1.97	Defendants	801; A
1943				37 CFR 1.98	Defendants	801; A
1944		7/1/2010		Manual of Patent Examining Procedure Eighth Edition, Revision No. 8	Defendants	801; A
1945		8/1/2012		Manual of Patent Examining Procedure Eighth Edition, Revision No. 9	Defendants	801; A
1946	ICOSAPENT_DFNDT00016285- ICOSAPENT_DFNDT00016292	7/18/2007		Bansal, et al., Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women, AMA. 2007 Jul 18;298(3):309-16	Defendants	801
1947	AMRN00290275-81	1/1/2004		Buckley et al., Circulating Triacylglycerol and ApoE Levels in Response to EPA and Docosahexaenoic Acid Supplementation in Adult Human Subjects, 92 British J. Nutrition 477 (2004) ("Buckley").	Defendants	801
1948	ICOSAPENT_DFNDT00016662-70	1/1/2008		Concin, et al., Mineral oil paraffins in human body fat and milk, 46(2) Food Chem Toxicol. 544-52, 551 (2008) ("Concin")	Defendants	402; 403; 702; 801
1949	AMRN00290326	8/22/1996		Conquer et al., Supplementation with an Algae Source of Docosahexaenoic Acid Increases (n-3) Fatty Acid Status and Alters Selected Risk Factors for Heart Disease in Vegetarian Subjects, 126 J. Nutrition 3032 (1996) ("Conquer").	Defendants	801; DESC
1950		8/10/2018		Claim construction order in this case on August 10, 2018 Order (D.I. 135)	Defendants	801; A
1951		9/29/2017		Joint Claim Construction Prehearing Statement Exhibit A: Constructions of the Claim Terms on which Parties Agree (D.I. 83-2, September 29, 2017).	Defendants	801; A
1952	ICOSAPENT_DFNDT00017638-49	2/1/2004		Cucuzzella, Why should we treat high triglycerides?, J Fam Pract. 2004 February; 53(2):138-156	Defendants	801
1953		7/11/2017		Amarin's Preliminary Validity Contentions	Defendants	402, 403, 701, 801

Trial Ex. No.	Bates Range	Doc Date	Dep. Ex. No. (if applicable)	Description	Party:	Plaintiffs' Objections
1954		1/1/2011		ECS/EAS Guidelines for the Management of Dyslipidemias, 32 Eur. Heart J. 1769–1818 (2011)	Defendants	801
1955	AMRN03106502-617	10/16/2013		FDA Briefing Document, Endocrinologic and Metabolic Drugs, Advisory Committee Meeting (Oct. 16, 2013)	Defendants	801
1956	ICOSAPENT_DFNDT00018532-38	1/1/2006		Harris et al., Why do omega-3 fatty acids lower serum triglycerides?, 17 Curr. Opin. Lipidol. 387 (2006)	Defendants	402; 403; 702; 801
1957	ICOSAPENT_DFNDT00016590- ICOSAPENT_DFNDT00016613	1/1/2017		Dean G. Karalis, A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids, 34 ADV. THER. 300-323 (2017)	Defendants	402; 403; 702; 801
1958	ICOSAPENT_DFNDT00016150- ICOSAPENT_DFNDT00016158	10/2/2003		Lembo et al., Chronic Constipation, 349 N. Eng. J. Med 1360-8, 1364 (2003)	Defendants	402; 403; 702; 801
1959	AMRN03059165–229	10/17/2004		FDA, Approval Package NDA 21-654, Statistical Review (2004)	Defendants	801
1960	AMRN00291100–39	1/1/2009		Michael A. Miller, Disorders of Hypertriglyceridemia, in THE JOHNS HOPKINS TEXTBOOK OF DYSLIPIDEMIA 74 (Kwiterovich Jr. ed., 2009)	Defendants	801; DESC
1961	ICOSAPENT_DFNDTS00006763–69	1/1/1996		Rambjør et al., Eicosapentaenoic Acid Is Primarily Responsible for Hypotriglyceridemic Effect of Fish Oil in Humans, 31 Lipids S-45 (1996)	Defendants	801
1962	AMRN03168745	2/27/2019		REDUCE-IT Clinical Study Report (Feb. 27, 2019)	Defendants	801; DESC
1963		7/1/2013		Endocrine Society Releases Guidelines on Diagnosis and Management of Hypertriglyceridemia, 88(2) Am. Fam. Phys. 143–144 (July 2013)	Defendants	801
1964	AMRN-PEXP-0008415–22	5/1/1993		Westerveld et al., Effects of Low-Dose EPA-E on Glycemic Control, Lipid Profile, Lipoprotein(a), Platelet Aggregation, Viscosity, and Platelet and Vessel Wall Interaction in NIDDM, 16 Diabetes Care 683, 686 (1993)	Defendants	801
1965	ICOSAPENT_DFNDTS00007033-57	1/1/1970		Classification of Hyperlipidaemias and Hyperlipoproteinaemias, Bulletin of the World Health Organization, 43(6): 891–915 (1970)	Defendants	402; 403; 702; 801
1966	ICOSAPENT_DFNDT00015568-70	3/28/2019		Amarin Corp., Press Release, Amarin Submits Supplemental New Drug Application (sNDA) to U.S. FDA Seeking New Indication for Vascepa® (icosapent ethyl) to Reduce the Risk of Major Adverse Cardiovascular Events Based on Landmark REDUCE-IT™ Cardiovascular Outcomes Study (Mar. 28, 2019), available at https://investor.amarincorp.com/news-releases/news-release-details/amarin-submitssupplemental-new-drug-application-snda-us-fda .	Defendants	402; 403; 801; A
1967	AMRN03164797–802	1/1/2013		Blacher et al., Cardiovascular Effects of B-Vitamins and/or n-3 Fatty Acids: the Su.Fol.Om3 Trial, 167 Int'l J. Cardiology 508 (2013)	Defendants	801
1968	AMRN00862631–39	3/17/2014		Bonds et al., Effect of Long-Chain ω-3 Fatty Acids and Lutein + Zeaxanthin Supplements on Cardiovascular Outcomes: Results of the Age-Related Eye Disease Study 2 (AREDS2) Randomized Clinical Trial, 174 JAMA Internal Med. 763 (2014)	Defendants	801
1969	AMRN00866721-45	8/14/2013		Email between Riedell and Dist.Sales Professionals re Rapid Overview Webcast Presentation with attachment	Defendants	106; 402; 403; 801; A
1970	AMRN03147161–70	7/26/2012		Bosch et al., n-3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia, 367 N. Eng. J. Med. 309 (2012)	Defendants	801
1971	AMRN-PEXP-0000701–11	10/18/2018		Bowman et al., Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus, 379 N. Eng. J. Med. 1540 (2018)	Defendants	801
1972	AMRN00291613-89	5/17/2012		Center for Drug Evaluation and Research, Vascepa® Statistical Review (May 17, 2012),	Defendants	801
1973	ICOSAPENT_DFNDT00019836-20045	1/1/1998		Cowan G. Statistical Data Analysis. Oxford University Press; 1998.	Defendants	402; 403; 702; 801; A

Trial Ex. No.	Bates Range	Doc Date	Dep. Ex. No. (if applicable)	Description	Party:	Plaintiffs' Objections
1974	DRLEPA 0095595-96			DRL Label	Defendants	JTX; DESC
1975	AMRN02642567-72	10/1/2010		Einvik et al., A Randomized Clinical Trial on n-3 Polyunsaturated Fatty Acids Supplementation and All-Cause Mortality in Elderly Men at High Cardiovascular Risk, 17 Eur. J. Cardiovascular Prevention & Rehabilitation 588 (2010)	Defendants	402; 403; 702; 801
1976	AMRN03129984-94	5/1/2014		Epanova® Label	Defendants	801
1977	ICOSAPENT_DFNDT00015688-710	11/1/2015		Fosamax Label	Defendants	801; A
1978	ICOSAPENT_DFNDT00019255-835	1/1/2018		Goodman MS. Biostatistics for clinical and public health research. Milton Park, Abingdon, Oxon ; New York, NY: Routledge; 2018.	Defendants	402; 403; 702; 801
1979	ICOSAPENT_DFNDT00018272-314	6/21/1984		H.R. Rep. No. 98-857, pt. I (1984), reprinted in 1984 U.S.C.C.A.N. 2647-48	Defendants	801; A
1980	ICOSAPENT_DFNDT00018067			FDA Adverse Events Reporting System (FAERS) Public Dashboard https://fis.fda.gov/sense/app/d10be6bb-494e-4cd2-82e4-0135608ddc13/sheet/8eef7d83-7945-4091-b349-e5c41ed49f99/state/analysis .	Defendants	801; A
1981	ICOSAPENT_DFNDT00018371-81			Chapter 5: Atherosclerosis Lipoprotein Entry and Modification Contents, https://wrhhs.org/chapter-5-atherosclerosis/2/	Defendants	106; 402; 403; 702; 801; DESC
1982	ICOSAPENT_DFNDT00018063-66			https://www.vascepa.com/high-triglycerides-cause .	Defendants	402; 403; 801; A; DESC
1983	AMRN01404742-01404753	11/18/2010		Kromhout et al., n-3 Fatty Acids and Cardiovascular Events After Myocardial Infarction, 363 N. Eng. J. Med. 2015 (2010)	Defendants	801; A
1984	ICOSAPENT_DFNDT00015617-629	3/1/2019		Lamisil® Label	Defendants	801; A
1985	ICOSAPENT_DFNDT00015630-687	10/1/2018		Levaquin® Label	Defendants	801; A
1986	ICOSAPENT_DFNDT00015752-776	4/1/2019		Lipitor Label	Defendants	801; A
1987	AMRN-PEXP-0000712-721	1/3/2019		Manson et al., Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer, 380 N. Eng. J. Med. 23 (2019)	Defendants	801
1988	ICOSAPENT_DFNDT00020046-630	1/1/2018		Marcello Pagano, Kimberlee Gauveau. Principles of biostatistics. Chapman and Hall/CRC; 2018	Defendants	402; 403; 702; 801
1989	AMRN00482979-85	7/26/2012		NDA No. 202057, FDA Approval Letter (July 26, 2012)	Defendants	801; A
1990	ICOSAPENT_DFNDT00019084-254	1/1/2018		Thomopoulos, Nick T. Thomopoulos. Probability distributions: with truncated, log and bivariate extensions (2018)	Defendants	402; 403; 702; 801
1991	AMRN-PEXP-0001667-72	5/3/2000		Niacor® Label	Defendants	801
1992		1/1/1992		Oberman, et al., Chapter 4 Lipoprotein Transport, PRINCIPLES AND MANAGEMENT OF LIPID DISORDERS: A PRIMARY CARE APPROACH. PHARMACOLOGIC THERAPY OF LIPID DISORDERS. Williams and Wilkins, Baltimore; 87-105 (1992)	Defendants	106; 402; 403; 702; 801; DESC; MD
1993	ICOSAPENT_DFNDT00006366-68	11/10/2004		Omacor® Approval Letter	Defendants	801; A
1994	AMRN03130027-41	4/1/2014		Omtryg® Label	Defendants	801
1995	AMRN-PEXP-0001737-44	5/1/2016		ORIGIN Trial Investigators, Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE), 39 Diabetes Care 709 (2016)	Defendants	801
1996	ICOSAPENT_DFNDT00015571-616	9/1/2018		Oxycontin Label	Defendants	801; A
1997	AMRN01521522-30	11/8/2010		Rauch et al., OMEGA, a Randomized, Placebo-Controlled Trial to Test the Effect of Highly Purified Omega-3 Fatty Acids on Top of Modern Guideline-Adjusted Therapy After Myocardial Infarction, 122 Circulation 2152 (2010)	Defendants	801
1998	AMRN03147275-83	5/9/2013		Roncaglioni et al., n-3 Fatty Acids in Patients with Multiple Cardiovascular Risk Factors, 368 N. Eng. J. Med. 1800 (2013)	Defendants	801

Trial Ex. No.	Bates Range	Doc Date	Dep. Ex. No. (if applicable)	Description	Party:	Plaintiffs' Objections
1999	ICOSAPENT_DFNDT00015828-839	10/1/2018		Saxenda® Label	Defendants	801; A
2000	ICOSAPENT_DFNDT00015777-814	11/1/2018		Tricor® 2018 Label	Defendants	801; A
2001	ICOSAPENT_DFNDT00017548-600	5/7/2019		U.S. Patent No. 10,278,936	Defendants	402; 403; 801
2002	ICOSAPENT_DFNDT00015815-827	8/1/2017		Victoza® Label	Defendants	801; A
2003	AMRN03147654-57	3/1/2017		Vital News Volume 3, Issue 1 March 2017	Defendants	402; 403; 801
2004	ICOSAPENT_DFNDT00018558-19083	1/1/2012		Vittinghoff E, Glidden, David V., Shiboski, Stephen C., McCulloch, Charles E. Regression methods in biostatistics: linear, logistic, survival, and repeated measures models. 2nd ed. New York: Springer; 2012. 509 p. (Statistics for biology and health).	Defendants	402; 403; 702; 801
2005	ICOSAPENT_DFNDT00018539-57	5/1/2007		Zocor® (simvastatin) 2007 label	Defendants	402; 403; 801; A
2006		10/31/2016		Complaint for Patent Infringement, Amarin Pharma, Inc. and Amarin Pharmaceuticals Ireland Limited v. Roxane Laboratories, Inc. and Hikma Pharmaceuticals PLC, Case No. 2:16-cv-02525, filed October 31, 2016	Defendants	801; A
2007		1/9/2017		Answer, Affirmative Defenses, and Counterclaims, Amarin Pharma, Inc. and Amarin Pharmaceuticals Ireland Limited v. Roxane Laboratories, Inc. and Hikma Pharmaceuticals PLC, Case No. 2:16-cv-02525-MMD-NJK, filed January 9, 2017	Defendants	801; A
2008		11/4/2016		Complaint for Patent Infringement, Amarin Pharma, Inc. and Amarin Pharmaceuticals Ireland Limited v. Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd., Case No. 2:16-cv-2562, filed November 4, 2016	Defendants	801; A; DESC
2009		1/13/2017		Answer, Affirmative Defenses, and Counterclaims of Defendants Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories Ltd., Amarin Pharma, Inc. and Amarin Pharmaceuticals Ireland Limited v. Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd., Case No.: 2:14-cv-02562 / 2:16-cv-02525 (Consolidated), filed January 13, 2017	Defendants	801; A
2010	ICOSAPENT_DFNDT00016784-85			Orange Book at https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=002&Appl_No=202057&Appl_type=N , accessed April 22, 2019	Defendants	402; 403; 801; A
2011		11/7/2017		Consolidation Order, filed November 7, 2017	Defendants	801; A
2012	ICOSAPENT_DFNDT00016589			https://www.news-medical.net/health/Hypertriglyceridemia-Cause-and-Symptoms.aspx , accessed April 29, 2019.	Defendants	402; 403; 702; 801; A
2013	ICOSAPENT_DFNDT00016579-88	5/1/2006		https://www.jabfm.org/content/19/3/310 , accessed April 16, 2019.	Defendants	402; 403; 702; 801; A
2014	ICOSAPENT_DFNDT00018035-42	6/20/2018		Sweeney, Mary Ellen T., and Romesh Khardori, "Hypertriglyceridemia Medication," Medscape, available at https://emedicine.medscape.com/article/126568-medication	Defendants	402; 403; 702; 801
2015	ICOSAPENT_DFNDT00016813-16			https://www.mayoclinic.org/diseases-conditions/high-blood-cholesterol/in-depth/statin-side-effects/art-20046013	Defendants	402; 403; 702; 801; A
2016	ICOSAPENT_DFNDT00016817-20	7/17/2017		https://www.medicalnewstoday.com/articles/8274.php , accessed April 25, 2019.	Defendants	402; 403; 702; 801; A
2017	ICOSAPENT_DFNDT00016834-43	6/1/2014		https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4028601/ , accessed April 29, 2019.	Defendants	402; 403; 702; 801; A
2018	ICOSAPENT_DFNDT00016314-15			https://healthengine.com.au/info/fibrates , accessed April 29, 2019.	Defendants	402; 403; 702; 801; A

Trial Ex. No.	Bates Range	Doc Date	Dep. Ex. No. (if applicable)	Description	Party:	Plaintiffs' Objections
2019	ICOSAPENT_DFNDT00016614-21	11/1/2018		Lipofen® FDA Label, revised November 2018, see https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021612s017lbl.pdf	Defendants	402; 403; 801; A
2020	ICOSAPENT_DFNDT00016293-95	3/25/2019		https://medlineplus.gov/druginfo/meds/a601052.html , accessed May 9, 2019.	Defendants	402; 403; 702; 801; A
2021	ICOSAPENT_DFNDT00016882-83			https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021656	Defendants	402; 403; 801; A
2022	ICOSAPENT_DFNDT00016146-47			http://tricortablets.com/ , accessed April 29, 2019	Defendants	402; 403; 702; 801; A
2023	ICOSAPENT_DFNDT00016622-23			Lipofen, Drugs@FDA: FDA Approved Drugs Products https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021612 , accessed April 23, 2019	Defendants	402; 403; 801; A
2024	ICOSAPENT_DFNDT00016884-900	11/1/2018		Triglide® FDA Label, revised May 2018, see https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021350s020lbl.pdf	Defendants	402; 403; 801; A
2025	ICOSAPENT_DFNDT00016901-02			Triglide Drugs@FDA: FDA Approved Drugs Products https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021350 , accessed April 23, 2019	Defendants	402; 403; 801; A
2026	ICOSAPENT_DFNDT00016121-39	10/1/2018		Antara® FDA Label, revised October 2018, see https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021695s018lbl.pdf	Defendants	402; 403; 801; A
2027	ICOSAPENT_DFNDT00016119-20			Antara Website, http://www.antararx.com/ , accessed April 23, 2019.	Defendants	402; 403; 801; A
2028	ICOSAPENT_DFNDT00016296-311	3/1/2019		Fenoglide® FDA Label, revised March 2019, see https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022118s009lbl.pdf	Defendants	702; 801; A
2029	ICOSAPENT_DFNDT00016908-27	11/1/2018		Trilipix® FDA Label, revised November 2018, see https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022224s014lbl.pdf	Defendants	702; 801; A
2030	ICOSAPENT_DFNDT00016928-30			Trilipix Drugs@FDA: FDA Approved Drugs Products https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022224	Defendants	801; A
2031	ICOSAPENT_DFNDT00016316-33	5/1/2018		Fibricor® FDA Label, revised May 2018, see https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022418s014lbl.pdf	Defendants	702; 801; A
2032	ICOSAPENT_DFNDT00016334-35			Fibricor Drugs@FDA: FDA Drug Products https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022418 , accessed April 24, 2019.	Defendants	702; 801; A
2033	ICOSAPENT_DFNDT00016624-38	4/1/2017		Lopid® FDA Label, revised April 2017, see https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018422s056lbl.pdf	Defendants	702; 801; A
2034	ICOSAPENT_DFNDT00016639-40			LOPID, Drugs@FDA: FDA Approved Drugs Products https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018422 , accessed April 24, 2019	Defendants	801; A
2035	ICOSAPENT_DFNDT00016671-99	2/1/2013		Niaspan® FDA Label, revised February 2013, see https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020381s048lbl.pdf	Defendants	702; 801; A

Trial Ex. No.	Bates Range	Doc Date	Dep. Ex. No. (if applicable)	Description	Party:	Plaintiffs' Objections
2036	ICOSAPENT_DFNDT00016700-03			Niaspan Drugs@FDA: FDA Approved Drugs Products https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020381	Defendants	801; A
2037	ICOSAPENT_DFNDT00017635-37			https://www.niaspan.com/what-is-niaspan , accessed May 1, 2019.	Defendants	801; A; DESC
2038	ICOSAPENT_DFNDT00016830	9/20/2013		https://www.tevapharm.com/news/teva_announces_exclusive_launch_of_generic_niaspan_in_the_united_states_09_13.aspx , accessed April 25, 2019	Defendants	402; 403; 801; A; DESC
2039	ICOSAPENT_DFNDT00016657-61	5/1/2007		OH, Management of Hypertriglyceridemia, American Family Physician, https://www.aafp.org/afp/2007/0501/p1365.html	Defendants	801
2040	ICOSAPENT_DFNDT00016812	5/1/2007		McKenney, Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia, https://www.ncbi.nlm.nih.gov/pubmed/17461707 ;	Defendants	106; 402; 403; 702; 801; A; B; DESC
2041	ICOSAPENT_DFNDT00016235-247	2/20/208		Moloudizargari, Effects of the polyunsaturated fatty acids, EPA and DHA, on hematological malignancies: a systematic review https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837752/ , accessed May 8, 2019	Defendants	402; 403; 702; 801
2042	ICOSAPENT_DFNDT00016644-56			Lovasa Drugs@FDA: FDA Approved Drugs Products https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021654 , accessed April 29, 2019	Defendants	801; A; DESC
2043	AMRN-PEXP-0006773-7098	8/10/2007		Reliant Pharmaceuticals, Inc., Pre-effective Amendment No. 3 to Form S-1 dated August 10, 2007	Defendants	801
2044	ICOSAPENT_DFNDT00016704-10	5/1/2008		Koski, Omega-3-acid Ethyl Esters (Lovaza) For Severe Hypertriglyceridemia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2683599/ , accessed April 17, 2019	Defendants	402; 403; 702; 801; A
2045	ICOSAPENT_DFNDT00016526-27	11/21/2007		GSK to Acquire Reliant Pharmaceuticals for \$1.65B. https://www.genengnews.com/news/gsk-to-acquire-reliant-pharmaceuticals-for-1-65b/27018604/	Defendants	402; 403; 801; A
2046	ICOSAPENT_DFNDT00016831-33	4/8/2014		Teva Announces First Approval and Launch of Generic Lovaza® Capsules in the United States. https://www.tevapharm.com/news/teva_announces_first_approval_and_launch_of_generic_lovaza_capsules_in_the_united_states_04_14.aspx , accessed April 30, 2019	Defendants	402; 403; 801; A
2047	ICOSAPENT_DFNDT00016821-22	8/10/1984		S.2748 - Drug Price Competition and Patent Term Restoration Act of 1984. https://www.congress.gov/bill/98th-congress/senate-bill/2748 , accessed April 26, 2019	Defendants	801; A; B; DESC
2048	ICOSAPENT_DFNDT00016563-78	6/19/2007		Coster, The Waxman-Hatch Generic Drug Law. https://www.uspharmacist.com/article/the-waxman-hatch-generic-drug-law , accessed April 26, 2019	Defendants	801; A
2049	AMRN-PEXP-0005699-833	12/31/2013		Amarin, SEC Form 10-K for Fiscal Year Ended December 31, 2013	Defendants	801
2050	AMRN03171432	12/31/2018		Quarterly Financial Summary Q1 2013-Q4 2018	Defendants	801
2051	AMRN-PEXP-0005520-698	12/31/2012		Amarin, SEC Form 10-K for Fiscal Year Ended December 31, 2012	Defendants	801
2052	ICOSAPENT_DFNDT00015890-95	9/25/2008		Amarin Corporation plc, Second Quarter 2008 Earnings Call Transcript, https://seekingalpha.com/article/97385-amarin-corporation-plc-q2-2008-earningscall-transcript?part=single , accessed April 17, 2019	Defendants	402; 403; 801; A

Trial Ex. No.	Bates Range	Doc Date	Dep. Ex. No. (if applicable)	Description	Party:	Plaintiffs' Objections
2053	ICOSAPENT_DFNDT00016548-62	8/15/2009		The Pharmacy Times article, dated August 15, 2009, "The Hatch-Waxman Act – 25 Years Later: Keeping the Pharmaceutical Scales Balances," https://www.pharmacytimes.com/publications/supplement/2009/genericsupplement0809/generic-hatchwaxman-0809 , accessed April 26, 2019	Defendants	402; 403; 801; A
2054	AMRN-PEXP-0007482-685	12/31/2018		Amarin, SEC Form 10-K for Fiscal Year Ended December 31, 2018	Defendants	801
2055	AMRN-PEXP-0005304-519	12/31/2011		Amarin, SEC Form 10-K for Fiscal Year Ended December 31, 2011	Defendants	801
2056	AMRN03151453-514	1/1/2017		Amarin Presentation, "2017 Operating Plan,"	Defendants	801
2057	ICOSAPENT_DFNDT00015869-81	2/27/2019		Amarin Corporation plc, Fourth Quarter 2018 Earnings Call Transcript, see https://seekingalpha.com/article/4244867-amarin-corporation-plc-amrn-ceo-john-thero-q4-2018-results-earningscall-transcript?part=single , accessed April 17, 2019	Defendants	402; 403; 801; A
2058	AMRN-PEXP-0007737-47	1/6/2019		Boris, John T., et al., "Lowering Sales on Slower Ramp & Execution Risk; Keener Focus on Shareholder Value Needed," SunTrust Robinson Humphrey	Defendants	801
2059	AMRN-PEXP-0007220-54	1/30/2019		Chen, Louise et al., "Don't Die of a Broken Heart; Physician Survey Shows How Vascepa Can Help," Cantor Fitzgerald.	Defendants	801
2060	AMRN-PEXP-0003460-65	2/20/2018		Diabetes Patient Advocacy Coalition, "How the FDA Drug Approval Process Works," available at http://diabetespac.org/fda-drug-approval-process/	Defendants	801
2061	ICOSAPENT_DFNDT00016540-47	5/11/2015		H.C. Wainwright & Co. Earnings Update, May 11, 2015	Defendants	402; 403; 801; A
2062	AMRN-PEXP-0007718-22	2/28/2019		Fein, Andrew S., et al., "Embracing a Decidedly Non-Orphan Disease Company; Reit Buy and Raising PT to \$51," H.C. Wainwright & Co.	Defendants	801
2063	AMRN-PEXP-0007205-19	2/27/2019		Chen, Louise et al., "If You Had Any Concerns Going Into 2019, REDUCE-IT," Cantor Fitzgerald.	Defendants	801
2064	AMRN-PEXP-0007725-35	2/27/2019		Yee, Michael J. et al., "Easy and great tuck-in for pharma global salesforce," Jefferies Research Services	Defendants	801
2065	ICOSAPENT_DFNDT00016528-34	2/26/2016		H.C. Wainwright & Co. Earnings Update, dated February 26, 2016	Defendants	801; A
2066	ICOSAPENT_DFNDT00016535-39	3/1/2017		H.C. Wainwright & Co. Earnings Update, dated March 1, 2017	Defendants	801; A
2067	AMRN-PEXP-0007099	11/30/2012		Amarin NDTI Jan 08 to Nov 12 010819.xlsx,	Defendants	801
2068	ICOSAPENT_DFNDT00016159-234	5/7/2015		Complaint, Amarin Pharma, Inc. v. U.S. Food & Drug Admin., No. 1:15-cv-03588 (S.D.N.Y. May 7, 2015).	Defendants	402; 403; 801; A
2069	ICOSAPENT_DFNDT00016711-81	8/7/2015		Opinion & Order, Amarin Pharma, Inc. v. U.S. Food & Drug Admin., No. 1:15-cv-03588 (S.D.N.Y. Aug. 7, 2015)	Defendants	402; 403; 801; A
2070	ICOSAPENT_DFNDT00016091-101	11/4/2015		Amarin Corporation plc, Third Quarter 2015 Earnings Call Transcript, see https://seekingalpha.com/article/3644706-amarins-amrn-ceo-john-thero-q3-2015-results-earnings-calltranscript?part=single , accessed May 6, 2019	Defendants	402; 403; 801; A
2071	ICOSAPENT_DFNDT00015949-6021	3/31/2019		Amarin Corporation plc, Form 10-Q, for the Quarter ended March 31, 2019, pg. 7, see https://www.sec.gov/Archives/edgar/data/897448/000156459019014555/amrn-10q_20190331.htm , accessed May 3, 2019	Defendants	402; 403; 801; A
2072	ICOSAPENT_DFNDT00016068-80	5/1/2019		Amarin Corporation plc, First Quarter 2019 Earnings Call Transcript, see https://seekingalpha.com/article/4258570-amarins-amrn-ceo-john-thero-q1-2019-results-earnings-calltranscript?part=single?part=single , accessed May 3, 2019	Defendants	402; 403; 801; A

Trial Ex. No.	Bates Range	Doc Date	Dep. Ex. No. (if applicable)	Description	Party:	Plaintiffs' Objections
2073	ICOSAPENT_DFNDT00016102-18	2/25/2016		Amarin Corporation plc, Fourth Quarter 2015 Earnings Call Transcript, see https://seekingalpha.com/article/3931496-amarins-amrn-ceo-john-thero-q4-2015-results-earnings-calltranscript?part=single , accessed April 29, 2019	Defendants	402; 403; 801; A
2074	ICOSAPENT_DFNDT00015882-89	3/13/2019		Amarin Corporation plc, Presents at Cowen Health Care Conference, see https://seekingalpha.com/article/4248486-amarin-corporation-plc-amrn-presents-cowen-health-care-brokerconference-call-transcript?part=single , accessed May 7, 2019.	Defendants	402; 403; 801; A
2075	AMRN03152279-308	9/1/2017		GfK Presentation, "VASCEPA SFE, Q3 2017, Quantitative Research, Final Report Prepared for Amarin" September 1, 2017.	Defendants	801
2076	AMRN03152472-521	11/1/2014		PharmaSight Research Presentation, "Vascepa® New Promotional Campaign Exploration: Phase 1: Message Testing"	Defendants	801
2077	AMRN03151938-2047	1/1/2016		AplusA Report, "Vascepa® (Icosapent ethyl), US Market Surveillance Study (ATU), Final Report of Findings," January 2016 v.2b	Defendants	801
2078	AMRN03151826-937	8/19/2014		ZS Associates Presentation, "Vascepa Wave 2 PhysPulse Findings,"	Defendants	801
2079	ICOSAPENT_DFNDT00016057-67	3/9/2014		Amarin Corporation plc, First Quarter 2014 Earnings Call Transcript, see https://seekingalpha.com/article/2206783-amarins-amrn-ceo-john-thero-on-q1-2014-results-earnings-calltranscript?part=single , accessed April 17, 2019	Defendants	402; 403; 801; A
2080	ICOSAPENT_DFNDT00015928-37	2/28/2013		Amarin Corporation plc, Fourth Quarter 2012 Earnings Call Transcript, see https://seekingalpha.com/article/1236761-amarin-corporations-ceo-discusses-q4-2012-results-earnings-calltranscript?part=single , accessed April 18, 2019	Defendants	402; 403; 801; A
2081	AMRN-PEXP-0005984-6145	12/31/2015		Amarin, SEC Form 10-K for Fiscal Year Ended December 31, 2015	Defendants	801
2082	ICOSAPENT_DFNDT00016043-56	11/7/2013		Amarin Corporation plc, Third Quarter 2013 Earnings Call Transcript, see https://seekingalpha.com/article/1820862-amarins-ceo-discusses-q3-2013-results-earnings-calltranscript?part=single	Defendants	402; 403; 801; A
2083	ICOSAPENT_DFNDT00015938-48	2/27/2014		Amarin Fourth Quarter 2013 Earnings Call Transcript, see https://seekingalpha.com/article/2057373-amarin-management-discusses-q4-2013-results-earnings-calltranscript?part=single , accessed April 18, 2019	Defendants	402; 403; 801; A
2084	ICOSAPENT_DFNDT00016797-811			https://www.kowapharma.com/products/ , accessed April 16, 2019	Defendants	402; 403; 702; 801; A; DESC
2085	ICOSAPENT_DFNDT00015856-68	5/9/2013		Amarin Corporation plc, First Quarter 2013 Earnings Call Transcript, see https://seekingalpha.com/article/1421861-amarin-corporation-ceo-discusses-q1-2013-results-earnings-call-transcript?part=single , accessed April 26, 2019	Defendants	402; 403; 801; A
2086	ICOSAPENT_DFNDT00016081-90	8/8/014		Amarin Corporation plc, Second Quarter 2014 Earnings Call Transcript, see https://seekingalpha.com/article/2404405-amarins-amrn-ceo-john-thero-on-q2-2014-results-earnings-calltranscript?part=single , accessed April 28, 2019	Defendants	402; 403; 801; A
2087	ICOSAPENT_DFNDT00015896-903	5/5/2016		Amarin Corporation plc, First Quarter 2016 Earnings Call Transcript, see https://seekingalpha.com/article/3971859-amarin-corporations-amrn-ceo-john-thero-q1-2016-results-earnings-calltranscript?part=single , accessed April 23, 2019	Defendants	402; 403; 801; A
2088	AMRN-PEXP-0007105	4/30/2018		Total Promotional Dollars.xlsx	Defendants	801
2089	ICOSAPENT_DFNDT00016030-42	8/8/2013		Amarin Corporation plc, Second Quarter 2013 Earnings Call Transcript, see https://seekingalpha.com/article/1621292-amarins-ceo-discusses-q2-2013-resultsearnings-call-transcript?part=single , accessed April 29, 2019.	Defendants	402; 403; 801; A

Trial Ex. No.	Bates Range	Doc Date	Dep. Ex. No. (if applicable)	Description	Party:	Plaintiffs' Objections
2090	ICOSAPENT_DFNDT00015904-14	5/3/2017		Amarin Corporation plc, First Quarter 2017 Earnings Call Transcript, see https://seekingalpha.com/article/4068455-amarin-corporations-amrn-ceo-john-thero-q1-2017-results-earnings-calltranscript?part=single and https://www.vascepa.com/savings-program , accessed April 5, 2019	Defendants	402; 403; 801; A
2091	ICOSAPENT_DFNDT00017601-11			https://www.vascepa.com/savings-program , accessed April 28, 2019	Defendants	402; 403; 801; A
2092	ICOSAPENT_DFNDT00015915-27	2/28/2017		Amarin Corporation plc, Fourth Quarter 2016 Earnings Call Transcript, see https://seekingalpha.com/article/4050593-amarin-corporations-amrn-ceo-john-thero-q4-2016-results-earnings-calltranscript?part=single , accessed April 29, 2019	Defendants	402; 403; 801; A
2093	AMRN-PEXP-0007103	1/2/2019		Monthly Module Views- Sales (NSP) 1 Jan-02-2019.xlsx,	Defendants	801
2094	ICOSAPENT_DFNDT00016782-3			Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Product Details for NDA 202057, Vascepa 500MG and Vascepa 1GM, https://www.accessdata.fda.gov/scripts/cder/ob/results_product.cfm?Appl_Type=N&Appl_No=202057 , accessed April 22, 2019	Defendants	801; A; DESC
2095	ICOSAPENT_DFNDT00015853-55	1/24/2013		Amarin Announces Market Introduction of Vascepa 01.24.2013, https://investor.amarincorp.com/news-releases/news-release-details/amarin-announces-market-introductionvascepar-icosapent-ethyl , accessed April 23, 2019.	Defendants	801; A; DESC
2096	ICOSAPENT_DFNDT00015850-52	10/25/2016		Amarin Pure EPA Vascepa Now Available 10.25.2016, https://investor.amarincorp.com/news-releases/news-release-details/pure-epavascepar-now-available-new-smaller-half-gram-capsule , accessed April 23, 2019.	Defendants	801; A; DESC
2097	ICOSAPENT_DFNDT00016140-42			Antara-Drugs@FDA: FDA Approved Drug Products, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021695	Defendants	801; A
2098	ICOSAPENT_DFNDT00016312-13			Fenoglide, Drugs@FDA: FDA Drug Products, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022118 , accessed April 24, 2019.	Defendants	801; A
2099		5/1/2014		Lovaza® FDA Label (revised 05/2014), see https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021654s041lbl.pdf	Defendants	801; A
2100	ICOSAPENT_DFNDTS00016342-525	12/31/2007		https://www.gsk.com/media/2682/annual-report-2007.pdf	Defendants	402; 403; 801; A
2101	AMRN00206290-308	1/1/2008		Bays, et al. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev. Cardiovasc. Ther. 6(3): 391-409 (2008)	Defendants	801
2102	AMRN00290221-264	3/1/2008		Bays, et al. Rationale for Prescription Omega-3-Acid Ethyl Ester Therapy for Hypertriglyceridemia: A Primer for Clinicians. Drugs of Today 44(3): 205-246 (March 2008)	Defendants	801
2103	AMRN-PEXP-0000366			High Cholesterol/Very High Triglycerides. https://www.cardiosmart.org/Heart-Conditions/High-Cholesterol/High-Cholesterol-Home/Very-High-Triglycerides	Defendants	801; DESC
2104	AMRN03024268-80	6/24/2014		Amarin Pharma, Inc. Citizen Petition to FDA	Defendants	402; 403; 801; A; DESC

Trial Ex. No.	Bates Range	Doc Date	Dep. Ex. No. (if applicable)	Description	Party:	Plaintiffs' Objections
2105	AMRN01408774-784	11/26/2014		FDA Letter responding to Amarin Citizen Petition	Defendants	402; 403; 801; A; DESC
2106	AMRN00112253	10/16/2013		Transcript of Endocrinologic and Metabolic Drugs Advisory Committee Meeting, Oct. 16, 2013	Defendants	801; DESC
2107	AMRN00302233	1/1/2012		Jacobson et al., Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: A review, J. Clin. Lipid. 6(1):5-18 (2012)	Defendants	801; DESC
2108	AMRN00540152	1/9/2014		Jan. 9, 2014 Comparative Literature Review of Statin Add-On Therapies Conducted by Amarin Pharma for the FDA DMEP (2014)	Defendants	801; A; DESC
2109	AMRN00934595	1/1/2006		Otvos, J. D. et al., Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial, Circulation;113, (2006)	Defendants	402; 403; 702; 801; DESC
2110	AMRN01213101	1/1/2004		American Diabetes Association Dyslipidemia Management in Adults with Diabetes, Diabetes Care, 27(Supp. 1) S68-S71 (2004)	Defendants	801; DESC
2111	AMRN01235590	1/1/1998		Downs, J. R. et al., Primary Prevention of Acute Coronary Events with Lovastatin in Men and Women with Average Cholesterol Levels: Results of (AFCAPS/TexCAPS), JAMA;279(20); (1998)	Defendants	402; 403; 702; 801; DESC
2112	AMRN01382864	1/1/2003		Heart Protection Study Collaborative Group, MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial, The Lancet 361 (2003)	Defendants	801; DESC
2113	AMRN02283764	1/1/2011		Miller et al., Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association, Circulation 2011;123:00-00 (2011)	Defendants	801; DESC
2114	AMRN02488139	7/26/2012		7/26/2012 Amarin Press Release	Defendants	801; A; DESC
2115	AMRN02993597	1/1/2003		Thies F. et al., Association of n-3 Polyunsaturated Fatty Acids with Stability of Atherosclerotic Plaques: a Randomised Controlled Trial, The Lancet, 361(9356) (2003)	Defendants	801; DESC
2116	AMRN03105942	7/25/2012		FDA Medical Review	Defendants	801; DESC
2117	AMRN03106618	10/16/2013		Oct. 16, 2013 Amarin Briefing Materials Document for the Endocrinologic and Metabolic Drugs Advisory Committee (EDMAC) (2013)	Defendants	801; A; DESC
2118	AMRN03130052	1/1/2016		Mason et al., Eicosapentaenoic Acid Inhibits Oxidation of ApoB Containing Lipoprotein Particles of Different Size In-Vitro when Administered Alone or in Combination with Atorvastatin Active Metabolite Compared with Other Triglyceride-Lowering Agents, 68 J. Cardiovasc. Pharmacol. 33-39 (2016)	Defendants	801; DESC
2119	AMRN03144838	1/1/2012		Ballantyne, et al., Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients with Persistent High Triglycerides (from the ANCHOR Study), Am. J. Cardiol. 110:984-992 (2012)	Defendants	801; DESC
2120	AMRN03146139	1/1/2010		Ginsberg et al., Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus, 362 NEJM 1563, 1563 (2010)	Defendants	801; DESC
2121	AMRN03164735			Supplementary Appendix to Bhatt	Defendants	801; DESC
2122	AMRN03168530	2/27/2019		Clinical Study Report: A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR 101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease REDUCE-IT (Reduction of Cardiovascular Events with EPA –Intervention Trial (Feb. 27, 2019) (“REDUCE-IT Study Report”)	Defendants	801; DESC

Trial Ex. No.	Bates Range	Doc Date	Dep. Ex. No. (if applicable)	Description	Party:	Plaintiffs' Objections
2123	AMRN-PEXP-0000722	1/1/2009		American Diabetes Association Standards of Medical Care in Diabetes, Diabetes Care, 32(Supp. 1) S13-S61 (2009)	Defendants	801; DESC
2124	AMRN-PEXP-0007748	1/1/2019		American Diabetes Association Standards of Medical Care in Diabetes, Diabetes Care, 42(Supp. 1) S1-S193 (2019)	Defendants	801; DESC
2125	ICOSAPENT_DFNDT00017769-79	2/16/2017		Leading a New Paradigm in Cardiovascular Health Management (2/16/2017) https://investor.amarincorp.com/static-files/9c8a04ec-dda7-4e68-a52b-418a7a378f01	Defendants	402; 403; 801; A
2126	ICOSAPENT_DFNDT00017840-61			Elam et al., The ACCORD-Lipid Study: Implications for Treatment of Dyslipidemia in Type 2 Diabetes Mellitus, Clin Lipidol. 691 (2011) 9-20 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4509601/pdf/nihms296246.pdf	Defendants	801
2127	ICOSAPENT_DFNDT00018001-03	10/25/2016		Pure EPA Vascepa® Now Available in New, Smaller Half-Gram Capsule Size, available at https://investor.amarincorp.com/static-files/17ffc8ce-9628-4950-bf43-c83866820f4e	Defendants	402; 403; 801; A
2128	ICOSAPENT_DFNDT00017650-747	9/10/2019		2019 ACC/AHA Multi-Society Guidelines at 4, available at https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000000678	Defendants	402; 403; 801; A
2129	ICOSAPENT_DFNDT00017935-89	1/1/2019		LeRoith et al., Treatment of Diabetes in Older Adults: An Endocrine Society Clinical Practice Guideline, J. Clin. Endocrinol. Metab. 104(5):1520-1574 (2019), available at https://academic.oup.com/jcem/article/104/5/1520/5413486	Defendants	801
2130	ICOSAPENT_DFNDT00017821-22	1/1/2011		Cymet, Tyler, Should We Treat Moderately Elevated Triglycerides?, Am. Fam. Physician 83(3):246-248 (2011), available at https://www.aafp.org/afp/2011/0201/p246.html	Defendants	801
2131	ICOSAPENT_DFNDT00017908-23	1/1/2018		Hartz, et al., Hypertriglyceridemia in Diabetes Mellitus: Implications for Pediatric Care, J. Endocr. Soc. 2(6) 497-512 (2018) ("Hartz"), available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5961027/pdf/js.2018-00079.pdf	Defendants	801
2132	ICOSAPENT_DFNDT00018382-503	8/30/2017		Complaint, In re Certain Synthetically Produced, Predominantly EPA Omega-3 Products In Ethyl Ester Or Re-esterified Triglyceride Form, 337-TA-3247 (USITC Aug. 30, 2017)	Defendants	402; 403; 801; A
2133	ICOSAPENT_DFNDT00018315-32	5/1/2019		Amarin Pharma, Inc. v. ITC, No. 2018-1247, 2019 U.S. App. LEXIS 13136 (Fed. Cir. May 1, 2019)	Defendants	402; 403; 801; A
2134		3/27/2019		2019 ADA Guidelines March 27, 2019 Supplement, Section 10, Annotation ("2019 ADA Guidelines Supplement"), available at http://care.diabetesjournals.org/content/42/Supplement_1/S103	Defendants	801; DUP
2135	ICOSAPENT_DFNDT00017993-94	1/1/2007		Miller, Michael, Question: Is it safe to combine statins and fibrates? (2007), available at https://www.medscape.org/viewarticle/563490	Defendants	801; A
2136	ICOSAPENT_DFNDT00018004-05	1/1/2001		Shek, et al., Statin-fibrate combination therapy, Ann. Pharmacother. 35(7-8):908-917 (2001), available at https://www.ncbi.nlm.nih.gov/pubmed/11485144	Defendants	801
2137	ICOSAPENT_DFNDT00016834-43	10/17/2013		Berglund et al., Treatment Options for Hypertriglyceridemia: from Risk Reduction to Pancreatitis, Best Pract Res Clin Endocrinol Metab. 28(3):423-427 available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4028601/	Defendants	402; 403; 702; 801
2138	ICOSAPENT_DFNDT00017924-34	1/1/2002		Kris-Etherton, P. M. et al., Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease, Circulation 106:2747-2757, available at https://www.ahajournals.org/doi/full/10.1161/01.CIR.0000038493.65177.94 ; impeachment	Defendants	801

Trial Ex. No.	Bates Range	Doc Date	Dep. Ex. No. (if applicable)	Description	Party:	Plaintiffs' Objections
2139	ICOSAPENT_DFNDT00018048-62	1/1/2017		Dr. Matthew Budoff, Understanding How Vascepa Fits in the Prescription-Based, Pure EPA Market in Treating Hypertriglyceridemia, Slingshot Insights (2017) 1-15	Defendants	402; 403; 801; A
2140	ICOSAPENT_DFNDT00017823-39	1/1/2018		Dr. Matthew Budoff, Preparing for Amarin's REDUCE-IT Data Read Out for Vascepa in Patients with Elevated Cardiovascular Risk, Slingshot Insights (2018)	Defendants	402; 403; 801; A
2141	ICOSAPENT_DFNDT00017808-20	1/1/2017		Brinton, E. A. and Mason, R. P., Prescription Omega-3 Fatty Acid Products Containing Highly Purified Eicosapentaenoic Acid (EPA), Lipids in Health and Disease, 16(1) (2017) available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282870/	Defendants	801
2142	ICOSAPENT_DFNDT00018045-47	1/1/2018		What is Amarin's Opinion on the ASCEND Clinical Trial (2018), available at https://investor.amarincorp.com/static-files/7cb6fad5-e22b-4d15-98b9-28eb4c43f95f	Defendants	402; 403; 801; A
2143	ICOSAPENT_DFNDT00016823-29	1/1/1986		Terano, T. et al., Eicosapentaenoic Acid as a Modulator of Inflammation, Biochemical Pharmacology, 35(5), (1986) 779-785	Defendants	801
2144	ICOSAPENT_DFNDT00018024-27	1/1/2008		Surette, M. E., The Science Behind Dietary Omega-3 Fatty Acids, CMAJ, 178(2)(2008) 177-180, available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2174995/pdf/20080115s00023p177.pdf	Defendants	801
2145	ICOSAPENT_DFNDT00017995-8000	1/1/2001		Omura, M. et al., Eicosapentaenoic Acid (EPA) Induces Ca ²⁺ -Independent Activation and Translocation of Endothelial Nitric Oxide Synthase and Endothelium-Dependent Vasorelaxation, FEBS Letters, 487(3), 361-366 (2001) available at https://febs.onlinelibrary.wiley.com/doi/epdf/10.1016/S0014-5793%2800%2902351-6	Defendants	801
2146	ICOSAPENT_DFNDT00018028-34	1/1/2003		Suzuki, T. et al., Eicosapentaenoic Acid Protects Endothelial Cells Against Anoikis Through Restoration of cFLIP, Hypertension, 42, 342-348 (2003) available at https://www.ahajournals.org/doi/pdf/10.1161/01.HYP.0000084602.06114.AD	Defendants	801
2147	AMRN03171442-52	3/29/2017		Executed Research Proposal, Comparative Inhibition of Oxidation for EPA versus DHA and an EPA/DHA Combination in High Density Lipoproteins (HDL)	Defendants	402; 403; 801; A
2148	AMRN03171453-70	6/11/2009		Research Agreement between Amarin, APIL and Elucida	Defendants	402; 403; 801; A
2149	AMRN03171471-77	1/4/2017		Executed Research Proposal, Comparative Inhibition of Oxidation for EPA versus DHA in Small Dense LDL (sdLDL): A Kinetics Analysis between Amarin and Elucida	Defendants	402; 403; 801; A
2150	AMRN03171478-86	9/6/2011		Executed Research Proposal, Comparative Effects of Eicosapentaenoic Acid (EPA) versus Docosahexaenoic Acid (DHA) Human Endothelial Function between Amarin and Elucida	Defendants	402; 403; 801; A
2151	AMRN03171487-88	2/28/2012		Executed Schedule 1: Services -- Extension # 1 between Amarin and Elucida	Defendants	106; 402; 403; 801; A
2152	AMRN03171489-99	7/24/2012		Executed Research Proposal, Effects of Eicosapentaenoic Acid (EPA) and Statins on Human Endothelial Function and Nitric Oxide Release: Basis for Synergistic Actions between Amarin and Elucida	Defendants	402; 403; 801; A

Trial Ex. No.	Bates Range	Doc Date	Dep. Ex. No. (if applicable)	Description	Party:	Plaintiffs' Objections
2153	AMRN03171500-512	7/24/2012		Executed Research Services Agreement, Comparative Effects of Eicosapentaenoic Acid (EPA), Docosapentaenoic Acid (DPA) versus Docosahexaenoic Acid (DHA) and EPA/DHA on Membrane Domains: X-ray Diffraction Analysis between Amarin and Elucida	Defendants	402; 403; 801; A
2154	AMRN03171513-522	4/24/2012		Executed Research Services Agreement, Synergistic Effects of Eicosapentaenoic Acid (EPA) and Statins in Human Endothelial Function, Schedule 1: Services between Amarin and Elucida	Defendants	402; 403; 801; A
2155	AMRN03171523-31	4/24/2012		Executed Research Proposal, Comparative Effects of Eicosapentaenoic Acid (EPA) versus Docosahexaenoic Acid (DHA) and EPA/DHA on Membrane Domains: X-ray Diffraction Analysis, Schedule 1: Services between Amarin and Elucida	Defendants	402; 403; 801; A
2156	AMRN03171532-44	6/24/2013		Executed Research Proposal, Effects of Eicosapentaenoic Acid (EPA) on Cholesterol Crystal Domains in Membranes with Hyperglycemia: X-ray Diffraction Study, Schedule 1: Services between Amarin and Elucida	Defendants	402; 403; 801; A
2157	AMRN03171545-55	6/25/2013		Executed Research Proposal, Inhibition of Oxidation by Eicosapentaenoic Acid (EPA) in Human LDL Subfractions: A Focus on Small Dense LDL between Amarin and Elucida	Defendants	402; 403; 801; A
2158	AMRN03171556-69	3/18/2014		Executed Research Proposal, Comparative Effects of Eicosapentaenoic Acid (EPA), Fenofibrate, Niacin, and Gemfibrozil - Alone or in Combination with Statins - on Oxidation of Small Dense and Unfractionated Human Low Density Lipoprotein (LDL) between Amarin and Elucida	Defendants	402; 403; 801; A
2159	AMRN03171570-79	7/24/2014		Executed Research Proposal, Effects of Eicosapentaenoic Acid (EPA) versus Docosahexaenoic Acid (DHA), Fenofibrate, Niacin, and Gemfibrozil on Disruption of Established Membrane Cholesterol Domains between Amarin and Elucida	Defendants	402; 403; 801; A
2160	AMRN03171580-90	7/24/2014		Executed Research Proposal, Effects of Small Dense LDL on Human Endothelial Function after Treatment with Eicosapentaenoic Acid (EPA) - Alone or in Combination with Statin - Versus Fenofibrate, Niacin, Gemfibrozil and Docosahexaenoic Acid (DHA) Under Conditions of Oxidative Stress and more between Amarin and Elucida	Defendants	402; 403; 801; A
2161	AMRN03171591-605	5/7/2014		Executed Research Proposal, Comparative Effects of Eicosapentaenoic Acid (EPA), Docosahexanoic Acid (DHA), Fenofibrate, Niacin, Gemfibrozil - Alone or in Combination with Atorvastatin Metabolite - on Human Endothelial Function Following Exposure to oxLDL between Amarin and Elucida	Defendants	402; 403; 801; A
2162	AMRN03171606-617	9/9/2014		Executed Research Proposal for Completion of BBA Manuscript, Dose-Dependent Effects of Vascepa between Amarin and Elucida	Defendants	402; 403; 801; A
2163	AMRN03171618-29	2/13/2014		Executed Research Proposal, Comparative Effects of Eicosapentaenoic Acid (EPA), Fenofibrate, Niacin, and Gemfibrozil - Alone or in Combination with Select Statins - on Lipid Peroxidation in Model Membranes Exposed to Hyperglycemic Conditions and more between Amarin and Elucida	Defendants	402; 403; 801; A
2164	AMRN03171630-639	9/9/2015		Executed Research Proposal, Distinct Effect of EPA Plus/Minus Atorvastatin Active Metabolite on Inhibiting Rat Glomerular Endothelial Dysfunction with Hyperglycemia and oxLDL Ex Vivo: Comparison to other TG-Lowering Agents and DHA between Amarin and Elucida	Defendants	402; 403; 801; A
2165	AMRN03171640-58	9/10/2015		Executed Research Proposal, Comparative Effects of EPA vs DHA on membrane Lipid Dynamics and Structure: Fluorescence Anisotropy and X-Ray Diffraction Analyses between Amarin and Elucida	Defendants	402; 403; 801; A

Trial Ex. No.	Bates Range	Doc Date	Dep. Ex. No. (if applicable)	Description	Party:	Plaintiffs' Objections
2166	AMRN03171659-69	1/21/2015		Executed Research Proposal, Time-Dependent Effects of Eicosapentaenoic Acid (EPA) Pretreatment of HUVECS - Alone or in Combination with Atorvastatin Metabolite - versus Docosahexaenoic Acid (DHA), Fenofibrate, Niacin and Gemfibrozil on Endothelial Function with Oxidized LDL Exposure and more between Amarin and Elucida	Defendants	402; 403; 801; A
2167	AMRN03171670-78	1/5/2015		Executed Research Proposal, Dose Dependent Effects of Eicosapentaenoic Acid (EPA) on Disruption of Established Membrane Cholesterol Domains	Defendants	402; 403; 801; A
2168	AMRN03171679-88	1/5/2015		Executed Research Proposal, Comparative Effects of Eicosapentaenoic Acid (EPA) plus/minus Atorvastatin Active Metabolite (ATM) on Oxidation of Small Dense Human Low Density Lipoprotein (sdLDL) with Hyperglycemia	Defendants	402; 403; 801; A
2169	AMRN03171689-97	7/15/2015		Executed Research Proposal, Comparative Effects of EPA, DHA, Niacin, Fenofibrate and Vitamin E on Membrane Oxidation over a Broad Cholesterol Range under conditions of Hyperglycemia and more	Defendants	402; 403; 801; A
2170	AMRN03171698-704	6/16/2015		Executed Research Proposal, Comparative and Time-Dependent Effects of Eicosapentaenoic Acid (EPA), Docosahexaenoic Acid (DHA), EPA/DHA Combination and Vitamin E on sdLDL Oxidation	Defendants	402; 403; 801; A
2171	AMRN03171705-13	10/28/2015		Executed Research Proposal, Effects of Eicosapentaenoic Acid (EPA) - Alone or in Combination with the ortho-hydroxy metabolite of Atorvastatin and more	Defendants	402; 403; 801; A
2172	AMRN03171714-20	1/28/2016		Executed Schedule 1 to The Research Services Agreement Between Amarin, APIL, and Elucida	Defendants	106; 402; 403; 801; A
2173	AMRN03171721-31	1/11/2017		Executed Schedule 1 to The Research Services Agreement Between Amarin, APIL, and Elucida	Defendants	106; 402; 403; 801; A
2174	AMRN03171732-34	10/12/2015		Executed Services Agreement between Amarin and R. Preston Mason for 10/20/2015 - 10/26/2015	Defendants	402; 403; 801; A
2175	AMRN03171735-37	7/25/2013		Amendment # 1 to The Research Services Agreement between Amarin, APIL, and Elucida	Defendants	106; 402; 403; 801; A
2176	AMRN03171738-40	4/23/2009		Amarin Confidentiality Agreement between Amarin and R. Preston Mason	Defendants	402; 403; 801; A
2177	AMRN03171741-42	4/8/2015		Executed Schedule 1 Services	Defendants	106; 402; 403; 801; A
2178	AMRN03171743-51	7/12/2018		Consultancy Agreement between Amarin and R. Preston Mason	Defendants	402; 403; 801; A
2179	AMRN03171752-56	5/2/2016		Services Agreement between Amarin and R. Preston Mason for 4/14/2016 - 6/30/2016	Defendants	402; 403; 801; A
2180	AMRN03171757-59	10/14/2015		Services Agreement between Amarin and R. Preston Mason for 10/1/2015 - 11/6/2015	Defendants	402; 403; 801; A
2181	AMRN03171760-62	10/1/2015		Mutual Confidentiality Agreement between Amarin and R. Preston Mason	Defendants	402; 403; 801; A
2182	AMRN03171763-83	10/5/2015		Amendment # 1 to The Research Services Agreement between Amarin, APIL, and Elucida	Defendants	106; 402; 403; 801; A
2183	AMRN03171784	2/7/2017		Executed IIT Study Review & Support Agreement Form - EPA Preserves HDL and Endothelial Function	Defendants	106; 402; 403; 801; A
2184	AMRN03171785	4/10/2017		Executed IIT Study Review & Support Agreement Form - Comparative Inhibition of Oxidation for EPA versus DHA and an EPA/DHA Combination in High Density Lipoproteins (HDL)	Defendants	106; 402; 403; 801; A
2185	AMRN03171786-90	1/6/2017		Services Agreement between Amarin and R. Preston Mason for 12/9/2016 - 1/15/2017	Defendants	402; 403; 801; A
2186	AMRN03171791-95	1/6/2017		Services Agreement between Amarin and R. Preston Mason for 12/9/2016 - 1/15/2017	Defendants	402; 403; 801; A
2187	AMRN03171796-804			W-9 Form for Elucida Research LLC	Defendants	402; 403; 801; A

Trial Ex. No.	Bates Range	Doc Date	Dep. Ex. No. (if applicable)	Description	Party:	Plaintiffs' Objections
2188	AMRN03171805-11	6/16/2015		Executed Research Proposal, Comparative and Time-Dependent Effects of Eicosapentaenoic Acid (EPA), Docosahexaenoic Acid (DHA), EPA/DHA Combination and Vitamin E on sdLDL Oxidation	Defendants	106; 402; 403; 801; A
2189	AMRN03171812-15	1/14/2019		Executed Schedule 1 to The Research Services Agreement Between Amarin, APIL, and Elucida - Comparative Inhibition of Eicosapentenoic Acid (EPA) versus Similar Fatty Acid on Membrane Oxidation - Addendum for Additional cholesterol crystal domain investigations (phase 2c)	Defendants	106; 402; 403; 801; A
2190	AMRN03171816-20	1/30/2018		Executed Schedule 1 to The Research Services Agreement Between Amarin, APIL, and Elucida - Effects Eicosapentenoic Acid (EPA) in Combination with Atorvastatin and Compared to Docosahexanoic Acid (DHA) on Human Endothelial Cell Dysfunction Caused by Lipolzed TG-Rich Lipoprotein (VLDL)	Defendants	106; 402; 403; 801; A
2191	AMRN03171821-32	5/29/2018		Executed Schedule 1 to The Research Services Agreement Between Amarin, APIL, and Elucida - Comparative Inhibition of Eicosapentenoic Acid (EPA) versus Similar Fatty Acid on Membrane Oxidation	Defendants	106; 402; 403; 801; A
2192	AMRN03171833-45	1/11/2017		Executed Schedule 1 to The Research Services Agreement Between Amarin, APIL, and Elucida - Comparative Inhibition of Oxidation for EPA versus ETE, AA, EA, DHA, DPA, ALA, OA, LA, and SA in Human Small Dense LDL (sdLDL)	Defendants	106; 402; 403; 801; A
2193	AMRN03171846-48	1/19/2016		Services Agreement between Amarin and R. Preston Mason for 1/1/2016 - 1/31/2016	Defendants	106; 402; 403; 801; A
2194	AMRN03171849-60	2/13/2014		Executed Research Proposal, Comparative Effects of Eicosapentaenoic Acid (EPA), Fenofibrate, Niacin, and Gemfibrozil - Alone or in Combination with Select Statins - on Lipid Peroxidation in Model Membranes Exposed to Hyperglycemic Conditions and more between Amarin and Elucida	Defendants	106; 402; 403; 801; A
2195	AMRN03171861-65	5/29/2018		Executed Schedule 1 to The Research Services Agreement Between Amarin, APIL, and Elucida - Effects of Eicosapentenoic Acid (EPA) on Human LDL and Model Membrane Oxidation: A Dose - ranging Analysis of Potential Threshold Activity in Vitro - Addendum for additional aliquotes, timepoints and concentrations	Defendants	106; 402; 403; 801; A
2196	AMRN03171866-79	6/18/2018		Executed Research Proposal, Effects of Eicosapentenoic Acid (EPA) on Human LDL and Model Membrane Oxidation	Defendants	106; 402; 403; 801; A
2197	AMRN03171880-81	12/17/2015		Executed Schedules between APIL, Amarin, and Elucida	Defendants	106; 402; 403; 801; A
2198	AMRN03171882-94	6/2/2016		Executed Research Proposal , Comparative and Time-Dependent Effects of sdLDL Treated with either Eicosapentaenoic Acid (EPA) or Docosahexanoic Acid (DHA) under Oxidative Stress Conditions on Human Endothelial Function	Defendants	106; 402; 403; 801; A
2199	ICOSAPENT_DFDTS00007276-83	1/1/1999		Ando, Eicosapent Acid Reduces Plasma Levels of Remnant Lipoproteins and Prevents in Vivo Peroxidation of LDL in Dialysis Patients. J Am Nephrol 10:2177 (1999)	Defendants	402; 403; 702; 801
2200	ICOSAPENT_DFDTS00005926-35	1/1/2002		Chan, et al. Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity. European Journal of Clinical Investigation 32:429-436 (2002)	Defendants	402; 403; 702; 801
2201	ICOSAPENT_DFDTS00005944-52	1/1/1993		Contacos, et al. Effect of Pravastatin and w-3 Fatty Acids on Plasma Lipids and Lipoproteins in Patients With Combined Hyperlipidemia. Arterior Thromb Vasc Biol. 13:1755-1762 (1993)	Defendants	402; 403; 702; 801
2202	ICOSAPENT DFDTS00005953-76	12/23/1987		European Patent Application EP 0 273 708 A2	Defendants	402; 403; 801

Trial Ex. No.	Bates Range	Doc Date	Dep. Ex. No. (if applicable)	Description	Party:	Plaintiffs' Objections
2203	ICOSAPENT_DFDTS00005977-83	1/26/1988		European Patent Application EP 0 277 747 A2	Defendants	402; 403; 801
2204	ICOSAPENT_DFDTS00005984-96	6/21/1988		European Patent Application EP 0 347 509 A1	Defendants	402; 403; 801
2205	ICOSAPENT_DENDTS00006201-6212	8/1/2007		Kelley et al., Docosaheaxaenoic Acid Supplementation Improves Fasting and Postprandial Lipid Profiles in Hypertriglyceridemic Men, pp. 324-333, Clinical Nutrition, Volume 86, No. 2 (August 2007)	Defendants	402; 403; 702; 801
2206	ICOSAPENT_DFNDTS00006245-55	1/1/2002		Leigh-Firbank, et al, Eicosapentaenoic Acid and Docosaheaxaenic Acid from Fish Oils: Differential Associations with Lipid Responses, British Journal of Nutrition (2002), Volume 87, pp. 435-445.	Defendants	801
2207	ICOSAPENT_DFNDTS00006383-91	1/1/2004		Lovegrove, et al., Moderate Fish-oil Supplementation Reverses Low-Platelet, Long-chain n-3 Polyunsaturated Fatty Acid Status and Reduces Plasma Triacylglycerol Concentrations in British Indo-Asians, Clinical Nutrition Volume 79, pp. 974-982 (2004)	Defendants	402; 403; 702; 801
2208	ICOSAPENT_DFNDTS00006437-39	3/1998		Mataki, et al., Effect of Eicosapentaenoic Acid in Combination with HMG-CoA Reductase Inhibitor on Lipid Metabolism, International Medical Journal, Vol. 5, No. 1, pp. 35-36 (March 1998)	Defendants	402; 403; 702; 801
2209	ICOSAPENT_DFNDTS00011379-91	1/1/1999		Pownall, et al., Correlation of Serum Triglyceride and Its Reduction by ω -3 Fatty Acids with Lipid Transfer Activity and the Neutral Lipid Compositions of High-density and Low-density Lipoproteins, Atherosclerosis (1998)	Defendants	402; 403; 702; 801
2210	ICOSAPENT_DFNDTS00006905-12	4/1/2004		Theobald, et al., LDL Cholesterol-raising Effect of Low-dose Docosaheaxaenoic Acid in Middle-aged Men and Women, Clinical Nutrition, Volume 79, No. 4, pp. 558-563 (April 2004)	Defendants	402; 403; 702; 801
2211	ICOSAPENT_DFDTS00012204-214	1/1/1993		U.S. Patent 5,215,630	Defendants	402; 403; 801
2212	ICOSAPENT_DFDTS00012337-343	11/24/1998		U.S. Patent 5,840,944	Defendants	402; 403; 801
2213	ICOSAPENT_DFDTS00005855-62	11/6/2001		U.S. Patent 6,303,330	Defendants	402; 403; 801
2214	ICOSAPENT_DFDTS00007000-13	5/7/2002		U.S. Patent 6,384,077	Defendants	402; 403; 801
2215	ICOSAPENT_DFDTS00005863-67	1/25/2005		U.S. Patent 6,846,942	Defendants	402; 403; 801
2216	ICOSAPENT_DFDTS00006913-45	6/5/2003		U.S. Patent Application Publication 2003/0104048	Defendants	402; 403; 801
2217	ICOSAPENT_DFDTS00006946-63	6/22/2006		U.S. Patent Application Publication 2006/0134178	Defendants	402; 403; 801
2218	ICOSAPENT_DFDTS00007014-20	1/1/2007		Virani and Nambi, The Role of Lipoprotein-associated Phospholipase A2 As a Marker for Atherosclerosis. Current Atherosclerosis Reports 9:97-103	Defendants	402; 403; 702; 801
2219	AMRN0290951-973	1/1/2007		Rader, Lipid Disorders. In Textbook of Cardiovascular Medicine, Chapter 5 (3d ed. 2007)	Defendants	106; 402; 403; 702; 801
2220	AMRN0291030-1036	10/1/1995		Sanders, Triglyceride-Lowering Effect of Marine Polyunsaturates in Patients with Hypertriglyceridemia. Arteriosclerosis 5:459-465 (1985)	Defendants	402; 403; 702; 801
2221				Nicholas P. Godici Curriculum Vitae		801; A
2222				Jay W. Heinecke, M.D. Curriculum Vitae		801; A
2223				Ivan T. Hofmann Curriculum Vitae		801; A
2224		11/14/2018		John Kornak, PhD Curriculum Vitae		801; A
2225				Jonathan I. Sheinberg, MD, FACC Curriculum Vitae		801; A
2226		11/14/2019		Endocrinologic and Metabolic Drugs Advisory Committee Briefing Document: Vascepa® REDUCE-IT® (Reduction of Cardiovascular Events with EPA - Intervention Trial)		106; 801
2227		11/14/2019		Errata to the Amarin Pharmaceutical Ireland Limited (Amarin) Briefing Document for the Advisory Committee meeting on 14 November 2019.		106; 801
2228		11/14/2019		FDA Briefing Document, Endocrinologic and Metabolic Drugs, Advisory Committee Meeting, November 14, 2019		106; 801
2229		11/14/2019		Erratum to FDA Briefing Document: Endocrinologic and Metabolic Drugs Advisory Committee Meeting (EDMAC) Meeting, November 14, 2019		106; 801

Trial Ex. No.	Bates Range	Doc Date	Dep. Ex. No. (if applicable)	Description	Party:	Plaintiffs' Objections
2230		11/14/2019		Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Roster		801
2231		11/14/2019		Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting, November 14, 2019, Draft Agenda		801
2232		11/14/2019		Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting, November 14, 2019, Draft Meeting Roster		801
2233		11/14/2019		Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting, November 14, 2019, Draft Questions		801
2234		11/14/2019		November 14, 2019 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) - Webcast Information		801
2235		11/14/2019		Icosapent Ethyl (VASCEPA®): Amarin Pharmaceuticals Presentation to the Endocrinologic and Metabolic Drugs Advisory Committee, NDA 202057		801
2236		11/14/2019		FDA Introductory Remarks, Endocrinologic and Metabolic Drugs, Advisory Committee (EMDAC) Meeting, John Sharretts, M.D.		801
2237		7/31/2018		Plaintiffs' Responses and Objections to Defendants' Joint First Set of Interrogatories to Amarin (Nos. 1-8)		106; 801; A
2238		11/14/2019		November 14, 2019, Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) - Webcast Recording, Start of Meeting to Morning Break. https://collaboration.fda.gov/poku8qu000zj/?launcher=false&fcsContent=true&pbMode=normal		801; NE
2239		11/14/2019		November 14, 2019, Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) - Webcast Recording, Morning Break to Afternoon Break. https://collaboration.fda.gov/pgu58b2olhgv/?launcher=false&fcsContent=true&pbMode=normal		801; NE
2240		11/14/2019		November 14, 2019, Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) - Webcast Recording, Afternoon Break to End of Meeting. https://collaboration.fda.gov/pegir9sba12n/?launcher=false&fcsContent=true&pbMode=normal		801; NE

Amarin's Objection Codes for Defendants' Trial Exhibit List

Key	Objection
106	Incomplete document (<i>see</i> F.R.E. Rule 106).
402	This document or testimony is not relevant to any issue in this case (<i>see</i> F.R.E. 401 and 402).
403	This document's probative value is substantially outweighed by a danger of unfair prejudice, confusion of issues, undue delay, waste of time, or presentation of needlessly cumulative evidence (<i>see</i> F.R.E. 403).
701	This document is improper and expresses scientific, technical, or specialized opinions by a non-expert (<i>see</i> F.R.E. 701).
702	This document is an improper expert document and the underlying facts, data, principals, and/or methods are questionable (<i>see</i> F.R.E. 702).
801	This document contains or embodies an out-of-court statement. It is inadmissible as hearsay if offered to prove the truth of that statement unless the proponent can qualify it as non-hearsay or an exception to hearsay (<i>see</i> F.R.E. 801 et seq.). To the extent that it is offered for another purpose, it is confusing and prejudicial.
A	The exhibit has not been properly authenticated (<i>see, e.g.,</i> F.R.E. 901, 902, and 903).
B	This is not the best evidence of the document it purports to be (<i>see</i> F.R.E. 1002, 1003, 1004).
F	Lacks foundation (<i>see, e.g.,</i> F.R.E. 602 and 901).
DESC	Description inaccurate.
DUP	Duplicate of another exhibit.
JTX	Move to Joint Exhibit List.
MD	Multiple documents.
NE	No exhibit provided.

EXHIBIT C

Plaintiffs' Deposition Designations

Plaintiffs' Deposition Designations

Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.
Civil Action No. 2:16-cv-02525-MMD-NJK

Jerald M. Andry November 8, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ¹ Designations	Defendants' Objections to Rebuttal Designations
8:1-6					
8:15-23					
15:13-16:7					
16:20-23	402, 403, FRCP 30(b)(6)				
17:3-10	402, 403, FRCP 30(b)(6)				
18:24-19:1	402, 403, FRCP 30(b)(6)	19:2-3	801		
19:4-9	402, 403, FRCP 30(b)(6)	19:2-3	801		
19:13-15	402, 403, FRCP 30(b)(6)	19:16-17	801		
19:18-23	402, 403, FRCP 30(b)(6)	19:16-17	801		
20:3-6	402, 403, FRCP 30(b)(6)	20:7-8	801		
20:9	402, 403, FRCP 30(b)(6)	20:7-8	801		
20:11-20:14	402, 403, FRCP 30(b)(6)	20:7-8	801		
20:19-21	402, 403, FRCP 30(b)(6)	20:22-23	801		
20:24-21:4	402, 403, FRCP 30(b)(6)	20:22-23	801		
21:9-12	402, 403, FRCP 30(b)(6)	21:13-14	801		
21:15-20	402, 403, FRCP 30(b)(6)	21:13-14	801		
21:25-22:3	402, 403, FRCP 30(b)(6)	22:4-5	801		
22:6-11	402, 403, FRCP 30(b)(6)	22:4-5	801		
22:22-24					
23:5-14					
29:3-9					
38:3-11					
40:22-23					

¹ In addition to the designations identified in the "Rebuttal Designations" column, Plaintiffs reserve the right to also rely on any of Plaintiffs' original deposition designations or Defendants' counter-designations in rebuttal to Defendants' counter-designations.

Jerald M. Andry November 8, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ¹ Designations	Defendants' Objections to Rebuttal Designations
40:25–42:8					
42:10–25					
43:23–44:18	402, 403				
47:23–49:17	106, 403, 602, 701, F, SP, MC, FRCP 30(b)(6)	49:24–50:13	106, 403, 801, C, CQ	57:1–58:9	OS, 106, 403, 602, FRCP 30(b)(6)
		50:21–51:16	106, 403, 801, C, CQ, OS		
		51:20–53:6	106, 403, 801, C, CQ, OS		
		53:25–54:2	106, 403, 801, AM, C, OS		
		54:4–22	106, 403, 801, AM, C, OS		
49:21–23	106, 403, 602, 701, FRCP 30(b)(6), IQ	49:24–50:13	106, 403, 801, C, CQ	57:1–58:9	OS, 106, 403, 602, FRCP 30(b)(6)
		50:21–51:16	106, 403, 801, C, CQ, OS		
		51:20–53:6	106, 403, 801, C, CQ, OS		
		53:25–54:2	106, 403, 801, AM, C, OS		
		54:4–22	106, 403, 801, AM, C, OS		
57:1–58:9	106, 403, 602, FRCP 30(b)(6)	49:24–50:13	106, 403, 801, C, CQ	47:23–49:17; 49:21–50:8	OS, 106, 403, 602, 701, F, SP, MC, FRCP 30(b)(6)
		50:21–51:16	106, 403, 801, C, CQ, OS		
		51:20–53:6	106, 403, 801, C, CQ, OS		
		53:25–54:2	106, 403, 801, AM, C, OS		
		54:4–22	106, 403, 801, AM, C, OS		
61:24–62:18	402, 403				
63:13–64:4	402, 403, 801				
66:10–67:5	402, 403, 801				
67:17–69:3	402, 403				
71:23–72:21	402, 403, 801				
73:19–74:8	402, 403				
74:11–75:9	402, 403				
75:20–76:19	402, 403, 801				
77:11–78:6	402, 403, 801				
79:3–79:21	402, 403, 801				

Jerald M. Andry November 8, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ¹ Designations	Defendants' Objections to Rebuttal Designations
80:14–81:21	402, 403, 801				
82:10–83:1	402, 403				
83:8–84:3	402, 403				
105:15–106:22	402, 403				
107:18–108:1	106, 402, 403	108:2–15			
108:16–109:17	402, 403				
110:2–111:19	402, 403, CQ				
111:21–113:18	402, 403				
115:5–20	403, 403				
116:1–2	402, 403, 701, AM, SP, FRCP 30(b)(6)				
116:5–21	402, 403, 701, AM, SP, FRCP 30(b)(6)				
116:23–117:7	402, 403, 701, CQ, SP, AM, FRCP 30(b)(6)				
118:4–6	402, 403, 701, CQ, SP, AM, FRCP 30(b)(6)	137:18–21	106, 402, 403, 801, C, NR, OS	129:19–22; 130:1–15; 138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17	OS, 106, 402, 403, AM, F, MC
		137:24–138:5	106, 402, 403, 801, C, NR, OS		
		151:14–15	801, C		
		151:18–21	801, C		
118:9–20	402, 403, 701, CQ, SP, AM, AA, FRCP 30(b)(6)	128:13–15	106, 402, 403, 801, AM, C, CQ, NR, OS	129:19–22; 130:1–15; 138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17	OS, 106, 402, 403, AM, F, MC
		128:18–129:11	106, 402, 403, 801, AM, C, CQ, NR, OS		
		137:18–21	106, 402, 403, 801, C, NR, OS		
		137:24–138:5	106, 402, 403, 801, C, NR, OS		
		151:14–15	801, C		
		151:18–21	801, C		
118:23–119:9	402, 403, 701, CQ, SP, AM,	128:13–15	106, 402, 403, 801, AM, C, CQ, NR	129:19–22; 130:1–15; 138:15–17;	OS, 106, 402, 403, AM, F, MC

Jerald M. Andry November 8, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ¹ Designations	Defendants' Objections to Rebuttal Designations
	AA, FRCP 30(b)(6)	128:18–129:11	106, 402, 403, 801, AM, C, CQ, NR	138:19–21; 138:23–24; 139:1–13; 139:16–17	
		137:18–21	106, 402, 403, 801, C, NR, OS		
		137:24–138:5	106, 402, 403, 801, C, NR, OS		
		151:14–15	801, C		
		151:18–21	801, C		
120:23–25	402, 403, 701, CQ, SP, AM, FRCP 30(b)(6), MC, F, AA	128:13–15	106, 402, 403, 801, AM, C, CQ, NR	129:19–22; 130:1–15; 138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17	OS, 106, 402, 403, AM, F, MC
		128:18–129:11	106, 402, 403, 801, AM, C, CQ, NR		
		137:18–21	106, 402, 403, 801, C, NR, OS		
		137:24–138:5	106, 402, 403, 801, C, NR, OS		
		151:14–15	801, C		
		151:18–21	801, C		
121:4–19	402, 403, 701, CQ, SP, AM, FRCP 30(b)(6), MC, F	128:13–15	106, 402, 403, 801, AM, C, CQ, NR	129:19–22; 130:1–15; 138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17	OS, 106, 402, 403, AM, F, MC
		128:18–129:11	106, 402, 403, 801, AM, C, CQ, NR		
		137:18–21	106, 402, 403, 801, C, NR, OS		
		137:24–138:5	106, 402, 403, 801, C, NR, OS		
		151:14–15	801, C		
		151:18–21	801, C		
124:19–21	402, 403, 701, CQ, SP, AM, FRCP 30(b)(6), MC, F, AA	128:13–15	106, 402, 403, 801, AM, C, CQ, NR, OS	129:19–22; 130:1–15; 138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17	OS, 106, 402, 403, AM, F, MC
		128:18–129:11	106, 402, 403, 801, AM, C, CQ, NR, OS		
		137:18–21	106, 402, 403, 801, C, NR, OS		
		137:24–138:5	106, 402, 403, 801, C, NR, OS		

Jerald M. Andry November 8, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ¹ Designations	Defendants' Objections to Rebuttal Designations
		151:14–15	801, C		
		151:18–21	801, C		
124:24–125:6	402, 403, 701, CQ, SP, AM, FRCP 30(b)(6), MC, F, AA	128:13–15	106, 402, 403, 801, AM, C, CQ, NR, OS	129:19–22; 130:1–15; 138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17	OS, 106, 402, 403, AM, F, MC
		128:18–129:11	106, 402, 403, 801, AM, C, CQ, NR, OS		
		137:18–21	106, 402, 403, 801, C, NR, OS		
		137:24–138:5	106, 402, 403, 801, C, NR, OS		
		151:14–15	801, C		
		151:18–21	801, C		
126:25–127:16	402, 403, 701, FRCP 30(b)(6)	128:13–15	106, 402, 403, 801, AM, C, CQ, NR	129:19–22; 130:1–15; 138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17	OS, 106, 402, 403, AM, F, MC
		128:18–129:11	106, 402, 403, 801, AM, C, CQ, NR		
		137:18–21	106, 402, 403, 801, C, NR, OS		
		137:24–138:5	106, 402, 403, 801, C, NR, OS		
		151:14–15	801, C		
		151:18–21	801, C		
130:17–19	402, 403, 701, CQ, SP, AM, FRCP 30(b)(6), MC, F, AA	128:13–15	106, 402, 403, 801, AM, C, CQ, NR, OS	129:19–22; 130:1–15; 138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17	OS, 106, 402, 403, AM, F, MC
		128:18–129:11	106, 402, 403, 801, AM, C, CQ, NR, OS		
		137:18–21	106, 402, 403, 801, C, NR, OS		
		137:24–138:5	106, 402, 403, 801, C, NR, OS		
		151:14–15	801, C		
		151:18–21	801, C		
130:22–131:5	402, 403, 701, CQ, SP, AM,	128:13–15	106, 402, 403, 801, AM, C, CQ, NR, OS	129:19–22; 130:1–15; 138:15–17;	OS, 106, 402, 403, AM, F, MC

Jerald M. Andry November 8, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ¹ Designations	Defendants' Objections to Rebuttal Designations
	FRCP 30(b)(6), MC, F, AA	128:18–129:11	106, 402, 403, 801, AM, C, CQ, NR, OS	138:19–21; 138:23–24; 139:1–13; 139:16–17	
		137:18–21	106, 402, 403, 801, C, NR, OS		
		137:24–138:5	106, 402, 403, 801, C, NR, OS		
		151:14–15	801, C		
		151:18–21	801, C		
131:7–15	402, 403, 701, CQ, SP, AM, FRCP 30(b)(6), MC, F, AA	128:13–15	106, 402, 403, 801, AM, C, CQ, NR, OS	129:19–22; 130:1–15; 138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17	OS, 106, 402, 403, AM, F, MC
		128:18–129:11	106, 402, 403, 801, AM, C, CQ, NR, OS		
		137:18–21	106, 402, 403, 801, C, NR, OS		
		137:24–138:5	106, 402, 403, 801, C, NR, OS		
		151:14–15	801, C		
		151:18–21	801, C		
131:19–132:15	402, 403, 701, CQ, SP, AM, FRCP 30(b)(6), MC, F, AA	128:13–15	106, 402, 403, 801, AM, C, CQ, NR, OS	129:19–22; 130:1–15; 138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17	OS, 106, 402, 403, AM, F, MC
		128:18–129:11	106, 402, 403, 801, AM, C, CQ, NR, OS		
		137:18–21	106, 402, 403, 801, C, NR, OS		
		137:24–138:5	106, 402, 403, 801, C, NR, OS		
		151:14–15	801, C		
		151:18–21	801, C		
132:18–133:15	402, 403, 701, CQ, SP, AM, FRCP 30(b)(6), MC, F, AA	128:13–15	106, 402, 403, 801, AM, C, CQ, NR, OS	129:19–22; 130:1–15; 138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17	OS, 106, 402, 403, AM, F, MC
		128:18–129:11	106, 402, 403, 801, AM, C, CQ, NR, OS		
		137:18–21	106, 402, 403, 801, C, NR, OS		
		137:24–138:5	106, 402, 403, 801, C, NR, OS		

Jerald M. Andry November 8, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ¹ Designations	Defendants' Objections to Rebuttal Designations
		151:14–15	801, C		
		151:18–21	801, C		
136:16–19	402, 403, 701, CQ, SP, AM, FRCP 30(b)(6), MC, F, AA	128:13–15	106, 402, 403, 801, AM, C, CQ, NR, OS	129:19–22; 130:1–15; 138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17	OS, 106, 402, 403, AM, F, MC
		128:18–129:11	106, 402, 403, 801, AM, C, CQ, NR, OS		
		137:18–21	106, 402, 403, 801, C, NR, OS		
		137:24–138:5	106, 402, 403, 801, C, NR, OS		
136:22–137:4	402, 403, 701, CQ, SP, AM, FRCP 30(b)(6), MC, F, AA	128:13–15	106, 402, 403, 801, AM, C, CQ, NR, OS	129:19–22; 130:1–15; 138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17	OS, 106, 402, 403, AM, F, MC
		128:18–129:11	106, 402, 403, 801, AM, C, CQ, NR, OS		
		137:18–21	106, 402, 403, 801, C, NR, OS		
		137:24–138:5	106, 402, 403, 801, C, NR, OS		
137:7–16	402, 403, 701, CQ, SP, AM, FRCP 30(b)(6), MC, F, AA	128:13–15	106, 402, 403, 801, AM, C, CQ, NR, OS	129:19–22; 130:1–15; 138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17	OS, 106, 402, 403, AM, F, MC
		128:18–129:11	106, 402, 403, 801, AM, C, CQ, NR, OS		
		137:18–21	106, 402, 403, 801, C, NR, OS		
		137:24–138:5	106, 402, 403, 801, C, NR, OS		
141:6–13	402, 403, 701, CQ, SP, AM, FRCP 30(b)(6), F, AA	128:13–15	106, 402, 403, 801, AM, C, CQ, NR, OS	129:19–22; 130:1–15; 138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17	OS, 106, 402, 403, AM, F, MC
		128:18–129:11	106, 402, 403, 801, AM, C, CQ, NR, OS		
		137:18–21	106, 402, 403, 801, C, NR, OS		
		137:24–138:5	106, 402, 403, 801, C, NR, OS		

Jerald M. Andry November 8, 2018					
Plaintiffs’ Designations	Defendants’ Objections	Defendants’ Counter– Designations	Plaintiffs’ Objections to Counter– Designations	Plaintiffs’ Rebuttal ¹ Designations	Defendants’ Objections to Rebuttal Designations
141:16–24	402, 403, 701, CQ, SP, AM, FRCP 30(b)(6), F, AA	128:13–15	106, 402, 403, 801, AM, C, CQ, NR, OS	129:19–22; 130:1–15; 138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17	OS, 106, 402, 403, AM, F, MC
		128:18–129:11	106, 402, 403, 801, AM, C, CQ, NR, OS		
		137:18–21	106, 402, 403, 801, C, NR, OS		
		137:24–138:5	106, 402, 403, 801, C, NR, OS		
142:2–9	402, 403, 701, CQ, SP, AM, FRCP 30(b)(6), F, AA	128:13–15	106, 402, 403, 801, AM, C, CQ, NR, OS	129:19–22; 130:1–15; 138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17	OS, 106, 402, 403, AM, F, MC
		128:18–129:11	106, 402, 403, 801, AM, C, CQ, NR, OS		
		137:18–21	106, 402, 403, 801, C, NR, OS		
		137:24–138:5	106, 402, 403, 801, C, NR, OS		
		151:14–15	801, C		
		151:18–21	801, C		
142:18–143:1	402, 403, 701, CQ, SP, AM, FRCP 30(b)(6), F, AA	128:13–15	106, 402, 403, 801, AM, C, CQ, NR	129:19–22; 130:1–15; 138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17	OS, 106, 402, 403, AM, F, MC
		128:18–129:11	106, 402, 403, 801, AM, C, CQ, NR		
		137:18–21	106, 402, 403, 801, C, NR, OS		
		137:24–138:5	106, 402, 403, 801, C, NR, OS		
		151:14–15	801, C		
		151:18–21	801, C		
151:23–152:11	402, 403, CQ, SP, AM, FRCP 30(b)(6), F	125:22–126:4	106, 801	125:8–12; 125:15–20; 126:5–8	OS, 106, 402, 403, SP
		153:17–19	106, 402, 403, 801, AA, NR, OS	125:8–12; 125:15–20; 125:22–126:8	
		153:22–154:3	106, 402, 403, 801, AA, NR, OS		

Jerald M. Andry November 8, 2018					
Plaintiffs’ Designations	Defendants’ Objections	Defendants’ Counter– Designations	Plaintiffs’ Objections to Counter– Designations	Plaintiffs’ Rebuttal ¹ Designations	Defendants’ Objections to Rebuttal Designations
		156:11–15	106, 403, 801, AA, C		
		156:19–21	106, 403, 801, AA, C	125:8–12; 125:15–20; 125:22–126:8; 155:3–6; 155:9– 11; 155:15–18	
152:14–21	402, 403, 701, CQ, SP, AM, FRCP 30(b)(6), F, AA	125:22–126:4	106, 801	125:8–12; 125:15–20; 126:5–8	OS, 106, 402, 403, SP
		153:17–19	106, 402, 403, 801, AA, NR, OS	125:8–12; 125:15–20; 125:22–126:8	
		153:22–154:3	106, 402, 403, 801, AA, NR, OS		
		156:11–15	106, 403, 801, AA, C		
		156:19–21	106, 403, 801, AA, C		
152:24–153:6	402, 403, 701, CQ, SP, AM, FRCP 30(b)(6), F, AA, 602	125:22–126:4	106, 801	125:8–12; 125:15–20; 126:5–8	OS, 106, 402, 403, SP
		153:17–19	106, 402, 403, 801, AA, NR, OS	125:8–12; 125:15–20; 125:22–126:8	
		153:22–154:3	106, 402, 403, 801, AA, NR, OS		
		156:11–15	106, 403, 801, AA, C		
		156:19–21	106, 403, 801, AA, C		
153:10–12	402, 403, 701, CQ, SP, AM, FRCP 30(b)(6), F, AA, 602	125:22–126:4	106, 801	125:8–12; 125:15–20; 126:5–8	OS, 106, 402, 403, SP
		153:17–19	106, 402, 403, 801, AA, NR, OS	125:8–12; 125:15–20; 125:22–126:8	
		153:22–154:3	106, 402, 403, 801, AA, NR, OS		

Jerald M. Andry November 8, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ¹ Designations	Defendants' Objections to Rebuttal Designations
		156:11–15	106, 403, 801, AA, C		
		156:19–21	106, 403, 801, AA, C		
155:3–6	402, 403, CQ, SP, FRCP 30(b)(6), F, 602				
155:9–11	402, 403, CQ, SP, AM, FRCP 30(b)(6), F, AA, 602				
155:15–18	402, 403, CQ, SP, AM, FRCP 30(b)(6), F, AA, 602				
158:23–159:5	402, 403, 701, SP, AM, FRCP 30(b)(6), F	161:20–22	106, 402, 403, 801, AA, AM, FRCP 30(b)(6), OS	163:11–15; 163:19–23	OS, 106, 402, 403, SP, AF, F, FRCP 30(b)(6)
		162:2–8	106, 402, 403, 801, AA, AM, FRCP 30(b)(6), OS		
		163:1–4	106, 402, 403, 801, AA, AM, FRCP 30(b)(6), CQ, OS		
		163:7–9	106, 402, 403, 801, AA, AM, CQ, FRCP 30(b)(6), OS		
159:8	402, 403, 701, SP, AM, FRCP 30(b)(6), F, 602	161:20–22	106, 402, 403, 801, AA, AM, FRCP 30(b)(6), OS	163:11–15; 163:19–23	OS, 106, 402, 403, SP, AF, F, FRCP 30(b)(6)
		162:2–8	106, 402, 403, 801, AA, AM, FRCP 30(b)(6), OS		
		163:1–4	106, 402, 403, 801, AA, AM, FRCP 30(b)(6), CQ, OS		

Jerald M. Andry November 8, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ¹ Designations	Defendants' Objections to Rebuttal Designations
		163:7–9	106, 801, 402, 403, AA, AM, CQ, FRCP 30(b)(6), OS		
159:11–19	402, 403, 701, CQ, SP, AM, FRCP 30(b)(6), F, 602	161:20–22	106, 402, 403, 801, AA, AM, FRCP 30(b)(6), OS	163:11–15; 163:19–23	OS, 106, 402, 403, SP, AF, F, FRCP 30(b)(6)
		162:2–8	106, 402, 403, 801, AA, AM, FRCP 30(b)(6), OS		
		163:1–4	106, 402, 403, 801, AA, AM, FRCP 30(b)(6), CQ, OS		
		163:7–9	106, 402, 403, 801, AA, AM, CQ, FRCP 30(b)(6), OS		
159:21–160:1	402, 403, 701, SP, AM, FRCP 30(b)(6), F, 602	161:20–22	106, 402, 403, 801, AA, AM, FRCP 30(b)(6)	163:11–15; 163:19–23	OS, 106, 402, 403, SP, AF, F, FRCP 30(b)(6)
		162:2–8	106, 402, 403, 801, AA, AM, FRCP 30(b)(6)		
		163:1–4	106, 402, 403, 801, AA, AM, FRCP 30(b)(6), CQ		
		163:7–9	106, 402, 403, 801, AA, AM, CQ, FRCP 30(b)(6)		
160:5–6	402, 403, 701, SP, AM, FRCP 30(b)(6), F, 602	161:20–22	106, 402, 403, 801, AA, AM, FRCP 30(b)(6)	163:11–15; 163:19–23	OS, 106, 402, 403, SP, AF, F, FRCP 30(b)(6)
		162:2–8	106, 402, 403, 801, AA, AM, FRCP 30(b)(6)		

Jerald M. Andry November 8, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ¹ Designations	Defendants' Objections to Rebuttal Designations
		163:1–4	106, 402, 403, 801, AA, AM, FRCP 30(b)(6), CQ		
		163:7–9	106, 402, 403, 801, AA, AM, CQ, FRCP 30(b)(6), OS		
161:11–13	402, 403, 701, SP, AM, FRCP 30(b)(6), F, 602, MC, AA	161:20–22	106, 402, 403, 801, AA, AM, FRCP 30(b)(6), OS	163:11–15; 163:19–23	OS, 106, 402, 403, SP, AF, F, FRCP 30(b)(6)
		162:2–8	106, 402, 403, 801, AA, AM, FRCP 30(b)(6), OS		
		163:1–4	106, 402, 403, 801, AA, AM, FRCP 30(b)(6), CQ, OS		
		163:7–9	106, 402, 403, 801, AA, AM, CQ, FRCP 30(b)(6), OS		
161:17–18	402, 403, 701, SP, AM, FRCP 30(b)(6), F, 602, MC, AA	161:20–22	106, 402, 403, 801, AA, AM, FRCP 30(b)(6), OS	163:11–15; 163:19–23	OS, 106, 402, 403, SP, AF, F, FRCP 30(b)(6)
		162:2–8	106, 402, 403, 801, AA, AM, FRCP 30(b)(6), OS		
		163:1–4	106, 402, 403, 801, AA, AM, FRCP 30(b)(6), CQ, OS		
		163:7–9	106, 402, 403, 801, AA, AM, CQ, FRCP 30(b)(6), OS		

Jerald M. Andry November 8, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ¹ Designations	Defendants' Objections to Rebuttal Designations
165:1–9	402, 403, SP, AM, FRCP 30(b)(6), F, 602, AA	206:18–207:8	106, 402, 403, 801, C, L, OS	138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17	OS, 106, 402, 403, AM, F, MC
165:13–166:8	402, 403, 701, SP, AM, FRCP 30(b)(6), F, 602, AA	206:18–207:8	106, 402, 403, 801, C, L, OS	138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17	OS, 106, 402, 403, AM, F, MC
170:17–171:5	402, 403, 701, SP, AM, FRCP 30(b)(6), F, 602, AA	206:18–207:8	106, 402, 403, 801, C, L	138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17	OS, 106, 402, 403, AM, F, MC
171:8–12	402, 403, 701, SP, AM, FRCP 30(b)(6), F, 602, AA	206:18–207:8	106, 402, 403, 801, C, L	138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17	OS, 106, 402, 403, AM, F, MC
171:15–172:5	402, 403, 701, SP, AM, FRCP 30(b)(6), F, 602, AA	206:18–207:8	106, 402, 403, 801, C, L	138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17	OS, 106, 402, 403, AM, F, MC
172:9–21	402, 403, 701, SP, AM, FRCP 30(b)(6), F, 602, MC	137:18–21	106, 402, 403, 801, C, NR, OS	129:19–22; 130:1–15; 138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17	OS, 106, 402, 403, AM, F, MC
		137:24–138:5	106, 402, 403, 801, C, NR, OS		
		206:18–207:8	106, 402, 403, 801, C, L		
		174:19–23	106, AM, C, NR, SP		
		175:3–12	106, AM, C, NR, SP		
172:24–173:6	402, 403, 701, SP, AM, FRCP 30(b)(6), F, 602	137:18–21	106, 402, 403, 801, C, NR, OS	129:19–22; 130:1–15; 138:15–17; 138:19–21; 138:23–24; 139:1–13;	OS, 106, 402, 403, AM, F, MC, SP, FRCP 30(b)(6)
		137:24–138:5	106, 402, 403, 801, C, NR, OS		
		206:18–207:8	106, 402, 403, 801, C, L		

Jerald M. Andry November 8, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ¹ Designations	Defendants' Objections to Rebuttal Designations
		174:19–23	106, 402, 403, 801, AM, C, NR, SP	139:16–17; 143:3–4; 143:7–14	
		175:3–12	106, 402, 403, 801, AM, C, NR, SP		
178:5–6	402, 403, SP, AM, FRCP 30(b)(6), F, 602	174:19–23	106, 402, 403, 801, AM, C, NR, OS, SP	138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17; 143:3–4; 143:7–14	OS, 106, 402, 403, AM, F, MC, SP, FRCP 30(b)(6)
		175:3–12	106, 402, 403, 801, AM, C, NR, OS, SP		
		206:18–207:8	106, 402, 403, 801, C, L, OS		
178:8	402, 403, SP, AM, FRCP 30(b)(6), F, 602	174:19–23	106, 402, 403, 801, AM, C, NR, OS, SP	138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17; 143:3–4; 143:7–14	OS, 106, 402, 403, AM, F, MC, SP, FRCP 30(b)(6)
		175:3–12	106, 402, 403, 801, AM, C, NR, OS, SP		
		206:18–207:8	106, 402, 403, 801, C, L, OS		
178:10–12	402, 403, SP, AM, FRCP 30(b)(6), F, 602	174:19–23	106, 402, 403, 801, AM, C, NR, OS, SP	138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17; 143:3–4; 143:7–14	OS, 106, 402, 403, AM, F, MC, SP, FRCP 30(b)(6)
		175:3–12	106, 402, 403, 801, AM, C, NR, OS, SP		
		206:18–207:8	106, 402, 403, 801, C, L, OS		
178:15	402, 403, SP, AM, FRCP 30(b)(6), F, 602	174:19–23	106, 402, 403, 801, AM, C, NR, OS, SP	138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17; 143:3–4; 143:7–14	OS, 106, 402, 403, AM, F, MC, SP, FRCP 30(b)(6)
		175:3–12	106, 402, 403, 801, AM, C, NR, OS, SP		
		206:18–207:8	106, 402, 403, 801, C, L, OS		
178:17–19	402, 403, SP, AM, FRCP	174:19–23	106, 402, 403, 801, AM, C, NR, OS, SP	138:15–17; 138:19–21; 138:23–24;	OS, 106, 402, 403, AM, F,

Jerald M. Andry November 8, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ¹ Designations	Defendants' Objections to Rebuttal Designations
	30(b)(6), F, 602, AA	175:3–12	106, 402, 403, 801, AM, C, NR, OS, SP	139:1–13; 139:16–17; 143:3–4; 143:7–14	MC, SP, FRCP 30(b)(6)
		206:18–207:8	106, 402, 403, 801, C, L, OS		
178:21	402, 403, SP, AM, FRCP 30(b)(6), F, 602	174:19–23	106, 402, 403, 801, AM, C, NR, OS, SP	138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17; 143:3–4; 143:7–14	OS, 106, 402, 403, AM, F, MC, SP, FRCP 30(b)(6)
		175:3–12	106, 402, 403, 801, AM, C, NR, OS, SP		
		206:18–207:8	106, 402, 403, 801, C, L, OS		
178:23–179:5	402, 403, SP, AM, FRCP 30(b)(6), F, 602, AA	174:19–23	106, 402, 403, 801, AM, C, NR, OS, SP	138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17; 143:3–4; 143:7–14	OS, 106, 402, 403, AM, F, MC, SP, FRCP 30(b)(6)
		175:3–12	106, 402, 403, 801, AM, C, NR, OS, SP		
		206:18–207:8	106, 402, 403, 801, C, L, OS		
179:7	402, 403, SP, AM, FRCP 30(b)(6), F, 602	174:19–23	106, 402, 403, 801, AM, C, NR, OS, SP	138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17; 143:3–4; 143:7–14	OS, 106, 402, 403, AM, F, MC, SP, FRCP 30(b)(6)
		175:3–12	106, 402, 403, 801, AM, C, NR, OS, SP		
		206:18–207:8	106, 402, 403, 801, C, L, OS		
179:9–12	402, 403, SP, AM, FRCP 30(b)(6), F, 602, AA	174:19–23	106, 402, 403, 801, AM, C, NR, OS, SP	138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17; 143:3–4; 143:7–14	OS, 106, 402, 403, AM, F, MC, SP, FRCP 30(b)(6)
		175:3–12	106, 402, 403, 801, AM, C, NR, OS, SP		
		206:18–207:8	106, 402, 403, 801, C, L, OS		
179:16–18	402, 403, SP, AM, FRCP 30(b)(6), F, 602, AA	174:19–23	106, 402, 403, 801, AM, C, NR, OS, SP	138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17; 143:3–4;	OS, 106, 402, 403, AM, F, MC, SP, FRCP 30(b)(6)
		175:3–12	106, 402, 403, 801, AM, C, NR, OS, SP		

Jerald M. Andry November 8, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ¹ Designations	Defendants' Objections to Rebuttal Designations
		206:18–207:8	106, 402, 403, 801, C, L, OS	143:7–14	
199:7–14	402, 403, SP, AM, FRCP 30(b)(6), F, 602, AA	174:19–23	106, 402, 403, 801, AM, C, NR, OS, SP	138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17; 143:3–4; 143:7–14	OS, 106, 402, 403, AM, F, MC, SP, FRCP 30(b)(6)
		175:3–12	106, 402, 403, 801, AM, C, NR, OS, SP		
		206:18–207:8	106, 402, 403, 801, C, L, OS		
199:17–21	402, 403, SP, AM, FRCP 30(b)(6), F, 602, AA	174:19–23	106, 402, 403, 801, AM, C, NR, OS, SP	138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17; 143:3–4; 143:7–14	OS, 106, 402, 403, AM, F, MC, SP, FRCP 30(b)(6)
		175:3–12	106, 402, 403, 801, AM, C, NR, OS, SP		
		206:18–207:8	106, 402, 403, 801, C, L, OS		
199:23–201:17	402, 403, SP, AM, FRCP 30(b)(6), F, 602, AA	174:19–23	106, 402, 403, 801, AM, C, NR, OS, SP	138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17; 143:3–4; 143:7–14	OS, 106, 402, 403, AM, F, MC, SP, FRCP 30(b)(6)
		175:3–12	106, 402, 403, 801, AM, C, NR, OS, SP		
		206:18–207:8	106, 402, 403, 801, C, L, OS		
201:20	402, 403, SP, AM, FRCP 30(b)(6), F, 602, AA	174:19–23	106, 402, 403, 801, AM, C, NR, OS, SP	138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17; 143:3–4; 143:7–14	OS, 106, 402, 403, AM, F, MC, SP, FRCP 30(b)(6)
		175:3–12	106, 402, 403, 801, AM, C, NR, OS, SP		
		206:18–207:8	106, 402, 403, 801, C, L, OS		
201:22–202:10	402, 403, SP, AM, FRCP 30(b)(6), F, 602, AA	174:19–23	106, 402, 403, 801, AM, C, NR, OS, SP	138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17; 143:3–4; 143:7–14	OS, 106, 402, 403, AM, F, MC, SP, FRCP 30(b)(6)
		175:3–12	106, 402, 403, 801, AM, C, NR, OS, SP		
		206:18–207:8	106, 402, 403, 801, C, L, OS		

Jerald M. Andry November 8, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ¹ Designations	Defendants' Objections to Rebuttal Designations
202:12	402, 403, SP, AM, FRCP 30(b)(6), F, 602, AA	174:19–23	106, 402, 403, 801, AM, C, NR, OS, SP	138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17; 143:3–4; 143:7–14	OS, 106, 402, 403, AM, F, MC, SP, FRCP 30(b)(6)
		175:3–12	106, 402, 403, 801, AM, C, NR, OS, SP		
		206:18–207:8	106, 402, 403, 801, C, L, OS		
203:3–4	402, 403, SP, AM, FRCP 30(b)(6), F, 602, AA	174:19–23	106, 402, 403, 801, AM, C, NR, OS, SP	138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17; 143:3–4; 143:7–14	OS, 106, 402, 403, AM, F, MC, SP, FRCP 30(b)(6)
		175:3–12	106, 402, 403, 801, AM, C, NR, OS, SP		
		206:18–207:8	106, 402, 403, 801, C, L, OS		
203:6–7	402, 403, SP, AM, FRCP 30(b)(6), F, 602, AA	174:19–23	106, 402, 403, 801, AM, C, NR, OS, SP	138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17; 143:3–4; 143:7–14	OS, 106, 402, 403, AM, F, MC, SP, FRCP 30(b)(6)
		175:3–12	106, 402, 403, 801, AM, C, NR, OS, SP		
		206:18–207:8	106, 402, 403, 801, C, L, OS		
203:9–16	402, 403, SP, AM, FRCP 30(b)(6), F, 602, AA	174:19–23	106, 402, 403, 801, AM, C, NR, OS, SP	138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17; 143:3–4; 143:7–14	OS, 106, 402, 403, AM, F, MC, SP, FRCP 30(b)(6)
		175:3–12	106, 402, 403, 801, AM, C, NR, OS, SP		
		206:18–207:8	106, 402, 403, 801, C, L, OS		
203:18	402, 403, SP, AM, FRCP 30(b)(6), F, 602, AA	174:19–23	106, 402, 403, 801, AM, C, NR, OS, SP	138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17; 143:3–4; 143:7–14	OS, 106, 402, 403, AM, F, MC, SP, FRCP 30(b)(6)
		175:3–12	106, 402, 403, 801, AM, C, NR, OS, SP		
		206:18–207:8	106, 402, 403, 801, C, L, OS		
203:20–22	402, 403, SP, AM, FRCP	174:19–23	106, 402, 403, 801, AM, C, NR, OS, SP	138:15–17; 138:19–21; 138:23–24;	OS, 106, 402, 403, AM, F,

Jerald M. Andry November 8, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ¹ Designations	Defendants' Objections to Rebuttal Designations
	30(b)(6), F, 602, AA	175:3–12	106, 402, 403, 801, AM, C, NR, OS, SP	139:1–13; 139:16–17; 143:3–4; 143:7–14	MC, SP, FRCP 30(b)(6)
		206:18–207:8	106, 402, 403, 801, C, L, OS		
204:1	402, 403, 701, SP, AM, FRCP 30(b)(6), F, 602, AA	174:19–23	106, 402, 403, 801, AM, C, NR, OS, SP	138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17; 143:3–4; 143:7–14	OS, 106, 402, 403, AM, F, MC, SP, FRCP 30(b)(6)
		175:3–12	106, 402, 403, 801, AM, C, NR, OS, SP		
		206:18–207:8	106, 402, 403, 801, C, L, OS		
204:3–5	402, 403, 701, SP, AM, FRCP 30(b)(6), F, 602, AA	174:19–23	106, 402, 403, 801, AM, C, NR, OS, SP	138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17; 143:3–4; 143:7–14	OS, 106, 402, 403, AM, F, MC, SP, FRCP 30(b)(6)
		175:3–12	106, 402, 403, 801, AM, C, NR, OS, SP		
		206:18–207:8	106, 402, 403, 801, C, L, OS		
204:8–25	402, 403, 701, SP, AM, FRCP 30(b)(6), F, 602, AA	174:19–23	106, 402, 403, 801, AM, C, NR, OS, SP	138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17; 143:3–4; 143:7–14	OS, 106, 402, 403, AM, F, MC, SP, FRCP 30(b)(6)
		175:3–12	106, 402, 403, 801, AM, C, NR, OS, SP		
		206:18–207:8	106, 402, 403, 801, C, L, OS		
205:3–14	402, 403, 701, SP, AM, FRCP 30(b)(6), F, 602, AA	174:19–23	106, 402, 403, 801, AM, C, NR, OS, SP	138:15–17; 138:19–21; 138:23–24; 139:1–13; 139:16–17; 143:3–4; 143:7–14	OS, 106, 402, 403, AM, F, MC, SP, FRCP 30(b)(6)
		175:3–12	106, 402, 403, 801, AM, C, NR, OS, SP		
		206:18–207:8	106, 402, 403, 801, C, L, OS		

Jaya Lakshmi Ayyagari October 25, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter- Designations	Plaintiffs' Objections to Counter- Designations	Plaintiffs' Rebuttal ² Designations	Defendants' Objections to Rebuttal Designations
5:1–6					
5:9–21					
11:17–24					
13:11–14:12					
14:22–16:9					
26:20–27:7	106	27:8–12, 27:17–23	801		
27:25–29:1					
31:16–32:10					
32:13–33:12					
44:18–46:1					
50:21–52:18	106	49:21–50:20, 71:19–23	801		
68:23–70:14					
82:14–83:8	701				
83:18–84:22	402, 403, 701				
85:21–86:17	106, 402, 403, MC	84:23–85:17	801		
86:19–89:7	402, 403, 701				
89:10–25	402, 403, AM				
90:3–93:2	402, 403				
93:10–94:18	402, 403, 801, SP				
94:22–96:1					
96:4–19	402, 403, 801				
98:22–99:9					
99:17–100:12					
102:4–16	403, MC				
102:19–20					
102:22–24	403, AM				
103:1–8	403, AM				
103:10–13					
109:9–19	FRCP 30(b)(6)				
113:12–114:17	106, 403	114:18–115:6	402, 403, 801, OS		
115:7–18					
116:9–13					

² In addition to the designations identified in the “Rebuttal Designations” column, Plaintiffs reserve the right to also rely on any of Plaintiffs’ original deposition designations or Defendants’ counter-designations in rebuttal to Defendants’ counter-designations.

Jaya Lakshmi Ayyagari October 25, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ² Designations	Defendants' Objections to Rebuttal Designations
116:21–118:2	402, 403, 602, FRCP 30(b)(6)				
119:11–24	402, 403, FRCP 30(b)(6)				
121:20–122:7	402, 403, 602, FRCP 30(b)(6)	122:8–10	801		
125:10–17	402, 403, 602, FRCP 30(b)(6)	126:13–14	801		
126:8–12	402, 403, 602, FRCP 30(b)(6)	126:13–14	801		
128:13–23	402, 403, 602, FRCP 30(b)(6)				
130:2–12	402, 403, 602, 701, AM, FRCP 30(b)(6)				
130:15–131:8	402, 403, 602, FRCP 30(b)(6)				
135:12–17	402, 403, 602, FRCP 30(b)(6)				
135:22–136:5	402, 403, 602, FRCP 30(b)(6)				
139:22–140:14	402, 403, 602, FRCP 30(b)(6)	144:7–15	801		
142:1–14	402, 403, 602, FRCP 30(b)(6)	144:7–15	801		
145:4–11	402, 403, 602, FRCP 30(b)(6)	144:7–15	801		
145:17–146:1	402, 403, 602, FRCP 30(b)(6)	144:7–15	801		
149:17–19					
150:9–13					
151:21–152:1	403, 701				
152:6–8	403, 701				
153:13–21	106, AA	152:13–16, 152:19–23	106, 801	151:1; 151:11–19; 152:25–153:6	403, 602, 701, FRCP 30(b)(6)
153:25–154:4	106, AA	152:13–16, 152:19–23	106, 801	151:1; 151:11–19; 152:25–153:6	403, 602, 701, FRCP 30(b)(6)
157:1–12					
158:10–160:16	AM, CQ				
160:18–161:25					
162:6–7					

Jaya Lakshmi Ayyagari October 25, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ² Designations	Defendants' Objections to Rebuttal Designations
162:24–163:10					
163:14–23					
167:10–168:14					
168:20–171:9					
172:1–173:17					
173:21–177:23	AM, FRCP (30(b)(6))				
178:1–179:21					
180:1–188:4					
188:19–190:5					
190:24–191:8	402, 403, 602, F, FRCP 30(b)(6), SP				
191:10–11					
191:13–18	402, 403, 602, AA, F, FRCP 30(b)(6), SP				
191:23–192:11	402, 403, F, FRCP 30(b)(6)				
201:14–17	402, 403, AA, F, FRCP 30(b)(6)				
201:22–202:5					
203:19–24	402, 403, AA, F, FRCP 30(b)(6)				
204:12–23	AM				
204:25–207:3					
207:24–209:24					
210:2–8					
210:13–23	402, 403, AA				
210:25–211:2					
214:23–24	402, 403, AA, FRCP 30(b)(6)				
215:1–4					
215:9–12	402, 403, AA, FRCP 30(b)(6)				
215:15–19					
215:21–24	402, 403, F, FRCP (30)(b)(6)				
216:3–20					
217:12–218:11	AM				
218:14–219:4	402, 403, 701, AM, F				
219:6–7					

Jaya Lakshmi Ayyagari October 25, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter- Designations	Plaintiffs' Objections to Counter- Designations	Plaintiffs' Rebuttal ² Designations	Defendants' Objections to Rebuttal Designations
220:8–13	AA				
220:22–24	AA				
221:1–2					
221:4–13					
221:15–23	AA				
221:25–222:1					
222:8–10	AA				
222:12–224:3	402, 403, 602, AA, F, FRCP 30(b)(6)				

Andrea Cady October 26, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ³ Designations	Defendants' Objections to Rebuttal Designations
8:18–23					
9:5–16					
12:16–32:19	402, 403				
34:1–16					
37:3–38:7					
41:12–42:5					
42:16–43:25	402, 403, AM				
44:2–9	402, 403, AA, FRCP 30(b)(6)				
45:14–46:25	402, 403, FRCP 30(b)(6)				
48:12–14	402, 403, AM, FRCP 30(b)(6)	53:7–11	106, 402, 403, 602, 801, AM, C, F, OS, SP	47:14–48:11	OS, 106, 402, 403
		53:16–54:6			
48:16–49:12	402, 403, AM, FRCP 30(b)(6)	53:7–11	106, 402, 403, 602, 801, AM, C, F, OS, SP	47:14–48:11	OS, 106, 402, 403
		53:16–54:6			
49:22–50:2	402, 403, AM, F, FRCP 30(b)(6)	53:7–11	106, 402, 403, 602, 801, AM, C, F, OS, SP	47:14–48:11	OS, 106, 402, 403
		53:16–54:6			
50:4–53:1	402, 403, AM, F, 602, FRCP 30(b)(6)	53:7–11	106, 402, 403, 602, 801, AM, C, F, OS, SP	47:14–48:11	OS, 106, 402, 403
		53:16–54:6			
54:21–55:21	402, 403				
57:7–24	402, 403				
66:7–18	402, 403, F, SP	67:5–6	402, 403, 801, AM, F, OS		
		67:8–17			
66:20–67:4	402, 403, F, SP	67:5–6	402, 403, 801, AM, F, OS		
		67:8–17			
67:23–68:2	402, 403	68:3–4	402, 403, 801, AM, F, OS		
		68:6–13			
68:15–69:19	402, 403	68:3–4	402, 403, 801, AM, F, OS		
		68:6–13			
70:13–71:7	402, 403, F, SP, AF, AA				
71:9–72:5	402, 403, 701, F, SP, AF, AA, FRCP 30(b)(6)				

³ In addition to the designations identified in the “Rebuttal Designations” column, Plaintiffs reserve the right to also rely on any of Plaintiffs’ original deposition designations or Defendants’ counter-designations in rebuttal to Defendants’ counter-designations.

Andrea Cady October 26, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ³ Designations	Defendants' Objections to Rebuttal Designations
72:10–18	402, 403, 701, F, SP, AF, AA, FRCP 30(b)(6)				
72:20–24	402, 403, 701, F, SP, AF, AA				
73:1	402, 403, 701, F, SP, AF, AA				
73:3–16	402, 403, F, SP, AF, AA				
73:19–74:9	402, 403, F, SP, AF, AA				
74:12–22	402, 403, F, SP, AF, AA				
74:24–75:7	402, 403, 701, F, SP, AF, AA				
75:10	402, 403, 701, F, SP, AF, AA				
75:14–77:1	402, 403, F	77:2	801		
		77:4–8			
78:4–15	402, 403, 701, F, SP, AF	79:1–2	106, 402, 403, 801, NR, OS	57:25–59:4; 77:10–24; 78:1–2; 79:13–15; 79:17–19; 79:21–81:11	OS, 106, 402, 403, 701, 801, AM, F
		79:4–12			
78:18–24	402, 403, 701, F, SP, AF	79:1–2	106, 402, 403, 801, NR, OS	57:25–59:4; 77:10–24; 78:1–2; 79:13–15; 79:17–19; 79:21–81:11	OS, 106, 402, 403, 701, 801, AM, F
		79:4–12			
81:12–21	402, 403, 701, F, SP, AF, FRCP 30(b)(6)	83:8–10	106, 402, 403, 602, 701, AM, F, SP	77:10–19; 79:21–81:11	OS, 106, 402, 403, 701, 801, AM, F
		83:13–16			
81:24–82:19	402, 403, 701, F, SP, AF, FRCP 30(b)(6)	83:8–10	106, 402, 403, 602, 701, AM, F, SP	77:10–19; 79:21–81:11	OS, 106, 402, 403, 701, 801, AM, F
		83:13–16			
82:22–83:7	402, 403, 701, F, SP, AF, FRCP 30(b)(6)	83:8–10	106, 402, 403, 602, 701, AM, F, SP	77:10–19; 79:21–81:11	OS, 106, 402, 403, 701, 801, AM, F
		83:13–16			
85:15–23	402, 403, F, AF				
85:25–86:1	402, 403, F, AF				
87:19–88:9	106, 402, 403	88:10–11	801		

Andrea Cady October 26, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ³ Designations	Defendants' Objections to Rebuttal Designations
89:21–91:4	106, 402, 403	93:2–9	801	92:20–93:1	OS, 106, 402, 403
91:8–92:10	106, 402, 403	93:2–9	801	92:20–93:1	OS, 106, 402, 403
93:10–24	402, 403				
96:3–98:24	402, 403, F, AF, S, CQ, AM				
99:1–3	402, 403, F, AF, S, CQ, AM				
99:5–100:4	402, 403, F				
100:20–101:2	402, 403, 701				
101:11–13	402, 403, F, AF, 701, AM				
101:16–102:7	402, 403, F, AF, 701, AM, CQ				
102:9–17	402, 403, F, AF, 701, AM, CQ				
103:15–18	402, 403				
103:23–104:19	402, 403, 701, F, AM, SP				
104:21–107:5	402, 403, F, AM, SP, 701				
107:9–13	402, 403, 701, F, AM, SP, CQ				
107:18–108:1	402, 403, AA, AM, 701				
108:3–12	402, 403, AA, AM, 701, CQ				
108:14–111:11	402, 403, AA, AM, 701, CQ, SP				
111:13–113:7	402, 403, AA, AM, 701, CQ, SP				
113:9–114:5	402, 403, AA, AM, 701, CQ, SP				
115:21–116:4	402, 403, 701				
117:2–6	402, 403, 701, AA, AM, CQ, IQ	118:2–6	402, 403, 801, AM, CQ, IQ, OS		

Andrea Cady October 26, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ³ Designations	Defendants' Objections to Rebuttal Designations
117:8–14	402, 403, 701, AA, AM	118:2–6	402, 403, 801, AM, CQ, IQ, OS		
119:1–8	402, 403, AA, AM, CQ, MC	121:4–16	106, 402, 403, 801, AM, CQ, OS	118:21–25	
		121:19–122:4			
119:10–18	402, 403, AA, AM, CQ, MC	121:4–16	402, 403, 801, AM, CQ, OS, SP		
		121:19–122:4			
119:20–120:4	402, 403, 701, AA, AM, CQ, MC	121:4–16	402, 403, 801, AM, CQ, OS, SP		
		121:19–122:4			
120:6–9	402, 403, 701, AA, AM, CQ, MC, SP	121:4–16	402, 403, 801, AM, CQ, OS, SP		
		121:19–122:4			
120:12–14	402, 403, 701, AA, AM, CQ, MC, SP	121:4–16	402, 403, 801, AM, CQ, OS, SP		
		121:19–122:4			
123:6–9	402, 403, 701, AM, CQ, MC, SP	121:4–16	402, 403, 801, C, CQ, SP		
		121:19–122:4			
123:12–124:11	402, 403, 701, AA, AM, CQ, SP	121:4–16	402, 403, 801, C, CQ, SP		
		121:19–122:4			
124:14–125:10	402, 403, 701, AA, AM, CQ, MC, SP	121:4–16	402, 403, 801, C, CQ, SP		
		121:19–122:4			
125:13–15	402, 403, 701, AA, AM, CQ, MC, SP	121:4–16	402, 403, 801, C, CQ, SP		
		121:19–122:4			
126:8–11	402, 403, AM, CQ	129:6–7	402, 403, 801, AM, CQ, OS, SP		
		129:9–14			
126:13–127:5	402, 403, 701, AA, AM, CQ, MC, SP	129:6–7	402, 403, 801, AM, CQ, OS, SP		
		129:9–14			
127:8–128:7	402, 403, 701, AA, AM, CQ, MC, SP	129:6–7	402, 403, 801, AM, CQ, OS, SP		
		129:9–14			
128:11–13		129:6–7			

Andrea Cady October 26, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ³ Designations	Defendants' Objections to Rebuttal Designations
	402, 403, 701, AA, AM, CQ, MC, SP	129:9–14	402, 403, 801, AM, CQ, OS, SP		
133:21–135:1	402, 403, AM				
135:3–8	402, 403, AM				
135:10–136:8	402, 403, AM, SP, CQ				
136:10–12	402, 403, AM, SP, CQ				
136:15–137:22	402, 403, AM, SP, CQ, MC, AA				
137:24–138:13	402, 403, AM, SP, CQ, MC, AA				
138:15–24	402, 403, AM, SP, CQ, MC, AA				
139:22–24	402, 403, AM				
140:1–10	402, 403, AM, CQ, MC				
140:12–141:1	402, 403, AM, CQ, AA, MC				
141:3–13	402, 403, AM, CQ, AA, MC				
141:16–22	402, 403, AM, CQ, AA, MC				
141:25–142:16	402, 403, AM, CQ, AA, MC				
142:19–143:1	402, 403, AM, AA, MC				
143:3–13	402, 403, AM, AA, MC				
144:3–146:7	402, 403, AM, CQ, SP				
146:9–147:14	402, 403, AM, CQ, SP, MC, AA				
147:16–22	402, 403, AM, CQ, SP, MC,				
147:24–148:12	402, 403, AM, CQ, SP, MC, AA				

Andrea Cady October 26, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ³ Designations	Defendants' Objections to Rebuttal Designations
148:15–149:9	402, 403, 701, AM, CQ, SP, MC, AA				
149:12–17	402, 403, 701, AM	149:19–25	106, 402, 801	150:1–12	OS, 106, 402, 403, 601, 701, SP, AM
150:13–15	402, 403, AM, CQ, SP, MC, 701				
150:17–151:6	402, 403, AM, CQ, 701, SP				
151:22–152:11	402, 403				
152:14–23	402, 403				
153:16–154:6	402, 403				
155:2–156:9	402, 403, SP, AM, MC, F				
156:11–23	402, 403, SP, AM, MC, F				
156:25–157:9	402, 403, SP, AM, MC, F				
158:6–20	402, 403				
159:2–160:25	402, 403				
161:15–162:5	402, 403, SP, F, AM, FRCP 30(b)(6)	162:12–13	801		
		162:15–23			
162:7–10	402, 403, SP, F, AM, FRCP 30(b)(6)	162:12–13	801		
		162:15–23			
164:2–22	106, 402, 403	165:1–3	106, 801, OS	164:23–25; 165:14–19	106, 402, 403
		165:5–12			
167:2–15	402, 403				
168:1–6	402, 403, F, AM, AF, MC, CQ				
168:8–21	402, 403, F, AM, AF, MC, CQ				
169:1–12	402, 403, 801	170:12–15	106, 801, OS	169:13–170:11; 170:16–171:19	106, 402, 403, SP, 601, 701
171:24–172:21	106, 402, 403	172:22–173:16	106, 402, 801	175:4–7	
174:10–24	106, 402, 403	174:25–175:3	106, 801	175:4–7	
176:20–177:7	402, 403				
180:2–12	402, 403				

Andrea Cady October 26, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter- Designations	Plaintiffs' Objections to Counter- Designations	Plaintiffs' Rebuttal ³ Designations	Defendants' Objections to Rebuttal Designations
181:18–182:9	402, 403, 801	182:10–25	402, 801, OS		
183:5–19	402, 403				
184:5–16	402, 403, F, AM AF, MC				
184:18–185:3	402, 403, F, AM AF				
186:20–21	402, 403, AM, AA				
186:23	402, 403, AM, AA				
187:3–7	402, 403, FRCP 30(b)(6)				
191:5–22	402, 403				
193:23–194:11	106, 402, 403	194:12–24	402, 801, OS		
197:20–198:11	402, 403				
198:13–199:7	402, 403, 701, F, AM, SP, CQ				
199:9–21	402, 403, 701, F, AM, SP, CQ, FRCP 30(b)(6)				
199:23–200:15	402, 403, 701, F, AM, SP, CQ, FRCP 30(b)(6)				
200:17–22	402, 403, 701, F, AM, SP, CQ, FRCP 30(b)(6)				
201:4–10	402, 403, 801				
201:13–202:19	402, 403, 801, 602, FRCP 30(b)(6)				
202:21–24	402, 403, F, 801, SP, AM, 602, FRCP 30(b)(6)				
203:1–8	402, 403, F, 801, SP, AM, 602, CQ				
203:10–16	402, 403, F, 801, SP, AM, 602, CQ				

Andrea Cady October 26, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter- Designations	Plaintiffs' Objections to Counter- Designations	Plaintiffs' Rebuttal ³ Designations	Defendants' Objections to Rebuttal Designations
203:18–204:20	402, 403, F, 801, SP, AM, 602, CQ, FRCP 30(b)(6)				
209:22–211:1	402, 403, FRCP 30(b)(6)				
211:7–212:4	402, 403, AM, CQ				
212:6–20	402, 403, AM, CQ, SP				
212:22–213:11	402, 403, AM, CQ, SP, FRCP 30(b)(6)				

Mehar Manku November 7, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal⁴ Designations	Defendants' Objections to Rebuttal Designations
8:1–5					
8:9–13					
8:22–23					
8:25–9:3					
9:5–6					
9:12–17					
10:5–6					
10:8–13					
10:15–12:11					
14:19–15:24	106, 402, 403	16:8–10 16:12–13	106, 402, 403, AM	15:21–24; 16:1–6	106, 402, 403
16:1–6	106, 402, 403	16:8–10 16:12–13	106, 402, 403, AM	29:14–16; 29:18–20	OS, 106, 402, 403, AM, SP
17:7–14	106	21:5–23 23:18–24:1 29:3–6 29:8	106, 402, 403, AM, C	29:14–16; 29:18–20	OS, 106, 402, 403, AM, SP
17:18–18:7	106, 402, 403	21:5–23 23:18–24:1 29:3–6 29:8	106, 402, 403, AM, C	29:14–16; 29:18–20	OS, 106, 402, 403, AM, SP
18:9–19:6	106, 402, 403	21:5–23 23:18–24:1 29:3–6 29:8	106, 402, 403, AM, C	29:14–16; 29:18–20	OS, 106, 402, 403, AM, SP
24:22–27:7	106, 402, 403	27:8–28:3 29:3–6 29:8	106, 402, 403, AM	28:10–16	OS, 106, 402, 403, AM, SP
28:10–16	106, 402, 403	29:3–6 29:8	106, 402, 403, AM	29:14–16; 29:18–20	OS, 106, 402, 403, AM, SP
29:14–20	106, ID	29:3–6 29:8	106, 402, 403, AM, SP	29:14–16; 29:18–20	OS, 106, 402, 403, AM, SP
29:22–30:3	106, ID	29:3–6 29:8	106, 402, 403, AM	29:14–16; 29:18–20	OS, 106, 402, 403, AM, SP
30:5–31:4	106, 402, 403	29:3–6 29:8 32:25–34:1	106, 402, 403, AM	29:14–16; 29:18–20	OS, 106, 402, 403, AM, SP
31:10–32:12	106, 402, 403	29:3–6			

⁴ In addition to the designations identified in the “Rebuttal Designations” column, Plaintiffs reserve the right to also rely on any of Plaintiffs’ original deposition designations or Defendants’ counter-designations in rebuttal to Defendants’ counter-designations.

Mehar Manku November 7, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal⁴ Designations	Defendants' Objections to Rebuttal Designations
		29:8 32:25–34:1	106, 402, 403, AM	29:14–16; 29:18–20	OS, 106, 402, 403, AM, SP
32:20–23	106, 402, 403	29:3–6 29:8 32:25–34:1	106, 402, 403, AM	29:14–16; 29:18–20	OS, 106, 402, 403, AM, SP
38:8–11	106, 402, 403, 701	36:25–38:7 39:1–3 39:6–8	106, 402, 403, 701, AF, AM, F, OS	36:25–37:7	
38:13–15	106, 402, 403, 701	36:25–38:7 39:1–3 39:6–8	106, 402, 403, 701, AF, AM, F, OS	36:25–37:7	
39:10–13	106, 402, 403, 701	39:1–3 39:6–8	701, AM, C		
39:15–40:5	106, 402, 403, 701	39:1–3 39:6–8	701, AM, C		
40:12–41:15	106, 402, 403, 602	41:16–17 41:19	106, 701, AM, F, MC, SP	41:7–41:15	OS, 106, 402, 403, 601, 701
42:11–25					
43:23–44:3	106, 402, 403	43:17–22	106, AM, AF	44:24–46:1	OS, 106, 402, 403, 602
44:24–46:1	106, 402, 403, 602	43:17–22 46:2–12	106, 402, 403, 602, C, SP	43:23–44:3	OS, 106, 402, 403
46:25–47:7					
48:19–25	106, 402, 403	50:12–51:2 50:5 50:7–8 50:10–15	106, AM, ID, OS	50:1–16; 51:16–17; 51:19–20	
49:2–15	106, 402, 403	50:12–51:2 50:5 50:7–8 50:10–15	106, 701, AF, AM, AR, F, ID, OS	50:1–16; 51:16–17; 51:19–20	
49:17–50:11	106, 402, 403	50:12–51:2 50:5 50:7–8 50:10–15	106, 701, AF, AM, AR, F, ID, OS	50:1–16; 51:16–17; 51:19–20	
51:16–17	106, 402, 403	51:22–23	AM, MC		
51:19–20	106, 402, 403	51:22–23	AM, MC		
51:24–52:1	106	50:12–51:2 50:5 50:7–8 50:10–15	106, 701, AF, AM, AR, F, ID, OS	50:1–16; 51:16–17; 51:19–20	
52:3–19	106	50:12–51:2			

Mehar Manku November 7, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal⁴ Designations	Defendants' Objections to Rebuttal Designations
		50:5	106, 701, AF, AM, AR, F, ID, OS	50:1-16; 51:16-17; 51:19-20	
		50:7-8			
		50:10-15			
55:9-11					
55:13-18					
58:19-60:3	106, 402, 403	60:4-61:1	602, AM, SP		
62:18-23	106	62:24-63:6	106, 402, 403, 602, AM, C, MC, OS, SP	63:7-15	402, 403, SP, 601, 701
		63:16-25			
		64:2-4			
64:6-21	106, 402, 403	62:24-63:6	106, 402, 403, 602, AM, C, MC, OS, SP	63:7-15	402, 403, SP, 601, 701
		63:16-25			
		64:2-4			
65:22-66:10	106	68:9-10	402, 403, AF, AM, F		
		68:12-14			
		68:16-24			
		69:1-5			
72:9-22	402, 403				
72:25-73:23					
76:23-77:3	106	77:8-14	402, 403, 602, SP		
77:5-6					
78:3-21	106, 402, 403	78:22-25	106, 402, 403, 701, AM, AR, MC, C	79:21-81:3; 81:5-24; 82:1-7; 82:9-18; 84:5-88:4	106, 402, 403, 602, 701, 801
		79:2			
		79:4-13			
		79:16-19			
79:21-81:3	106, 402, 403, 701	78:3-25	106, 402, 403, 701, AM, AR, MC, C	79:21-81:3; 81:5-24; 82:1-7; 82:9-18; 84:5-88:4	106, 402, 403, 602, 701, 801
		79:2			
		79:4-13			
		79:16-19			
		83:11-23			
		83:25-84:3			
81:5-24	106, 402, 403	78:3-25	106, 402, 403, 701, AM, AR, MC, C	79:21-81:3; 81:5-24; 82:1-7; 82:9-18; 84:5-88:4	106, 402, 403, 602, 701, 801
		79:2			
		79:4-13			
		79:16-19			
		83:11-23			
		83:25-84:3			
82:1-7	106, 402, 403	78:3-25	106, 402, 403, 701, AM, AR, MC, C	79:21-81:3; 81:5-24; 82:1-7; 82:9-18; 84:5-88:4	106, 402, 403, 602, 701, 801
		79:2			
		79:4-13			
		79:16-19			
		83:11-23			

Mehar Manku November 7, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal⁴ Designations	Defendants' Objections to Rebuttal Designations
		83:25–84:3			
82:9–18	106, 402, 403, 602, 801	78:3–25	106, 402, 403, 701, AM, AR, MC, C	79:21–81:3; 81:5–24; 82:1–7; 82:9–18; 84:5–88:4	106, 402, 403, 602, 701, 801
		79:2			
		79:4–13			
		79:16–19			
		83:11–23			
		83:25–84:3			
82:20–83:1	106, 402, 403	78:3–25	106, 402, 403, 701, AM, AR, MC, C	79:21–81:3; 81:5–24; 82:1–7; 82:9–18; 84:5–88:4	106, 402, 403, 602, 701, 801
		79:2			
		79:4–13			
		79:16–19			
		83:11–23			
		83:25–84:3			
83:3–5	106, 402, 403, 602	78:3–25	106, 402, 403, 701, AM, AR, MC, C	79:21–81:3; 81:5–24; 82:1–7; 82:9–18; 84:5–88:4	106, 402, 403, 602, 701, 801
		79:2			
		79:4–13			
		79:16–19			
		83:11–23			
		83:25–84:3			
83:7–10	106, 402, 403, 602	78:3–25	106, 402, 403, 701, AM, AR, MC, C	79:21–81:3; 81:5–24; 82:1–7; 82:9–18; 84:5–88:4	106, 402, 403, 602, 701, 801
		79:2			
		79:4–13			
		79:16–19			
		83:11–23			
		83:25–84:3			
84:5–88:4					
89:6–93:25	106, 402, 403, 602, 701, 801	95:24–96:6	106, 701, AF, AM, ID, IQ, MC, OS, SO	97:6–8	
		96:9–12			
		96:24–97:4			
		97:10–98:10			
94:3–95:23	106, 402, 403	95:24–96:6	106, 701, AF, AM, ID, IQ, MC, OS, SO	97:6–8	
		96:9–12			
		96:24–97:4			
		97:10–98:10			
104:12–105:15	ID, 106, 602	101:10–14	106, 402, 403, 602, 701, AM, MC, OS, SP	104:12–15; 104:17–105:15	ID, OS, 106, 602
		101:16–19			
		101:21–104:11			
107:9–25		108:1–11	602, SP		
109:14–25					
110:11–113:21		113:22–114:12	701, AF, AM, C, MC		
		114:16–19			
		115:6–17			

Mehar Manku November 7, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal⁴ Designations	Defendants' Objections to Rebuttal Designations
131:15–19	402, 403				
132:1–2	402, 403				
132:4	402, 403				
132:6–17	402, 403				
133:6–8	106	135:1–2	OS, AM		
133:10–134:25	106, 602, 801	135:1–2	AM		
135:3–24	106, 602	135:1–2	AM		
		135:25–136:11			
136:17–137:4	106, 602, 701	137:5–8	402, 403, 602, 701, AF, AM, CQ, MC, SP		
		137:10–13			
		137:15–19			
		137:22–24			
		138:1–23			
		138:25–139:7			
		139:9–13			
140:1–5	106, 402, 403	139:16–24	402, 403, 602, 701, AF, AM, CQ, MC, SP		
		137:5–8			
		137:10–13			
		137:15–19			
		137:22–24			
		138:1–23			
		138:25–139:7			
		139:9–13			
		139:16–24			
140:7–141:24	106, 402, 403, 602, 701	142:1–5	402, 403, 602, 701, AF, AM, CQ, MC, SP		
		142:7–8			
		137:5–8			
		137:10–13			
		137:15–19			
		137:22–24			
		138:1–23			
		138:25–139:7			
		139:9–13			
142:14–143:21	106, 602, 801	139:16–24	402, 403, AM, ID, OS	140:1–5; 140:7–141:24	OS, 106, 402, 403, 602, 701
		142:1–5			
		142:7–8			
146:17–24	106	146:25–149:9		149:10–15; 149:17–20	OS, 106
149:10–15	106	146:25–149:9			

Mehar Manku November 7, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal⁴ Designations	Defendants' Objections to Rebuttal Designations
149:17–20	106	146:25–149:9			
149:25–150:7	106, 402, 403	146:25–149:9			
150:9–19	106, 402, 403, 602, 701, 801	146:25–149:9			
153:1–4					
153:8–11					
153:13–16					
153:18–154:4					
162:5–164:4	402, 403, 602, 801				
164:6–11	402, 403				
164:13–16	402, 403, 602, 801				
165:5–10	106	166:11–21	402, 403, 602, AM, F, SP		
		167–2–12			
165:16–166:10	106	166:11–21	402, 403, 602, AM, F, SP		
		167–2–12			
180:16–181:7	106, 402, 403, 602, 701	177:19–179:19	402, 403, 602, 701, AF, AM, B, F, MC, OS, SP		
		179:21–180:10			
		180:12–14			
		181:25–182:24			
181:13–24	106, 402, 403, 602	177:19–179:19	402, 403, 602, 701, AF, AM, B, F, MC, OS, SP		
		179:21–180:10			
		180:12–14			
		181:25–182:24			
184:8–24	106	185:4–7	402, 403, AM, CQ, OS		
		185:9–13			
		185:15–23			
185:1–2	106	185:4–7	402, 403, AM, CQ, OS		
		185:9–13			
		185:15–23			
213:11–17	106	214:8–25	402, 403, AM, MC		
214:1–7	106	214:8–25			
221:13–15	106, 402, 403	220:14–18	402, 403, ID, IQ, OS		
		220:21–23			
		220:25–221:12			
		222:1–3			
221:18–24	106, 402, 403	220:14–18	402, 403, ID, IQ, OS		
		220:21–23			
		220:25–221:12			
		222:1–3			

Ian Osterloh November 5, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ⁵ Designations	Defendants' Objections to Rebuttal Designations
6:25–7:4					
8:22–9:18					
12:16–13:17					
14:8–16:21	402, 403				
22:24–23:24	106, 801	23:25–25:4	106, 801	25:7–25:8; 25:12–24; 26:1– 26:6; 26:8–26:20	OS, 106
25:7–8	IQ, ID, 106	25:13–24	106, 801, AF, AM	26:1–26:6; 26:8– 26:20	OS, 106
25:12–24					
26:1–6					
26:8–20					
27:14–20					
33:3					
33:16–24	IQ, ID, 106	33:25–34:7	106, 801		
39:13–16	IQ, ID				
45:16–20	402, 403				
48:17–49:3					
49:14–23	402, 403				
49:25–50:2	402, 403				
50:16–51:17	402, 403				
51:19–52:9	402, 403				
52:11–16	402, 403				
52:22–53:14	106, 402, 403	54:6–55:4	106, 402, 403, 801, SP, AM, ID	54:14–54:18; 54:20–55:19; 180:9-182:9; 182:11-184:14; 184:16-185:20; 185:22-186:24; 187:1-187:4	AA, OS, 106, 402, 403, 602, 801, Leading

⁵ In addition to the designations identified in the “Rebuttal Designations” column, Plaintiffs reserve the right to also rely on any of Plaintiffs’ original deposition designations or Defendants’ counter-designations in rebuttal to Defendants’ counter-designations.

Ian Osterloh November 5, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ⁵ Designations	Defendants' Objections to Rebuttal Designations
53:16–54:5	106	54:6–55:4	106, 402, 403, 801, SP, AM, ID	54:14–54:18; 54:20–55:19; 180:9-182:9; 182:11-184:14; 184:16-185:20; 185:22-186:24; 187:1-187:4	AA, OS, 106, 402, 403, 602, 801, Leading
59:11–60:20					
60:24–61:11					
61:20–62:7	402, 403, 701				
71:11–13	106, 402, 403	59:11–60:20	106, 701, 801, AA, C, SP	180:9-182:9; 182:11-184:14; 184:16-185:20; 185:22-186:24; 187:1-187:4	AA, OS, 106, 402, 403, 602, 801, Leading
		60:24–61:11			
71:16–24	106, 402, 403	59:11–60:20	106, 701, 801, AA, C, SP	180:9-182:9; 182:11-184:14; 184:16-185:20; 185:22-186:24; 187:1-187:4	AA, OS, 106, 402, 403, 602, 801, Leading
		60:24–61:11			
72:1–13	106, 402, 403, 602, 801	59:11–60:20	106, 701, 801, AA, C, SP	180:9-182:9; 182:11-184:14; 184:16-185:20; 185:22-186:24; 187:1-187:4	AA, OS, 106, 402, 403, 602, 801, Leading
		60:24–61:11			
72:15–19	106, 402, 403	59:11–60:20	106, 701, 801, AA, C, SP	180:9-182:9; 182:11-184:14; 184:16-185:20; 185:22-186:24; 187:1-187:4	AA, OS, 106, 402, 403, 602, 801, Leading
		60:24–61:11			
72:21–73:23	106, 402, 403, 602, 701	59:11–60:20	106, 701, 801, AA, C, SP	180:9-182:9; 182:11-184:14; 184:16-185:20; 185:22-186:24; 187:1-187:4	AA, OS, 106, 402, 403, 602, 801, Leading
		60:24–61:11			
73:25–75:11	106, 402, 403, 602	59:11–60:20	106, 701, 801, AA, C, SP	180:9-182:9; 182:11-184:14; 184:16-185:20; 185:22-186:24; 187:1-187:4	AA, OS, 106, 402, 403, 602, 801, Leading
		60:24–61:11			
76:8–14	402, 403				
76:16–22					
81:5–8	106, 402, 403	82:5–11			

Ian Osterloh November 5, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ⁵ Designations	Defendants' Objections to Rebuttal Designations
		82:13–14 82:16–25	106, 801, AF, AM, CQ	83:1–83:4; 83:6–83:10	OS, 106, 402, 403, 602
81:10–82:3	106, 402, 403, 701	82:5–11 82:13–14 82:16–25	106, 801, AF, AM, CQ	83:1–83:4; 83:6–83:10	OS, 106, 402, 403, 602
86:5–13					
86:15–19					
96:5–6	106, 402, 403	98:7–18	106, 402, 403, 801, AF, OS		
96:8–14	106, 402, 403	98:7–18	106, 402, 403, 801, AF, OS		
97:12–20	106, 402, 403	98:7–18	106, 402, 403, 801, AF, OS		
105:19–106:8	106, 402, 403	105:8–10 105:12–17	106, 801, AA, AM, MC, CQ	104:24–105:10; 105:12–105:17	OS, 106, 402, 403
106:10	106, 402, 403	105:8–10 105:12–17	106, 801, AA, AM, MC, CQ	104:24–105:10; 105:12–105:17	OS, 106, 402, 403
106:13–17	106, 402, 403	105:8–10 105:12–17	106, 801, AA, AM, MC, CQ	104:24–105:10; 105:12–105:17	OS, 106, 402, 403
106:20–107:14	106, 402, 403	105:8–10 105:12–17	106, 801, AA, AM, MC, CQ	104:24–105:10; 105:12–105:17	OS, 106, 402, 403
116:16–19					
117:7–16	402, 403				
117:18–24	402, 403, 602, 701				
118:21–119:1					
119:3–121:8					
122:9–123:12	402, 403				
124:3–22	106, 402, 403	125:24–126:3 126:5–12	106, 801, AA, AM, C		
124:24–125:11	106	125:24–126:3 126:5–12	106, 801, AA, AM, C		
125:13–22	106	125:24–126:3 126:5–12	106, 801, AA, AM, C		
128:1–14	402, 403, 602				
130:12–14	106, 402, 403, 602	132:9–11 133:11–15 133:17–19 133:21–134:4 134:6–10 134:12–14 134:18–19	106, 801, AA, AF, AM, C, IQ, SP	132:2–4; 132:6–7; 132:9–15; 132:17–133:5; 134:1–4; 134:6–10; 134:21–135:6	

Ian Osterloh November 5, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ⁵ Designations	Defendants' Objections to Rebuttal Designations
		134:21–135:6			
130:17–132:4	106, 402, 403, 602, 701	132:9–11	106, 801, AA, AF, AM, C, IQ, SP	132:2–4; 132:6–7; 132:9–15; 132:17–133:5; 134:1–4; 134:6–10; 134:21–135:6	OS, 106
		133:11–15			
		133:17–19			
		133:21–134:4			
		134:6–10			
		134:12–14			
		134:18–19			
		134:21–135:6			
132:6–7	106	132:9–11	106, 801, AA, AF, AM, C, IQ, SP	132:2–4; 132:6–7; 132:9–15; 132:17–133:5; 134:1–4; 134:6–10; 134:21–135:6	OS, 106
		133:11–15			
		133:17–19			
		133:21–134:4			
		134:6–10			
		134:12–14			
		134:18–19			
		134:21–135:6			
132:12–15	106, 402, 403	132:9–11	106, 801, AA, AF, AM, C, IQ, SP	132:2–4; 132:6–7; 132:9–15; 132:17–133:5; 134:1–4; 134:6–10; 134:21–135:6	OS, 106
		133:11–15			
		133:17–19			
		133:21–134:4			
		134:6–10			
		134:12–14			
		134:18–19			
		134:21–135:6			
132:17–133:5	106, 402, 403, 701	132:9–11	106, 801, AA, AF, AM, C, IQ, SP	132:2–4; 132:6–7; 132:9–15; 132:17–133:5; 134:1–4; 134:6–10; 134:21–135:6	OS, 106
		133:11–15			
		133:17–19			
		133:21–134:4			
		134:6–10			
		134:12–14			
		134:18–19			
		134:21–135:6			
135:8–9	106	136:15–17	106, 402, 403, 801, AF, F, IQ	137:7–12; 137:15–19; 137:21–138:9; 138:12–14	AF, AM, OS, 106, 402, 403, 602
		136:19			
		136:21–137:6			
135:11–136:1	106	136:15–17	106, 402, 403, 801, AF, F, IQ	137:7–12; 137:15–19; 137:21–138:9; 138:12–14	AF, AM, OS, 106, 402, 403, 602
		136:19			
		136:21–137:6			
136:3–13	106, 602, 701	136:15–17			

Ian Osterloh November 5, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ⁵ Designations	Defendants' Objections to Rebuttal Designations
		136:19	106, 402, 403, 801, AF, F, IQ	137:7-12; 137:15-19; 137:21-138:9; 138:12-14	AF, AM, OS, 106, 402, 403, 602
		136:21-137:6			
138:16-22	402, 403				
139:20-22	106, 402, 403, 602	140:8-10	106; 801; AM, MC	139:24-140:6; 140:8-10; 140:12-141:11; 142:13-22	OS, 106, 402, 403, 602, 801
		140:12-17			
139:24-140:6	106, 402, 403, 602, 801	140:8-10	106; 801; AM, MC	139:20-22; 140:8-10; 140:12-141:11; 142:13-22	OS, 106, 402, 403, 602, 801
		140:12-17			
167:25-168:4	402, 403, 602, 801				
168:6-169:1	402, 403, 602, 801				
170:14-16	402, 403				
170:19-171:13					
179:13-180:4	402, 403				
180:9-182:9	106, 402, 403, 801, 602, Leading	162:15-16	106, 801, 402, 403, AF, AM, SP, F, ID, IQ, MC	167:25-168:4; 167:25-168:4; 168:6-169:1; 170:14-16; 170:19-171:13; 179:13-180:4; 189:17-21; 189:24-190:3; 192:18-21; 192:24-193:9; 193:12-18	AF, AM, F, SP, OS, 106, 402, 403, 602, 801
		162:18-20			
		167:25-168:4			
		168:6-11			
		188:17-189:16			
		194:6-9			
		194:12-18			
		194:20-21			
		194:24-195:20			
		195:22-23			
		196:1-5			
		196:7-9			
		196:11-13			
182:11-184:14	106, 402, 403, 801, 602, Leading	162:15-16	106, 801, 402, 403, AF, AM, SP, F, ID, IQ, MC	167:25-168:4; 167:25-168:4; 168:6-169:1; 170:14-16; 170:19-171:13; 179:13-180:4; 189:17-21; 189:24-190:3; 192:18-21;	AF, AM, F, SP, OS, 106, 402, 403, 602, 801
		162:18-20			
		167:25-168:4			
		168:6-11			
		188:17-189:16			
		194:6-9			
		194:12-18			
		194:20-21			
		194:24-195:20			

Ian Osterloh November 5, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ⁵ Designations	Defendants' Objections to Rebuttal Designations
		195:22–23 196:1–5 196:7–9 196:11–13		192:24–193:9; 193:12–18	
184:16–185:20	106, 402, 403, AA, 801, 602	162:15–16 162:18–20 167:25–168:4 168:6–11 188:17–189:16 194:6–9 194:12–18 194:20–21 194:24–195:20 195:22–23 196:1–5 196:7–9 196:11–13	106, 801, 402, 403, AF, AM, SP, F, ID, IQ, MC	167:25–168:4; 167:25–168:4; 168:6–169:1; 170:14–16; 170:19–171:13; 179:13–180:4; 189:17–21; 189:24–190:3; 192:18–21; 192:24–193:9; 193:12–18	AF, AM, F, SP, OS, 106, 402, 403, 602, 801
185:22–186:24	106, 402, 403, 801, 602, Leading	162:15–16 162:18–20 167:25–168:4 168:6–11 188:17–189:16 194:6–9 194:12–18 194:20–21 194:24–195:20 195:22–23 196:1–5 196:7–9 196:11–13	106, 801, 402, 403, AF, AM, SP, F, ID, IQ, MC	167:25–168:4; 167:25–168:4; 168:6–169:1; 170:14–16; 170:19–171:13; 179:13–180:4; 189:17–21; 189:24–190:3; 192:18–21; 192:24–193:9; 193:12–18	AF, AM, F, SP, OS, 106, 402, 403, 602, 801
187:1–4	106, 402, 403, 801, 602	162:15–16 162:18–20 167:25–168:4 168:6–11 188:17–189:16 194:6–9 194:12–18 194:20–21 194:24–195:20 195:22–23 196:1–5 196:7–9	106, 801, 402, 403, AF, AM, SP, F, ID, IQ, MC	167:25–168:4; 167:25–168:4; 168:6–169:1; 170:14–16; 170:19–171:13; 179:13–180:4; 189:17–21; 189:24–190:3; 192:18–21; 192:24–193:9; 193:12–18	AF, AM, F, SP, OS, 106, 402, 403, 602, 801

Ian Osterloh November 5, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal⁵ Designations	Defendants' Objections to Rebuttal Designations
		196:11–13			
188:17–189:7	402, 403				

Anuj Srivastava October 18, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ⁶ Designations	Defendants' Objections to Rebuttal Designations
5:2-8					
5:20-6:8					
9:12-10:6	AM				
10:9-16					
11:10-18					
16:14-24					
17:8-10					
17:15-18:10	MC				
18:12-23					
22:21-23:2	402, 403, FRCP 30(b)(6)				
23:5-19					
24:17-24					
25:12-30:9					
32:16-33:12	AM, F				
33:14-25					
35:23-36:12	403, 602, SP				
38:16-17	AM, MC				
38:19-39:8					
39:13-14	AM, F				
39:18-40:8	402, 403, FRCP 30(b)(6)				
40:10-18	AM, CQ				
40:20-22					
43:1-44:6					
45:13-25	106	46:13-20	106, 801	46:1-6; 46:8-12; 46:21-47:3; 47:6-12	AA, AM, CQ
48:11-25					
49:2-12	403, AA				
49:14-20	403, AA				
49:23-52:23	403, MC				
52:25-54:5					
58:19-22					
58:24-25					
59:3-6					
59:12-20					

⁶ In addition to the designations identified in the "Rebuttal Designations" column, Plaintiffs reserve the right to also rely on any of Plaintiffs' original deposition designations or Defendants' counter-designations in rebuttal to Defendants' counter-designations.

Anuj Srivastava October 18, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ⁶ Designations	Defendants' Objections to Rebuttal Designations
59:23–60:2	106	60:3–16	106, 402, 801	60:17–61:23	602, 801, SP
61:24–63:12	106, 402, 403	63:24–64:1	801		
64:2–9	AF				
64:13–21					
64:24–25	AF				
65:2–66:8					
67:3–68:10	402, 403				
68:18–69:6	402, 403				
69:9–19	402, 403, AM				
70:2–73:13	402, 403				
76:22–80:5	402, 403				
92:11–93:9	402, 403, AM, MC				
93:11–14	402, 403, AM, MC				
94:7–95:7	402, 403				
95:17–96:11	402, 403, AM, CQ				
96:13–97:8	402, 403				
98:3–13	402, 403, 602, FRCP 30(b)(6)				
101:21–102:4	402, 403				
102:8–11					
102:16–103:9	106, 402, 403	103:10–13	402, 801		
103:14–104:20	402, 403, 602, SP				
104:23–105:4	402, 403, 602				
105:7–8					
106:16–109:23	402, 403				
112:14–113:8					
113:12–25	402, 403, AM, MC				
114:15–17					
114:19–24	402, 403, 602				
117:10–119:10	106	119:11–12	402, 801		
119:19–120:25	402, 403, 602				
121:3–6					
122:2–16					
122:20–124:6	106, 402, 403	124:7–125:6	402, 602, 801, C, SP		
125:19–126:8					
127:2–9					

Anuj Srivastava October 18, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter- Designations	Plaintiffs' Objections to Counter- Designations	Plaintiffs' Rebuttal ⁶ Designations	Defendants' Objections to Rebuttal Designations
133:11-14	402, 403, AM, FRCP 30(b)(6)				
133:16-24	402, 403, AM				
134:1-8	402, 403, AM				
134:10-16	402, 403, AM				
141:3-18	402, 403, 602, FRCP 30(b)(6)				
142:13-20	402, 403				
143:2-12	402, 403				
143:14-22	402, 403				

Howard S. Weintraub September 14, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ⁷ Designations	Defendants' Objections to Rebuttal Designations
7:17–18					
8:19–9:7					
9:25–10:16					
27:12–15					
27:17–25					
28:10–29:14	402, 403				
30:20–23	402, 403				
32:10–33:10	106, 402, 403, 602, 801	35:9–36:14	106, 402, 403, AM, C, CQ, OS, SP	35:18–37:6; 109:12–15	OS, 106, 402, 403
		37:7–21			
		38:14–17			
33:13–35:7	106, 402, 403, 602, 801	35:9–36:14	106, 402, 403, AM, C, CQ, OS, SP	35:18–37:6; 109:12–15	OS, 106, 402, 403
		37:7–21			
		38:14–17			
39:1–9	106, 402, 403, 602, 801	35:9–36:14	106, 402, 403, AM, C, CQ, OS, SP	35:18–37:6; 109:12–15	OS, 106, 402, 403
		37:7–21			
		38:14–17			
46:25–47:2	106	47:18–21	106, 402, 403, AA, AM	40:3–41:3; 42:4–6; 43:14–44:10; 45:10–24; 47:3–4; 47:6–16; 47:22–49:6; 65:3–5; 65:7–16; 65:18–66:1; 67:7–16; 67:18–21; 67:24–68:3; 68:3–69:8	OS ,106, 402, 403, 602, 701
		48:13–16			
		51:4–52:10			
52:15–18	106, 402, 403	51:4–52:10	106, 402, 403, 701, AA, AM, C, MC	40:3–41:3; 42:4–6; 43:14–44:10; 45:10–24; 47:3–4; 47:6–16; 47:22–49:6; 65:3–5; 65:7–16; 65:18–66:1; 67:7–16; 67:18–21; 67:24–68:3; 68:5–69:8	OS ,106, 402, 403, 602, 701
		56:21–57:5			
		57:15–58:19			
52:23	106, 402, 403, 701	51:4–52:10	106, 402, 403, 701, AA, AM, C, MC	40:3–41:3; 42:4–6; 43:14–44:10; 45:10–24; 47:3–	OS ,106, 402, 403, 602, 701
		56:21–57:5			
		57:15–58:19			

⁷ In addition to the designations identified in the “Rebuttal Designations” column, Plaintiffs reserve the right to also rely on any of Plaintiffs’ original deposition designations or Defendants’ counter-designations in rebuttal to Defendants’ counter-designations.

Howard S. Weintraub September 14, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ⁷ Designations	Defendants' Objections to Rebuttal Designations
		58:21–59:6		4; 47:6–16; 47:22–49:6; 65:3–5; 65:7–16; 65:18–66:1; 67:7–16; 67:18–21; 67:24–68:3; 68:5–69:8	
52:25–53:17	106, 402, 403, 701	51:4–52:10	106, 402, 403, 701, AA, AM, C, MC	40:3–41:3; 42:4–6; 43:14–44:10; 45:10–24; 47:3–4; 47:6–16; 47:22–49:6; 65:3–5; 65:7–16; 65:18–66:1; 67:7–16; 67:18–21; 67:24–68:3; 68:5–69:8	OS ,106, 402, 403, 602, 701
		56:21–57:5			
		57:15–58:19			
		58:21–59:6			
53:22–54:16	106, 402, 403, 701	51:4–52:10	106, 402, 403, 701, AA, AM, C, MC	40:3–41:3; 42:4–6; 43:14–44:10; 45:10–24; 47:3–4; 47:6–16; 47:22–49:6; 65:3–5; 65:7–16; 65:18–66:1; 67:7–16; 67:18–21; 67:24–68:3; 68:5–69:8	OS ,106, 402, 403, 602, 701
		56:21–57:5			
		57:15–58:19			
		58:21–59:6			
62:10–17	106, 402, 403, 701	60:22–61:1	602, 701, AA, AF, AM, F, MC, OS, SP		
		61:4–12			
		63:19–64:9			
		64:13–65:1			
75:7–19	106, 402, 403	76:6–10	701, AA, AM, AR, MC	67:7–16; 67:18–21; 67:24–68:3; 68:5–69:8	OS ,106, 402, 403, 602, 701
		76:13–21			
		76:25–78:5			
75:22–76:4	106, 402, 403, 701	76:6–10	106, 701, AA, AM, AR, MC	67:7–16; 67:18–21; 67:24–68:3; 68:5–69:8	OS ,106, 402, 403, 602, 701
		76:13–21			
		76:25–78:5			
114:20–25					
115:2–19					
160:15–17	106	163:3–10	106, 701, A, B, AF, AM, F, OS	164:16–17; 164:20–165:16	OS, 106, 402, 403
		163:12–14			
160:20–161:19	106, 701	163:3–10	106, 701, A, B, AF, AM, F, OS	164:16–17; 164:20–165:16	OS, 106, 402, 403
		163:12–14			

Howard S. Weintraub September 14, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ⁷ Designations	Defendants' Objections to Rebuttal Designations
180:12–182:17	106, 402, 403, 701	180:7–11	106, 701, AA, AM, C	178:21–23; 178:25–179:2; 179:4–6; 179:13–180:5	
183:23–184:2					
185:9–11					
185:16–22					
186:4–9					
186:11–187:9					
190:4–8					
190:10–191:10	ID, 106; 402, 403; 701	188:18–190:8	106, 402, 403, 701, AA, AM, C	65:3–5; 65:7–16; 65:18–66:1; 76:17–21; 76:25–77:5	ID, IQ, MC, OS, 106, 402, 403, 602, 701
		191:12–19			
193:15–25	106, 402, 403; 701	195:8–10	106, 701, AM, OS	76:17–21; 76:25–77:5	ID, IQ, MC, OS, 106, 402, 403
		195:12–22			
219:12–220:3	106, 402, 403	222:21–23	106, 402, 403, 701, AF, AM, F, MC	226:3–12; 226:16–227:21	AM, OS, 106, 402, 403
		223:1–4			
		223:6–8			
		223:16–224:6			
		224:8–11			
		224:15–25			
220:10–221:3	106, 402, 403; 602; 701	222:21–23	106, 402, 403, 701, AF, AM, F, MC	226:3–12; 226:16–227:21	AM, OS, 106, 402, 403
		223:1–4			
		223:6–8			
		223:16–224:6			
		224:8–11			
		224:15–25			
221:5–222:14	106, 402, 403; 602; 701	222:21–23	106, 402, 403, 701, AF, AM, F, MC	226:3–12; 226:16–227:21	AM, OS, 106, 402, 403
		223:1–4			
		223:6–8			
		223:16–224:6			
		224:8–11			
		224:15–25			
261:11–15	106, 402, 403, 701	262:9–13	701, AM		
		262:19–263:1			
261:17–262:7	106, 402, 403, 701	262:9–13	701, AM		
		262:19–263:1			
263:3–5	106, 402, 403, 701	262:9–13	701, AM		
		262:19–263:1			
263:10–19		262:9–13	701, AM		

Howard S. Weintraub September 14, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ⁷ Designations	Defendants' Objections to Rebuttal Designations
	106, 402, 403, 701	262:19–263:1			

Ronald Howard Wharton January 24, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ⁸ Designations	Defendants' Objections to Rebuttal Designations
6:8–13					
6:16–17					
7:20–25					
8:2–7					
8:19–25					
9:2–17					
47:25	106	49:17–50:2	106, 402, 403, 801, AM, C, ID	60:4–11; 60:15–20; 104:20–24; 105:14–16	OS, 106, 402, 403, 701, FRCP 30(b)(6)
		50:5–20			
		50:25–51:3			
		51:8–14			
48:2–3	106; 402; 403; 701	49:17–50:2	106, 402, 403, 801, AM, C, ID	60:4–11; 60:15–20; 104:20–24; 105:14–16	OS, 106, 402, 403, 701, FRCP 30(b)(6)
		50:5–20			
		50:25–51:3			
		51:8–14			
48:5–9	106; 402; 403; 701	49:17–50:2	106, 402, 403, 801, AM, C, ID	60:4–11; 60:15–20; 104:20–24; 105:14–16	OS, 106, 402, 403, 701, FRCP 30(b)(6)
		50:5–20			
		50:25–51:3			
		51:8–14			
48:11–22	106; 402; 403; 701	49:17–50:2	106, 402, 403, 801, AM, C, ID	60:4–11; 60:15–20; 104:20–24; 105:14–16	OS, 106, 402, 403, 701, FRCP 30(b)(6)
		50:5–20			
		50:25–51:3			
		51:8–14			
48:24	106; 402; 403; 701	49:17–50:2	106, 402, 403, 801, AM, C, ID	60:4–11; 60:15–20; 104:20–24; 105:14–16	OS, 106, 402, 403, 701, FRCP 30(b)(6)
		50:5–20			
		50:25–51:3			
		51:8–14			
60:4–11	106, 402, 403, 701	60:21–24	106, 402, 403, 801, AA, AF,	63:19–25; 64:2–13	OS, 106
		61:4–16			

⁸ In addition to the designations identified in the “Rebuttal Designations” column, Plaintiffs reserve the right to also rely on any of Plaintiffs’ original deposition designations or Defendants’ counter-designations in rebuttal to Defendants’ counter-designations.

Ronald Howard Wharton January 24, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ⁸ Designations	Defendants' Objections to Rebuttal Designations
		61:19–20 61:22–62:20	AM, C, F, ID, IQ, OS		
60:15–20	106, 402, 403, 701	60:21–24 61:4–16 61:19–20 61:22–62:20	106, 402, 403, 801, AA, AF, AM, C, F, ID, IQ, OS	63:19–25; 64:2– 13	OS, 106
134:7–19	106, 402, 403, 701	131:14–16 131:18–132:12 132:17–19 133:12–14 133:16–20 136:10–20 136:22–137:8 137:20–24 138:2–5 143:3–5 143:8–12 143:15–16	106, 602, 801, AM, C, ID, IQ, NR, OS, SP	130:12–15; 130:19–25; 131:2–13; 132:20–25; 133:2–10; 133:12–14; 133:16–20; 167:4–21; 167:23–25; 168:2–25; 169:2–7; 169:9– 22; 169:24–25; 170:9–17; 170:19–24	AF, AM, F, OS, 106, 402, 403, 602, 701
135:6–25	106, 402, 403, 701	131:14–16 131:18–132:12 132:17–19 133:12–14 133:16–20 136:10–20 136:22–137:8 137:20–24 138:2–5 143:3–5 143:8–12 143:15–16	106, 602, 801, AM, C, ID, IQ, NR, OS, SP	130:12–15; 130:19–25; 131:2–13; 132:20–25; 133:2–10; 133:12–14; 133:16–20; 167:4–21; 167:23–25; 168:2–25; 169:2–7; 169:9– 22; 169:24–25; 170:9–17; 170:19–24	AF, AM, F, OS, 106, 402, 403, 602, 701
136:2–6	106, 402, 403, 701	131:14–16 131:18–132:12 132:17–19 133:12–14 133:16–20 136:10–20 136:22–137:8 137:20–24 138:2–5	106, 602, 801, AM, C, ID, IQ, NR, OS, SP	130:12–15; 130:19–25; 131:2–13; 132:20–25; 133:2–10; 133:12–14; 133:16–20; 167:4–21; 167:23–25;	AF, AM, F, OS, 106, 402, 403, 602, 701

Ronald Howard Wharton January 24, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ⁸ Designations	Defendants' Objections to Rebuttal Designations
		143:3-5 143:8-12 143:15-16		168:2-25; 169:2-7; 169:9-22; 169:24-25; 170:9-17; 170:19-24	
137:9-11	106, 402, 403, 701	131:14-16 131:18-132:12 132:17-19 133:12-14 133:16-20 136:10-20 136:22-137:8 137:20-24 138:2-5 143:3-5 143:8-12 143:15-16	106, 602, 801, AM, C, ID, IQ, NR, OS, SP	130:12-15; 130:19-25; 131:2-13; 132:20-25; 133:2-10; 133:12-14; 133:16-20; 167:4-21; 167:23-25; 168:2-25; 169:2-7; 169:9-22; 169:24-25; 170:9-17; 170:19-24	AF, AM, F, OS, 106, 402, 403, 602, 701
137:14-19	106, 402, 403, 701	131:14-16 131:18-132:12 132:17-19 133:12-14 133:16-20 136:10-20 136:22-137:8 137:20-24 138:2-5 143:3-5 143:8-12 143:15-16	106, 602, 801, AM, C, ID, IQ, NR, OS, SP	130:12-15; 130:19-25; 131:2-13; 132:20-25; 133:2-10; 133:12-14; 133:16-20; 167:4-21; 167:23-25; 168:2-25; 169:2-7; 169:9-22; 169:24-25; 170:9-17; 170:19-24	AF, AM, F, OS, 106, 402, 403, 602, 701
138:18-23	106, 402, 403, 701	131:14-16 131:18-132:12 132:17-19 133:12-14 133:16-20 136:10-20 136:22-137:8 137:20-24 138:2-5 143:3-5	106, 602, 801, AM, C, ID, IQ, NR, OS, SP	130:12-15; 130:19-25; 131:2-13; 132:20-25; 133:2-10; 133:12-14; 133:16-20; 167:4-21; 167:23-25; 168:2-25;	AF, AM, F, OS, 106, 402, 403, 602, 701

Ronald Howard Wharton January 24, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter-Designations	Plaintiffs' Objections to Counter-Designations	Plaintiffs' Rebuttal ⁸ Designations	Defendants' Objections to Rebuttal Designations
		143:8–12		169:2–7; 169:9–22; 169:24–25; 170:9–17; 170:19–24	
		143:15–16			
139:23–24	106, 402, 403, 701	131:14–16	106, 602, 801, AM, C, ID, IQ, NR, OS, SP	130:12–15; 130:19–25; 131:2–13; 132:20–25; 133:2–10; 133:12–14; 133:16–20; 167:4–21; 167:23–25; 168:2–25; 169:2–7; 169:9–22; 169:24–25; 170:9–17; 170:19–24	AF, AM, F, OS, 106, 402, 403, 602, 701
		131:18–132:12			
		132:17–19			
		133:12–14			
		133:16–20			
		136:10–20			
		136:22–137:8			
		137:20–24			
		138:2–5			
		143:3–5			
		143:8–12			
		143:15–16			
140:2–7	106, 402, 403, 701	131:14–16	106, 602, 801, AM, C, ID, IQ, NR, OS, SP	130:12–15; 130:19–25; 131:2–13; 132:20–25; 133:2–10; 133:12–14; 133:16–20; 167:4–21; 167:23–25; 168:2–25; 169:2–7; 169:9–22; 169:24–25; 170:9–17; 170:19–24	AF, AM, F, OS, 106, 402, 403, 602, 701
		131:18–132:12			
		132:17–19			
		133:12–14			
		133:16–20			
		136:10–20			
		136:22–137:8			
		137:20–24			
		138:2–5			
		143:3–5			
		143:8–12			
		143:15–16			
140:11–25	106, 402, 403, 701	131:14–16	106, 602, 801, AM, C, ID, IQ, NR, OS, SP	130:12–15; 130:19–25; 131:2–13; 132:20–25; 133:2–10; 133:12–14; 133:16–20; 167:4–21; 167:23–25; 168:2–25; 169:2–7; 169:9–	AF, AM, F, OS, 106, 402, 403, 602, 701
		131:18–132:12			
		132:17–19			
		133:12–14			
		133:16–20			
		136:10–20			
		136:22–137:8			
		137:20–24			
		138:2–5			
		143:3–5			
		143:8–12			
		143:15–16			

Ronald Howard Wharton January 24, 2018					
Plaintiffs' Designations	Defendants' Objections	Defendants' Counter- Designations	Plaintiffs' Objections to Counter- Designations	Plaintiffs' Rebuttal ⁸ Designations	Defendants' Objections to Rebuttal Designations
		143:15–16		22; 169:24–25; 170:9–17; 170:19–24	
141:2–10	106, 402, 403, 701	131:14–16	106, 602, 801, AM, C, ID, IQ, NR, OS, SP	130:12–15;	AF, AM, F, OS, 106, 402, 403, 602, 701
		131:18–132:12		130:19–25;	
		132:17–19		131:2–13;	
		133:12–14		132:20–25;	
		133:16–20		133:2–10;	
		136:10–20		133:12–14;	
		136:22–137:8		133:16–20;	
		137:20–24		167:4–21;	
		138:2–5		167:23–25;	
		143:3–5		168:2–25;	
		143:8–12		169:2–7; 169:9–	
		143:15–16		22; 169:24–25; 170:9–17; 170:19–24	

Defendants' Objection Legends – 11/22/2019
Subject to Supplementation and Revision

Objection Key for Defendants' Objections to Amarin's Deposition Designations

Code	Objection
106	This testimony is objectionable because it is incomplete and the introduction and the remaining portions ought, in fairness, to be considered contemporaneously with it (<i>see</i> F.R.E. 106).
402	This testimony is objectionable because it is not relevant (<i>see</i> F.R.E. 402).
403	Misleading, confusion of issues, and/or cumulative. This testimony is objectionable because its probative value is substantially outweighed by the danger of unfair prejudice (<i>see</i> F.R.E. 403).
408	<i>See</i> F.R.E. 408 (Compromise Offers and Negotiations).
602	This testimony is objectionable because it constitutes testimony on a matter as to which the witness lacks personal knowledge (<i>see</i> F.R.E. 602).
701	This testimony is objectionable because it is opinion testimony by a lay witness that is not reasonably based on perception and helpful to a clear understanding of the witnesses' testimony or the determination of a fact in dispute (<i>see</i> F.R.E. 701), and/or it calls for a legal conclusion, and/or it is attempted expert testimony from a witness who was not designated as an expert and who did not submit an expert report (<i>see</i> F.R.C.P. 26).
702	<i>See</i> F.R.E. 702.
703	<i>See</i> F.R.E. 703.
801	Hearsay. This testimony is objectionable because it is a statement made by one other than the declarant while testifying at trial, offered into evidence to prove the truth of the matter asserted and not subject to any hearsay exception (<i>see</i> F.R.E. 801 and 802).
1006	<i>See</i> F.R.E. 1006.
A or 901	This testimony is objectionable because it concerns documents for which authentication is lacking (<i>see</i> F.R.E. 901).
AA	Asked and answered.
AF	Assumes facts not in evidence.
AM	Ambiguous, vague, or unintelligible.
CQ	Compound question.
F	Lacks foundation (<i>see</i> F.R.E. 901).
FRCP 30(b)(6)	Outside the scope of witness designation.

Defendants' Objection Legends – 11/22/2019
Subject to Supplementation and Revision

Code	Objection
ID	Improper deposition designation.
IQ	Incomplete question/incomplete answer.
MC	Mischaracterizes testimony or misstates evidence.
OS	Outside scope of original designation.
SP	Speculation; calls for speculation.

Plaintiff's Objection Legend

Code	Objection
106	This testimony is objectionable because it is incomplete and the introduction of the remaining portions ought, in fairness, to be considered contemporaneously with it (<i>see</i> F.R.E. 106).
402	This testimony is objectionable because it is not relevant or immaterial (<i>see</i> F.R.E. 401 and 402).
403	Misleading, confusion of issues, and/or cumulative. This testimony is objectionable because its probative value is substantially outweighed by the danger of unfair prejudice.
404	Improper character evidence
408	<i>See</i> F.R.E. 408 (Compromise Offers and Negotiations).
602	This testimony is objectionable because it constitutes testimony on a matter as to which the witness lacks personal knowledge or competency (<i>see</i> F.R.E. 602).
701	This testimony is objectionable because it is opinion testimony by a lay witness that is not reasonably based on perception and helpful to a clear understanding of the witness' testimony or the determination of a fact in dispute (<i>see</i> F.R.E. 701), and/or it calls for a legal conclusion, and/or it is attempted expert testimony from a witness who was not designated as an expert and who did not submit an expert report (<i>see</i> FRCP 26).
702	Improper expert opinion (<i>see</i> F.R.E. 702).
801	Hearsay. This testimony is objectionable because it is a statement made by one other than the declarant while testifying at trial, offered into evidence to prove the truth of the matter asserted and not subject to any hearsay exception (<i>see</i> F.R.E. 801 and 802).
1006	Improper summary, chart or calculation (<i>see</i> F.R.E. 1006).
A	This testimony is objectionable because it concerns a document for which authentication is lacking (<i>see</i> F.R.E. 901 et seq.).
AA	Asked and answered.
AF	Assumes a fact not in evidence.
AM	Ambiguous, vague, confusing, unintelligible or overbroad (<i>e.g.</i> , F.R.E. 611)
AR	Argumentative
B	Best evidence (<i>see</i> F.R.E. 1002, 1003, 1004)

Code	Objection
C	Cumulative, Duplicative, Wasteful or Undue Delay (<i>see</i> F.R.E. 403)
CQ	Compound question.
F	Lacks foundation (<i>see</i> F.R.E. 901; <i>see also</i> F.R.E. 103, 104, 105).
FRCP 30(b)(6)	Outside the scope of witness designation.
ID	Improper deposition designation (<i>e.g.</i> , attorney objections not removed, etc.)
IM	Improper impeachment (<i>see</i> F.R.E. 613)
IQ	Incomplete question/incomplete answer.
JTX	Should be moved to Joint Exhibit List
L	Leading (<i>see</i> F.R.E. 611).
MC	Mischaracterizes testimony, misleading or misstates evidence.
MIL	Subject to motion <i>in limine</i> .
N	Calls for narrative response.
FRCP 26(a)(2)	Expert improperly disclosed.
NR	Nonresponsive or volunteered answer.
OS	Outside scope of original deposition designation
SP	Speculation; calls for speculation.

EXHIBIT D

Defendants' Deposition Designations

EXHIBIT D – DEFENDANTS’ INITIAL DEPOSITION DESIGNATIONS

In addition to the rebuttal designations below, Defendants reserve the right to use any of their affirmative deposition designations as rebuttal designations to Plaintiffs’ counter deposition designations.

Witness: Harold Bays

Date: Nov. 5, 2018

Defendants’ Affirmative Designations	Plaintiffs’ Objections	Plaintiffs’ Counter Designations	Defendants’ Objections to Plaintiffs’ Counter Designations	Defendants’ Rebuttal Designations	Plaintiffs’ Objections to Defendants’ Rebuttal Designations
2:8-14	402, 801, ID				
10:2-9	402, 801, ID				
10:10-17	402, 801				
12:1-5	402, 801, F, ID, IQ				
12:7-18	402, 801, F				
12:23-13:13	801, AM				
19:24-25	402, 801				
20:1-2	402, 801				
20:4-10	106, 402, 801	20:11–21:3			
21:4-7	106, 402, 801	21:21–22:18	OS, 106, 402, 403		
22:19-21	106, 402, 801	21:21–22:18	OS, 106, 402, 403		
23:12-24:1	106, 801	23:9–11; 24:2–4	402, 403		
24:5-12	106, 801, AR	24:2–4; 24:24–25:3	OS, 402, 403		
25:22-27:10	106, 801	24:24–25:3	OS, 402, 403		
29:8-18	106, 402, 801	28:5–29:7	402, 403		
30:15-18	402, 801				
30:20-31:19	106, 402, 801, A, F	31:20–32:18	402, 403		
32:19-33:23	106, 801	31:20–32:18	OS, 402, 403		

Defendants' Affirmative Designations	Plaintiffs' Objections	Plaintiffs' Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
34:18-35:4	402, 602, 801, SP				
35:5-19	701, 801				
37:9-20	106, 602, 801	35:23–36:12	OS, 106, 402, 403		
38:15-39:1	402, 801, A, F				
39:15-23	106, 402, 602, 801, A, CQ, F	40:5–12	OS, 106, 402, 403	40:13-41:10; 41:12-23	402, 403, 801, AM
39:25-40:3	106, 402, 602, 801, A, CQ, F	40:5–12	OS, 106, 402, 403	40:13-41:10; 41:12-23	402, 403, 801, AM
42:18-43:19	402, 602, 801, A, F				
48:12-24	402, 602, 801, A, F				
49:1-2	402, 602, 801, A, F				
55:3-25	402, 602, 801, A, F				
57:13-58:8	402, 602, 801, A, F				
59:25-60:2	402, 602, 801, A, F				
60:6-61:1	106, 402, 602, 801, A, F	61:2–4	ID, IQ, 403		
62:5-12	106, 402, 801	62:13–16	ID, 402, 403		
67:23-68:4	402, 801, A				
68:6-8	402, 801, A				
68:10-14	402, 801, A				
69:8-15	106, 801	69:16–70:11	ID, OS, 106, 402, 403		
70:12-71:7	106, 801, CQ	69:16–70:11	ID, OS, 106, 402, 403		
71:12-15	402, 801				
71:17-72:8	402, 801				
72:10-21	106, 402, 801, AM	72:22–24	402, 403		

Defendants' Affirmative Designations	Plaintiffs' Objections	Plaintiffs' Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
72:25-73:7	106, 402, 701, 801, AM	72:22-24	402, 403		
73:10-16	106, 402, 701, 801	74:2-6	402, 403		
74:18-21	106, 402, 801, AM	74:22-75:3	106, 402, 403		
75:4-6	106, 402, 701, 801	74:22-75:3	106, 402, 403		
75:9	801				
75:11-12	402, 701, 801				
75:14-17	402, 701, 801				
75:19-76:16	402, 701, 801, AM, CQ				
76:22-77:11	402, 701, 801, AM, AR				
77:12-17	106, 402, 701, 801, AM, AR	78:3-19	OS, 106, 402, 403	78:20-22	402, 403, 801
77:19	106, 402, 701, 801	78:3-19	OS, 106, 402, 403	78:20-22	402, 403, 801
78:23-79:2	106, 402, 801, AM	79:14-80:14	ID, OS, 106, 402, 403	78:20-22	402, 403, 801
79:4-12	106, 402, 801	79:14-80:14	ID, OS, 106, 402, 403	78:20-22	402, 403, 801
80:16-19	106, 402, 701, 801, AR, AM, MC	79:14-80:14	ID, OS, 106, 402, 403	78:20-22	402, 403, 801
80:22-81:3	402, 701, 801				
86:17-87:11	402, 701, 801, AM				
87:13-16	402, 701, 801				
88:2-5	402, 701, 801, AM				
88:7-12	106, 402, 701, 801	88:18-89:9	ID, OS, 106, 402, 403		
89:10-90:15	402, 701, 801				

Defendants' Affirmative Designations	Plaintiffs' Objections	Plaintiffs' Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
91:11-13	402, 801				
94:6-10	402, 701, 801, AM				
94:13-14	402, 701, 801				
96:15-19	402, 801				
97:7-11	801				
97:13-15	801				
97:17-18	801				
97:21-98:5	701, 801				
98:7-17	801				
98:24-99:3	801, SP				
99:5	801				
99:7-8	106, 701, 801, AM	99:15-20	ID, OS, 402, 403		
99:10-13	106, 801	99:15-20	ID, OS, 402, 403		
99:22-24	801				
100:2-3	801				
100:5-6	701, 801, AM				
100:8-10	801				
100:12-14	602, 701, 801, SP				
100:17-20	801				
101:10-12	801				
101:16-102:5	106, 801	102:11-15; 103:11-104:13; 105:15-107:1; 117:3-119:23	ID, OS, 106, 402, 403	104:15-17, 104:20-25, 107:7-108:8, 108:10-22, 108:24-109:2	402, 403, 701, 801, AM, CQ, MC
119:24-120:2	801				
120:4-21	106, 801	106:2-107:1; 117:3-119:23; 120:22-121:20	ID, OS, 106, 402, 403, 601, 701	107:7-108:8, 108:10-22, 108:24-109:2	402, 403, 701, 801, AM, CQ

Defendants' Affirmative Designations	Plaintiffs' Objections	Plaintiffs' Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
123:17-25	106, 801	106:2–107:1; 117:3–119:23; 120:22–121:20	ID, OS, 106, 402, 403, 601, 701	107:7-108:8, 108:10-22, 108:24- 109:2	402, 403, 701, 801, AM, CQ
135:18-136:3	106, 402, 403, 701, 801, AM, MC	117:3–119:23	ID, OS, 106, 402, 403	107:7-108:8, 108:10-22, 108:24- 109:2	402, 403, 701, 801, AM, CQ, OS
136:5-7	106, 402, 403, 701, 801, AM, MC	117:3–119:23	ID, OS, 106, 402, 403	107:7-108:8, 108:10-22, 108:24- 109:2	402, 403, 701, 801, AM, CQ, OS
136:9-137:8	106, 402, 403, 701, 801, AM, MC	117:3–119:23	ID, OS, 106, 402, 403	107:7-108:8, 108:10-22, 108:24- 109:2	402, 403, 701, 801, AM, CQ, OS
137:10-11	106, 701, 801	117:3–119:23	ID, OS, 106, 402, 403	107:7-108:8, 108:10-22, 108:24- 109:2	402, 403, 701, 801, AM, CQ, OS
137:21-138:2	106, 402, 801	138:3–25	ID, OS, 106, 402, 403		
139:1-4	106, 701, 801	138:3–25	ID, OS, 106, 402, 403		
139:6-140:4	106, 701, 801	138:3–25	ID, OS, 106, 402, 403		
140:6-8	701, 801, AM, CQ				
140:10-11	701, 801, AM, CQ				
140:14-141:2	701, 801				
141:4-8	701, 801				
142:10-14	701, 801, AM, CQ				
142:17-143:7	701, 801				
143:9-11	701, 801, AM				

Defendants' Affirmative Designations	Plaintiffs' Objections	Plaintiffs' Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
143:13-19	701, 801				
143:21-144:3	701, 801, AM, AR, CQ				
144:5-10	701, 801				
144:12-21	801				
144:23-145:9	701, 801				
145:11-146:6	701, 801, AM, CQ				
145:20-21	801				
151:14-17	801				
151:21-152:21	801, A, F				
153:3-5	801				
153:9-154:20	106, 801, A, F	154:21–155:8	ID, 106, 402, 403		
155:9-12	106, 801, AM	154:21–155:8; 155:13–157:16	ID, OS, 106, 402, 403, 601, 701, Non-responsive	157:19-158:8	402, 403, 801, AR, ID
158:9-18	106, 801	155:13–157:16; 158:19–159:1	ID, OS, 106, 402, 403, 601, 701, Non-responsive	157:19-158:8	402, 403, 801, AR, ID
159:2-160:3	106, 801, AM, AR, CQ	158:19–159:1; 160:4–25	ID, OS, 106, 402, 403		
161:2-18	801, AM, AR				
162:13-163:12	106, 801, A, F	163:13–166:6	OS, 402, 403		
166:7-23	801, A, F				
166:25-167:2	602, 801				
168:16-18	801, AM, SP				
168:20	602, 801				
168:22-169:13	801				
176:22-177:7	801				

Defendants' Affirmative Designations	Plaintiffs' Objections	Plaintiffs' Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
177:19-179:4	402, 801, AM, CQ				
179:5-8	402, 801, CQ				
179:10-17	801				
180:1-13	402, 403, 801, A, AM, F, ID, SP				
182:6-21	801, ID				
183:4-21	801				
184:2-5	801, AM				
184:16-185:5	402, 801, A, F				
186:2-24	402, 801				
188:16-24	402, 801, MC				
189:13-20	402, 801, AM, AR				
189:22	801				
189:24-190:7	106, 402, 801, AF, F	190:8-23	ID, OS, 106, 402, 403, 601, 701, Non-responsive		
190:24-191:2	402, 801, AM, AR, SP				
191:5-15	106, 402, 801	191:16-192:16	ID, OS, 106, 402, 403		
192:17-22	402, 602, 701, 801, AM, AR, SP				
195:7-10	402, 801				
195:12-196:10	106, 402, 801	196:11-13	402, 403		
196:14-20	106, 402, 801, AM, CQ	196:11-13	402, 403		
196:23	402, 801				
196:25-197:14	402, 801				

Defendants' Affirmative Designations	Plaintiffs' Objections	Plaintiffs' Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
198:2-200:2	106, 402, 801, AR, AM	200:3–5	402, 403		
200:6-12	106, 402, 801, AM, AR	200:3–5			
202:6-203:3	402, 801				
203:5-204:3	801				
204:7-14	801				
208:10-209:6	402, 801, AR				
211:14-15	801				
211:19-212:3	801				
212:4-13	402, 801, AM				
212:15	801				
212:17	801				
212:19	801				
213:2-17	106, 402, 801	155:13–157:16	ID, OS, 106, 402, 403, 601, 701, Non-responsive	157:19-158:8	402, 403, 801, AR, ID

Witness: Aaron Berg

Date: Oct. 16, 2018

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
6:2-9	402, 801, ID, IQ				
7:6-7	402, 801				
7:13-8:3	106, 801	8:4-7	402, 403		
8:8-10:22	801				
14:21-25	801, AM				
15:2-9	801, AF, F, FRCP 30(b)(6)				
15:11	402, 801				
16:6-18	402, 801, A, F				
16:20-17:5	402, 801, A, F				
22:2-21	106, 402, 602, 801, AF, F, FRCP 30(b)(6), SP	21:13-25	ID, 402, 403		
22:23-23:3	402, 602, 801, FRCP 30(b)(6), SP				
26:14-27:2	106, 801, AF, F	25:2-14	OS, ID, 106, 402, 403	24:23-25, 25:15-26:5, 26:9-13	106, 402, 403, 801, AM, AR, MC, SP
27:9-22	106, 801	25:2-14	OS, ID, 106, 402, 403	24:23-25, 25:15-26:5, 26:9-13	106, 402, 403, 801, AM, AR, MC, SP
27:23-28:9	801, AF, F				
30:6-19	801, AM, FRCP 30(b)(6)				
33:7-15	801, AM				
33:17-23	106, 801	33:24-35:8	ID, 106, 402, 403		
35:9-13	801, AM				

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
35:15	801				
37:12-15	602, 801, AF, AR				
37:17-38:10	801, AM, CQ				
43:12-44:9	402, 801, A, F				
52:17-20	402, 801, AM, CQ, ID, IQ				
52:22-53:5	106, 701, 801, CQ	53:6–54:4	106, 402, 403		
54:5-22	106, 801, AM	53:6–54:4	106, 402, 403		
56:6-11	801, AM, CQ				
56:13-16	801, AM				
56:18-57:13	801, AF, AM, F				
59:16-60:4	801, AM, CQ				
60:6-61:15	801, AM				
61:17-22	602, 701, 801, AR, SP				
61:24-25	801				
62:2-7	602, 701, 801, SP				
62:9-13	602, 701, 801, AR				
62:15-63:8	801				
63:17-64:20	106, 801, A, F	64:21–66:14	OS, 402, 403, 601		
71:21-24	801, A, AM, F, MC				
72:2-11	801, AM, AR				
72:13-21	106, 801	72:22–73:12	ID, 402, 403		
75:16-22	801, AM, CQ				
75:24-77:7	801, AM, SP				
77:9-13	106, 801	77:14–79:20	ID, OS, 106, 402, 403	79:21-80:20	402, 403, 801

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
81:10-82:2	402, 801, A, F				
84:21-85:3	402, 801, A, F				
94:6-96:2	801, AM, MC				
96:3-25	801, A, F				
99:7-100:17	402, 403, 801, A, AM, F				
122:9-12	106, 801, AM	39:9-12; 40:2-13; 122:24-123:13; 123:25-124:6	ID, OS, IQ, 106, 402, 403	40:14-41:4, 41:6-42:2, 77:9-13, 124:7-10, 124:12-19, 124:21-125:1-6, 125:8-10, 125:12	106, 402, 403, 801, AF, AM, CQ, ID, IQ, MC, SP
122:14-20	106, 801, AM	39:9-12; 40:2-13; 122:24-123:13; 123:25-124:6	ID, OS, IQ, 106, 402, 403	40:14-41:4, 41:6-42:2, 77:9-13, 124:7-10, 124:12-19, 124:21-125:1-6, 125:8-10, 125:12	106, 402, 403, 801, AF, AM, CQ, ID, IQ, MC, SP
122:22-23	106, 801	39:9-12; 40:2-13; 122:24-123:13; 123:25-124:6	ID, OS, IQ, 106, 402, 403	40:14-41:4, 41:6-42:2, 77:9-13, 124:7-10, 124:12-19, 124:21-125:1-6, 125:8-10, 125:12	106, 402, 403, 801, AF, AM, CQ, ID, IQ, MC, SP
126:12-127:5	402, 801, A, F				
137:4-138:2	106, 801, A, AM, F	138:3-139:15	ID, OS, IQ, 106, 402, 403, 601, 701	139:16-141:4	402, 403, 801, AM, CQ, MC
143:13-15	106, 801, A, F	143:16-20	ID, OS, IQ, 402, 403		
143:21-25	801				

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
144:2-145:19	402, 403, 801, A, AM, CQ, F				
145:24-146:15	801, AF				
146:16-18	801				
147:10-149:22	106, 801, AM, CQ	150:9-21; 192:16-193:10	ID, OS, 106, 402, 403	149:23-150:8	402, 403, 801
150:22-151:20	106, 801, A, F	152:5-21	OS, 106, 402, 403	152:22-155:13	402, 403, 801, AM, CQ, MC
155:14-25	106, 801, AM, CQ	156:2-7	OS, 106, 402, 403		
156:8-14	801, AM				
157:21-158:11	801, A, F				
161:8-162:10	106, 801, A, F	162:15-166:9	ID, OS, 402, 403		
169:23-170:25	106, 402, 801, AM	173:15-174:16	OS, 106, 402, 403	172:16-173:14, 174:17-175:4	402, 403, 801
175:18-22	801, A, F				
176:4-25	106, 402, 403, 801, A, F	177:2-13	OS, 106, 402, 403	178:17-179:15	402, 403, 801, AM, OS
179:16-180:9	106, 801, A, F	181:14-183:14; 192:16-193:10	OS, 106, 402, 403		
189:20-190:25	106, 801, A, AM, F	187:2-188:6	OS, 106, 402, 403	188:7-23, 188:25-189:3	402, 403, 801, AM, CQ
193:23-194:8	801, A, F				
196:11-197:15	106, 801, A, AM, F, MC	194:9-196:10	ID, OS, 402, 403		
197:17-198:3	801				
198:5-8	801				

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
198:16-17	8402, 801, FRCP30(b)(6), OS, SP				
198:19-21	602, 801, SP				
200:21-23	402, 801, A, F				
201:11-202:13	402, 801				
207:16-208:8	402, 801				
211:9-212:10	402, 801				
214:9-25	106, 801, AM, CQ	216:7-12	OS, 106, 402, 403	215:2-20	402, 403, 801, AM
217:7-16	106, 801	216:13-217:6	OS, 106, 402, 403	215:2-20	402, 403, 801, AM, OS
218:19-219:18	801, AM				
228:6-229:5	106, 801, A, AM, F	227:12-228:5; 232:13-233:17	ID, OS, 106, 402, 403	226:16-227:8, 227:10-11, 229:6-230:23, 231:16-232:12, 233:18-22	402, 403, 801, AM
230:5-23	106, 402, 801, A, AM, F	227:12-228:5; 232:13-233:17	ID, OS, 106, 402, 403	226:16-227:8, 227:10-11, 228:6-229:6-230:4, 231:16-232:12, 233:18-22	402, 403, 801, AM
234:5-235:2	801, A, AM, F				
235:4	801				
237:5-22	402, 801, A, F				
238:2-9	402, 801, A, F				
242:24-243:23	402, 801, A, F				
245:4-18	801				
245:23-246:5	801				

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
250:23-251:7	801				
251:13-23	801, AM, CQ				
254:21-22	801, AM				
254:24-255:7	801, AM				
255:8-18	801				
255:22-256:3	801				
256:3-14	801				
257:8-11	402, 801, ID				
257:17-21	106, 801, AM, ID, IQ	257:22–258:5			
258:6-10	106, 801, ID, IQ	257:22–258:5			
258:22-25	602, 801, AM, CQ, SP				
259:2-7	602, 801, AM, CQ, SP				
261:7-16	402, 801				
262:2-10	402, 801, AM				
262:12-263:19	402, 801, AM				
266:19-22	602, 701, 801, FRCP 30(b)(6), OS				
266:23-24	602, 701, 801, FRCP 30(b)(6), OS				
267:4-5	801, FRCP 30(b)(6), OS				

Witness: Rebecca Juliano

Date: Oct. 30, 2018

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
5:2-11	801				
6:19-20	402				
7:12-15	801				
8:6-25	801				
9:2-25	801				
10:2-15	801				
11:11-13	602, 801, A, F				
11:19-23	602, 801, A, AM, F				
12:3-20	801, AM, CQ				
14:7-12					
22:7-25	106, 402, 602, 801, A, F	44:3-7; 44:9-13	OS, 106, 402, 403, 601	44:14-18, 44:20-23	106, 402, 403, 801, AF, AM, FRCP 30(b)(6), MC, OS
23:2-14	106, 402, 602, 801, A, AM, CQ, F, FRCP 30(b)(6)	44:3-7; 44:9-13	OS, 106, 402, 403, 601	44:14-18, 44:20-23	106, 402, 403, 801, AF, AM, FRCP 30(b)(6), MC, OS
23:16-25	106, 402, 602, 801, A, AM, CQ, F, FRCP 30(b)(6)	44:3-7; 44:9-13	OS, 106, 402, 403, 601	44:14-18, 44:20-23	106, 402, 403, 801, AF, AM, FRCP 30(b)(6), MC, OS

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
24:2-11	106, 402, 602, 801, A, F, FRCP 30(b)(6), ID	27:20–25; 28:2–3; 28:6–12; 44:3–7; 44:9–13	OS, 106, 402, 403, 601	27:8-10, 27:13-19, 44:14-18, 44:20-23	106, 402, 403, 602, 801, AF, AM, F, FRCP 30(b)(6), MC, OS, SP
24:13-18	106, 402, 602, 801, A, F, FRCP 30(b)(6)	27:20–25; 28:2–3; 28:6–12; 44:3–7; 44:9–13	OS, 106, 402, 403, 601	27:8-10, 27:13-19, 44:14-18, 44:20-23	106, 402, 403, 602, 801, AF, AM, F, FRCP 30(b)(6), MC, OS, SP
24:19-24	106, 402, 602, 801, A, F, FRCP 30(b)(6)	44:3–7; 44:9–13	OS, 106, 402, 403, 601	44:14-18, 44:20-23	106, 402, 403, 801, AF, AM, FRCP 30(b)(6), MC, OS
25:2-8	106, 402, 602, 801, A, AF, AM, F, FRCP 30(b)(6), SP	44:3–7; 44:9–13	OS, 106, 402, 403, 601	44:14-18, 44:20-23	106, 402, 403, 801, AF, AM, FRCP 30(b)(6), MC, OS
25:10	106, 402, 602, 801, A, AF, AM, F, FRCP 30(b)(6), SP	44:3–7; 44:9–13	OS, 106, 402, 403, 601	44:14-18, 44:20-23	106, 402, 403, 801, AF, AM, FRCP 30(b)(6), MC, OS
25:17-21	106, 402, 602, 801, A, AF, AM, F, FRCP 30(b)(6), SP	44:3–7; 44:9–13	OS, 106, 402, 403, 601	44:14-18, 44:20-23	106, 402, 403, 801, AF, AM, FRCP 30(b)(6), MC, OS
25:23-25	106, 402, 602, 801, A, AF, AM, F, FRCP 30(b)(6), SP	44:3–7; 44:9–13	OS, 106, 402, 403, 601	44:14-18, 44:20-23	106, 402, 403, 801, AF, AM, FRCP 30(b)(6), MC, OS
26:2-7	106, 402, 602, 801, A, F, FRCP 30(b)(6), SP	44:3–7; 44:9–13	OS, 106, 402, 403, 601	44:14-18, 44:20-23	106, 402, 403, 801, AF, AM, FRCP 30(b)(6), MC, OS

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
26:9-15	106, 402, 602, 801, A, F, FRCP 30(b)(6), SP	44:3-7; 44:9-13	OS, 106, 402, 403, 601	44:14-18, 44:20-23	106, 402, 403, 801, AF, AM, MC, OS
30:13-25	106, 402, 602, 801, A, AM, CQ, F, FRCP 30(b)(6), SP	27:20-25; 28:2-3; 28:6-12	OS, 106, 402, 403	27:8-10, 27:13-19,	106, 402, 403, 602, 801, AF, AM, F, FRCP 30(b)(6), MC, OS, SP
31:2-7	106, 402, 602, 801, A, AM, CQ, F, FRCP 30(b)(6), SP	27:20-25; 28:2-3; 28:6-12	OS, 106, 402, 403	27:8-10, 27:13-19,	106, 402, 403, 602, 801, AF, AM, F, FRCP 30(b)(6), MC, OS, SP
31:9-13	106, 402, 602, 801, A, AM, CQ, F, FRCP 30(b)(6), SP	27:20-25; 28:2-3; 28:6-12	OS, 106, 402, 403	27:8-10, 27:13-19,	106, 402, 403, 602, 801, AF, AM, F, FRCP 30(b)(6), MC, OS, SP
31:21-32:10	106, 402, 602, 801, F, ID	18:5-19; 20:13-25; 21:2-6	OS, 106, 402, 403	17:13-18:4, 20:6-12	106, 402, 403, 801, AM, ID, IQ, OS
32:19-24	106, 402, 801, AM	18:5-19; 20:13-25; 21:2-6	OS, 106, 402, 403	17:13-18:4, 20:6-12	106, 402, 403, 801, AM, ID, IQ, OS
34:25	106, 402, 602, 801, AM, F, FRCP 30(b)(6), MC, SP	44:3-7; 44:9-13	OS, 106, 402, 403, 601	44:14-18, 44:20-23	106, 402, 403, 801, AF, AM, FRCP 30(b)(6), MC, OS
35:2-25	106, 402, 602, 801, AM, F, FRCP 30(b)(6), MC, SP	44:3-7; 44:9-13	OS, 106, 402, 403, 601	44:14-18, 44:20-23	106, 402, 403, 801, AF, AM, FRCP 30(b)(6), MC, OS
36:2-12	106, 402, 602, 801, AM, F, FRCP 30(b)(6), SP	91:21-22; 91:24-25; 92:2; 117:18-25; 118:4-14	OS, 106, 402, 403	91:15-17, 91:19-20, 92:12-93:6, 93:9-15	106, 402, 403, 701, 801, AA, AF, AM,

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
					FRCP 30(b)(6), ID, MC, OS
36:14-15	106, 402, 602, 801, AM, F, FRCP 30(b)(6), SP	91:21-22; 91:24-25; 92:2; 117:18-25; 118:4-14	OS, 106, 402, 403	91:15-17, 91:19-20, 92:12-93:6, 93:9-15	106, 402, 403, 701, 801, AA, AF, AM, FRCP 30(b)(6), ID, MC, OS
37:3-5	402, 602, 801, F, FRCP 30(b)(6)				
37:7-25	402, 602, 801, AF, AM, F, FRCP 30(b)(6)				
38:2-5	402, 602, 801, AF, AM, F, FRCP 30(b)(6)				
38:7	402, 602, 801, AF, AM, F, FRCP 30(b)(6)				
39:13-20	106, 402, 602, 801, AM, F, FRCP 30(b)(6)	103:17-19; 103:21-25; 104:2-7; 104:18-21; 104:24-25; 105:2-5; 105:8-23	OS, 106, 402, 403	105:24-106:8	106, 402, 403, 602, 701, 801, AM, C, CQ, F, FRCP 30(b)(6), ID, OS, SP
39:22-25	106, 402, 602, 801, AM, F, FRCP 30(b)(6)	103:17-19; 103:21-25; 104:2-7; 104:18-21; 104:24-25; 105:2-5; 105:8-23	OS, 106, 402, 403	105:24-106:8	106, 402, 403, 602, 701, 801, AM, C, CQ, F, FRCP 30(b)(6), ID, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
40:2-7	106, 402, 602, 801, AM, F, FRCP 30(b)(6)	103:17-19; 103:21-25; 104:2-7; 104:18-21; 104:24-25; 105:2-5; 105:8-23	OS, 106, 402, 403	105:24-106:8	106, 402, 403, 602, 701, 801, AM, C, CQ, F, FRCP 30(b)(6), ID, OS, SP
40:9-17	106, 402, 602, 801, AM, F, FRCP 30(b)(6)	103:17-19; 103:21-25; 104:2-7; 104:18-21; 104:24-25; 105:2-5; 105:8-23	OS, 106, 402, 403	105:24-106:8	106, 402, 403, 602, 701, 801, AM, C, CQ, F, FRCP 30(b)(6), ID, OS, SP
40:19-21	402, 602, 801, AM, F, FRCP 30(b)(6)				
41:8-16	402, 801				
42:12-15	402, 602, 701, 801, AM, F, FRCP 30(b)(6), SP				
42:18-43:10	402, 602, 701, 801, A, AM, F, FRCP 30(b)(6), ID, SP				
48:6-7	402, 602, 801, F				
48:12-15	402, 602, 801, F				
49:9-15	402, 602, 801, F, ID				
49:20-25	402, 602, 801, F				
50:2-7	402, 403, 602, 801, AM, F, FRCP 30(b)(6), SP				

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
50:9-22	402, 403, 602, 801, AM, F, FRCP 30(b)(6), SP				
51:10-16	106, 402, 403, 602, 801, AM, F, IQ, SP	55:25; 56:2-3; 56:5-14; 56:19-25; 57:2-4; 57:7-13; 103:17-19; 103:21-25; 104:2-7; 104:18-21; 104:24-25; 105:2-5; 105:8-23; 169:8-12; 169:14-21	OS, 106, 402, 403, SP, 601, 701	54:6-7, 54:10-14, 105:24-106:8, 168:20-169:4, 169:6-7, 169:22-170:6	106, 402, 403, 602, 701, 801, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, OS, SP
52:13-53:12	106, 801, ID	149:13-16; 149:18-25; 150:2-9; 150:11-19	OS, 106, 402, 403	150:20-151:2, 151:7-16, 151:18-21	106, 402, 403, 801, AA, AM, ID, OS
53:17-25	106, 402, 701, 801, AM	18:5-19; 20:13-25; 21:2-6; 54:24-25; 55:2; 55:9-14; 55:18-24; 55:25; 56:2-3; 56:5-14; 56:19-25; 57:2-4; 57:7-13; 64:3-4; 64:6-24; 65:3-9; 65:10-13; 65:15-25; 66:2; 67:13-18; 67:20-22; 78:22-24; 79:10-15; 80:10-11; 80:15-	ID, OS, 106, 402, 403, 601, 701, 801	17:13-18:4, 20:6-12, 54:6-7, 54:10-14, 67:6-12, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 79:16-18, 79:20-80:3, 80:7-9, 80:23-81:12, 150:20-151:2, 151:7-16, 151:18-21, 156:19-22, 157:14-18, 163:19-24, 164:2-5,	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, IQ, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		16; 149:13–16; 149:18–25; 150:2–9; 150:11–19; 155:20–25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–25; 166:2–4; 172:2–7; 172:10–16; 179:9–14; 179:16–21; 182:3–25; 183:2–16; 183:19–24		179:22–25, 180:4–10, 180:13–16, 184:5–6, 184:9–11	
54:2–5	106, 402, 701, 801, AM	18:5–19; 20:13–25; 21:2–6; 54:24–25; 55:2; 55:9–14; 55:18–24; 55:25; 56:2–3; 56:5–14; 56:19–25; 57:2–4; 57:7–13; 64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 67:13–18; 67:20–22; 78:22–24; 79:10–15; 80:10–11; 80:15–16; 149:13–16; 149:18–25; 150:2–	ID, OS, 106, 402, 403, 601, 701, 801	17:13–18:4, 20:6–12, 54:6–7, 54:10–14, 67:6–12, 67:23–68:4, 68:9–16, 68:18–69:3, 69:7–11, 79:16–18, 79:20–80:3, 80:7–9, 80:23–81:12, 150:20–151:2, 151:7–16, 151:18–21, 156:19–22, 157:14–18, 163:19–24, 164:2–5, 179:22–25, 180:4–	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, IQ, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		9; 150:11–19; 155:20–25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–25; 166:2–4; 172:2–7; 172:10–16; 179:9–14; 179:16–21; 182:3–25; 183:2–16; 183:19–24		10, 180:13-16, 184:5-6, 184:9-11	
63:11-16	106, 402, 801, AM	18:5–19; 20:13–25; 21:2–6; 64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 67:13–18; 67:20–22; 78:22–24; 79:10–15; 80:10–11; 80:15–16; 149:13–16; 149:18–25; 150:2–9; 150:11–19; 155:20–25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–25; 166:2–4; 172:2–7; 172:10–	ID, OS, 106, 402, 403, 601, 701, 801	17:13-18:4, 20:6-12, 54:6-7, 54:10-14, 67:6-12, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 79:16-18, 79:20-80:3, 80:7-9, 80:23-81:12, 150:20-151:2, 151:7-16, 151:18-21, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 179:22-25, 180:4-10, 180:13-16, 184:5-6, 184:9-11	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, IQ, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		16; 179:9–14; 179:16–21; 182:3–25; 183:2–16; 183:19–24			
63:18-25	106, 402, 801, AM	18:5–19; 20:13–25; 21:2–6; 64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 67:13–18; 67:20–22; 78:22–24; 79:10–15; 80:10–11; 80:15–16; 149:13–16; 149:18–25; 150:2–9; 150:11–19; 155:20–25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–25; 166:2–4; 172:2–7; 172:10–16; 179:9–14; 179:16–21; ; 183:2–16; 183:19–24	ID, OS, 106, 402, 403, 601, 701, 801	17:13-18:4, 20:6-12, 54:6-7, 54:10-14, 67:6-12, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 79:16-18, 79:20-80:3, 80:7-9, 80:23-81:12, 150:20-151:2, 151:7-16, 151:18-21, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 179:22-25, 180:4-10, 180:13-16, 184:5-6, 184:9-11	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, IQ, MC, OS, SP
64:2	106, 402, 801, AM	18:5–19; 20:13–25; 21:2–6; 64:3–4; 64:6–24; 65:3–9;	ID, OS, 106, 402, 403, 601, 701, 801	17:13-18:4, 20:6-12, 54:6-7, 54:10-14, 67:6-12, 67:23-	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F,

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		65:10–13; 65:15–25; 66:2; 67:13–18; 67:20–22; 78:22–24; 79:10–15; 80:10–11; 80:15–16; 149:13–16; 149:18–25; 150:2–9; 150:11–19; 155:20–25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–25; 166:2–4; 172:2–7; 172:10–16; 179:9–14; 179:16–21; 182:3–25; 183:2–16; 183:19–24		68:4, 68:9–16, 68:18–69:3, 69:7–11, 79:16–18, 79:20–80:3, 80:7–9, 80:23–81:12, 150:20–151:2, 151:7–16, 151:18–21, 156:19–22, 157:14–18, 163:19–24, 164:2–5, 179:22–25, 180:4–10, 180:13–16, 184:5–6, 184:9–11	FRCP 30(b)(6), ID, IQ, MC, OS, SP
71:15–23	106, 402, 801, AM	18:5–19; 20:13–25; 21:2–6; 64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 66:3–7; 66:9–10; 66:12–25; 67:2–5; 67:13–18; 67:20–22; 72:9–17; 78:22–24; 79:10–15; 80:10–11;	ID, OS, 106, 402, 403, 601, 701, 801	17:13–18:4, 20:6–12, 54:6–7, 54:10–14, 67:6–12, 67:23–68:4, 68:9–16, 68:18–69:3, 69:7–11, 79:16–18, 79:20–80:3, 80:7–9, 80:23–81:12, 150:20–151:2, 151:7–16, 151:18–	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, IQ, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		80:15–16; 149:13–16; 149:18–25; 150:2–9; 150:11–19; 155:20–25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–25; 166:2–4; 172:2–7; 172:10–16; 179:9–14; 179:16–21; 182:3–25; 183:2–16; 183:19–24		21, 156:19–22, 157:14–18, 163:19–24, 164:2–5, 179:22–25, 180:4–10, 180:13–16, 184:5–6, 184:9–11	
71:25	106, 402, 801, AM	18:5–19; 20:13–25; 21:2–6; 64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 67:13–18; 67:20–22; 72:9–17; 78:22–24; 79:10–15; 80:10–11; 80:15–16; 149:13–16; 149:18–25; 150:2–9; 150:11–19; 155:20–25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–	ID, OS, 106, 402, 403, 601, 701, 801	17:13–18:4, 20:6–12, 54:6–7, 54:10–14, 67:6–12, 67:23–68:4, 68:9–16, 68:18–69:3, 69:7–11, 79:16–18, 79:20–80:3, 80:7–9, 80:23–81:12, 150:20–151:2, 151:7–16, 151:18–21, 156:19–22, 157:14–18, 163:19–24, 164:2–5, 179:22–25, 180:4–	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, IQ, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		11; 165:19–25; 166:2–4; 172:2–7; 172:10–16; 179:9–14; 179:16–21; 182:3–25; 183:2–16; 183:19–24		10, 180:13-16, 184:5-6, 184:9-11	
72:2-8	106, 402, 801, AM	18:5–19; 20:13–25; 21:2–6; 64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 67:13–18; 67:20–22; 72:9–17; 78:22–24; 79:10–15; 80:10–11; 80:15–16; 149:13–16; 149:18–25; 150:2–9; 150:11–19; 155:20–25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–25; 166:2–4; 172:2–7; 172:10–16; 179:9–14; 179:16–21; 182:3–25; 183:2–16; 183:19–24	ID, OS, 106, 402, 403, 601, 701, 801	17:13-18:4, 20:6-12, 54:6-7, 54:10-14, 67:6-12, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 79:16-18, 79:20-80:3, 80:7-9, 80:23-81:12, 150:20-151:2, 151:7-16, 151:18-21, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 179:22-25, 180:4-10, 180:13-16, 184:5-6, 184:9-11	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, IQ, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
76:7-17	106, 402, 403, 602, 801, AM				
76:19-25	106, 402, 403, 602, 701, 801, AM, AR	18:5–19; 20:13–25; 21:2–6; 64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 66:3–7; 66:9–10; 66:12–25; 67:2–5; 67:13–18; 67:20–22; 78:22–24; 79:10–15; 80:10–11; 80:15–16; 103:17–19; 103:21–25; 104:2–7; 104:18–21; 104:24–25; 105:2–5; 105:8–23; 155:20–25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–25; 166:2–4; 172:2–7; 172:10–16; 179:9–14; 179:16–21; 182:3–25; 183:2–16; 183:19–24	ID, OS, 106, 402, 403, 601, 701, 801	17:13-18:4, 20:6-12, 54:6-7, 54:10-14, 67:6-12, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 79:20-80:3, 80:7-9, 80:23-81:12, 150:20-151:2, 151:7-16, 151:18-21, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 179:22-25, 180:4-10, 180:13-16, 184:5-6, 184:9-11	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, IQ, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
77:2	106, 402, 403, 602, 701, 801, AM, AR	18:5–19; 20:13–25; 21:2–6; 64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 66:3–7; 66:9–10; 66:12–25; 67:2–5; 67:13–18; 67:20–22; 103:17–19; 103:21–25; 104:2–7; 104:18–21; 104:24–25; 105:2–5; 105:8–23; 155:20–25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–25; 166:2–4; 172:2–7; 172:10–16; 179:9–14; 179:16–21; 182:3–25; 183:2–16; 183:19–24	ID, OS, 106, 402, 403, 601, 701, 801	17:13-18:4, 20:6-12, 54:6-7, 54:10-14, 67:6-12, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 79:20-80:3, 80:7-9, 80:23-81:12, 150:20-151:2, 151:7-16, 151:18-21, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 179:22-25, 180:4-10, 180:13-16, 184:5-6, 184:9-11	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, IQ, MC, OS, SP
77:7-18	106, 402, 403, 602, 701, 801, AM, AR	18:5–19; 20:13–25; 21:2–6; 64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 66:3–7; 66:9–10; 66:12–25;	ID, OS, 106, 402, 403, 601, 701, 801	17:13-18:4, 20:6-12, 54:6-7, 54:10-14, 67:6-12, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 79:20-80:3,	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, IQ, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		67:2-5; 67:13-18; 67:20-22; 78:22-24; 79:10-15; 80:10-11; 80:15-16; 103:17-19; 103:21-25; 104:2-7; 104:18-21; 104:24-25; 105:2-5; 105:8-23; 155:20-25; 156:2-18; 157:19-25; 158:2-3; 158:5-16; 164:6-11; 165:19-25; 166:2-4; 172:2-7; 172:10-16; 179:9-14; 179:16-21; 182:3-25; 183:2-16; 183:19-24		80:7-9, 80:23-81:12, 150:20-151:2, 151:7-16, 151:18-21, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 179:22-25, 180:4-10, 180:13-16, 184:5-6, 184:9-11	
82:3-5	402, 801				
82:12-14	106, 402, 602, 801, AM, F, IQ, FRCP 30(b)(6), SP	83:24-25; 84:2; 84:5-23; 91:21-22; 91:24-25; 92:2; 93:16-19; 93:23-25; 94:2-11; 94:15-25; 95:2-6; 95:14-17; 95:19-25; 96:2-21;	OS, 106, 402, 403, 601, 701, 801	91:15-17, 91:19-20, 92:12-93:6, 93:9-15,	106, 402, 403, 701, 801, AA, AF, AM, FRCP 30(b)(6), ID, MC, OS

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		99:13–15; 99:18–25; 100:2–3			
82:17-18	106, 402, 602, 801, AM, F, IQ, FRCP 30(b)(6), SP	83:24–25; 84:2; 84:5–23; 91:21–22; 91:24–25; 92:2; 93:16–19; 93:23–25; 94:2–11; 94:15–25; 95:2–6; 95:14–17; 95:19–25; 96:2–21; 99:13–15; 99:18–25; 100:2–3	OS, 106, 402, 403, 601, 701, 801	91:15-17, 91:19-20, 92:12-93:6, 93:9-15	106, 402, 403, 701, 801, AA, AF, AM, FRCP 30(b)(6), ID, MC, OS
82:21-25	106, 402, 602, 801, AM, F, IQ, FRCP 30(b)(6), SP	83:24–25; 84:2; 84:5–23; 91:21–22; 91:24–25; 92:2; 93:16–19; 93:23–25; 94:2–11; 94:15–25; 95:2–6; 95:14–17; 95:19–25; 96:2–21; 99:13–15; 99:18–25; 100:2–3	OS, 106, 402, 403, 601, 701, 801	91:15-17, 91:19-20, 92:12-93:6, 93:9-15	106, 402, 403, 701, 801, AA, AF, AM, FRCP 30(b)(6), ID, MC, OS
83:2-16	106, 402, 602, 801, AM, F, FRCP 30(b)(6), SP	83:24–25; 84:2; 84:5–23; 91:21–22; 91:24–25; 92:2; 93:16–19; 93:23–25; 94:2–11; 94:15–25; 95:2–6;	OS, 106, 402, 403, 601, 701, 801	91:15-17, 91:19-20, 92:12-93:6, 93:9-15	106, 402, 403, 701, 801, AA, AF, AM, FRCP 30(b)(6), ID, MC, OS

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		95:14–17; 95:19–25; 96:2–21; 99:13–15; 99:18–25; 100:2–3			
83:18-23	106, 402, 602, 801, AM, F, FRCP 30(b)(6), SP	83:24–25; 84:2; 84:5–23; 91:21–22; 91:24–25; 92:2; 93:16–19; 93:23–25; 94:2–11; 94:15–25; 95:2–6; 95:14–17; 95:19–25; 96:2–21; 99:13–15; 99:18–25; 100:2–3	OS, 106, 402, 403, 601, 701, 801	91:15-17, 91:19-20, 92:12-93:6, 93:9-15	106, 402, 403, 701, 801, AA, AF, AM, FRCP 30(b)(6), ID, MC, OS
84:24-25	106, 402, 602, 801, AM, F, FRCP 30(b)(6), MC, SP	83:24–25; 84:2; 84:5–23; 93:16–19; 93:23–25; 94:2–11; 94:15–25; 95:2–6; 95:14–17; 95:19–25; 96:2–21; 99:13–15; 99:18–25; 100:2–3	OS, 106, 402, 403, 601, 701, 801	91:15-17, 91:19-20, 92:12-93:6, 93:9-15	106, 402, 403, 701, 801, AA, AF, AM, FRCP 30(b)(6), ID, MC, OS
85:2-4	106, 402, 602, 801, AM, F, FRCP 30(b)(6), MC, SP	83:24–25; 84:2; 84:5–23; 91:21–22; 91:24–25; 92:2; 93:16–19; 93:23–25; 94:2–11; 94:15–25; 95:2–6;	OS, 106, 402, 403, 601, 701, 801	91:15-17, 91:19-20, 92:12-93:6, 93:9-15	106, 402, 403, 701, 801, AA, AF, AM, FRCP 30(b)(6), ID, MC, OS

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		95:14–17; 95:19–25; 96:2–21; 99:13–15; 99:18–25; 100:2–3			
85:7-13	106, 402, 602, 801, AM, F, FRCP 30(b)(6), MC, SP	83:24–25; 84:2; 84:5–23; 91:21–22; 91:24–25; 92:2; 93:16–19; 93:23–25; 94:2–11; 94:15–25; 95:2–6; 95:14–17; 95:19–25; 96:2–21; 99:13–15; 99:18–25; 100:2–3	OS, 106, 402, 403, 601, 701, 801	91:15-17, 91:19-20, 92:12-93:6, 93:9-15	106, 402, 403, 701, 801, AA, AF, AM, FRCP 30(b)(6), ID, MC, OS
85:18-21	106, 402, 701, 801, AM, FRCP 30(b)(6)	83:24–25; 84:2; 84:5–23; 86:6–10; 86:13–20; 88:8–11; 88:13–25; 89:2–13; 91:21–22; 91:24–25; 92:2	OS, 106, 402, 403, 601, 701, 801	91:15-17, 91:19-20	106, 402, 403, 701, 801, AA, FRCP 30(b)(6), OS
85:23-24	106, 402, 403, 701, 801, AM, FRCP 30(b)(6)	83:24–25; 84:2; 84:5–23; 86:6–10; 86:13–20; 88:8–11; 88:13–25; 89:2–13; 91:21–22; 91:24–25; 92:2	OS, 106, 402, 403, 601, 701, 801	91:15-17, 91:19-20	106, 402, 403, 701, 801, AA, FRCP 30(b)(6), OS

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
86:2-5	106, 402, 403, 701, 801, AM, FRCP 30(b)(6)	83:24-25; 84:2; 84:5-23; 86:6-10; 86:13-20; 88:8-11; 88:13-25; 89:2-13; 91:21-22; 91:24-25; 92:2	OS, 106, 402, 403, 601, 701, 801	91:15-17, 91:19-20	1106, 402, 403, 701, 801, AA, FRCP 30(b)(6), OS
87:7-10	106, 402, 403, 701, 801, AM, FRCP 30(b)(6)	83:24-25; 84:2; 84:5-23; 86:6-10; 86:13-20; 88:8-11; 88:13-25; 89:2-13; 91:21-22; 91:24-25; 92:2	OS, 106, 402, 403, 601, 701, 801	91:15-17, 91:19-20	106, 402, 403, 701, 801, AA, FRCP 30(b)(6), OS
87:14-19	106, 402, 403, 701, 801, AM, FRCP 30(b)(6)	83:24-25; 84:2; 84:5-23; 86:6-10; 86:13-20; 88:8-11; 88:13-25; 89:2-13; 91:21-22; 91:24-25; 92:2	OS, 106, 402, 403, 601, 701, 801	91:15-17, 91:19-20	106, 402, 403, 701, 801, AA, FRCP 30(b)(6), OS
87:23-25	106, 402, 403, 602, 701, 801, AM, FRCP 30(b)(6), SP	83:24-25; 84:2; 84:5-23; 86:6-10; 86:13-20; 88:8-11; 88:13-25; 89:2-13; 91:21-22; 91:24-25; 92:2	OS, 106, 402, 403, 601, 701, 801	91:15-17, 91:19-20	106, 402, 403, 701, 801, AA, FRCP 30(b)(6), OS
88:2-11	106, 402, 403, 602, 701, 801, AM, FRCP 30(b)(6), SP	83:24-25; 84:2; 84:5-23; 86:6-10; 86:13-20; 88:8-11; 88:13-25; 89:2-13;	OS, 106, 402, 403, 601, 701, 801	91:15-17, 91:19-20	106, 402, 403, 701, 801, AA, FRCP 30(b)(6), OS

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		91:21-22; 91:24-25; 92:2			
88:13-25	106, 402, 403, 602, 701, 801, AM, FRCP 30(b)(6), SP	83:24-25; 84:2; 84:5-23; 86:6-10; 86:13-20; 91:21-22; 91:24-25; 92:2	OS, 106, 402, 403, 601, 701, 801	91:15-17, 91:19-20	106, 402, 403, 701, 801, AA, FRCP 30(b)(6), OS
89:2-13	106, 402, 403, 602, 701, 801, AM, FRCP 30(b)(6), SP	83:24-25; 84:2; 84:5-23; 86:6-10; 86:13-20; 91:21-22; 91:24-25; 92:2	OS, 106, 402, 403, 601, 701, 801	91:15-17, 91:19-20	106, 402, 403, 701, 801, AA, FRCP 30(b)(6), OS
96:22-23	106, 402, 602, 701, 801, AM, F, FRCP 30(b)(6), SP	94:2-11; 94:15-25; 95:2-6; 95:14-17; 95:19-25; 96:2-21; 99:13-15; 99:18-25; 100:2-3	OS, 106, 402, 403, 601, 701, 801	92:12-93:6, 93:9-15	106, 402, 403, 801, AF, AM, FRCP 30(b)(6), ID, MC, OS
97:2-4	106, 402, 602, 701, 801, AM, F, FRCP 30(b)(6), SP	94:2-11; 94:15-25; 95:2-6; 95:14-17; 95:19-25; 96:2-21; 99:13-15; 99:18-25; 100:2-3	OS, 106, 402, 403, 601, 701, 801	92:12-93:6, 93:9-15	106, 402, 403, 801, AF, AM, FRCP 30(b)(6), ID, MC, OS
98:12-21	402, 801				
100:4-10	402, 602, 701, 801, A, F, FRCP 30(b)(6)				
100:12-19	106, 402, 602, 701, 801, A, AM, F, FRCP 30(b)(6)	64:3-4; 64:6-24; 65:3-9; 65:10-13; 65:15-25; 66:2; 95:14-17; 95:19-	OS, 106, 402, 403, 601, 701, 801	67:6-12, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 92:12-93:6,	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F,

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		25; 96:2–21; 99:13–15; 99:18–25; 100:2–3; 103:17–19; 103:21–25; 104:2–7; 104:18–21; 104:24–25; 105:2–5; 105:8–23; 126:20–22; 126:24–25; 127:2–16; 155:20–25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–25; 166:2–4; 172:2–7; 172:10–16; 179:9–14; 179:16–21; 182:3–25; 183:2–16; 183:19–24		93:9-15, 105:24-106:8, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 179:22-25, 180:4-10, 180:13-16, 184:5-6, 184:9-11	FRCP 30(b)(6), ID, MC, OS, SP
100:22-25	106, 402, 602, 701, 801, A, AM, F, FRCP 30(b)(6)	64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 67:13–18; 67:20–22; 95:14–17; 95:19–25; 96:2–21; 99:13–15; 99:18–25; 100:2–3;	OS, 106, 402, 403, 601, 701, 801	67:6-12, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 92:12-93:6, 93:9-15, 105:24-106:8, 156:19-22, 157:14-18, 163:19-24, 164:2-5,	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		103:17–19; 103:21–25; 104:2–7; 104:18–21; 104:24–25; 105:2–5; 105:8–23; 126:20–22; 126:24–25; 127:2–16; 155:20–25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–25; 166:2–4; 172:2–7; 172:10–16; 179:9–14; 179:16–21; 182:3–25; 183:2–16; 183:19–24		179:22–25, 180:4–10, 180:13–16, 184:5–6, 184:9–11	
101:2–7	106, 402, 602, 701, 801, AM, F, FRCP 30(b)(6)	64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 67:13–18; 67:20–22; 95:14–17; 95:19–25; 96:2–21; 99:13–15; 99:18–25; 100:2–3; 103:17–19; 103:21–25; 104:2–7; 104:18–21; 104:24–	OS, 106, 402, 403, 601, 701, 801	67:6–12, 67:23–68:4, 68:9–16, 68:18–69:3, 69:7–11, 92:12–93:6, 93:9–15, 105:24–106:8, 156:19–22, 157:14–18, 163:19–24, 164:2–5, 179:22–25, 180:4–10, 180:13–16, 184:5–6, 184:9–11	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		25; 105:2–5; 105:8–23; 126:20–22; 126:24–25; 127:2–16; 155:20–25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–25; 166:2–4; 172:2–7; 172:10–16; 179:9–14; 179:16–21; 182:3–25; 183:2–16; 183:19–24			
101:11-13	106, 402, 602, 701, 801, AF, AM, FRCP 30(b)(6), ID, IQ	64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 67:13–18; 67:20–22; 95:14–17; 95:19–25; 96:2–21; 99:13–15; 99:18–25; 100:2–3; 101:8–13; 101:17–25; 102:2–13; 103:17–19; 103:21–25; 104:2–7; 104:18–21; 104:24–25; 105:2–5;	OS, 106, 402, 403, 601, 701, 801	67:6-12, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 92:12-93:6, 93:9-15, 105:24-106:8, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 179:22-25, 180:4-10, 180:13-16, 184:5-6, 184:9-11	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		105:8–23; 126:20–22; 126:24–25; 127:2–16; 155:20–25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–25; 166:2–4; 172:2–7; 172:10–16; 179:9–14; 179:16–21; 182:3–25; 183:2–16; 183:19–24			
101:17-18	106, 402, 701, 801, AF, AM, FRCP 30(b)(6), ID, IQ	64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 67:13–18; 67:20–22; 95:14–17; 95:19–25; 96:2–21; 99:13–15; 99:18–25; 100:2–3; 101:8–13; 101:17–25; 102:2–13; 103:17–19; 103:21–25; 104:2–7; 104:18–21; 104:24–25; 105:2–5; 105:8–23; 126:20–	OS, 106, 402, 403, 601, 701, 801	67:6-12, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 92:12-93:6, 93:9-15, 105:24-106:8, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 179:22-25, 180:4-10, 180:13-16, 184:5-6, 184:9-11	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		22; 126:24–25; 127:2–16; 155:20– 25; 156:2–18; 157:19–25; 158:2– 3; 158:5–16; 164:6–11; 165:19– 25; 166:2–4; 172:2–7; 172:10– 16; 179:9–14; 179:16–21; 182:3– 25; 183:2–16; 183:19–24			
102:14-17	106, 402, 602, 701, 801, A, AF, AM, F, FRCP 30(b)(6), SP	64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 66:3–7; 66:9–10; 66:12–25; 67:2–5; 67:13–18; 67:20– 22; 95:14–17; 95:19–25; 96:2–21; 99:13–15; 99:18– 25; 100:2–3; 103:17–19; 103:21– 25; 104:2–7; 104:18–21; 104:24– 25; 105:2–5; 105:8–23; 126:20– 22; 126:24–25;	OS, 106, 402, 403, 601, 701, 801	67:6-12, 67:23- 68:4, 68:9-16, 68:18-69:3, 69:7- 11, 92:12-93:6, 93:9-15, 105:24- 106:8, 156:19-22, 157:14-18, 163:19- 24, 164:2-5, 179:22-25, 180:4- 10, 180:13-16, 184:5-6, 184:9-11	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		127:2-16; 155:20-25; 156:2-18; 157:19-25; 158:2-3; 158:5-16; 164:6-11; 165:19-25; 166:2-4; 172:2-7; 172:10-16; 179:9-14; 179:16-21; 182:3-25; 183:2-16; 183:19-24			
102:20-25	106, 402, 602, 701, 801, A, AF, AM, F, FRCP 30(b)(6), SP	64:3-4; 64:6-24; 65:3-9; 65:10-13; 65:15-25; 66:2; 66:3-7; 66:9-10; 66:12-25; 67:2-5; 67:13-18; 67:20-22; 95:14-17; 95:19-25; 96:2-21; 99:13-15; 99:18-25; 100:2-3; 103:17-19; 103:21-25; 104:2-7; 104:18-21; 104:24-25; 105:2-5; 105:8-23; 126:20-22; 126:24-25; 127:2-16; 155:20-	OS, 106, 402, 403, 601, 701, 801	67:6-12, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 92:12-93:6, 93:9-15, 105:24-106:8, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 179:22-25, 180:4-10, 180:13-16, 184:5-6, 184:9-11	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–25; 166:2–4; 172:2–7; 172:10–16; 179:9–14; 179:16–21; 182:3–25; 183:2–16; 183:19–24			
103:2-6	106, 402, 602, 701, 801, A, AF, AM, F, FRCP 30(b)(6), SP	64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 66:3–7; 66:9–10; 66:12–25; 67:2–5; 67:13–18; 67:20–22; 95:14–17; 95:19–25; 96:2–21; 99:13–15; 99:18–25; 100:2–3; 103:17–19; 103:21–25; 104:2–7; 104:18–21; 104:24–25; 105:2–5; 105:8–23; 126:20–22; 126:24–25; 127:2–16; 155:20–	OS, 106, 402, 403, 601, 701, 801	67:6-12, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 92:12-93:6, 93:9-15, 105:24-106:8, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 179:22-25, 180:4-10, 180:13-16, 184:5-6, 184:9-11	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–25; 166:2–4; 172:2–7; 172:10–16; 179:9–14; 179:16–21; 182:3–25; 183:2–16; 183:19–24			
104:8-10	106, 402, 602, 701, 801, A, AF, AM, F, FRCP 30(b)(6), SP	64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 66:3–7; 66:9–10; 66:12–25; 67:2–5; 67:13–18; 67:20–22; 95:14–17; 95:19–25; 96:2–21; 99:13–15; 99:18–25; 100:2–3; 103:17–19; 103:21–25; 104:2–7; 104:18–21; 104:24–25; 105:2–5; 105:8–23; 126:20–22; 126:24–25; 127:2–16; 155:20–	OS, 106, 402, 403, 601, 701, 801	67:6-12, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 92:12-93:6, 93:9-15, 105:24-106:8, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 179:22-25, 180:4-10, 180:13-16, 184:5-6, 184:9-11	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–25; 166:2–4; 172:2–7; 172:10–16; 179:9–14; 179:16–21; 182:3–25; 183:2–16; 183:19–24			
104:13-17	106, 402, 602, 701, 801, A, AF, AM, F, FRCP 30(b)(6), SP	64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 66:3–7; 66:9–10; 66:12–25; 67:2–5; 67:13–18; 67:20–22; 95:14–17; 95:19–25; 96:2–21; 99:13–15; 99:18–25; 100:2–3; 103:17–19; 103:21–25; 104:2–7; 104:18–21; 104:24–25; 105:2–5; 105:8–23; 126:20–22; 126:24–25; 127:2–16; 155:20–25; 156:2–18;	OS, 106, 402, 403, 601, 701, 801	67:6-12, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 92:12-93:6, 93:9-15, 105:24-106:8, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 179:22-25, 180:4-10, 180:13-16, 184:5-6, 184:9-11	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–25; 166:2–4; 172:2–7; 172:10–16; 179:9–14; 179:16–21; 182:3–25; 183:2–16; 183:19–24			
107:6-13	106, 402, 602, 701, 801, A, AF, AM, F, FRCP 30(b)(6), SP	64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 66:3–7; 66:9–10; 66:12–25; 67:2–5; 67:13–18; 67:20–22; 95:14–17; 95:19–25; 96:2–21; 99:13–15; 99:18–25; 100:2–3; 103:17–19; 103:21–25; 104:2–7; 104:18–21; 104:24–25; 105:2–5; 105:8–23; 126:20–22; 126:24–25; 127:2–16; 155:20–25; 156:2–18; 157:19–25; 158:2–	OS, 106, 402, 403, 601, 701, 801	67:6-12, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 92:12-93:6, 93:9-15, 105:24-106:8, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 179:22-25, 180:4-10, 180:13-16, 184:5-6, 184:9-11	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		3; 158:5–16; 164:6–11; 165:19–25; 166:2–4; 172:2–7; 172:10–16; 179:9–14; 179:16–21; 182:3–25; 183:2–16; 183:19–24			
107:18-25	106, 402, 602, 701, 801, A, AF, AM, F, FRCP 30(b)(6), SP	64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 66:3–7; 66:9–10; 66:12–25; 67:2–5; 67:13–18; 67:20–22; 95:14–17; 95:19–25; 96:2–21; 99:13–15; 99:18–25; 100:2–3; 103:17–19; 103:21–25; 104:2–7; 104:18–21; 104:24–25; 105:2–5; 105:8–23; 126:20–22; 126:24–25; 127:2–16; 155:20–25; 156:2–18; 157:19–25; 158:2–3; 158:5–16;	OS, 106, 402, 403, 601, 701, 801	67:6-12, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 92:12-93:6, 93:9-15, 105:24-106:8, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 179:22-25, 180:4-10, 180:13-16, 184:5-6, 184:9-11	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		164:6–11; 165:19–25; 166:2–4; 172:2–7; 172:10–16; 179:9–14; 179:16–21; 182:3–25; 183:2–16; 183:19–24			
108:2-16	106, 402, 602, 701, 801, A, AF, AM, F, FRCP 30(b)(6), SP	64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 66:3–7; 66:9–10; 66:12–25; 67:2–5; 67:13–18; 67:20–22; 83:24–25; 84:2; 84:5–23; 93:16–19; 93:23–25; 94:2–11; 94:15–25; 95:2–6; 95:14–17; 95:19–25; 96:2–21; 99:13–15; 99:18–25; 100:2–3; 103:17–19; 103:21–25; 104:2–7; 104:18–21; 104:24–25; 105:2–5; 105:8–23; 126:20–22; 126:24–25; 127:2–16; 155:20–	OS, 106, 402, 403, 601, 701, 801	67:6-12, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 92:12-93:6, 93:9-15, 105:24-106:8, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 179:22-25, 180:4-10, 180:13-16, 184:5-6, 184:9-11	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–25; 166:2–4; 172:2–7; 172:10–16; 179:9–14; 179:16–21; 182:3–25; 183:2–16; 183:19–24			
108:18-25	106, 402, 602, 701, 801, A, AF, AM, F, FRCP 30(b)(6), SP	64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 66:3–7; 66:9–10; 66:12–25; 67:2–5; 67:13–18; 67:20–22; 83:24–25; 84:2; 84:5–23; 93:16–19; 93:23–25; 94:2–11; 94:15–25; 95:2–6; 95:14–17; 95:19–25; 96:2–21; 99:13–15; 99:18–25; 100:2–3; 103:17–19; 103:21–25; 104:2–7; 104:18–21; 104:24–25; 105:2–5;	OS, 106, 402, 403, 601, 701, 801	67:6-12, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 92:12-93:6, 93:9-15, 105:24-106:8, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 179:22-25, 180:4-10, 180:13-16, 184:5-6, 184:9-11	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		105:8–23; 126:20–22; 126:24–25; 127:2–16; 155:20–25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–25; 166:2–4; 172:2–7; 172:10–16; 179:9–14; 179:16–21; 182:3–25; 183:2–16; 183:19–24			
109:2-3	106, 402, 602, 701, 801, A, AF, AM, F, FRCP 30(b)(6), SP	64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 66:3–7; 66:9–10; 66:12–25; 67:2–5; 67:13–18; 67:20–22; 83:24–25; 84:2; 84:5–23; 93:16–19; 93:23–25; 94:2–11; 94:15–25; 95:2–6; 95:14–17; 95:19–25; 96:2–21; 99:13–15; 99:18–25; 100:2–3; 103:17–19; 103:21–	OS, 106, 402, 403, 601, 701, 801	67:6-12, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 92:12-93:6, 93:9-15, 105:24-106:8, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 179:22-25, 180:4-10, 180:13-16, 184:5-6, 184:9-11	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		25; 104:2-7; 104:18-21; 104:24-25; 105:2-5; 105:8-23; 126:20-22; 126:24-25; 127:2-16; 155:20-25; 156:2-18; 157:19-25; 158:2-3; 158:5-16; 164:6-11; 165:19-25; 166:2-4; 172:2-7; 172:10-16; 179:9-14; 179:16-21; 182:3-25; 183:2-16; 183:19-24			
110:13-16	402, 602, 801, A, AM, CQ, F, FRCP 30(b)(6)				
110:18-20	402, 602, 801, A, AM, CQ, F, FRCP 30(b)(6)				
112:16-113:17	402, 801				
117:8-9	106, 402, 602, 801, A, AM, F, FRCP 30(b)(6)	44:3-7; 44:9-13	OS, 106, 402, 403, 601	23:3-14, 23:16-18, 44:14-18, 44:20-23	106, 402, 403, 801, AF, AM, FRCP 30(b)(6), MC, OS

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
117:11-17	106, 402, 602, 801, A, AM, F, FRCP 30(b)(6)	44:3-7; 44:9-13	OS, 106, 402, 403, 601	23:3-14, 23:16-18, 44:14-18, 44:20-23	106, 402, 403, 801, AF, AM, FRCP 30(b)(6), MC, OS
118:22-119:6	402, 602, 801, A, F, ID				
119:7-19	402, 602, 801, A, F				
122:2-3	402, 602, 801, A, F				
122:8-11	402, 602, 801, A, F, FRCP 30(b)(6)				
122:13-18	402, 602, 801, A, F, FRCP 30(b)(6)				
124:10-17	106, 402, 403, 602, A, C, F, FRCP 30(b)(6), SP	64:3-4; 64:6-24; 65:3-9; 65:10-13; 65:15-25; 66:2; 66:3-7; 66:9-10; 66:12-25; 67:2-5; 67:13-18; 67:20-22; 83:24-25; 84:2; 84:5-23; 93:16-19; 93:23-25; 94:2-11; 94:15-25; 95:2-6; 95:14-17; 95:19-25; 96:2-21; 99:13-15; 99:18-25; 100:2-3; 103:17-19; 103:21-25; 104:2-7; 104:18-21; 104:24-	OS, 106, 402, 403, 601, 701, 801	67:6-12, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 92:12-93:6, 93:9-15, 105:24-106:8, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 179:22-25, 180:4-10, 180:13-16, 184:5-6, 184:9-11	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		25; 105:2–5; 105:8–23; 126:20–22; 126:24–25; 127:2–16; 155:20–25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–25; 166:2–4; 182:3–25; 183:2–16; 183:19–24			
124:19-25	106, 402, 403, 602, A, C, F, FRCP 30(b)(6), SP	64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 66:3–7; 66:9–10; 66:12–25; 67:2–5; 67:13–18; 67:20–22; 83:24–25; 84:2; 84:5–23; 93:16–19; 93:23–25; 94:2–11; 94:15–25; 95:2–6; 95:14–17; 95:19–25; 96:2–21; 99:13–15; 99:18–25; 100:2–3; 103:17–19; 103:21–25; 104:2–7; 104:18–21; 104:24–	OS, 106, 402, 403, 601, 701, 801	67:6-12, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 92:12-93:6, 93:9-15, 105:24-106:8, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 179:22-25, 180:4-10, 180:13-16, 184:5-6, 184:9-11	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		25; 105:2–5; 105:8–23; 126:20– 22; 126:24–25; 127:2–16; 155:20– 25; 156:2–18; 157:19–25; 158:2– 3; 158:5–16; 164:6–11; 165:19– 25; 166:2–4; 182:3–25; 183:2– 16; 183:19–24			
125:2-12	106, 402, 403, 602, A, C, F, FRCP 30(b)(6), SP	64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 66:3–7; 66:9–10; 66:12–25; 67:2–5; 67:13–18; 67:20– 22; 83:24–25; 84:2; 84:5–23; 93:16–19; 93:23–25; 94:2–11; 94:15–25; 95:2–6; 95:14–17; 95:19– 25; 96:2–21; 99:13–15; 99:18– 25; 100:2–3; 103:17–19; 103:21– 25; 104:2–7; 104:18–21; 104:24–	OS, 106, 402, 403, 601, 701, 801	67:6-12, 67:23- 68:4, 68:9-16, 68:18-69:3, 69:7- 11, 92:12-93:6, 93:9-15, 105:24- 106:8, 156:19-22, 157:14-18, 163:19- 24, 164:2-5, 179:22-25, 180:4- 10, 180:13-16, 184:5-6, 184:9-11	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		25; 105:2–5; 105:8–23; 126:20–22; 126:24–25; 127:2–16; 155:20–25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–25; 166:2–4; 182:3–25; 183:2–16; 183:19–24			
126:9-11	402, 801				
126:16-17	402, 602, 801, F, FRCP 30(b)(6)				
126:19-22	402, 602, 801, AM, AF, F, FRCP 30(b)(6)				
126:24-25	402, 602, 801, AM, AF, F, FRCP 30(b)(6)				
127:2	402, 602, 801, AM, AF, F, FRCP 30(b)(6)				
129:15-17	106, 402, 403, AF, AM, AR, MC, F, FRCP 30(b)(6), SP	126:20–22; 126:24–25; 127:2	OS, 106		

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
129:19-25	106, 402, 403, AF, AM, AR, MC, F, FRCP 30(b)(6), SP	126:20–22; 126:24–25; 127:2	OS, 106		
130:2-3	106, 402, 403, AF, AM, AR, MC, F, FRCP 30(b)(6), SP	126:20–22; 126:24–25; 127:2	OS, 106		
130:6-16	106, 602, 403, AF, AM, AR, MC, F, FRCP 30(b)(6), SP	126:20–22; 126:24–25; 127:2; 130:17–25; 131:2–5	OS, 106, 402, 403		
131:6-25	402, 602, 801, A, F				
133:3-11	402, 602, 801, A, F				
154:20-25	106, 402, 403, 602, 801, AF, AM, F	18:5–19; 20:13–25; 64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 66:3–7; 66:9–10; 66:12–25; 67:2–5; 67:13–18; 67:20–22; 93:23–25; 94:2–11; 94:15–25; 95:2–6; 95:14–17; 95:19–25; 96:2–21; 99:13–15; 99:18–25; 100:2–3; 103:17–19; 103:21–25; 104:2–7; 104:18–21; 104:24–25; 105:2–5;	OS, 106, 402, 403, 601, 701, 801	17:13-18:4, 20:6-12, 67:6-11, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 92:12-93:6, 93:9-15, 105:24-106:8, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 168:20-169:4, 169:6-7	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, IQ, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		105:8–23; 126:20–22; 126:24–25; 127:2–16; 155:20–25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–25; 166:2–4			
155:2-3	106, 402, 403, 602, 801, AF, AM, F	18:5–19; 20:13–25; 64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 66:3–7; 66:9–10; 66:12–25; 67:2–5; 67:13–18; 67:20–22; 93:23–25; 94:2–11; 94:15–25; 95:2–6; 95:14–17; 95:19–25; 96:2–21; 99:13–15; 99:18–25; 100:2–3; 103:17–19; 103:21–25; 104:2–7; 104:18–21; 104:24–25; 105:2–5; 105:8–23; 126:20–22; 126:24–25; 127:2–16; 155:20–	OS, 106, 402, 403, 601, 701, 801	17:13-18:4, 20:6-12, 67:6-11, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 92:12-93:6, 93:9-15, 105:24-106:8, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 168:20-169:4, 169:6-7	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, IQ, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–25; 166:2–4			
155:7-16	106, 402, 801, AM	18:5–19; 20:13–25; 71:15–23; 71:25; 72:2–8; 72:9–17; 78:22–24; 79:10–15; 80:10–11; 80:15–16; 155:20–25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–25; 166:2–4	OS, 106, 402, 403, 601, 701, 801	17:13-18:4, 20:6-12, 67:6-11, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 92:12-93:6, 93:9-15, 105:24-106:8, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 168:20-169:4, 169:6-7	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, IQ, MC, OS, SP
166:5-6	106, 402, 403, 602, 801, A, C, F	18:5–19; 20:13–25; 21:2–6; 64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 66:3–7; 66:9–10; 66:12–25; 67:2–5; 67:13–18; 67:20–22; 83:24–25; 84:2; 84:5–23; 95:14–17; 95:19–25; 96:2–21; 99:13–15; 99:18–	OS, 106, 402, 403, 601, 701, 801	17:13-18:4, 20:6-12, 67:6-11, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 92:12-93:6, 93:9-15, 105:24-106:8, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 168:20-169:4, 169:6-7, 179:22-25, 180:4-10, 180:13-	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, IQ, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		25; 100:2–3; 103:17–19; 103:21–25; 104:2–7; 104:18–21; 104:24–25; 105:2–5; 105:8–23; 126:20–22; 126:24–25; 127:2–16; 155:20–25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–25; 166:2–4; 179:9–14; 179:16–21; 182:3–25; 183:2–16; 183:19–24		16, 184:5-6, 184:9-11	
166:9-16	106, 402, 403, 602, 701, 801, A, AM, C, F	18:5–19; 20:13–25; 21:2–6; 64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 66:3–7; 66:9–10; 66:12–25; 67:2–5; 67:13–18; 67:20–22; 83:24–25; 84:2; 84:5–23; 95:14–17; 95:19–25; 96:2–21;	OS, 106, 402, 403, 601, 701, 801	17:13-18:4, 20:6-12, 67:6-11, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 92:12-93:6, 93:9-15, 105:24-106:8, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 168:20-169:4, 169:6-7, 179:22-25,	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, IQ, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		99:13–15; 99:18–25; 100:2–3; 103:17–19; 103:21–25; 104:2–7; 104:18–21; 104:24–25; 105:2–5; 105:8–23; 126:20–22; 126:24–25; 127:2–16; 155:20–25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–25; 166:2–4; 179:9–14; 179:16–21; 182:3–25; 183:2–16; 183:19–24		180:4-10, 180:13-16, 184:5-6, 184:9-11	
166:19-25	106, 402, 403, 602, 701, 801, A, AM, C, F	18:5–19; 20:13–25; 21:2–6; 64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 66:3–7; 66:9–10; 66:12–25; 67:2–5; 67:13–18; 67:20–22; 83:24–25; 84:2; 84:5–23; 95:14–17; 95:19–	OS, 106, 402, 403, 601, 701, 801	17:13-18:4, 20:6-12, 67:6-11, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 92:12-93:6, 93:9-15, 105:24-106:8, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 168:20-169:4,	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, IQ, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		25; 96:2–21; 99:13–15; 99:18–25; 100:2–3; 103:17–19; 103:21–25; 104:2–7; 104:18–21; 104:24–25; 105:2–5; 105:8–23; 126:20–22; 126:24–25; 127:2–16; 155:20–25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–25; 166:2–4; 179:9–14; 179:16–21; 182:3–25; 183:2–16; 183:19–24		169:6-7, 179:22-25, 180:4-10, 180:13-16, 184:5-6, 184:9-11	
167:2-14	106, 402, 403, 602, 701, 801, A, AM, C, F	18:5–19; 20:13–25; 21:2–6; 64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 66:3–7; 66:9–10; 66:12–25; 67:2–5; 67:13–18; 67:20–22; 83:24–25; 84:2; 84:5–23;	OS, 106, 402, 403, 601, 701, 801	17:13-18:4, 20:6-12, 67:6-11, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 92:12-93:6, 93:9-15, 105:24-106:8, 156:19-22, 157:14-18, 163:19-24, 164:2-5,	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, IQ, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		95:14–17; 95:19–25; 96:2–21; 99:13–15; 99:18–25; 100:2–3; 103:17–19; 103:21–25; 104:2–7; 104:18–21; 104:24–25; 105:2–5; 105:8–23; 126:20–22; 126:24–25; 127:2–16; 155:20–25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–25; 166:2–4; 179:9–14; 179:16–21; 182:3–25; 183:2–16; 183:19–24		168:20-169:4, 169:6-7, 179:22-25, 180:4-10, 180:13-16, 184:5-6, 184:9-11	
167:18-25	106, 402, 403, 602, 701, 801, AM, C, MC	18:5–19; 20:13–25; 21:2–6; 64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 66:3–7; 66:9–10; 66:12–25; 67:2–5; 67:13–18; 67:20–22; 83:24–	OS, 106, 402, 403, 601, 701, 801	17:13-18:4, 20:6-12, 67:6-11, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 92:12-93:6, 93:9-15, 105:24-106:8, 156:19-22, 157:14-18, 163:19-	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, IQ, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		25; 84:2; 84:5–23; 95:14–17; 95:19–25; 96:2–21; 99:13–15; 99:18–25; 100:2–3; 103:17–19; 103:21–25; 104:2–7; 104:18–21; 104:24–25; 105:2–5; 105:8–23; 126:20–22; 126:24–25; 127:2–16; 155:20–25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–25; 166:2–4; 168:10–13; 168:16–19; 169:8–12; 169:14–21; 179:9–14; 179:16–21; 182:3–25; 183:2–16; 183:19–24		24, 164:2-5, 168:20-169:4, 169:6-7, 179:22-25, 180:4-10, 180:13-16, 184:5-6, 184:9-11	
168:2-7	106, 402, 403, 602, 701, 801, A, AM, C, CQ, F, ID, IQ	18:5–19; 20:13–25; 21:2–6; 64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 66:3–7;	OS, 106, 402, 403, 601, 701, 801	17:13-18:4, 20:6-12, 67:6-11, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 92:12-93:6,	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, IQ, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		66:9–10; 66:12–25; 67:2–5; 67:13–18; 67:20–22; 83:24–25; 84:2; 84:5–23; 95:14–17; 95:19–25; 96:2–21; 99:13–15; 99:18–25; 100:2–3; 103:17–19; 103:21–25; 104:2–7; 104:18–21; 104:24–25; 105:2–5; 105:8–23; 126:20–22; 126:24–25; 127:2–16; 155:20–25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–25; 166:2–4; 168:10–13; 168:16–19; 169:8–12; 169:14–21; 179:9–14; 179:16–21; 182:3–25; 183:2–16; 183:19–24		93:9–15, 105:24–106:8, 156:19–22, 157:14–18, 163:19–24, 164:2–5, 168:20–169:4, 169:6–7, 179:22–25, 180:4–10, 180:13–16, 184:5–6, 184:9–11	

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
168:9	106, 402, 403, 602, 701, 801, A, AM, C, CQ, F, ID, IQ	18:5–19; 20:13–25; 21:2–6; 64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 66:3–7; 66:9–10; 66:12–25; 67:2–5; 67:13–18; 67:20–22; 83:24–25; 84:2; 84:5–23; 95:14–17; 95:19–25; 96:2–21; 99:13–15; 99:18–25; 100:2–3; 103:17–19; 103:21–25; 104:2–7; 104:18–21; 104:24–25; 105:2–5; 105:8–23; 126:20–22; 126:24–25; 127:2–16; 155:20–25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–25; 166:2–4; 168:10–13; 168:16–19; 169:8–12; 169:14–21; 179:9–	OS, 106, 402, 403, 601, 701, 801	17:13-18:4, 20:6-12, 67:6-11, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 92:12-93:6, 93:9-15, 105:24-106:8, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 168:20-169:4, 169:6-7, 179:22-25, 180:4-10, 180:13-16, 184:5-6, 184:9-11	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, IQ, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		14; 179:16–21; 182:3–25; 183:2–16; 183:19–24			
170:15-25	106, 402, 403, 602, 701, 801, A, AM, C, CQ, F, MC	18:5–19; 20:13–25; 64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 66:3–7; 66:9–10; 66:12–25; 67:2–5; 67:13–18; 67:20–22; 95:14–17; 95:19–25; 96:2–21; 99:13–15; 99:18–25; 100:2–3; 104:18–21; 104:24–25; 105:2–5; 105:8–23; 155:20–25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–25; 166:2–4; 172:2–7; 172:10–16; 179:9–14; 179:16–21; 182:3–25; 183:2–16; 183:19–24	OS, 106, 402, 403, 601, 701, 801	17:13-18:4, 20:6-12, 67:6-11, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 92:12-93:6, 93:9-15, 105:24-106:8, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 168:20-169:4, 169:6-7, 179:22-25, 180:4-10, 180:13-16, 184:5-6, 184:9-11	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, IQ, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
171:2-6	106, 402, 403, 602, 701, 801, AF, AM, C, MC, FRCP 30(b)(6)	18:5-19; 20:13-25; 64:3-4; 64:6-24; 65:3-9; 65:10-13; 65:15-25; 66:2; 66:3-7; 66:9-10; 66:12-25; 67:2-5; 67:13-18; 67:20-22; 95:14-17; 95:19-25; 96:2-21; 99:13-15; 99:18-25; 100:2-3; 104:18-21; 104:24-25; 105:2-5; 105:8-23; 155:20-25; 156:2-18; 157:19-25; 158:2-3; 158:5-16; 164:6-11; 165:19-25; 166:2-4; 172:2-7; 172:10-16; 179:9-14; 179:16-21; 182:3-25; 183:2-16; 183:19-24	OS, 106, 402, 403, 601, 701, 801	17:13-18:4, 20:6-12, 67:6-11, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 92:12-93:6, 93:9-15, 105:24-106:8, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 168:20-169:4, 169:6-7, 179:22-25, 180:4-10, 180:13-16, 184:5-6, 184:9-11	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, IQ, MC, OS, SP
171:9-25	106, 402, 403, 602, 701, 801, AF, AM, C, MC, FRCP 30(b)(6)	18:5-19; 20:13-25; 64:3-4; 64:6-24; 65:3-9; 65:10-13; 65:15-25; 66:2;	OS, 106, 402, 403, 601, 701, 801	17:13-18:4, 20:6-12, 67:6-11, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F,

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		66:3-7; 66:9-10; 66:12-25; 67:2-5; 67:13-18; 67:20-22; 95:14-17; 95:19-25; 96:2-21; 99:13-15; 99:18-25; 100:2-3; 104:18-21; 104:24-25; 105:2-5; 105:8-23; 155:20-25; 156:2-18; 157:19-25; 158:2-3; 158:5-16; 164:6-11; 165:19-25; 166:2-4; 172:2-7; 172:10-16; 179:9-14; 179:16-21; 182:3-25; 183:2-16; 183:19-24		11, 92:12-93:6, 93:9-15, 105:24-106:8, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 168:20-169:4, 169:6-7, 179:22-25, 180:4-10, 180:13-16, 184:5-6, 184:9-11	FRCP 30(b)(6), ID, IQ, MC, OS, SP
172:17-25	106, 402, 403, 602, 701, 801, AM, C, CQ, SP, FRCP 30(b)(6)	18:5-19; 20:13-25; 64:3-4; 64:6-24; 65:3-9; 65:10-13; 65:15-25; 66:2; 67:13-18; 67:20-22; 95:14-17; 95:19-25; 96:2-21; 99:13-15; 99:18-	OS, 106, 402, 403, 601, 701, 801	17:13-18:4, 20:6-12, 67:6-11, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 92:12-93:6, 93:9-15, 105:24-106:8, 156:19-22, 157:14-18, 163:19-	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, IQ, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		25; 100:2-3; 104:18-21; 104:24-25; 105:2-5; 105:8-23; 155:20-25; 156:2-18; 157:19-25; 158:2-3; 158:5-16; 164:6-11; 165:19-25; 166:2-4; 172:2-7; 172:10-16; 179:9-14; 179:16-21; 182:3-25; 183:2-16; 183:19-24		24, 164:2-5, 168:20-169:4, 169:6-7, 179:22-25, 180:4-10, 180:13-16, 184:5-6, 184:9-11	
173:3-24	106, 402, 403, 602, 701, 801, AM, C, CQ, SP, FRCP 30(b)(6)	18:5-19; 20:13-25; 64:3-4; 64:6-24; 65:3-9; 65:10-13; 65:15-25; 66:2; 66:3-7; 66:9-10; 66:12-25; 67:2-5; 67:13-18; 67:20-22; 95:14-17; 95:19-25; 96:2-21; 99:13-15; 99:18-25; 100:2-3; 104:18-21; 104:24-25; 105:2-5; 105:8-23; 155:20-	OS, 106, 402, 403, 601, 701, 801	17:13-18:4, 20:6-12, 67:6-11, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 92:12-93:6, 93:9-15, 105:24-106:8, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 168:20-169:4, 169:6-7, 179:22-25, 180:4-10, 180:13-16, 184:5-6, 184:9-11	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, IQ, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–25; 166:2–4; 172:2–7; 172:10–16; 179:9–14; 179:16–21; 182:3–25; 183:2–16; 183:19–24			
174:15-25	106, 402, 403, 602, 801, A, AM, C, CQ, F	18:5–19; 20:13–25; 64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 66:3–7; 66:9–10; 66:12–25; 67:2–5; 67:13–18; 67:20–22; 95:14–17; 95:19–25; 96:2–21; 99:13–15; 99:18–25; 100:2–3; 104:18–21; 104:24–25; 105:2–5; 105:8–23; 155:20–25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–	OS, 106, 402, 403, 601, 701, 801	17:13-18:4, 20:6-12, 67:6-11, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 92:12-93:6, 93:9-15, 105:24-106:8, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 168:20-169:4, 169:6-7, 179:22-25, 180:4-10, 180:13-16, 184:5-6, 184:9-11	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, IQ, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		25; 166:2-4; 169:8-12; 169:14-21; 172:2-7; 172:10-16; 179:9-14; 179:16-21; 182:3-25; 183:2-16; 183:19-24			
175:2-9	106, 402, 403, 602, 801, A, AM, C, CQ, F, MC	18:5-19; 20:13-25; 64:3-4; 64:6-24; 65:3-9; 65:10-13; 65:15-25; 66:2; 66:3-7; 66:9-10; 66:12-25; 67:2-5; 67:13-18; 67:20-22; 95:14-17; 95:19-25; 96:2-21; 99:13-15; 99:18-25; 100:2-3; 104:18-21; 104:24-25; 105:2-5; 105:8-23; 155:20-25; 156:2-18; 157:19-25; 158:2-3; 158:5-16; 164:6-11; 165:19-25; 166:2-4; 169:8-12; 169:14-21; 172:2-7;	OS, 106, 402, 403, 601, 701, 801	17:13-18:4, 20:6-12, 67:6-11, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 92:12-93:6, 93:9-15, 105:24-106:8, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 168:20-169:4, 169:6-7, 179:22-25, 180:4-10, 180:13-16, 184:5-6, 184:9-11	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, IQ, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		172:10–16; 179:9–14; 179:16–21; 182:3–25; 183:2–16; 183:19–24			
175:11-21	106, 402, 403, 602, 801, A, AM, C, CQ, F, MC	18:5–19; 20:13–25; 64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 66:3–7; 66:9–10; 66:12–25; 67:2–5; 67:13–18; 67:20–22; 95:14–17; 95:19–25; 96:2–21; 99:13–15; 99:18–25; 100:2–3; 104:18–21; 104:24–25; 105:2–5; 105:8–23; 155:20–25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–25; 166:2–4; 169:8–12; 169:14–21; 172:2–7; 172:10–16; 179:9–14; 179:16–21;	OS, 106, 402, 403, 601, 701, 801	17:13-18:4, 20:6-12, 67:6-11, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 92:12-93:6, 93:9-15, 105:24-106:8, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 168:20-169:4, 169:6-7, 179:22-25, 180:4-10, 180:13-16, 184:5-6, 184:9-11	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, IQ, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		182:3–25; 183:2–16; 183:19–24			
176:21-23	106, 402, 602, 801, F	18:5–19; 20:13–25; 64:3–4; 64:6–24; 65:3–9; 65:10–13; 65:15–25; 66:2; 66:3–7; 66:9–10; 66:12–25; 67:2–5; 67:13–18; 67:20–22; 95:14–17; 95:19–25; 96:2–21; 99:13–15; 99:18–25; 100:2–3; 104:18–21; 104:24–25; 105:2–5; 105:8–23; 118:22–25; 119:2–6; 155:20–25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–25; 166:2–4; 169:8–12; 169:14–21; 172:2–7; 172:10–16; 179:9–14; 179:16–21; 182:3–25; 183:2–16; 183:19–24	OS, 106, 402, 403, 601, 701, 801	17:13-18:4, 20:6-12, 67:6-11, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 92:12-93:6, 93:9-15, 105:24-106:8, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 168:20-169:4, 169:6-7, 179:22-25, 180:4-10, 180:13-16, 184:5-6, 184:9-11	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, IQ, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
177:2-7	106, 402, 403, 602, 701, 801, AM, C, F	18:5-19; 20:13-25; 64:3-4; 64:6-24; 65:3-9; 65:10-13; 65:15-25; 66:2; 66:3-7; 66:9-10; 66:12-25; 67:2-5; 67:13-18; 67:20-22; 95:14-17; 95:19-25; 96:2-21; 99:13-15; 99:18-25; 100:2-3; 104:18-21; 104:24-25; 105:2-5; 105:8-23; 118:22-25; 119:2-6; 155:20-25; 156:2-18; 157:19-25; 158:2-3; 158:5-16; 164:6-11; 165:19-25; 166:2-4; 169:8-12; 169:14-21; 172:2-7; 172:10-16; 179:9-14; 179:16-21; 182:3-25; 183:2-16; 183:19-24	OS, 106, 402, 403, 601, 701, 801	17:13-18:4, 20:6-12, 67:6-11, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 92:12-93:6, 93:9-15, 105:24-106:8, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 168:20-169:4, 169:6-7, 179:22-25, 180:4-10, 180:13-16, 184:5-6, 184:9-11	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, IQ, MC, OS, SP
177:10-25	106, 402, 403, 602, 701, 801, AM, C, F	18:5-19; 20:13-25; 64:3-4; 64:6-24;	OS, 106, 402, 403, 601, 701, 801	17:13-18:4, 20:6-12, 67:6-11, 67:23-	106, 402, 403, 602, 701, 801, AA, AM,

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		65:3-9; 65:10-13; 65:15-25; 66:2; 66:3-7; 66:9-10; 66:12-25; 67:2-5; 67:13-18; 67:20-22; 95:14-17; 95:19-25; 96:2-21; 99:13-15; 99:18-25; 100:2-3; 104:18-21; 104:24-25; 105:2-5; 105:8-23; 118:22-25; 119:2-6; 155:20-25; 156:2-18; 157:19-25; 158:2-3; 158:5-16; 164:6-11; 165:19-25; 166:2-4; 169:8-12; 169:14-21; 172:2-7; 172:10-16; 179:9-14; 179:16-21; 182:3-25; 183:2-16; 183:19-24		68:4, 68:9-16, 68:18-69:3, 69:7-11, 92:12-93:6, 93:9-15, 105:24-106:8, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 168:20-169:4, 169:6-7, 179:22-25, 180:4-10, 180:13-16, 184:5-6, 184:9-11	AR, C, CQ, F, FRCP 30(b)(6), ID, IQ, MC, OS, SP
178:2-25	106, 402, 403, 602, 701, 801, AM, C, CQ, F	18:5-19; 20:13-25; 64:3-4; 64:6-24; 65:3-9; 65:10-13; 65:15-25; 66:2;	OS, 106, 402, 403, 601, 701, 801	17:13-18:4, 20:6-12, 67:6-11, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F,

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		66:3-7; 66:9-10; 66:12-25; 67:2-5; 67:13-18; 67:20-22; 95:14-17; 95:19-25; 96:2-21; 99:13-15; 99:18-25; 100:2-3; 104:18-21; 104:24-25; 105:2-5; 105:8-23; 118:22-25; 119:2-6; 155:20-25; 156:2-18; 157:19-25; 158:2-3; 158:5-16; 164:6-11; 165:19-25; 166:2-4; 169:8-12; 169:14-21; 172:2-7; 172:10-16; 179:9-14; 179:16-21; 182:3-25; 183:2-16; 183:19-24		11, 92:12-93:6, 93:9-15, 105:24-106:8, 156:19-22, 157:14-18, 163:19-24, 164:2-5, 168:20-169:4, 169:6-7, 179:22-25, 180:4-10, 180:13-16, 184:5-6, 184:9-11	FRCP 30(b)(6), ID, IQ, MC, OS, SP
179:2-8	106, 402, 403, 602, 701, 801, AM, C, F	18:5-19; 20:13-25; 64:3-4; 64:6-24; 65:3-9; 65:10-13; 65:15-25; 66:2; 66:3-7; 66:9-10; 66:12-25; 67:2-5;	OS, 106, 402, 403, 601, 701, 801	17:13-18:4, 20:6-12, 67:6-11, 67:23-68:4, 68:9-16, 68:18-69:3, 69:7-11, 92:12-93:6, 93:9-15, 105:24-	106, 402, 403, 602, 701, 801, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, IQ, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		67:13–18; 67:20–22; 95:14–17; 95:19–25; 96:2–21; 99:13–15; 99:18–25; 100:2–3; 104:18–21; 104:24–25; 105:2–5; 105:8–23; 118:22–25; 119:2–6; 155:20–25; 156:2–18; 157:19–25; 158:2–3; 158:5–16; 164:6–11; 165:19–25; 166:2–4; 169:8–12; 169:14–21; 172:2–7; 172:10–16; 179:9–14; 179:16–21; 182:3–25; 183:2–16; 183:19–24		106:8, 156:19–22, 157:14–18, 163:19–24, 164:2–5, 168:20–169:4, 169:6–7, 179:22–25, 180:4–10, 180:13–16, 184:5–6, 184:9–11	
191:6-7	402, 403, 701, 801, AM, C, F, FRCP 30(b)(6)				
191:10-13	402, 403, 701, 801, AM, C, F, FRCP 30(b)(6)				

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
191:16-17	402, 403, 701, 801, AM, C, F, FRCP 30(b)(6)				
191:22-25	402, 801				
192:2-5	402, 801				
192:14-25	402, 403, 801, AM, IQ, ID				
194:2	402, 403, 801, IQ, ID				
194:18-19	106, 402, 602, 701, 801, AM, F, FRCP 30(b)(6)	185:11–12; 185:14–25; 186:2–25; 187:2–8; 187:15–17; 187:19–25; 188:2–10; 188:13–14; 189:2–3; 189:5; 189:7–14; 189:16–22; 190:6–7; 190:9–10; 190:12–20; 196:3–15; 196:16–18; 196:22–25; 197:2–25; 198:2–18	OS, 106, 402, 403, 601, 701	188:15-16, 188:18, 188:20-25, 189:23-25, 190:3-5, 198:19-20, 198:24-199:4	106, 402, 403, 701, 801, AM, FRCP 30(b)(6), OS
194:23-25	106, 402, 602, 701, 801, AM, F, FRCP 30(b)(6)	185:11–12; 185:14–25; 186:2–25; 187:2–8; 187:15–17; 187:19–25; 188:2–10; 188:13–14; 189:2–3; 189:5;	OS, 106, 402, 403, 601, 701	188:15-16, 188:18, 188:20-25, 189:23-25, 190:3-5, 198:19-20, 198:24-199:4	106, 402, 403, 701, 801, AM, FRCP 30(b)(6), OS

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		189:7-14; 189:16-22; 190:6-7; 190:9-10; 190:12-20; 196:3-15; 196:16-18; 196:22-25; 197:2-25; 198:2-18			
195:2-10	106, 402, 602, 701, 801, AM, F, FRCP 30(b)(6)	185:11-12; 185:14-25; 186:2-25; 187:2-8; 187:15-17; 187:19-25; 188:2-10; 188:13-14; 189:2-3; 189:5; 189:7-14; 189:16-22; 190:6-7; 190:9-10; 190:12-20; 196:3-15; 196:16-18; 196:22-25; 197:2-25; 198:2-18	OS, 106, 402, 403, 601, 701	188:15-16, 188:18, 188:20-25, 189:23-25, 190:3-5, 198:19-20, 198:24-199:4	106, 402, 403, 701, 801, AM, FRCP 30(b)(6), OS
195:15-18	106, 402, 602, 701, 801, AM, F, FRCP 30(b)(6), IQ	185:11-12; 185:14-25; 186:2-25; 187:2-8; 187:15-17; 187:19-25; 188:2-10; 188:13-14; 189:2-3; 189:5; 189:7-14; 189:16-22; 190:6-7;	OS, 106, 402, 403, 601, 701	188:15-16, 188:18, 188:20-25, 189:23-25, 190:3-5, 198:19-20, 198:24-199:4	106, 402, 403, 701, 801, AM, FRCP 30(b)(6), OS

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		190:9–10; 190:12–20; 196:3–15; 196:16–18; 196:22–25; 197:2–25; 198:2–18			
195:22-25	106, 402, 602, 701, 801, AM, F, FRCP 30(b)(6), IQ	185:11–12; 185:14–25; 186:2–25; 187:2–8; 187:15–17; 187:19–25; 188:2–10; 188:13–14; 189:2–3; 189:5; 189:7–14; 189:16–22; 190:6–7; 190:9–10; 190:12–20; 196:3–15; 196:16–18; 196:22–25; 197:2–25; 198:2–18	OS, 106, 402, 403, 601, 701	188:15-16, 188:18, 188:20-25, 189:23-25, 190:3-5, 198:19-20, 198:24-199:4	106, 402, 403, 701, 801, AM, FRCP 30(b)(6), OS
196:2	106, 402, 602, 701, 801, AM, F, FRCP 30(b)(6), IQ	185:11–12; 185:14–25; 186:2–25; 187:2–8; 187:15–17; 187:19–25; 188:2–10; 188:13–14; 189:2–3; 189:5; 189:7–14; 189:16–22; 190:6–7; 190:9–10; 190:12–20; 196:3–15;	OS, 106, 402, 403, 601, 701	188:15-16, 188:18, 188:20-25, 189:23-25, 190:3-5, 198:19-20, 198:24-199:4	106, 402, 403, 701, 801, AM, FRCP 30(b)(6), OS

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		196:16–18; 196:22–25; 197:2–25; 198:2–18			

Witness: Steven Ketchum

Date: October 24, 2018

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
1:14-20					
5:2-7					
6:8-12	801				
6:16-25	801				
7:2-4	801				
7:9-25	801, A				
8:2-12:19	801, A, ID, FRCP 30(b)(6)				
12:24-13:2					
13:8-17	106, 801, CQ, ID, IQ	13:18–25; 14:2–5	ID, 402, 403		
14:6-25	106, 801, AM	13:18–25; 14:2–5	ID, 402, 403		
15:2-6	801, AM				
17:8-18:2	402, 801, AM, ID				
18:4-19:2	402, 801, ID				

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
19:8-18	402, 801, AM				
20:5-23	106, 402, 801	21:7-25; 22:2-3; 22:8-11; 22:13-24; 23:8-25; 24:2-6; 25:12-25; 26:2-24	OS, 106, 402, 403	24:7-11, 24:13-25:8	106, 402, 403, 801, CQ, AM, ID, OS
21:7-25	106, 402, 602, 801, F, AM, CQ	22:2-3; 22:8-11; 22:13-24; 23:8-25; 24:2-6; 25:12-25; 26:2-24	OS, 106, 402, 403	24:7-11, 24:13-25:8	106, 402, 403, 801, CQ, AM, ID, OS
22:2-3	106, 402, 602, 801, F, AM, CQ	21:7-25; 22:8-11; 22:13-24; 23:8-25; 24:2-6; 25:12-25; 26:2-24	OS, 106, 402, 403	24:7-11, 24:13-25:8	106, 402, 403, 801, CQ, AM, ID, OS
25:12-25	106, 402, 602, 801, SP	21:7-25; 22:2-3; 22:8-11; 22:13-24; 23:8-25; 24:2-6; 26:2-4	OS, 106, 402, 403	24:7-11, 24:13-25:8	106, 402, 403, 801, CQ, AM, ID, OS
26:2-24	106, 402, 602, 801, SP	21:7-25; 22:2-3; 22:8-11; 22:13-24; 23:8-25; 24:2-6; 25:12-25	OS, 106, 402, 403	24:7-11, 24:13-25:8	106, 402, 403, 801, CQ, AM, ID, OS
28:13-25	801, CQ				
29:2-3	801, CQ				
30:17-25	106, 402, 801, A, AM, FRCP 30(b)(6)	33:14-16; 33:18-24	OS, 106, 402, 403	33:7-9, 33:11-13, 34:1-4, 34:7-8	106, 402, 403, 801, AM, F, FRCP 30(b)(6), ID, IQ, OS

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
31:3-15	106, 402, 602, 801, A, AF, AM, F, CQ, FRCP 30(b)(6)	33:14-16; 33:18-24	OS, 106, 402, 403	33:7-9, 33:11-13, 34:1-4, 34:7-8	106, 402, 403, 801, AM, F, FRCP 30(b)(6), ID, IQ, OS
31:18-22	106, 402, 602, 801, A, AF, AM, F, CQ, FRCP 30(b)(6)	33:14-16; 33:18-24	OS, 106, 402, 403	33:7-9, 33:11-13, 34:1-4, 34:7-8	106, 402, 403, 801, AM, F, FRCP 30(b)(6), ID, IQ, OS
39:19-25	402, 801, FRCP 30(b)(6)				
40:4-5	402, 801, AM, FRCP 30(b)(6)				
40:9-12	402, 801, AM, FRCP 30(b)(6)				
52:5-7	801				
52:14-25	801				
53:2-8	801, AF, AM				
53:10-25	106, 402, 801, AA, AF, AM; FRCP 30(b)(6)	56:4-22; 60:2-14	OS, 106, 402, 403	56:23-25, 57:3-6, 57:8-14	106, 402, 403, 801, AA, AM, AR, CQ, FRCP 30(b)(6), MC, OS
54:4-5	106, 402, 801, AM, FRCP 30(b)(6)	56:4-22; 60:2-14	OS, 106, 402, 403	56:23-25, 57:3-6, 57:8-14	106, 402, 403, 801, AA, AM, AR, CQ, FRCP 30(b)(6), MC, OS
55:7-8	106, 402, 801, AA, AM, SP; IQ; CQ	56:4-22; 60:2-14	OS, 106, 402, 403	56:23-25, 57:3-6, 57:8-14	106, 402, 403, 801, AA, AM, AR, CQ,

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
					FRCP 30(b)(6), MC, OS
55:10-16	106, 402, 801, AA, AM, SP	56:4-22; 60:2-14	OS, 106, 402, 403	56:23-25, 57:3-6, 57:8-14	106, 402, 403, 801, AA, AM, AR, CQ, FRCP 30(b)(6), MC, OS
55:18-25	106, 402, 801, AA, AM, CQ, SP	56:4-22; 60:2-14	OS, 106, 402, 403	56:23-25, 57:3-6, 57:8-14	106, 402, 403, 801, AA, AM, AR, CQ, FRCP 30(b)(6), MC, OS
56:2-3	106, 402, 801, AM, SP	56:4-22	OS, 106, 402, 403	56:23-25, 57:3-6, 57:8-14	106, 402, 403, 801, AA, AM, AR, CQ, FRCP 30(b)(6), MC, OS
58:6-8	106, 402, 801, AA, AM	56:4-22; 60:2-14	OS, 106, 402, 403	56:23-25, 57:3-6, 57:8-14	106, 402, 403, 801, AA, AM, AR, CQ, FRCP 30(b)(6), MC, OS
58:10-13	106, 402, 801, AA, AM	56:4-22; 60:2-14	OS, 106, 402, 403	56:23-25, 57:3-6, 57:8-14	106, 402, 403, 801, AA, AM, AR, CQ, FRCP 30(b)(6), MC, OS
60:2-14	106, 402, 801	56:4-22		56:23-25, 57:3-6, 57:8-14	106, 402, 403, 801, AA, AM, AR, CQ, FRCP 30(b)(6), MC, OS
60:17-25	106, 402, 602, 801, AM, AF, F	14:10-25; 15:2-6; 56:4-22; 60:2-14;	ID, OS, 106, 402, 403, 601, 701	33:7-9, 33:11-13, 34:1-4, 34:7-8,	106, 402, 403, 602, 701, 801, AA, AM,

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		61:13-14; 61:16-18; 82:9-20; 82:22-25; 83:2; 83:14-20; 84:5-7; 84:9-19; 85:11-13; 85:15-19; 122:8-21		56:23-25, 57:3-6, 57:8-14, 85:20-86:9, 86:11, 122:22-123:3, 123:5-14, 123:19-23, 124:3-11, 124:13-22, 125:3-6, 125:9-17, 125:20-126:3	AR, CQ, F, FRCP 30(b)(6), ID, IQ, MC, OS, SP
61:2-4	106, 402, 801, AM	56:4-22; 60:2-14; 61:13-14; 61:16-18; 82:9-20; 82:22-25; 83:2; 83:14-20; 84:5-7; 84:9-19; 85:11-13; 85:15-19; 122:8-21	OS, 106, 402, 403, 601, 701	33:7-9, 33:11-13, 34:1-4, 34:7-8, 56:23-25, 57:3-6, 57:8-14, 85:20-86:9, 86:11, 122:22-123:3, 123:5-14, 123:19-23, 124:3-11, 124:13-22, 125:3-6, 125:9-17, 125:20-126:3	106, 402, 403, 602, 701, 801, AA, AM, AR, CQ, F, FRCP 30(b)(6), ID, IQ, MC, OS, SP
61:6-14	106, 402, 801, AM	14:10-25; 15:2-6; 56:4-22; 60:2-14; 61:13-14; 61:16-18; 82:9-20; 82:22-25; 83:2; 83:14-20; 84:5-7; 84:9-19; 85:11-13; 85:15-19; 122:8-21	ID, OS, 106, 402, 403, 601, 701	33:7-9, 33:11-13, 34:1-4, 34:7-8, 56:23-25, 57:3-6, 57:8-14, 85:20-86:9, 86:11, 122:22-123:3, 123:5-14, 123:19-23, 124:3-11,	106, 402, 403, 602, 701, 801, AA, AM, AR, CQ, F, FRCP 30(b)(6), ID, IQ, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
				124:13-22, 125:3-6, 125:9-17, 125:20-126:3	
61:16-18	106, 402, 801, AM	14:10-25; 15:2-6; 56:4-22; 60:2-14; 61:13-14; 82:9-20; 82:22-25; 83:2; 83:14-20; 84:5-7; 84:9-19; 85:11-13; 85:15-19; 122:8-21	ID, OS, 106, 402, 403, 601, 701	33:7-9, 33:11-13, 34:1-4, 34:7-8, 56:23-25, 57:3-6, 57:8-14, 85:20-86:9, 86:11, 122:22-123:3, 123:5-14, 123:19-23, 124:3-11, 124:13-22, 125:3-6, 125:9-17, 125:20-126:3	106, 402, 403, 602, 701, 801, AA, AM, AR, CQ, F, FRCP 30(b)(6), ID, IQ, MC, OS, SP
64:22-23	106, 602, 801, A, F	65:11-12	106, 402, 403	65:13-66:14, 66:16-25	106, 402, 403, 801, AM, C, CQ, ID, OS
65:3-10	106, 602, 801, A, CQ, F	65:11-12	106, 402, 403	65:13-66:14, 66:16-25	106, 402, 403, 801, AM, C, CQ, ID, OS
67:7-12	801, A, F				
71:12-16	106, 402, 403, 602, 801, A, AM, F, SP, FRCP 30(b)(6)	96:25; 97:2-12; 114:6-19; 118:19-25; 119:2-25; 120:2-25; 121:2-15; 126:24-25; 127:2; 127:8-25; 128:2-14	OS, 106, 402, 403, 601, 701, 801	121:16-18, 121:20-25, 126:10-14, 126:15-23	106, 402, 403, 801, AA, AM, C, CQ, ID, MC, OS

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
71:19-25	106, 402, 403, 602, 801, A, AM, F, SP, FRCP 30(b)(6)	96:25; 97:2-12; 101:23-25; 102:2-14; 105:2; 105:4-20; 105:21-23; 105:25; 106:2-16; 114:6-19; 118:19-25; 119:2-25; 120:2-25; 121:2-15; 126:24-25; 127:2; 127:8-25; 128:2-14; 136:10-18; 169:4-23; 186:10-11; 186:14-25	OS, 106, 402, 403, 601, 701, 801	100:19-24, 101:12-22, 106:17-107:2, 121:16-18, 121:20-25, 126:10-14, 126:15-23, 136:3-9, 136:19-21, 136:23-137:3	106, 402, 403, 801, AA, AM, AR, C, CQ, ID, MC, OS
72:2-11	106, 402, 403, 602, 801, A, AM, F, SP, FRCP 30(b)(6)	96:25; 97:2-12; 101:23-25; 102:2-14; 105:2; 105:4-20; 105:21-23; 105:25; 106:2-16; 114:6-19; 118:19-25; 119:2-25; 120:2-25; 121:2-15; 126:24-25; 127:2; 127:8-25; 128:2-14; 136:10-18; 169:4-23; 186:10-11; 186:14-25	OS, 106, 402, 403, 601, 701, 801	100:19-24, 101:12-22, 106:17-107:2, 121:16-18, 121:20-25, 126:10-14, 126:15-23,;3-9, 136:19-21, 136:23-137:3	106, 402, 403, 801, AA, AM, AR, C, CQ, ID, MC, OS

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
72:13-21	106, 402, 403, 602, 701, 801, A, AM, F, SP, FRCP 30(b)(6)	96:25; 97:2-12; 101:23-25; 102:2-14; 105:2; 105:4-20; 105:21-23; 105:25; 106:2-16; 114:6-19; 118:19-25; 119:2-25; 120:2-25; 121:2-15; 126:24-25; 127:2; 127:8-25; 128:2-14; 136:10-18; 169:4-23; 186:10-11; 186:14-25	OS, 106, 402, 403, 601, 701, 801	100:19-24, 101:12-22, 106:17-107:2, 121:16-18, 121:20-25, 126:10-14, 126:15-23, 136:3-9, 136:19-21, 136:23-137:3	106, 402, 403, 801, AA, AM, AR, C, CQ, ID, MC, OS
77:21-78:13	402, 602, 801, A, F, ID				
79:10-12	106, 402, 602, 801, A, F	64:22-23; 65:3-12	OS		
79:17-25	106, 402, 602, 801, A, F	64:22-23; 65:3-12	OS		
80:2-12	106, 402, 602, 801, A, AM, F	56:4-22; 60:2-14; 64:22-23; 65:3-12	OS, 106, 402, 403	56:23-25, 57:3-6, 57:8-14	106, 402, 403, 801, AA., AM, AR, F, FRCP 30(b)(6), MC, OS
80:14-23	106, 402, 602, 801, A, AM, F	56:4-22; 60:2-14; 64:22-23; 65:3-12	OS, 106, 402, 403	56:23-25, 57:3-6, 57:8-14	106, 402, 403, 801, AA., AM, AR, F, FRCP 30(b)(6), MC, OS

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
80:25	106, 402, 602, 801, A, AM, F	56:4-22; 60:2-14; 64:22-23; 65:3-12	OS, 106, 402, 403	56:23-25, 57:3-6, 57:8-14	106, 402, 403, 801, AA., AM, AR, Fr, FRCP 30(b)(6), MC, OS
81:2-3	106, 402, 602, 801, A, AM, F	64:22-23; 65:3-12	OS		
81:5-11	106, 402, 403, 602, 701, 801, A, AF, AM, CQ, F, FRCP 30(b)(6), SP	64:22-23; 65:3-12	OS		
81:14-25	106, 402, 403, 602, 701, 801, A, AF, AM, CQ, F, FRCP 30(b)(6), SP	64:22-23; 65:3-12	OS		
82:2-8	106, 402, 403, 602, 701, 801, A, AF, AM, CQ, F, FRCP 30(b)(6), SP	64:22-23; 65:3-12; 82:9-20; 82:22-25; 83:2	OS, 106, 402, 403, 601, 701	85:20-86:9, 86:11	106, 402, 403, 801, AA, AM, AR, C, OS
83:3-9	106, 402, 403, 801, AM, CQ, IQ	82:9-20; 82:22-25; 83:2; 83:14-20; 84:5-7; 84:9-19; 85:11-13; 85:15-19; 122:8-21	OS, 106, 402, 403, 601, 701	85:20-86:9, 86:11, 122:22-123:3, 123:5-14, 123:19-23, 124:3-11, 124:13-22, 125:3-6, 125:9-17, 125:20-126:3	106, 402, 403, 602, 701, 801, A, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, MC, OS, SP
83:21-25	106, 402, 403, 801, AM, IQ	82:9-20; 82:22-25; 83:2; 83:14-20; 84:5-7; 84:9-19;	OS, 106, 402, 403, 601, 701	85:20-86:9, 86:11, 122:22-123:3, 123:5-14, 123:19-	106, 402, 403, 602, 701, 801, A, AA, AM, AR, C, CQ, F,

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		85:11–13; 85:15–19; 122:8–21		23, 124:3-11, 124:13-22, 125:3-6, 125:9-17, 125:20-126:3	FRCP 30(b)(6), ID, MC, OS, SP
84:2-4	106, 402, 801, AM, IQ, FRCP 30(b)(6)	82:9–20; 82:22–25; 83:2; 83:14–20; 84:5–7; 84:9–19; 85:11–13; 85:15–19; 122:8–21	OS, 106, 402, 403, 601, 701	85:20-86:9, 86:11, 122:22-123:3, 123:5-14, 123:19-23, 124:3-11, 124:13-22, 125:3-6, 125:9-17, 125:20-126:3	106, 402, 403, 602, 701, 801, A, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, MC, OS, SP
84:20-23	106, 402, 801, AM, IQ, FRCP 30(b)(6)	82:9–20; 82:22–25; 83:2; 83:14–20; 84:5–7; 84:9–19; 85:11–13; 85:15–19; 122:8–21	OS, 106, 402, 403, 601, 701	85:20-86:9, 86:11, 122:22-123:3, 123:5-14, 123:19-23, 124:3-11, 124:13-22, 125:3-6, 125:9-17, 125:20-126:3	106, 402, 403, 602, 701, 801, A, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, MC, OS, SP
84:25	106, 402, 801, AM, IQ, FRCP 30(b)(6)	82:9–20; 82:22–25; 83:2; 83:14–20; 84:5–7; 84:9–19; 85:11–13; 85:15–19; 122:8–21	OS, 106, 402, 403, 601, 701	85:20-86:9, 86:11, 122:22-123:3, 123:5-14, 123:19-23, 124:3-11, 124:13-22, 125:3-6, 125:9-17, 125:20-126:3	106, 402, 403, 602, 701, 801, A, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, MC, OS, SP
85:2-5	106, 402, 801, AM, IQ, FRCP 30(b)(6)	82:9–20; 82:22–25; 83:2; 83:14–20; 84:5–7; 84:9–19;	OS, 106, 402, 403, 601, 701	85:20-86:9, 86:11, 122:22-123:3, 123:5-14, 123:19-	106, 402, 403, 602, 701, 801, A, AA, AM, AR, C, CQ, F,

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		85:11–13; 85:15–19; 122:8–21		23, 124:3-11, 124:13-22, 125:3-6, 125:9-17, 125:20-126:3	FRCP 30(b)(6), ID, MC, OS, SP
87:9-16	106, 402, 801, AM	14:10–25; 15:2–6; 82:9–20; 82:22–25; 83:2; 83:14–20; 84:5–7; 84:9–19; 85:11–13; 85:15–19; 99:14–25; 100:2–5; 101:23–25; 102:2–14; 122:8–21; 132:8–18; 133:13–22	ID, OS, 106, 402, 403, 601, 701	85:20-86:9, 86:11, 100:19-24, 101:12-22, 122:22-123:3, 123:5-14, 123:19-23, 124:3-11, 124:13-22, 125:3-6, 125:9-17, 125:20-126:3, 132:19-133:9, 133:11-12	106, 402, 403, 602, 701, 801, A, AA, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, MC, OS, SP
87:18	106, 402, 801, AM	14:10–25; 15:2–6; 82:9–20; 82:22–25; 83:2; 83:14–20; 84:5–7; 84:9–19; 85:11–13; 85:15–19; 99:14–25; 100:2–5; 101:23–25; 102:2–14; 122:8–21; 132:8–18; 133:13–22	ID, OS, 106, 402, 403, 601, 701	85:20-86:9, 86:11, 100:19-24, 101:12-22, 122:22-123:3, 123:5-14, 123:19-23, 124:3-11, 124:13-22, 125:3-6, 125:9-17, 125:20-126:3, 132:19-133:9, 133:11-12	106, 402, 403, 602, 701, 801, A, AA, AF, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, MC, OS, SP
89:6-12	402, 602, 801, A, F				
89:16-24	402, 602, 801, A, F				
92:4-5	106, 801	92:20–25; 93:2–25; 94:2–25; 95:2–6	OS, 106, 402, 403	95:10-11, 95:13-19	106, 402, 403, 801, AA, AR, C

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
92:10-19	106, 801	92:20-25; 93:2-25; 94:2-25; 95:2-6	OS, 106, 402, 403	95:10-11, 95:13-19	106, 402, 403, 801, AA, AR, C
96:7-24	106, 402, 403, 602, 801, F, SP	92:20-25; 93:2-25; 94:2-25; 95:2-6; 96:25; 97:2-12; 99:14-25; 100:2-5; 100:6-14; 101:23-25; 102:2-14; 105:2; 105:4-20; 105:21-23; 105:25; 106:2-16; 114:6-19; 118:19-25; 119:2-25; 120:2-25; 121:2-15; 126:24-25; 127:2; 127:8-25; 128:2-14; 169:4-23; 186:10-11; 186:14-25	ID, OS, 106, 402, 403, 601, 701	95:10-11, 95:13-19, 100:19-24, 101:12-22, 106:17-107:2, 114:20-25, 115:4-5, 121:16-18, 121:20-25, 126:10-14, 126:15-23	106, 402, 403, 801, AA, AF, AM, AR, C, CQ, ID, MC, OS
97:13-15	106, 402, 403, 602, 701, 801, AM, F, FRCP 30(b)(6)	96:25; 97:2-12; 99:14-25; 100:2-5; 100:6-14; 101:23-25; 102:2-14; 105:2; 105:4-20; 105:21-23; 105:25; 106:2-16; 114:6-19; 118:19-25; 119:2-25; 120:2-	ID, OS, 106, 402, 403, 601, 701	95:10-11, 95:13-19, 100:19-24, 101:12-22, 106:17-107:2, 114:20-25, 115:4-5, 121:16-18, 121:20-25, 126:10-14, 126:15-23	106, 402, 403, 801, AA, AF, AM, AR, C, CQ, ID, MC, OS

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		25; 121:2–15; 126:24–25; 127:2; 127:8–25; 128:2– 14; 169:9–23; 186:10–11; 186:14– 25			
97:17-19	106, 402, 403, 801, AM, SP	96:25; 97:2–12; 99:14–25; 100:2–5; 100:6–14; 101:23– 25; 102:2–14; 105:2; 105:4–20; 105:21–23; 105:25; 106:2–16; 114:6– 19; 118:19–25; 119:2–25; 120:2– 25; 121:2–15; 126:24–25; 127:2; 127:8–25; 128:2– 14; 169:9–23; 186:10–11; 186:14– 25	ID, OS, 106, 402, 403, 601, 701	95:10-11, 95:13-19, 100:19-24, 101:12- 22, 106:17-107:2, 114:20-25, 115:4-5, 121:16-18, 121:20- 25, 126:10-14, 126:15-23	106, 402, 403, 801, AA, AF, AM, AR, C, CQ, ID, MC, OS
97:21-25	106, 402, 403, 801, AM, SP	96:25; 97:2–12; 99:14–25; 100:2–5; 100:6–14; 101:23– 25; 102:2–14; 105:2; 105:4–20; 105:21–23; 105:25; 106:2–16; 114:6–	ID, OS, 106, 402, 403, 601, 701	95:10-11, 95:13-19, 100:19-24, 101:12- 22, 106:17-107:2, 114:20-25, 115:4-5, 121:16-18, 121:20- 25, 126:10-14, 126:15-23	106, 402, 403, 801, AA, AF, AM, AR, C, CQ, ID, MC, OS

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		19; 118:19–25; 119:2–25; 120:2–25; 121:2–15; 126:24–25; 127:2; 127:8–25; 128:2–14; 169:9–23; 186:10–11; 186:14–25			
97:17-19					
97:21-25					
98:13-17	106, 402, 801, AM, CQ, IQ	101:23–25; 102:2–14	OS, 106, 402, 403	100:19-24, 101:12-22	106, 402, 403, 801, MC, OS
98:19-22	106, 402, 801, AM, CQ	101:23–25; 102:2–14	OS, 106, 402, 403	100:19-24, 101:12-22	106, 402, 403, 801, MC, OS
98:24-25	106, 402, 801, AM, CQ	101:23–25; 102:2–14	OS, 106, 402, 403	100:19-24, 101:12-22	106, 402, 403, 801, MC, OS
99:2-6	106, 402, 801, AM, CQ	101:23–25; 102:2–14	OS, 106, 402, 403	100:19-24, 101:12-22	106, 402, 403, 801, MC, OS
99:14-25	106, 402, 403, 602, 801, AM, F, SP	92:20–25; 93:2–25; 94:2–25; 95:2–6; 96:25; 97:2–12; 99:14–25; 100:2–5; 100:6–14; 101:23–25; 102:2–14; 132:8–18; 133:13–22	OS, 106, 402, 403	95:10-11, 95:13-19, 100:19-24, 101:12-22, 132:19-133:9, 133:11-12	106, 402, 403, 801, AA, AM, AR, C, ID, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
100:2-5	106, 402, 403, 602, 801, AM, F, SP	92:20-25; 93:2-25; 94:2-25; 95:2-6; 96:25; 97:2-12; 99:14-25; 100:2-5; 100:6-14; 101:23-25; 102:2-14; 132:8-18; 133:13-22	OS, 106, 402, 403	95:10-11, 95:13-19, 100:19-24, 101:12-22, 132:19-133:9, 133:11-12	106, 402, 403, 801, AA, AM, AR, C, ID, MC, OS, SP
104:17-25	106, 402, 403, 602, 701, 801, AA, AF, AM, F, SP, FRCP 30(b)(6)	92:20-25; 93:2-25; 94:2-25; 95:2-6; 96:25; 97:2-12; 99:14-25; 100:2-5; 100:6-14; 101:23-25; 102:2-14; 105:21-23; 105:25; 106:2-16; 114:6-19; 132:8-18; 169:4-23	OS, 106, 402, 403	95:10-11, 95:13-19, 100:19-24, 101:12-22, 132:19-133:9, 133:11-12	106, 402, 403, 801, AA, AM, AR, C, ID, MC, OS, SP
105:2	106, 402, 403, 602, 701, 801, AA, AF, AM, F, SP, FRCP 30(b)(6)	92:20-25; 93:2-25; 94:2-25; 95:2-6; 96:25; 97:2-12; 99:14-25; 100:2-5; 100:6-14; 101:23-25; 102:2-14; 105:2; 105:4-20; 105:21-23; 105:25; 106:2-16; 114:6-19; 118:19-25;	OS, 106, 402, 403, 601, 701	95:10-11, 95:13-19, 100:19-24, 101:12-22, 106:17-107:2, 114:20-25, 115:4-5, 121:16-18, 121:20-25, 126:10-14, 126:15-23	106, 402, 403, 801, AA, AF, AM, AR, C, CQ, ID, MC, OS

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		119:2-25; 120:2-25; 121:2-15; 126:24-25; 127:2; 127:8-25; 128:2-14; 169:4-23; 186:10-11; 186:14-25			
105:4-20	106, 402, 403, 602, 701, 801, AA, AF, AM, F, SP, FRCP 30(b)(6)	92:20-25; 93:2-25; 94:2-25; 95:2-6; 96:25; 97:2-12; 99:14-25; 100:2-5; 100:6-14; 101:23-25; 102:2-14; 105:2; 105:4-20; 105:21-23; 105:25; 106:2-16; 114:6-19; 118:19-25; 119:2-25; 120:2-25; 121:2-15; 126:24-25; 127:2; 127:8-25; 128:2-14; 169:4-23; 186:10-11; 186:14-25	OS, 106, 402, 403, 601, 701	95:10-11, 95:13-19, 100:19-24, 101:12-22, 106:17-107:2, 114:20-25, 115:4-5, 121:16-18, 121:20-25, 126:10-14, 126:15-23	106, 402, 403, 801, AA, AF, AM, AR, C, CQ, ID, MC, OS
109:14-15	106, 402, 801, AA, AF, AM, CQ, SP	92:20-25; 93:2-25; 94:2-25; 95:2-6; 99:14-25; 100:2-5; 100:6-14; 101:23-	OS, 106, 402, 403	95:10-11, 95:13-19, 100:19-24, 101:12-22, 132:19-133:9, 133:11-12	106, 402, 403, 801, AA, AM, AR, C, ID, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		25; 102:2-14; 132:8-18; 133:13-22; 169:4-23			
109:17-20	106, 402, 801, AA, AF, AM, CQ, SP	92:20-25; 93:2-25; 94:2-25; 95:2-6; 99:14-25; 100:2-5; 100:6-14; 101:23-25; 102:2-14; 132:8-18; 133:13-22; 169:4-23	OS, 106, 402, 403	95:10-11, 95:13-19, 100:19-24, 101:12-22, 132:19-133:9, 133:11-12	106, 402, 403, 801, AA, AM, AR, C, ID, MC, OS, SP
112:9-13	106, 402, 701, 801, AA, AF, AM, AR, C, CQ, MC	92:20-25; 93:2-25; 94:2-25; 95:2-6; 99:14-25; 100:2-5; 100:6-14; 101:23-25; 102:2-14; 114:6-19; 132:8-18; 133:13-22; 136:10-18; 169:4-23	OS, 106, 402, 403	95:10-11, 95:13-19, 100:19-24, 101:12-22, 114:20-25, 115:4-5, 132:19-133:9, 133:11-12	106, 402, 403, 801, AA, AM, AR, C, ID, MC, OS, SP
112:16-25	106, 402, 701, 801, AA, AF, AM, AR, C, CQ, MC	92:20-25; 93:2-25; 94:2-25; 95:2-6; 99:14-25; 100:2-5; 100:6-14; 101:23-25; 102:2-14; 114:6-19; 132:8-18; 133:13-22; 136:10-18; 169:4-23	OS, 106, 402, 403	95:10-11, 95:13-19, 100:19-24, 101:12-22, 114:20-25, 115:4-5, 132:19-133:9, 133:11-12	106, 402, 403, 801, AA, AM, AR, C, ID, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
113:2-8	106, 402, 701, 801, AA, AF, AM, AR, C, CQ, MC	92:20-25; 93:2-25; 94:2-25; 95:2-6; 99:14-25; 100:2-5; 100:6-14; 101:23-25; 102:2-14; 113:20-21; 114:6-19; 132:8-18; 133:13-22; 136:10-18; 169:4-23	OS, 106, 402, 403	95:10-11, 95:13-19, 100:19-24, 101:12-22, 114:20-25, 115:4-5, 132:19-133:9, 133:11-12	106, 402, 403, 801, AA, AM, AR, C, ID, MC, OS, SP
113:10-19	106, 402, 701, 801, AA, AF, AM, AR, C, CQ, MC	92:20-25; 93:2-25; 94:2-25; 95:2-6; 99:14-25; 100:2-5; 100:6-14; 101:23-25; 102:2-14; 113:20-21; 114:6-19; 132:8-18; 133:13-22	OS, 106, 402, 403	95:10-11, 95:13-19, 100:19-24, 101:12-22, 114:20-25, 115:4-5, 132:19-133:9, 133:11-12	106, 402, 403, 801, AA, AM, AR, C, ID, MC, OS, SP
113:22-25	106, 402, 403, 602, 701, 801, AM, F	96:25; 97:2-12; 101:23-25; 102:2-14; 105:2; 105:4-20; 105:21-23; 105:25; 106:2-16; 114:6-19; 118:19-25; 119:2-25; 120:2-25; 121:2-15; 126:24-25; 127:2; 127:8-25; 128:2-14; 169:4-	OS, 106, 402, 403, 601, 701	100:19-24, 101:12-22, 106:17-107:2, 114:20-25, 115:4-5, 121:16-18, 121:20-25, 126:10-14, 126:15-23	106, 402, 403, 801, AA, AF, AM, AR, C, CQ, ID, MC, OS

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		23; 186:10–11; 186:14–25			
114:2-5	106, 402, 403, 602, 701, 801, AM, F	96:25; 97:2–12; 101:23–25; 102:2–14; 105:2; 105:4–20; 105:21–23; 105:25; 106:2–16; 114:6–19; 118:19–25; 119:2–25; 0120:2–25; 121:2–15; 126:24–25; 127:2; 127:8–25; 128:2–14; 169:4–23; 186:10–11; 186:14–25	OS, 106, 402, 403, 601, 701	100:19-24, 101:12-22, 106:17-107:2, 114:20-25, 115:4-5, 121:16-18, 121:20-25, 126:10-14, 126:15-23	106, 402, 403, 801, AA, AF, AM, AR, C, CQ, ID, MC, OS
128:15-20	106, 402, 403, 801	96:25; 97:2–12; 101:23–25; 102:2–14; 105:2; 105:4–20; 105:21–23; 105:25; 106:2–16; 114:6–19; 118:19–25; 119:2–25; 120:2–25; 121:2–15; 126:24–25; 127:2; 127:8–25; 128:2–14; 169:4–23; 186:10–11; 186:14–25	OS, 106, 402, 403, 601, 701	100:19-24, 101:12-22, 106:17-107:2, 114:20-25, 115:4-5, 121:16-18, 121:20-25, 126:10-14, 126:15-23	106, 402, 403, 801, AA, AF, AM, AR, C, CQ, ID, MC, OS

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
129:5-6	106, 402, 602, 801, A, F	129:7			
129:12-19	402, 602, 801, A, F				
130:20-25	106, 402, 403, 602, 801, A, AM, CQ, F	93:7-25; 94:2-25; 95:2-6; 96:25; 97:2-12; 101:23-25; 102:2-14; 105:2; 105:4-20; 105:21-23; 105:25; 106:2-16; 114:6-19; 118:19-25; 119:2-25; 120:2-25; 121:2-15; 122:8-21; 126:24-25; 127:2; 127:8-25; 128:2-14; 129:5-7; 129:12-19; 132:8-18; 133:13-22; 169:4-23; 186:10-11; 186:14-25	OS, 106, 402, 403, 601, 701	95:10-11, 95:13-19, 100:19-24, 101:12-22, 106:17-107:2, 114:20-25, 115:4-5, 121:16-18, 121:20-25, 122:22-123:3, 123:5-14, 123:19-23, 124:3-11, 124:13-22, 125:3-6, 125:9-17, 125:20-126:3, 126:10-14, 126:15-23, 132:19-133:9, 133:11-12	106, 402, 403, 801, AA, AF, AM, AR, C, CQ, ID, MC, OS, SP
131:3-6	106, 402, 403, 602, 801, A, AM, CQ, F	93:7-25; 94:2-25; 95:2-6; 96:25; 97:2-12; 101:23-25; 102:2-14; 105:2; 105:4-20; 105:21-23; 105:25; 106:2-16; 114:6-	OS, 106, 402, 403, 601, 701	95:10-11, 95:13-19, 100:19-24, 101:12-22, 106:17-107:2, 114:20-25, 115:4-5, 121:16-18, 121:20-25, 122:22-123:3, 123:5-14, 123:19-	106, 402, 403, 801, AA, AF, AM, AR, C, CQ, ID, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		19; 118:19–25; 119:2–25; 120:2–25; 121:2–15; 122:8–21; 126:24–25; 127:2; 127:8–25; 128:2–14; 129:5–7; 129:12–19; 132:8–18; 133:13–22; 169:4–23; 186:10–11; 186:14–25		23, 124:3-11, 124:13-22, 125:3-6, 125:9-17, 125:20-126:3, 126:10-14, 126:15-23, 132:19-133:9, 133:11-12	
131:13-22	106, 402, 403, 602, 801, A, F, IQ, ID	93:7–25; 94:2–25; 95:2–6; 96:25; 97:2–12; 101:23–25; 102:2–14; 105:2; 105:4–20; 105:21–23; 105:25; 106:2–16; 114:6–19; 118:19–25; 119:2–25; 120:2–25; 121:2–15; 122:8–21; 126:24–25; 127:2; 127:8–25; 128:2–14; 129:5–7; 129:12–19; 132:8–18; 133:13–22; 169:4–	OS, 106, 402, 403, 601, 701	95:10-11, 95:13-19, 100:19-24, 101:12-22, 106:17-107:2, 114:20-25, 115:4-5, 121:16-18, 121:20-25, 122:22-123:3, 123:5-14, 123:19-23, 124:3-11, 124:13-22, 125:3-6, 125:9-17, 125:20-126:3, 126:10-14, 126:15-23, 132:19-133:9, 133:11-12	106, 402, 403, 801, AA, AF, AM, AR, C, CQ, ID, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		23; 186:10–11; 186:14–25			
132:2-3	106, 402, 403, 602, 801, A, F, MC, ID, IQ	93:7–25; 94:2–25; 95:2–6; 96:25; 97:2–12; 101:23–25; 102:2–14; 105:2; 105:4–20; 105:21–23; 105:25; 106:2–16; 114:6–19; 118:19–25; 119:2–25; 120:2–25; 121:2–15; 122:8–21; 126:24–25; 127:2; 127:8–25; 128:2–14; 129:5–7; 129:12–19; 132:8–18; 133:13–22; 169:4–23; 186:10–11; 186:14–25	OS, 106, 402, 403, 601, 701	95:10-11, 95:13-19, 100:19-24, 101:12-22, 106:17-107:2, 114:20-25, 115:4-5, 121:16-18, 121:20-25, 122:22-123:3, 123:5-14, 123:19-23, 124:3-11, 124:13-22, 125:3-6, 125:9-17, 125:20-126:3, 126:10-14, 126:15-23, 132:19-133:9, 133:11-12	106, 402, 403, 801, AA, AF, AM, AR, C, CQ, ID, MC, OS, SP
132:6-7	106, 402, 403, 602, 801, A, F, MC, ID, IQ	93:7–25; 94:2–25; 95:2–6; 96:25; 97:2–12; 101:23–25; 102:2–14; 105:2; 105:4–20; 105:21–23; 105:25; 106:2–16; 114:6–19; 118:19–25;	OS, 106, 402, 403, 601, 701	95:10-11, 95:13-19, 100:19-24, 101:12-22, 106:17-107:2, 114:20-25, 115:4-5, 121:16-18, 121:20-25, 122:22-123:3, 123:5-14, 123:19-23, 124:3-11,	106, 402, 403, 801, AA, AF, AM, AR, C, CQ, ID, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		119:2–25; 120:2–25; 121:2–15; 122:8–21; 126:24–25; 127:2; 127:8–25; 128:2–14; 129:5–7; 129:12–19; 132:8–18; 133:13–22; 169:4–23; 186:10–11; 186:14–25		124:13–22, 125:3–6, 125:9–17, 125:20–126:3, 126:10–14, 126:15–23, 132:19–133:9, 133:11–12	
134:12–135:19	402, 801, ID				
137:4–18	106, 402, 403, 801, FRCP 30(b)(6)	138:6–25; 139:2–4; 139:14–21; 143:25; 144:2–3; 144:6–15; 149:11–25; 150:2–25; 151:2–3; 152:8–11; 152:14–16; 152:18–25; 153:2–4; 159:14–17; 159:20–25; 160:2	OS, 106, 402, 403	139:22, 139:25–140:6, 144:16–19, 144:22–145:9, 151:4–7, 151:9–21, 159:5–8, 159:10–13, 160:3–11, 160:13–15	106, 402, 403, 602, 801, AF, AM, C, CQ, F, FRCP 30(b)(6), ID, OS, SP
162:7–16	402, 801, FRCP 30(b)(6)				
163:2–3	402, 801, AM, FRCP 30(b)(6)				
163:5–165:3	402, 801, AM, FRCP 30(b)(6), ID, IQ				

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
165:20-166:5	106, 402, 801, AM, SP, ID	168:10-15	OS, 106, 402, 403		
166:7-167:7	106, 402, 801, SP, ID	168:10-15	OS, 106, 402, 403		
168:16-25	106, 402, 403, 801, AM	96:25; 97:2-12; 101:23-25; 102:2-14; 105:2; 105:4-20; 105:21-23; 105:25; 106:2-16; 114:6-19; 118:19-25; 119:2-25; 120:2-25; 121:2-15; 126:24-25; 127:2; 127:8-25; 128:2-14; 168:10-15; 169:4-23; 186:10-11; 186:14-25	OS, 106, 402, 403, 601, 701	100:19-24, 101:12-22, 106:17-107:2, 114:20-25, 115:4-5, 121:16-18, 121:20-25, 126:10-14, 126:15-23	106, 402, 403, 801, AA, AF, AM, AR, C, CQ, ID, MC, OS
169:2-25	106, 402, 403, 801, AM	96:25; 97:2-12; 101:23-25; 102:2-14; 105:2; 105:4-20; 105:21-23; 105:25; 106:2-16; 114:6-19; 118:19-25; 119:2-25; 120:2-25; 121:2-15; 126:24-25; 127:2; 127:8-25;	OS, 106, 402, 403, 601, 701	100:19-24, 101:12-22, 106:17-107:2, 114:20-25, 115:4-5, 121:16-18, 121:20-25, 126:10-14, 126:15-23	106, 402, 403, 801, AA, AF, AM, AR, C, CQ, ID, MC, OS

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		128:2–14; 168:10–15; 169:4–23; 186:10–11; 186:14–25			
170:2	106, 402, 403, 801, AM	96:25; 97:2–12; 101:23–25; 102:2–14; 105:2; 105:4–20; 105:21–23; 105:25; 106:2–16; 114:6–19; 118:19–25; 119:2–25; 120:2–25; 121:2–15; 126:24–25; 127:2; 127:8–25; 128:2–14; 168:10–15; 169:4–23; 186:10–11; 186:14–25	OS, 106, 402, 403, 601, 701	100:19-24, 101:12-22, 106:17-107:2, 114:20-25, 115:4-5, 121:16-18, 121:20-25, 126:10-14, 126:15-23	106, 402, 403, 801, AA, AF, AM, AR, C, CQ, ID, MC, OS
170:7-10	106, 402, 403, 801, AM	96:25; 97:2–12; 101:23–25; 102:2–14; 105:2; 105:4–20; 105:21–23; 105:25; 106:2–16; 114:6–19; 118:19–25; 119:2–25; 120:2–25; 121:2–15; 126:24–25; 127:2; 127:8–25;	OS, 106, 402, 403, 601, 701	100:19-24, 101:12-22, 106:17-107:2, 114:20-25, 115:4-5, 121:16-18, 121:20-25, 126:10-14, 126:15-23	106, 402, 403, 801, AA, AF, AM, AR, C, CQ, ID, MC, OS

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		128:2–14; 168:10–15; 169:4–23; 186:10–11; 186:14–25			
170:16-18	402, 801				
170:23-25	402, 801				
171:2-8	402, 403, 801, AF, AR, C, CQ, AM, MC				
172:7-21	106, 402, 403, 801, AA, AF, AR, C, CQ, AM, MC	94:17–25; 95:2–6; 96:25; 97:2–12; 101:23–25; 102:2–14; 105:2; 105:4–20; 105:21–23; 105:25; 106:2–16; 114:6–19; 118:19–25; 119:2–25; 120:2–25; 121:2–15; 122:8–21; 126:24–25; 127:2; 127:8–25; 128:2–14; 132:8–18; 169:4–23; 173:10–13; 173:16–25; 174:2–8; 186:10–11; 186:14–23	OS, 106, 402, 403, 601, 701	95:10-11, 95:13-19, 100:19-24, 101:12-22, 106:17-107:2, 114:20-25, 115:4-5, 121:16-18, 121:20-25, 122:22-123:3, 123:5-14, 123:19-23, 124:3-11, 124:13-22, 125:3-6, 125:9-17, 125:20-126:3, 126:10-14, 126:15-23, 132:19-133:9, 133:11-12	106, 402, 403, 602, 701, 801, A, AA, AF, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
172:23-25	106, 402, 403, 801, AA, AF, AR, C, CQ, AM, MC	94:17-25; 95:2-6; 96:25; 97:2-12; 101:23-25; 102:2-14; 105:2; 105:4-20; 105:21-23; 105:25; 106:2-16; 114:6-19; 118:19-25; 119:2-25; 120:2-25; 121:2-15; 122:8-21; 126:24-25; 127:2; 127:8-25; 128:2-14; 132:8-18; 169:4-23; 173:10-13; 173:16-25; 174:2-8; 186:10-11; 186:14-23	OS, 106, 402, 403, 601, 701	95:10-11, 95:13-19, 100:19-24, 101:12-22, 106:17-107:2, 114:20-25, 115:4-5, 121:16-18, 121:20-25, 122:22-123:3, 123:5-14, 123:19-23, 124:3-11, 124:13-22, 125:3-6, 125:9-17, 125:20-126:3, 126:10-14, 126:15-23, 132:19-133:9, 133:11-12	106, 402, 403, 602, 701, 801, A, AA, AF, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, MC, OS, SP
173:2-9	106, 402, 403, 801, AF, AR, C, CQ, AM, MC	94:17-25; 95:2-6; 101:23-25; 102:2-14; 105:2; 105:4-20; 122:8-21; 132:8-18; 173:10-13; 173:16-25; 174:2-8	OS, 106, 402, 403, 601, 701	95:10-11, 95:13-19, 100:19-24, 101:12-22, 106:17-107:2, 122:22-123:3, 123:5-14, 123:19-23, 124:3-11, 124:13-22, 125:3-6, 125:9-17, 125:20-126:3, 132:19-133:9, 133:11-12,	106, 402, 403, 602, 701, 801, A, AA, AF, AM, AR, C, CQ, F, FRCP 30(b)(6), ID, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
175:5-177:3	106, 402, 801, ID, FRCP 30(b)(6)	138:18-25; 139:2-4; 142:7-25; 143:2-3; 143:4-14; 143:16-24; 149:11-25; 150:2-25; 151:2-3	OS, 106, 402, 403	139:22, 139:25-140:6, 144:16-19, 144:22-145:9, 151:4-7, 151:9-21	106, 402, 403, 602, 801, AF, AM, C, CQ, F, FRCP 30(b)(6), ID, OS, SP
178:14-180:3	402, 602, 801, F, ID				
181:14-182:13	106, 402, 602, 801, A, F, SP, ID	182:14-19; 182:22-25; 183:2-22	OS, 402, 403		
183:23-25	402, 801				
184:8-11	106, 402, 801, AM, MC	185:20-22; 185:24-25; 186:2-11; 186:14-25	OS		
184:14-25	106, 402, 801, AM, MC	185:20-22; 185:24-25; 186:2-11; 186:14-25	OS		
185:2-22	106, 402, 801, AM, MC, NR	185:24-25; 186:2-11; 186:14-25	OS		
185:24-25	106, 402, 801, AM	185:20-22; 186:2-11; 186:14-25	OS		
186:2-11	106, 402, 801, AM, IQ, NR	185:20-22; 185:24-25; 186:14-25	OS		
186:14-15	106, 402, 403, 801, AM, IQ	185:20-22; 185:24-25; 186:2-11; 186:14-25	OS		
187:2-13	402, 403, 602, 801, A, AM, F, IQ				

Witness: Steven Ketchum

Date: March 1, 2019

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
5:6-15	801, AF, AM, F, FRCP 30(b)(6)				
8:22-9:19	801, ID, FRCP 30(b)(6)				
22:10-23:12	106, 402, 403, 801, AM, ID, FRCP 30(b)(6)	23:13-23	OS, 106, 402, 403	23:24-24:18	106, 402, 403, 801, FRCP 30(b)(6), ID
25:19-21	402, 403, AM, FRCP 30(b)(6)				
25:23-27:23	402, 403, 801, AM, ID, FRCP 30(b)(6)				
29:7-33:12	402, 801, AM, ID, FRCP 30(b)(6)				
33:14-21	106, 801, FRCP 30(b)(6)				
33:23	106, 801, FRCP 30(b)(6)	33:24-25; 34:2-9; 54:23-25; 55:2-5	402, 403		
34:10-36:2	106, 402, 801, AM, CQ, ID, FRCP 30(b)(6)	33:19-25; 34:2-9; 54:23-25; 55:2-5	402, 403		
36:6-15	106, 402, 801, AM, FRCP 30(b)(6)	42:16-25; 43:2-25; 44:2-13	OS, 106, 402, 403	41:22-42-15	106, 402, 403, 801, AM, ID, FRCP 30(b)(6), SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
36:21-37:13	106, 402, 403, 602, 801, AM, F, ID, SP, FRCP 30(b)(6)	42:16-25; 43:2-25; 44:2-13	OS, 106, 402, 403	41:22-42-15	106, 402, 403, 801, AM, ID, FRCP 30(b)(6), SP
41:9-21	106, 402, 403, 602, 801, AA, AM, F, SP, FRCP 30(b)(6)	42:16-25; 43:2-25; 44:2-13	OS, 106, 402, 403	41:22-42-15	106, 402, 403, 801, AM, ID, FRCP 30(b)(6), SP
44:14-45:4	106, 402, 403, 801, AA, AM, CQ, ID, FRCP 30(b)(6)	42:16-25; 43:2-25; 44:2-13	OS, 106, 402, 403	41:22-42-15	106, 402, 403, 801, AM, ID, FRCP 30(b)(6), SP
46:5-49:5	106, 402, 403, 801, AM, MC, ID, FRCP 30(b)(6)	45:10-25; 46:2-4; 50:7-14; 50:16-25; 51:2-7; 51:19-25; 52:2-25; 55:14-25; 56:2-25; 57:2-8	OS, 106, 402, 403		
49:6-9	106, 402, 403, 801, AA, CQ, FRCP 30(b)(6)	45:10-25; 46:2-4; 50:7-14; 50:16-25; 51:2-7; 51:19-25; 52:2-25	OS, 106, 402, 403		
49:11-25	106, 402, 403, 801, AA, CQ, FRCP 30(b)(6)	45:10-25; 46:2-4; 50:7-14; 50:16-25; 51:2-7; 51:19-25; 52:2-25	OS, 106, 402, 403		
50:2-6	106, 402, 403, 801, AA, CQ, FRCP 30(b)(6)	45:10-25; 46:2-4; 50:7-14; 50:16-25; 51:2-7; 51:19-25; 52:2-25	OS, 106, 402, 403		
51:9-18	106, 402, 403, 801, AA, FRCP 30(b)(6)	45:10-25; 46:2-4; 50:7-14; 50:16-25;	OS, 106, 402, 403		

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		51:2-7; 51:19-25; 52:2-25			
55:14-25	106, 801, FRCP 30(b)(6)	56:2-25; 57:2-8	402, 403		
56:21-57:25	106, 801, AM, MC, ID, FRCP 30(b)(6)	55:14-25; 56:2-20	402, 403		
64:7-65:17	106, 402, 801, ID, FRCP 30(b)(6)	61:19-25; 62:2-23	OS, 106, 402, 403	60:25-61:18, 62:24-64:6, 65:18-66:25	106, 402, 403, 801, AM, CQ, ID, FRCP 30(b)(6), OS, SP
80:21-83:7	402, 403, 801, AM, ID, IQ, FRCP 30(b)(6)				
91:24-92:3	106, 402, 403, 801, AF, AM, C, CQ, ID, FRCP 30(b)(6)	83:9-25; 84:2-25; 85:2-23; 86:2-24; 95:13-15; 95:17-25; 96:2-25; 97:2-25; 98:2-25; 99:2-15	OS, 106, 402, 403	91:9-23, 100:12-101:4	106, 402, 403, 801, ID, AM, AA, AR, FRCP 30(b)(6), OS
92:5-93:11	106, 402, 403, 801, AF, AM, AR, C, CQ, ID, FRCP 30(b)(6)	83:9-25; 84:2-25; 85:2-23; 86:2-24; 95:13-15; 95:17-25; 96:2-25; 97:2-25; 98:2-25; 99:2-15	OS, 106, 402, 403	91:9-23, 100:12-101:4	106, 402, 403, 801, ID, AM, AA, AR, FRCP 30(b)(6), OS
93:15-94:25	106, 402, 403, 801, AF, AM, AR, C, CQ, ID, FRCP 30(b)(6)	83:9-25; 84:2-25; 85:2-23; 86:2-24; 95:13-15; 95:17-25; 96:2-25; 97:2-	OS, 106, 402, 403	91:9-23, 100:12-101:4	106, 402, 403, 801, ID, AM, AA, AR, FRCP 30(b)(6), OS

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		25; 98:2–25; 99:2–15			
101:5-19	106, 402, 403, 801, AM, MC, FRCP 30(b)(6)	83:9–25; 84:2–25; 85:2–23; 86:2–24; 95:13–15; 95:17–25; 96:2–25; 97:2–25; 98:2–25; 99:2–15	OS, 106, 402, 403	91:9-23, 100:12-101:4	106, 402, 403, 801, ID, AM, AA, AR, FRCP 30(b)(6), OS
109:8-9	402, 602, 801, A, F, FRCP 30(b)(6)				
109:12-19	402, 602, 801, A, F, FRCP 30(b)(6)				
109:23-110:12	402, 602, 801, A, F, ID, FRCP 30(b)(6)				
133:14-134:19	106, 402, 602, 801, A, F, ID, FRCP 30(b)(6)	134:20–25; 135:2–25; 136:11–22	OS, 402, 403, 601, 701		
173:3-5	106, 402, 403, 801, AF, AM, FRCP 30(b)(6)	156:16–20; 156:22–25; 157:2–25; 158:2–25; 159:2–25; 160:2–25; 161:2–25; 162:2–25; 163:2–25; 164:2–25; 165:2–25; 166:2–25; 167:2–25; 168:2–3; 168:5–25; 169:2–25; 170:2–25;	OS, 106, 402, 403, 601, 701, 801	211:17-213:11	106, 402, 403, 801, C, FRCP 30(b)(6), ID, OS

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		171:2–25; 172:2–25; 173:2; 176:22–25; 177:3–25; 178:2–25; 179:2–25; 180:2–25; 181:2–21; 213:12–14; 213:16–25; 214:2–25; 215:2–8; 215:24–25; 216:2; 216:4–7			
173:7-176:21	106, 402, 403, 801, AF, AM, ID, FRCP 30(b)(6)	156:16–20; 156:22–25; 157:2–25; 158:2–25; 159:2–25; 160:2–25; 161:2–25; 162:2–25; 163:2–25; 164:2–25; 165:2–25; 166:2–25; 167:2–25; 168:2–3; 168:5–25; 169:2–25; 170:2–25; 171:2–25; 172:2–25; 173:2; 176:22–25; 177:3–25; 178:2–25; 179:2–25; 180:2–25; 181:2–21; 213:12–14; 213:16–25;	OS, 106, 402, 403, 601, 701, 801	211:17-213:11	106, 402, 403, 801, C, FRCP 30(b)(6), ID, OS

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		214:2-25; 215:2-8; 215:24-25; 216:2; 216:4-7			
181:22-23	106, 402, 403, 602, 801, AM, F, FRCP 30(b)(6)	156:16-20; 156:22-25; 157:2-25; 158:2-25; 159:2-25; 160:2-25; 161:2-25; 162:2-25; 163:2-25; 164:2-25; 165:2-25; 166:2-25; 167:2-25; 168:2-3; 168:5-25; 169:2-25; 170:2-25; 171:2-25; 172:2-25; 173:2; 176:22-25; 177:3-25; 178:2-25; 179:2-25; 180:2-25; 181:2-21; 213:12-14; 213:16-25; 214:2-25; 215:2-8; 215:24-25; 216:2; 216:4-7	OS, 106, 402, 403, 601, 701, 801	211:17-213:11	106, 402, 403, 801, C, FRCP 30(b)(6), ID, OS
181:25-184:13	106, 402, 403, 602, 801, AM, F, ID, FRCP 30(b)(6)	156:16-20; 156:22-25; 157:2-25; 158:2-25; 159:2-25; 160:2-25;	OS, 106, 402, 403, 601, 701, 801	211:17-213:11	106, 402, 403, 801, C, FRCP 30(b)(6), ID, OS

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		161:2–25; 162:2–25; 163:2–25; 164:2–25; 165:2–25; 166:2–25; 167:2–25; 168:2–3; 168:5–25; 169:2–25; 170:2–25; 171:2–25; 172:2–25; 173:2; 176:22–25; 177:3–25; 178:2–25; 179:2–25; 180:2–25; 181:2–21; 213:12–14; 213:16–25; 214:2–25; 215:2–8; 215:24–25; 216:2; 216:4–7			
187:20-189:16	402, 801, ID, IQ, FRCP 30(b)(6)				
194:20-196:10	106, 402, 403, 801, AM, ID, FRCP 30(b)(6)	156:16–20; 156:22–25; 157:2–25; 158:2–25; 159:2–25; 160:2–25; 161:2–25; 162:2–25; 163:2–25; 164:2–25; 165:2–25; 166:2–25; 167:2–25; 168:2–3;	OS, 106, 402, 403, 601, 701, 801	211:17-213:11	106, 402, 403, 801, C, FRCP 30(b)(6), ID, OS

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		168:5–25; 169:2–25; 170:2–25; 171:2–25; 172:2–25; 173:2; 176:22–25; 177:3–25; 178:2–25; 179:2–25; 180:2–25; 181:2–21; 213:12–14; 213:16–25; 214:2–25; 215:2–8; 215:24–25; 216:2; 216:4–7			
215:9-216:2	106, 801, AM, MC, ID, FRCP 30(b)(6)	213:12–14; 213:16–25; 214:2–25; 215:2–8; 216:4–7	OS, 106, 402, 403	211:17-213:11	106, 402, 403, 801, C, FRCP 30(b)(6), ID, OS
216:4-217:5	106, 801, AM, MC, ID, FRCP 30(b)(6)	213:12–14; 213:16–25; 214:2–25; 215:2–8; 215:24–25; 216:2; 216:4–7	OS, 106, 402, 403	211:17-213:11	106, 402, 403, 801, C, FRCP 30(b)(6), ID, OS
217:23-218:16	106, 402, 403, 801, ID, FRCP 30(b)(6)	218:17–25; 219:2–13	OS, 402, 403		
219:14-220:2	106, 402, 403, 801, ID, IQ, FRCP 30(b)(6)	220:4–7	OS, 106, 402, 403	220:8-12, 220:14-221:19, 221:21-222:5	106, 402, 403, 801, FRCP 30(b)(6), AF, AM, CQ, ID, MC, OS
222:12-223:6	106, 402, 403, 602, 801, AM, F, SP, ID, FRCP 30(b)(6)	223:25; 224:2–25; 225:2–25; 226:2–11; 230:5–25;	OS, 106, 402, 403, 601, 701	223:7-10, 223:12-22, 236:8-10, 236:12-238:10	106, 402, 403, 801, AA, AM, F, FRCP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		231:2–25; 232:2–25; 233:2–6; 233:15–18; 233:20–25; 234:2–25; 235:2–25; 236:2–7			30(b)(6), ID, IQ, SP, OS
226:17-227:5	402, 801, FRCP 30(b)(6)		OS, 106, 402, 403, 601, 701	223:7-10, 223:12-22, 236:8-10, 236:12-238:10	106, 402, 403, 801, AA, AM, F, FRCP 30(b)(6), ID, IQ, SP, OS
229:19-22	106, 402, 403, 602, 801, AM, MC, F, SP, FRCP 30(b)(6)	223:25; 224:2–25; 225:2–25; 226:2–11; 230:5–25; 231:2–25; 232:2–25; 233:2–6; 233:15–18; 233:20–25; 234:2–25; 235:2–25; 236:2–7	OS, 106, 402, 403, 601, 701	223:7-10, 223:12-22, 236:8-10, 236:12-238:10	106, 402, 403, 801, AA, AM, F, FRCP 30(b)(6), ID, IQ, SP, OS
229:24-230:4	106, 402, 403, 602, 801, AM, MC, F, SP, ID, FRCP 30(b)(6)	223:25; 224:2–25; 225:2–25; 226:2–11; 230:5–25; 231:2–25; 232:2–25; 233:2–6; 233:15–18; 233:20–25; 234:2–25; 235:2–25; 236:2–7	OS, 106, 402, 403, 601, 701	223:7-10, 223:12-22, 236:8-10, 236:12-238:10	106, 402, 403, 801, AA, AM, F, FRCP 30(b)(6), ID, IQ, SP, OS
238:11-22	402, 403, 801, FRCP 30(b)(6)				

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
242:17-23	402, 801, FRCP 30(b)(6)				
242:24-244:5	106, 402, 403, 801, ID, FRCP 30(b)(6)	223:25; 224:2-25; 225:2-25; 226:2-11; 230:5-25; 231:2-25; 232:2-25; 233:2-6; 233:15-18; 233:20-25; 234:2-25; 235:2-25; 236:2-7	OS, 106, 402, 403, 601, 701	223:7-10, 223:12-22, 236:8-10, 236:12-238:10	106, 402, 403, 801, AA, AM, F, FRCP 30(b)(6), ID, IQ, SP, OS
248:4-6	106, 402, 403, 801, AM, ID, FRCP 30(b)(6)	223:25; 224:2-25; 225:2-25; 226:2-11; 230:5-25; 231:2-25; 232:2-25; 233:2-6; 233:15-18; 233:20-25; 234:2-25; 235:2-25; 236:2-7	OS, 106, 402, 403, 601, 701	223:7-10, 223:12-22, 236:8-10, 236:12-238:10	106, 402, 403, 801, AA, AM, F, FRCP 30(b)(6), ID, IQ, SP, OS
248:8-249:18	106, 402, 403, 801, AM, ID, FRCP 30(b)(6)	223:25; 224:2-25; 225:2-25; 226:2-11; 230:5-25; 231:2-25; 232:2-25; 233:2-6; 233:15-18; 233:20-25; 234:2-25; 235:2-25; 236:2-7	OS, 106, 402, 403, 601, 701	223:7-10, 223:12-22, 236:8-10, 236:12-238:10	106, 402, 403, 801, AA, AM, F, FRCP 30(b)(6), ID, IQ, SP, OS

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
249:19-250:25	402, 403, 602, 801, A, ID, F, FRCP 30(b)(6)				

Witness: Philip Lavin

Date: Sept. 21, 2018

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
8:2-11	402, 403, 801, MIL				
9:3-14	402, 403, 801, MIL				
9:16-10:4	402, 403, 801, MIL				
10:7-11:7	402, 403, 801, MIL				
11:11-19	402, 403, 801, MIL				
12:6-11	402, 403, 801, MIL				
14:10-14	402, 403, 801, MIL				
14:16-15:9	402, 403, 801, MIL				
16:18-23	402, 403, 801, MIL				
16:25-17:14	402, 403, 801, MIL				
19:24-20:8	402, 403, 801, MIL				
20:12-23	402, 403, 801, MIL				
21:13-15	402, 403, 801, MIL				
22:1-23:6	402, 403, 801, MIL				

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
26:8-22	106, 402, 403, 801, MIL	27:22-28:10; 79:21-23; 79:25-80:12	OS, 106, 402, 403	28:11-18, 80:14-19, 80:21, 80:23-81:2	106, 402, 403, 701, 801, AM, AR, CQ, IM, MC, MIL, OS
28:19-29:16	106, 402, 403, 801, MIL, ID, IQ, AM	29:17-21	OS, 106, 402, 403	29:22-30:4	106, 402, 403, 801, AM, AF, C, MIL, OS
34:1-5	402, 403, 701, MIL				
34:10-36:5	402, 403, MIL, ID				
38:12-39:1	402, 403, MIL, ID				
49:21-50:1	MIL, 402, 403, 106, 701, SP, AM	44:13-45:15; 74:8-75:3; 79:10-13; 79:21-79:23; 79:25-80:12; 90:23-91:3; 100:2-20	OS, 106, 402, 403	43:10-44:12, 80:14-19, 80:21, 80:23-81:2, 86:9-87:8	106, 402, 403, 701, 801, AM, AR, C, CQ, IM, IQ, MIL, OS
55:6-22	402, 403, 701, 801, MIL				
56:19-23	106, 402, 403, 701, 801, MIL	56:24-57:3; 57:5-8; 57:10-20	OS, 106, 402, 403	57:21-58:11	106, 402, 403, 701, 801, AM, MIL, OS
58:21-59:2	402, 403, 801, MIL				
59:8-11	402, 403, 801, MIL				
59:14-17	402, 403, 801, MIL				
59:20-21	402, 403, 801, MIL				
59:24-60:2	402, 403, 801, MIL				
60:6-19	402, 403, 801, MIL				
62:10-63:1	402, 403, 801, MIL, A	63:2-5	OS, 106, 402, 403	63:6-18	106, 402, 403, 801, AR, ID, MIL, OS

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
63:19-64:13	402, 403, 801, MIL, A				
64:14-65:19	106, 402, 403, 602, 801, MIL, AM, F	65:20–22; 65:24–66:2; 66:20–67:5; 67:17–23; 67:25–68:2; 68:4–69:13; 69:15–16; 70:9–20	OS, 402, 403		
66:4-19	106, 402, 403, 801, MIL, AM, F, SP	65:1–19; 65:20–22; 65:24–66:2; 66:20–67:5; 67:17–23; 67:25–68:2; 68:4–69:13; 69:15–16; 70:9–20; 74:8–75:3; 109:18–110:2	OS, 106, 402, 403		
69:18-70:8	106, 402, 403, 801, MIL, AM, SP	67:17–23; 67:25–68:2; 68:4–69:13; 69:15–16; 70:9–23; 70:25–71:7; 72:14–73:7; 74:8–75:3; 79:10–13; 79:21–23; 79:25–80:12; 90:23–91:3; 108:15–21; 109:18–110:2	OS, 106, 402, 403		
72:14-73:7	106, 402, 403, 701, 801, MIL	69:18–25; 70:9–20; 74:8–75:3; 79:10–13; 79:21–23; 79:25–80:12;	OS, 106, 402, 403		

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		90:23–91:3; 109:18–110:2			
73:21–75:3	106, 402, 403, 801, MIL	69:18–25; 70:9–20; 79:10–13; 79:21–23; 79:25–80:12; 90:23–91:3; 109:18–110:2	OS, 106, 402, 403		
75:4–19	106, 402, 403, 801, MIL, AM, CQ	69:18–25; 70:9–20; 72:14–73:7; 74:8–75:3; 79:10–13; 79:21–23; 79:25–80:12; 90:23–91:3; 109:18–110:2	OS, 106, 402, 403		
75:21–76:1	106, 402, 403, 701, 801, MIL, AM, CQ	69:18–25; 70:9–20; 74:8–75:3; 79:10–13; 79:21–23; 79:25–80:12; 90:23–91:3; 109:18–110:2	OS, 106, 402, 403		
76:3–77:3	106, 402, 403, 701, 801, MIL, AM, AF	69:18–25; 70:9–20; 74:8–75:3; 79:10–13; 79:21–23; 79:25–80:12; 90:23–91:3; 109:18–110:2	OS, 106, 402, 403		
77:5–9	106, 402, 403, 701, 801, MIL, AA, AM, CQ	69:18–25; 70:9–20; 74:8–75:3; 79:10–13; 79:21–23;	OS, 106, 402, 403		

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		79:25–80:12; 90:23–91:3; 109:18–110:2			
77:11-13	106, 402, 403, 701, 801, MIL, AA, AM, CQ	69:18–25; 70:9–20; 74:8–75:3; 79:10–13; 79:21–23; 79:25–80:12; 90:23–91:3; 109:18–110:2	OS, 106, 402, 403		
77:15-25	106, 402, 403, 701, 801, MIL, AM	69:18–25; 70:9–20; 70:21–23; 70:25–71:7; 74:8–75:3; 79:10–13; 79:21–23; 79:25–80:12; 90:23–91:3; 108:15–21; 109:18–110:2	OS, 106, 402, 403		
78:1-3	402, 403, 701, 801, MIL, AA, CQ				
78:5	402, 403, 701, 801, MIL, AA, CQ				
78:7-15	106, 402, 403, 602, 701, 801, 1006, MIL, AM, AF, F, SP	70:9–70:20; 70:21–23; 70:25–71:7; 74:8–75:3; 79:10–13; 79:21–23; 79:25–80:12; 90:23–91:3;	OS, 106, 402, 403, 601, 701		

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		108:15–21; 109:18–110:2			
78:17	106, 402, 403, 701, 801, MIL, AM, F	70:9–70:20; 70:21–23; 70:25–71:7; 74:8–75:3; 79:10–13; 79:21–23; 79:25–80:12; 90:23–91:3; 108:15–21; 109:18–110:2	OS, 106, 402, 403, 601, 701		
78:19-20	106, 402, 403, 701, 801, MIL, AM, F	70:9–70:20; 70:21–23; 70:25–71:7; 74:8–75:3; 79:10–13; 79:21–23; 79:25–80:12; 90:23–91:3; 108:15–21; 109:18–110:2	OS, 106, 402, 403, 601, 701		
78:22	106, 402, 403, 701, 801, MIL, AM, F	70:9–70:20; 70:21–23; 70:25–71:7; 74:8–75:3; 79:10–13; 79:21–23; 79:25–80:12; 90:23–91:3; 108:15–21; 109:18–110:2	OS, 106, 402, 403, 601, 701		

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
78:24-79:9	106, 402, 403, 701, 801, MIL, MC, CQ, AM	70:9-20; 70:21-23; 70:25-71:7; 71:9-12; 71:14-72:3; 72:5-13; 74:8-75:3; 79:10-13; 79:21-23; 79:25-80:12; 90:23-91:3; 108:15-21; 109:18-110:2	OS, 106, 402, 403, 601, 701		
79:14-17	402, 403, 701, 801, MIL	70:9-20; 70:21-23; 70:25-71:7; 74:8-75:3; 79:10-13; 79:21-23; 79:25-80:12; 90:23-91:3; 108:15-21; 109:18-110:2	OS, 106, 402, 403, 601, 701		
79:19	402, 403, 701, 801, MIL	70:9-20; 70:21-23; 70:25-71:7; 74:8-75:3; 79:10-13; 79:21-23; 79:25-80:12; 90:23-91:3; 108:15-21; 109:18-110:2	OS, 106, 402, 403, 601, 701		
81:3-17	106, 402, 403, 701, 801, MIL, AM, AF, CQ, MC	70:9-20; 70:21-23; 70:25-71:7; 71:9-12; 71:14-72:3; 72:5-13; 74:8-75:3; 79:10-13;	OS, 106, 402, 403, 601, 701		

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		79:21–23; 79:25–80:12; 90:23–91:3; 108:15–21; 109:18–110:2			
81:19-82:7	106, 402, 403, 701, 801, MIL, AM, AF, CQ, MC	70:9–20; 71:9–12; 71:14–72:3; 72:5–13; 74:8–75:3; 79:10–13; 79:21–23; 79:25–80:12; 90:23–91:3; 109:18–110:2	OS, 106, 402, 403, 601, 701		
82:9-13	106, 402, 403, 701, 801, MIL, AM, CQ	70:9–20; 74:8–75:3; 79:10–13; 79:21–23; 79:25–80:12; 90:23–91:3; 108:15–21; 109:18–110:2	OS, 106, 402, 403, 601, 701		
82:21-24	106, 402, 403, 701, 801, MIL, AM, CQ	70:9–20; 71:9–12; 74:8–75:3; 79:10–13; 79:21–23; 79:25–80:12; 90:23–91:3; 108:15–21; 109:18–110:2	OS, 106, 402, 403, 601, 701		
83:1-6	106, 402, 403, 701, 801, MIL, AM, CQ	70:9–20; 71:9–12; 74:8–75:3; 79:10–13; 79:21–23; 79:25–80:12;	OS, 106, 402, 403, 601, 701		

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		90:23–91:3; 108:15–21; 109:18–110:2			
83:8-16	106, 402, 403, 701, 801, MIL, AM, CQ	70:9–20; 71:9–12; 74:8–75:3; 79:10–13; 79:21–23; 79:25–80:12; 83:17–84:7; 90:23–91:3; 91:14–92:6; 108:15–21; 109:18–110:2	OS, 106, 402, 403, 601, 701		
84:8-14	106, 402, 403, 701, 801, MIL, AM, CQ	70:9–20; 71:9–12; 74:8–75:3; 79:10–13; 79:21–23; 79:25–80:12; 83:17–84:7; 90:23–91:3; 91:14–92:6; 108:15–21; 109:18–110:2	OS, 106, 402, 403, 601, 701		
84:25-85:17	106, 402, 403, 701, 801, MIL, AM, CQ	85:18–86:8	OS, 106, 402, 403	86:9-87:8	106, 402, 403, 701, 801, C, OS, MIL, SP
90:1-22	106, 402, 403, 602, 701, 801, 1006, MIL, AF, AM, SP, F	70:21–71:23; 70:25–71:7; 74:8–75:3; 79:10–13; 79:21–79:23; 79:25–80:12; 90:23–91:3; 91:14–	OS, 106, 402, 403, 601, 701		

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		92:6; 108:15–21; 109:18–110:2			
91:4-11	106, 402, 403, 701, 801, MIL, AF, AM, MC, CQ	70:9–20; 70:21–23; 70:25–71:7; 71:9–12; 71:14–72:3; 72:5–13; 74:8–75:3; 79:10–13; 79:21–23; 79:25–80:12; 90:23–91:3; 108:15–21; 109:18–110:2	OS, 106, 402, 403, 601, 701		
95:2-4	402, 403, 801, MIL				
95:7-10	402, 403, 801, MIL				
95:13-16	402, 403, 801, MIL				
95:19-22	402, 403, 801, MIL				
96:7-97:12	402, 403, 801, MIL				
98:9-19	402, 403, 602, 801, MIL, AM, F, SP, IQ				
98:21-23	402, 403, 602, 801, MIL, AM, F, SP, IQ				
99:15-18	402, 403, 801, MIL				
99:19-100:24	106, 402, 403, 701, 801, MIL, AA, AM, MC	44:13–45:15; 70:9–20; 70:21–23; 70:25–71:7; 74:8–75:3; 79:10–13; 79:21–23; 79:25–	OS, 106, 402, 403, 601, 701	43:10-44:12, 80:14-81:2, 107:18-108:14	106, 402, 403, 701, 801, AM, AR, C, CQ, IM, ID, IQ, MIL, OS

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		80:12; 90:23–91:3; 108:15–21; 109:18–110:2; 110:11–111:5; 111:7–12			
101:1-4	106, 402, 403, 701, 801, MIL, AA, AM, MC	44:13–45:15; 70:9–20; 70:21–23; 70:25–71:7; 74:8–75:3; 79:10–13; 79:21–23; 79:25–80:12; 83:17–84:14; 100:2–100:20; 101:16–102:12; 110:11–111:5; 111:7–12	OS, 106, 402, 403, 601, 701	43:10-44:12, 80:14-81:2, 86:9-87 107:18-108:14	106, 402, 403, 701, 801, AM, AR, C, CQ, IM, ID, IQ, MIL, OS, SP
101:6-15	106, 402, 403, 701, 801, MIL, AA, AM, AF, CQ, MC, SP	44:13–45:15; 70:9–20; 70:21–23; 70:25–71:7; 74:8–75:3; 79:10–13; 79:21–23; 79:25–80:12; 83:17–84:14; 100:2–100:20; 101:16–102:12; 110:11–111:5; 111:7–12	OS, 106, 402, 403, 601, 701	43:10-44:12, 80:14-81:2, 86:9-87 107:18-108:14	106, 402, 403, 701, 801, AM, AR, C, CQ, IM, ID, IQ, MIL, OS, SP
102:13-20	106, 402, 403, 701, 801, MIL, AA, AM, AF, CQ, MC, SP, C	44:13–45:15; 70:9–20; 70:21–23; 70:25–71:7; 74:8–75:3; 79:10–13;	OS, 106, 402, 403, 601, 701	43:10-44:12, 80:14-81:2, 86:9-87 107:18-108:14	106, 402, 403, 701, 801, AM, AR, C, CQ, IM, ID, IQ, MIL, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		79:21–23; 79:25–80:12; 83:17–84:14; 100:2–100:20; 101:16–102:12; 108:15–21; 110:11–111:5; 111:7–12			
102:22	106, 402, 403, 701, 801, MIL, AA, AM, AF, CQ, MC, SP, C	44:13–45:15; 70:9–20; 70:21–23; 70:25–71:7; 74:8–75:3; 79:10–13; 79:21–23; 79:25–80:12; 83:17–84:14; 100:2–100:20; 101:16–102:12; 108:15–21; 110:11–111:5; 111:7–12	OS, 106, 402, 403, 601, 701	43:10-44:12, 80:14-81:2, 86:9-87 107:18-108:14	106, 402, 403, 701, 801, AM, AR, C, CQ, IM, ID, IQ, MIL, OS, SP
102:24-103:1	106, 402, 403, 701, 801, MIL, AA, AM, AF, CQ, MC, SP	44:13–45:15; 70:9–20; 70:21–23; 70:25–71:7; 74:8–75:3; 79:10–13; 79:21–23; 79:25–80:12; 83:17–84:14; 100:2–100:20; 101:16–102:12; 108:15–21;	OS, 106, 402, 403, 601, 701	43:10-44:12, 80:14-81:2, 86:9-87 107:18-108:14	106, 402, 403, 701, 801, AM, AR, C, CQ, IM, ID, IQ, MIL, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		110:11–111:5; 111:7–12			
103:3-4	106, 402, 403, 701, 801, MIL, AA, AM, AF, CQ, MC, SP	44:13–45:15; 70:9–20; 79:21–23; 70:25–71:7; 74:8–75:3; 79:10–13; 79:21–23; 79:25–80:12; 83:17–84:14; 100:2–100:20; 101:16–102:12; 108:15–21; 110:11–111:5; 111:7–12	OS, 106, 402, 403, 601, 701	43:10-44:12, 80:14-81:2, 86:9-87 107:18-108:14	106, 402, 403, 701, 801, AM, AR, C, CQ, IM, ID, IQ, MIL, OS, SP
103:6-21	106, 402, 403, 701, 801, MIL, AA, AM, AF, CQ, MC, SP	44:13–45:15; 70:9–20; 79:21–23; 70:25–71:7; 74:8–75:3; 79:10–13; 79:21–23; 79:25–80:12; 83:17–84:14; 100:2–100:20; 101:16–102:12; 108:15–21; 110:11–111:5; 111:7–12	OS, 106, 402, 403, 601, 701	43:10-44:12, 80:14-81:2, 86:9-87 107:18-108:14	106, 402, 403, 701, 801, AM, AR, C, CQ, IM, ID, IQ, MIL, OS, SP
103:23	106, 402, 403, 701, 801, MIL, AA, AM, AF, CQ, MC, SP	44:13–45:15; 70:9–20; 79:21–23; 70:25–71:7; 74:8–75:3; 79:10–13;	OS, 106, 402, 403, 601, 701	43:10-44:12, 80:14-81:2, 86:9-87 107:18-108:14	106, 402, 403, 701, 801, AM, AR, C, CQ, IM, ID, IQ, MIL, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		79:21–23; 79:25–80:12; 83:17–84:14; 100:2–100:20; 101:16–102:12; 108:15–21; 110:11–111:5; 111:7–12			
103:25-104:8	106, 402, 403, 701, 801, AM, MIL, MC	70:9–20; 70:21–23; 70:25–71:7; 72:17–73:7; 74:8–75:3; 79:10–13; 79:21–23; 79:25–80:12; 90:23–91:3; 108:15–21; 109:18–110:2; 110:11–111:5; 111:7–12	OS, 106, 402, 403, 601, 701	80:14-81:2, 86:9-87 107:18-108:14	106, 402, 403, 701, 801, AM, AR, C, ID, MIL, OS
104:9-17	106, 402, 403, 701, 801, AM, MIL, MC, CQ	69:18–25; 70:9–20; 74:8–75:3; 79:10–13; 79:21–23; 79:25–80:12; 90:23–91:3; 109:18–110:2; 110:11–111:5; 111:7–12	OS, 106, 402, 403, 601, 701	80:14-81:2, 86:9-87 107:18-108:14	106, 402, 403, 701, 801, AM, AR, C, ID, MIL, OS
104:22-105:1	402, 403, 602, 701, 801, MIL, CQ, AA, AF, AM, F				

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
111:19-113:15	402, 403, 801, CQ, MIL, SP				
114:18-21	402, 403, 701, 801, AM, MIL, SP				
114:23-115:1	402, 403, 701, 801, AM, MIL, SP				
115:3-5	402, 403, 701, 801, AM, MIL, SP				

Witness: Mehar Manku

Date: Nov. 7, 2018

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
7:2-9	106, 801	8:1-5			
8:7-23	106, 801	8:22-23; 8:25-9:3; 9:5-7; 9:12-17; 10:5-6; 10:8-13	106, 402, 403		
8:25-9:3	106, 801	8:18-23; 9:5-6; 9:12-17; 10:5-6; 10:8-13	106, 402, 403		
10:5-6	106, 801	8:18-23; 8:25-9:3; 9:5-6; 9:12-17;	106, 402, 403		

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		10:8–13; 10:15–12:11			
10:8-13	106, 801	8:18–23; 8:25–9:3; 9:5–6; 9:12–17; 10:5–6; 10:15–12:11	106, 402, 403		
10:15-12:25	106, 801	8:18–23; 8:25–9:3; 9:5–6; 9:12–17; 10:8–13; 10:15–12:11; 14:19–15:24; 16:1–6	OS, 106, 402, 403	16:8-10, 16:12-13	106, 402, 403, AM
17:7-17	106, 801	9:5–6; 9:12–17; 10:5–6; 10:15–12:11; 14:19–15:24; 16:1–6; 17:7–14; 17:18–18:7; 18:9–19:6;	OS, 106, 402, 403	16:8-10, 16:12-13	106, 402, 403, AM
17:22-18:4	106, 801, AF	17:18–18:7; 18:9–19:6; 24:22–27:7; 28:10–16; 30:5–31:4; 31:10–12; 32:20–23	OS, 106, 402, 403		
21:5-23	106, 402, 403, 801, C	18:5–7; 18:9–19:6; 24:22–27:7; 28:10–16; 32:20–23	OS, 106, 402, 403		
23:18-24:1	106, 402, 403, 801, C	18:5–7; 18:9–19:6; 24:22–27:7; 28:10–	OS, 106, 402, 403		

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		16; 31:10–32:12; 32:20–23			
24:22–25:18	106, 801	24:22–27:7; 28:10–16; 30:5–31:4	OS, 106, 402, 403		
27:8–28:3	106, 801, AF, F	24:22–27:7; 28:10–16	OS, 106, 402, 403		
29:3–6	106, 402, 801	24:22–27:8; 28:10–16	OS, 106, 402, 403		
29:8	106, 402, 801	24:22–27:8; 28:10–16	OS, 106, 402, 403		
29:14–16	106, 402, 801	10:5–7; 10:8–13; 10:15–12:11; 14:19–15:24; 16:1–6; 29:22–24; 30:1–3	OS, 106, 402, 403	16:8–10, 16:12–13	106, 402, 403, AM
29:18–20	106, 402, 801	10:5–7; 10:8–13; 10:15–12:11; 14:19–15:24; 16:1–6	OS, 106, 402, 403	16:8–10, 16:12–13	106, 402, 403, AM
29:22–24	106, 801	10:5–7; 10:8–13; 10:15–12:11; 14:19–15:24; 16:1–6; 29:14–16; 29:18–20	OS, 106, 402, 403	16:8–10, 16:12–13,	106, 402, 403, AM
30:1–3	106, 801	10:5–7; 10:8–13; 10:15–12:11; 14:19–15:24; 16:1–	OS, 106, 402, 403	16:8–10, 16:12–13	106, 402, 403, AM

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		6; 29:14–16; 29:18–20			
32:25-34:1	106, 402, 801, AM	30:18–31:4; 31:10– 32:12; 32:20–23	OS, 106, 402, 403		
35:2-6	106, 801	24:22–27:7; 28:10– 16; 30:5–31:4	OS, 106, 402, 403		
36:25-38:7	106, 801, AF, AM, F	24:22–27:7; 32:9– 12; 38:8–11; 38:13–15	OS, 106, 402, 403		
39:1-3	106, 701, 801, AM	38:8–11; 38:13–15; 39:10–13; 39:15– 40:5	106, 402, 403	41:16-17, 41:19	106, 701, AM, F, MC, OS, SP
39:6-8	106, 701, 801, AM	38:8–11; 38:13–15; 39:10–13; 39:15– 40:5	106, 402, 403	41:16-17, 41:19	106, 701, AM, F, MC, OS, SP
40:12-15	106, 801, AF, AM, F	36:25–37:7; 40:24– 41:15; 42:11–25; 43:23–44:3; 44:24– 46:1; 46:25–47:7	106, 402, 403	41:16-17, 41:19, 43:17-22, 46:2-12	106, 701, AM, F, MC, OS, SP
40:17	106, 801, AF, AM, F	36:25–37:7; 40:24– 41:15; 42:11–25; 43:23–44:3; 44:24– 46:1; 46:25–47:7	106, 402, 403	41:16-17, 41:19, 43:17-22, 46:2-12	106, 701, AM, F, MC, OS, SP
40:19-23	106, 801	40:24–41:15; 42:11–25; 43:23– 44:3; 44:24–46:1; 46:25–47:7	106, 402, 403	41:16-17, 41:19, 43:17-22, 46:2-12	106, 701, AM, F, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
42:6-25	106, 801	40:24–41:15; 42:11–25; 43:23– 44:3; 44:24–46:1; 46:25–47:7	106, 402, 403	41:16-17, 41:19, 43:17-22, 46:2-12	106, 701, AM, F, MC, OS, SP
46:23-47:15	106, 801, ID, SP	40:24–41:15; 42:11–25; 43:23– 44:3; 44:24–46:1; 46:25–47:7	106, 402, 403	41:16-17, 41:19, 43:17-22, 46:2-12	106, 701, AM, F, MC, OS, SP
50:51:2	106, 701, 801, AF, AM, AR, F, ID	10:5–6; 10:8–13; 10:15–12:11; 14:19–15:24; 16:1– 6; 18:5–7; 18:9– 19:6; 24:22–26:18; 28:10–16; 30:5– 31:5; 31:10–32:12; 48:19–25; 49:2–15; 49:17–50:11	OS, 106, 402, 403	16:8-10, 16:12-13	106, 402, 403, AM
51:5	106, 701, 801, AF, AM, AR, F	10:5–6; 10:8–13; 10:15–12:11; 14:19–15:24; 16:1– 6; 18:5–7; 18:9– 19:6; 24:22–26:18; 28:10–16; 30:5– 31:5; 31:10–32:12; 48:19–25; 49:2–15; 49:17–50:11	OS, 106, 402, 403	16:8-10, 16:12-13	106, 402, 403, AM
51:7-8	106, 402, 403, 701, 801, AM, AR	10:5–6; 10:8–13; 10:15–12:11;	OS, 106, 402, 403	16:8-10, 16:12-13	106, 402, 403, AM

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		14:19–15:24; 16:1–6; 18:5–7; 18:9–19:6; 24:22–26:18; 28:10–16; 30:5–31:5; 31:10–32:12; 48:19–25; 49:2–15; 49:17–50:11			
51:10-17	106, 801, AM	10:5–6; 10:8–13; 10:15–12:11; 14:19–15:24; 16:1–6; 18:5–7; 18:9–19:6; 24:22–26:18; 28:10–16; 30:5–31:5; 31:10–32:12; 48:19–25; 49:2–15; 49:17–50:11	OS, 106, 402, 403	16:8-10, 16:12-13	106, 402, 403, AM
51:19-20	106, 402, 801, AM	10:5–6; 10:8–13; 10:15–12:11; 14:19–15:24; 16:1–6; 18:5–7; 18:9–19:6; 24:22–26:18; 28:10–16; 30:5–31:5; 31:10–32:12; 48:19–25; 49:2–15; 49:17–50:11; 51:16–17; 51:24–52:1; 52:3–19	OS, 106, 402, 403	16:8-10, 16:12-13	106, 402, 403, AM

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
51:22-52:19	106, 801, AM, F, ID, SP	51:16-17; 52:3-19	106		
53:5-16	106, 602, 801, SP	32:25-34:1; 40:12-15; 40:17; 40:19-41:15; 42:11-25; 43:23-44:3; 44:24-46:1; 46:25-47:7	OS, 106, 402, 403	41:16-17, 41:19, 43:17-22, 46:2-12	106, 402, 403, 602, 701, AM, C, OS, SP
55:9-11	106, 801	55:13-18	106		
55:13-56:18	106, 801, SP	55:9-11	106		
57:23-58:1	106, 602, 801, IQ	58:19-60:3	106		
59:11-61:1	106, 602, 801, AM, SP	40:12-15; 40:17; 40:19-41:15; 42:11-25; 43:23-44:3; 44:24-46:1; 46:25-47:7; 55:9-11; 55:13-18; 58:19-60:3	OS, 106, 402, 403	41:16-17, 41:19, 43:17-22, 46:2-12	106, 402, 403, 602, 701, AM, C, OS, SP
61:17-62:11	106, 402, 801, MC, SP	40:12-15; 40:17; 40:19-41:15; 42:11-25; 43:23-44:3; 44:24-46:1; 46:25-47:7; 55:9-11; 55:13-18; 58:19-60:3	OS, 106, 402, 403	41:16-17, 41:19, 43:17-22, 46:2-12	106, 402, 403, 602, 701, AM, C, OS, SP
62:18-20	106, 801	39:10-13; 39:15-40:5	OS, 106, 402, 403	41:16-17, 41:19	106, 701, AM, F, MC, OS, SP
62:24-63:5	106, 402, 801	39:10-13; 39:15-40:5	OS, 106, 402, 403	41:16-17, 41:19	106, 701, AM, F, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
63:22-25	106, 602, 801, AM, MC, SP	39:10–13; 39:15–40:5	OS, 106, 402, 403	41:16-17, 41:19	106, 701, AM, F, MC, OS, SP
64:2-4	106, 602, 801, AM, MC, SP	39:10–13; 39:15–40:5	OS, 106, 402, 403	41:16-17, 41:19	106, 701, AM, F, MC, OS, SP
68:9-10	106, 402, 801, AF, AM, F	72:9–22; 72:25–73:23	OS, 106, 402, 403	73:25-74:7, 74:19-75:1	106, 403, AM, C, MC
68:12-14	106, 402, 801, AF, AM, F	72:9–22; 72:25–73:23	OS, 106, 402, 403	73:25-74:7, 74:19-75:1	106, 403, AM, C, MC
68:16-24	106, 402, 801, AF, AM, F	68:9–10; 68:12–14; 72:9–22; 72:25–73:23	OS, 106, 402, 403	67:21-68:8, 73:25-74:7, 74:19-75:1	106, 402, 403, 701, AM, C, MC
69:1-5	106, 402, 801, AF, AM, F	68:9–10; 68:12–14; 72:9–22; 72:25–73:23	OS, 106, 402, 403	67:21-68:8, 73:25-74:7, 74:19-75:1	106, 402, 403, 701, AM, C, MC
76:23-77:3	106, 801, B, AM	65:22–66:10	OS, 106, 402, 403	67:21-68:8	402, 403, 701, AM, C
77:5-6	106, 801	65:22–66:10	OS, 106, 402, 403	67:21-68:8	402, 403, 701, AM, C
77:8-14	106, 402, 602, 801, SP	65:22–66:10	OS, 106, 402, 403	67:21-68:8	402, 403, 701, AM, C
78:3-25	106, 402, 801, ID	65:22–66:10; 76:23–77:3; 77:5–6; 78:3–21	OS, 106, 402, 403	67:21-68:8, 73:25-74:7, 74:19-75:1	402, 403, 701, AM, C
79:2	106, 402, 801	65:22–66:10; 76:23–77:3; 77:5–6; 78:3–21	OS, 106, 402, 403	67:21-68:8, 73:25-74:7, 74:19-75:1	402, 403, 701, AM, C

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
79:4-13	106, 402, 403, 701, 801, AM, AR, C, MC	8:22-24; 8:25-9:4; 9:5-6; 9:12-17; 10:5-6; 10:8-13; 10:15-12:11; 14:19-15:24; 16:1-617:18-18:7; 18:9-19:6; 24:22-27:7; 28:10-16; 30:5-31:4; 31:10-32:12; 48:19-49:15; 49:17-50:11; 51:24-52:1; 52:3-19; 72:9-22; 72:25-73:23; 79:21-81:3; 81:5-82:7; 82:9-82:18; 82:20-83:1; 83:3-5; 83:7-10 ; 89:6-93:25; 94:3-95:23	OS, 106, 402, 403	16:8-10, 16:12-13, 73:25-74:7, 74:19-75:1, 83:11-23, 83:25-84:3, 95:24-96:6, 96:9-12, 96:14-22, 96:24-97:4	106, 402, 403, 701, AF, AM, C, MC, OS, SP
79:16-19	106, 801, C	8:22-24; 8:25-9:4; 9:5-6; 9:12-17; 10:5-6; 10:8-13; 10:15-12:11; 14:19-15:24; 16:1-617:18-18:7; 18:9-19:6; 24:22-27:7; 28:10-16; 30:5-31:4; 31:10-32:12;	OS, 106, 402, 403	16:8-10, 16:12-13, 73:25-74:7, 74:19-75:1, 83:11-23, 83:25-84:3, 95:24-96:6, 96:9-12, 96:14-22, 96:24-97:4	106, 402, 403, 701, AF, AM, C, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		48:19–49:15; 49:17–50:11; 51:24–52:1; 52:3–19; 72:9–22; 72:25–73:23; 79:21–81:3; 81:5–82:7; 82:9–82:18; 82:20–83:1; 83:3–5; 83:7–10; 89:6–93:25; 94:3–95:23			
84:5–88:4	106, 801, AM	10:5–6; 10:8–13; 10:15–12:11; 14:19–15:24; 16:1–617:18–18:7; 18:9–19:6; 24:22–27:7; 28:10–16; 30:5–31:4; 31:10–32:12; 48:19–49:15; 49:17–50:11; 51:24–52:1; 52:3–19; 72:9–22; 72:25–73:23; 79:21–81:3; 81:5–82:7; 82:9–82:18; 82:20–83:1; 83:3–5; 83:7–10; 89:6–93:25; 94:3–95:23	OS, 106, 402, 403	16:8–10, 16:12–13, 73:25–74:7, 74:19–75:1, 83:11–23, 83:25–84:3, 95:24–96:6, 96:9–12, 96:14–22, 96:24–97:4	106, 402, 403, 701, AF, AM, C, MC, OS, SP
97:10–98:10	402, 701, 801, AM				

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
101:10-14	106, 402, 602, 701, 801, AM, F, SP	72:9-16	OS, 106, 402, 403	73:25-74:7	106, 403, AM, C, MC
101:16-19	106, 402, 602, 701, 801, AM, F, SP	72:9-16	OS, 106, 402, 403	73:25-74:7	106, 403, AM, C, MC
101:21-104:15	106, 402, 602, 701, 801, AM, F, SP	10:5-6; 10:8-13; 10:15-12:11; 14:19-15:24; 16:1-617:18-18:7; 18:9-19:6; 24:22-27:7; 28:10-16; 30:5-31:4; 31:10-32:12; 48:19-49:15; 49:17-50:11; 51:24-52:1; 52:3-19; 72:9-22; 72:25-73:23; 79:21-81:3; 81:5-82:7; 82:9-82:18; 82:20-83:1; 83:3-5; 83:7-10; 89:6-93:25; 94:3-95:23; 104:12-15; 104:17-105:15	OS, 106, 402, 403	16:8-10, 16:12-13, 73:25-74:7, 74:19-75:1, 83:11-23, 83:25-84:3, 95:24-96:6, 96:9-12, 96:14-22, 96:24-97:4	106, 402, 403, 701, AF, AM, C, MC, OS, SP
104:17-105:15	106, 801	10:5-6; 10:8-13; 10:15-12:11; 14:19-15:24; 16:1-617:18-18:7; 18:9-19:6; 24:22-27:7;	OS, 106, 402, 403	16:8-10, 16:12-13, 73:25-74:7, 74:19-75:1, 83:11-23, 83:25-84:3, 95:24-96:6, 96:9-12,	106, 402, 403, 701, AF, AM, C, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		28:10–16; 30:5–31:4; 31:10–32:12; 48:19–49:15; 49:17–50:11; 51:24–52:1; 52:3–19; 72:9–22; 72:25–73:23; 79:21–81:3; 81:5–82:7; 82:9–82:18; 82:20–83:1; 83:3–5; 83:7–10; 89:6–93:25; 94:3–95:23; 104:12–15; 104:17–105:15		96:14–22, 96:24–97:4	
107:9–108:11	801				
110:11–25	106, 801	40:12–15; 40:17; 40:19–41:15; 42:11–25; 43:23–44:3; 44:24–46:1; 46:25–47:7; 109:14–25	OS, 106, 402, 403	41:16–17, 41:18, 43:17–22, 46:2–12	106, 402, 403, 602, 701, AM, C, F, ID, MC, OS, SP
111:1–114:12	106, 701, 801, AF, AM, MC	40:12–15; 40:17; 40:19–41:15; 42:11–25; 43:23–44:3; 44:24–46:1; 46:25–47:7; 109:14–25; 110:11–113:21	OS, 106, 402, 403	41:16–17, 41:18, 43:17–22, 46:2–12	106, 402, 403, 602, 701, AM, C, F, ID, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
114:16-19	701, 801, AF, AM				
115:6-17	701, 801, AF, AM, MC				
116:3-10	106, 801, B, MC	40:12–15; 40:17; 40:19–41:15; 42:11–25; 43:23–44:3; 44:24–46:1; 46:25–47:7; 109:14–25; 110:11–113:21	OS, 106, 402, 403	41:16-17, 41:18, 43:17-22, 46:2-12,	106, 402, 403, 602, 701, AM, C, F, ID, MC, OS, SP
116:14-117:14	106, 602, 801, B, MC, SP	40:12–15; 40:17; 40:19–41:15; 42:11–25; 43:23–44:3; 44:24–46:1; 46:25–47:7; 109:14–25; 110:11–113:21	OS, 106, 402, 403	41:16-17, 41:18, 43:17-22, 46:2-12,	106, 402, 403, 602, 701, AM, C, F, ID, MC, OS, SP
118:16-119:9	801				
120:7-10	801				
120:12-21	801				
124:14-125:14	106, 602, 801, F, MC, SP	10:5–6; 10:8–13; 10:15–12:11; 14:19–15:24; 16:1–617:18–18:7; 18:9–19:6; 24:22–27:7; 28:10–16; 30:5–31:4; 31:10–32:12; 48:19–49:15;	OS, 106, 402, 403	16:8-10, 16:12-13, 73:25-74:7, 74:19-75:1, 83:11-23, 83:25-84:3, 95:24-96:6, 96:9-12, 96:14-22, 96:24-97:4	106, 402, 403, 701, AF, AM, C, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		49:17–50:11; 51:24–52:1; 52:3–19; 72:9–22; 72:25–73:23; 79:21–81:3; 81:5–82:7; 82:9–82:18; 82:20–83:1; 83:3–5; 83:7–10; 89:6–93:25; 94:3–95:23; 104:12–15; 104:17–105:15; 110:11–113:21; 120:13–21			
127:3-8	106, 402, 701, 801, B, F	10:5–6; 10:8–13; 10:15–12:11; 14:19–15:24; 16:1–617:18–18:7; 18:9–19:6; 24:22–27:7; 28:10–16; 30:5–31:4; 31:10–32:12; 48:19–49:15; 49:17–50:11; 51:24–52:1; 52:3–19; 72:9–22; 72:25–73:23; 79:21–81:3; 81:5–82:7; 82:9–82:18; 82:20–83:1; 83:3–5; 83:7–10; 89:6–	OS, 106, 402, 403	16:8-10, 16:12-13, 73:25-74:7, 74:19-75:1, 83:11-23, 83:25-84:3, 95:24-96:6, 96:9-12, 96:14-22, 96:24-97:4	106, 402, 403, 701, AF, AM, C, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		93:25; 94:3–95:23; 104:12–15; 104:17–105:15; 110:11–113:21; 120:13–21; 127:9–13; 127:18–128:14			
127:18-25	106, 402, 701, 801, AM, B, F	10:5–6; 10:8–13; 10:15–12:11; 14:19–15:24; 16:1–617:18–18:7; 18:9–19:6; 24:22–27:7; 28:10–16; 30:5–31:4; 31:10–32:12; 48:19–49:15; 49:17–50:11; 51:24–52:1; 52:3–19; 72:9–22; 72:25–73:23; 79:21–81:3; 81:5–82:7; 82:9–82:18; 82:20–83:1; 83:3–5; 83:7–10; 89:6–93:25; 94:3–95:23; 104:12–15; 104:17–105:15; 110:11–113:21; 120:13–21; 127:9–13; 127:18–128:14	OS, 106, 402, 403	16:8-10, 16:12-13, 73:25-74:7, 74:19-75:1, 83:11-23, 83:25-84:3, 95:24-96:6, 96:9-12, 96:14-22, 96:24-97:4	106, 402, 403, 701, AF, AM, C, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
128:20-129:6	106, 402, 801, B, MC	40:12–15; 40:17; 40:19–41:15; 42:11–25; 43:23–44:3; 44:24–46:1; 46:25–47:7; 109:14–25; 110:11–113:21	OS, 106, 402, 403	41:16-17, 41:19, 43:17-22, 46:2-12	106, 402, 403, 602, 701, AM, C, F, MC, OS, SP
133:6-8	801				
133:10-136:11	402, 801	136:12–16			
136:17-137:8	106, 402, 602, 801, AM, AF, CQ, MC, SP	136:17–137:4	106		
137:10-13	106, 402, 602, 801, AM, AF, MC, SP	136:17–137:4	106		
137:15-19	106, 402, 602, 801, AM, AF, MC, SP	136:17–137:4	106		
137:22-24	106, 402, 602, 801, AM, AF, MC, SP	136:17–137:4	106		
138:1-23	106, 602, 701, 801, AM, AF, MC, SP	136:17–137:4	106		
138:25-139:7	106, 602, 701, 801, AM, AF, MC, SP	136:17–137:4	106		
139:9-13	106, 602, 701, 801, AM, AF, MC, SP	136:17–137:4	106		
139:16-24	106, 602, 701, 801, AM, AF, MC, SP	136:17–137:4	106		
142:1-5	106, 801, AM	140:1–5; 140:7–141:24	106		

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
142:7-8	106, 801, AM	140:1-5; 140:7-141:24	106		
142:10-16	106, 801, AF, AM, B, F, MC	140:1-5; 140:7-141:24	106		
142:18-144:18	106, 801, AM, MC	82:1-7; 82:9-18; 82:20-83:1; 83:3-5; 83:7-10; 84:5-88:4; 107:9-25; 109:14-25; 110:11-113:21; 133:6-8; 133:10-134:25; 135:3-24; 142:14-143:21	OS, 106, 402, 403	83:11-23, 83:25-84:3, 110:1-10, 132:19-20, 132:22-133:4, 135:1-2,	106, 402, 403, 602, AM, C, CQ, MC, OS, SP
144:20-21	106, 801, AM, MC	82:1-7; 82:9-18; 82:20-83:1; 83:3-5; 83:7-10; 84:5-88:4; 107:9-25; 109:14-25; 110:11-113:21; 133:6-8; 133:10-134:25; 135:3-24; 142:14-143:21	OS, 106, 402, 403	83:11-23, 83:25-84:3, 110:1-10, 132:19-20, 132:22-133:4, 135:1-2,	106, 402, 403, 602, AM, C, CQ, MC, OS, SP
144:23-145:19	106, 801, AM, MC	82:1-7; 82:9-18; 82:20-83:1; 83:3-5; 83:7-10; 84:5-88:4; 107:9-25; 109:14-25; 110:11-113:21; 133:6-8;	OS, 106, 402, 403	83:11-23, 83:25-84:3, 110:1-10, 132:19-20, 132:22-133:4, 135:1-2,	106, 402, 403, 602, AM, C, CQ, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		133:10–134:25; 135:3–24; 140:1–5; 140:7–141:24; 142:14–143:21			
146:17-20	106, 801	149:25–150:7; 150:9–19	106, 402, 403		
146:22-149:15	106, 801	82:1–7; 82:9–18; 82:20–83:1; 83:3– 5; 83:7–10; 84:5– 88:4; 107:9–25; 109:14–25; 110:11– 113:21; 133:6–8; 133:10–134:25; 135:3–24; 140:1–5; 140:7–141:24; 146:17–24; 147:11– 17; 149:25–150:7; 150:9–19	OS, 106, 402, 403	83:11-23, 83:25- 84:3, 110:1-10, 132:19-20, 132:22- 133:4, 135:1-2,	106, 402, 403, 602, AM, C, CQ, MC, OS, SP
149:17-20	106, 801	82:1–7; 82:9–18; 82:20–83:1; 83:3– 5; 83:7–10; 84:5– 88:4; 107:9–25; 109:14–25; 110:11– 113:21; 133:6–8; 133:10–134:25; 135:3–24; 140:1–5; 140:7–141:24; 146:17–24; 147:11–	OS, 106, 402, 403	83:11-23, 83:25- 84:3, 110:1-10, 132:19-20, 132:22- 133:4, 135:1-2,	106, 402, 403, 602, AM, C, CQ, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		17; 149:25–150:7; 150:9–19			
151:24-152:2	106, 801, AM, AF, B, MC	140:1–5; 140:7–141:24; 149:25–150:7; 150:9–19	106, 402, 403		
152:4-7	106, 801, AM, AF, B, MC	149:25–150:7; 150:9–19	106, 402, 403		
152:9-10	106, 402, 801, AM, AF, B, F, MC	149:25–150:7; 150:9–19	106, 402, 403		
153:1-4	106, 402, 801, AM, B	72:9–16	OS, 16, 402, 403	73:25-74:7, 74:19-75:1	106, 403, AM, C, MC
153:8-11	106, 402, 801, AM, B	72:9–16	OS, 106, 402, 403	73:25-74:7, 74:19-75:1	106, 403, AM, C, MC
153:13-16	106, 801, AM	221:13–15; 221:18–24	OS, 106, 402, 403	220:14-18, 220:21-23, 220:25-221:12, 222:1-3	402, 403, AR, B, ID, IQ, OS
153:18-154:4	106, 801, AM	221:13–15; 221:18–24	OS, 106, 402, 403	220:14-18, 220:21-23, 220:25-221:12, 222:1-3	402, 403, AR, B, ID, IQ, OS
154:16-19	106, 801	40:12–15; 40:17; 40:19–41:15; 42:11–25; 43:23–44:3; 44:24–46:1; 46:25–47:7; 109:14–25; 110:11–113:21	OS, 106, 402, 403	41:16-17, 41:19, 43:17-22, 46:2-12	106, 402, 403, 602, 701, AM, C, F, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
156:11-159:5	106, 801, AM, MC	40:12–15; 40:17; 40:19–41:15; 42:11–25; 43:23–44:3; 44:24–46:1; 46:25–47:7; 109:14–25; 110:11–113:21; 157:20–159:5	OS, 106, 402, 403	41:16-17, 41:19, 43:17-22, 46:2-12	106, 402, 403, 602, 701, AM, C, F, MC, OS, SP
159:23-160:4	106, 701, 801, AM, CQ, F	40:12–15; 40:17; 40:19–41:15; 42:11–25; 43:23–44:3; 44:24–46:1; 46:25–47:7; 109:14–25; 110:11–113:21; 157:20–159:5	OS, 106, 402, 403	41:16-17, 41:19, 43:17-22, 46:2-12	106, 402, 403, 602, 701, AM, C, F, MC, OS, SP
160:7-20	106, 701, 801, AM, CQ, F	40:12–15; 40:17; 40:19–41:15; 42:11–25; 43:23–44:3; 44:24–46:1; 46:25–47:7; 109:14–25; 110:11–113:21; 157:20–159:5	OS, 106, 402, 403	41:16-17, 41:19, 43:17-22, 46:2-12,	106, 402, 403, 602, 701, AM, C, F, MC, OS, SP
160:24-161:14	106, 801, AF, AM, CQ, F	120:7–21; 124:14–125:3; 127:18–128:14	OS, 106, 402, 403		

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
161:16-19	106, 801, AF, AM, CQ, F	120:7-21; 124:14-125:3; 127:18-128:14	OS, 106, 402, 403		
161:21-25	106, 801, AF, AM, CQ, F	120:7-21; 124:14-125:3; 127:18-128:14	OS, 106, 402, 403		
162:2-3	106, 801, AF, AM, CQ, F	120:7-21; 124:14-125:3; 127:18-128:14	OS, 106, 402, 403		
162:2-3	106, 801, AF, AM, CQ, F	120:7-21; 124:14-125:3; 127:18-128:14	OS, 106, 402, 403		
162:5-163:6	106, 801	94:3-23; 162:5-164:4; 164:6-11; 164:13-16	OS, 106, 402, 403	95:24-96:6, 96:9-12, 96:14-22, 96:24-97:4	106, 701, AF, AM, C, MC, OS, SP
165:5-19	106, 402, 801	165:16-166:10	106		
165:21-166:21	106, 801	165:16-166:10	106		
167:2-12	106, 402, 602, 801, AF, AM, F, SP	165:16-166:10	106		
168:23-170:5	402, 602, 801, AM, SP				
171:24-173:2	402, 701, 801, AM				
174:1-2	106, 602, 701, 801, SP	168:23-169:4	106		
174:4-6	106, 602, 701, 801, SP	168:23-169:4	106		
174:9-15	106, 602, 701, 801, SP	168:23-169:4	106		

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
174:19-21	106, 602, 701, 801, SP	168:23–169:4	106		
174:23-175:8	801	168:23–169:4	106		
175:10-19	106, 602, 701, 801, SP	168:23–169:4	106		
175:21	106, 602, 701, 801, SP	168:23–169:4	106		
175:23-177:5	106, 602, 701, 801, SP	168:23–169:4	106		
177:19-179:17	106, 602, 701, 801, AM, AF, B, F, MC, SP	10:5–6; 10:8–13; 10:15–12:11; 14:19–15:24; 16:1–617:18–18:7; 18:9–19:6; 24:22–27:7; 28:10–16; 30:5–31:4; 31:10–32:12; 48:19–49:15; 49:17–50:11; 51:24–52:1; 52:3–19; 72:9–22; 72:25–73:23; 79:21–81:3; 81:5–82:7; 82:9–82:18; 82:20–83:1; 83:3–5; 83:7–10; 89:6–93:25; 94:3–95:23; 104:12–15; 104:17–105:15; 110:11–	OS, 106, 402, 403	16:8-10, 16:12-13, 73:25-74:7, 74:19-75:1, 83:11-23, 83:25-84:3, 95:24-96:6, 96:9-12, 96:14-22, 96:24-97:4, 97:6-8, 142:1-13	106, 402, 403, 701, AF, AM, B, C, ID, MC, OS, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		113:21; 120:13–21; 127:9–13; 127:18– 128:14; 140:1–5; 140:7–141:24			
181:25-182:7	106, 402, 602, 801, AM, AF, F, SP	180:16–181:5; 181:7; 181:13–24	OS, 106, 402, 403	179:18-19, 179:21- 180:10, 180:12-14	106, 402, 403, AF, AM, F, MC, OS, SP
182:9-24	106, 402, 801	180:16–181:5; 181:7; 181:13–24	OS, 106, 402, 403	179:18-19, 179:21- 180:10, 180:12-14	106, 402, 403, AF, AM, F, MC, OS, SP
183:16-18	402, 801				
184:1-10	106, 402, 801	165:5–10; 165:16– 166:10; 184:8–24; 185:1–2	OS, 106, 402, 403		
184:12-24	106, 801	165:5–10; 165:16– 166:10; 184:8–24; 185:1–2	OS, 106, 402, 403		
185:1-2	106, 801	165:5–10; 165:16– 166:10; 184:8–24; 185:1–2	OS, 106, 402, 403		
185:4-7	402, 801, AM, CQ				
185:9-13	402, 801				
185:15-186:1	402, 602, 801, A, AM, AF, F				
186:3-8	402, 602, 801, A, AM, AF, F				
186:16-25	402, 602, 801, A, AM, AF, F				

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
187:18-22	106, 402, 602, 801, A, AM, AF, F	187:1–187:17; 187:23–188:8	OS, 106, 402, 403		
192:8-193:8	402, 801				

Witness: Michael Miller

Date: Feb. 15, 2018

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
11:12-12:5	402, 801				
12:14-13:5	402, 801, 602, CQ				
13:25-15:5	402, 801				
16:3-23	402, 801				
22:10-14	402, 801, F				
22:16-23:13	402, 801, CQ				
23:16-21	402, 801				

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
24:12-19	402, 801				
27:8-10	402, 801				
27:15-28:7	402, 801				
29:25-30:10	402, 801	117:9–118:14; 241:12–242:2; 248:5–249:4; 261:7–25; 262:7– 263:1; 265:7–15	OS, 106, 402, 403	116:19-20, 116:25- 117:8, 119:19- 120:8, 241:4-11, 247:14-248:4, 249:5-250:8, 262:1- 6, 264:2-265:6, 265:16-266:1	106, 402, 403, 801, CQ, ID, IQ, OS
30:21-31:6	402, 801, CQ				
31:13-17	402, 801				
31:19-33:14	106, 402, 801, CQ	33:15–34:22	OS, 402, 403		
36:3-20	106, 402, 801, AM	33:15–34:22	OS, 402, 403		
37:6-16	402, 801				
38:2-13	402, 801, AF, AM, F				
42:12-43:5	106, 801, CQ	41:1–18; 43:6–7; 43:14–16	ID, OS, 402, 403		
44:3-9	106, 801, ID, CQ	44:10–18	OS, 402, 403		
47:7-8	402, 801				
47:13-48:7	106, 402, 602, 801, CQ, F	74:21–75:6	OS, 402, 403		
52:22-53:19	106, 602, 801, F	51:17–52:18	OS, 402, 403		
55:19-56:19	106, 602, 801, F	56:20–57:22, 59:8– 22, 86:21–87:8, 138:4–23, 139:22– 140:9, 141:22–	ID, OS, 106, 402, 403	59:23-60:1, 146:9- 22, 147:10-22, 186:1-187:1	106, 402, 403, 801, AM, AR, CQ

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		142:11, 142:19–25, 146:23–147:9, 148:19–149:12, 185:3–25			
58:2-6	801, AM				
58:8-59:6	106, 801	56:20–57:22; 59:8–22, 86:21–87:8, 138:4–23, 139:22–140:9, 141:22–142:11, 142:19–25, 146:23–147:9, 148:19–149:12, 185:3–25	ID, OS, 106, 402, 403	59:23-60:1, 146:9-22, 147:10-22, 186:1-187:1	106, 402, 403, 801, AM, AR, CQ
60:12-18	402, 801, F				
60:20-61:5	106, 402, 602, 801, F	61:6–21	OS, 401, 402		
61:22-62:10	106, 402, 602, 801, F	61:6–21	OS, 401, 402		
62:15-25	402, 602, 801, F				
63:1-2	402, 801, ID				
63:4-6	402, 801, F				
63:21-64:7	402, 602, 801, F				
64:10-11	402, 801				
64:16-65:18	402, 602, 801, F				
66:23-67:12	402, 801				
72:21-73:10	106, 801, AM	118:23–119:6	OS, 106, 402, 403	119:19-120:8	106, 402, 403, 801, CQ
75:8-10	801				

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
75:15-76:9	106, 602, 801, F	76:10-77:9	OS, 402, 403		
77:10-16	106, 402, 801	77:17-79:8	OS, 402, 403		
88:7-17	402, 602, 701, 801				
93:16-94:12	106, 801, AM	93:1-15	OS, 402, 403		
94:14	801				
94:16	801, AM				
94:18-95:4	106, 801	95:5-8	OS, 106, 402, 403	95:9-12	402, 403, 801, AM
100:17-21	402, 602, 701, 801, AA				
100:24-101:5	402, 602, 701, 801				
101:7-9	402, 602, 701, 801, AR, CQ				
101:11	402, 602, 701, 801				
108:9-110:15	106, 801, CQ	83:23-84:9; 84:13-85:8; 85:12-16; 86:2-5; 86:12-18; 86:21-87:8	OS, 106, 402, 403	83:6-22	402, 403, 801, CQ, OS
110:17-20	801				
110:22-111:6	801	111:13-19, 112:23-113:11	OS, 402, 403		
111:13-19	106, 801	111:21-112:6	OS, 402, 403		
112:7-22	106, 801	111:3-19, 111:21-112:6; 112:23-113:11	OS, 402, 403		
113:12-22	801	111:3-19, 112:23-113:11	OS, 402, 403		
113:24-114:1	801, AM, AR	111:3-19, 112:23-113:11	OS, 402, 403		

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
114:3-5	801	111:3–19, 112:23–113:11	OS, 402, 403		
121:6-24	106, 801	121:25–122:6; 122:10–24; 124:13–125:2	OS, 106, 402, 403	123:22-124:12, 125:3-126:7	402, 403, 801, AM, MC
125:3-126:7	106, 801, AM, MC	121:25–122:6; 122:10–24; 124:13–125:2	OS, 106, 402, 403	123:22-124:12, 125:3-126:7	402, 403, 801, AM, MC
128:10-12	801, AM				
128:14	801				
128:16-129:8	106, 801, AM	129:11–130:3	OS, 402, 403		
130:12-13	801, AM				
130:15-17	801				
130:19-23	801, AM, CQ				
130:25-131:11	801				
131:13-133:8	801, AM, MC				
133:10-21	801, AM				
134:17-20	801, AM, CQ				
135:10-136:9	801, MC				
136:14-137:14	801				
137:16-19	801				
137:21-138:3	106, 402, 801	138:4–23	OS, 402, 403		
138:24-139:13	106, 402, 801	56:20–57:22, 59:8–22, 86:21–87:8, 138:4–23; 139:22–140:9; 141:22–142:11; 142:19–25, 146:23–147:9,	ID, OS, 106, 402, 403	59:23-60:1, 146:9-22, 147:10-22, 186:1-187:1	106, 402, 403, 801, AM, AR, CQ

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		148:19–149:12, 185:3–25			
143:15-18	402, 801, IQ				
144:22-145:5	402, 801, AR				
145:7-13	801				
145:15-23	106, 801, AM, CQ, MC	56:20–57:22, 59:8–22, 86:21–87:8, 138:4–23, 139:22–140:9, 141:22–142:11, 142:19–25, 146:23–147:9; 148:19–149:12, 185:3–25	ID, OS, 106, 402, 403	59:23-60:1, 146:9-22, 147:10-22, 186:1-187:1	106, 402, 403, 801, AM, AR, CQ
149:17-150:4	402, 701, 801	111:3–19, 112:23–113:11	OS, 402, 403		
152:23-153:3	106, 801, AM, CQ	153:4–12	OS, 402, 403		
153:13-154:12	106, 801	153:4–12	OS, 402, 403		
154:14-22	801				
155:8-12	801				
162:18-21	801				
163:10-17	801				
164:1-12	801, AM				
164:22-25	801				
165:2-3	801, AM				
165:5-19	801, MC				
165:21-166:1	801				
166:3-6	801, AM				
166:8-12	801				

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
166:14-21	801, AM				
166:23-167:16	801				
167:18-21	801, AA, AR				
167:24-168:6	801, AA, AR				
168:8-19	801				
168:21-169:2	801, AA, AM, AR				
169:4-5	801				
171:9-172:21	801, CQ				
172:23-173:8	801				
176:24-177:5	801				
177:7-25	106, 801	180:11–25	OS, 106, 402, 403	179:13-180:10	106, 402, 403, 801
181:1-13	106, 801	56:20–57:22, 59:8–22, 86:21–87:8, 138:4–23, 139:22–140:9, 141:22–142:11, 142:19–25, 146:23–147:9, 148:19–149:12, 180:11–25, 185:3–25	ID, OS, 106, 402, 403	59:23-60:1, 146:9-22, 147:10-22, 186:1-187:1	106, 402, 403, 801, AM, AR, CQ
182:5-185:2	106, 801, AM, AR, MC	56:20-57:22, 59:8–22, 86:21–87:8, 138:4–23, 139:22–140:9, 141:22–142:11, 142:19–25, 146:23–147:9, 148:19–149:12, 185:3–25	ID, OS, 106, 402, 403	59:23-60:1, 146:9-22, 147:10-22, 186:1-187:1	106, 402, 403, 801, AM, AR, CQ

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
187:12-15	801				
187:19-191:14	402, 801				
202:3-203:7	106, 402, 801				
204:11-24	801				
206:14-20	801				
207:5-22	801				
208:210:2	801, AM, CQ, ID				
210:5	801, AM				
210:7-9	801				
210:11-16	602, 801, AM, CQ, SP				
210:18-20	801				
216:24-217:8	402, 801, AM				
217:10-14	801				
217:16-23	402, 801				
218:4-19	402, 801				
219:21-221:9	801				
221:18-222:10	402, 701, 801				
222:13-16	402, 801, AR				
225:4-10	801				
227:18-228:11	402, 701, 801				
229:8-230:1	402, 701, 801				
230:14-18	106, 801	233:13–22	OS, 106, 402, 403	232:12-233:7, 233:9-11	402, 403, 801, AM, CQ
233:23-234:10	106, 801	233:13–22	OS, 106, 402, 403	232:12-233:7, 233:9-11	402, 403, 801, AM, CQ
234:12-24	801				

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
237:12-25	801, AM, ID, IQ				
240:2-8	106, 801, ID, IQ	239:22-25; 241:12-242:2; 248:5-249:4; 261:7-25; 262:7-263:1; 265:7-15	OS, 106, 402, 403	241:4-11, 247:14-248:4, 249:5-250:8, 262:1-6, 264:2-265:6, 265:16-266:1	402, 403, 801, CQ

Witness: Ian Osterloh

Date: Nov. 5, 2018

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
6:2-9	106, 801	6:2-9			
7:6-10	106, 801	8:22-9:18			
8:22-10:18	106, 801	8:22-9:18; 12:16-13:17; 14:8-16:21		11:11-12:2	106; 801
22:24-25:4	106, 801, SP	22:24-23:24; 25:7-25:8; 25:12-26:6; 26:8-26:20;	ID, OS, 402, 403		
25:13-24	106, 801, AF, AM	25:8; 25:12-26:6; 26:8-26:20;	ID, OS, 402, 403		
26:1-6	106, 801, AM	25:8; 25:12-26:6; 26:8-26:20;	ID, OS, 106, 402, 403	23:25-25:4, 25:13-24	106, 801, AF, AM, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
26:8-20	106, 801	25:8; 25:12-26:6; 26:8-26:20;	ID, OS, 106, 402, 403	23:25-25:4, 25:13-24	106, 801, AF, AM, SP
27:16-17	106, 801	27:14-21	ID, 403		
27:19-23	106, 801	27:16-28:4	ID, 403		
33:16-34:7	106, 801	33:16-34:7	ID, 403		
39:11-22	106; 801	180:9-182:9; 182:11-184:14; 184:16-185:20; 185:22-186:24; 187:1-187:4	OS, 106, 402, 403, 601, 701, 801	187:14-17, 187:20, 187:22-25, 188:17-189:16, 194:6-9, 194:12-18, 194:20-21, 194:24-195:20, 195:22-23, 196:1-5, 196:7-9, 196:11-13	106, 801, 402, 403, AF, AM, SP, F, ID, IQ, MC
48:17-49:3	106, 801	48:17-49:3;	ID, 403		
51:2-6	106, 801	48:17-49:3; 49:14-49:23; 49:25-50:2; 50:16-51:14	ID, OS, 106, 402, 403	50:10-11, 50:13-14	106, 801, AM
51:8-9	106, 801; AM; SP	48:17-49:3; 49:14-49:23; 49:25-50:2; 50:16-51:17; 51:19-52:9; 52:11-16; 52:22-53:14; 53:16-54:5	ID, OS, 106, 402, 403	50:10-11, 50:13-14	106, 801, AM
51:15-17	106, 801	48:17-49:3; 49:14-49:23; 49:25-50:2; 50:16-51:17; 51:19-52:9; 52:11-16; 52:22-53:14; 53:16-54:5; 180:9-182:9;	ID, OS, 106, 402, 403, 601, 701, 801	50:10-11, 50:13-14, 187:14-17, 187:20, 187:22-25, 188:17-189:16, 194:6-9, 194:12-18, 194:20-21, 194:24-195:20,	106, 801, 402, 403, AF, AM, SP, F, ID, IQ, MC

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		182:11-184:14; 184:16-185:20; 185:22-186:24; 187:1-187:4		195:22-23, 196:1-5, 196:7-9, 196:11-13	
51:19-52:4	106, 801	48:17-49:3; 49:14- 49:23; 49:25-50:2; 50:16-51:17; 51:19- 52:9; 52:11-16; 52:22-53:14; 53:16- 54:5; 180:9-182:9; 182:11-184:14; 184:16-185:20; 185:22-186:24; 187:1-187:4	ID, OS, 106, 402, 403, 601, 701, 801	50:10-11, 50:13-14, 187:14-17, 187:20, 187:22-25, 188:17- 189:16, 194:6-9, 194:12-18, 194:20- 21, 194:24-195:20, 195:22-23, 196:1-5, 196:7-9, 196:11-13	106, 801, 402, 403, AF, AM, SP, F, ID, IQ, MC
53:10-14	106, 801, AM	51:15-17; 51:19- 52:9; 52:11-16; 52:22-53:14; 53:16- 54:5; 180:9-182:9; 182:11-184:14; 184:16-185:20; 185:22-186:24; 187:1-187:4	ID, OS, 106, 402, 403, 601, 701, 801	50:10-11, 50:13-14, 187:14-17, 187:20, 187:22-25, 188:17- 189:16, 194:6-9, 194:12-18, 194:20- 21, 194:24-195:20, 195:22-23, 196:1-5, 196:7-9, 196:11-13	106, 801, 402, 403, AF, AM, SP, F, ID, IQ, MC
53:16-18	106, IQ	51:15-17; 51:19- 52:9; 52:11-16; 52:22-53:14; 53:16- 54:5; 180:9-182:9; 182:11-184:14; 184:16-185:20;	ID, OS, 106, 402, 403, 601, 701, 801	50:10-11, 50:13-14, 187:14-17, 187:20, 187:22-25, 188:17- 189:16, 194:6-9, 194:12-18, 194:20- 21, 194:24-195:20,	106, 801, 402, 403, AF, AM, SP, F, ID, IQ, MC

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		185:22-186:24; 187:1-187:4		195:22-23, 196:1-5, 196:7-9, 196:11-13	
53:20	801, IQ				
53:21-54:18	106, 402, 403, 801, SP, AM	51:15-17; 51:19- 52:9; 52:11-16; 52:22-53:14; 53:16- 54:5; 54:14-54:18; 54:20-55:19; 180:9- 182:9; 182:11- 184:14; 184:16- 185:20; 185:22- 186:24; 187:1- 187:4	ID, OS, 106, 402, 403, 601, 701, 801	50:10-11, 50:13-14, 187:14-17, 187:20, 187:22-25, 188:17- 189:16, 194:6-9, 194:12-18, 194:20- 21, 194:24-195:20, 195:22-23, 196:1-5, 196:7-9, 196:11-13	106, 801, 402, 403, AF, AM, SP, F, ID, IQ, MC
54:20-55:4	106, 801	51:15-17; 51:19- 52:9; 52:11-16; 52:22-53:14; 53:16- 54:5; 54:14-54:18; 54:20-55:19; 180:9- 182:9; 182:11- 184:14; 184:16- 185:20; 185:22- 186:24; 187:1- 187:4	ID, OS, 106, 402, 403, 601, 701, 801	50:10-11, 50:13-14, 187:14-17, 187:20, 187:22-25, 188:17- 189:16, 194:6-9, 194:12-18, 194:20- 21, 194:24-195:20, 195:22-23, 196:1-5, 196:7-9, 196:11-13	106, 801, 402, 403, AF, AM, SP, F, ID, IQ, MC
59:11-60:20	106, 701, 801, AA, C, SP	51:15-17; 51:19- 52:9; 52:11-16; 52:22-53:14; 53:16- 54:5; 59:11-60:20; 60:24-61:11; 61:20-	ID, OS, 106, 402, 403, 601, 701, 801	50:10-11, 50:13-14, 70:9-24, 71:1-9, 75:12-14, 75:16-17, 187:14-17, 187:20, 187:22-25, 188:17-	106, 801, 402, 403, AF, AM, SP, F, ID, IQ, MC

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		62:7; 71:11-13; 71:16-71:24; 72:1-72:13; 72:15-72:19; 72:21-73:23; 73:25-75:11; 76:8-14; 76:16-22; 180:9-182:9; 182:11-184:14; 184:16-185:20; 185:22-186:24; 187:1-187:4		189:16, 194:6-9, 194:12-18, 194:20-21, 194:24-195:20, 195:22-23, 196:1-5, 196:7-9, 196:11-13	
60:24-61:11	106, 801	51:15-17; 51:19-52:9; 52:11-16; 52:22-53:14; 53:16-54:5; 59:11-60:20; 60:24-61:11; 61:20-62:7; 71:11-13; 71:16-71:24; 72:1-72:13; 72:15-72:19; 72:21-73:23; 73:25-75:11; 76:8-14; 76:16-22; 180:9-182:9; 182:11-184:14; 184:16-185:20; 185:22-186:24; 187:1-187:4	ID, OS, 106, 402, 403, 601, 701, 801	50:10-11, 50:13-14, 70:9-24, 71:1-9, 75:12-14, 75:16-17, 187:14-17, 187:20, 187:22-25, 188:17-189:16, 194:6-9, 194:12-18, 194:20-21, 194:24-195:20, 195:22-23, 196:1-5, 196:7-9, 196:11-13	106, 801, 402, 403, AF, AM, SP, F, ID, IQ, MC

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
73:11-17	106, 801, AF, SP	71:11-13; 71:16-71:24; 72:1-72:13; 72:15-72:19; 72:21-73:23; 73:25-75:11; 76:8-14; 76:16-22	ID, OS, 106, 402, 403	70:9-24, 71:1-9, 75:12-14, 75:16-17	106, 801, 402, 403, AF, AM, F, ID, SP
77:6-78:4	106, 801, 402, 403,	27:16-28:4; 54:14-54:18; 54:20-55:19;	OS, 106, 402, 403	55:20-22, 55:24-56:8, 56:10-25	106, 402, 403, 801, AF, AM, F, SP
79:24-80:6	106, 801	81:5-81:8; 81:10-82:3	OS, 106, 402, 403	80:7-11, 83:12-16, 83:18-84:3	106, 402, 403, 801, AM
82:5-11	106, 801, AF, AM, CQ	81:5-81:8; 81:10-82:3	OS, 106, 402, 403	80:7-11, 83:12-16, 83:18-84:3	106, 402, 403, 801, AM
82:13-14	106, 801, IQ				
82:16-25	106, 801	81:5-81:8; 81:10-82:3; 83:1-83:4; 83:6-83:10	OS, 106, 402, 403	80:7-11, 83:12-16, 83:18-84:3	106, 402, 403, 801, AM
86:5-13	106, 701, 801, AM	85:12-21; 85:24-86:3; 86:5-13; 86:15-19	ID, OS, 106, 402, 403	85:2-11	106, 402, 403, 801, AM
86:15-19	106, 801	85:12-21; 85:24-86:3; 86:5-13; 86:15-19	ID, OS, 106, 402, 403	85:2-11	106, 402, 403, 801, AM
87:8-9	801				
87:11-16	106, 801	87:17			
87:24-89:14	106, 801, MC, SP	81:5-81:8; 81:10-82:3; 83:1-83:4; 83:6-83:10; 85:12-21; 85:24-86:3;	OS, 106, 402, 403	80:7-11, 83:12-16, 83:18-84:3, 85:2-11	106, 402, 403, 801, AM

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		86:5-13; 86:15-19; 89:15-91:14			
91:15-25	106, 402, 403, 801, SP	89:15-91:14; 92:1-12	OS, 106, 402, 403		
98:19-99:12	106, 801	51:15-17; 51:19-52:9; 52:11-16; 52:22-53:14; 53:16-54:5; 59:11-60:20; 60:24-61:11; 61:20-62:7; 71:11-13; 71:16-71:24; 72:1-72:13; 72:15-72:19; 72:21-73:23; 73:25-75:11; 76:8-14; 76:16-22; 99:13-99:19; 180:9-182:9; 182:11-184:14; 184:16-185:20; 185:22-186:24; 187:1-187:4	ID, OS, 106, 402, 403, 601, 701, 801	50:10-11, 50:13-14, 70:9-24, 71:1-9, 75:12-14, 75:16-17, 187:14-17, 187:20, 187:22-25, 188:17-189:16, 194:6-9, 194:12-18, 194:20-21, 194:24-195:20, 195:22-23, 196:1-5, 196:7-9, 196:11-13	106, 801, 402, 403, AF, AM, SP, F, ID, IQ, MC
99:20-100:14	106, 801, AA, AM, C	51:15-17; 51:19-52:9; 52:11-16; 52:22-53:14; 53:16-54:5; 59:11-60:20; 60:24-61:11; 61:20-62:7; 71:11-13; 71:16-71:24; 72:1-72:13; 72:15-72:19;	ID, OS, 106, 402, 403, 601, 701, 801	50:10-11, 50:13-14, 70:9-24, 71:1-9, 75:12-14, 75:16-17, 187:14-17, 187:20, 187:22-25, 188:17-189:16, 194:6-9, 194:12-18, 194:20-21, 194:24-195:20,	106, 801, 402, 403, AF, AM, SP, F, ID, IQ, MC

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		72:21-73:23; 73:25-75:11; 76:8-14; 76:16-22; 180:9-182:9; 182:11-184:14; 184:16-185:20; 185:22-186:24; 187:1-187:4		195:22-23, 196:1-5, 196:7-9, 196:11-13	
100:16-17	801				
100:19-101:5	106, 801, AA, AM, C	51:15-17; 51:19-52:9; 52:11-16; 52:22-53:14; 53:16-54:5; 59:11-60:20; 60:24-61:11; 61:20-62:7; 71:11-13; 71:16-71:24; 72:1-72:13; 72:15-72:19; 72:21-73:23; 73:25-75:11; 76:8-14; 76:16-22; 81:5-81:8; 81:10-82:3; 83:1-83:4; 83:6-83:10; 180:9-182:9; 182:11-184:14; 184:16-185:20; 185:22-186:24; 187:1-187:4	ID, OS, 106, 402, 403, 601, 701, 801	50:10-11, 50:13-14, 70:9-24, 71:1-9, 75:12-14, 75:16-17, 187:14-17, 187:20, 187:22-25, 188:17-189:16, 194:6-9, 194:12-18, 194:20-21, 194:24-195:20, 195:22-23, 196:1-5, 196:7-9, 196:11-13	106, 801, 402, 403, AF, AM, SP, F, ID, IQ, MC

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
101:14-16	106, 801, AA, C	81:5-81:8; 81:10-82:3; 83:1-83:4; 83:6-83:10	OS, 106, 402, 403	80:7-11, 83:12-16, 83:18-84:3	106, 402, 403, 801, AM
101:19-102:9	106, 801	81:5-81:8; 81:10-82:3; 83:1-83:4; 83:6-83:10; 102:2-102:23	OS, 106, 402, 403	80:7-11, 83:12-16, 83:18-84:3	106, 402, 403, 801, AM
102:24-104:4-12	106, 801, AA, AM, C, MC	81:5-81:8; 81:10-82:3; 83:1-83:4; 83:6-83:10; 102:2-102:23; 103:17-24; 104:5-12	ID, OS, 106, 402, 403	80:7-11, 83:12-16, 83:18-84:3	106, 402, 403, 801, AM
105:8-10	106, 801, AA, AM, MC, CQ	104:24-105:10; 105:12-105:17; 105:19-106:8; 106:14-106:17; 106:20-107:14	ID, OS, 106, 402, 403		
105:12-17	106, 801	104:24-105:10; 105:12-105:17; 105:19-106:8; 106:14-106:17; 106:20-107:14	ID, OS, 106, 402, 403		
108:1-21	106, 701, 801, AM	81:5-81:8; 81:10-82:3; 83:1-83:4; 83:6-83:10; 102:2-102:23; 103:17-24; 104:5-12; 108:19-21; 108:23-109:8	ID, OS, 106, 402, 403	80:7-11, 83:12-16, 83:18-84:3	106, 402, 403, 801, AM

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
108:23-109:8	106, 801	81:5-81:8; 81:10-82:3; 83:1-83:4; 83:6-83:10; 102:2-102:23; 103:17-24; 104:5-12; 108:19-21; 108:23-109:8	ID, OS, 106, 402, 403	80:7-11, 83:12-16, 83:18-84:3	106, 402, 403, 801, AM
110:2-5	106, 801, AA, AM, CQ	102:2-102:23; 103:17-24; 104:5-12; 108:19-21; 108:23-109:8; 110:7-18	OS, 402, 403		
110:7-18	106, 801	102:2-102:23; 103:17-24; 104:5-12; 108:19-21; 108:23-109:8; 110:7-18	ID, OS, 402, 403		
111:8-24	106, 801, MC	102:2-102:23; 103:17-24; 104:5-12; 108:19-21; 108:23-109:8; 110:7-18; 110:25-111:7; 111:8-24; 111:25-112:5; 112:6-113:2	ID, OS, 402, 403		
113:4-6	801				
116:1-4	106, 801, AF, MC	116:6-15	ID, 403		
116:6-15	106, 801	116:6-15	ID, 403		

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
116:17-117:6	106, 801	116:16-19; 117:7-16; 117:18-24; 118:21-119:1; 119:3-121:8	ID, OS, 402, 403		
118:21-119:1	106, 801, C, MC	116:16-19; 117:7-16; 117:18-24; 118:21-119:1; 119:3-121:8	ID, OS, 402, 403		
119:3-16	106, 801	116:16-19; 117:7-16; 117:18-24; 118:21-119:1; 119:3-121:8	ID, OS, 402, 403		
119:18-120:15	106, 801, AM, C, MC	116:16-19; 117:7-16; 117:18-24; 118:21-119:1; 119:3-121:8	ID, OS, 402, 403		
124:19-22	106, 801, AF, AM	122:9-123:12; 124:3-22; 124:24-125:11; 125:13-22; 128:1-14; 130:12-14; 130:17-132:4; 132:6-7; 132:12-15; 132:17-133:5; 170:14-16; 170:19-171:13	ID, OS, 106, 402, 403, 601, 701	121:9-23, 129:19-130:11	106, 402, 403, 801, IQ
124:24-125:6	106, 801	122:9-123:12; 124:3-22; 124:24-125:11; 125:13-22;	ID, OS, 106, 402, 403, 601, 701	121:9-23, 129:19-130:11	106, 402, 403, 801, IQ

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		128:1-14; 130:12-14; 130:17-132:4; 132:6-7; 132:12-15; 132:17-133:5; 170:14-16; 170:19-171:13			
125:8-11	106, 402, 402, 801, AM, C	122:9-123:12; 124:3-22; 124:24-125:11; 125:13-22; 128:1-14; 130:12-14; 130:17-132:4; 132:6-7; 132:12-15; 132:17-133:5; 170:14-16; 170:19-171:13	ID, OS, 106, 402, 403, 601, 701	121:9-23, 129:19-130:11	106, 402, 403, 801, IQ
125:13-22	106, 801	122:9-123:12; 124:3-22; 124:24-125:11; 125:13-22; 128:1-14; 130:12-14; 130:17-132:4; 132:6-7; 132:12-15; 132:17-133:5; 170:14-16; 170:19-171:13	ID, OS, 106, 402, 403, 601, 701	121:9-23, 129:19-130:11	106, 402, 403, 801, IQ
125:24-126:3	106, 801, AA, AM, C	122:9-123:12; 124:3-22; 124:24-125:11; 125:13-22; 128:1-14; 130:12-	ID, OS, 106, 402, 403, 601, 701	121:9-23, 129:19-130:11	106, 402, 403, 801, IQ

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		14; 130:17-132:4; 132:6-7; 132:12-15; 132:17-133:5; 170:14-16; 170:19-171:13			
126:5-12	106, 801	122:9-123:12; 124:3-22; 124:24-125:11; 125:13-22; 128:1-14; 130:12-14; 130:17-132:4; 132:6-7; 132:12-15; 132:17-133:5; 170:14-16; 170:19-171:13	ID, OS, 106, 402, 403, 601, 701	121:9-23, 129:19-130:11	106, 402, 403, 801, IQ
132:2-4	106, 801, AM, SP	132:2-4; 132:6-7	ID, 403		
132:6-7	106, 801	132:2-4; 132:6-7	ID, 403		
132:9-11	106, 801, AM, IQ, SP	132:9-132:15; 132:17-133:5	ID, OS, 402, 403		
133:12-15	106, 801, AM				
133:21-25	106, 801, AA, C	122:9-123:12; 124:3-22; 124:24-125:11; 125:13-22; 128:1-14; 130:12-14; 130:17-132:4; 132:6-7; 132:12-15; 132:17-133:5; 134:6-10; 134:21-135:6; 135:8-9;	ID, OS, 106, 402, 403		

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		135:11-136:1; 136:3-13			
134:1-4	106, 801, AF, CQ	122:9-123:12; 124:3-22; 124:24- 125:11; 125:13-22; 128:1-14; 130:12- 14; 130:17-132:4; 132:6-7; 132:12-15; 132:17-133:5; 134:6-10; 134:21- 135:6; 135:8-9; 135:11-136:1; 136:3-13	ID, OS, 106, 402, 403		
134:6-10	106, 801	122:9-123:12; 124:3-22; 124:24- 125:11; 125:13-22; 128:1-14; 130:12- 14; 130:17-132:4; 132:6-7; 132:12-15; 132:17-133:5; 134:6-10; 134:21- 135:6; 135:8-9; 135:11-136:1; 136:3-13	ID, OS, 106, 402, 403		
134:12-14	106, 801, AA, C	122:9-123:12; 124:3-22; 124:24- 125:11; 125:13-22; 128:1-14; 130:12-	ID, OS, 106, 402, 403		

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		14; 130:17-132:4; 132:6-7; 132:12-15; 132:17-133:5; 134:6-10; 134:21- 135:6; 135:8-9; 135:11-136:1; 136:3-13			
134:18-19	106, 801, AA, AM, C, IQ	122:9-123:12; 124:3-22; 124:24- 125:11; 125:13-22; 128:1-14; 130:12- 14; 130:17-132:4; 132:6-7; 132:12-15; 132:17-133:5; 134:6-10; 134:21- 135:6; 135:8-9; 135:11-136:1; 136:3-13	ID, OS, 106, 402, 403		
134:21-135:6	106, 801	122:9-123:12; 124:3-22; 124:24- 125:11; 125:13-22; 128:1-14; 130:12- 14; 130:17-132:4; 132:6-7; 132:12-15; 132:17-133:5; 134:6-10; 134:21- 135:6; 135:8-9;	ID, OS, 106, 402, 403		

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		135:11-136:1; 136:3-13			
135:8-9	106, 801, AA, AF, C, SP	122:9-123:12; 124:3-22; 124:24-125:11; 125:13-22; 128:1-14; 130:12-14; 130:17-132:4; 132:6-7; 132:12-15; 132:17-133:5; 134:6-10; 134:21-135:6; 135:8-9; 135:11-136:1; 136:3-13	ID, OS, 106, 402, 403		
135:11-21	106, 801	122:9-123:12; 124:3-22; 124:24-125:11; 125:13-22; 128:1-14; 130:12-14; 130:17-132:4; 132:6-7; 132:12-15; 132:17-133:5; 134:6-10; 134:21-135:6; 135:8-9; 135:11-136:1; 136:3-13	ID, OS, 106, 402, 403		
135:23-136:1	106, 801, AA, AM, C	122:9-123:12; 124:3-22; 124:24-125:11; 125:13-22; 128:1-14; 130:12-	ID, OS, 106, 402, 403		

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		14; 130:17-132:4; 132:6-7; 132:12-15; 132:17-133:5; 134:6-10; 134:21-135:6; 135:8-9; 135:11-136:1; 136:3-13			
136:3-13	106, 801	122:9-123:12; 124:3-22; 124:24-125:11; 125:13-22; 128:1-14; 130:12-14; 130:17-132:4; 132:6-7; 132:12-15; 132:17-133:5; 134:6-10; 134:21-135:6; 135:8-9; 135:11-136:1; 136:3-13	ID, OS, 106, 402, 403		
136:15-17	106, 402, 403, 801, AF, F	137:21-138:9; 138:12-14	OS, 402, 403		
136:19	106, 801, IQ	137:7-12; 137:15-19; 137:21-138:9; 138:12-14	OS, 402, 403		
136:21-137:6	106, 402, 403, 801, AM, IQ	137:7-12; 137:15-19; 137:21-138:9; 138:12-14	OS, 402, 403		
142:2-11	106, 402, 403, 801, MC	138:16-22; 139:20-22; 139:24-140:6;	OS, 106, 402, 403	141:12-20, 141:23-24	106, 402, 403, 801, AF

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		140:8-10; 140:12-141:11; 142:13-22			
142:13-22	106, 801	138:16-22; 139:20-22; 139:24-140:6; 140:8-10; 140:12-141:11; 142:13-22	ID, OS, 106, 402, 403	141:12-20, 141:23-24	106, 402, 403, 801, AF
143:9-144:5	106, 402, 403, 801	144:25-145:9	OS, 402, 403		

Witness: Howard Weintraub

Date: Sept. 14, 2018

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
6:4-12	402, 801, AM				
7:17-18	801				
8:17-21	106, 402, 801	8:19-9:7; 9:25-10:16	402, 403	9:8-24, 10:17-11:1	402, 403, AM, C
9:25-10:12	106, 801	8:19-9:7; 9:25-10:16	402, 403	9:8-24, 10:17-11:1	402, 403, AM, C
12:15-14:4	402, 801				
16:13-15	106, 402, 403, 801, AM	16:19-17:12; 17:16-18:7; 21:19-22:20	402, 403	18:9-21	402, 403, AM, C, IQ, OS

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
16:19-17:5	106, 402, 403, 801, AM, SP	16:19–17:12; 17:16–18:7; 21:19–22:20	ID, 106, 402, 403	18:9-21	402, 403, AM, C, IQ, OS
24:25-25:5	106, 402, 403, 801, AM	16:19–17:12; 17:16–18:7; 21:19–22:20	106, 402, 403	18:9-21	402, 403, AM, C, IQ, OS
25:10-19	106, 402, 403, 801, AM	16:19–17:12; 17:16–18:7; 21:19–22:20	106, 402, 403	18:9-21	402, 403, AM, C, IQ, OS
25:21-27:11	106, 402, 403, 801, AM, AF, F	16:19–17:12; 17:16–18:7; 21:19–22:20; 27:12–15; 27:17–25; 28:10–29:14; 30:20–23; 32:10–33:10; 33:13–35:7; 109:12–15	OS, 106, 402, 403	18:9-21	402, 403, AM, C, IQ, OS
26:18-24	106, 801, AM, IQ	27:12–15; 27:17–25; 28:10–29:14; 30:20–23; 32:10–33:10; 33:13–35:7; 109:12–15	OS, 402, 403, 601		
27:12-15	106, 402, 801, AM, AF, F	27:12–15; 27:17–25; 28:10–29:14; 30:20–23; 32:10–33:10; 33:13–35:7; 109:12–15	ID, OS, 402, 403, 601		

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
30:9-12	106, 402, 801, AF, F, MC	27:12–15; 27:17–25; 28:10–29:14; 30:20–23; 32:10–33:10; 33:13–35:7	OS, 402, 403		
32:10-33:5	106, 801	27:12–15; 27:17–25; 28:10–29:14; 30:20–23; 32:10–33:10; 33:13–35:7	ID, OS, 402, 403		
33:24-34:1	106, 801, 402, 403, AM, AF, F, IQ	27:12–15; 27:17–25; 28:10–29:14; 30:20–23; 32:10–33:10; 33:13–35:7	ID, OS, 402, 403		
34:17-19	106, 801, 402, 403, AM, AF, F, IQ	27:12–15; 27:17–25; 28:10–29:14; 30:20–23; 32:10–33:10; 33:13–35:7	ID, OS, 402, 403		
35:9-36:14	106, 402, 403, 801, AM, CQ, SP	27:12–15; 27:17–25; 28:10–29:14; 30:20–23; 32:10–33:10; 33:13–35:7; 36:15–37:6	OS, 402, 403		
37:7-21	106, 402, 403, 801, AM	36:15–37:6; 39:1–9	OS, 402, 403		
38:14-17	106, 801, AM, CQ	39:1–9	ID, 403		
39:1-14	106, 801, AM, SP	39:1–9	ID, 403		
40:23	106, 402, 801, AM, IQ	40:3–41:3	ID, 403		

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
41:1-3	106, 402, 801, AM, IQ	40:3-41:3	ID, 403		
41:22-42:6	106, 402, 801, AM	42:4-6	ID, 403		
43:21-22	106, 402, 801, AM, IQ	43:14-44:10; 45:10-24; 46:25-47:2			
44:13-24	106, 801, AM	45:10-24; 46:25-47:2; 62:10-17	ID, 106, 403	62:18-19, 62:21-24, 63:6-8	106, 402, 403, A, AF, AM, F, MC, OS
45:7-47:3-4	106, 402, 701, 801, AM	45:10-24; 46:25-47:2			
47:6-16	106, 402, 801	45:10-24; 46:25-47:2			
47:18-49:6	106, 402, 801, AM	45:10-24; 46:25-47:2; 47:22-49:6			
49:23-25	106, 402, 801, AA, AM	45:10-24; 46:25-47:2; 47:22-49:6			
50:2	106, 402, 801, AA, AM	45:10-24; 46:25-47:2; 47:22-49:6; 50:4-50:14			
50:4-5	106, 402, 801, AA, AM	45:10-24; 46:25-47:2; 47:22-49:6; 50:4-14			
51:4-52:10	106, 402, 801, AA, AM	45:10-24; 46:25-47:2; 47:22-49:6; 50:4-14; 52:15-18; 52:23; 52:25-53:17; 53:22-54:16	OS, 106, 402, 403		

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
55:15-57:5	106, 402, 701, 801, AA, AM, MC	45:10-24; 46:25-47:2; 47:22-49:6; 50:4-14; 53:12-17; 53:22-54:16	OS, 402, 403		
57:15-58:19	106, 402, 701, 801, AA, AM, MC	45:10-24; 46:25-47:2; 47:22-49:6; 50:4-14; 53:12-17; 53:22-54:16	OS, 402, 403		
58:21-59:6	106, 402, 701, 801, AA, AM, MC	45:10-24; 46:25-47:2; 47:22-49:6; 50:4-14; 53:12-17; 53:22-54:16	OS, 402, 403		
59:14-19	402, 602, 701, 801, AM, AF, F, SP				
59:22-60:3	402, 602, 701, 801, AM, AF, F, SP				
60:22-61:1	602, 701, 801, AM, AF, F, SP				
61:4-12	602, 701, 801, AM, AF, F, SP				
63:19-64:9	106, 701, 801, AM, AF, F, MC	52:15-18; 52:23; 52:25-53:17; 53:22-54:16; 65:3-5; 65:7-16; 65:18-19	402, 403		
64:13-65:1	106, 701, 801, AA, AM, AF, F, MC	52:15-18; 52:23; 52:25-53:17; 53:22-54:16; 65:3-	402, 403		

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		5; 65:7–16; 65:18–19			
65:20-66:1	106, 701, 801, AA, AM	52:15–18; 52:23; 52:25–53:17; 53:22–54:16; 65:3–5; 65:7–16; 65:18–19	402, 403		
67:7-16	106, 701, 801, AA, AM	52:15–18; 52:23; 52:25–53:17; 53:22–54:16; 65:3–5; 65:7–16; 65:18–19	402, 403		
67:18-21	106, 701, 801, AM	52:15–18; 52:23; 52:25–53:17; 53:22–54:16; 65:3–5; 65:7–16; 65:18–19; 75:7–19; 75:22–76:4	106, 402, 403		
67:24-68:3	106, 701, 801, AM	52:15–18; 52:23; 52:25–53:17; 53:22–54:16; 65:3–5; 65:7–16; 65:18–19; 75:7–19; 75:22–76:4	106, 402, 403		
68:5-69:8	106, 701, 801, AM	52:15–18; 52:23; 52:25–53:17; 53:22–54:16; 65:3–5; 65:7–16; 65:18–	106, 402, 403		

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		19; 75:7–19; 75:22–76:4			
73:14-20	106, 701, 801, AM	75:7–19; 75:22– 76:4	106, 402, 403		
73:24	106, 701, 801, AM	52:15–18; 52:23; 52:25–53:17; 53:22–54:16; 65:3– 5; 65:7–16; 65:18– 19; 75:7–19; 75:22–76:4	106, 402, 403		
76:6-10	106, 701, 801, AA, AM, MC	52:15–18; 52:23; 52:25–53:17; 53:22–54:16; 65:3– 5; 65:7–16; 65:18– 19; 75:7–19; 75:22–76:4	106, 402, 403		
76:13-21	106, 701, 801, AM, AR, MC	52:15–18; 52:23; 52:25–53:17; 53:22–54:16; 65:3– 5; 65:7–16; 65:18– 19; 75:7–19; 75:22–76:4; 76:17– 21; 75:25–78:5	106, 402, 403		
76:25-78:5	106, 701, 801, AM	52:15–18; 52:23; 52:25–53:17; 53:22–54:16; 65:3– 5; 65:7–16; 65:18– 19; 75:7–19;	106, 402, 403		

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		75:22–76:4; 76:17–21; 75:25–78:5			
78:16-18	106, 701, 801, AM	79:8–9; 79:11–17; 261:11–15; 261:17–262:7; 263:3–5; 263:10–19	OS, 106, 402, 403	262:9-13, 262:19-263:1	701, AM, MC
78:20-22	106, 701, 801, AM	79:8–9; 79:11–17; 261:11–15; 261:17–262:7; 263:3–5; 263:10–19	OS, 106, 402, 403	262:9-13, 262:19-263:1	701, AM, MC
81:24-82:4	801, AF, AM, F, MC				
82:6	801, AF, AM, F, MC				
83:21-22	402, 701, 801, AF, AM, F, MC				
83:24-84:10	402, 701, 801, AF, AM, F, MC				
85:7-13	106, 402, 701, 801, AF, AM, F, MC	86:12–87:2	402, 403		
85:16-19	106, 402, 701, 801, AF, AM, F, MC	86:12–87:2	402, 403		
87:3-16	106, 402, 701, 801, AF, AM, F, MC	86:12–87:2	402, 403		
87:18-88:1	801				
93:10-16	402, 403, 801, AF, AM, F, MC				

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
93:19-24	402, 403, 801, AF, AM, F, MC				
94:2-95:10	106, 402, 403, 801, AF, AM, F, MC, SP	95:11-16; 95:19-96:3; 96:5-12	402, 403		
96:13-14	106, 402, 403, 801, AF, AM, F, MC, SP	96:20-21	402, 403		
96:16-18	106, 402, 403, 801, AF, AM, F, MC, SP	96:20-21	402, 403		
96:22-97:20	106, 402, 403, 801, AF, AM, CQ, F, MC, SP	97:16-20; 97:23-98:2	402, 403		
97:23-98:2	106, 402, 403, 801, AF, AM, CQ, F, MC, SP	97:16-20; 97:23-98:2	106, 402, 403		
98:4-11	402, 403, 801, AM				
100:4-9	106, 402, 403, 602, 801, A, AF, AM, F, MC	101:6-14	106, 402, 403		
100:11-101:11	106, 402, 403, 602, 801, A, AF, AM, F, MC	101:6-14; 102:1-5	106, 402, 403		
101:15-25	106, 402, 403, 602, 801, A, AF, AM, F	101:6-14; 102:1-5	106, 402, 403		

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
102:12-24	106, 402, 403, 801, AM	102:20–103:5; 103:7–17; 103:19–104:10	106, 402, 403		
103:19-104:6	106, 402, 403, 801, A, F, AM	102:20–103:5; 103:7–17; 103:19–104:10	106, 402, 403		
106:17-22	402, 403, 801, A, AF, AM, F				
106:24-107:2	402, 403, 801, A, AF, AM, F				
107:11-108:12	402, 403, 801, A, AF, AM, F				
111:1-6	106, 402, 403, 801, A, AF, AM, F	111:8–18; 112:8–14	106, 402, 403		
111:8-112:1	106, 402, 403, 602, 801, A, AF, AM, F	111:8–18; 112:8–14	106, 402, 403		
112:4-7	106, 402, 403, 602, 801, A, AF, AM, F	111:8–18; 112:8–14	106, 402, 403		
112:15-17	106, 402, 403, 602, 801, A, AF, AM, F	111:8–18; 112:8–14	106, 402, 403		
112:19	106, 402, 403, 602, 801, A, AF, AM, F	111:8–18; 112:8–14	106, 402, 403		
113:2-114:16	106, 402, 403, 602, 801, A, AF, AM, F	111:8–18; 112:8–14; 114:17–19	106, 402, 403		
114:20-25	106, 602, 801, ID, AF, AM, F	115:2–19	106, 402, 403		
115:2-116:2	106, 602, 801, ID, AF, AM, F	115:2–19	106, 402, 403		

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
116:4-25	106, 402, 602, 801, AF, AM, F, MC, ID	111:8-18; 112:8-14; 114:17-19	106, 402, 403		
119:5-11	106, 402, 602, 801, AF, AM, F	119:13-23	106, 402, 403		
119:24-120:14	106, 402, 602, 801, AF, AM, F	119:13-23; 120:15-17; 120:21-24	OS, 106, 402, 403		
121:10-24	106, 402, 602, 801, AF, AM, F	119:13-23; 120:15-17; 120:21-24	OS, 106, 402, 403		
122:2-3	106, 402, 602, 801, AF, AM, F	119:13-23; 120:15-17; 120:21-24	OS, 106, 402, 403		
122:5-6	106, 402, 602, 801, AF, AM, F, SP	119:13-23; 120:15-17; 120:21-24	OS, 106, 402, 403		
122:8-14	106, 402, 403, 602, 801, AF, AM, F, SP	119:13-23; 120:15-17; 120:21-24	OS, 106, 402, 403		
122:16-24	106, 402, 403, 602, 801, AF, AM, AR, F, MC, SP	119:13-23; 120:15-17; 120:21-24	OS, 106, 402, 403		
123:3-124:1	106, 402, 403, 602, 801, AF, AM, F, MC, SP	119:13-23; 120:15-17; 120:21-24	OS, 106, 402, 403		
124:3-4	106, 402, 403, 602, 801, AF, AM, F, MC, SP	119:13-23; 120:15-17; 120:21-24	OS, 106, 402, 403		
147:8-16	106, 701, 801, AM, SP	147:22-24; 148:2-4; 148:6-10; 148:14-20	OS, 106, 402, 403		
147:18-20	801, AM, AF, F, MC				

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
151:14-154:2	701, 801, AM, AF, F, MC				
154:4-7	701, 801, AM, AF, F, MC				
154:9-155:12	701, 801, AM, AF, F, MC				
155:17-158:20	106, 402, 701, 801, AM, AF, F, ID	160:15–17; 160:20–161:19	ID, 106, 403		
160:15-17	106, 701, 801, AM, AF, F	160:20–19	ID, 106, 403		
160:20-161:19	106, 701, 801, AM, AF, F	160:20–19	ID, 106, 403		
163:3-10	106, 701, 801, A, B, AM, AF, F	164:16–17; 164:20–165:16	OS, 402, 403		
163:12-14	106, 701, 801, A, B, AM, AF, F	164:16–17; 164:20–165:16	OS, 402, 403		
170:6-19	106, 602, 701, 801, AM, AF, F	167:15–23	OS, 106, 402, 403	167:24-168:17	106, 602, AF, AM, F, SP
170:25-171:4	106, 602, 701, 801, AM, AF, F	167:15–23	OS, 106, 402, 403	167:24-168:17	106, 602, AF, AM, F, SP
171:6-8	106, 602, 701, 801, AM, AF, F	167:15–23	OS, 106, 402, 403	167:24-168:17	106, 602, AF, AM, F, SP
171:11-12	106, 602, 701, 801, AM, AF, F	167:15–23	OS, 106, 402, 403	167:24-168:17	106, 602, AF, AM, F, SP
172:22-173:1	106, 602, 701, 801, AM, AF, F	167:15–23	OS, 106, 402, 403	167:24-168:17	106, 602, AF, AM, F, SP
173:4	106, 602, 701, 801, AM, AF, F	167:15–23	OS, 106, 402, 403	167:24-168:17	106, 602, AF, AM, F, SP

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
173:6-9	106, 602, 701, 801, AM, AF, F, MC	167:15–23	OS, 106, 402, 403	167:24-168:17	106, 602, AF, AM, F, SP
173:12-174:1	106, 602, 701, 801, AM, AF, F	167:15–23	OS, 106, 402, 403	167:24-168:17	106, 602, AF, AM, F, SP
174:4	106, 602, 701, 801, AM, AF, F	167:15–23	OS, 106, 402, 403	167:24-168:17	106, 602, AF, AM, F, SP
175:13-176:1	106, 602, 701, 801, AM, AF, F	167:15–23	OS, 106, 402, 403	167:24-168:17	106, 602, AF, AM, F, SP
176:4-20	106, 602, 701, 801, AM, AF, F	167:15–23	OS, 106, 402, 403	167:24-168:17	106, 602, AF, AM, F, SP
176:23-24	106, 602, 701, 801, AM, AF, F	167:15–23	OS, 106, 402, 403	167:24-168:17	106, 602, AF, AM, F, SP
177:2-3	106, 602, 701, 801, AM, AF, F	167:15–23	OS, 106, 402, 403	167:24-168:17	106, 602, AF, AM, F, SP
178:12-15	106, 701, 801, AM	178:21–23; 178:25–179:2; 179:4–6; 179:13–180:5; 180:12–182:17	106, 402, 403, 601, 701		
178:17-19	106, 701, 801, AM	178:21–23; 178:25–179:2; 179:4–6; 179:13–180:5; 180:12–182:17	106, 402, 403, 601, 701		
180:7-16	106, 701, 801, AM	180:12–182:17	106, 403		
183:25-184:7	801	183:23–184:2	106, 403		
185:16-188:4	106, 801, AF, AM, F, ID	183:23–184:2; 185:16–22; 186:4–9; 186:11–187:9			

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
188:18-190:8	106, 701, 801, AM	52:15–18; 52:23; 52:25–53:17; 65:20–66:1; 67:7–67:16; 67:18–21; 67:24–68:3; 68:5–69:8; 75:7–19; 75:22–76:4; 76:17–21; 75:25–78:5; 190:4–8; 190:10–191:10; 193:15–25	OS, 106, 402, 403	191:12-19	106, 402, 403, 701, AA, AM, C, SP
190:10-191:10	106, 701, 801, AM	52:15–18; 52:23; 52:25–53:17; 65:20–66:1; 67:7–67:16; 67:18–21; 67:24–68:3; 68:5–69:8; 75:7–19; 75:22–76:4; 76:17–21; 75:25–78:5; 190:4–8; 190:10–191:10; 193:15–25	ID, OS, 106, 402, 403	191:12-19	106, 402, 403, 701, AA, AM, C, SP
195:8-10	701, 801, AM				
195:12-22	701, 801, AM				
196:7-17	106, 701, 801, AA, AM, ID	178:21–23; 178:25–179:2; 179:4–6; 179:13–180:5; 180:12–182:17; 197:5–7; 197:9; 197:13	OS, 106, 402, 403		

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
196:19-197:3	106, 701, 801, AA, AM	178:21–23; 178:25–179:2; 179:4–6; 179:13–180:5; 180:12–182:17; 197:5–7; 197:9; 197:13	OS, 106, 402, 403		
197:5-7	106, 701, 801, AM	178:21–23; 178:25–179:2; 179:4–6; 179:13–180:5; 180:12–182:17; 197:5–7; 197:9; 197:13	ID, OS, 106, 402, 403		
197:15-22	106, 701, 801, AM	178:21–23; 178:25–179:2; 179:4–6; 179:13–180:5; 180:12–182:17; 197:5–7; 197:9; 197:13	OS, 106, 402, 403		
206:1-7	106, 701, 801, AF, AM, F	219:12–220:3; 220:10–221:3; 221:5–222:14	OS, 106, 402, 403	222:21-23, 223:1-8, 223:16-224:6	106, 402, 403, 701, AF, AM, F, MC
206:9-208:8	106, 701, 801, AF, AM, F	208:10–12; 219:12–220:3; 220:10–221:3; 221:5–222:14	OS, 106, 402, 403	222:21-23, 223:1-8, 223:16-224:6	106, 402, 403, 701, AF, AM, F, MC
208:10-12	106, 701, 801, AF, AM, F	219:12–220:3; 220:10–221:3; 221:5–222:14	OS, 106, 402, 403	222:21-23, 223:1-8, 223:16-224:6	106, 402, 403, 701, AF, AM, F, MC

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
224:8-11	106, 701, 801, AF, AM, F	219:12–220:3; 220:10–221:3; 221:5–222:14; 226:3–12; 226:16–227:21	OS, 106, 402, 403	222:21-23, 223:1-8	106, 402, 403, 701, AF, AM, F, MC
224:15-18	106, 701, 801, AF, AM, F	219:12–220:3; 220:10–221:3; 221:5–222:14; 226:3–12; 226:16–227:21	OS, 106, 402, 403	222:21-23, 223:1-8, 223:16-224:6	106, 402, 403, 701, AF, AM, F, MC
224:20-25	106, 701, 801, AF, AM, F	219:12–220:3; 220:10–221:3; 221:5–222:14; 226:3–12; 226:16–227:21	OS, 106, 402, 403	222:21-23, 223:1-8, 223:16-224:6	106, 402, 403, 701, AF, AM, F, MC
226:3-9	106, 801, AM, B, C	226:10–12; 226:16–227:21			
228:8-13	106, 801, AM, B, C	226:3–12; 226:16–227:21; 178:21–23; 178:25–179:2; 179:4–6; 179:13–180:5; 180:12–182:17	ID, OS, 106, 402, 403		
228:17-19	106, 801, AM, B, C	226:3–12; 226:16–227:21; 178:21–23; 178:25–179:2; 179:4–6; 179:13–	ID, OS, 106, 402, 403		

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		180:5; 180:12–182:17			
228:21-229:2	106, 801, AM, MC	178:21–23; 178:25–179:2; 179:4–6; 179:13–180:5; 180:12–182:17	ID, OS, 106, 402, 403		
229:6-7	106, 801, AM, MC	178:21–23; 178:25–179:2; 179:4–6; 179:13–180:5; 180:12–182:17	ID, OS, 106, 402, 403		
236:17-21	106, 402, 701, 801, AM, SP	237:13–19; 237:21–22	ID, 106		
236:24-237:19	106, 402, 701, 801, AM, SP	237:13–19; 237:21–22	ID, 106		
237:21-22	106, 402, 701, 801, AM, SP	237:13–19; 237:21–22	ID, 106		
237:24-238:1	106, 402, 701, 801, AM, SP	237:13–19; 237:21–22	ID, 106		
246:3-9	602, 701, 801, AF, AM, B, F				
248:5-8	801	254:4–5; 254:7–19	OS, 106, 402, 403	254:21-24, 255:2-3	AM, OS
248:13-249:1	402, 602, 701, 801, AM	254:4–5; 254:7–19	OS, 106, 402, 403	254:21-24, 255:2-3	AM, OS
252:20-253:19	701, 602, 801, AM	254:4–5; 254:7–19	OS, 106, 402, 403	254:21-24, 255:2-3	AM, OS
254:21-24	402, 701, 602, 801, AM	254:4–5; 254:7–19	OS, 106, 402, 403		
255:2-3	106, 402, 701, 602, 801, AM	254:4–5; 254:7–19	OS, 106, 402, 403		

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
266:18-267:15	106, 701, 801, AA, AF, AM, F, ID	178:21-23; 178:25-179:2; 179:4-6; 179:13-180:5; 180:12-182:17; 219:12-220:3; 220:10-221:3; 221:5-222:14	ID, OS, 106, 402, 403	222:21-23, 223:1-8, 223:16-224:6	106, 402, 403, 701, AF, AM, F, MC, OS
278:9-15	402, 801, AA, AF, AM, MC				
280:16-18	106, 701, 801, AA, AM	43:14-44:10; 45:10-24; 195:8-10; 195:12-22	OS, 106, 402, 403		
280:21-281:6	106, 701, 801, AA, AM	43:14-44:10; 45:10-24; 195:8-10; 195:12-22	OS, 106, 402, 403		
287:5-9	106, 701; 801, AA, AM, AR, B, C	219:12-220:3; 220:10-221:3; 221:5-222:14	OS, 106, 402, 403	222:21-23, 223:1-8, 223:16-224:6	106, 402, 403, 701, AF, AM, F, MC
287:11-12	106, 701; 801, AA, AM, AR, B, C	219:12-220:3; 220:10-221:3; 221:5-222:14	OS, 106, 402, 403	222:21-23, 223:1-8, 223:16-224:6	106, 402, 403, 701, AF, AM, F, MC

Witness: Ronald Howard Wharton

Date: Jan. 24, 2018

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
6:16-17	801; FRCP 26(a)(2)				
7:20-25	801; FRCP 26(a)(2)				
8:2-25	801; FRCP 26(a)(2)				
9:2-10	106, 801; FRCP 26(a)(2)	9:11-17			
16:10-17:5	402, 801, ID; FRCP 26(a)(2)				
42:25-43:44:6	801, ID; FRCP 26(a)(2)				
47:25-48:24	801, ID; FRCP 26(a)(2)				
49:17-25	106, 402, 801, AM, C; FRCP 26(a)(2)	47:25; 48:2-3; 48:5-9; 48:11-22; 48:24; 60:4-11; 60:15-20	OS, 106, 402, 403	60:21-24, 61:4-14	106, 402, 403, 801, AA, AF, AM, C, F, OS, FRCP 26(a)(2)
50:2	106, 402, 801, AM, C; FRCP 26(a)(2)	47:25; 48:2-3; 48:5-9; 48:11-22; 48:24; 60:4-11; 60:15-20	OS, 106, 402, 403	60:21-24, 61:4-14	106, 402, 403, 801, AA, AF, AM, C, F, OS, FRCP 26(a)(2)
50:5-20	106, 402, 801, AM, C; FRCP 26(a)(2)	47:25; 48:2-3; 48:5-9; 48:11-22; 48:24; 60:4-11; 60:15-20	OS, 106, 402, 403	60:21-24, 61:4-14	106, 402, 403, 801, AA, AF, AM, C, F, OS, FRCP 26(a)(2)

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
50:25-51:3	106, 402, 801, AF, AM, C; FRCP 26(a)(2)	47:25; 48:2-3; 48:5-9; 48:11-22; 48:24; 60:4-11; 60:15-20	OS, 106, 402, 403	60:21-24, 61:4-14	106, 402, 403, 801, AA, AF, AM, C, F, OS, FRCP 26(a)(2)
51:8-14	106, 402, 801, AM, C; FRCP 26(a)(2)	47:25; 48:2-3; 48:5-9; 48:11-22; 48:24; 60:4-11; 60:15-20	OS, 106, 402, 403	60:21-24, 61:4-14	106, 402, 403, 801, AA, AF, AM, C, F, OS, FRCP 26(a)(2)
52:14-17	106, 402, 801, AM, C; FRCP 26(a)(2)	47:25; 48:2-3; 48:5-9; 48:11-22; 48:24; 60:4-11; 60:15-20	OS, 106, 402, 403	60:21-24, 61:4-14	106, 402, 403, 801, AA, AF, AM, C, F, OS, FRCP 26(a)(2)
52:21-53:-9	106, 402, 801, AM, C, ID; FRCP 26(a)(2)	47:25; 48:2-3; 48:5-9; 48:11-22; 48:24; 60:4-11; 60:15-20	OS, 106, 402, 403	60:21-24, 61:4-14	106, 402, 403, 801, AA, AF, AM, C, F, OS, FRCP 26(a)(2)
53:11	106, 801, AM; FRCP 26(a)(2)	47:25; 48:2-3; 48:5-9; 48:11-22; 48:24; 60:4-11; 60:15-20	OS, 106, 402, 403	60:21-24, 61:4-14	106, 402, 403, 801, AA, AF, AM, C, F, OS, FRCP 26(a)(2)
53:13-17	106, 801, AM, C, ID; FRCP 26(a)(2)	47:25; 48:2-3; 48:5-9; 48:11-22; 48:24; 60:4-11; 60:15-20	OS, 106, 402, 403	60:21-24, 61:4-14	106, 402, 403, 801, AA, AF, AM, C, F, OS, FRCP 26(a)(2)
61:15-16	801, AF, AM, C, IQ; FRCP 26(a)(2)				

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
61:22-25	801, AF, AM, C, F, IQ; FRCP 26(a)(2)	47:25; 48:2-3; 48:5-9; 48:11-22; 48:24; 60:4-11; 60:15-20	OS, 106, 402, 403	60:21-24, 61:4-14	106, 402, 403, 801, AA, AF, AM, C, F, OS, FRCP 26(a)(2)
62:2-20	801, AF, AM, C, F, IQ; FRCP 26(a)(2)	47:25; 48:2-3; 48:5-9; 48:11-22; 48:24; 60:4-11; 60:15-20	OS, 106, 402, 403	60:21-24, 61:4-14	106, 402, 403, 801, AA, AF, AM, C, F, OS, FRCP 26(a)(2)
63:19-64:13	106, 801, AF, C, ID; FRCP 26(a)(2)	47:25; 48:2-3; 48:5-9; 48:11-22; 48:24; 60:4-11; 60:15-20; 130:12-15; 130:19-25; 131:2-13; 133:12-14; 133:16-20; 134: 2-19; 135:6-25; 136:2-6; 137:9-11; 137:14-19; 138:18-23; 139:23-24; 140:2-7; 140:11-25; 141:2-10	OS, 106, 402, 403	60:21-24, 61:4-14, 131:14-16, 131:18-132:15, 132:17-19, 136:10-20, 136:22-137:8, 137:20-24, 143:3-5	106, 402, 403, 602, 801, AA, AF, AM, C, F, NR, OS, SP, FRCP 26(a)(2)
88:18-89:16	801, ID, C; FRCP 26(a)(2)				
106:4-107:21	106, 801, AM, ID; FRCP 26(a)(2)	63:19-25; 64:2-13; 104:20-24; 105:14-16; 106:4-17	OS, 106, 402, 403	60:21-24, 61:4-14	106, 402, 403, 801, AA, AF, AM, C, F, OS, FRCP 26(a)(2)

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
116:8-117:23	801, AM, ID; FRCP 26(a)(2)				
117:25-118:21	801, AM, ID, IQ; FRCP 26(a)(2)				
119:2-5	801, AM, ID, IQ; FRCP 26(a)(2)				
119:7-13	402, 801, AM; FRCP 26(a)(2)				
117:15-16	801, AM, ID, IQ, C; FRCP 26(a)(2)				
119:18-22	402, 801, AM; FRCP 26(a)(2)				
119:24-120:24	106, 801, AM, C, ID; FRCP 26(a)(2)	63:19-25; 64:2-13; 130:12-15; 130:19-25; 131:2-13; 133:12-14; 133:16-20; 134: 2-19; 135:6-25; 136:2-6; 137:9-11; 137:14-19; 138:18-23; 139:23-24; 140:2-7; 140:11-25; 141:2-10	OS, 106, 402, 403	60:21-24, 61:4-14, 131:14-16, 131:18-132:15, 132:17-19, 136:10-20, 136:22-137:8, 137:20-24, 143:3-5	106, 402, 403, 602, 801, AA, AF, AM, C, F, NR, OS, SP, FRCP 26(a)(2)
121:2-5	106, 801, AM; FRCP 26(a)(2)	63:19-25; 64:2-13; 130:12-15; 130:19-25; 131:2-13; 133:12-14; 133:16-20; 134: 2-19;	OS, 106, 402, 403	60:21-24, 61:4-14, 131:14-16, 131:18-132:15, 132:17-19, 136:10-20, 136:22-	106, 402, 403, 602, 801, AA, AF, AM, C, F, NR, OS, SP, FRCP 26(a)(2)

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		135:6–25; 136:2–6; 137:9–11; 137:14–19; 138:18–23; 139:23–24; 140:2–7; 140:11–25; 141:2–10		137:8, 137:20–24, 143:3–5	
121:7–15	106, 801, AM; FRCP 26(a)(2)	63:19–25; 64:2–13; 130:12–15; 130:19–25; 131:2–13; 133:12–14; 133:16–20; 134: 2–19; 135:6–25; 136:2–6; 137:9–11; 137:14–19; 138:18–23; 139:23–24; 140:2–7; 140:11–25; 141:2–10	OS, 106, 402, 403	60:21–24, 61:4–14, 131:14–16, 131:18–132:15, 132:17–19, 136:10–20, 136:22–137:8, 137:20–24, 143:3–5	106, 402, 403, 602, 801, AA, AF, AM, C, F, NR, OS, SP, FRCP 26(a)(2)
127:24–128:4	106, 801, AM, ID; FRCP 26(a)(2)	63:19–25; 64:2–13; 130:12–15; 130:19–25; 131:2–13; 133:12–14; 133:16–20; 134: 2–19; 135:6–25; 136:2–6; 137:9–11; 137:14–19; 138:18–23; 139:23–24; 140:2–7; 140:11–25; 141:2–10	OS, 106, 402, 403	60:21–24, 61:4–14, 131:14–16, 131:18–132:15, 132:17–19, 136:10–20, 136:22–137:8, 137:20–24, 143:3–5	106, 402, 403, 602, 801, AA, AF, AM, C, F, NR, OS, SP, FRCP 26(a)(2)

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
128:19-130:11	106, 801, AM, ID; FRCP 26(a)(2)	63:19-25; 64:2-13; 130:12-15; 130:19-25; 131:2-13; 133:12-14; 133:16-20; 134: 2-19; 135:6-25; 136:2-6; 137:9-11; 137:14-19; 138:18-23; 139:23-24; 140:2-7; 140:11-25; 141:2-10	OS, 106, 402, 403	60:21-24, 61:4-14, 131:14-16, 131:18-132:15, 132:17-19, 136:10-20, 136:22-137:8, 137:20-24, 143:3-5	106, 402, 403, 602, 801, AA, AF, AM, C, F, NR, OS, SP, FRCP 26(a)(2)
150:25-151:15	801, ID; FRCP 26(a)(2)				
163:4-5	801, AM, AF; FRCP 26(a)(2)				
163:7-17	801, AM, AF; FRCP 26(a)(2)				
166:5-167:3	106, 801, ID; FRCP 26(a)(2)	167:4-21; 167:23-25; 168:2-25; 169:2-7; 169:9-22; 169:24-25; 170:9-17; 170:19-24	OS, 106, 402, 403, 601, 701	170:2-4, 170:6-8	106, 402, 403, 701, 702, 801, AM, NR, FRCP 26(a)(2)
172:14-22	106, 801, AF, AM; FRCP 26(a)(2)	63:19-25; 64:2-13; 130:12-15; 130:19-25; 131:2-13; 133:12-14; 133:16-20; 134: 2-19; 135:6-25; 136:2-6;	OS, 106, 402, 403	60:21-24, 61:4-14, 131:14-16, 131:18-132:15, 132:17-19, 136:10-20, 136:22-137:8, 137:20-24, 143:3-5	106, 402, 403, 602, 801, AA, AF, AM, C, F, NR, OS, SP, FRCP 26(a)(2)

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
		137:9–11; 137:14–19; 138:18–23; 139:23–24; 140:2–7; 140:11–25; 141:2–10			
172:24-174:5	106, 801, AF, AM; FRCP 26(a)(2)	63:19–25; 64:2–13; 130:12–15; 130:19–25; 131:2–13; 133:12–14; 133:16–20; 134: 2–19; 135:6–25; 136:2–6; 137:9–11; 137:14–19; 138:18–23; 139:23–24; 140:2–7; 140:11–25; 141:2–10	OS, 106, 402, 403	60:21-24, 61:4-14, 131:14-16, 131:18-132:15, 132:17-19, 136:10-20, 136:22-137:8, 137:20-24, 143:3-5	106, 402, 403, 602, 801, AA, AF, AM, C, F, NR, OS, SP, FRCP 26(a)(2)
175:18-24	106, 801, AM; FRCP 26(a)(2)	178:9–25; 179:2–6; 179:9	ID, IQ, OS, 106, 402, 403	177:25-178:4, 178:7, 179:10-25, 180:9-14, 180:16	402, 403, 801, AM, F, ID, NR, OS, SP, FRCP 26(a)(2)
176:5-24	106, 801, AM; FRCP 26(a)(2)	178:9–25; 179:2–6; 179:9	ID, IQ, OS, 106, 402, 403	177:25-178:4, 178:7, 179:10-25, 180:9-14, 180:16	402, 403, 801, AM, F, C, MC, OS, SP, FRCP 26(a)(2)
196:22-197:20	106, 402, 801, ID, AM; FRCP 26(a)(2)	200:13–25; 201:2–25; 202:2–25; 203:2–5	OS, 106, 402, 403		
197:23-198:2	106, 402, 801, ID, AM; FRCP 26(a)(2)	200:13–25; 201:2–25; 202:2–25; 203:2–5	OS, 106, 402, 403		

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
198:7-17	106, 402, 801, AM; FRCP 26(a)(2)	200:13-25; 201:2-25; 202:2-25; 203:2-5	OS, 106, 402, 403		
201:5-202:8	106, 801, AF, AM, F, ID; FRCP 26(a)(2)	200:13-25; 201:2-25; 202:2-25; 203:2-5	ID, OS, 106, 402, 403		
207:24-208:5	106, 801, AF, AM, ID; FRCP 26(a)(2)	200:13-25; 201:2-25; 202:2-25; 203:2-5	OS, 106, 402, 403		
209:2-210:10	402, 801, AF, AM, C, F, ID; FRCP 26(a)(2)				
222:16-18	402, 801, AF, AM, F; FRCP 26(a)(2)	224:15-25	106		
222:20-24	106, 402, 801, AF, AM, F; FRCP 26(a)(2)	224:15-25	106		
223:20-25	402, 801, AF, AM, F; FRCP 26(a)(2)	224:15-25	106		
224:3-10	402, 801, AF, AM, F; FRCP 26(a)(2)	224:15-25	106		
224:12-25	106, 801, AM; FRCP 26(a)(2)	224:15-25	ID, 106		
225:4-14	106, 801, AM; FRCP 26(a)(2)	224:15-25	106		
226:17-227:11	801, AM, F, ID; FRCP 26(a)(2)	230:24-25; 231:2-3; 231:7-19	106		

Defendants' Affirmative Designations	Plaintiff's Objections	Plaintiff's Counter Designations	Defendants' Objections to Plaintiffs' Counter Designations	Defendants' Rebuttal Designations	Plaintiffs' Objections to Defendants' Rebuttal Designations
228:22-229:15	801, AF, AM, F, ID; FRCP 26(a)(2)	230:24-25; 231:2-3; 231:7-19	106		
229:18-230:9	801, ID; FRCP 26(a)(2)	230:24-25; 231:2-3; 231:7-19	106		
230:11-231:3	801, C, ID; FRCP 26(a)(2)	230:24-25; 231:2-3; 231:7-19	ID, 106		
231:7-19	801; FRCP 26(a)(2)	230:24-25; 231:2-3; 231:7-19	ID, 106		

Plaintiff's Objection Legend

Code	Objection
106	This testimony is objectionable because it is incomplete and the introduction of the remaining portions ought, in fairness, to be considered contemporaneously with it (<i>see</i> F.R.E. 106).
402	This testimony is objectionable because it is not relevant or immaterial (<i>see</i> F.R.E. 401 and 402).
403	Misleading, confusion of issues, and/or cumulative. This testimony is objectionable because its probative value is substantially outweighed by the danger of unfair prejudice.
404	Improper character evidence
408	<i>See</i> F.R.E. 408 (Compromise Offers and Negotiations).
602	This testimony is objectionable because it constitutes testimony on a matter as to which the witness lacks personal knowledge or competency (<i>see</i> F.R.E. 602).
701	This testimony is objectionable because it is opinion testimony by a lay witness that is not reasonably based on perception and helpful to a clear understanding of the witness' testimony or the determination of a fact in dispute (<i>see</i> F.R.E. 701), and/or it calls for a legal conclusion, and/or it is attempted expert testimony from a witness who was not designated as an expert and who did not submit an expert report (<i>see</i> FRCP 26).
702	Improper expert opinion (<i>see</i> F.R.E. 702).
801	Hearsay. This testimony is objectionable because it is a statement made by one other than the declarant while testifying at trial, offered into evidence to prove the truth of the matter asserted and not subject to any hearsay exception (<i>see</i> F.R.E. 801 and 802).
1006	Improper summary, chart or calculation (<i>see</i> F.R.E. 1006).
A	This testimony is objectionable because it concerns a document for which authentication is lacking (<i>see</i> F.R.E. 901 et seq.).
AA	Asked and answered.
AF	Assumes a fact not in evidence.
AM	Ambiguous, vague, confusing, unintelligible or overbroad (<i>e.g.</i> , F.R.E. 611)
AR	Argumentative
B	Best evidence (<i>see</i> F.R.E. 1002, 1003, 1004)

Code	Objection
C	Cumulative, Duplicative, Wasteful or Undue Delay (<i>see</i> F.R.E. 403)
CQ	Compound question.
F	Lacks foundation (<i>see</i> F.R.E. 901; <i>see also</i> F.R.E. 103, 104, 105).
FRCP 30(b)(6)	Outside the scope of witness designation.
ID	Improper deposition designation (<i>e.g.</i> , attorney objections not removed, etc.)
IM	Improper impeachment (<i>see</i> F.R.E. 613)
IQ	Incomplete question/incomplete answer.
JTX	Should be moved to Joint Exhibit List
L	Leading (<i>see</i> F.R.E. 611).
MC	Mischaracterizes testimony, misleading or misstates evidence.
MIL	Subject to motion <i>in limine</i> .
N	Calls for narrative response.
FRCP 26(a)(2)	Expert improperly disclosed.
NR	Nonresponsive or volunteered answer.
OS	Outside scope of original deposition designation
SP	Speculation; calls for speculation.

Objection Key for Defendants' Objections to Amarin's Deposition Designations

Code	Objection
106	This testimony is objectionable because it is incomplete and the introduction and the remaining portions ought, in fairness, to be considered contemporaneously with it (<i>see</i> F.R.E. 106).
402	This testimony is objectionable because it is not relevant (<i>see</i> F.R.E. 402).
403	Misleading, confusion of issues, and/or cumulative. This testimony is objectionable because its probative value is substantially outweighed by the danger of unfair prejudice (<i>see</i> F.R.E. 403).
408	<i>See</i> F.R.E. 408 (Compromise Offers and Negotiations).
602	This testimony is objectionable because it constitutes testimony on a matter as to which the witness lacks personal knowledge (<i>see</i> F.R.E. 602).
701	This testimony is objectionable because it is opinion testimony by a lay witness that is not reasonably based on perception and helpful to a clear understanding of the witnesses' testimony or the determination of a fact in dispute (<i>see</i> F.R.E. 701), and/or it calls for a legal conclusion, and/or it is attempted expert testimony from a witness who was not designated as an expert and who did not submit an expert report (<i>see</i> F.R.C.P. 26).
702	<i>See</i> F.R.E. 702.
703	<i>See</i> F.R.E. 703.
801	Hearsay. This testimony is objectionable because it is a statement made by one other than the declarant while testifying at trial, offered into evidence to prove the truth of the matter asserted and not subject to any hearsay exception (<i>see</i> F.R.E. 801 and 802).
1006	<i>See</i> F.R.E. 1006.
A or 901	This testimony is objectionable because it concerns documents for which authentication is lacking (<i>see</i> F.R.E. 901).
AA	Asked and answered.
AF	Assumes facts not in evidence.
AM	Ambiguous, vague, or unintelligible.
CQ	Compound question.
F	Lacks foundation (<i>see</i> F.R.E. 901).
FRCP 30(b)(6)	Outside the scope of witness designation.

Code	Objection
ID	Improper deposition designation.
IQ	Incomplete question/incomplete answer.
MC	Mischaracterizes testimony or misstates evidence.
OS	Outside scope of original designation.
SP	Speculation; calls for speculation.